PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	KUHLBRANDT, W; WANG, DN				KUHLBRANDT, W; WANG, DN			3-DIMENSIONAL STRUCTURE OF PLANT LIGHT-HARVESTING COMPLEX DETERMINED BY ELECTRON CRYSTALLOGRAPHY	NATURE			English	Article							A/B-PROTEIN COMPLEX; PHOTOSYNTHETIC REACTION CENTER; RHODOPSEUDOMONAS-VIRIDIS; SENSITIVE SPECIMENS; PURPLE MEMBRANE; CHLOROPHYLL; RESOLUTION; MICROGRAPHS; CRYSTALS; BEAM	The structure of the light-harvesting chlorophyll a/b-protein complex, a membrane protein serving as the major antenna of solar energy in plant photosynthesis, has been determined at 6 angstrom resolution by electron crystallography. Within the complex, three membrane-spanning alpha-helices and 15 chlorophyll molecules are resolved. There is an intramolecular diad relating two of the alpha-helices and some of the chlorophylls. The spacing of the chlorophylls suggests energy transfer by delocalized exciton coupling and Forster mechanisms.			KUHLBRANDT, W (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.			Kuhlbrandt, Werner/0000-0002-2013-4810; Wang, Da-Neng/0000-0002-6496-4699				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; BALDWIN J, 1984, ULTRAMICROSCOPY, V14, P319, DOI 10.1016/0304-3991(84)90217-1; BRODY SS, 1957, REV SCI INSTRUM, V28, P1021, DOI 10.1063/1.1715792; BULLOUGH P, 1987, ULTRAMICROSCOPY, V21, P223, DOI 10.1016/0304-3991(87)90147-1; BURGI R, 1987, BIOCHIM BIOPHYS ACTA, V890, P346, DOI 10.1016/0005-2728(87)90162-9; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CHOTHIA C, 1985, REV BIOCH, V53, P537; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DOWNING KH, 1986, ULTRAMICROSCOPY, V20, P269, DOI 10.1016/0304-3991(86)90191-9; FORD RC, 1990, EMBO J, V9, P3067, DOI 10.1002/j.1460-2075.1990.tb07503.x; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; GLAESER RM, 1989, ULTRAMICROSCOPY, V27, P307, DOI 10.1016/0304-3991(89)90021-1; HAYWARD SB, 1980, ULTRAMICROSCOPY, V5, P3, DOI 10.1016/0304-3991(80)90005-4; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HENDERSON R, 1985, ULTRAMICROSCOPY, V16, P139, DOI 10.1016/0304-3991(85)90069-5; HOFFMANN NE, 1986, P NATL ACAD SCI USA, V84, P8844; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; KARLINNEUMANN GA, 1985, J MOL APPL GENET, V3, P45; KUHLBRANDT W, 1984, NATURE, V307, P478, DOI 10.1038/307478a0; KUHLBRANDT W, 1983, J CELL BIOL, V96, P1414, DOI 10.1083/jcb.96.5.1414; KUHLBRANDT W, 1989, J MOL BIOL, V207, P823, DOI 10.1016/0022-2836(89)90247-7; MATTHEWS BW, 1979, J MOL BIOL, V131, P259, DOI 10.1016/0022-2836(79)90076-7; MICHEL H, 1986, ENCY PLANT PHYSL PHO, V19, P371; MULLET JE, 1983, J BIOL CHEM, V258, P9941; SAUER K, 1986, ENCY PLANT PHYSL, V19, P85; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SHIPMAN LL, 1976, J AM CHEM SOC, V98, P8222, DOI 10.1021/ja00441a056; SIEFERMANNHARMS D, 1985, BIOCHIM BIOPHYS ACTA, V811, P325, DOI 10.1016/0304-4173(85)90006-0; SIMPSON DJ, 1979, CARLSBERG RES COMMUN, V44, P305, DOI 10.1007/BF02906493; STARK W, 1984, EMBO J, V3, P777, DOI 10.1002/j.1460-2075.1984.tb01884.x; VANGRONDELLE R, 1985, BIOCHIM BIOPHYS ACTA, V811, P147, DOI 10.1016/0304-4173(85)90017-5; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG DN, 1991, IN PRESS J MOL BIOL; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438	39	425	432	5	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					130	134						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005962				2022-12-01	WOS:A1991FB64500048
J	LAITINEN, K; LAMBERG-ALLARDT, C; TUNNINEN, R; KARONEN, SL; TAHTELA, R; YLIKAHRI, R; VALIMAKI, M				LAITINEN, K; LAMBERG-ALLARDT, C; TUNNINEN, R; KARONEN, SL; TAHTELA, R; YLIKAHRI, R; VALIMAKI, M			TRANSIENT HYPOPARATHYROIDISM DURING ACUTE ALCOHOL-INTOXICATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAGNESIUM-DEFICIENCY; PARATHYROID-HORMONE; MINERAL METABOLISM; CALCIUM; ETHANOL; SERUM; BONE; SECRETION; OSTEOPOROSIS; ABSORPTION	Background. Persons with chronic alcoholism frequently have hypocalcemia, hypomagnesemia, and osteoporosis. The short-term effects of alcohol ingestion on calcium and magnesium metabolism are poorly understood, however. Methods. We measured serum calcium, magnesium, and phosphate concentrations in 17 normal men and 7 normal women before and at intervals up to 16 hours after the ingestion of 1.2 to 1.5 g of alcohol per kilogram of body weight over a 3-hour period (doses sufficient to cause acute intoxication). Urinary excretion of calcium, magnesium, and phosphate and serum calciotropic hormone levels were measured in 16 of these subjects. As a control, the same measurements were made after the ingestion of fruit juice instead of alcohol. Results. The mean (+/- SE) peak blood alcohol level in the men was 37.5 +/- 1.6 mmol per liter, and in the women it was 38.0 +/- 3.2 mmol per liter. In the men the mean serum parathyroid hormone concentration decreased from 16.1 +/- 2.1 to 6.8 +/- 0.9 ng per liter at the end of the three-hour drinking period. The value at this time was 30 percent of that at the end of the three-hour session during which the men drank fruit juice (P = 0.004). The serum concentration of ionized calcium reached a nadir eight hours after the beginning of alcohol administration (decreasing from 1.18 +/- 0.01 to 1.15 +/- 0.01 mmol per liter; P < 0.001 as compared with values during the fruit-juice study), and urinary excretion of calcium increased from 0.34 +/- 0.08 to 0.36 +/- 0.08 mmol per hour (P < 0.01 as compared with values during the fruit-juice study). Serum parathyroid hormone levels exceeded base-line values during the last 4 hours of the 16-hour study period; this increase was accompanied by a decrease in the urinary excretion of calcium. Both serum levels of magnesium (in the first 6 hours) and urinary levels (in the first 12 hours) increased after the ingestion of alcohol. In the women, serum parathyroid hormone levels decreased from 29.2 +/- 2.8 to 17.3 +/- 2.6 ng per liter two hours after the administration of alcohol was begun (P < 0.001) and increased above base-line values during the last four hours of the study period. The serum concentration of ionized calcium decreased from 1.20 +/- 0.01 to 1.16 +/- 0.01 mmol per liter, reaching a nadir 8 to 12 hours after alcohol administration was begun (P < 0.001). Conclusions. Short-term alcohol administration causes transitory hypoparathyroidism. This decline in the secretion of parathyroid hormone accounts at least in part for the transient hypocalcemia, hypercalciuria, and hypermagnesuria that follow alcohol ingestion.	UNIV HELSINKI, ALCOHOL DIS RES UNIT, SF-00100 HELSINKI 10, FINLAND; UNITED LABS, HELSINKI, FINLAND; MINERVA FDN, INST MED RES, HELSINKI, FINLAND; ALKO LTD, FINNISH STATE ALCOHOL CO, RES LABS, HELSINKI, FINLAND; UNIV HELSINKI, DEPT MED 3, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, DEPT CLIN CHEM, SF-00100 HELSINKI 10, FINLAND	University of Helsinki; University of Helsinki; University of Helsinki								AVERY DH, 1983, J STUD ALCOHOL, V44, P205, DOI 10.15288/jsa.1983.44.205; BETHUNE JE, 1968, J CLIN ENDOCR METAB, V28, P673, DOI 10.1210/jcem-28-5-673; BIKLE DD, 1985, ANN INTERN MED, V103, P42, DOI 10.7326/0003-4819-103-1-42; BJORNEBOE GEA, 1988, ALCOHOL CLIN EXP RES, V12, P229, DOI 10.1111/j.1530-0277.1988.tb00185.x; BJORNEBOE GEA, 1986, AM J CLIN NUTR, V44, P678, DOI 10.1093/ajcn/44.5.678; BOHMER T, 1982, SCAND J CLIN LAB INV, V42, P633; Chanard J, 1980, Adv Exp Med Biol, V128, P495; DECHAVANNE M, 1974, NOUV PRESSE MED, V3, P2549; DIAMOND T, 1989, AM J MED, V86, P282, DOI 10.1016/0002-9343(89)90297-0; DICK M, 1969, J CLIN PATHOL, V22, P152, DOI 10.1136/jcp.22.2.152; DIXON WJ, 1988, BMDP STATISTICAL SOF; EARLL JM, 1976, AVIAT SPACE ENVIR MD, V47, P808; ERIKSSON CJP, 1977, ANAL BIOCHEM, V80, P116, DOI 10.1016/0003-2697(77)90631-5; FEITELBERG S, 1987, METABOLISM, V36, P322, DOI 10.1016/0026-0495(87)90201-0; FLINK EB, 1986, ALCOHOL CLIN EXP RES, V10, P590, DOI 10.1111/j.1530-0277.1986.tb05150.x; GRAHAM LA, 1960, METABOLISM, V9, P646; HEMMINGSEN R, 1980, PSYCHOPHARMACOLOGY, V67, P255, DOI 10.1007/BF00431266; JOHNELL O, 1982, BRIT J ADDICT, V77, P93; KALBFLEISCH JM, 1963, J CLIN INVEST, V42, P1471, DOI 10.1172/JCI104831; LALOR BC, 1986, Q J MED, V59, P497; LINDEMAN RD, 1967, J LAB CLIN MED, V70, P236; LINKOLA J, 1979, ACTA PHYSIOL SCAND, V107, P333, DOI 10.1111/j.1748-1716.1979.tb06484.x; LJUNGHALL S, 1985, EXP CLIN ENDOCRINOL, V85, P365, DOI 10.1055/s-0029-1210464; LUISIER M, 1977, SCHWEIZ MED WSCHR, V107, P1529; LUND B, 1977, ACTA MED SCAND, V202, P221; MARKKANEN T, 1966, EXPERIENTIA, V22, P753, DOI 10.1007/BF01901361; MARX SJ, 1987, CLIN DISORDERS FLUID, P207; MILSOM S, 1987, BRIT MED J, V295, P231, DOI 10.1136/bmj.295.6592.231; NIKKILA EA, 1975, DIABETES, V24, P933, DOI 10.2337/diabetes.24.10.933; PAK CYC, 1988, CALCIFIED TISSUE INT, V43, P55, DOI 10.1007/BF02555147; Pitts T O, 1986, Recent Dev Alcohol, V4, P357; Quamme GA, 1987, CLIN DISORDERS FLUID, P297; RATCLIFFE WA, 1989, CLIN CHEM, V35, P1957; RICO H, 1987, BONE MINER, V2, P221; RUDE RK, 1978, J CLIN ENDOCR METAB, V47, P800, DOI 10.1210/jcem-47-4-800; RUDE RK, 1976, CLIN ENDOCRINOL, V5, P209, DOI 10.1111/j.1365-2265.1976.tb01947.x; SAVILLE PD, 1965, J BONE JOINT SURG AM, VA 47, P492, DOI 10.2106/00004623-196547030-00005; SPENCER H, 1986, AM J MED, V80, P393, DOI 10.1016/0002-9343(86)90712-6; TORNQUIST K, 1987, ACTA ENDOCRINOL-COP, V115, P225, DOI 10.1530/acta.0.1150225; TORNQUIST K, 1987, ACTA ENDOCRINOL-COP, V116, P568, DOI 10.1530/acta.0.1160568; VODOZ JF, 1977, SCHWEIZ MED WSCHR, V107, P1525; WILLIAMS GA, 1978, P SOC EXP BIOL MED, V159, P187	42	79	82	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					721	727		10.1056/NEJM199103143241103	http://dx.doi.org/10.1056/NEJM199103143241103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB556	1997837				2022-12-01	WOS:A1991FB55600003
J	MORROW, JD; MARGOLIES, GR; ROWLAND, J; ROBERTS, LJ				MORROW, JD; MARGOLIES, GR; ROWLAND, J; ROBERTS, LJ			EVIDENCE THAT HISTAMINE IS THE CAUSATIVE TOXIN OF SCOMBROID-FISH POISONING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN MAST-CELLS; PROSTAGLANDIN-D2; RELEASE; SYMPTOMS; INVIVO; ACID; RAT	Background. The highest morbidity world-wide from fish poisoning results from the ingestion of spoiled scombroid fish, such as tuna and mackerel, and its cause is not clear. Histamine could be responsible, because spoiled scombroid fish contain large quantities of histamine. Whether histamine is the causative toxin, however, has remained in question. To address this issue, we investigated whether histamine homeostasis is altered in poisoned people. Methods. The urinary excretion of histamine and its metabolite, N-methylhistamine, was measured in three persons who had scombroid-fish poisoning (scombrotoxism) after the ingestion of marlin. We measured 9-alpha, 11-beta-dihydroxy-15-oxo-2,3,18,19-tetranorprost-5-ene-1,20-dioic acid (PGD-M), the principal metabolite of prostaglandin D2, a mast-cell secretory product, to assess whether mast cells had been activated to release histamine. Results. The fish contained high levels of histamine (842 to 2503-mu-mol per 100 g of tissue). Symptoms of scombrotoxism - flushing and headache - began 10 to 30 minutes after the ingestion of fish. In urine samples collected one to four hours after fish ingestion, the levels of histamine and N-methylhistamine were 9 to 20 times and 15 to 20 times the normal mean, respectively. During the subsequent 24 hours, the levels fell to 4 to 15 times and 4 to 11 times the normal values. Levels of both were normal 14 days later. PGD-M excretion was not increased at any time. Two persons treated with diphenhydramine had prompt amelioration of symptoms. Conclusions. Scombroid-fish poisoning is associated with urinary excretion of histamine in quantities far exceeding those required to produce toxicity. The histamine is most likely derived from the spoiled fish. These results identify histamine as the toxin responsible for scombroid-fish poisoning.	VANDERBILT UNIV, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; NASHVILLE DAVIDSON CTY METROPOLITAN BOARD HLTH, DIV FOOD INSPECT, NASHVILLE, TN USA; VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NHLBI NIH HHS [HL-02499] Funding Source: Medline; NIGMS NIH HHS [GM-33040, GM-15431] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033040, P50GM015431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARZUBIAGA C, IN PRESS J ALLERGY C; BAGNIS R, 1970, B WORLD HEALTH ORGAN, V42, P69; Bean N H, 1990, MMWR CDC Surveill Summ, V39, P15; BLAKESLEY ML, 1983, ANN EMERG MED, V12, P104, DOI 10.1016/S0196-0644(83)80386-2; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHURCH MK, 1989, INT ARCH ALLER A IMM, V88, P70, DOI 10.1159/000234752; DICKINSON G, 1982, ANN EMERG MED, V11, P487, DOI 10.1016/S0196-0644(82)80069-3; GRANERUS G, 1968, SCAND J CLIN LAB INV, VS 22, P49; HUGHES JM, 1976, NEW ENGL J MED, V295, P1117, DOI 10.1056/NEJM197611112952006; HUI JY, 1985, TOXICOL APPL PHARM, V81, P241, DOI 10.1016/0041-008X(85)90160-7; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; LERKE PA, 1978, WESTERN J MED, V129, P381; LEVISCHAFFER F, 1989, INT ARCH ALLER A IMM, V90, P352, DOI 10.1159/000235052; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LUKTON A., 1958, FOOD RES, V23, P611, DOI 10.1111/j.1365-2621.1958.tb17612.x; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MORROW JD, 1989, PROSTAGLANDINS, V38, P263, DOI 10.1016/0090-6980(89)90088-9; MORROW JD, IN PRESS ANAL BIOCH; MURPHY RC, 1982, METHOD ENZYMOL, V86, P547; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OTIL KJ, 1979, TOXICOL LETT, V3, P219; PRAKASH C, 1988, J CHEM SOC PERK T 1, P2821, DOI 10.1039/p19880002821; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROBERTS LJ, 1979, NEW ENGL J MED, V300, P236, DOI 10.1056/NEJM197902013000506; ROBERTS LJ, 1984, ANAL BIOCHEM, V136, P258, DOI 10.1016/0003-2697(84)90333-6; ROBERTS LJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P185, DOI 10.1016/0005-2760(79)90020-1; TAYLOR SL, 1986, CRC CR REV TOXICOL, V17, P91, DOI 10.3109/10408448609023767; TAYLOR SL, 1989, J TOXICOL-CLIN TOXIC, V27, P225, DOI 10.3109/15563658908994420; Weiss S, 1932, ARCH INTERN MED, V49, P360, DOI 10.1001/archinte.1932.00150100017002; WILLIAMS S, 1984, OFFICIAL METHODS ANA, P341; 1989, MMWR, V38, P140; 1982, FED REGISTER, V47, P40487	33	211	220	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					716	720		10.1056/NEJM199103143241102	http://dx.doi.org/10.1056/NEJM199103143241102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB556	1997836				2022-12-01	WOS:A1991FB55600002
J	MULKEY, RM; ZUCKER, RS				MULKEY, RM; ZUCKER, RS			ACTION-POTENTIALS MUST ADMIT CALCIUM TO EVOKE TRANSMITTER RELEASE	NATURE			English	Article							NEUROTRANSMITTER RELEASE; NERVE TERMINALS; FACILITATION; DEPOLARIZATION; CRAYFISH; ENTRY; INFLUX	THERE are two hypotheses to explain how neurons release transmitter. The calcium hypothesis proposes that membrane depolarization is necessary only for opening calcium channels and increasing internal calcium concentration ([Ca2+]i) near membrane transmitter-release sites 1-3. These calcium ions trigger a transient release of neurotransmitter 4,5. The calcium-voltage hypothesis postulates that voltage induces a conformational change in a membrane protein rendering it sensitive to calcium such that, in the presence of high [Ca2+]i, depolarization directly triggers transmitter release 6-9. Here we report that when calcium influx is blocked by cobalt or manganese ions in a calcium-free Ringer, as measured with Fura-2, and [Ca2+]i is elevated by liberation from a caged calcium compound, transmitter release at the crayfish neuromuscular junction is unaffected by presynaptic action potentials. These results support the calcium hypothesis.			MULKEY, RM (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720, USA.		Zucker, Robert S/J-9995-2012	Zucker, Robert S/0000-0003-1068-2343				BITTNER GD, 1988, J NEUROBIOL, V20, P386; DELANEY KR, 1990, J PHYSIOL-LONDON, V426, P473, DOI 10.1113/jphysiol.1990.sp018150; DELANEY KR, 1989, J NEUROSCI, V9, P3558; DUDEL J, 1983, PFLUG ARCH EUR J PHY, V399, P1, DOI 10.1007/BF00652515; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; FOGELSON AL, 1985, BIOPHYS J, V48, P1003, DOI 10.1016/S0006-3495(85)83863-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1988, BIOCHEM J, V255, P179, DOI 10.1042/bj2550179; HOCHNER B, 1989, NATURE, V342, P433, DOI 10.1038/342433a0; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; Katz B., 1969, RELEASE NEURAL TRANS; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MILEDI R, 1973, PROC R SOC SER B-BIO, V183, P421, DOI 10.1098/rspb.1973.0026; NARITA K, 1990, BRAIN RES, V510, P289, DOI 10.1016/0006-8993(90)91379-U; PARNAS H, 1986, PFLUG ARCH EUR J PHY, V406, P121, DOI 10.1007/BF00586672; PARNAS I, 1986, PFLUG ARCH EUR J PHY, V406, P131, DOI 10.1007/BF00586673; ZUCKER RS, 1986, J PHYSIOL-PARIS, V81, P237; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1986, SCIENCE, V231, P574, DOI 10.1126/science.2868525; ZUCKER RS, 1988, NATURE, V335, P360, DOI 10.1038/335360a0	20	104	104	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					153	155		10.1038/350153a0	http://dx.doi.org/10.1038/350153a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1672444				2022-12-01	WOS:A1991FB64500058
J	RAYMOND, M; CALLAGHAN, A; FORT, P; PASTEUR, N				RAYMOND, M; CALLAGHAN, A; FORT, P; PASTEUR, N			WORLDWIDE MIGRATION OF AMPLIFIED INSECTICIDE RESISTANCE GENES IN MOSQUITOS	NATURE			English	Article							ORGANO-PHOSPHATE RESISTANCE; CULEX-PIPIENS L; DROSOPHILA-MELANOGASTER; L DIPTERA; QUINQUEFASCIATUS DIPTERA; DETOXIFYING ESTERASES; ALCOHOL-DEHYDROGENASE; CULICIDAE; COMPLEX; POPULATIONS	IN Culex pipiens, overproduction of nonspecific esterases is a common mechanism of resistance to organophosphate insecticides 1,2. The esterases are attributed to closely linked loci named A and B according to substrate preference 3-6, and overproduction of all esterases B is due to gene amplification 7,8. Distribution of electrophoretically distinct variants of overproduced esterases A and B is geographically restricted, with the exception of esterases A2 and B2, always found together throughout at least three continents (Fig. 1). To determine whether this situation is due to migration or to a high mutation rate, esterase B structural genes and their flanking regions were compared by sequence and/or restriction fragment length polymorphism analysis. Whereas structural genes were similar, flanking regions of electrophoretically dissimilar esterases B varied considerably. In contrast, flanking sequences of esterases B2 from different geographical locations (Africa, Asia, North America) were identical. These results suggest that amplified esterase B2 genes originated from an initial event that has subsequently spread organophosphate insecticide resistance by migration.	UNIV MONTPELLIER 2,BIOL MOLEC LAB,URA 1191,F-34095 MONTPELLIER,FRANCE	Universite de Montpellier	RAYMOND, M (corresponding author), INST SCI EVOLUT,GENET & ENVIRONM LAB,URA 327,CASE COURRIER 64,F-34095 MONTPELLIER,FRANCE.		Raymond, Michel/C-9049-2015; Fort, Philippe/M-9498-2015	Fort, Philippe/0000-0001-5997-8722; Callaghan, Amanda/0000-0002-2731-3352; Raymond, Michel/0000-0002-1714-6984				AGUADE M, 1988, GENETICS, V119, P135; ANDREADIS TG, 1988, J AM MOSQUITO CONTR, V4, P256; AQUADRO CF, 1986, GENETICS, V114, P1165; ASAHINA S, 1970, JPN J MED SCI BIOL, V23, P255, DOI 10.7883/yoken1952.23.255; BEYSSATARNAOUTY V, 1989, J AM MOSQUITO CONTR, V5, P196; BEYSSATARNAOUTY V, 1989, THESIS U MONTPELLIER; CALLAGHAN A, 1989, THESIS U LONDON; CURTIS CF, 1981, B ENTOMOL RES, V71, P153, DOI 10.1017/S0007485300051129; DESTORDEUR E, 1976, BIOCHEM GENET, V14, P481, DOI 10.1007/BF00486128; FOURNIER D, 1987, PESTIC BIOCHEM PHYS, V27, P211, DOI 10.1016/0048-3575(87)90048-4; GEORGHIOU GP, 1980, J ECON ENTOMOL, V73, P489, DOI 10.1093/jee/73.4.489; GEORGHIOU GP, 1966, B WORLD HEALTH ORGAN, V35, P691; HEMINGWAY J, 1989, MED VET ENTOMOL, V3, P445; HIGHTON RB, 1970, B WORLD HEALTH ORGAN, V42, P334; KREITMAN M, 1986, P NATL ACAD SCI USA, V83, P3562, DOI 10.1073/pnas.83.10.3562; MAGNIN M, 1988, J MED ENTOMOL, V25, P99, DOI 10.1093/jmedent/25.2.99; MAGNIN M, 1986, THESIS U PARIS 6; MOUCHES C, 1990, P NATL ACAD SCI USA, V87, P2574, DOI 10.1073/pnas.87.7.2574; MOUCHES C, 1986, SCIENCE, V233, P778, DOI 10.1126/science.3755546; MOUCHES C, 1987, P NATL ACAD SCI USA, V84, P2113, DOI 10.1073/pnas.84.8.2113; PASTEUR N, 1981, BIOCHEM GENET, V19, P499, DOI 10.1007/BF00484622; PASTEUR N, 1981, BIOCHEM GENET, V19, P909, DOI 10.1007/BF00504256; PASTEUR N, 1989, J ECON ENTOMOL, V82, P347, DOI 10.1093/jee/82.2.347; RAYMOND M, 1987, J MED ENTOMOL, V24, P24, DOI 10.1093/jmedent/24.1.24; RAYMOND M, 1985, CR ACAD SCI III-VIE, V300, P509; RAYMOND M, 1989, BIOCHEM GENET, V27, P417, DOI 10.1007/BF02399670; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMONS GM, 1989, EVOLUTION, V43, P393, DOI 10.1111/j.1558-5646.1989.tb04235.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; URBANELLI S, 1985, B ENTOMOL RES, V75, P291, DOI 10.1017/S0007485300014383; VILLANI F, 1987, PESTIC BIOCHEM PHYS, V27, P218, DOI 10.1016/0048-3575(87)90049-6; VILLANI F, 1983, B ENTOMOL RES, V73, P153, DOI 10.1017/S0007485300013882; WIRTH MC, 1990, J MED ENTOMOL, V27, P202, DOI 10.1093/jmedent/27.2.202	33	262	290	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					151	153		10.1038/350151a0	http://dx.doi.org/10.1038/350151a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005964				2022-12-01	WOS:A1991FB64500057
J	SAAD, MF; LILLIOJA, S; NYOMBA, BL; CASTILLO, C; FERRARO, R; DEGREGORIO, M; RAVUSSIN, E; KNOWLER, WC; BENNETT, PH; HOWARD, BV; BOGARDUS, C				SAAD, MF; LILLIOJA, S; NYOMBA, BL; CASTILLO, C; FERRARO, R; DEGREGORIO, M; RAVUSSIN, E; KNOWLER, WC; BENNETT, PH; HOWARD, BV; BOGARDUS, C			RACIAL-DIFFERENCES IN THE RELATION BETWEEN BLOOD-PRESSURE AND INSULIN RESISTANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESSENTIAL-HYPERTENSION; LIPID-METABOLISM; PIMA-INDIANS; GLUCOSE; HYPERINSULINEMIA; CHILDREN; SODIUM; MASS	Background. Insulin resistance and the concomitant compensatory hyperinsulinemia have been implicated in the pathogenesis of hypertension. However, reports on the relation between insulin and blood pressure are inconsistent. This study was designed to investigate the possibility of racial differences in this relation. Methods. We studied 116 Pima Indians, 53 whites, and 42 blacks who were normotensive and did not have diabetes; the groups were comparable with respect to mean age (29, 30, and 31 years, respectively) and blood pressure (113/70, 111/68, and 113/68 mm Hg, respectively). Insulin resistance was determined by the euglycemic-hyperinsulinemic clamp technique during low-dose (40 mU per square meter of body-surface area per minute) and high-dose (400 mU per square meter per minute) insulin infusions. Results. The Pima Indians had higher fasting plasma insulin concentrations than the whites or blacks (176, 138, and 122 pmol per liter, respectively; P = 0.002) and lower rates of whole-body glucose disposal during both the low-dose (12.7, 17.1, and 19.5 mmol per minute; P < 0.001) and the high-dose (38.0, 43.1, and 45.7 mmol per minute; P < 0.001) insulin infusions. After adjustment for age, sex, body weight, and percentage of body fat, mean blood pressure (calculated as 1/3 systolic pressure + 2/3 diastolic pressure) was significantly correlated with the fasting plasma insulin concentration (r = 0.42) and the rate of glucose disposal during the low-dose (r = -0.41) and high-dose (r = -0.49) insulin infusions (P < 0.01 for each) in whites, but not in Pima Indians (r = -0.06, -0.02, and -0.04, respectively) or blacks (r = -0.10, -0.04, and 0.02, respectively. Conclusions. The relations between insulinemia, insulin resistance, and blood pressure differ among racial groups and may be mediated by mechanisms active in whites, but not in Pima Indians or blacks.	NIDDKD,PHOENIX EPIDEMIOL & CLIN RES BRANCH,PHOENIX,AZ; MEDLANTIC RES FDN,WASHINGTON,DC	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Castillo, Carlos Fenandez-del/AAO-2602-2020; Steib, Lori/B-6628-2014; Ravussin, Eric/N-1985-2017; Lillioja, Stephen/A-8185-2012	Steib, Lori/0000-0001-8274-318X; Ravussin, Eric/0000-0003-2129-547X; Nyomba, B. L. Gregoire/0000-0001-9472-607X; Lillioja, Stephen/0000-0001-5333-5240				ALBERTI KGM, 1989, DIABETES S2, V38, pA92; ANNEST JL, 1979, AM J EPIDEMIOL, V110, P492, DOI 10.1093/oxfordjournals.aje.a112830; [Anonymous], 1985, WHO TECH REP SER, V727, P1; AVIV A, 1989, HYPERTENSION, V14, P584, DOI 10.1161/01.HYP.14.6.584; BERNTORP K, 1985, Diabetes Research and Clinical Practice, V1, P307, DOI 10.1016/S0168-8227(86)80042-0; BONORA E, 1987, DIABETOLOGIA, V30, P719, DOI 10.1007/BF00296995; CAMBIEN F, 1987, ARTERIOSCLEROSIS, V7, P197, DOI 10.1161/01.ATV.7.2.197; CHANNICK BJ, 1969, ARCH INTERN MED, V123, P131, DOI 10.1001/archinte.123.2.131; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; DONAHUE RP, 1987, AM J EPIDEMIOL, V125, P650, DOI 10.1093/oxfordjournals.aje.a114578; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; Ferrannini E, 1989, J NEPHROL, V1, P3; FERRARI P, 1990, J HYPERTENS, V8, P491, DOI 10.1097/00004872-199006000-00001; FOURNIER AM, 1986, AM J MED, V80, P861, DOI 10.1016/0002-9343(86)90629-7; FUH MMT, 1987, ARCH INTERN MED, V147, P1035, DOI 10.1001/archinte.147.6.1035; HAFFNER SM, 1988, METABOLISM, V37, P338, DOI 10.1016/0026-0495(88)90133-3; LILLIOJA S, 1985, J CLIN INVEST, V75, P1106, DOI 10.1172/JCI111804; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; LUCAS CP, 1985, HYPERTENSION, V7, P702, DOI 10.1161/01.HYP.7.5.702; MANICARDI V, 1986, J CLIN ENDOCR METAB, V62, P1302, DOI 10.1210/jcem-62-6-1302; MANOLIO TA, 1990, ARTERIOSCLEROSIS, V10, P430, DOI 10.1161/01.ATV.10.3.430; MARIGLIANO A, 1990, AM J HYPERTENS, V3, P521, DOI 10.1093/ajh/3.7.521; MBANYA JCN, 1988, LANCET, V1, P733; MOORE RD, 1983, BIOCHIM BIOPHYS ACTA, V737, P1, DOI 10.1016/0304-4157(83)90013-8; NAGULESPARAN M, 1982, DIABETES, V31, P952, DOI 10.2337/diacare.31.11.952; NOSADINI R, 1990, DIABETES S1, V39, pA87; POLLARE T, 1990, METABOLISM, V39, P167, DOI 10.1016/0026-0495(90)90071-J; PRATT JH, 1989, NEW ENGL J MED, V321, P1152, DOI 10.1056/NEJM198910263211703; REAVEN GM, 1987, LANCET, V2, P435; RESNICK LM, 1990, AM J HYPERTENS, V3, P373, DOI 10.1093/ajh/3.5.373; ROSE HG, 1987, HYPERTENSION, V9, P421; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; SAAD MF, 1990, DIABETES, V39, P1430, DOI 10.2337/diabetes.39.11.1430; SHEN DC, 1988, J CLIN ENDOCR METAB, V66, P580, DOI 10.1210/jcem-66-3-580; SINGER P, 1985, HYPERTENSION, V7, P182, DOI 10.1161/01.HYP.7.2.182; STOUT RW, 1975, CIRC RES, V36, P319, DOI 10.1161/01.RES.36.2.319; SWISLOCKI ALM, 1989, AM J HYPERTENS, V2, P419, DOI 10.1093/ajh/2.6.419; UUSITUPA M, 1987, DIABETES RES CLIN EX, V4, P19; VOORS AW, 1981, AM J EPIDEMIOL, V113, P347, DOI 10.1093/oxfordjournals.aje.a113103; WEINBERGER MH, 1986, HYPERTENSION, V8, P127, DOI 10.1161/01.HYP.8.6_Pt_2.II127; WELBORN TA, 1966, LANCET, V1, P1336; 1978, WHO TECH REP SER, V628, P7; 1985, SAS USERS GUIDE STAT	43	416	428	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					733	739		10.1056/NEJM199103143241105	http://dx.doi.org/10.1056/NEJM199103143241105			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB556	1997839	Green Published			2022-12-01	WOS:A1991FB55600005
J	SCHNORR, TM; GRAJEWSKI, BA; HORNUNG, RW; THUN, MJ; EGELAND, GM; MURRAY, WE; CONOVER, DL; HALPERIN, WE				SCHNORR, TM; GRAJEWSKI, BA; HORNUNG, RW; THUN, MJ; EGELAND, GM; MURRAY, WE; CONOVER, DL; HALPERIN, WE			VIDEO DISPLAY TERMINALS AND THE RISK OF SPONTANEOUS-ABORTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FINNISH CASE-REFERENT; BIRTH-DEFECTS; PREGNANCY; WORK; EXPOSURE; SCREENS	Background. The relation between spontaneous abortion and the use of video display terminals (VDTs) is of great public health concern. Previous investigators of this issue have reported inconsistent findings. Methods. To determine whether electromagnetic fields emitted by VDTs are associated with an increased risk of spontaneous abortion, a cohort of female telephone operators who used VDTs at work was compared with a cohort of operators who did not use VDTs. To obtain reliable estimates of exposure, we determined the number of hours of VDT use per week from company records and measured electromagnetic fields at VDT workstations and, for purposes of comparison, at workstations without VDTs. Operators who used VDTs had higher abdominal exposure to very-low-frequency (15 kHz) electromagnetic fields (workstations without VDTs did not emit very-low-frequency energy). Abdominal exposure to extremely-low-frequency fields (45 to 60 Hz) was similar for both operators who used VDTs and those who did not. Among 2430 women interviewed, there were 882 pregnancies that met our criteria for inclusion in the study. Results. We found no excess risk of spontaneous abortion among women who used VDTs during the first trimester of pregnancy (odds ratio = 0.93; 95 percent confidence interval, 0.63 to 1.38), and no dose-response relation was apparent when we examined the women's hours of VDT use per week (odds ratio for 1 to 25 hours per week = 1.04; 95 percent confidence interval, 0.61 to 1.79; odds ratio for >25 hours per week = 1.00; 95 percent confidence interval, 0.61 to 1.64). There continued to be no risk associated with the use of VDTs when we accounted for multiple pregnancies, conducted separate analyses of early abortion, late abortion, and all fetal losses, or limited our analyses to spontaneous abortions for which a physician was consulted. Conclusions. The use of VDTs and exposure to the accompanying electromagnetic fields were not associated with an increased risk of spontaneous abortion in this study.	AMER CANC SOC,ATLANTA,GA	American Cancer Society	SCHNORR, TM (corresponding author), NIOSH,DIV SURVEILLANCE HAZARD EVALUAT & FIELD STUDIES,CINCINNATI,OH 45226, USA.							BARNES FS, 1985, JUN ANN M BIOEL SOC; Bergquist U.O., 1984, SCAND J WORK ENV S2, V10, P62; Bowman JD, 1988, APPL IND HYG, V3, P189; BRANDT LPA, 1990, SCAND J WORK ENV HEA, V16, P329, DOI 10.5271/sjweh.1776; BRYANT HE, 1989, INT J EPIDEMIOL, V18, P132, DOI 10.1093/ije/18.1.132; ERICSON A, 1986, AM J IND MED, V9, P459, DOI 10.1002/ajim.4700090507; ERICSON A, 1986, AM J IND MED, V9, P447, DOI 10.1002/ajim.4700090506; GOLDHABER MK, 1988, AM J IND MED, V13, P695, DOI 10.1002/ajim.4700130608; GUY AW, 1987, MEASUREMENT ANAL ELE; GUY AW, 1987, WORK DISPLAY UNITS 8, P69; HARLAP S, 1980, LANCET, V2, P173, DOI 10.1016/S0140-6736(80)90061-6; HARRELL FE, 1986, LOGIST PROCEDURE SUG; KLINE J, 1980, LANCET, V2, P176, DOI 10.1016/S0140-6736(80)90062-8; Kline J, 1989, MONOGRAPHS EPIDEMIOL, V14; KURPPA K, 1985, SCAND J WORK ENV HEA, V11, P353, DOI 10.5271/sjweh.2213; MCDONALD AD, 1988, BRIT J IND MED, V45, P509; NIELSEN CV, 1990, SCAND J WORK ENV HEA, V16, P323, DOI 10.5271/sjweh.1777; NURMINEN T, 1988, SCAND J WORK ENV HEA, V14, P293, DOI 10.5271/sjweh.1917; POTTER JD, 1980, SURG GYNECOL OBSTET, V150, P251; SCHNORR TM, 1991, INVSTIGATION SPONTAN; SCHNORR TM, 1985, CURRENT CONCEPTS, V8; STUCHLY MA, 1983, HEALTH PHYS, V45, P713, DOI 10.1097/00004032-198309000-00013; TELL R, 1990, PB91130500; TELL RA, 1983, BIOL EFFECTS DOSIMET, P95; WERTHEIMER N, 1986, BIOELECTROMAGNETICS, V7, P13, DOI 10.1002/bem.2250070103; WERTHEIMER N, 1989, AM J EPIDEMIOL, V129, P220, DOI 10.1093/oxfordjournals.aje.a115112; WESTERHOLM P, 1987, WORK DISPLAY UNITS 8, P104; WINDHAM GC, 1990, AM J IND MED, V18, P675, DOI 10.1002/ajim.4700180606; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1983, DHHS NIOSH833291498; 1984, DHHS NIOSH842971609; 1984, 84191 NAT I OCC SAF	32	107	106	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					727	733		10.1056/NEJM199103143241104	http://dx.doi.org/10.1056/NEJM199103143241104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB556	1997838				2022-12-01	WOS:A1991FB55600004
J	STROBEL, SA; DERVAN, PB				STROBEL, SA; DERVAN, PB			SINGLE-SITE ENZYMATIC CLEAVAGE OF YEAST GENOMIC DNA MEDIATED BY TRIPLE HELIX FORMATION	NATURE			English	Article							GEL-ELECTROPHORESIS; SACCHAROMYCES-CEREVISIAE; SEQUENCE; ENDONUCLEASE; RECOGNITION; SEPARATION; PROTEINS; MATURASE; BINDING	PHYSICAL mapping of chromosomes would be facilitated by methods of breaking large DNA into manageable fragments, or cutting uniquely at genetic markers of interest. Key issues in the design of sequence-specific DNA cleaving reagents are the specificity of binding, the generalizability of the recognition motif, and the cleavage yield. Oligonucleotide-directed triple helix formation is a generalizable motif for specific binding to sequences longer than 12 base pairs within DNA of high complexity 1-3. Studies with plasmid DNA show that triple helix formation can limit the operational specificity of restriction enzymes to endonuclease recognition sequences that overlap oligonucleotide-binding sites 4,5. Triple helix formation, followed by methylase protection, triple helix-disruption, and restriction endonuclease digestion produces near quantitative cleavage at the single overlapping triple helix-endonuclease site 4,5. As a demonstration that this technique may be applicable to the orchestrated cleavage of large genomic DNA, we report the near quantitative single-site enzymatic cleavage of the Saccharomyces cerevisiae genome mediated by triple helix formation. The 340-kilobase yeast chromosome III was cut uniquely at an overlapping homopurine-EcoRI target site 27 base pairs long to produce two expected cleavage products of 110 and 230 kilobases. No cleavage of any other chromosome was detected. The potential generalizability of this technique, which is capable of near quantitative cleavage at a single site in at lease 14 megabase pairs of DNA, could enable selected regions of chromosomal DNA to be isolated without extensive screening of genomic libraries.	CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology								ANDREADIS A, 1982, CELL, V31, P319, DOI 10.1016/0092-8674(82)90125-8; BARLOW DP, 1987, TRENDS GENET, V3, P167, DOI 10.1016/0168-9525(87)90219-8; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; KEESEY JK, 1979, J BIOL CHEM, V254, P7427; KOOB M, 1988, SCIENCE, V241, P1084, DOI 10.1126/science.2842862; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PATEL Y, 1990, NUCLEIC ACIDS RES, V18, P1603, DOI 10.1093/nar/18.6.1603; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; WEIL MD, 1989, P NATL ACAD SCI USA, V86, P51, DOI 10.1073/pnas.86.1.51; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6	27	135	142	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					172	174		10.1038/350172a0	http://dx.doi.org/10.1038/350172a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1848684				2022-12-01	WOS:A1991FB64500066
J	WICKNER, S; HOSKINS, J; MCKENNEY, K				WICKNER, S; HOSKINS, J; MCKENNEY, K			FUNCTION OF DNAJ AND DNAK AS CHAPERONES IN ORIGIN-SPECIFIC DNA-BINDING BY REPA	NATURE			English	Article							P1 PLASMID REPLICATION; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; GENE	HEAT-shock proteins are normal constituents of cells whose synthesis is increased on exposure to various forms of stress. They are interesting because of their ubiquity and high conservation during evolution. Two families of heat-shock proteins, hsp60s and hsp70s, have been implicated in accelerating protein folding and oligomerization and also in maintaining proteins in an unfolded state, thus facilitating membrane transport 1-5. The Escherichia coli hsp70 analogue, DnaK, and two other heat-shock proteins, DnaJ and GrpE, are required for cell viability at high temperatures and are involved in DNA replication of phage-lambda and plasmids P1 and F 6-10. These three proteins are involved in replication in vitro of P1 DNA along with many host replication proteins and the P1 RepA initiator protein 11,12. RepA exists in a stable protein complex with DnaJ containing a dimer each of RepA and DnaJ 11. We report here that DnaK and DnaJ mediate an alteration in the P1 initiator protein, rendering it much more active for oriP1 DNA binding.	NATL INST STAND & TECHNOL,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850	National Institute of Standards & Technology (NIST) - USA	WICKNER, S (corresponding author), NCI,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; ABELES AL, 1986, J BIOL CHEM, V261, P3548; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MORIMOTO R I, 1990, P1; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P1334; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; TILLY K, 1990, NEW BIOL, V2, P1; WICKNER SH, 1987, P NATL ACAD SCI USA, V84, P3668, DOI 10.1073/pnas.84.11.3668; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	16	199	201	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					165	167		10.1038/350165a0	http://dx.doi.org/10.1038/350165a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005967				2022-12-01	WOS:A1991FB64500063
J	WILLIAMSON, DF; MADANS, J; ANDA, RF; KLEINMAN, JC; GIOVINO, GA; BYERS, T				WILLIAMSON, DF; MADANS, J; ANDA, RF; KLEINMAN, JC; GIOVINO, GA; BYERS, T			SMOKING CESSATION AND SEVERITY OF WEIGHT-GAIN IN A NATIONAL COHORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-WEIGHT; CIGARETTE-SMOKING; ENERGY-EXPENDITURE; PHYSICAL-ACTIVITY; NICOTINE; OBESITY; CONSUMPTION; WOMEN	Background. Many believe that the prospect of weight gain discourages smokers from quitting. Accurate estimates of the weight gain related to the cessation of smoking in the general population are not available, however. Methods. We related changes in body weight to changes in smoking status in adults 25 to 74 years of age who were weighed in the First National Health and Nutrition Examination Survey (NHANES I, 1971 to 1975) and then weighed a second time in the NHANES I Epidemiologic Follow-up Study (1982 to 1984). The cohort included continuing smokers (748 men and 1137 women) and those who had quit smoking for a year or more (409 men and 359 women). Results. The mean weight gain attributable to the cessation of smoking, as adjusted for age, race, level of education, alcohol use, illnesses related to change in weight, base-line weight, and physical activity, was 2.8 kg in men and 3.8 kg in women. Major weight gain (> 13 kg) occurred in 9.8 percent of the men and 13.4 percent of the women who quit smoking. The relative risk of major weight gain in those who quit smoking (as compared with those who continued to smoke) was 8.1 (95 percent confidence interval, 4.4 to 14.9) in men and 5.8 (95 percent confidence interval, 3.7 to 9.1) in women, and it remained high regardless of the duration of cessation. For both sexes, blacks, people under the age of 55, and people who smoked 15 cigarettes or more per day were at higher risk of major weight gain after quitting smoking. Although at base line the smokers weighed less than those who had never smoked, they weighed nearly the same at follow-up. Conclusions. Major weight gain is strongly related to smoking cessation, but it occurs in only a minority of those who stop smoking. Weight gain is not likely to negate the health benefits of smoking cessation, but its cosmetic effects may interfere with attempts to quit. Effective methods of weight control are therefore needed for smokers trying to quit.	CTR DIS CONTROL,CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30333; NATL CTR HLTH STAT,HYATTSVILLE,MD 20782	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)								ABRAHAM S, 1983, VITAL HLTH STATIS 11, V230; BENNETT W, 1987, ANN NY ACAD SCI, V499, P250, DOI 10.1111/j.1749-6632.1987.tb36216.x; BLITZER PH, 1977, J CHRON DIS, V30, P415, DOI 10.1016/0021-9681(77)90035-2; BOSSE R, 1980, INT J ADDICT, V15, P969, DOI 10.3109/10826088009040072; CARNEY RM, 1984, NEW ENGL J MED, V310, P614, DOI 10.1056/NEJM198403083101002; COHEN BB, 1987, VITAL HLTH STATIST 1, V22; FRIEDMAN GD, 1980, CIRCULATION, V61, P716, DOI 10.1161/01.CIR.61.4.716; GRITZ E R, 1989, Annals of Behavioral Medicine, V11, P144, DOI 10.1207/s15324796abm1104_4; GRUNBERG N E, 1989, Annals of Behavioral Medicine, V11, P154, DOI 10.1207/s15324796abm1104_5; GRUNBERG NE, 1987, PSYCHOPHARMACOLOGY, V91, P221; GRUNBERG NE, 1988, LIFE SCI, V42, P161, DOI 10.1016/0024-3205(88)90679-0; GRUNBERG NE, 1988, PSYCHOPHARMACOLOGY, V94, P536, DOI 10.1007/BF00212851; GRUNBERG NE, 1985, PHARMACOL BIOCHEM BE, V23, P851, DOI 10.1016/0091-3057(85)90081-4; GRUNBERG NE, 1985, PSYCHOPHARMACOLOGY, V87, P198, DOI 10.1007/BF00431807; Grunberg NE, 1986, ADV BEHAVIORAL MED, V2, P97; GRUNBERG NE, 1990, RES ADV ALCOHOL DRUG, P273; HATZIANDREU EJ, 1989, AM J PUBLIC HEALTH, V79, P1020, DOI 10.2105/AJPH.79.8.1020; HOFSTETTER A, 1986, NEW ENGL J MED, V314, P79, DOI 10.1056/NEJM198601093140204; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KLESGES RC, 1989, ANN BEHAV MED, V11, P123; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; NOPPA H, 1980, PREV MED, V9, P534, DOI 10.1016/0091-7435(80)90048-1; PERKINS KA, 1989, NEW ENGL J MED, V320, P898, DOI 10.1056/NEJM198904063201404; RIGOTTI NA, 1989, NEW ENGL J MED, V320, P931, DOI 10.1056/NEJM198904063201409; RISSANEN A, 1988, INT J OBESITY, V12, P391; SCHWARTZ JL, 1987, NIH872940 DEP HLTH H; WACK JT, 1982, AM J CLIN NUTR, V35, P366, DOI 10.1093/ajcn/35.2.366; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; 1985, DHHS8550207 DEP HLTH; [No title captured]; 1990, DHHS CDC908416 PUBL; 1988, DHHS CDC888406 PUBL; 1989, DHHS CDC8988411 PUBL; 1985, SAS USERS GUIDE STAT, P655; 1990, OM902004 DEP HLTH HU	36	633	638	0	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					739	745		10.1056/NEJM199103143241106	http://dx.doi.org/10.1056/NEJM199103143241106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB556	1997840				2022-12-01	WOS:A1991FB55600006
J	BLOT, WJ; DEVESA, SS; KNELLER, RW; FRAUMENI, JF				BLOT, WJ; DEVESA, SS; KNELLER, RW; FRAUMENI, JF			RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							UNITED-STATES; BARRETTS ESOPHAGUS; CANCER	Analyses of cancer incidence data from nine areas of the United States revealed steadily rising rates from 1976 to 1987 of adenocarcinomas of the esophagus and gastric cardia. The increases among men in this period ranged from 4% to 10% per year, and thus exceeded those of any other type of cancer. In contrast, there were relatively stable trends for squamous cell carcinoma of the esophagus and slight declines for adenocarcinoma of more distal portions of the stomach. Adenocarcinomas of the esophagus and gastric cardia disproportionately affected white men and rarely occurred among women. By the mid-1980s, among white men, adenocarcinomas accounted for about one third of all esophageal cancers, while cardia cancers accounted for about one half of all stomach cancers with specified subsites. The rising incidence rates and similar demographic patterns point to the need for investigation into the causes of these poorly understood cancers.			BLOT, WJ (corresponding author), NCI,BIOSTAT BRANCH,EPIDEMIOL & BIOSTAT PROGRAM,EPN,SUITE 431,BETHESDA,MD 20892, USA.							[Anonymous], 1976, INT CLASSIFICATION D; CAMERON AJ, 1985, NEW ENGL J MED, V313, P857, DOI 10.1056/NEJM198510033131404; DYA NE, 1982, CANCER EPIDEMIOLOGY, P596; FIORE MC, 1989, JAMA-J AM MED ASSOC, V261, P49, DOI 10.1001/jama.261.1.49; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LEVI F, 1990, INT J CANCER, V45, P852, DOI 10.1002/ijc.2910450511; LI JY, 1989, INT J CANCER, V43, P755, DOI 10.1002/ijc.2910430502; MACDONALD WC, 1987, CANCER, V60, P1094, DOI 10.1002/1097-0142(19870901)60:5<1094::AID-CNCR2820600529>3.0.CO;2-4; MOELLER H, 1988, 6TH ANN ECP S INT S; POWELL J, 1990, BRIT J CANCER, V59, P440; RIES LAG, 1990, NIH902789 US DEP HLT; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; WANG HH, 1986, HUM PATHOL, V17, P482, DOI 10.1016/S0046-8177(86)80038-7; YANG PC, 1988, INT J EPIDEMIOL, V17, P293, DOI 10.1093/ije/17.2.293; YANG PC, 1988, CANCER, V61, P612, DOI 10.1002/1097-0142(19880201)61:3<612::AID-CNCR2820610332>3.0.CO;2-Q; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P1	16	1980	2036	0	33	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1287	1289		10.1001/jama.265.10.1287	http://dx.doi.org/10.1001/jama.265.10.1287			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995976				2022-12-01	WOS:A1991FA51100024
J	BOICE, JD; MORIN, MM; GLASS, AG; FRIEDMAN, GD; STOVALL, M; HOOVER, RN; FRAUMENI, JF				BOICE, JD; MORIN, MM; GLASS, AG; FRIEDMAN, GD; STOVALL, M; HOOVER, RN; FRAUMENI, JF			DIAGNOSTIC-X-RAY PROCEDURES AND RISK OF LEUKEMIA, LYMPHOMA, AND MULTIPLE-MYELOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ACTIVE BONE-MARROW; CANCER MORTALITY; IONIZING-RADIATION; BREAST-CANCER; UNITED-STATES; RADIOGRAPHY; WORKERS; RADIOLOGISTS; CERVIX	Exposure to diagnostic x-rays and the risk of leukemia, non-Hodgkin's lymphoma (NHL), and multiple myeloma were studied within two prepaid health plans. Adult patients with leukemia (n = 565), NHL (n = 318), and multiple myeloma (n = 208) were matched to controls (n = 1390), and over 25 000 x-ray procedures were abstracted from medical records. Dose response was evaluated by assigning each x-ray procedure a score based on estimated bone marrow dose. X-ray exposure was not associated with chronic lymphocytic leukemia, one of the few malignant conditions never linked to radiation (relative risk [RR], 0.66). For all other forms of leukemia combined (n = 358), there was a slight elevation in risk (RR, 1.17) but no evidence of a dose-response relationship when x-ray procedures near the time of diagnosis were excluded. Similarly, patients with NHL were exposed to diagnostic x-ray procedures more often than controls (RR, 1.32), but the RR fell to 0.99 when the exposure to diagnostic x-ray procedures within 2 years of diagnosis was ignored. For multiple myeloma, overall risk was not significantly high (RR, 1.14), but there was consistent evidence of increasing risk with increasing numbers of diagnostic x-ray procedures. These data suggest that persons with leukemia and NHL undergo x-ray procedures frequently just prior to diagnosis for conditions related to the development or natural history of their disease. There was little evidence that diagnostic x-ray procedures were causally associated with leukemia or NHL. The risk for multiple myeloma, however, was increased among those patients who were frequently exposed to x-rays.	KAISER PERMANENTE MED CARE PROGRAM, PORTLAND, OR USA; KAISER PERMANENTE MED CARE PROGRAM, OAKLAND, CA USA; MD ANDERSON CANC CTR, HOUSTON, TX USA	Kaiser Permanente; Kaiser Permanente; University of Texas System; UTMD Anderson Cancer Center	BOICE, JD (corresponding author), NCI, DIV CANC ETIOL, RADIAT EPIDEMIOL BRANCH, EPIDEMIOL & BIOSTAT PROGRAM, 6130 EXECUT BLVD, BETHESDA, MD 20852 USA.				NCI NIH HHS [N01-CP0-1047, N01-CP1-1009, N01-CP0-1054] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP001047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		ABRAMS HL, 1979, NEW ENGL J MED, V300, P1213, DOI 10.1056/NEJM197905243002110; ANDERSON RE, 1964, ANN INTERN MED, V61, P853, DOI 10.7326/0003-4819-61-5-853; ANTOKU S, 1971, RADIOLOGY, V101, P669, DOI 10.1148/101.3.669; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BOICE JD, 1988, RADIAT RES, V116, P3, DOI 10.2307/3577477; BOICE JD, 1987, J NATL CANCER I, V79, P1295; BOICE JD, 1986, NEW ENGL J MED, V315, P828, DOI 10.1056/NEJM198609253151310; BOICE JD, 1979, AM J PUBLIC HEALTH, V69, P137, DOI 10.2105/AJPH.69.2.137; CHECKOWAY H, 1985, BRIT J IND MED, V42, P525; COHEN M, 1985, CRITERIA METHODS Q S, V18, P134; CUZICK J, 1988, BRIT J CANCER, V57, P516, DOI 10.1038/bjc.1988.118; CUZICK J, 1981, NEW ENGL J MED, V304, P204, DOI 10.1056/NEJM198101223040404; DARBY SC, 1987, BRIT J CANCER, V55, P179, DOI 10.1038/bjc.1987.35; DAVIS FG, 1989, CANCER RES, V49, P6130; EVANS JS, 1986, NEW ENGL J MED, V315, P810, DOI 10.1056/NEJM198609253151306; FRIEDMAN GD, 1982, J CHRON DIS, V35, P233, DOI 10.1016/0021-9681(82)90079-0; FRIEDMAN GD, 1986, INT J EPIDEMIOL, V15, P424, DOI 10.1093/ije/15.3.424; GIBSON R, 1972, JNCI-J NATL CANCER I, V48, P301; GILBERT ES, 1989, HEALTH PHYS, V56, P11, DOI 10.1097/00004032-198901000-00001; GRAHAM S, 1963, ANN NY ACAD SCI, V107, P557, DOI 10.1111/j.1749-6632.1963.tb13300.x; GUNZ FW, 1964, BMJ-BRIT MED J, V1, P389, DOI 10.1136/bmj.1.5380.389; HOFFMAN DA, 1989, J NATL CANCER I, V81, P1307, DOI 10.1093/jnci/81.17.1307; JABLON S, 1980, PREV MED, V9, P219, DOI 10.1016/0091-7435(80)90079-1; JANKOWSKI J, 1984, HEALTH PHYS, V46, P229; JOHNSON DW, 1986, HEALTH PHYS, V50, P107, DOI 10.1097/00004032-198601000-00010; KEREIAKES JG, 1980, HDB RAD DOSES NUCLEA; KOHN HI, 1984, NEW ENGL J MED, V310, P504, DOI 10.1056/NEJM198402233100807; LAND CE, 1980, SCIENCE, V209, P1197, DOI 10.1126/science.7403879; LEWIS EB, 1963, SCIENCE, V142, P1492, DOI 10.1126/science.142.3598.1492; LINOS A, 1980, NEW ENGL J MED, V302, P1101, DOI 10.1056/NEJM198005153022001; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; MATANOSKI GM, 1975, AM J EPIDEMIOL, V101, P199, DOI 10.1093/oxfordjournals.aje.a112087; MILLER RW, 1986, RAD CARCINOGENESIS, P245; PRESTONMARTIN S, 1989, BRIT J CANCER, V59, P639, DOI 10.1038/bjc.1989.130; RALL JE, 1985, NIH852748 US DEP HLT; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SHLEIEN B, 1978, HEALTH PHYS, V34, P587, DOI 10.1097/00004032-197806000-00007; SHRIMPTON PC, 1986, BRIT J RADIOL, V59, P749, DOI 10.1259/0007-1285-59-704-749; SMITH PG, 1981, BRIT J RADIOL, V54, P187, DOI 10.1259/0007-1285-54-639-187; SMITH PG, 1986, BRIT MED J, V293, P845, DOI 10.1136/bmj.293.6551.845; SPENGLER RF, 1983, PEDIATRICS, V71, P235; STEWART A, 1962, BMJ-BRIT MED J, P882, DOI 10.1136/bmj.2.5309.882; STEWART A, 1973, HEALTH PHYS, V24, P223, DOI 10.1097/00004032-197302000-00002; WANG JX, 1988, J NATL CANCER I, V80, P344, DOI 10.1093/jnci/80.5.344; WW. B. Exposure of the U. S, 1989, 100 NAT COUNC RAD PR; 1972, REPORT GENERAL ASS S, V25; 1970, INT COMM RAD PROTECT, V16; 1990, BEIR, V5; 1986, E86IX9 UN SCI COMM E; 1979, CALIFORNIA STANDARD; 1988, E88IX7 UN SCI COMM E; 1983, WHO TRS689 PUBL; 1977, REPORT GENERAL ASS S, V40; 1962, REPORT GENERAL ASS S, V16; 1990, LANCET, V336, P681	55	95	96	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1290	1294		10.1001/jama.265.10.1290	http://dx.doi.org/10.1001/jama.265.10.1290			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	2053936				2022-12-01	WOS:A1991FA51100025
J	COHEN, C; BENJAMIN, M				COHEN, C; BENJAMIN, M			ALCOHOLICS AND LIVER-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Two arguments underlie a widespread unwillingness to consider patients with alcoholic cirrhosis of the liver as candidates for transplantation. First, alcoholics are morally blameworthy, their condition the result of their own misconduct; such blameworthiness disqualifies alcoholics in unavoidable competition for organs with others who are equally sick but blameless. Second, because of their habits, alcoholics will not exhibit satisfactory rates of survival after transplantation; good stewardship of a scarce lifesaving resource therefore requires that alcoholics not be considered for liver transplantation. These arguments are carefully analyzed and shown to be defective. There is not good moral or medical reason for categorically precluding alcoholics as candidates for liver transplantation. It would, in addition, be unjust to implement such a preclusion simply because others might respond negatively if we do not.			COHEN, C (corresponding author), TRANSPLANT & HLTH POLICY CTR,115 WASHTENAW PL,BOX 0716,ANN ARBOR,MI 48109, USA.							BERESFORD TP, 1990, PSYCHOSOMATICS, V31, P241, DOI 10.1016/S0033-3182(90)72160-3; BERGLUND M, 1984, ACTA PSYCHIAT SCAND, V70, P407, DOI 10.1111/j.1600-0447.1984.tb01228.x; Childress JF., 1970, SOUNDINGS, V53, P339; FINGARETTE H, 1988, PUBLIC INTEREST, V91, P3; FINGARETTE H, 1989, PUBLIC INTEREST, V95, P118; Gordon R D, 1987, Clin Transpl, P43; GORDON RD, 1988, ORGAN TRANSPLANTATIO, P511; JELLINEK EM, 1960, DISEASE CONCEPT ALCO; KLERMAN GL, 1989, NEW ENGL J MED, V320, P394, DOI 10.1056/NEJM198902093200611; MADSEN W, 1989, PUBLIC INTEREST, V95, P112; ROSE RM, 1988, ALCOHOLISM ORIGINS O; SCHARSCHMIDT BF, 1984, HEPATOLOGY, V4, P95; SCHENKER S, 1990, HEPATOLOGY, V11, P314, DOI 10.1002/hep.1840110223; STARZL TE, 1988, JAMA-J AM MED ASSOC, V260, P2542, DOI 10.1001/jama.260.17.2542; STARZL TE, 1988, TRANSPLANT P, V20, P131; Vaillant G.E., 1995, WISDOM EGO; 1987, DHHS ADM871519 US DE; 1983, JAMA-J AM MED ASSOC, V250, P2961	18	94	94	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1299	1301		10.1001/jama.265.10.1299	http://dx.doi.org/10.1001/jama.265.10.1299			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FA511	1995978				2022-12-01	WOS:A1991FA51100027
J	FOOTE, A; ERFURT, JC				FOOTE, A; ERFURT, JC			THE BENEFIT TO COST RATIO OF WORK-SITE BLOOD-PRESSURE CONTROL PROGRAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE COSTS; HYPERTENSION; PROMOTION; TRIAL	Reduction in the cost of health care claims among hypertensive employees was examined over a 4-year period after exposure to a 3-year blood pressure control program, to see whether work-site monitoring and counseling produced a subsequent benefit. Hypertensive employees at three experimental sites (N = 183 to 367 subjects) were compared with subjects at a control site (N = 169) who had received no postscreening follow-up or monitoring, and with matched normotensive employees. The cost of subsequent health care claims for hypertensive employees at the experimental sites was lower than claims for those at the control site, but there was no significant difference across the sites in claims for normotensive employees. After adjusting to a standard 1982 dollar, the data showed from $1.89 to $2.72 in reduced health care claims per dollar spent operating the hypertension control program.			FOOTE, A (corresponding author), UNIV MICHIGAN,INST LABOR & IND RELAT,WORKER HLTH PROGRAM,1111 E CATHERINE,ANN ARBOR,MI 48109, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028929] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL28929] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1979, PREV MED, V8, P123; ALDERMAN MH, 1976, B NEW YORK ACAD MED, V52, P697; ALDERMAN MH, 1983, HYPERTENSION S5, V5, P138; BLY JL, 1986, JAMA-J AM MED ASSOC, V256, P3235, DOI 10.1001/jama.256.23.3235; ERFURT JC, 1984, J OCCUP ENVIRON MED, V26, P892, DOI 10.1097/00043764-198412000-00007; ERFURT JC, 1990, J OCCUP ENVIRON MED, V32, P513, DOI 10.1097/00043764-199006000-00007; ERFURT JC, 1982, PB83113399; FIELDING JE, 1982, J OCCUP ENVIRON MED, V24, P907; FOOTE A, 1983, NEW ENGL J MED, V308, P809, DOI 10.1056/NEJM198304073081404; GIBBS JO, 1985, J OCCUP ENVIRON MED, V27, P826, DOI 10.1097/00043764-198511000-00016; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; LOGAN AG, 1979, LANCET, V2, P1175; WARNER KE, 1988, J OCCUP ENVIRON MED, V30, P106; 1970, JAMA-J AM MED ASSOC, V212, P1143; 1990, JAMA-J AM MED ASSOC, V263, P1795; 1982, NEW ENGL J MED, V307, P976; 1980, LANCET, V1, P1261; 1979, JAMA-J AM MED ASSOC, V242, P2562	18	24	24	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1283	1286		10.1001/jama.265.10.1283	http://dx.doi.org/10.1001/jama.265.10.1283			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1899894				2022-12-01	WOS:A1991FA51100023
J	KELLIE, SE; KELLY, JT				KELLIE, SE; KELLY, JT			MEDICARE PEER-REVIEW ORGANIZATION PREPROCEDURE REVIEW CRITERIA - AN ANALYSIS OF CRITERIA FOR 3 PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENDARTERECTOMY; POPULATION	The Medicare Peer Review Organization (PRO) program includes preprocedure review using explicit criteria to assess the appropriateness of specific procedures. This study evaluates the variability in the PRO preprocedure criteria for the three procedures most frequently reviewed by PROs: carotid endarterectomy, cataract removal, and cardiac pacemaker implants. In August 1989, the PRO review criteria were received from the Health Care Financing Administration. To provide a reference point for reviewing the PRO criteria, national practice guidelines for these three procedures were identified. Wide variability was demonstrated in the PRO procedure-specific carotid endarterectomy and cataract removal review criteria among PROs, and the criteria differed significantly from the identified practice guidelines. The criteria for cardiac pacemaker implants were somewhat less variable, and were based, to varying degrees, on practice guidelines developed by the American College of Cardiology (ACC). Greater attention is needed to improve the development of review criteria, including the use of relevant practice guidelines, to ensure that review criteria are optimal.			KELLIE, SE (corresponding author), AMER MED ASSOC,DEPT TECHNOL ASSESSMENT,OFF QUAL ASSURANCE,515 N STATE ST,CHICAGO,IL 60610, USA.							[Anonymous], 1990, CLIN PRACTICE GUIDEL; DONABEDIAN A, 1981, AM J PUBLIC HEALTH, V71, P409, DOI 10.2105/AJPH.71.4.409; FALK RH, 1990, J AM COLL CARDIOL, V15, P1087, DOI 10.1016/0735-1097(90)90245-K; FRYE R L, 1984, Journal of the American College of Cardiology, V4, P434; GREENSPAN AM, 1988, NEW ENGL J MED, V318, P158, DOI 10.1056/NEJM198801213180306; Kelly J T, 1990, QRB Qual Rev Bull, V16, P54; KELLY JT, 1990, ARCH PATHOL LAB MED, V114, P1119; KELLY JT, 1990, DIRECTORY PRACTICE P; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LEVIT KR, 1990, HEALTH AFFAIR, V9, P171, DOI 10.1377/hlthaff.9.2.171; LOHR KN, 1989, MED CARE, V27, pS1, DOI 10.1097/00005650-198903001-00001; Mariano L A, 1989, Health Care Financ Rev, V10, P123; MERRICK NJ, 1986, R32046CWFHFPMTRWJ RA; MITCHELL JB, 1989, HEALTH AFFAIR, V8, P21, DOI 10.1377/hlthaff.8.1.21; PARK RE, 1989, R3280CWFHFPMTRWJ RAN; POKRAS R, 1988, STROKE, V19, P1289, DOI 10.1161/01.STR.19.10.1289; SCHAFFARZICK RW, 1988, QUALITY CARE TECHNOL; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; 1988, CATARACT SURGERY; 1989, MEDICARE IMPROVEMENT; 1989, MED REV SYSTEM; 1988, PB88954099; 1989, EFFECTIVENESS RES PR; 1990, MEDICARE STRATEGY QU; 1984, HCFA PRO MANUAL, V2, P37; 1989, CONTROLLING COSTS CH; 1989, CATARACT OTHERWISE H; 1989, ANN INTERN MED, V111, P675; 1989, MEDICARE COVERAGE IS; 1987, STUDY PREADMISSION R, P1; 1974, JAMA-J AM MED ASSOC, V229, P166; 1987, MINIMUM CRITERIA CAT	32	28	28	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1265	1270		10.1001/jama.265.10.1265	http://dx.doi.org/10.1001/jama.265.10.1265			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995973				2022-12-01	WOS:A1991FA51100020
J	MOSS, AH; SIEGLER, M				MOSS, AH; SIEGLER, M			SHOULD ALCOHOLICS COMPETE EQUALLY FOR LIVER-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE TECHNOLOGY; ORGAN-TRANSPLANTATION; RESOURCE-ALLOCATION; RATIONING DECISIONS; MEDICAL-CARE; INEVITABILITY; CIRRHOSIS; NO	The circumstances of liver transplantation are unique among organ transplantation because of the dire, absolute scarcity of donor livers and the predominance of one disease-alcohol-related end-stage liver disease-as the principal cause of liver failure. We propose that patients who develop end-stage liver disease through no fault of their own should have higher priority for receiving a liver transplant than those whose end-stage liver disease results from failure to obtain treatment for alcoholism. We base our proposal on considerations of fairness and on whether public support for liver transplantation can be maintained if, as a result of a first-come, first-served approach, patients with alcohol-related end-stage liver disease receive more than half the available donor livers. We conclude that since not all can live, priorities must be established for the use of scarce health care resources.	UNIV CHICAGO, PRITZKER SCH MED, CTR CLIN MED ETH, CHICAGO, IL 60637 USA	University of Chicago	MOSS, AH (corresponding author), W VIRGINIA UNIV, HLTH SCI CTR N, CTR HLTH ETH & LAW, MORGANTOWN, WV 26506 USA.		Embrett, Mark G./H-4466-2014	Embrett, Mark G./0000-0002-3969-0219				ANNAS GJ, 1985, AM J PUBLIC HEALTH, V75, P187, DOI 10.2105/AJPH.75.2.187; ARONSON MD, 1987, ALCOHOLISM GUIDE PRI, P9; ATTERBURY CE, 1986, J CLIN GASTROENTEROL, V8, P1, DOI 10.1097/00004836-198602000-00001; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P256; BERESFORD TP, 1990, PSYCHOSOMATICS, V31, P241, DOI 10.1016/S0033-3182(90)72160-3; BIGBY JA, 1987, ALCOHOLISM GUIDE PRI, P66; BLANK RH, 1988, RATIONING MED, P1; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; CALLAHAN D, 1988, HASTINGS CENT REP, V18, P14, DOI 10.2307/3562403; CAPER P, 1988, NEW ENGL J MED, V318, P1535, DOI 10.1056/NEJM198806093182310; DANIELS N, 1986, NEW ENGL J MED, V314, P1380, DOI 10.1056/NEJM198605223142109; ENGELHARDT HT, 1984, NEW ENGL J MED, V311, P66, DOI 10.1056/NEJM198407053110135; EVANS R W, 1983, Journal of the American Medical Association, V249, P2047, DOI 10.1001/jama.249.15.2047; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; FISHMAN R, 1986, ALCOHOL ALCOHOLISM, P27; FLAVIN DK, 1988, JAMA-J AM MED ASSOC, V259, P1546, DOI 10.1001/jama.259.10.1546; FOX RC, 1978, COURAGE FAIL, P226; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; GALANTER M, 1990, AM J PSYCHIAT, V147, P64; GRANT BF, 1988, SEMIN LIVER DIS, V8, P12, DOI 10.1055/s-2008-1040525; JOHNSON B, 1989, J GEN INTERN MED, V4, P445, DOI 10.1007/BF02599698; KLERMAN GL, 1989, NEW ENGL J MED, V320, P394, DOI 10.1056/NEJM198902093200611; KNOWLES JH, 1977, SCIENCE, V198, P1103, DOI 10.1126/science.198.4322.1103; KUMAR S, 1990, HEPATOLOGY, V11, P159, DOI 10.1002/hep.1840110202; MENDELSON JH, 1985, DIAGNOSIS TREATMENT, P1; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; OLBRISCH ME, 1989, JAMA-J AM MED ASSOC, V261, P2958, DOI 10.1001/jama.1989.03420200048032; Outka Gene, 1974, J Relig Ethics, V2, P11; RAMSEY P, 1970, PATIENT PERSON, P242; SAXE L, 1983, EFFECTIVENESS COSTS, P3; SCHARSCHMIDT BF, 1984, HEPATOLOGY, V4, pS95, DOI 10.1002/hep.1840040723; SCHROEDER JS, 1987, JAMA-J AM MED ASSOC, V258, P3142, DOI 10.1001/jama.258.21.3142; STARZL TE, 1988, JAMA-J AM MED ASSOC, V260, P2542, DOI 10.1001/jama.260.17.2542; SURMAN OS, 1989, AM J PSYCHIAT, V146, P972; THORESON RW, 1987, TREATMENT PREVENTION, P157; THUROW LC, 1984, NEW ENGL J MED, V311, P1569, DOI 10.1056/NEJM198412133112410; WELCH HG, 1988, NEW ENGL J MED, V319, P171, DOI 10.1056/NEJM198807213190310; WINSLOW GR, 1982, TRIAGE JUSTICE, P39; 1990, ASSESSMENT LIVER TRA, V3, P25; 1987, MAKING DIFFICULT HLT, P73; 1990, 901656 US DEP HLTH H; 1986, ORGAN TRANSPLANTATIO, P9; 1990, FED REGISTER, V55, P3545	43	157	158	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1295	1298		10.1001/jama.265.10.1295	http://dx.doi.org/10.1001/jama.265.10.1295			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995977				2022-12-01	WOS:A1991FA51100026
J	SHULKIN, DJ				SHULKIN, DJ			PREVENTION AND MANAGEMENT OF HIV-CONTAMINATED NEEDLESTICKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SHULKIN, DJ (corresponding author), UNIV PENN,SCH MED,ROBERT WOOD JOHNSON FDN,PHILADELPHIA,PA 19104, USA.							HAMMOND JS, 1990, J TRAUMA, V30, P555, DOI 10.1097/00005373-199005000-00005; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; SACKS HS, 1990, J GEN INTERN MED, V5, P132, DOI 10.1007/BF02600514; 1990, MMWR, V39, P19; 1990, MMWR, V39, P1	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1262	1262		10.1001/jama.265.10.1262	http://dx.doi.org/10.1001/jama.265.10.1262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995972				2022-12-01	WOS:A1991FA51100019
J	SLOANE, PD; MATHEW, LJ; SCARBOROUGH, M; DESAI, JR; KOCH, GG; TANGEN, C				SLOANE, PD; MATHEW, LJ; SCARBOROUGH, M; DESAI, JR; KOCH, GG; TANGEN, C			PHYSICAL AND PHARMACOLOGICAL RESTRAINT OF NURSING-HOME PATIENTS WITH DEMENTIA - IMPACT OF SPECIALIZED UNITS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERMEDIATE-CARE FACILITY; ALZHEIMERS-DISEASE; MECHANICAL RESTRAINTS; DRUG-USE; RESIDENTS; AGITATION	This case-control study of 31 specialized dementia units and 32 traditional units in five states investigated use of physical and pharmacologic restraints among 625 patients with the diagnosis of dementia. Physical restraints were observed in use on 18.1% of dementia unit patients and on 51.6% of comparison unit patients who were out of bed during the day (adjusted odds ratio, 0.283; 95% confidence interval, 0.129 to 0.619). Pharmacologic restraints were routinely given to 45.3% of dementia unit patients and 43.4% of comparison unit patients (adjusted odds ratio, 0.950; 95% confidence interval, 0.611 to 1.477). We used multivariate logistic regression to identify residence in a nonspecialized nursing home unit, nonambulatory status, transfer dependency, mental status impairment, hip fracture history, and a high nursing staff-to-patient ratio, which we found to be independent predictors of physical restraint use. Physically abusive behavior, severe mental status impairment, and frequent family visitation were found to be significant predictors of pharmacologic restraint use, while advanced patient age, large nursing home size, and patient nonambulatory status were protective against such use. These results support the conclusion that physical and pharmacologic restraints constitute separate treatment modalities with different risk factors for use, and indicate that specialized dementia units are successful in reducing the use of physical but not pharmacologic restraints.	UNIV N CAROLINA, SCH PUBL HLTH, DEPT EPIDEMIOL, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, SCH PUBL HLTH, DEPT BIOSTAT, CHAPEL HILL, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	SLOANE, PD (corresponding author), UNIV N CAROLINA, SCH MED, DEPT FAMILY MED, CAMPUS BOX 7595, CHAPEL HILL, NC 27599 USA.				NATIONAL INSTITUTE ON AGING [K08AG000341] Funding Source: NIH RePORTER; NIA NIH HHS [1K08AG00341-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackermann J O, 1985, J Long Term Care Adm, V13, P90; APPELBAUM PS, 1984, AM J PSYCHIAT, V141, P202; BASEN MM, 1977, PUBLIC HEALTH REP, V92, P43; BEARDSLEY RS, 1989, J AM GERIATR SOC, V37, P327, DOI 10.1111/j.1532-5415.1989.tb05499.x; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BUCK JA, 1988, J AM GERIATR SOC, V36, P409, DOI 10.1111/j.1532-5415.1988.tb02379.x; Calkins M P, 1989, Provider, V15, P7; COHENMANSFIELD J, 1986, J AM GERIATR SOC, V34, P722, DOI 10.1111/j.1532-5415.1986.tb04303.x; COVERT AB, 1977, J AM GERIATR SOC, V25, P85, DOI 10.1111/j.1532-5415.1977.tb00236.x; DOANE KW, 1989, CONSULTANT PHARM, V4, P367; EVANS LK, 1989, J AM GERIATR SOC, V37, P65, DOI 10.1111/j.1532-5415.1989.tb01571.x; FOLMAR S, 1989, GERONTOLOGIST, V29, P650, DOI 10.1093/geront/29.5.650; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; Goldman L S, 1988, Clin Geriatr Med, V4, P589; Gwyther L P, 1986, Provider, V12, P20; HELMES E, 1987, J GERONTOL, V42, P395, DOI 10.1093/geronj/42.4.395; KASHGARIAN M, 1980, AM J PUBLIC HEALTH, V70, P1217, DOI 10.2105/AJPH.70.11.1217-b; Kolcaba K, 1989, J Gerontol Nurs, V15, P29; LOFGREN RP, 1989, AM J PUBLIC HEALTH, V79, P735, DOI 10.2105/AJPH.79.6.735; MAAS M, 1988, NURS CLIN N AM, V23, P57; *MACE NL, 1990, DEMENTIA CARE PATIEN; MION LC, 1989, J AM GERIATR SOC, V37, P949, DOI 10.1111/j.1532-5415.1989.tb07280.x; OHTA RJ, 1988, GERONTOLOGIST, V28, P803, DOI 10.1093/geront/28.6.803; PRUCHNO RA, 1988, J GERONTOL, V43, pP164, DOI 10.1093/geronj/43.6.P164; RABINS PV, 1986, HOSP COMMUNITY PSYCH, V37, P120; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; ROBBINS LJ, 1987, J AM GERIATR SOC, V35, P290, DOI 10.1111/j.1532-5415.1987.tb04633.x; Rubenstein H S, 1983, Law Med Health Care, V11, P271; SHAH BV, 1984, SURVEY DATA ANAL SOF; SOBEL KG, 1983, DRUG INTEL CLIN PHAR, V17, P539; TERI L, 1989, J AM GERIATR SOC, V37, P109; Wagner L, 1987, Mod Healthc, V17, P40; Weiner A S, 1989, J Long Term Care Adm, V17, P14; WERNER P, 1989, J AM GERIATR SOC, V37, P1122, DOI 10.1111/j.1532-5415.1989.tb06675.x; WILLIAMS CC, 1989, GERONTOLOGIST, V29, P585, DOI 10.1093/geront/29.5.585; ZIMMER JG, 1984, AM J PUBLIC HEALTH, V74, P1118, DOI 10.2105/AJPH.74.10.1118; 1986, SUGI SUPPLEMENTAL LI; 1990, RESTRAINTS PACKET B; 1987, TABA323 C OFF TECHN; 1984, USE RESTRAINTS FEDER	40	82	82	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1278	1282		10.1001/jama.265.10.1278	http://dx.doi.org/10.1001/jama.265.10.1278			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995975				2022-12-01	WOS:A1991FA51100022
J	BALARAJAN, R				BALARAJAN, R			ETHNIC-DIFFERENCES IN MORTALITY FROM ISCHEMIC-HEART-DISEASE AND CEREBROVASCULAR-DISEASE IN ENGLAND AND WALES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HIGH-DENSITY-LIPOPROTEIN; ASIAN POPULATION GROUPS; CORONARY RISK-FACTORS; BLOOD-PRESSURE; INDIAN DESCENT; EAST LONDON; BIRMINGHAM; PREVALENCE; WHITE; MEN	Objective - To examine mortality from ischaemic heart disease and cerebrovascular disease in England and Wales by country of birth of the deceased. Design - Standardised mortality ratios were computed by country of birth groups for ischaemic heart disease and cerebrovascular disease for 1979-83 and 1970-2 by using the five year age-sex specific rates for England and Wales for 1979-83 as standard. Setting - England and Wales 1970-2 and 1979-83. Results - In 1979-83 mortality from ischaemic heart disease was highest in men and women born in the Indian subcontinent (standardised mortality ratio 136 and 146 respectively). Young Indian men suffered the greatest excess (313 at ages 20-29). Other groups with raised mortality included Irish, Scottish, and Polish born immigrants. Those born in the Caribbean, the old Commonwealth, west Europe, and the United States had low death rates. In England and Wales mortality from ischaemic heart disease declined by 5% in men and 1% in women between 1970-2 and 1979-83, with greatest percentage declines in immigrants born in the United States, South Africa, the old Commonwealth, the Caribbean, and France. Immigrant groups with raised mortality in the earlier period showed little improvement, and mortality from ischaemic heart disease increased among Indians (6% in men and 13% in women). In 1979-83 mortality from cerebrovascular disease was highest in Caribbeans (standardised mortality ratios 176 in men and 210 in women), followed by Africans, Indians, and Irish. Rates were low in west Europeans. Mortality from stroke declined by 28% overall in this period, a rate of decline shared by most groups. Men from the Indian subcontinent showed a decline of only 3%. Conclusion - In the 1980s mortality from ischaemic heart disease and cerebrovascular disease differed significantly between ethnic groups in England and Wales. In general, ethnic groups that experienced lower mortality from ischaemic heart disease in the 1970s showed the greatest improvement over the following decade.			BALARAJAN, R (corresponding author), UNIV SURREY, EPIDEMIOL & PUBL HLTH RES UNIT, GUILDFORD GU2 5XH, SURREY, ENGLAND.							BALARAJAN R, 1986, COMMUNITY MED, V8, P237; BALARAJAN R, 1990, DS9 OFF POP CENS SUR; BALARAJAN R, 1984, BRIT MED J, V289, P185; BECKLES GLA, 1986, LANCET, V1, P1298; CRUICKSHANK JK, 1980, BRIT MED J, V281, P1108, DOI 10.1136/bmj.281.6248.1108; CRUICKSHANK JK, 1983, POSTGRAD MED J, V59, P622, DOI 10.1136/pgmj.59.696.622; DEGIOVANNI JV, 1983, POSTGRAD MED J, V59, P627, DOI 10.1136/pgmj.59.696.627; DERRY CW, 1987, S AFR MED J, V72, P698; DISLER PB, 1987, S AFR MED J, V72, P408; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GRELL GAC, 1983, POSTGRAD MED J, V59, P616, DOI 10.1136/pgmj.59.696.616; KEIL JE, 1980, J EPIDEMIOL COMMUN H, V34, P45, DOI 10.1136/jech.34.1.45; Malhotra S L, 1971, J Assoc Physicians India, V19, P211; MARMOR MG, 1984, 47 OFF POP CENS SURV; MARMOT MG, 1984, SCI F CARDIOLOGY; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1985, LANCET, V2, P1086; MILLER GJ, 1982, LANCET, V2, P200; MILLER GJ, 1975, LANCET, V1, P16; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; OMAR MAK, 1985, S AFR MED J, V67, P924; POCOCK SJ, 1986, BMJ-BRIT MED J, V292, P515, DOI 10.1136/bmj.292.6519.515; POONKING T, 1968, LANCET, V1, P155; Seedat Y K, 1983, J Hypertens, V1, P7; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SILMAN A, 1985, J EPIDEMIOL COMMUN H, V39, P301, DOI 10.1136/jech.39.4.301; STOUT RW, 1987, LANCET, V1, P1077; STOUT RW, 1969, LANCET, V1, P1078; ZIMMET P, 1983, AM J EPIDEMIOL, V118, P673, DOI 10.1093/oxfordjournals.aje.a113678; 1986, LANCET, V1, P1307; 1988, CORONARY HEART DISEA, V1; 1989, NATIONAL HLTH SERVIC	34	328	328	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	1991	302	6776					560	564		10.1136/bmj.302.6776.560	http://dx.doi.org/10.1136/bmj.302.6776.560			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021718	Bronze, Green Published			2022-12-01	WOS:A1991FB93600017
J	BIGRIGG, MA; READ, MD				BIGRIGG, MA; READ, MD			MANAGEMENT OF WOMEN REFERRED TO EARLY-PREGNANCY ASSESSMENT UNIT - CARE AND COST-EFFECTIVENESS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the efficiency of an early pregnancy assessment unit in the care of women with bleeding or pain in early pregnancy. Design - Analysis of women attending in the first year of the unit's operation and in the six months immediately before its introduction. Setting - Early pregnancy assessment unit in a district general hospital serving a population of 310 000. Patients - 1141 women referred with bleeding or pain in early pregnancy. Main outcome measures - Length of stay in hospital required for diagnosis and treatment. Results - Before the unit was established the mean admission time was one and a half (range half to three) days for women who required no treatment and three (one and a half to five) days in women requiring evacuation of uterus. These times were reduced to two hours as an outpatient and one day respectively for most women after the unit was established . Between 318 and 505 women were estimated to have been saved from unnecessary admission and 233 had their stay reduced; the associated saving was between 95 000 pounds and 120 000 pounds in one year. Conclusions - The early pregnancy assessment unit improved the quality of care and also produced considerable savings in financial and staff resources.	GLOUCESTER ROYAL HOSP,OBSTET & GYNAECOL,GLOUCESTER GL1 3NN,ENGLAND									BUCK N, 1989, REPORT CONFIDENTIAL; 1982, MATERNITY CARE ACT 1; 1982, REPORT ROYAL COLLEGE; 1990, QUALITY MED CARE	4	86	87	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					577	579		10.1136/bmj.302.6776.577	http://dx.doi.org/10.1136/bmj.302.6776.577			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB936	1902383	Green Published, Bronze			2022-12-01	WOS:A1991FB93600025
J	CHADWICK, DJ; GILLATT, DA; GINGELL, JC				CHADWICK, DJ; GILLATT, DA; GINGELL, JC			MEDICAL OR SURGICAL ORCHIECTOMY - THE PATIENTS CHOICE	BRITISH MEDICAL JOURNAL			English	Article							PROSTATIC-CARCINOMA; ORCHIECTOMY				CHADWICK, DJ (corresponding author), SOUTHMEAD GEN HOSP,DEPT UROL,BRISTOL BS10 5NB,AVON,ENGLAND.							CASSILETH BR, 1989, UROLOGY, V33, P57, DOI 10.1016/0090-4295(89)90108-8; LUNGLMAYR G, 1987, INT C S SERIES, V125, P47; MCCLINTON S, 1989, BRIT J UROL, V63, P309, DOI 10.1111/j.1464-410X.1989.tb05195.x; PEELING WB, 1989, UROLOGY, V33, P45, DOI 10.1016/0090-4295(89)90106-4; 1990, MIMS             DEC, P248	5	33	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					572	572		10.1136/bmj.302.6776.572	http://dx.doi.org/10.1136/bmj.302.6776.572			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	1827036	Green Published, Bronze			2022-12-01	WOS:A1991FB93600023
J	DAVIES, MJ; WILSON, RG; KESTON, M; NIXON, SJ				DAVIES, MJ; WILSON, RG; KESTON, M; NIXON, SJ			AN IMPLANTABLE DEVICE FOR LONG-TERM VENOUS ACCESS IN CHRONIC LUNG CONDITIONS	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,SURG UNIT,D BLOCK,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh								BALL ABS, 1989, RESP MED, V83, P429, DOI 10.1016/S0954-6111(89)80076-9; CASSEY J, 1988, CLIN PEDIATR, V27, P91, DOI 10.1177/000992288802700206; GEBARSKI SS, 1984, CANCER, V54, P38, DOI 10.1002/1097-0142(19840701)54:1<38::AID-CNCR2820540110>3.0.CO;2-9; THOMPSON AM, 1989, INTENSIVE THERAP MAY, P142	4	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					570	571		10.1136/bmj.302.6776.570	http://dx.doi.org/10.1136/bmj.302.6776.570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021722	Green Published, Bronze			2022-12-01	WOS:A1991FB93600021
J	KINSELLA, J; CARTER, R; REID, WH; CAMPBELL, D; CLARK, CJ				KINSELLA, J; CARTER, R; REID, WH; CAMPBELL, D; CLARK, CJ			INCREASED AIRWAYS REACTIVITY AFTER SMOKE-INHALATION	LANCET			English	Article							BRONCHIAL HYPERREACTIVITY; ASTHMA; INJURY; SENSITIVITY; EXPOSURE; BURNS	13 fire victims who required treatment after smoke inhalation underwent lung function assessment within 3 days of injury and 3 months later. Initial airways hyperreactivity improved over this period, but FEV1 and airways specific conductance did not change significantly. There was a strong correlation between exposure carboxyhaemoglobin concentration (an indicator of smoke exposure) and initial airways specific conductance (r + 0.79; p = 0.006). Airways obstruction after smoke inhalation in house fires may be more common and more persistent than is generally recognised. Early lung function tests would allow the incidence of pulmonary complications after smoke inhalation and the potential benefits of early use of inhaled anti-inflammatory drugs to be assessed.	HAIRMYRES HOSP,DEPT RESP MED,GLASGOW G7S 8RG,SCOTLAND; UNIV GLASGOW,DEPT ANAESTHESIA,GLASGOW G12 8QQ,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT RESP MED,GLASGOW G4 0SF,SCOTLAND; GLASGOW ROYAL INFIRM,REG BURNS UNIT,GLASGOW G4 0SF,SCOTLAND	University Hospital Hairmyres; University of Glasgow; University of Glasgow; University of Glasgow			Kinsella, John/B-8252-2011					BARNES PJ, 1989, BRIT MED J, V299, P695, DOI 10.1136/bmj.299.6701.695; BOSCHETTO P, 1989, European Respiratory Journal, V2, p456S; BOULET LP, 1988, CHEST, V94, P476, DOI 10.1378/chest.94.3.476; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; CLARK CJ, 1981, LANCET, V1, P1332; CLARK CJ, 1986, BRIT MED J, V292, P1303, DOI 10.1136/bmj.292.6531.1303; CLARK CJ, 1988, LANCET, V2, P872, DOI 10.1016/S0140-6736(88)92471-3; CLARK CJ, 1988, THORAX, V43, P828; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DJUKANOVIC R, 1989, HOSP UPDATE, V16, P266; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; ISLAM MS, 1972, INT ARCH ARBEITSMED, V29, P221, DOI 10.1007/BF00539250; OLIVIERI D, 1989, European Respiratory Journal, V2, p540S; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; STENTON SC, 1988, BRIT J DIS CHEST, V82, P436, DOI 10.1016/0007-0971(88)90102-7; Sumi K., 1973, J FIRE FLAMMABILITY, V4, P15; TRUNKEY D, 1978, SURG CLIN N AM, V135, P250; VINCENT NJ, 1970, J APPL PHYSIOL, V29, P336; VIVORI E, 1977, BRIT MED J, V2, P1462, DOI 10.1136/bmj.2.6100.1462; 1970, BR PLASTICS, V44, P59; 1987, AM REV RESPIR DIS, V136, P225; 1986, UK FIRE STATISTICS 1	24	34	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					595	597		10.1016/0140-6736(91)91650-J	http://dx.doi.org/10.1016/0140-6736(91)91650-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671952				2022-12-01	WOS:A1991FA70200013
J	LILJA, GMC				LILJA, GMC			SINGLE UMBILICAL ARTERY AND MATERNAL SMOKING	BRITISH MEDICAL JOURNAL			English	Article											LILJA, GMC (corresponding author), UNIV LUND,DEPT EMBRYOL,S-22362 LUND,SWEDEN.							ASMUSSEN I, 1975, CIRC RES, V36, P579, DOI 10.1161/01.RES.36.5.579; BRYAN EM, 1974, ARCH DIS CHILD, V49, P844, DOI 10.1136/adc.49.11.844; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; LILJA M, 1991, PAEDIATRIC PERINATAL, V1, P27; MANTEL N, 1959, J NATL CANCER I, V22, P719	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					569	570		10.1136/bmj.302.6776.569	http://dx.doi.org/10.1136/bmj.302.6776.569			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB936	2021721	Bronze, Green Published			2022-12-01	WOS:A1991FB93600020
J	MASUDA, T; SHIMURA, S; SASAKI, H; TAKISHIMA, T				MASUDA, T; SHIMURA, S; SASAKI, H; TAKISHIMA, T			SURFACTANT APOPROTEIN-A CONCENTRATION IN SPUTUM FOR DIAGNOSIS OF PULMONARY ALVEOLAR PROTEINOSIS	LANCET			English	Article							HUMAN AMNIOTIC-FLUID; MONOCLONAL-ANTIBODIES; IMMUNOASSAY; LAVAGE; MANAGEMENT	Pulmonary alveolar proteinosis (PAP), a disease characterised by accumulation of surfactant in alveoli, is diagnosed on the basis of invasive biopsy procedures. We have measured apoprotein A (SP-A) concentrations in sputum to see if this is useful for the diagnosis of PAP. Sputum samples from three patients with PAP and twenty patients with other pulmonary disease were assayed using monoclonal antibodies to SP-A. SP-A concentrations were 400 times higher in patients with PAP than in the controls, suggestions that this measurement is useful for the diagnosis of PAP, especially where lung biopsy is contraindicated.	TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,SENDAI,MIYAGI 980,JAPAN	Tohoku University								AKINO T, 1989, CLIN CHEM, V34, P1513; CLAYPOOL WD, 1984, CHEST, V85, P605; CORRIN B, 1970, THORAX, V25, P230, DOI 10.1136/thx.25.2.230; COSTELLO JF, 1975, THORAX, V30, P121, DOI 10.1136/thx.30.2.121; GONZALEZROTHI RJ, 1986, CHEST, V90, P656, DOI 10.1378/chest.90.5.656; HONDA Y, 1989, CLIN CHIM ACTA, V181, P11, DOI 10.1016/0009-8981(89)90312-4; KING RJ, 1972, AM J PHYSIOL, V223, P715, DOI 10.1152/ajplegacy.1972.223.3.715; KUROKI Y, 1985, BIOCHIM BIOPHYS ACTA, V836, P201; KUROKI Y, 1985, PEDIATR RES, V19, P1017, DOI 10.1203/00006450-198510000-00013; LARSON RK, 1965, ANN INTERN MED, V62, P292, DOI 10.7326/0003-4819-62-2-292; MARTIN RJ, 1980, AM REV RESPIR DIS, V121, P819; ROGERS RM, 1978, AM REV RESPIR DIS, V118, P255; SATO S, 1978, TOHOKU J EXP MED, V126, P257; SHIMIZU H, 1989, TOHOKU J EXP MED, V157, P269, DOI 10.1620/tjem.157.269; SINGH G, 1983, CHEST, V83, P82, DOI 10.1378/chest.83.1.82; SMITH LJ, 1980, CHEST, V78, P765, DOI 10.1378/chest.78.5.765; SNYDER JM, 1988, PEDIATR RES, V24, P728, DOI 10.1203/00006450-198812000-00016; VIDONE RA, 1966, DIS CHEST, V49, P326, DOI 10.1378/chest.49.3.326	18	33	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					580	582		10.1016/0140-6736(91)91640-G	http://dx.doi.org/10.1016/0140-6736(91)91640-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671943				2022-12-01	WOS:A1991FA70200004
J	NEWTON, CRJC; KIRKHAM, FJ; WINSTANLEY, PA; PASVOL, G; PESHU, N; WARRELL, DA; MARSH, K				NEWTON, CRJC; KIRKHAM, FJ; WINSTANLEY, PA; PASVOL, G; PESHU, N; WARRELL, DA; MARSH, K			INTRACRANIAL-PRESSURE IN AFRICAN CHILDREN WITH CEREBRAL MALARIA	LANCET			English	Article							EDEMA	Opening lumbar cerebrospinal fluid (CSF) pressure was measured with a paediatric spinal fluid manometer in 26 of 61 Kenyan children (mean age 39 months) with cerebral malaria. In all cases pressure was above normal (mean [SD] 22.6 [7.4] cm CSF, range 10.5-36). Clinical features of our patients suggest that intracranial hypertension is important in the pathogenesis of cerebral malaria in children, especially as a cause of death. We suggest that raised intracranial pressure is secondary to increased cerebral blood volume. Lowering intracranial pressure may significantly reduce the mortality and morbidity of cerebral malaria. The potential risks and benefits of lumbar puncture should be considered carefully in patients with suspected cerebral malaria.	INST CHILD HLTH, DEPT NEUROL, 30 GUILFORD ST, LONDON WC1N 2AP, ENGLAND; KENYA GOVT MED RES CTR, KILIFI COASTAL UNIT, KILIFI, KENYA; JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD OX3 9DU, ENGLAND	University of London; University College London; Kenya Medical Research Institute; University of Oxford			Newton, Charles RJC/B-7578-2014; Kirkham, Fenella/C-2442-2009; Pasvol, Geoffrey/B-7113-2009; Newton, Charles/C-6222-2009	Newton, Charles RJC/0000-0002-6999-5507; Kirkham, Fenella/0000-0002-2443-7958; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Commey J. O. O., 1980, Ghana Medical Journal, V19, P68; GOITEIN KJ, 1983, ARCH DIS CHILD, V58, P184, DOI 10.1136/adc.58.3.184; HASSLER W, 1988, J NEUROSURG, V68, P745; JENSEN MD, 1983, J PARASITOL, V69, P1060, DOI 10.2307/3280864; KINGSTON ME, 1971, J TROP MED HYG, V74, P249; KIRKHAM FJ, 1987, J NEUROL NEUROSUR PS, V50, P1504, DOI 10.1136/jnnp.50.11.1504; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LOOAREESUWAN S, 1983, LANCET, V1, P434; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; Miller J D, 1972, Prog Brain Res, V35, P411; MINNS RA, 1989, ARCH DIS CHILD, V64, P814, DOI 10.1136/adc.64.6.814; MOLYNEUX ME, 1989, Q J MED, V71, P441; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SCHMUTZHARD E, 1984, T ROY SOC TROP MED H, V78, P351, DOI 10.1016/0035-9203(84)90118-4; TASKER RC, 1988, ARCH DIS CHILD, V63, P888, DOI 10.1136/adc.63.8.888; THAPA B R, 1988, Indian Pediatrics, V25, P61; THOMAS JD, 1971, TROP GEOGR MED, V23, P232; WARRELL DA, 1988, LANCET, V2, P534; WARRELL DA, 1986, AM J TROP MED HYG, V35, P882, DOI 10.4269/ajtmh.1986.35.882; [No title captured]	23	169	171	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 9	1991	337	8741					573	576		10.1016/0140-6736(91)91638-B	http://dx.doi.org/10.1016/0140-6736(91)91638-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671941				2022-12-01	WOS:A1991FA70200002
J	ROSE, GE; PEARSON, RV				ROSE, GE; PEARSON, RV			UNEQUAL PUPIL SIZE IN PATIENTS WITH UNILATERAL RED EYE	BRITISH MEDICAL JOURNAL			English	Article											ROSE, GE (corresponding author), MOORFIELDS EYE HOSP,LONDON EC1V 2PD,ENGLAND.							ALEXANDRIDIS E, 1985, PUPIL; ARMITAGE P, 1985, STATISTICAL METHODS, P111; ELKINGTON AR, 1988, BRIT MED J, V296, P1720, DOI 10.1136/bmj.296.6638.1720; Loewenfeld IE., 1979, TOPICS NEUROOPHTHALM, P124; MEYER BC, 1947, ARCH NEURO PSYCHIATR, V57, P464, DOI 10.1001/archneurpsyc.1947.02300270082005	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					571	572		10.1136/bmj.302.6776.571	http://dx.doi.org/10.1136/bmj.302.6776.571			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021723	Bronze, Green Published			2022-12-01	WOS:A1991FB93600022
J	ROTHWELL, PM; UDWADIA, ZF; LAWLER, PG				ROTHWELL, PM; UDWADIA, ZF; LAWLER, PG			CORTISOL RESPONSE TO CORTICOTROPIN AND SURVIVAL IN SEPTIC SHOCK	LANCET			English	Note								Corticotropin stimulation tests were used to assess adrenocortical function in 32 patients with septic shock. 13 patients had a poor cortisol response (rise < 250 nmol/l) to corticotropin, all of whom died. However, there were only 6 deaths among the 19 patients with adequate responses (p < 0.001). These results suggest that some patients with septic shock may have relative adrenocortical insufficiency.	S CLEVELAND HOSP,INTENS THERAPY UNIT,MIDDLESBROUGH,ENGLAND				Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				FINLAY WEI, 1982, LANCET, V1, P1414; HERMAN AH, 1971, SURG GYNECOL OBSTETR, V132, P795; HINSHAW LB, 1985, CIRC SHOCK, V16, P265; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; NICHOLSON DP, 1989, CRIT CARE CLIN, V5, P151; SCHEIN RMH, 1990, CRIT CARE MED, V18, P259, DOI 10.1097/00003246-199003000-00002; SIBBALD WJ, 1977, ANN SURG, V186, P29, DOI 10.1097/00000658-197707000-00005	7	314	329	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					582	583		10.1016/0140-6736(91)91641-7	http://dx.doi.org/10.1016/0140-6736(91)91641-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671944				2022-12-01	WOS:A1991FA70200005
J	SAUNDERS, N; PATERSON, C				SAUNDERS, N; PATERSON, C			CAN WE ABANDON NAEGELE RULE	LANCET			English	Editorial Material								A pregnant woman may become anxious if she has not delivered by the date given to her by her physician. Much anxiety would be alleviated if a range of dates (38-42 weeks) was substituted for a specific date of delivery. 1			SAUNDERS, N (corresponding author), ST MARYS HOSP,SCH MED,DEPT OBSTET & GYNAECOL,NORFOLK PL,LONDON W2 1PG,ENGLAND.							DENMAN T, 1782, INTRO PRACTICE MIDWI; HENDERSON M, 1967, ARCH ENVIRON HEALTH, V14, P905; MONTGOMERY WF, 1837, EXPOSITION SIGNS SYM; NESBITT R E Jr, 1955, Obstet Gynecol Surv, V10, P311, DOI 10.1097/00006254-195506000-00001; PARK GL, 1968, LANCET, V2, P1388; SPEERT H, 1958, ESSAYS EPONYMY; STEWART HL, 1952, JAMA-J AM MED ASSOC, V148, P1079	7	20	20	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					600	601		10.1016/0140-6736(91)91653-C	http://dx.doi.org/10.1016/0140-6736(91)91653-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671954				2022-12-01	WOS:A1991FA70200015
J	SMIRNE, S; IANNACCONE, S; FERINISTRAMBI, L; COMOLA, M; COLOMBO, E; NEMNI, R				SMIRNE, S; IANNACCONE, S; FERINISTRAMBI, L; COMOLA, M; COLOMBO, E; NEMNI, R			MUSCLE-FIBER TYPE AND HABITUAL SNORING	LANCET			English	Article							OBSTRUCTIVE SLEEP-APNEA; SKELETAL-MUSCLES; STIMULATION; AIRWAY	Although anatomical abnormalities of the upper airway have been recorded in some patients with obstructive sleep apnoea (OSA), a muscle tone dysregulation also seems to have an important role in this disorder. Since habitual snoring is the initial stage of OSA, the structural characteristics of upper airway muscles (medium pharyngeal constrictor muscle [MPCM]) from 13 men (9 non-snorers and 4 habitual snorers) were studied. MPCM fibre structure in non-snorers was broadly similar to that in normal limb muscles, with the exception that fibre diameters were smaller for all fibre types. Compared with limb muscles, MPCM had a smaller proportion of type IIb fibres and a higher proportion of types I and IIa fibres. MPCM in habitual snorers had an abnormal distribution of fibre types (low percentage of type I and type IIb fibres and high percentage of type IIa fibres) compared with non-snorers (p < 0.001) and the type IIa fibres were hypertrophic. No myopathic or neurogenic changes were seen. Two possible hypotheses explain the abnormal distribution of fibre types in snorers. First, a constitutionally determined reduction of slow alpha-motor neurons induces an adaptive transformation of type IIb to type IIa fibres and a hypertrophy of type IIa fibres; or, second, motor neurons change their patterns of discharge and, hence, of activation, and modify fibre-type distribution of MPCM as an adaptation to the anatomical characteristic of upper airway and habitual snoring.	UNIV MILAN,CTR SLEEP DISORDERS,I-20122 MILAN,ITALY; HOSP NIGUARDA CA GRANDA,DEPT OTOLARYNGOL,MILAN,ITALY	University of Milan	SMIRNE, S (corresponding author), UNIV MILAN,SCI INST HS RAFFAELE,DEPT NEUROL,VIA PRINETTI 29,I-20127 MILAN,ITALY.		STRAMBI, Luigi FERINI/K-3620-2018; Iannaccone, sandro/K-4252-2018	STRAMBI, Luigi FERINI/0000-0003-2867-5424; Iannaccone, sandro/0000-0002-8333-3972				ALAMOOD WS, 1987, J PHYSIOL-LONDON, V392, P377, DOI 10.1113/jphysiol.1987.sp016786; Astrom K.E., 1981, DISORDERS VOLUNTARY, P151; BARNARD RJ, 1970, J APPL PHYSIOL, V28, P762, DOI 10.1152/jappl.1970.28.6.762; BASMAJIAN JV, 1955, ARCH NEURO PSYCHIATR, V73, P224, DOI 10.1001/archneurpsyc.1955.02330080102019; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; Buller AJ, 1974, DISORDERS VOLUNTARY, P20; COTTER M, 1986, EXP NEUROL, V93, P531, DOI 10.1016/0014-4886(86)90173-1; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI, P82; GRIMBY G, 1983, CLIN PHYSIOL, V3, P209, DOI 10.1111/j.1475-097X.1983.tb00704.x; GRIMBY G, 1982, ACTA PHYSL SCAND, V115, P124; GUILLEMINAULT C, 1978, EXP NEUROL, V62, P48, DOI 10.1016/0014-4886(78)90040-7; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HISHIKAWA Y, 1965, ELECTROEN CLIN NEURO, V18, P487, DOI 10.1016/0013-4694(65)90129-X; HORNER RL, 1989, EUR RESPIR J, V2, P613; LEESE G, 1986, ACTA ANAT, V127, P77; LEXELL J, 1983, ACTA PHYSIOL SCAND, V117, P115, DOI 10.1111/j.1748-1716.1983.tb07185.x; LUGARESI E, 1983, B EUR PHYSIOPATH RES, V19, P590; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; ROJEWSKI TE, 1984, OTOLARYNG HEAD NECK, V92, P127, DOI 10.1177/019459988409200201; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; SULLIVAN CE, 1987, SLEEP AGING RELATED, P47; SURATT PM, 1983, AM REV RESPIR DIS, V127, P487, DOI 10.1164/arrd.1983.127.4.487; TAUBER ES, 1977, ANN NEUROL, V2, P66, DOI 10.1002/ana.410020112; THORSTENSSON A, 1976, ACTA PHYSL SCAND S, V443, P7; WADE AJ, 1990, LANCET, V335, P805, DOI 10.1016/0140-6736(90)90933-V	25	89	92	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 9	1991	337	8741					597	599						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA702	1671953				2022-12-01	WOS:A1991FA70200014
J	ADELSTEIN, S; PRITCHARDBRISCOE, H; ANDERSON, TA; CROSBIE, J; GAMMON, G; LOBLAY, RH; BASTEN, A; GOODNOW, CC				ADELSTEIN, S; PRITCHARDBRISCOE, H; ANDERSON, TA; CROSBIE, J; GAMMON, G; LOBLAY, RH; BASTEN, A; GOODNOW, CC			INDUCTION OF SELF-TOLERANCE IN T-CELLS BUT NOT B-CELLS OF TRANSGENIC MICE EXPRESSING LITTLE SELF ANTIGEN	SCIENCE			English	Article							IMMUNOLOGICAL-TOLERANCE; LUPUS-ERYTHEMATOSUS; CLONAL ANALYSIS; LYMPHOCYTES-B; AUTOANTIBODIES; RECEPTOR; GENES; UNRESPONSIVENESS; DETERMINANT; SPECIFICITY	Self-tolerance to a transgene-encoded protein, hen egg lysozyme, was examined in the T and B cell repertoires of a series of lines of transgenic mice that expressed different serum concentrations of soluble lysozyme. T cells were tolerant in all lines in which lysozyme was expressed irrespective of the antigen concentration, whereas B cell tolerance did not occur when the serum lysozyme concentration was less than 1.5 nanograms per milliliter (0.1 nM). Induction of elevated transgene expression could restore B cell tolerance. These findings support the hypothesis that autoimmune disease may in some instances arise through a bypass of T cell tolerance.	UNIV SYDNEY, CENTENARY INST CANC MED & CELL BIOL, SYDNEY, NSW 2006, AUSTRALIA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL, LOS ANGELES, CA 90024 USA	University of Sydney; Centenary Institute; University of California System; University of California Los Angeles			Goodnow, Christopher C/V-8108-2018; Adelstein, Stephen/I-7936-2016	Goodnow, Christopher C/0000-0001-5296-6155; Adelstein, Stephen/0000-0001-7221-6298				ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; ARNOLD B, 1990, IMMUNOL TODAY, V11, P69, DOI 10.1016/0167-5699(90)90026-6; BACCALA R, 1989, P NATL ACAD SCI USA, V86, P4624, DOI 10.1073/pnas.86.12.4624; Burnet FM, 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CASALI P, 1989, ANNU REV IMMUNOL, V7, P513, DOI 10.1146/annurev.iy.07.040189.002501; CHILLER JM, 1971, SCIENCE, V171, P813, DOI 10.1126/science.171.3973.813; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; GAMMON G, 1987, IMMUNOL REV, V98, P53; GOODNOW CC, 1989, COLD SPRING HARB SYM, V54, P907, DOI 10.1101/SQB.1989.054.01.106; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARRIS DE, 1982, J EXP MED, V156, P567, DOI 10.1084/jem.156.2.567; IVERSON GM, 1972, EUR J IMMUNOL, V2, P195, DOI 10.1002/eji.1830020302; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LINDSTROM J, 1985, ANNU REV IMMUNOL, V3, P109; LORENZ RG, 1989, NATURE, V337, P560, DOI 10.1038/337560a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MCHEYZERWILLIAMS MG, 1988, J IMMUNOL, V141, P4118; MILLER JFAP, 1989, IMMUNOL REV, V107, P109, DOI 10.1111/j.1600-065X.1989.tb00005.x; NAPARSTEK Y, 1986, J EXP MED, V164, P614, DOI 10.1084/jem.164.2.614; NELL LJ, 1989, J IMMUNOL, V142, P3063; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; RAJEWSKY K, 1974, EUR J IMMUNOL, V4, P120, DOI 10.1002/eji.1830040211; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; REUTER R, 1986, P NATL ACAD SCI USA, V83, P8689, DOI 10.1073/pnas.83.22.8689; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; SMITH RT, 1961, ADV IMMUNOL, V1, P67, DOI 10.1016/S0065-2776(08)60763-4; TERNYNCK T, 1986, IMMUNOL REV, V94, P99; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; Weigle W O, 1973, Adv Immunol, V16, P61, DOI 10.1016/S0065-2776(08)60296-5; Weigle W O, 1980, Adv Immunol, V30, P159; WHITELEY PJ, 1990, J IMMUNOL, V145, P1376; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	41	199	201	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1991	251	4998					1223	1225		10.1126/science.1900950	http://dx.doi.org/10.1126/science.1900950			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1900950				2022-12-01	WOS:A1991FA69100038
J	AUWERX, J; SASSONECORSI, P				AUWERX, J; SASSONECORSI, P			IP-1 - A DOMINANT INHIBITOR OF FOS/JUN WHOSE ACTIVITY IS MODULATED BY PHOSPHORYLATION	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; CELLULAR FOS PROTEINS; DNA-BINDING PROTEINS; PROTO-ONCOGENE FOS; C-FOS; TRANSCRIPTION FACTOR; LEUCINE ZIPPER; JUN ENCODES; KINASE-C; AP-1	Transcription factor AP-1 is inducible by phorbol esters and thus could be considered to be one final target of the protein kinase C signal transduction pathway. AP-1 consists of the products of the fos and jun oncogenes, which associate as dimers to bind TPA-responsive promoter elements (TRE) efficiently. We show that AP-1 activity is modulated by an inhibitory protein (IP-1), present both in the nucleus and cytoplasm of several cell types. IP-1 specifically blocks DNA binding of AP-1 from nuclear extracts and of in vitro synthesized Fos/Jun proteins. It is a labile protein of 30-40 kd, which exerts its activity only in the nonphosphorylated form. Block of IP-1 function is obtained by PKA-mediated phosphorylation, possibly suggesting a cross talk mechanism at transcriptional level. Competition experiments with synthetic peptides suggest that IP-1 could interact with Fos and/or Jun leucine zippers. We speculate that IP-1 might act as a transcriptional antioncogene.			AUWERX, J (corresponding author), FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,F-67085 STRASBOURG,FRANCE.		Sassone-Corsi, Paolo/H-6182-2011	Auwerx, Johan/0000-0002-5065-5393				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MILLER AD, 1984, CELL, V36, P51; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	52	226	229	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					983	993		10.1016/0092-8674(91)90322-P	http://dx.doi.org/10.1016/0092-8674(91)90322-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900458				2022-12-01	WOS:A1991FA94000015
J	BARGMANN, CI; HORVITZ, HR				BARGMANN, CI; HORVITZ, HR			CONTROL OF LARVAL DEVELOPMENT BY CHEMOSENSORY NEURONS IN CAENORHABDITIS-ELEGANS	SCIENCE			English	Article							DAUER-INDUCING PHEROMONE; NERVOUS-SYSTEM; C-ELEGANS; CELL; MUTANTS; TEMPERATURE; GENETICS; FOOD	Larval development of the nematode Caenorhabditis elegans is controlled by the activities of four classes of chemosensory neurons. The choice between normal development and development into a specialized larval form called a dauer larva is regulated by competing environmental stimuli: food and a dauer pheromone. When the neuron classes ADF, ASG, ASI, and ASJ are killed, animals develop as dauer larvae regardless of environmental conditions. These neurons might sense food or dauer pheromone, or both, to initiate the specialized differentiation of many cell types that occurs during dauer formation. Entry into and exit from the dauer stage are primarily controlled by different chemosensory neurons. The analysis of mutants defective in dauer formation indicates that the chemosensory neurons are active in the absence of sensory inputs and that dauer pheromone inhibits the ability of these neurons to generate a signal necessary for normal development.			BARGMANN, CI (corresponding author), MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.			Bargmann, Cornelia/0000-0002-8484-0618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024663, R01GM024663] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERT PS, 1981, J COMP NEUROL, V198, P435, DOI 10.1002/cne.901980305; ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BARGMANN CI, UNPUB; BRENNER S, 1974, GENETICS, V77, P71; BROCKES JP, 1984, SCIENCE, V225, P1280, DOI 10.1126/science.6474177; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; CASSADA RC, 1975, DEV BIOL, V46, P326, DOI 10.1016/0012-1606(75)90109-8; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; Chappell L.H., 1982, P116; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; Crisp D.J., 1974, pUnpaginated; GOLDEN JW, 1985, MOL GEN GENET, V198, P534, DOI 10.1007/BF00332953; GOLDEN JW, 1984, P NATL ACAD SCI-BIOL, V81, P819, DOI 10.1073/pnas.81.3.819; GOLDEN JW, 1984, J CHEM ECOL, V10, P1265, DOI 10.1007/BF00988553; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HUBBELL WL, 1979, ANNU REV NEUROSCI, V2, P17, DOI 10.1146/annurev.ne.02.030179.000313; KIMURA K, 1990, J NEUROSCI, V10, P403; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; Maggenti A. R., 1981, GENERAL NEMATOLOGY; MELLON D, 1978, NATURE, V272, P246, DOI 10.1038/272246a0; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SWANSON MM, 1981, DEV BIOL, V84, P27, DOI 10.1016/0012-1606(81)90367-5; TRUMAN JW, 1983, J COMP NEUROL, V216, P445, DOI 10.1002/cne.902160410; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Whitfield P.J., 1982, P34; ZALEWSKI AA, 1969, EXP NEUROL, V24, P285, DOI 10.1016/0014-4886(69)90022-3	38	326	349	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1243	1246		10.1126/science.2006412	http://dx.doi.org/10.1126/science.2006412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	2006412				2022-12-01	WOS:A1991FA69100045
J	CUNNINGHAM, CC; STOSSEL, TP; KWIATKOWSKI, DJ				CUNNINGHAM, CC; STOSSEL, TP; KWIATKOWSKI, DJ			ENHANCED MOTILITY IN NIH-3T3 FIBROBLASTS THAT OVEREXPRESS GELSOLIN	SCIENCE			English	Article							MYOSIN HEAVY-CHAIN; ACTIN-FILAMENTS; CA-2+ CONTROL; DICTYOSTELIUM; BINDING; GENE; INACTIVATION; EXPRESSION; PROTEIN; CELLS	Increasing the content of the actin-binding protein gelsolin in cultured mouse fibroblasts by up to 125 percent by gene transfection proportionally enhanced the rate at which the cells migrated through porous filters toward a gradient of serum and closed a wound made on a confluent monolayer of cells in a tissue culture dish. These results provide direct evidence that gelsolin, which promotes both actin assembly and disassembly in vitro, is an important element in fibroblast locomotion and demonstrate that the manipulation of intracellular machinery can increase cell motility.			CUNNINGHAM, CC (corresponding author), MASSACHUSETTS GEN HOSP,HEMATOL ONCOL UNIT,BLDG 149,13TH ST,BOSTON,MA 02129, USA.				NHLBI NIH HHS [HL07680, HL19429] Funding Source: Medline; NIAID NIH HHS [AI28465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028465] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; CHAPONNIER C, 1990, J CELL BIOL, V110, P1983; COOPER JA, 1987, J CELL BIOL, V104, P491, DOI 10.1083/jcb.104.3.491; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FRANCK Z, 1990, J CELL BIOL, V111, P2478; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HUCKRIEDE A, 1990, CELL MOTIL CYTOSKEL, V16, P229, DOI 10.1002/cm.970160403; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KUPFER A, 1982, P NATL ACAD SCI-BIOL, V79, P2603, DOI 10.1073/pnas.79.8.2603; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MEHL RE, 1988, J CELL BIOL, V106, P373; NOEGEL AA, 1988, DEV GENET, V9, P531, DOI 10.1002/dvg.1020090429; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; YIN HL, 1980, J BIOL CHEM, V255, P9494; YIN HL, 1981, J BIOL CHEM, V256, P9693	27	276	284	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1233	1236		10.1126/science.1848726	http://dx.doi.org/10.1126/science.1848726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1848726				2022-12-01	WOS:A1991FA69100042
J	FLANAGAN, JG; CHAN, DC; LEDER, P				FLANAGAN, JG; CHAN, DC; LEDER, P			TRANSMEMBRANE FORM OF THE KIT LIGAND GROWTH-FACTOR IS DETERMINED BY ALTERNATIVE SPLICING AND IS MISSING IN THE SI(D) MUTANT	CELL			English	Article							MOUSE AGGREGATION CHIMERAS; ANEMIC MICE; INVITRO DUPLICATION; PROTO-ONCOGENE; W-LOCUS; FIBROBLASTS; RECEPTOR; KINASE; CELLS; CURE	The ligand (KL) for the c-kit receptor is a growth factor encoded at the mouse steel (SI) locus. KL exists in both cell surface and soluble forms, though little is known of the regulation and functional significance of these forms. We show here that tissue-specific alternative splicing gives two types of KL mRNA. Both encode a transmembrane domain, but in transfected cells one produced the soluble form of KL at relatively high levels, whereas the other preferentially gave the cell surface form. Cell surface KL not only stimulated proliferation, but also mediated cell-cell adhesion. The SI(d) allele, which impairs development of hematopoietic cells, melanocytes, and germ cells, has a deletion in the KL gene removing the transmembrane and intracellular domains. Expression of a corresponding cDNA gave a soluble protein that stimulated cellular proliferation but was not associated with the cell surface. These results provide evidence that cell surface KL has a critical role in the intact organism.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	FLANAGAN, JG (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.		Chan, Doris/O-1227-2014; Flanagan, John/AAM-2995-2020	Chan, Doris/0000-0002-4990-986X; 				ALTUS MS, 1971, P SOC EXP BIOL MED, V138, P985; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; BERNSTEIN SE, 1960, MOUSE NEWS LETT, V23, P33; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DEXTER TM, 1977, NATURE, V269, P412, DOI 10.1038/269412a0; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; LANDRETH KS, 1984, J IMMUNOL, V132, P2724; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISONGRAHAM K, 1989, TRENDS GENET, V5, P116, DOI 10.1016/0168-9525(89)90042-5; NAKAYAMA H, 1988, DEVELOPMENT, V102, P117; NAKAYAMA H, 1988, DEVELOPMENT, V102, P107; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; STANLEY ER, 1990, GENETICS OF PATTERN FORMATION AND GROWTH CONTROL, P165; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	35	723	739	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					1025	1035		10.1016/0092-8674(91)90326-T	http://dx.doi.org/10.1016/0092-8674(91)90326-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1705866				2022-12-01	WOS:A1991FA94000019
J	GOLDSCHMIDTCLERMONT, PJ; KIM, JW; MACHESKY, LM; RHEE, SG; POLLARD, TD				GOLDSCHMIDTCLERMONT, PJ; KIM, JW; MACHESKY, LM; RHEE, SG; POLLARD, TD			REGULATION OF PHOSPHOLIPASE-C-GAMMA-1 BY PROFILIN AND TYROSINE PHOSPHORYLATION	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; BOVINE BRAIN; RECEPTOR	Epidermal growth factor and platelet-derived growth factor can stimulate the production of the second messenger inositol trisphosphate in responsive cells, but the biochemical pathway for these signaling events has been uncertain because the reactions have not been reconstituted with purified molecules in vitro. A reconstitution is described that requires not only the growth factor, its receptor with tyrosine kinase activity, and the soluble phospholipase C-gamma-1, but also the small soluble actin-binding protein profilin. Profilin binds to the substrate phosphatidylinositol 4,5-bisphosphate and inhibits its hydrolysis by unphosphorylated phospholipase C-gamma-1. Phosphorylation of phospholipase C-gamma-1 by the epidermal growth factor receptor tyrosine kinase overcomes the inhibitory effect of profilin and results in an effective activation of phospholipase C-gamma-1.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	GOLDSCHMIDTCLERMONT, PJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.		Machesky, Laura/Z-4554-2019	Machesky, Laura/0000-0002-7592-9856	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26338] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARTER HR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P119, DOI 10.1016/0167-4889(90)90213-W; GOLDSCHMIDTCLER.PJ, IN PRESS J CELL BIOL; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KIM JW, 1990, J BIOL CHEM, V265, P3940; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RHEE S, UNPUB; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, J BIOL CHEM, V262, P12511; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	29	512	515	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1231	1233		10.1126/science.1848725	http://dx.doi.org/10.1126/science.1848725			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1848725				2022-12-01	WOS:A1991FA69100041
J	GORVEL, JP; CHAVRIER, P; ZERIAL, M; GRUENBERG, J				GORVEL, JP; CHAVRIER, P; ZERIAL, M; GRUENBERG, J			RAB5 CONTROLS EARLY ENDOSOME FUSION INVITRO	CELL			English	Article							GTP-BINDING PROTEINS; CELL-FREE SYSTEM; RECEPTOR-MEDIATED ENDOCYTOSIS; ENDOPLASMIC-RETICULUM; ONCOGENE PRODUCT; GOLGI-APPARATUS; PLASMA-MEMBRANE; YEAST YPT1; TRANSPORT; SECRETION	The small GTP-binding protein rab5 was previously localized on early endosomes and on the cytoplasmic face of the plasma membrane. Using a cell-free assay, we have now tested whether rab5 is involved in controlling an early endocytic fusion event. Fusion could be inhibited by cytosol containing the overexpressed mutant rab5IIe133, which does not bind GTP on blots, and by antibodies against rab5, but not against rab2 or rab7. In contrast, fusion was stimulated with cytosol containing overexpressed wild-type rab5. Cytosols containing high levels of rab2 or mutant rab5 with the 9 carboxy-terminal amino acids deleted, which bind GTP on blots, had no effects. Finally, the inhibition mediated by anti-rab5 antibodies could be overcome by complementing the assay with the cytosol containing wild-type rab5, but not with the same cytosol depleted of rab5, nor with cytosol containing the rab5 mutants or rab2. These in vitro finding strongly suggest that rab5 is involved in the process of early endosome fusion.			GORVEL, JP (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,W-6900 HEIDELBERG,GERMANY.		CHAVRIER, Philippe/B-4707-2010; Gorvel, Jean-Pierre/O-1332-2018; CHAVRIER, Philippe/AAG-2645-2020	CHAVRIER, Philippe/0000-0002-7351-733X; Gorvel, Jean-Pierre/0000-0002-2829-9804; CHAVRIER, Philippe/0000-0002-7351-733X				BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BEKCERS CJM, 1989, NATURE, V339, P397; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; DAVEY J, 1985, CELL, V43, P643, DOI 10.1016/0092-8674(85)90236-3; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1990, J CELL SCI, V95, P441; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1987, P NATL ACAD SCI USA, V84, P5758, DOI 10.1073/pnas.84.16.5758; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Maizel JV, 1971, METHOD VIROL, V5, P179; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; VONFISCHER M, 1990, P NATL ACAD SCI USA, V87, P1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOODMAN PG, 1988, EUR J BIOCHEM, V173, P101, DOI 10.1111/j.1432-1033.1988.tb13972.x; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	59	928	941	2	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					915	925		10.1016/0092-8674(91)90316-Q	http://dx.doi.org/10.1016/0092-8674(91)90316-Q			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900457				2022-12-01	WOS:A1991FA94000009
J	HEITZ, D; ROUSSEAU, F; DEVYS, D; SACCONE, S; ABDERRAHIM, H; LEPASLIER, D; COHEN, D; VINCENT, A; TONIOLO, D; DELLAVALLE, G; JOHNSON, S; SCHLESSINGER, D; OBERLE, I; MANDEL, JL				HEITZ, D; ROUSSEAU, F; DEVYS, D; SACCONE, S; ABDERRAHIM, H; LEPASLIER, D; COHEN, D; VINCENT, A; TONIOLO, D; DELLAVALLE, G; JOHNSON, S; SCHLESSINGER, D; OBERLE, I; MANDEL, JL			ISOLATION OF SEQUENCES THAT SPAN THE FRAGILE-X AND IDENTIFICATION OF A FRAGILE-X RELATED CPG ISLAND	SCIENCE			English	Article							CHROMOSOME; DNA; EXPRESSION; SEGMENTS; SITES; YEAST; LOCUS	Yeast artificial chromosomes (YACs) were obtained from a 550-kilobase region that contains three probes previously mapped as very close to the locus of the fragile X syndrome. These YACs spanned the fragile site in Xq27.3 as shown by fluorescent in situ hybridization. An internal 200-kilobase segment contained four chromosomal breakpoints generated by induction of fragile X expression. A single CpG island was identified in the cloned region between markers DXS463 and DXS465 that appears methylated in mentally retarded fragile X males, but not in nonexpressing male carriers of the mutation nor in normal males. This CpG island may indicate the presence of a gene involved in the clinical phenotype of the syndrome.	UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL, I-27100 PAVIA, ITALY; CTR ETUD POLYMORPHISME HUMAIN, F-75010 PARIS, FRANCE; CNR, IST GENET BIOCHIM & EVOLUT, I-27100 PAVIA, ITALY; WASHINGTON UNIV, SCH MED, CTR GENET MED, ST LOUIS, MO 63110 USA	University of Pavia; Consiglio Nazionale delle Ricerche (CNR); Washington University (WUSTL)	HEITZ, D (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Toniolo, Daniela/AAE-2969-2019; Saccone, Salvatore/H-1548-2012	Toniolo, Daniela/0000-0001-9545-6032; Saccone, Salvatore/0000-0001-7568-5823; Le Paslier, Denis/0000-0003-4335-9956; Devys, Didier/0000-0001-9655-3512				ABIDI FE, 1990, GENOMICS, V7, P363, DOI 10.1016/0888-7543(90)90170-Y; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; FUJITA R, 1990, P NATL ACAD SCI USA, V87, P1796, DOI 10.1073/pnas.87.5.1796; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HARRISON CJ, 1983, J MED GENET, V20, P280, DOI 10.1136/jmg.20.4.280; HEITZ D, UNPUB; KANDPAL RP, 1990, NUCLEIC ACIDS RES, V18, P3081, DOI 10.1093/nar/18.10.3081; LAIRD CD, 1990, AM J HUM GENET, V46, P696; LAIRD CD, 1987, GENETICS, V117, P587; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MAESTRINI E, 1990, GENOMICS, V8, P664, DOI 10.1016/0888-7543(90)90253-Q; MONTANARO V, IN PRESS AM J HUM GE; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; POUSTKA A, 1988, GENET ENG, V10, P169; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; ROUSSEAU F, UNPUB; SHAW J, 1990, CYTOGENET CELL GENET, V53, P221, DOI 10.1159/000132936; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SOUTHERN EM, 1987, NUCLEIC ACIDS RES, V15, P5925, DOI 10.1093/nar/15.15.5925; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; SUTHERLAND GR, 1985, AM J MED GENET, V22, P433, DOI 10.1002/ajmg.1320220234; SVED JA, 1990, AM J HUM GENET, V46, P443; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; Vincent A. C., UNPUB; WADA M, 1990, AM J HUM GENET, V46, P95; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WILLARD HF, 1983, NUCLEIC ACIDS RES, V11, P2017, DOI 10.1093/nar/11.7.2017; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806	33	176	180	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1991	251	4998					1236	1239		10.1126/science.2006411	http://dx.doi.org/10.1126/science.2006411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	2006411				2022-12-01	WOS:A1991FA69100043
J	HOFMANN, JFX; GASSER, SM				HOFMANN, JFX; GASSER, SM			IDENTIFICATION AND PURIFICATION OF A PROTEIN THAT BINDS THE YEAST ARS CONSENSUS SEQUENCE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; SILENCER; ORIGIN; REQUIREMENTS; SEGREGATION; POLYMERASE; ELEMENTS; PLASMIDS; CLEAVAGE	We have identified a yeast protein that binds specifically to the ARS consensus sequence. By two-step chromatography we have purified the factor to apparent homogeneity as a single polypeptide of 67 kd. The purified ARS consensus-binding protein (ACBP) recognizes the ARS consensus of the four genomic ARS elements tested, binding preferentially to the T-rich single strand. Point mutations in the consensus significantly reduce the affinity of the single-strand binding. At the histone H4 ARS, ACBP recognizes both the perfect ARS consensus and a 9/11 match 3' of it. These two binding sites correlate with the boundaries of the minimal functional H4 ARS element. A similar configuration of binding sites is found at ARS1. We propose a model implicating this factor in an early step of the initiation of DNA replication.			HOFMANN, JFX (corresponding author), SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND.			Gasser, Susan/0000-0003-3610-9123				ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; ALLIGER P, 1988, BIOCHIM BIOPHYS ACTA, V951, P396, DOI 10.1016/0167-4781(88)90112-1; AMATI B, 1990, EMBO J, V9, P4007, DOI 10.1002/j.1460-2075.1990.tb07622.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; EISENBERG S, 1988, P NATL ACAD SCI USA, V85, P743, DOI 10.1073/pnas.85.3.743; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; HOLMES SG, 1989, MOL CELL BIOL, V9, P5464, DOI 10.1128/MCB.9.12.5464; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KEARSEY S, 1984, CELL, V37, P299, DOI 10.1016/0092-8674(84)90326-X; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KIPLING D, 1990, MOL CELL BIOL, V10, P265, DOI 10.1128/MCB.10.1.265; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; Maniatis T., 1982, MOL CLONING; NAWOTKA KA, 1988, MOL CELL BIOL, V8, P1408, DOI 10.1128/MCB.8.4.1408; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SMITH MM, 1983, J MOL BIOL, V169, P641, DOI 10.1016/S0022-2836(83)80163-6; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; TRAUT W, 1988, MOL CELL BIOL, V8, P903, DOI 10.1128/MCB.8.2.903; UMEK RM, 1989, BIOCHIM BIOPHYS ACTA, V1007, P1, DOI 10.1016/0167-4781(89)90123-1; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; VAUGHN JP, 1990, NUCLEIC ACIDS RES, V18, P1965, DOI 10.1093/nar/18.8.1965; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801	36	77	79	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					951	960		10.1016/0092-8674(91)90319-T	http://dx.doi.org/10.1016/0092-8674(91)90319-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	2001590				2022-12-01	WOS:A1991FA94000012
J	IRVING, BA; WEISS, A				IRVING, BA; WEISS, A			THE CYTOPLASMIC DOMAIN OF THE T-CELL RECEPTOR ZETA-CHAIN IS SUFFICIENT TO COUPLE TO RECEPTOR-ASSOCIATED SIGNAL TRANSDUCTION PATHWAYS	CELL			English	Article							NATURAL-KILLER CELLS; ANTIGEN RECEPTOR; LYMPHOCYTE-T; TYROSINE PHOSPHORYLATION; INOSITOL PHOSPHATES; SURFACE MOLECULES; CD3 COMPLEX; ACTIVATION; EXPRESSION; PROTEIN	The function of the T cell antigen receptor (TCR) invariant chains, CD3-gamma, delta, epsilon, and zeta, is poorly understood. Evidence suggests that CD3 couples receptor ligand binding to intracellular signaling events. To examine the role of the CD3-zeta-chain in TCR-mediated signal transduction, a chimeric protein linking the extracellular and transmembrane domains of CD8 to the cytoplasmic domain of the zeta-chain was constructed. The CD8/zeta-chimera is expressed independently of the TCR and is capable of transducing signals that, by criteria of early and late activation, are indistinguishable from those generated by the intact TCR. These data indicate that CD8/zeta can activate the appropriate signal transduction pathways in the absence of CD3-gamma, delta, and epsilon, and suggest that the role of CD3-zeta is to couple the TCR to intracellular signal transduction mechanisms.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	IRVING, BA (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALCOVER A, 1990, J BIOL CHEM, V265, P4131; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BERKHOUT B, 1988, J BIOL CHEM, V263, P8528; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; Frank S J, 1990, Semin Immunol, V2, P89; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GOLDSMITH MA, 1988, IMMUNOL TODAY, V9, P220, DOI 10.1016/0167-5699(88)91219-4; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HSI ED, 1989, J BIOL CHEM, V264, P10836; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KLAUSNER R D, 1989, New Biologist, V1, P3; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MERCEP M, 1988, SCIENCE, V242, P571, DOI 10.1126/science.2845582; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER N, 1986, J ORG CHEM, V51, P263, DOI 10.1021/jo00352a032; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PATEL MD, 1987, J BIOL CHEM, V262, P5831; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SNOW PM, 1983, J BIOL CHEM, V258, P4675; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TESTI R, 1989, J IMMUNOL, V142, P1854; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	57	728	795	4	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					891	901		10.1016/0092-8674(91)90314-O	http://dx.doi.org/10.1016/0092-8674(91)90314-O			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1705867				2022-12-01	WOS:A1991FA94000007
J	JOYNER, AL; HERRUP, K; AUERBACH, BA; DAVIS, CA; ROSSANT, J				JOYNER, AL; HERRUP, K; AUERBACH, BA; DAVIS, CA; ROSSANT, J			SUBTLE CEREBELLAR PHENOTYPE IN MICE HOMOZYGOUS FOR A TARGETED DELETION OF THE EN-2 HOMEOBOX	SCIENCE			English	Article							DROSOPHILA ENGRAILED GENE; PROTO-ONCOGENE INT-1; BOX-CONTAINING GENES; DNA-BINDING; HOMOLOGOUS RECOMBINATION; SEQUENCE HOMOLOGY; MOUSE CEREBELLUM; GRANULE CELL; EXPRESSION; EMBRYOGENESIS	The two mouse genes, En-1 and En-2, that are homologs of the Drosophila segmentation gene engrailed, show overlapping spatially restricted patterns of expression in the neural tube during embryogenesis, suggestive of a role in regional specification. Mice homozygous for a targeted mutation that deletes the homeobox were viable and showed no obvious defects in embryonic development. This may be due to functional redundancy of En-2 and the related En-1 gene product during embryogenesis. Consistent with this hypothesis, the mutant mice showed abnormal foliation in the adult cerebellum, where En-2, and not En-1, is normally expressed.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA; EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC, WALTHAM, MA 02254 USA	University of Toronto	JOYNER, AL (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Herrup, Karl/C-5313-2014	Herrup, Karl/0000-0001-7786-5844	NICHD NIH HHS [HD25334] Funding Source: Medline; NINDS NIH HHS [NS18381, NS20591] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018381, R01NS020591] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1972, J COMP NEUROL, V146, P355, DOI 10.1002/cne.901460305; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BRIVANLOU AH, 1989, DEVELOPMENT, V106, P611; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; COLEMAN KG, 1987, GENE DEV, V1, P19, DOI 10.1101/gad.1.1.19; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DAVIS CA, IN PRESS DEVELOPMENT; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FJOSE A, 1988, FEBS LETT, V231, P355, DOI 10.1016/0014-5793(88)80849-4; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GARDNER CA, 1988, J NEUROSCI RES, V21, P426, DOI 10.1002/jnr.490210234; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GOLDOWITZ D, 1982, J NEUROSCI, V2, P1474; HEMMATIBRIVANLO.A, IN PRESS DEVELOPMENT; HERRUP K, 1987, NEUROSCIENCE, V23, P871, DOI 10.1016/0306-4522(87)90164-3; HOEY T, 1988, MOL CELL BIOL, V8, P4598, DOI 10.1128/MCB.8.11.4598; INGHAM P, 1985, NATURE, V317, P634, DOI 10.1038/317634a0; INOUYE M, 1980, J COMP NEUROL, V190, P357, DOI 10.1002/cne.901900209; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1984, EMBO J, V3, P2839, DOI 10.1002/j.1460-2075.1984.tb02217.x; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LITTLE JW, COMMUNICATION; LOGAN C, 1989, GENOMICS, V4, P206, DOI 10.1016/0888-7543(89)90301-7; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; NEUMANN PE, 1990, BRAIN RES, V524, P85, DOI 10.1016/0006-8993(90)90495-W; NJOLSTAD PR, 1988, BIOCHEM BIOPH RES CO, V157, P426, DOI 10.1016/S0006-291X(88)80266-3; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; REZAI Z, 1972, DEV BIOL, V29, P17, DOI 10.1016/0012-1606(72)90039-5; Sidman Richard L., 1971, ATLAS MOUSE BRAIN SP; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TREISMAN J, 1989, CELL, V59, P553; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	46	360	365	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1991	251	4998					1239	1243		10.1126/science.1672471	http://dx.doi.org/10.1126/science.1672471			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1672471				2022-12-01	WOS:A1991FA69100044
J	KELLUM, R; SCHEDL, P				KELLUM, R; SCHEDL, P			A POSITION-EFFECT ASSAY FOR BOUNDARIES OF HIGHER-ORDER CHROMOSOMAL DOMAINS	CELL			English	Article							BETA-GLOBIN GENE; WHITE GENE; DROSOPHILA-MELANOGASTER; TRANSGENIC MICE; CHROMATIN; DNA; EXPRESSION; ORGANIZATION; ELEMENTS; SITES	Eukaryotic chromosomes are thought to be organized into a series of discrete higher order chromatin domains. This organization is believed to be important not only in the compaction of the chromatin fiber, but also in the utilization of genetic information. Each domain would define an independent unit of gene activity, insulated from the regulatory influences of adjacent domains. Critical to this model of chromosome organization and function are the domain boundaries: the special nucleoprotein structures that delimit each higher order domain and segregate the chromosome into units of independent gene activity. In the work reported here we have tested whether two putative domain boundaries, scs and scs', from the Drosophila 87A7 heat shock locus can establish a domain of independent gene activity in vivo and insulate against chromosomal position effects.			KELLUM, R (corresponding author), PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544, USA.							ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; ADOLPH KW, 1980, EXP CELL RES, V125, P95, DOI 10.1016/0014-4827(80)90193-7; BASLER J, 1981, BIOCHEMISTRY-US, V20, P6921, DOI 10.1021/bi00527a027; BELMONT AS, 1989, CHROMOSOMA, V98, P129, DOI 10.1007/BF00291049; BENYAJATI C, 1976, CELL, V9, P393, DOI 10.1016/0092-8674(76)90084-2; BOWEN BC, 1981, NUCLEIC ACIDS RES, V9, P5093, DOI 10.1093/nar/9.19.5093; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COOK PR, 1976, J CELL SCI, V22, P303; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; JUDD BH, 1976, GENETICS BIOL DROS B, V1, P767; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P325, DOI 10.1016/0022-2836(82)90332-1; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LEVIS R, 1985, EMBO J, V4, P3489, DOI 10.1002/j.1460-2075.1985.tb04108.x; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; PIRROTTA V, 1985, EMBO J, V4, P3501, DOI 10.1002/j.1460-2075.1985.tb04109.x; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; ROBERTSON HM, 1988, GENETICS, V118, P461; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SCHOLNICK SB, 1983, CELL, V34, P37, DOI 10.1016/0092-8674(83)90134-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42	32	544	569	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					941	950		10.1016/0092-8674(91)90318-S	http://dx.doi.org/10.1016/0092-8674(91)90318-S			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1848159				2022-12-01	WOS:A1991FA94000011
J	KUMAGAI, A; DUNPHY, WG				KUMAGAI, A; DUNPHY, WG			THE CDC25 PROTEIN CONTROLS TYROSINE DEPHOSPHORYLATION OF THE CDC2 PROTEIN IN A CELL-FREE SYSTEM	CELL			English	Article							ACTIVATED XENOPUS EGGS; CYCLIN MESSENGER-RNA; SEA-URCHIN EGGS; FISSION YEAST; PROMOTING FACTOR; MITOTIC CONTROL; KINASE; MITOSIS; MPF; DIVISION	As a prerequisite for the activation of MPF, the cdc2 protein kinase must undergo tyrosine dephosphorylation. Genetic studies have demonstrated that the cdc25 protein activates the cdc2 protein kinase once DNA replication has been completed. We have produced the cdc25 protein in bacteria and shown that it activates MPF in Xenopus extracts. In extracts that normally cannot enter mitosis owing to inhibition of DNA synthesis, the addition of active cdc25 protein efficiently elicits the mitotic state by inducing premature dephosphorylation of tyrosine on the cdc2 protein. The cdc25-dependent activation reaction can be reconstituted in a partially purified system lacking ATP. These biochemical experiments demonstrate that the cdc25 protein actively drives tyrosine dephosphorylation of the cdc2 protein and offer the prospect for characterizing the individual factors that regulate the activation of MPF during the progression from S phase to mitosis.			KUMAGAI, A (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.							BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1989, J CELL SCI, V92, P131; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TONKS NK, 1988, J BIOL CHEM, V263, P6731; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4	56	444	456	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					903	914		10.1016/0092-8674(91)90315-P	http://dx.doi.org/10.1016/0092-8674(91)90315-P			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1825803				2022-12-01	WOS:A1991FA94000008
J	LIN, YS; GREEN, MR				LIN, YS; GREEN, MR			MECHANISM OF ACTION OF AN ACIDIC TRANSCRIPTIONAL ACTIVATOR INVITRO	CELL			English	Article							RNA-POLYMERASE-II; PREINITIATION COMPLEX; INITIATION-FACTOR; FUNCTIONAL-ANALYSIS; GENE-TRANSCRIPTION; FACTOR ATF; PROMOTER; PURIFICATION; PROTEIN; GAL4	Transcription of a eukaryotic structural gene by RNA polymerase II requires the ordered assembly of general transcription factors on the promoter to form a preinitiation complex. Here we analyze affinity-purified complexes at various stages of assembly to determine the mechanism of action of an acidic transcriptional activator. We show that the activator can function in the absence of ATP and stimulates transcription by increasing the number of functional preinitiation complexes. The activator effects this increase by recruiting the general transcription factor TFIIB to the promoter. Using protein affinity chromatography we demonstrate a specific interaction between an acidic activating region and TFIIB. Based on these combined results, we propose that TFIIB is a direct target of an acidic activator.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University								ALBRECHT G, 1988, MOL CELL BIOL, V8, P1534, DOI 10.1128/MCB.8.4.1534; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DEVAUX B, 1987, MOL CELL BIOL, V7, P4560, DOI 10.1128/MCB.7.12.4560; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1989, NATURE, V341, P279, DOI 10.1038/341279a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.biochem.54.1.171; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TSUNG K, 1990, P NATL ACAD SCI USA, V87, P5940, DOI 10.1073/pnas.87.15.5940; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; ZINN K, 1986, CELL, V45, P611, DOI 10.1016/0092-8674(86)90293-X	47	490	499	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					971	981		10.1016/0092-8674(91)90321-O	http://dx.doi.org/10.1016/0092-8674(91)90321-O			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	2001592				2022-12-01	WOS:A1991FA94000014
J	MIGNARD, M; MALPELI, JG				MIGNARD, M; MALPELI, JG			PATHS OF INFORMATION-FLOW THROUGH VISUAL-CORTEX	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; STRIATE CORTEX; CORTICAL CONNECTIONS; LAMINAR ORIGINS; AREA 17; CAT; MONKEY; CELLS; PROJECTIONS; NEURONS	The main route of information flow in the cerebral cortex is from the middle layers of cortex to upper and lower layers. However, upper layers of the cat primary visual cortex can be directly driven by inputs from secondary visual cortex when activity in middle layers is disrupted. Upper-layer activity can be driven either by middle layers or by direct corticocortical inputs. One consequence of this result is that areas of cortex thought to be carrying out low-order analysis may be able to extract considerable information from higher order areas.	UNIV ILLINOIS,DEPT PSYCHOL,603 E DANIEL ST,CHAMPAIGN,IL 61820	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL EYE INSTITUTE [R01EY002695] Funding Source: NIH RePORTER; NEI NIH HHS [EY02695] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BULLIER J, 1988, EXP BRAIN RES, V70, P90; BULLIER J, 1984, J COMP NEUROL, V228, P329, DOI 10.1002/cne.902280304; FISKEN RA, 1975, PHILOS T ROY SOC B, V272, P487, DOI 10.1098/rstb.1975.0099; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; HENRY GH, 1991, EUR J NEUROSCI, V3, P186, DOI 10.1111/j.1460-9568.1991.tb00079.x; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Lee C., UNPUB; LEE CK, 1986, BRAIN RES, V364, P396, DOI 10.1016/0006-8993(86)90855-3; LEVAY S, 1976, BRAIN RES, V113, P1, DOI 10.1016/0006-8993(76)90002-0; LEVENTHAL AG, 1979, EXP BRAIN RES, V37, P349; MALPELI JG, 1983, J NEUROPHYSIOL, V49, P595, DOI 10.1152/jn.1983.49.3.595; MALPELI JG, 1986, J NEUROPHYSIOL, V56, P1062, DOI 10.1152/jn.1986.56.4.1062; MALPELI JG, 1979, J NEUROSCI METH, V1, P143, DOI 10.1016/0165-0270(79)90011-6; MALPELI JG, 1982, NEUROSCI LETT, V32, P29, DOI 10.1016/0304-3940(82)90224-5; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563; MITZDORF U, 1978, EXP BRAIN RES, V33, P371; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NAULT B, 1990, Society for Neuroscience Abstracts, V16, P1219; ORBAN GA, 1984, NEURONAL OPERATIONS, P47; OTSUKA R, 1962, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V203, P212, DOI 10.1007/BF00352744; ROCKLAND KS, 1979, BRAIN RES, V179, P3, DOI 10.1016/0006-8993(79)90485-2; ROSENQUIST AC, 1975, BRAIN RES, V80, P71; SANDELL JH, 1982, J NEUROPHYSIOL, V48, P38, DOI 10.1152/jn.1982.48.1.38; SYMONDS LL, 1984, J COMP NEUROL, V229, P39, DOI 10.1002/cne.902290104; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	25	135	136	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1249	1251		10.1126/science.1848727	http://dx.doi.org/10.1126/science.1848727			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FA691	1848727				2022-12-01	WOS:A1991FA69100047
J	MORRIS, CE; HORN, R				MORRIS, CE; HORN, R			FAILURE TO ELICIT NEURONAL MACROSCOPIC MECHANOSENSITIVE CURRENTS ANTICIPATED BY SINGLE-CHANNEL STUDIES	SCIENCE			English	Article							ACTIVATED ION CHANNELS; MEMBRANE; CELLS; CALCIUM; VOLUME; STRESS; YEAST	Mechanosensitive channels can be observed in most cell types during single-channel recording and have been implicated in many cellular processes. Potassium-selective single-channel currents, both stretch-activated and stretch-inactivated, can be observed in growth cones and cell bodies of Lymnaea stagnalis neurons. Equivalent macroscopic mechanosensitive currents could not, however, be elicited while applying various mechanical stimuli. This discrepancy suggests that single-channel mechanosensitivity is an artifact of patch recording.	UNIV OTTAWA,DEPT BIOL,OTTAWA K1N 6N5,ONTARIO,CANADA; ROCHE INST MOLEC BIOL,DEPT NEUROSCI,NUTLEY,NJ 07110	University of Ottawa				Morris, Catherine/0000-0002-7401-6545				BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; BELARDETTI F, 1987, NATURE, V325, P153, DOI 10.1038/325153a0; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; EDWARDS C, 1981, NEUROSCIENCE, V6, P1455, DOI 10.1016/0306-4522(81)90200-1; ERXLEBEN C, 1989, J GEN PHYSIOL, V94, P1071, DOI 10.1085/jgp.94.6.1071; FALKE LC, 1989, P NATL ACAD SCI USA, V86, P3919, DOI 10.1073/pnas.86.10.3919; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; GUSTIN MC, 1986, SCIENCE, V233, P1195, DOI 10.1126/science.2426783; KIMITSUKI T, 1990, AM J PHYSIOL, V258, pH247, DOI 10.1152/ajpheart.1990.258.1.H247; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; MEDINA IR, 1988, PROC R SOC SER B-BIO, V235, P95, DOI 10.1098/rspb.1988.0064; MILLS LR, 1988, NEUR SOC ABSTR, V14, P583; MILTON RL, 1990, PFLUG ARCH EUR J PHY, V416, P758, DOI 10.1007/BF00370626; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; MORRIS CE, 1989, SCIENCE, V243, P807, DOI 10.1126/science.2536958; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; SACKIN H, 1989, P NATL ACAD SCI USA, V86, P1731, DOI 10.1073/pnas.86.5.1731; SIGURDSON WJ, 1990, THESIS U OTTAWA; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SUGRDSON WJ, 1989, J NEUROSCI, V9, P2801; UBL J, 1988, J MEMBRANE BIOL, V104, P223, DOI 10.1007/BF01872324; VANDORPE D, UNPUB; [No title captured]	26	157	161	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1246	1249		10.1126/science.1706535	http://dx.doi.org/10.1126/science.1706535			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1706535				2022-12-01	WOS:A1991FA69100046
J	OTTEN, GR; GERMAIN, RN				OTTEN, GR; GERMAIN, RN			SPLIT ANERGY IN A CD8+ T-CELL - RECEPTOR-DEPENDENT CYTOLYSIS IN THE ABSENCE OF INTERLEUKIN-2 PRODUCTION	SCIENCE			English	Article							LYMPHOCYTES-T; CLASS-I; ANTIGEN; CLONES; INDUCTION; ACTIVATION; RESPONSIVENESS; TOLERANCE; INVIVO; EVENTS	Engagement of the antigen-specific receptor (TCR) of CD4+ T lymphocytes without a second (costimulatory) signal prevents the subsequent production of interleukin-2 (IL-2) by these cells. Because IL-2 is a key immunoregulatory lymphokine and is also produced by a subset of CD8+ T cells that are able to kill target cells, the effect of engaging the TCR of one such clone in the absence of costimulatory signals was examined. The capacity for TCR-dependent IL-2 production was lost, indicating comparable costimulator-dependent signaling requirements for IL-2 production in CD4+ and CD8+ T cells. However, TCR-mediated cytotoxicity was not impaired, implying that costimulation is required for only certain TCR-dependent effector functions.			OTTEN, GR (corresponding author), NIAID,LYMPHOCYTE BIOL SECT,IMMUNOL LAB,BETHESDA,MD 20892, USA.		Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019					ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; AZUMA T, 1989, J IMMUNOL, V143, P1; BAKER PE, 1979, J EXP MED, V149, P273, DOI 10.1084/jem.149.1.273; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; HSI ED, 1989, J BIOL CHEM, V264, P10836; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; LEGROS GS, 1985, J IMMUNOL, V135, P4009; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MATIS LA, 1985, J IMMUNOL, V135, P703; MIZUOCHI T, 1986, J EXP MED, V163, P603, DOI 10.1084/jem.163.3.603; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; QUILL H, 1987, J IMMUNOL, V138, P3704; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; ROOPENIAN DC, 1983, J IMMUNOL, V130, P542; ROSENBERG AS, 1988, J EXP MED, V168, P33, DOI 10.1084/jem.168.1.33; SCHWARTZ RH, 1989, COLD SPRING HARB SYM, V54, P605; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; VITIELLO A, 1989, J IMMUNOL, V143, P1512; VONBOEHMER H, 1983, EUR J IMMUNOL, V13, P176, DOI 10.1002/eji.1830130216; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WIDMER MB, 1981, NATURE, V294, P750, DOI 10.1038/294750a0	27	211	219	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1228	1231		10.1126/science.1900952	http://dx.doi.org/10.1126/science.1900952			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1900952				2022-12-01	WOS:A1991FA69100040
J	PRIOR, TI; FITZGERALD, DJ; PASTAN, I				PRIOR, TI; FITZGERALD, DJ; PASTAN, I			BARNASE TOXIN - A NEW CHIMERIC TOXIN COMPOSED OF PSEUDOMONAS EXOTOXIN-A AND BARNASE	CELL			English	Article							GENOMIC SEQUENCES; ESCHERICHIA-COLI; BARSTAR; CELLS; RIBONUCLEASE; IMMUNOTOXINS; AERUGINOSA; EXPRESSION; ANTIBODY; PROTEINS	We have constructed a chimeric toxin composed of Pseudomonas exotoxin A (PE) and the extracellular ribonuclease of Bacillus amyloliquefaciens, barnase. The chimeric protein, termed PE-Bar, reacted with both anti-PE and anti-barnase antisera and had both ADP ribosylation and ribonuclease activities. The chimeric toxin was cytotoxic to the murine fibroblast cell line L929 and to a murine hybridoma resistant to PE. A mutant form of PE-Bar lacking ADP-ribosylating activity was still cytotoxic to L929 cells. Because treatment of cells prelabeled with [H-3]uridine resulted in a decrease in their RNA content, we conclude that this cytotoxic effect was due to the ribonuclease activity of barnase molecules that had been translocated to the cytosol. It is now possible to construct chimeric toxins with two or more enzymatic activities that can be delivered to the cytosol of the target cells.			PRIOR, TI (corresponding author), NCI,DIV CANC BIOL & DIAG,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FITZGERALD D, 1989, J NATL CANCER I, V81, P1455, DOI 10.1093/jnci/81.19.1455; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; HARTLEY RW, 1973, J BIOL CHEM, V248, P5624; HARTLEY RW, 1989, TRENDS BIOCHEM SCI, V14, P450, DOI 10.1016/0968-0004(89)90104-7; HARTLEY RW, 1988, J MOL BIOL, V202, P913, DOI 10.1016/0022-2836(88)90568-2; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; KONDO T, 1988, J BIOL CHEM, V263, P9470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; MAUGUEN Y, 1982, NATURE, V297, P162, DOI 10.1038/297162a0; PADDON CJ, 1986, GENE, V40, P231, DOI DOI 10.1016/0378-1119(85)90045-9; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PASTAN I, 1989, J BIOL CHEM, V264, P15157; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SENIOR BW, 1971, P NATL ACAD SCI USA, V68, P959, DOI 10.1073/pnas.68.5.959; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SMEATON JR, 1967, BIOCHIM BIOPHYS ACTA, V145, P547, DOI 10.1016/0005-2787(67)90115-3; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WILLINGHAM MC, 1987, P NATL ACAD SCI USA, V84, P2474, DOI 10.1073/pnas.84.8.2474	26	64	77	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					1017	1023		10.1016/0092-8674(91)90325-S	http://dx.doi.org/10.1016/0092-8674(91)90325-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900455				2022-12-01	WOS:A1991FA94000018
J	ROCHA, B; VONBOEHMER, H				ROCHA, B; VONBOEHMER, H			PERIPHERAL SELECTION OF THE T-CELL REPERTOIRE	SCIENCE			English	Article							TRANSGENIC MICE; MONOCLONAL-ANTIBODY; BETA-GENES; TOLERANCE; RECEPTOR; THYMUS; EXPRESSION; THYMOCYTES; ANTIGENS; DELETION	T lymphocytes undergo selection events not only in the thymus, but also after they leave the thymus and reside in the periphery. Peripheral selection was found to be dependent on T cell receptor (TCR)-ligand interactions but to differ from thymic selection with regard to specificity and mechanism. Unlike thymic selection, peripheral selection required binding of antigen to the TCR, and it induced expansion of T cell clones. Tolerance to self antigens that are restricted to the periphery occurred through the elimination of self-reactive T cells and by the clonal anergy, which was associated with down-regulation of the alpha-beta-TCR and CD8.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND		ROCHA, B (corresponding author), HOP NECKER ENFANTS MALAD,CNRS,UA 122,INSERM,U25,F-75730 PARIS 15,FRANCE.							BEHLKE MA, 1987, J EXP MED, V165, P257, DOI 10.1084/jem.165.1.257; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FREITAS AA, 1975, EUR J IMMUNOL, V5, P831, DOI 10.1002/eji.1830051207; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P454; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1982, EUR J IMMUNOL, V12, P463, DOI 10.1002/eji.1830120603; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MILLER JFAP, 1979, THYMUS, V1, P3; MILLER RA, 1984, J IMMUNOL, V133, P2925; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; PENIT C, 1988, J IMMUNOL, V140, P3315; ROCHA B, 1990, EUR J IMMUNOL, V20, P1697, DOI 10.1002/eji.1830200812; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; ROCHA B, 1990, EUR J IMMUNOL, V20, P1919; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4	27	644	654	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1225	1228		10.1126/science.1900951	http://dx.doi.org/10.1126/science.1900951			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1900951				2022-12-01	WOS:A1991FA69100039
J	ROMEO, C; SEED, B				ROMEO, C; SEED, B			CELLULAR-IMMUNITY TO HIV ACTIVATED BY CD4 FUSED TO T-CELL OR FC RECEPTOR POLYPEPTIDES	CELL			English	Article							NATURAL-KILLER CELLS; RECOMBINANT SOLUBLE CD4; CLASS-II MHC; ANTIGEN RECEPTOR; ZETA-CHAIN; SURFACE EXPRESSION; MOLECULAR-CLONING; IMMUNODEFICIENCY VIRUS; TRANSFECTED CELLS; TRANS-ACTIVATOR	We describe functional simplified T cell and Fc receptor chimeras that are capable of directing CD8+ cytotoxic T lymphocytes (CTLs) to specifically recognize and lyse cells expressing HIV envelope proteins. Target cells bearing HLA-DR molecules are not recognized by CTL armed with the chimeras. The variety of cell types in which the native receptors are active suggests multiple possibilities for antiviral intervention through genetic means.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	ROMEO, C (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BERKHOUT B, 1988, J BIOL CHEM, V263, P8528; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BOYLE DB, 1988, GENE, V65, P123, DOI 10.1016/0378-1119(88)90424-6; BUONOCORE L, 1990, NATURE, V345, P625, DOI 10.1038/345625a0; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHAKRABARTI S, 1986, NATURE, V320, P535, DOI 10.1038/320535a0; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; CLAYTON LK, 1990, J EXP MED, V172, P1243, DOI 10.1084/jem.172.4.1243; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FANGER MW, 1989, IMMUNOL TODAY, V10, P92, DOI 10.1016/0167-5699(89)90234-X; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JOHN S, 1989, EUR J IMMUNOL, V19, P335, DOI 10.1002/eji.1830190218; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; KUSTER H, 1990, J BIOL CHEM, V265, P6448; KUWANA Y, 1987, BIOCHEM BIOPH RES CO, V149, P960, DOI 10.1016/0006-291X(87)90502-X; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MERCEP M, 1988, SCIENCE, V242, P571, DOI 10.1126/science.2845582; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PERUSSIA B, 1989, J EXP MED, V170, P73, DOI 10.1084/jem.170.1.73; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, 1990, SCI AM, V262, P62, DOI 10.1038/scientificamerican0590-62; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TILL MA, 1988, SCIENCE, V242, P1166, DOI 10.1126/science.2847316; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; WATANABE M, 1989, NATURE, V337, P267, DOI 10.1038/337267a0; WEISS A, 1984, J IMMUNOL, V133, P123; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	69	354	400	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					1037	1046		10.1016/0092-8674(91)90327-U	http://dx.doi.org/10.1016/0092-8674(91)90327-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900456				2022-12-01	WOS:A1991FA94000020
J	SCHIEBEL, E; DRIESSEN, AJM; HARTL, FU; WICKNER, W				SCHIEBEL, E; DRIESSEN, AJM; HARTL, FU; WICKNER, W			DELTA-MU-H+ AND ATP FUNCTION AT DIFFERENT STEPS OF THE CATALYTIC CYCLE OF PREPROTEIN TRANSLOCASE	CELL			English	Article							MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI SECB; PURIFIED PRECURSOR PROTEIN; BACTERIAL LEADER PEPTIDASE; ENDOPLASMIC-RETICULUM; TRIGGER FACTOR; COAT PROTEIN; PRO-OMPA; MEMBRANE TRANSLOCATION; CYTOPLASMIC MEMBRANE	Preprotein translocation in E. coli requires ATP, the membrane electrochemical potential DELTA-mu-H+, and translocase, an enzyme with an ATPase domain (SecA) and the membrane-embedded SecY/E. Studies of translocase and proOmpA reveal a five-step catalytic cycle: First, proOmpA binds to the SecA domain. Second, SecA binds ATP. Third, ATP-binding energy permits translocation of approximately 20 residues of proOmpA. Fourth, ATP hydrolysis releases proOmpA. ProOmpA may then rebind to SecA and reenter this cycle, allowing progress through a series of transmembrane intermediates. In the absence of DELTA-mu-H+ or association with SecA, proOmpA passes backward through the membrane, but moves forward when either ATP and SecA or a membrane electrochemical potential is supplied. However, in the presence of DELTA-mu-H+ (fifth step), proOmpA rapidly completes translocation. DELTA-mu-H+ - driven translocation is blocked by SecA plus nonhydrolyzable ATP analogs, indicating that DELTA-mu-H+ drives translocation when ATP and proOmpA are not bound to SecA.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	SCHIEBEL, E (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.		Hartl, F. Ulrich/Y-8206-2019; Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CHEN LL, 1986, J BACTERIOL, V168, P828, DOI 10.1128/jb.168.2.828-832.1986; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DRIESSEN AJM, 1991, IN PRESS P NATL ACAD; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GELLER BL, 1989, J BIOL CHEM, V264, P16465; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; ITO K, 1980, J BIOL CHEM, V255, P2123; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUHN A, 1987, EMBO J, V6, P501, DOI 10.1002/j.1460-2075.1987.tb04781.x; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; OHNOIWASHITA Y, 1983, J BIOL CHEM, V258, P1895; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESTWEBER D, 1988, J CELL BIOL, V107, P2045, DOI 10.1083/jcb.107.6.2045; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WILSON C, 1988, J CELL BIOL, V107, P69, DOI 10.1083/jcb.107.1.69; WOLFE PB, 1984, CELL, V36, P1067, DOI 10.1016/0092-8674(84)90056-4; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; ZIMMERMANN R, 1983, J BIOL CHEM, V258, P3920	58	402	408	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1991	64	5					927	939		10.1016/0092-8674(91)90317-R	http://dx.doi.org/10.1016/0092-8674(91)90317-R			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1825804				2022-12-01	WOS:A1991FA94000010
J	SCHILLER, PH; LEE, KM				SCHILLER, PH; LEE, KM			THE ROLE OF THE PRIMATE EXTRASTRIATE AREA V4 IN VISION	SCIENCE			English	Article							MONKEY VISUAL-CORTEX; STATE DEPENDENT ACTIVITY; DISCRIMINATION; MACAQUE; COLOR; HUE	Area V4 is a part of the primate visual cortex. Its role in vision has been extensively debated. Inferences about the functions of this area have now been made by examination of a broad range of visual capacities after ablation of V4 in rhesus monkeys. The results obtained suggest that this area is involved in more complex aspects of visual information processing than had previously been suggested. Monkeys had particularly severe deficits in situations where the task was to select target stimuli that had a lower contrast, smaller size, or slower rate of motion than the array of comparison stimuli from which they had to be discriminated. Extensive training on each specific task resulted in improved performance. However, after V4 ablation, the monkeys could not generalize the specific task to new stimulus configurations and to new spatial locations.			SCHILLER, PH (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139, USA.		Lee, Kyoung Min/J-2775-2012		NATIONAL EYE INSTITUTE [R01EY000676, R37EY000676] Funding Source: NIH RePORTER; NEI NIH HHS [EY00676] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Blake R., 1990, PERCEPTION; CAVANAGH P, 1990, J EXP PSYCHOL HUMAN, V16, P479, DOI 10.1037/0096-1523.16.3.479; DEAN P, 1979, EXP BRAIN RES, V35, P69; DESIMONE R, 1985, VISION RES, V25, P441, DOI 10.1016/0042-6989(85)90069-0; DESIMONE R, 1987, J NEUROPHYSIOL, V57, P835, DOI 10.1152/jn.1987.57.3.835; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; GROSS CG, 1973, PROGR PHYSL PSYCHOL; GROSS CG, 1977, LATERAL NERVOUS SYST; HAENNY PE, 1988, EXP BRAIN RES, V69, P225, DOI 10.1007/BF00247569; HAENNY PE, 1988, EXP BRAIN RES, V69, P245, DOI 10.1007/BF00247570; HEYWOOD CA, 1987, J NEUROSCI, V7, P2601; LOGOTHETIS NK, 1990, SCIENCE, V247, P214, DOI 10.1126/science.2294602; MAGUIRE WM, 1984, J NEUROSCI, V4, P1690; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; ROBINSON DA, 1963, IEEE T BIOMED ENG, V101, P131; SCHEIN SJ, 1990, J NEUROSCI, V10, P3369; SCHILLER PH, 1990, VISUAL NEUROSCI, V5, P321, DOI 10.1017/S0952523800000420; SCHILLER PH, 1990, NATURE, V343, P68, DOI 10.1038/343068a0; SCHILLER PH, 1990, TRENDS NEUROSCI, V13, P392, DOI 10.1016/0166-2236(90)90117-S; TREISMAN A, 1988, PSYCHOL REV, V95, P15, DOI 10.1037/0033-295X.95.1.15; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR; WILD HM, 1985, NATURE, V313, P133, DOI 10.1038/313133a0; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0	24	173	174	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1251	1253		10.1126/science.2006413	http://dx.doi.org/10.1126/science.2006413			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	2006413				2022-12-01	WOS:A1991FA69100048
J	ABRAHAM, N; MICELI, MC; PARNES, JR; VEILLETTE, A				ABRAHAM, N; MICELI, MC; PARNES, JR; VEILLETTE, A			ENHANCEMENT OF T-CELL RESPONSIVENESS BY THE LYMPHOCYTE-SPECIFIC TYROSINE PROTEIN-KINASE P56LCK	NATURE			English	Article							MONOCLONAL-ANTIBODY; CD4 RECEPTOR; SURFACE-ANTIGENS; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; ACTIVATION; EXPRESSION; DOMAIN; LINES	LYMPHOCYTE-specific tyrosine protein kinase p56lck is physically associated with CD4 and CD8 T-cell surface molecules, suggesting that it may transduce CD4/CD8-triggered tyrosine phosphorylation signals during antigen stimulation 1,2. Indeed, antibody-mediated aggregation of CD4 (to mimic interaction with its ligand, major histocompatibility complex (MHC) class II molecules), rapidly elevates the kinase activity of p56lck (refs 3, 4) and is associated with marked changes in tyrosine protein phosphorylation 4-6. Genetic analyses suggest that the interaction of CD4/CD8 with p56lck results in a positive signal during antigen-induced T-cell activation 7-10. To evaluate directly the role of p56lck in T-cell activation, we introduced a constitutively activated form of Lck protein (tyrosine 505 to phenylalanine 505 mutant; refs 11-13) in a CD4-negative, MHC-class II restricted mouse T-cell hybridoma 14. We report here that, as for transfection of CD4 10,15,16, expression of the Lck mutant enhanced T-lymphocyte responsiveness. The finding provides direct evidence that p56lck can positively regulate T-cell functions and that it mediates at least some of the effects of CD4 and CD8 on T-cell activation.	MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,QUEBEC,CANADA; STANFORD UNIV,MED CTR,DEPT MED,DIV IMMUNOL & RHEUMATOL,STANFORD,CA 94305	McGill University; McGill University; Stanford University			Abraham, Ninan/K-5572-2012	Abraham, Ninan/0000-0002-2747-1246				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON P, 1988, J IMMUNOL, V140, P1732; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; EINSPAHR KJ, 1990, J IMMUNOL, V145, P1490; GALLAGHER PF, 1989, P NATL ACAD SCI USA, V86, P10044, DOI 10.1073/pnas.86.24.10044; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARNES JR, 1989, COLD SPRING HARB SYM, V54, P649; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAERZ UD, 1985, J IMMUNOL, V134, P3994; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; WILDE DB, 1983, J IMMUNOL, V131, P2178; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	37	315	321	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					62	66		10.1038/350062a0	http://dx.doi.org/10.1038/350062a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1706070				2022-12-01	WOS:A1991FA69300065
J	BURTON, FH; HASEL, KW; BLOOM, FE; SUTCLIFFE, JG				BURTON, FH; HASEL, KW; BLOOM, FE; SUTCLIFFE, JG			PITUITARY HYPERPLASIA AND GIGANTISM IN MICE CAUSED BY A CHOLERA-TOXIN TRANSGENE	NATURE			English	Article							HORMONE-RELEASING-FACTOR; ADENYLATE-CYCLASE ACTIVITY; GROWTH-HORMONE; GENE; EXPRESSION; CELLS; MECHANISMS; INJECTION; ABLATION; INVITRO	CYCLIC AMP 1 is thought to act as an intracellular second messenger, mediating the physiological response of many cell types to extracellular signals 2,3. In the pituitary, growth hormone (GH)-producing cells (somatotrophs) proliferate and produce GH in response to hypothalamic GH-releasing factor 4-8, which binds a receptor that stimulates G(s) protein activation of adenylyl cyclase 3,9-12. We have now determined whether somatotroph proliferation and GH production are stimulated by cAMP alone 5,7,11,13-15, or require concurrent, non-G(s)-mediated induction of other regulatory molecules by designing a transgene to induce chronic supraphysiological concentrations of cAMP in somatotrophs. The rat GH promoter 16,17 was used to express an intracellular form of cholera toxin 18, a non-cytotoxic and irreversible activator of G(s) (ref. 19). Introduction of this transgene into mice caused gigantism, elevated serum GH levels, somatotroph proliferation and pituitary hyperplasia. These results support the direct triggering of these events by cAMP, and illustrate the utility of cholera toxin transgene as a tool for physiological engineering.	SCRIPPS RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	BURTON, FH (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							ASA SL, 1984, J CLIN ENDOCR METAB, V58, P796, DOI 10.1210/jcem-58-5-796; ASA SL, 1990, P SOC EXP BIOL MED, V193, P232; BARINAGA M, 1985, NATURE, V314, P279, DOI 10.1038/314279a0; BARTA A, 1981, P NATL ACAD SCI-BIOL, V78, P4867, DOI 10.1073/pnas.78.8.4867; BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BOURNE HR, 1987, NATURE, V330, P517, DOI 10.1038/330517a0; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; HAMMER RE, 1985, NATURE, V315, P413, DOI 10.1038/315413a0; HOEFFLER JP, 1985, ENDOCRINOLOGY, V117, P187, DOI 10.1210/endo-117-1-187; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHOFIELD JG, 1967, NATURE, V215, P1382, DOI 10.1038/2151382b0; SMIGEL M, 1984, ADV CYCLIC NUCL PROT, V17, P1; STEFANEANU L, 1989, ENDOCRINOLOGY, V125, P2710, DOI 10.1210/endo-125-5-2710; STRUTHERS RS, 1989, ENDOCRINOLOGY, V124, P24, DOI 10.1210/endo-124-1-24; SUTHERLAND EW, 1957, J AM CHEM SOC, V79, P3608, DOI 10.1021/ja01570a087; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0	27	179	180	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					74	77		10.1038/350074a0	http://dx.doi.org/10.1038/350074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1848356				2022-12-01	WOS:A1991FA69300069
J	DSOUZA, SE; GINSBERG, MH; MATSUEDA, GR; PLOW, EF				DSOUZA, SE; GINSBERG, MH; MATSUEDA, GR; PLOW, EF			A DISCRETE SEQUENCE IN A PLATELET INTEGRIN IS INVOLVED IN LIGAND RECOGNITION	NATURE			English	Article							IIB-IIIA COMPLEX; MEMBRANE GLYCOPROTEIN-IIB; CELL-BINDING DOMAIN; FIBRINOGEN BINDING; GAMMA-CHAIN; SYNTHETIC PEPTIDES; ALPHA-SUBUNITS; ACID SEQUENCES; FIBRONECTIN; RECEPTOR	PLATELET membrane glycoprotein IIb-IIIa (gpIIb-IIIa; alpha-IIb-beta-3), the most prominent member of the integrin family of adhesion receptors on these cells, mediates platelet aggregation by binding fibrinogen and is critical in thrombosis and haemostasis 1-5. A short amino-acid sequence at the carboxy terminus of the gamma-chain of fibrinogen is recognized by gpIIb-IIIa (ref. 6) and peptides containing this sequence are selectively crosslinked to residues 294-314 of gpIIb (ref. 7). Here we show that an 11-residue peptide from this region of gpIIb inhibits platelet aggregation and binding of fibrinogen to platelets and to purified gpIIb-IIIa, and that it interacts directly with fibrinogen. These results implicate this segment of gpIIb-IIIa in the ligand-binding function of the receptor. Moreover, as this region is highly conserved among integrins, it may have a general function in ligand recognition by this broadly distributed family of adhesion receptors.	PRINCETON UNIV, SQUIBB LABS BIOL, PRINCETON, NJ 08544 USA	Princeton University	DSOUZA, SE (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; CHARO IF, 1989, BLOOD, V74, pA497; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1987, J BIOL CHEM, V262, P5437; HAVERSTICK DM, 1985, BLOOD, V66, P946; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KOBAYASHI T, 1989, J BIOL CHEM, V264, P18247; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MATSUEDA GR, 1988, FASEB J, V2, P6480; PARISE LV, 1985, J BIOL CHEM, V260, P698; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1987, BLOOD, V70, P110; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; YAMADA KM, 1987, J CELL PHYSIOL, V130, P21, DOI 10.1002/jcp.1041300105; YASUDA T, 1988, J CLIN INVEST, V81, P1284, DOI 10.1172/JCI113446	29	197	202	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					66	68		10.1038/350066a0	http://dx.doi.org/10.1038/350066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002847				2022-12-01	WOS:A1991FA69300066
J	GOLINO, P; PISCIONE, F; WILLERSON, JT; CAPPELLIBIGAZZI, M; FOCACCIO, A; VILLARI, B; INDOLFI, C; RUSSOLILLO, E; CONDORELLI, M; CHIARIELLO, M				GOLINO, P; PISCIONE, F; WILLERSON, JT; CAPPELLIBIGAZZI, M; FOCACCIO, A; VILLARI, B; INDOLFI, C; RUSSOLILLO, E; CONDORELLI, M; CHIARIELLO, M			DIVERGENT EFFECTS OF SEROTONIN ON CORONARY-ARTERY DIMENSIONS AND BLOOD-FLOW IN PATIENTS WITH CORONARY ATHEROSCLEROSIS AND CONTROL PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIUM-DEPENDENT RELAXATION; VASOCONSTRICTOR ACTIVITY; SUBSELECTIVE MEASUREMENT; RECEPTOR ANTAGONISTS; THROMBOXANE; KETANSERIN; DOGS; 5-HYDROXYTRYPTAMINE; VASODILATOR; RESPONSES	Background. Studies in animals have shown that serotonin constricts coronary arteries if the endothelium is damaged, but in vitro studies have revealed a vasodilating effect on isolated coronary segments with an intact endothelium. To investigate the effect of serotonin in humans, we studied coronary-artery cross-sectional area and blood flow before and after the infusion of serotonin in seven patients with angiographically normal coronary arteries and in seven with coronary artery disease. Methods. We measured the cross-sectional area of the coronary artery by quantitative angiography and coronary blood flow with an intracoronary Doppler catheter. Measurements were obtained at base line and during intracoronary infusions of serotonin (0.1, 1, and 10-mu-g per kilogram of body weight per minute, for two minutes). We repeated the measurements after an infusion of ketanserin, an antagonist of serotonin receptors that is thought to block the effect of serotonin on receptors in the arterial wall but not in the endothelium. Results. In patients with normal coronary arteries, the highest dose of serotonin increased cross-sectional area by 52 percent (P < 0.001) and blood flow by 58 percent (P < 0.01). The effect was significantly potentiated by administration of ketanserin. In patients with coronary-artery atherosclerosis, serotonin reduced cross-sectional area by 64 percent (P < 0.001) and blood flow by 59 percent (P < 0.001). Ketanserin prevented this effect. Conclusions. Serotonin has a vasodilating effect on normal human coronary arteries; when the endothelium is damaged, as in coronary artery disease, serotonin has a direct, unopposed vasoconstricting effect. When considered with other evidence, these data suggest that platelet-derived factors such as serotonin may have a role in certain acute coronary ischemic syndromes.	NAPLES UNIV, SCH MED 2, DEPT INTERNAL MED, I-80131 NAPLES, ITALY; UNIV TEXAS, HLTH SCI CTR, DEPT INTERNAL MED, HOUSTON, TX 77225 USA; TEXAS HEART INST, HOUSTON, TX 77025 USA	University of Naples Federico II; University of Texas System; University of Texas Health Science Center Houston; Texas Heart Institute	GOLINO, P (corresponding author), NAPLES UNIV, SCH MED 2, DIV CARDIOL, VIA SERGIO PANSINI 5, I-80131 NAPLES, ITALY.			GOLINO, Paolo/0000-0002-3590-6983; INDOLFI, Ciro/0000-0003-1241-6487				ASHTON JH, 1986, CIRCULATION, V73, P572, DOI 10.1161/01.CIR.73.3.572; ASHTON JH, 1987, CIRCULATION, V76, P952, DOI 10.1161/01.CIR.76.4.952; ASHTON JH, 1986, CIRC RES, V59, P568, DOI 10.1161/01.RES.59.5.568; AWOUTERS F, 1985, DRUG DEVELOP RES, V6, P263, DOI 10.1002/ddr.430060402; BENEDICT CR, 1986, CIRC RES, V58, P58, DOI 10.1161/01.RES.58.1.58; BRAZENOR RM, 1982, EUR J PHARMACOL, V81, P569, DOI 10.1016/0014-2999(82)90346-6; BRUM JM, 1984, CIRCULATION, V70, P1066, DOI 10.1161/01.CIR.70.6.1066; BUSH LR, 1984, CIRCULATION, V69, P1161, DOI 10.1161/01.CIR.69.6.1161; CAPPELLIBIGAZZI M, 1990, AM J PHYSIOL, V259, pH1161, DOI 10.1152/ajpheart.1990.259.4.H1161; CHU A, 1987, CIRC RES, V61, P81; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; COHEN ML, 1988, J CARDIOVASC PHARM, V11, pS25; COHEN RA, 1983, AM J PHYSIOL, V245, P1077; COHEN RA, 1983, SCIENCE, V221, P273, DOI 10.1126/science.6574604; DECATERINA R, 1984, CIRCULATION, V69, P889, DOI 10.1161/01.CIR.69.5.889; GOLINO P, 1990, J AM COLL CARDIOL, V15, P718, DOI 10.1016/0735-1097(90)90652-6; GOLINO P, 1989, CIRCULATION, V79, P154, DOI 10.1161/01.CIR.79.1.154; GOLINO P, 1988, CIRCULATION, V78, P701, DOI 10.1161/01.CIR.78.3.701; HEISTAD DD, 1984, CIRC RES, V54, P711, DOI 10.1161/01.RES.54.6.711; HIRSH PD, 1981, NEW ENGL J MED, V304, P687; HOUSTON DS, 1985, AM J PHYSIOL, V248, pH389, DOI 10.1152/ajpheart.1985.248.3.H389; LAMPING KG, 1985, CIRC RES, V57, P46, DOI 10.1161/01.RES.57.1.46; NABEL EG, 1988, CIRCULATION, V77, P43, DOI 10.1161/01.CIR.77.1.43; RUBANYI GM, 1987, J AM COLL CARDIOL, V9, P1243, DOI 10.1016/S0735-1097(87)80462-X; SCHMITZ JM, 1985, CIRC RES, V57, P223, DOI 10.1161/01.RES.57.2.223; SIBLEY DH, 1986, J AM COLL CARDIOL, V8, P1332, DOI 10.1016/S0735-1097(86)80305-9; SPEARS JR, 1983, CIRCULATION, V68, P453, DOI 10.1161/01.CIR.68.2.453; VANDENBERG EK, 1989, CIRCULATION, V79, P116, DOI 10.1161/01.CIR.79.1.116; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; VANNUETEN JM, 1981, J PHARMACOL EXP THER, V218, P217; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; WILSON RF, 1985, CIRCULATION, V72, P82, DOI 10.1161/01.CIR.72.1.82; WILSON RF, 1986, CIRCULATION, V73, P444, DOI 10.1161/01.CIR.73.3.444	33	414	430	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1991	324	10					641	648		10.1056/NEJM199103073241001	http://dx.doi.org/10.1056/NEJM199103073241001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA144	1994246				2022-12-01	WOS:A1991FA14400001
J	ITO, N; PHILLIPS, SEV; STEVENS, C; OGEL, ZB; MCPHERSON, MJ; KEEN, JN; YADAV, KDS; KNOWLES, PF				ITO, N; PHILLIPS, SEV; STEVENS, C; OGEL, ZB; MCPHERSON, MJ; KEEN, JN; YADAV, KDS; KNOWLES, PF			NOVEL THIOETHER BOND REVEALED BY A 1.7-A CRYSTAL-STRUCTURE OF GALACTOSE-OXIDASE	NATURE			English	Article							RIBONUCLEOTIDE REDUCTASE; SUPEROXIDE-DISMUTASE; RADICAL SITE; COPPER; RESOLUTION; ENZYME; IDENTIFICATION; INVOLVEMENT; CATALYSIS; SYSTEM	GALACTOSE oxidase is an extracellular enzyme secreted by the fungus Dactylium dendroides. It is monomeric, with a relative molecular mass of 68,000, catalyses the stereospecific oxidation of a broad range of primary alcohol substrates and possesses a unique mononuclear copper site essential for catalysing a two-electron transfer reaction during the oxidation of primary alcohols to corresponding aldehydes 1. Recent evidence 2 arguing against a Cu(III)-Cu(I) couple 3 implies the existence of a second redox-active site proposed to involve pyrroloquinoline quinone 4 or a tyrosine radical 5,6. We now report the crystal structure of galactose oxidase at 1.7 angstrom resolution. This reveals a unique structural feature at the copper site with a novel thioether bond linking Cys 228 and Tyr 272 in a stacking interaction with Trp 290. We propose that these molecular components stabilize the protein free-radical species essential for catalysis and thus provide a 'built-in' secondary cofactor. This feature may represent a new mechanism for mediating electron transfer in metalloenzymes in the absence of exogenous cofactors.			ITO, N (corresponding author), UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.			McPherson, Michael/0000-0002-0719-6427; Phillips, Simon/0000-0001-8922-0250				ADMAN ET, 1981, ISRAEL J CHEM, V21, P8, DOI 10.1002/ijch.198100003; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BLACKBURN NJ, 1984, BIOCHEM J, V219, P985, DOI 10.1042/bj2190985; DOOLEY DM, 1987, LIFE CHEM REPORTS, V5, P91; GUSS JM, 1983, J MOL BIOL, V169, P521; HAMILTON GA, 1978, J AM CHEM SOC, V100, P1899, DOI 10.1021/ja00474a042; JACOBSON RR, 1988, J AM CHEM SOC, V110, P3690, DOI 10.1021/ja00219a071; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KOSMAN DJ, 1974, ARCH BIOCHEM BIOPHYS, V165, P456, DOI 10.1016/0003-9861(74)90271-9; KOSMAN DJ, 1984, COPPER PROTEINS COPP, V1, P1; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LERCH K, 1982, J BIOL CHEM, V257, P6414; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; POULOS TL, 1980, J BIOL CHEM, V255, P8199; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; PRINCE RC, 1990, TRENDS BIOCHEM SCI, V15, P170, DOI 10.1016/0968-0004(90)90152-2; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TRESSEL P, 1980, BIOCHEM BIOPH RES CO, V92, P781, DOI 10.1016/0006-291X(80)90771-8; VANDERMEER RA, 1989, J BIOL CHEM, V264, P7792; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WHITTAKER MM, 1988, J BIOL CHEM, V263, P6074; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104	30	693	705	2	67	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					87	90		10.1038/350087a0	http://dx.doi.org/10.1038/350087a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002850				2022-12-01	WOS:A1991FA69300073
J	JEWETT, ME; KRONAUER, RE; CZEISLER, CA				JEWETT, ME; KRONAUER, RE; CZEISLER, CA			LIGHT-INDUCED SUPPRESSION OF ENDOGENOUS CIRCADIAN AMPLITUDE IN HUMANS	NATURE			English	Article							RHYTHM; OSCILLATOR; INDUCTION; GONYAULAX; PULSES; CLOCK	WINFREE reported 20 years ago the intriguing finding that a light stimulus of a critical strength applied at a critical circadian phase could essentially stop the circadian clock in Drosophila pseudo-obscura by resetting the circadian oscillator close to its singularity (a phaseless position at which the amplitude of circadian oscillation is zero) 1. Since then, similar observations of attenuated circadian amplitude in response to critical stimuli have been limited to unicells, insects and plants 2-7. Our recent demonstration that the phase of the human circadian pacemaker could be inverted using an unconventional three-cycle stimulus 8,9 led us to investigate whether critically timed exposure to a more moderate stimulus could drive that oscillator towards its singularity. Here we report that exposure of humans to fewer cycles of bright light, centred around the time at which the human circadian pacemaker is most sensitive to light-induced phase shifts, can markedly attenuate endogenous circadian amplitude. In some cases this results in an apparent loss of rhythmicity, as expected to occur in the region of singularity.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CIRCADIAN & SLEEP DISORDERS MED LAB,BOSTON,MA 02115; HARVARD UNIV,DIV APPL SCI,CAMBRIDGE,MA 02138	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University								BROWN EN, 1987, THESIS HARVARD U, P1; CZEISLER CA, 1990, NEW ENGL J MED, V322, P1253, DOI 10.1056/NEJM199005033221801; CZEISLER CA, 1989, SCIENCE, V244, P1328, DOI 10.1126/science.2734611; ENGELMANN W, 1978, PHYSIOL PLANTARUM, V43, P68, DOI 10.1111/j.1399-3054.1978.tb01569.x; ENRIGHT JT, 1986, LECT MATH LIFE SCI, V19, P121; Eskin A., 1971, P55; GANDER PH, 1983, AM J PHYSIOL, V245, pR10, DOI 10.1152/ajpregu.1983.245.1.R10; Kronauer R.E., 1990, SLEEP 90 P 10 EUR C, P306; MALINOWSKI JR, 1985, J COMP PHYSIOL B, V155, P257, DOI 10.1007/BF00685221; MILLS JN, 1978, J PHYSIOL-LONDON, V285, P455, DOI 10.1113/jphysiol.1978.sp012582; PETERSON EL, 1980, J COMP PHYSIOL, V138, P201, DOI 10.1007/BF00657038; SAUNDERS DS, 1978, J COMP PHYSIOL, V124, P75, DOI 10.1007/BF00656393; STROGATZ SH, 1990, J BIOL RHYTHM, V5, P169, DOI 10.1177/074873049000500208; TAYLOR W, 1982, J COMP PHYSIOL, V148, P11, DOI 10.1007/BF00688883; WALZ B, 1979, P NATL ACAD SCI USA, V76, P6443, DOI 10.1073/pnas.76.12.6443; Winfree A.T., 1987, TIMING BIOL CLOCKS; WINFREE AT, 1973, J COMP PHYSIOL, V85, P105, DOI 10.1007/BF00696471; WINFREE AT, 1970, J THEOR BIOL, V28, P327, DOI 10.1016/0022-5193(70)90075-5	18	200	203	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					59	62		10.1038/350059a0	http://dx.doi.org/10.1038/350059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002845				2022-12-01	WOS:A1991FA69300064
J	NEUGEBAUER, KM; REICHARDT, LF				NEUGEBAUER, KM; REICHARDT, LF			CELL-SURFACE REGULATION OF BETA-1-INTEGRIN ACTIVITY ON DEVELOPING RETINAL NEURONS	NATURE			English	Article							GLYCOPROTEIN; PROTEINS; COMPLEX; LAMININ; CSAT	INTEGRINS are a family of alpha-beta-heterodimeric receptors that mediate cell-cell and cell-substratum interactions. Integrin binding to extracellular ligands regulates cell adhesion, shape, motility, intracellular signalling and gene expression 1-3. Mechanisms that regulate integrin function are, therefore, central to the participation of integrins in a diverse set of cellular events. Here we report the identification of TASC, a monoclonal antibody to a novel epitope on the integrin beta-1 subunit, which inhibits cell adhesion to vitronectin but promotes adhesion to laminin and collagen types I and IV. We show that developing retinal neurons that have lost responsiveness to laminin 4 regain the ability to bind laminin in the presence of TASC. Thus, beta-1-class integrins are likely to occupy multiple affinity states that can be modulated at the cell surface.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019090] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS019090, R01 NS019090-14] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; COHEN J, 1989, DEVELOPMENT, V107, P381; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FIGDOR CG, 1990, IMMUNOL TODAY, V11, P277, DOI 10.1016/0167-5699(90)90112-M; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GULINO D, 1990, J BIOL CHEM, V265, P9575; HALL DE, 1987, J CELL BIOL, V104, P623, DOI 10.1083/jcb.104.3.623; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORWITZ AF, 1984, MONOCLONAL ANTIBODIE, P103; KEIZER GD, 1988, J IMMUNOL, V140, P1393; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1177, DOI 10.1083/jcb.107.3.1177; NEUGEBAUER KM, IN PRESS NEURON; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; REICHARDT LF, 1991, REV NEUROSCI, V14, P531; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TIMPL R, 1979, J BIOL CHEM, V254, P9933; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	25	181	184	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					68	71		10.1038/350068a0	http://dx.doi.org/10.1038/350068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1706071	Green Accepted			2022-12-01	WOS:A1991FA69300067
J	NOJI, S; NOHNO, T; KOYAMA, E; MUTO, K; OHYAMA, K; AOKI, Y; TAMURA, K; OHSUGI, K; IDE, H; TANIGUCHI, S; SAITO, T				NOJI, S; NOHNO, T; KOYAMA, E; MUTO, K; OHYAMA, K; AOKI, Y; TAMURA, K; OHSUGI, K; IDE, H; TANIGUCHI, S; SAITO, T			RETINOIC ACID INDUCES POLARIZING ACTIVITY BUT IS UNLIKELY TO BE A MORPHOGEN IN THE CHICK LIMB BUD	NATURE			English	Article							RECEPTOR GENES; DIFFERENTIAL EXPRESSION; POSITIONAL INFORMATION; LOCAL APPLICATION; HOMEOBOX GENE; PATTERN; CELLS; IDENTIFICATION; ELEMENT; ALPHA	RETINOIC acid is a putative morphogen in limb formation in the chick and other vertebrates 1-5. In chick limb formation, it is thought that retinoic acid is released from the zone of polarizing activity (ZPA) and the concentration gradient of retinoic acid formed from the posterior to the anterior provides positional cues for digit formation 1-4,6. Implantation of a bead containing retinoic acid at the anterior margin of the limb bud induces a mirror-image symmetrical duplication of the digit pattern similar to that observed when the ZPA is grafted into the anterior margin of the host limb bud 7,8. Also, the level of endogenous retinoic acid (25 nM on average) is higher in the posterior one third of the limb bud 1,6. We found that when the bead containing either retinoic acid or an analogue but not the ZPA, was implanted in the anterior margin of the chick limb bud, expression of the retinoic acid receptor type-beta gene was induced around the bead within 4 h. These results indicate that exogenous retinoic acid is not identical with the ZPA morphogen. As the anterior tissue exposed to retinoic acid has polarizing activity 9, we conclude that the primary function of exogenous retinoic acid is to induce polarizing activity in the limb bud.	OKAYAMA UNIV, SCH DENT,DEPT ORAL & MAXILLOFACIAL SURG 1, OKAYAMA 700, JAPAN; OKAYAMA UNIV, SCH DENT,DEPT ORAL & MAXILLOFACIAL SURG 2, OKAYAMA 700, JAPAN; KAWASAKI MED SCH, DEPT PHARMACOL, KURASHIKI, OKAYAMA 70101, JAPAN; TOHOKU UNIV, INST BIOL, SENDAI, MIYAGI 980, JAPAN	Okayama University; Okayama University; Kawasaki Medical School; Tohoku University	NOJI, S (corresponding author), OKAYAMA UNIV, SCH DENT, DEPT BIOCHEM, 2-5-1 SHIKATA CHO, OKAYAMA 700, JAPAN.		Nohno, Tsutomu/B-6923-2008	Nohno, Tsutomu/0000-0002-0351-5603				BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EICHELE G, 1987, J CELL BIOL, V105, P1917, DOI 10.1083/jcb.105.4.1917; EICHELE G, 1984, ANAL BIOCHEM, V142, P542, DOI 10.1016/0003-2697(84)90504-9; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IDE H, 1990, DEV GROWTH DIFFER, V32, P1; NOJI S, 1989, FEBS LETT, V257, P93, DOI 10.1016/0014-5793(89)81794-6; NOJI S, 1990, ACTA HISTOCHEM CYTOC, V23, P353, DOI 10.1267/ahc.23.353; NOJI S, 1989, FEBS LETT, V259, P86, DOI 10.1016/0014-5793(89)81501-7; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; OSUMIYAMASHITA N, 1990, FEBS LETT, V264, P71, DOI 10.1016/0014-5793(90)80767-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P227; Summerbell D, 1983, Prog Clin Biol Res, V110 Pt A, P109; TAMURA K, 1990, CELL DIFFER DEV, V32, P17, DOI 10.1016/0922-3371(90)90095-E; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WOLPERT L, 1989, DEVELOPMENT, V107, P3; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	29	248	254	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					83	86		10.1038/350083a0	http://dx.doi.org/10.1038/350083a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1848357				2022-12-01	WOS:A1991FA69300072
J	TSUKAMOTO, T; MIURA, S; FUJIKI, Y				TSUKAMOTO, T; MIURA, S; FUJIKI, Y			RESTORATION BY A 35K MEMBRANE-PROTEIN OF PEROXISOME ASSEMBLY IN A PEROXISOME-DEFICIENT MAMMALIAN-CELL MUTANT	NATURE			English	Article							RAT-LIVER PEROXISOMES; ENDOPLASMIC-RETICULUM; ZELLWEGER SYNDROME; CARBOXY TERMINUS; POLYPEPTIDE; ENVELOPE; GENOME	PEROXISOMES are among the intracellular organelles of eukaryotic cells that contain specialized sets of enzymes with specific functions 1. Little is known of membranous components involved in assembly of the intracellular compartments 2-5. We isolated two peroxisome-deficient and mutually complementary, Chinese hamster ovary cell mutants, Z65 and Z24 6, which closely resembled fibroblasts from patients with autosomal recessive, peroxisome-defective disorders such as Zellweger syndrome 1,7. These patients show characteristic dysmorphism, severe hypotonia, psychomotor retardation, and peroxisomal dysfunctions and rarely survive early childhood. Here we report what seems to be the first direct cloning and characterization of a complementary DNA encoding a peroxisomal membrane protein of relative molecular mass 35,000 (M(r) 35K) that restores the biogenesis of peroxisomes and complements the defect of peroxisomal functions in the mutant Z65.	MEIJI INST HLTH SCI,MOLEC CELL BIOL LAB,ODAWARA,KANAGAWA 250,JAPAN									AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERTHET J, 1951, BIOCHEM J, V50, P174, DOI 10.1042/bj0500174; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BREITMAN ML, 1982, MOL CELL BIOL, V2, P966, DOI 10.1128/MCB.2.8.966; BRUL S, 1988, J CLIN INVEST, V81, P1710, DOI 10.1172/JCI113510; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; HESS R, 1965, NATURE, V208, P856, DOI 10.1038/208856a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; MARSHALL M, 1972, J BIOL CHEM, V247, P1641; MIURA S, 1984, J BIOL CHEM, V259, P6397; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MORI M, 1979, P NATL ACAD SCI USA, V76, P3719; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SONE T, 1987, J BIOL CHEM, V262, P5878; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	29	222	224	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					77	81		10.1038/350077a0	http://dx.doi.org/10.1038/350077a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1750930				2022-12-01	WOS:A1991FA69300070
J	WANEK, N; GARDINER, DM; MUNEOKA, K; BRYANT, SV				WANEK, N; GARDINER, DM; MUNEOKA, K; BRYANT, SV			CONVERSION BY RETINOIC ACID OF ANTERIOR CELLS INTO ZPA CELLS IN THE CHICK WING BUD	NATURE			English	Article							POLARIZING REGION; PATTERN-FORMATION; LIMB BUD; DIGITS	IN recent years there has been considerable interest in the role of retinoic acid (RA) in vertebrate-limb pattern formation. When RA is applied to the anterior of the chick wing bud, a mirror-image duplication of the limb pattern develops that is identical to the pattern resulting from grafts of posterior tissue (zone of polarizing activity, or ZPA) 1. It has been proposed that position along the anterior-posterior axis in the chick limb is specified by a gradient of a diffusible factor produced by the ZPA 2. The ZPA-mimicking action of RA has led to the hypothesis that exogenously applied RA acts by providing graded spatial information across the anterior-posterior limb axis 3,4. An alternative interpretation is that RA changes anterior cells into ZPA cells, which in turn provide the actual pattern-duplicating stimulus 3-5; there is already some preliminary evidence that this occurs 5. A hybrid interpretation has also been suggested whereby ZPA cells are formed in response to RA exposure and then begin to release retinoids that act as graded spatial cues 3. We have used a functional assay 6 to test anterior chick wing-bud cells for ZPA activity after exposure to RA. The results of our studies indicate that the action of RA is to change anterior cells into ZPA cells. Further, our results indicate that it is unlikely that RA-treated anterior cells then begin producing RA in such a way as to provide a graded positional signal.	UNIV CALIF IRVINE, CTR DEV BIOL, IRVINE, CA 92717 USA	University of California System; University of California Irvine				Muneoka, Ken/0000-0002-7520-6869				BRYANT SV, 1986, TRENDS GENET, V2, P153, DOI 10.1016/0168-9525(86)90210-6; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HONIG LS, 1981, NATURE, V291, P72, DOI 10.1038/291072a0; Javois L.C., 1984, PATTERN FORMATION PR, P557; LUDOLPH DC, 1990, DEV BIOL, V140, P41, DOI 10.1016/0012-1606(90)90051-J; MADEN M, 1982, NATURE, V295, P672, DOI 10.1038/295672a0; MEINHARDT H, 1989, DEVELOPMENT, V107, P169; SMITH JC, 1979, J EMBRYOL EXP MORPH, V52, P105; SMITH SM, 1989, DEVELOPMENT, V107, P121; STOCUM DL, 1984, J EXP ZOOL, V232, P207, DOI 10.1002/jez.1402320208; Summerbell D, 1983, Prog Clin Biol Res, V110 Pt A, P109; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0	19	219	228	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					81	83		10.1038/350081a0	http://dx.doi.org/10.1038/350081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002849				2022-12-01	WOS:A1991FA69300071
J	ADEBONOJO, FO				ADEBONOJO, FO			INFANT HEAD SHAPING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ADEBONOJO, FO (corresponding author), E TENNESSEE STATE UNIV,JOHNSON CITY,TN 37614, USA.							EPSTEIN F, 1973, LANCET, V1, P634; HENSHEN P, 1966, HUMAN SKULL CULTURAL; MARSHALL DS, 1956, AM J PHYS ANTHROPOL, V13, P405; McGibbon Walter, 1912, LARYNGOSCOPE, V22, P1165; NICHTER LS, 1986, PLAST RECONSTR SURG, V77, P325; SCHENDEL SA, 1986, PLAST RECONSTR SURG, V78, P267, DOI 10.1097/00006534-198608000-00038; SHAPIRO HL, 1928, ANTHR PAPERS MUSEU 1, P30; TROPINARD P, 1878, ANTHROPOLOGY	8	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1179	1179						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996005				2022-12-01	WOS:A1991EZ47400037
J	BUCHI, K				BUCHI, K			RADIATION PROCTITIS - THERAPY AND PROGNOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							LASER THERAPY; ENTERITIS				BUCHI, K (corresponding author), UNIV UTAH,HLTH SCI CTR,SALT LAKE CITY,UT 84112, USA.							AHLQUIST DA, 1986, MAYO CLIN PROC, V61, P927, DOI 10.1016/S0025-6196(12)62631-7; BLOOMER WD, 1975, NEW ENGL J MED, V293, P80, DOI 10.1056/NEJM197507102930206; BUCHI KN, 1987, GASTROINTEST ENDOSC, V33, P27, DOI 10.1016/S0016-5107(87)71481-3; GALLAND RB, 1986, SURGERY, V99, P133; GOLDSTEIN F, 1976, AM J GASTROENTEROL, V65, P201; LEUCHTER RS, 1982, OBSTET GYNECOL, V59, pS65; NOVAK JM, 1979, J CLIN GASTROENTEROL, V1, P9, DOI 10.1097/00004836-197903000-00003; Walsh D, 1897, Br Med J, V2, P272	8	41	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1180	1180		10.1001/jama.265.9.1180	http://dx.doi.org/10.1001/jama.265.9.1180			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996006				2022-12-01	WOS:A1991EZ47400039
J	CALLAHAM, M; BARTON, CW; KAYSER, S				CALLAHAM, M; BARTON, CW; KAYSER, S			POTENTIAL COMPLICATIONS OF HIGH-DOSE EPINEPHRINE THERAPY IN PATIENTS RESUSCITATED FROM CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT VASOPRESSOR RESPONSE; MYOCARDIAL OXYGEN DELIVERY; CARDIOPULMONARY RESUSCITATION; HUMAN-BEINGS; CPR	Adults resuscitated from nontraumatic cardiac arrest who received intravenous epinephrine in doses chosen by the treating physician and who survived at least 6 hours were studied to determine if high-dose epinephrine produced more complications than standard-dose. A total of 68 patients were enrolled and evaluated for postresuscitation complications attributable to epinephrine, using a two-tailed t test, and contingency analysis. The 33 patients receiving high-dose epinephrine and 35 patients receiving standard-dose epinephrine were similar in demographics and variables known to affect outcome. There was no difference in potential complications between groups except serum calcium, which was 1.97 mmol/L (SD, 0.20) in the high-dose epinephrine group and 2.10 (SD, 0.20) in the standard-dose group. Hospital discharge rates (18% in the high-dose vs 30% in the standard-dose group) and neurological status on discharge were not significantly different. High-dose epinephrine did not produce increased direct complications in this cardiac arrest population compared with standard-dose epinephrine.	UNIV CALIF SAN FRANCISCO,DIV CLIN PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	CALLAHAM, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,DIV EMERGENCY MED,SAN FRANCISCO,CA 94143, USA.			Callaham, Michael/0000-0003-2284-256X				BARTON CW, 1990, ANN EMERG MED, V19, P490; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1988, CRIT CARE MED, V16, P536, DOI 10.1097/00003246-198805000-00013; BROWN DD, 1988, SKELETAL RADIOL, V17, P302, DOI 10.1007/BF00401818; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; ERSOZ N, 1971, BRIT J ANAESTH, V43, P709, DOI 10.1093/bja/43.7.709; FRIEDMAN B, 1955, LANCET, P575; GOETTING MG, 1989, CRIT CARE MED, V17, P1258, DOI 10.1097/00003246-198912000-00004; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; HALL AH, 1987, AM J EMERG MED, V5, P64, DOI 10.1016/0735-6757(87)90293-2; KARCH SB, 1987, AM J FOREN MED PATH, V8, P3, DOI 10.1097/00000433-198703000-00002; KELLNER M, 1966, ACTA MED HUNG, V23, P37; KELLNER M, 1966, ACTA MED HUNG, V22, P335; KIRIMLI B, 1969, ANESTH ANAL CURR RES, V48, P649; KOSCOVE EM, 1988, JAMA-J AM MED ASSOC, V259, P3031, DOI 10.1001/jama.259.20.3031; KURACHEK SC, 1985, JAMA-J AM MED ASSOC, V253, P1441, DOI 10.1001/jama.253.10.1441; LONGSTRETH WT, 1987, WESTERN J MED, V147, P175; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; MARTIN D, 1990, ANN EMERG MED, V19, P322, DOI 10.1016/S0196-0644(05)82055-4; MARTIN GB, 1985, ANN EMERG MED, V14, P293, DOI 10.1016/S0196-0644(85)80089-5; MUSCH W, 1987, ANN EMERG MED, V16, P514; NOVEY HS, 1969, J AMER MED ASSOC, V207, P2435, DOI 10.1001/jama.207.13.2435; PARADIS N A, 1990, Critical Care Medicine, V18, pS221, DOI 10.1097/00003246-199012001-00087; PARADIS NA, 1990, ANN EMERG MED, V19, P491; RITTER G, 1985, AM HEART J, V110, P932, DOI 10.1016/0002-8703(85)90187-5; SALERNO DM, 1989, CRIT CARE MED, V17, P1181, DOI 10.1097/00003246-198911000-00016; STEINGRUB J, 1990, Critical Care Medicine, V18, pS223, DOI 10.1097/00003246-199012001-00090; URBAN P, 1988, ANN INTERN MED, V109, P110, DOI 10.7326/0003-4819-109-2-110; 1986, JAMA-J AM MED ASSOC, V255, P2905	29	35	35	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1117	1122		10.1001/jama.265.9.1117	http://dx.doi.org/10.1001/jama.265.9.1117			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995996				2022-12-01	WOS:A1991EZ47400027
J	GOLDMAN, L; WEINSTEIN, MC; GOLDMAN, PA; WILLIAMS, LW				GOLDMAN, L; WEINSTEIN, MC; GOLDMAN, PA; WILLIAMS, LW			COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITION FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; STAGE RENAL-DISEASE; 2 NATIONAL SURVEYS; SERUM-CHOLESTEROL; POLICY MODEL; RISK-FACTORS; MORTALITY; THERAPY; DIET; CHOLESTYRAMINE	To determine the cost-effectiveness of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors (such as lovastatin) for the primary and secondary prevention of coronary heart disease, we used the Coronary Heart Disease Policy Model, a computer-simulated model that estimates the risk factor-specific annual incidence of coronary heart disease and the risk of recurrent coronary events in persons with prevalent coronary heart disease. When used for secondary prevention, 20 mg/d of lovastatin was estimated to save lives and save costs in younger men with cholesterol levels above 250 mg/dL (6.47 mmol/L) and to have a favorable cost-effectiveness ratio regardless of the cholesterol level except in young women with cholesterol levels below 250 mg/dL (6.47 mmol/L). Doses of 40 mg/d of lovastatin had favorable incremental cost-effectiveness ratios in men with cholesterol levels above 250 mg/dL (6.47 mmol/L). By comparison, primary prevention had favorable cost-effectiveness ratios only in selected subgroups based on cholesterol levels and other established risk factors. We conclude that current national recommendations regarding medication for secondary prevention are not as aggressive as our projections would suggest, while recommendations regarding the use of medications for primary prevention should consider the cost of medication as well as the risk factor profile of the individual patient.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	GOLDMAN, L (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV CLIN EPIDEMIOL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				AHRQ HHS [HS06258] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CORDAY E, 1989, J AM COLL CARDIOL, V13, P497, DOI 10.1016/0735-1097(89)90531-7; DAYTON S, 1969, CIRCULATION, V40, pII1; DRUMMOND MF, 1987, HEALTH POLICY, V7, P309, DOI 10.1016/0168-8510(87)90072-8; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELVEBACK LR, 1981, MAYO CLIN PROC, V56, P665; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GOLDMAN L, 1989, CIRCULATION, V80, P254, DOI 10.1161/01.CIR.80.2.254; HAVEL RJ, 1987, ANN INTERN MED, V107, P609, DOI 10.7326/0003-4819-107-5-609; HIMMELSTEIN DU, 1984, NEW ENGL J MED, V311, P1511, DOI 10.1056/NEJM198412063112311; HJERMANN I, 1981, LANCET, V2, P1303; HOEG JM, 1986, AM J CARDIOL, V57, P933, DOI 10.1016/0002-9149(86)90733-2; ILLINGWORTH DR, 1984, ANN INTERN MED, V101, P598, DOI 10.7326/0003-4819-101-5-598; KANNEL WB, 1990, AM J CARDIOL, V66, pB1, DOI 10.1016/0002-9149(90)90434-3; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LEAVERTON PE, 1987, J CHRON DIS, V40, P775, DOI 10.1016/0021-9681(87)90129-9; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; MANTELL G, 1990, AM J CARDIOL, V66, pB11, DOI 10.1016/0002-9149(90)90435-4; MARTENS LL, 1989, AM J MED, V87, pS54, DOI 10.1016/S0002-9343(89)80600-X; MARTENS LL, 1990, AM J CARDIOL, V65, pF27; MCGEE D, 1976, NIH761083 PUBL; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; PALUMBO PJ, 1989, JAMA-J AM MED ASSOC, V262, P91, DOI 10.1001/jama.262.1.91; PELL S, 1985, NEW ENGL J MED, V312, P1005, DOI 10.1056/NEJM198504183121601; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; RUSSELL LB, 1989, SCIENCE, V246, P892, DOI 10.1126/science.2510299; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3527, DOI 10.1001/jama.258.24.3527; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; TOBERT JA, 1986, JAMA-J AM MED ASSOC, V256, P2829; TOSTESON ANA, 1990, AM J PUBLIC HEALTH, V80, P1481, DOI 10.2105/AJPH.80.12.1481; TSEVAT J, IN PRESS CIRCULATION; TURPEINEN O, 1979, CIRCULATION, V59, P1; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; 1973, SOME CHARACTERISTICS; 1989, LANCET, V1, P1423; 1971, BMJ, V4, P775; 1988, TECHNICAL APPENDICES; 1971, BMJ, V4, P767; 1981, VITAL STATISTICS U A, V2; 1982, CURRENT POPULATI P25, V922; 1982, CURRENT POPULATI P25, V917; 1988, JAMA-J AM MED ASSOC, V260, P359; 1987, NIH872703 US DEP HLT; 1984, CURRENT POPULATI P25, V949	63	305	305	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1145	1151		10.1001/jama.265.9.1145	http://dx.doi.org/10.1001/jama.265.9.1145			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1899896				2022-12-01	WOS:A1991EZ47400032
J	KAUFMAN, RH				KAUFMAN, RH			HUMAN PAPILLOMAVIRUS AND CERVICAL-CANCER - RISK TO MALE PARTNER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KAUFMAN, RH (corresponding author), BAYLOR UNIV,HOUSTON,TX 77030, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1179	1180						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1847486				2022-12-01	WOS:A1991EZ47400038
J	RAUB, W				RAUB, W			COMBINED AGENTS ELIMINATE HUMAN HIV-1 FROM T-CELL CULTURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1990, P NATL ACAD SCI USA, V87, P8889	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1075	1075						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995987				2022-12-01	WOS:A1991EZ47400005
J	RAUB, W				RAUB, W			NEW DRUG AMELIORATES EFFECTS OF ASTHMA AND ALLERGIC RHINITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1990, NEW ENGL J MED, V323, P1745; 1990, NEW ENGL J MED, V323, P1740	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1075	1075						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995987				2022-12-01	WOS:A1991EZ47400007
J	RAUB, W				RAUB, W			IMMUNOGENETIC DISTINCTION FOUND BETWEEN PAUCIARTICULAR AND POLYARTICULAR JUVENILE ARTHRITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1990, ARTHRITIS RHEUM, V33, P1787	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1075	1075						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995987				2022-12-01	WOS:A1991EZ47400006
J	RIGOTTI, NA; NEER, RM; SKATES, SJ; HERZOG, DB; NUSSBAUM, SR				RIGOTTI, NA; NEER, RM; SKATES, SJ; HERZOG, DB; NUSSBAUM, SR			THE CLINICAL COURSE OF OSTEOPOROSIS IN ANOREXIA-NERVOSA - A LONGITUDINAL-STUDY OF CORTICAL BONE MASS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY HYPERPARATHYROIDISM; GROWTH-HORMONE; FRACTURE RISK; SOMATOMEDIN-C; WOMEN; OSTEOPENIA; DENSITY; AMENORRHEA; PREDICTION; CALCIUM	Women with anorexia nervosa have reduced bone mass and may develop fractures. Neither the pathophysiology of this osteoporosis nor its natural history is known. To study the clinical course of osteoporosis, we followed up 27 women with anorexia nervosa for a median of 25 months (range, 9 to 53 months). At study entry, cortical bone density, measured by single-photon absorptiometry of the radial shaft, was low (mean +/- SD, 0.63 +/- 0.07 g/cm2) and inversely related to the duration of amenorrhea (r = -0.49). During follow-up, most patients gained weight (n = 19), took calcium supplements (n = 16), and exercised regularly (n = 22), but fewer than half reached 80% or more of ideal body weight (n = 11), resumed menses (n = 6), or received estrogen (n = 4). Cortical bone density was stable during follow-up for the group as a whole; the mean annual change (+/-SD) was +0.005 (+/- .015) g/cm2 (95% confidence interval, -0.0009 to +0.0109). There was no significant difference in the mean change in bone density between women who attained 80% of ideal weight and those who did not or between groups who did or did not regain menses, take estrogen or calcium, or exercise vigorously. Four fractures were clinically observed in three women during follow-up. The rate of 0.05 nonspine fractures per person-year (95% confidence interval, 0.02 to 0.13) exceeds that of normal women in this age range (relative risk, 7.1; 95% confidence interval, 2.3 to 18.5). We conclude that reductions in cortical bone density appear not to be rapidly reversed recovery from anorexia nervosa and that anorectic women may have an increased risk of fracture.	MASSACHUSETTS GEN HOSP,MED SERV,ENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,PSYCHIAT SERV,EATING DISORDERS UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	RIGOTTI, NA (corresponding author), MASSACHUSETTS GEN HOSP,MED SERV,GEN INTERNAL MED UNIT,BULFINCH 1,FRUIT ST,BOSTON,MA 02114, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AYERS JWT, 1984, FERTIL STERIL, V41, P224; BACHRACH LK, 1990, PEDIATRICS, V86, P440; BILLER BMK, 1989, J CLIN ENDOCR METAB, V68, P548, DOI 10.1210/jcem-68-3-548; BLOCK G, 1982, AM J EPIDEMIOL, V115, P492, DOI 10.1093/oxfordjournals.aje.a113331; Cameron J R, 1968, Invest Radiol, V3, P141, DOI 10.1097/00004424-196805000-00001; CANN CE, 1985, BONE, V6, P1, DOI 10.1016/8756-3282(85)90399-0; CHOLST IN, 1984, NEW ENGL J MED, V310, P1221, DOI 10.1056/NEJM198405103101904; CLEMMONS DR, 1979, NEW ENGL J MED, V301, P1138, DOI 10.1056/NEJM197911223012102; CLEMMONS DR, 1981, J CLIN ENDOCR METAB, V53, P1247, DOI 10.1210/jcem-53-6-1247; CROSBY LO, 1985, CLIN ORTHOP RELAT R, V201, P271; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DAVIES KM, 1990, BONE, V11, P143, DOI 10.1016/8756-3282(90)90207-F; DRINKWATER BL, 1984, NEW ENGL J MED, V311, P277, DOI 10.1056/NEJM198408023110501; DRINKWATER BL, 1986, JAMA-J AM MED ASSOC, V256, P380, DOI 10.1001/jama.256.3.380; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; FONESCA VA, 1988, J CLIN PATHOL, V41, P195; GARDSELL P, 1989, CALCIFIED TISSUE INT, V44, P235, DOI 10.1007/BF02553757; GARRAWAY WM, 1979, MAYO CLIN PROC, V54, P701; GRANDE F, 1980, MODERN NUTRITION HLT, P7; HINTZ RL, 1978, J PEDIATR-US, V92, P153, DOI 10.1016/S0022-3476(78)80099-7; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; ISAKSSON OGP, 1987, ENDOCR REV, V8, P426, DOI 10.1210/edrv-8-4-426; JOHANSEN JS, 1988, J CLIN ENDOCR METAB, V67, P701, DOI 10.1210/jcem-67-4-701; JOYCE JM, 1990, J NUCL MED, V31, P325; KAPLAN FS, 1986, CLIN ORTHOP RELAT R, V212, P250; KLIBANSKI A, 1980, NEW ENGL J MED, V303, P1511, DOI 10.1056/NEJM198012253032605; KLIBANSKI A, 1986, NEW ENGL J MED, V315, P542, DOI 10.1056/NEJM198608283150903; LINDBERG JS, 1984, ANN INTERN MED, V101, P647, DOI 10.7326/0003-4819-101-5-647; MARCUS R, 1985, ANN INTERN MED, V102, P158, DOI 10.7326/0003-4819-102-2-158; MARTIN P, 1986, ARCH INTERN MED, V146, P689, DOI 10.1001/archinte.146.4.689; MAZESS RB, 1974, AT1111422 U WISC MED; MELTON LJ, 1983, OSTEOPOROTIC SYNDROM, P45; MERIMEE TJ, 1982, J CLIN ENDOCR METAB, V55, P999, DOI 10.1210/jcem-55-5-999; NEWMAN MM, 1989, PSYCHIAT RES, V29, P105, DOI 10.1016/0165-1781(89)90190-X; PHILLIPS LS, 1978, ENDOCRINOLOGY, V103, P121, DOI 10.1210/endo-103-1-121; RAO DS, 1988, J CLIN ENDOCR METAB, V67, P1294, DOI 10.1210/jcem-67-6-1294; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RIGOTTI NA, 1986, JAMA-J AM MED ASSOC, V256, P385, DOI 10.1001/jama.256.3.385; RIGOTTI NA, 1984, NEW ENGL J MED, V311, P601; SZMUKLER GI, 1985, BRIT MED J, V290, P26, DOI 10.1136/bmj.290.6461.26; TREASURE J, 1986, SCOT MED J, V31, P206; TREASURE JL, 1987, BRIT MED J, V295, P474, DOI 10.1136/bmj.295.6596.474-a; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WYSHAK G, 1989, J ORTHOPAED RES, V7, P91, DOI 10.1002/jor.1100070113; 1987, DIAGNOSTIC STATISTIC; 1986, NEW ENGL J MED, V314, P39	46	287	288	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1133	1138		10.1001/jama.265.9.1133	http://dx.doi.org/10.1001/jama.265.9.1133			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995999				2022-12-01	WOS:A1991EZ47400030
J	SHULKIN, DJ				SHULKIN, DJ			RISKY BUSINESS - NEEDLESTICKS IN RESIDENCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SHULKIN, DJ (corresponding author), UNIV PENN, SCH MED, ROBERT WOOD JOHNSON FDN, PHILADELPHIA, PA 19104 USA.							AOUN H, 1989, NEW ENGL J MED, V321, P693, DOI 10.1056/NEJM198909073211020; GORDIN FM, 1990, J INFECT DIS, V161, P14, DOI 10.1093/infdis/161.1.14; HAMMOND JS, 1990, J TRAUMA, V30, P555, DOI 10.1097/00005373-199005000-00005; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; PORTEOUS MJL, 1990, BRIT MED J, V301, P167, DOI 10.1136/bmj.301.6744.167	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1181	1181		10.1001/jama.265.9.1181	http://dx.doi.org/10.1001/jama.265.9.1181			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996007				2022-12-01	WOS:A1991EZ47400040
J	WONG, ES; STOTKA, JL; CHINCHILLI, VM; WILLIAMS, DS; STUART, CG; MARKOWITZ, SM				WONG, ES; STOTKA, JL; CHINCHILLI, VM; WILLIAMS, DS; STUART, CG; MARKOWITZ, SM			ARE UNIVERSAL PRECAUTIONS EFFECTIVE IN REDUCING THE NUMBER OF OCCUPATIONAL EXPOSURES AMONG HEALTH-CARE WORKERS - A PROSPECTIVE-STUDY OF PHYSICIANS ON A MEDICAL-SERVICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NOSOCOMIAL INFECTIONS; RISK; HEPATITIS; HIV; PREVENTION; GUIDELINE; BLOOD; AIDS	Using a daily questionnaire, we prospectively studied 277 physicians from two hospital medical services for incidents of exposure to blood and body fluids and barrier use before and after the implementation of universal precautions. We found that implementation significantly increased the frequency of barrier use during exposure incidents from 54% before implementation to 73% after implementation of universal precautions. Implementation led to a decrease in the number of exposure incidents that resulted in direct contact with blood and body fluids (actual exposures), from 5.07 to 2.66 exposures per physician per patient care month, and to an increase in averted exposures in which direct contact was prevented by the use of barrier devices, from 3.41 exposures per patient care month before implementation to 5.90 exposures per patient care month after implementation. Implementation affected neither the types of body fluid or procedures involved nor the overall rate of exposure incidents (8.5 per patient care month) but, through an increase in barrier use, it did prevent direct contact with blood and body fluids and thus converted what would have been an actual exposure into an averted one. We conclude that universal precautions were effective in reducing the risk of occupational exposures among physicians on a medical service.	HUNTER HOLMES MCGUIRE DEPT VET AFFAIRS MED CTR,MED SERV,HOSP EPIDEMIOL UNIT,RICHMOND,VA 23249; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University	WONG, ES (corresponding author), HUNTER HOLMES MCGUIRE DEPT VET AFFAIRS MED CTR,MED SERV,INFECT DIS SECT 111C,RICHMOND,VA 23249, USA.							BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; DOEBBELING BN, 1990, JAMA-J AM MED ASSOC, V264, P2083, DOI 10.1001/jama.264.16.2083; Francis D P, 1981, Semin Liver Dis, V1, P27, DOI 10.1055/s-2008-1063927; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HAGAN MD, 1989, ARCH INTERN MED, V149, P1541; HENDERSON DK, 1986, ANN INTERN MED, V104, P644, DOI 10.7326/0003-4819-104-5-644; HOOFNAGLE JH, 1979, ANN INTERN MED, V91, P813, DOI 10.7326/0003-4819-91-6-813; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; KUHLS TL, 1987, AM J PUBLIC HEALTH, V77, P1306, DOI 10.2105/AJPH.77.10.1306; LYNCH P, 1987, ANN INTERN MED, V107, P243, DOI 10.7326/0003-4819-107-2-243; LYNCH P, 1990, AM J INFECT CONTROL, V18, P1, DOI 10.1016/0196-6553(90)90204-6; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MCEVOY M, 1987, BRIT MED J, V294, P1595, DOI 10.1136/bmj.294.6587.1595; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; PRENTICE RL, 1988, BIOMETRICS, V44, P1033, DOI 10.2307/2531733; SIMMONS BP, 1983, AM J INFECT CONTROL, V11, P183, DOI 10.1016/0196-6553(83)90079-2; WEISS SH, 1985, JAMA-J AM MED ASSOC, V254, P2089, DOI 10.1001/jama.254.15.2089; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; 1970, US DHEW PHS702054 PU; 1989, MMWR SS4, V38, P1; 1985, SAS USERS GUIDE BASI; 1987, MMWR S2S, V36, pS3; 1985, PROC IML VERSION 5	28	115	121	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1123	1128		10.1001/jama.265.9.1123	http://dx.doi.org/10.1001/jama.265.9.1123			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995997				2022-12-01	WOS:A1991EZ47400028
J	HANKEY, GJ; SLATTERY, JM; WARLOW, CP				HANKEY, GJ; SLATTERY, JM; WARLOW, CP			PROGNOSIS AND PROGNOSTIC FACTORS OF RETINAL INFARCTION - A PROSPECTIVE COHORT STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY-STROKE-PROJECT; CAROTID-ARTERY DISEASE; AMAUROSIS FUGAX; YOUNG-ADULTS; OCCLUSION; OBSTRUCTION; PATIENT; RISK	Objective - To determine the prognosis and adverse prognostic factors in patients with retinal infarction due to presumed atheromatous thromboembolism or cardiogenic embolism. Design - Prospective cohort study. Setting - University hospital departments of clinical neurology. Patients - 99 patients with retinal infarction, without prior stroke, referred to a single neurologist between 1976 and 1986 and evaluated and followed up prospectively until death or the end of 1986 (mean follow up 4.2 years). Interventions - Cerebral angiography (55 patients), aspirin treatment (37), oral anticoagulant treatment (eight), carotid endarterectomy (13), cardiac surgery (six), and peripheral vascular surgery (two). Main outcome measures - Death, stroke, coronary events, contralateral retinal infarction; survival analysis confined to 98 patients with retinal infarction due to presumed atheromatous thromboembolism or cardiogenic embolism (one patient with giant cell arteritis excluded), and Cox's proportional hazards regression analysis, including age as a prognostic factor. Results - During follow up 29 patients died (21 of vascular causes and eight of non-vascular or unknown causes), 10 had a first ever stroke, 19 had a coronary event, and only one developed contralateral retinal infarction. A coronary event accounted for more than half (59%) of the deaths whereas stroke was the cause of only one death (3%). Over the first five years after retinal infarction the actuarial average absolute risk of death was 8% per year; of stroke 2.5% per year (7.4% in the first year); of coronary events 5.3% per year, exceeding that of stroke; and of stroke, myocardial infarction, or vascular death 7.4% per year. Prognostic factors associated with an increased risk of death were increasing age, peripheral vascular disease, cardiomegaly, and carotid bruit. Adverse prognostic factors for serious vascular events were increasing age and carotid bruit for stroke, and increasing age, cardiomegaly, and carotid bruit both for coronary events and for stroke, myocardial infarction, or vascular death. Conclusions - Patients who present with retinal infarction due to presumed atherothromboembolism or cardiogenic embolism are at considerable risk of a coronary event. The risk of stroke, although high, is not so great. Not all strokes occurring after retinal infarction relate directly to disease of the ipsilateral carotid system, although this is probably the most common cause. Few patients experience contralateral retinal infarction. Non-arteritic retinal infarction should be diagnosed or confirmed by an ophthalmologist, and the long term care of patients with the condition should involve a physician who has an active interest in managing vascular disease.			HANKEY, GJ (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				[Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316; APPEN RE, 1975, AM J OPHTHALMOL, V79, P374, DOI 10.1016/0002-9394(75)90609-1; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BROWN GC, 1981, OPHTHALMOLOGY, V88, P18; CHAWLUK JB, 1988, NEUROLOGY, V38, P858, DOI 10.1212/WNL.38.6.858; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DOUGLAS DJ, 1988, ANN SURG, V208, P85, DOI 10.1097/00000658-198807000-00012; GOODMAN GK, 1982, CAN J OPHTHALMOL, V17, P124; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HANKEY GJ, IN PRESS J NEUROL NE; HARBISON JW, 1982, ANN NEUROL, V12, P74; HOLLENHORST RW, 1987, OCCLUSIVE CEREBROVAS, P82; HOPKINS A, 1985, BMDP STATISTICAL SOF, P576; HOWARD RS, 1987, J NEUROL NEUROSUR PS, V50, P1142, DOI 10.1136/jnnp.50.9.1142; JORGENSEN R, 1988, SURGERY, V104, P507; KOLLARITS CR, 1972, J AMER MED ASSOC, V222, P1273, DOI 10.1001/jama.222.10.1273; LIVERSEDGE L A, 1962, Trans Ophthalmol Soc U K, V82, P571; LORENTZEN SE, 1969, ACTA OPHTHALMOL, V47, P690; MACHIN D, 1989, STATISTICS CONFIDENC, P64; MARSHALL J, 1968, BRAIN, V91, P419, DOI 10.1093/brain/91.3.419; MERCHUT MP, 1988, STROKE, V19, P1239, DOI 10.1161/01.STR.19.10.1239; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; POOLE CJM, 1985, J NEUROL NEUROSUR PS, V48, P902, DOI 10.1136/jnnp.48.9.902; ROS MA, 1989, ANN OPHTHALMOL, V21, P103; RUSSELL RW, 1961, LANCET, V2, P1422; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; SAVINO PJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P1185, DOI 10.1001/archopht.1977.04450070083005; TIPPIN J, 1989, ANN NEUROL, V26, P69, DOI 10.1002/ana.410260111; TOMSAK RL, 1979, CLEVELAND CLIN Q, V46, P7, DOI 10.3949/ccjm.46.1.7; WILSON LA, 1979, LANCET, V1, P292; WRAY SH, 1988, AMAUROSIS FUGAX, P81	37	56	57	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1991	302	6775					499	504		10.1136/bmj.302.6775.499	http://dx.doi.org/10.1136/bmj.302.6775.499			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012845	Bronze, Green Published			2022-12-01	WOS:A1991FB05500018
J	HUNT, AJ; DAVIES, PM; WEATHERBURN, P; COXON, APM; MCMANUS, TJ				HUNT, AJ; DAVIES, PM; WEATHERBURN, P; COXON, APM; MCMANUS, TJ			CHANGES IN SEXUAL-BEHAVIOR IN A LARGE COHORT OF HOMOSEXUAL MEN IN ENGLAND AND WALES, 1988-9	BRITISH MEDICAL JOURNAL			English	Article									UNIV ESSEX,COLCHESTER CO4 3SQ,ESSEX,ENGLAND; UNIV LONDON KINGS COLL HOSP,LONDON SE5 8RX,ENGLAND	University of Essex; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	HUNT, AJ (corresponding author), S BANK POLYTECH,DEPT SOCIAL SCI,PROJECT SIGMA,LONDON SE1 0AA,ENGLAND.		Weatherburn, Peter/AAC-2701-2019	Weatherburn, Peter/0000-0002-4950-6163				GELLAN MCA, 1986, LANCET, V2, P920; HUNT AJ, 1990, GENITOURIN MED, V66, P423; MCMANUS TJ, 1987, BRIT J SEX MED, V20, P110; WEATHERBURN P, 1990, AIDS Care, V2, P319, DOI 10.1080/09540129008257747; 1988, SHORT TERM PREDICTIO	5	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					505	506		10.1136/bmj.302.6775.505	http://dx.doi.org/10.1136/bmj.302.6775.505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB055	2012847	Green Published, Bronze			2022-12-01	WOS:A1991FB05500020
J	LIP, GYH; MCCOLL, KEL; GOLDBERG, A; MOORE, MR				LIP, GYH; MCCOLL, KEL; GOLDBERG, A; MOORE, MR			SMOKING AND RECURRENT ATTACKS OF ACUTE INTERMITTENT PORPHYRIA	BRITISH MEDICAL JOURNAL			English	Article							ESTRADIOL		UNIV GLASGOW,WESTERN INFIRM,GARDINER INST,DEPT MED,GLASGOW G11 6NT,SCOTLAND	University of Glasgow			Moore, Michael R/C-4163-2012	Moore, Michael R/0000-0002-7012-9534				APPEL BR, 1990, AM J PUBLIC HEALTH, V80, P560, DOI 10.2105/AJPH.80.5.560; KANARKOWSKI R, 1988, CLIN PHARMACOL THER, V43, P23, DOI 10.1038/clpt.1988.7; KLAIBER EL, 1988, FERTIL STERIL, V50, P630; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; Moore M. R., 1987, DISORDERS PORPHYRIN	5	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					507	507		10.1136/bmj.302.6775.507	http://dx.doi.org/10.1136/bmj.302.6775.507			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB055	2012848	Green Published, Bronze			2022-12-01	WOS:A1991FB05500022
J	MCGUINNESS, BT; CLARKE, IN; LAMBDEN, PR; BARLOW, AK; POOLMAN, JT; JONES, DM; HECKELS, JE				MCGUINNESS, BT; CLARKE, IN; LAMBDEN, PR; BARLOW, AK; POOLMAN, JT; JONES, DM; HECKELS, JE			POINT MUTATION IN MENINGOCOCCAL POR-A GENE ASSOCIATED WITH INCREASED ENDEMIC DISEASE	LANCET			English	Article							OUTER-MEMBRANE PROTEIN; NEISSERIA-MENINGITIDIS; ANTIBODIES; SEROTYPES; EPITOPES; VACCINE	The por A gene, which encodes expression of meningococcal class 1 outer membrane protein, responsible for antigenic subtype specificity, has been cloned and sequenced in an isolate of Neisseria meningitidis (B:15:P1.7,16) from a patient in the Gloucester area with meningococcal meningitis. Comparison of the sequence with that of the equivalent gene from the P1.7,16 reference strain reveals a point mutation which generates a single amino acid change in the epitope responsible for P1.16 specificity. Monoclonal antibodies with P1.16 specificity do not react with synthetic peptides that correspond to the altered epitope, and do not promote complement-mediated bactericidal killing of the isolate. Analysis of other strains shows widespread distribution of infections due to B:15:P1.7,16 meningococci with the altered epitope (P1.16b) in England and Wales.	UNIV SOUTHAMPTON,SCH MED,DEPT MICROBIOL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; RIJKSINST VOLKSGEZONDHEID MILIEUHYG,3720 BA BILTHOVEN,NETHERLANDS; WITHINGTON HOSP,PUBL HLTH LAB SERV,MENINGOCOCCAL REFERENCE LAB,MANCHESTER M20 8LR,LANCS,ENGLAND	University of Southampton				Clarke, Ian/0000-0002-4938-1620				ABDILLAHI H, 1988, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V47, P139, DOI 10.1016/0378-1097(88)90023-7; ABDILLAHI H, 1988, MICROB PATHOGENESIS, V4, P27, DOI 10.1016/0882-4010(88)90045-9; BARLOW AK, 1989, MOL MICROBIOL, V3, P131, DOI 10.1111/j.1365-2958.1989.tb01802.x; BARLOW AK, 1987, INFECT IMMUN, V55, P2734, DOI 10.1128/IAI.55.11.2734-2740.1987; CARTWRIGHT KAV, 1987, EPIDEMIOL INFECT, V99, P591, DOI 10.1017/S0950268800066449; FRASCH CE, 1985, REV INFECT DIS, V7, P504; FRASCH CE, 1986, CLIN INVEST MED, V9, P101; JONES DM, 1990, LANCET, V336, P53, DOI 10.1016/0140-6736(90)91566-S; KNIGHT, 1990, LANCET, V335, P1182; MANDRELL RE, 1989, INFECT IMMUN, V57, P1590, DOI 10.1128/IAI.57.5.1590-1598.1989; MCGUINNESS B, 1990, J EXP MED, V171, P1871, DOI 10.1084/jem.171.6.1871; POOLMAN JT, 1986, LANCET, V2, P555; POOLMAN JT, 1987, A VAN LEEUW J MICROB, V53, P261; SAUKKONEN K, 1989, VACCINE, V7, P325, DOI 10.1016/0264-410X(89)90194-1; VIRJI M, 1987, J GEN MICROBIOL, V133, P3393; WEDEGE E, 1986, INFECT IMMUN, V51, P571, DOI 10.1128/IAI.51.2.571-578.1986	16	168	183	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					514	517		10.1016/0140-6736(91)91297-8	http://dx.doi.org/10.1016/0140-6736(91)91297-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1705642				2022-12-01	WOS:A1991EZ87400004
J	MORRIS, AJ; MADHOK, R; STURROCK, RD; CAPELL, HA; MACKENZIE, JF				MORRIS, AJ; MADHOK, R; STURROCK, RD; CAPELL, HA; MACKENZIE, JF			ENTEROSCOPIC DIAGNOSIS OF SMALL-BOWEL ULCERATION IN PATIENTS RECEIVING NONSTEROIDAL ANTIINFLAMMATORY DRUGS	LANCET			English	Note								15 patients with rheumatoid arthritis who were receiving non-steroidal anti-inflammatory drugs (NSAIDs) and who had chronic occult gastrointestinal bleeding underwent extended small bowel examination with a Sonde enteroscope. 7 patients (47%) were found to have jejunal or ileal ulceration. Small bowel enteroscopy may be a valuable technique for the investigation of undiagnosed gastrointestinal bleeding.	GLASGOW ROYAL INFIRM,GASTROINTESTINAL INVEST UNIT,GLASGOW G4 0SF,SCOTLAND; GLASGOW ROYAL INFIRM,CTR RHEUMAT DIS,GLASGOW G4 0SF,SCOTLAND	University of Glasgow; University of Glasgow								Bjarnason I., 1988, RECENT ADV GASTROENT, P23; KENT TH, 1969, AM J PATHOL, V54, P237; LEWIS BS, 1988, GASTROENTEROLOGY, V94, P1117, DOI 10.1016/0016-5085(88)90001-7; MADHOK R, 1986, Q J MED, V255, P53; UPADHYAY R, 1990, ANN RHEUM DIS, V49, P359, DOI 10.1136/ard.49.6.359	5	131	134	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					520	520		10.1016/0140-6736(91)91300-J	http://dx.doi.org/10.1016/0140-6736(91)91300-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671893				2022-12-01	WOS:A1991EZ87400007
J	SALOMAA, VV; STRANDBERG, TE; VANHANEN, H; NAUKKARINEN, V; SARNA, S; MIETTINEN, TA				SALOMAA, VV; STRANDBERG, TE; VANHANEN, H; NAUKKARINEN, V; SARNA, S; MIETTINEN, TA			GLUCOSE-TOLERANCE AND BLOOD-PRESSURE - LONG-TERM FOLLOW-UP IN MIDDLE-AGED MEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESSENTIAL-HYPERTENSION; INSULIN RESISTANCE; HYPERINSULINEMIA	Objective - To investigate the role of glucose tolerance in the development of hypertension. Design - Retrospective analysis of the results of a health check up in a group of clinically healthy middle aged men in the late 1960s (median year 1968). The subjects were invited to enter into a primary prevention trial for cardiovascular disease in 1974, when they underwent clinical examination for risk factors. The trial was completed in 1979, when the men were re-examined. Follow up was in 1986. Setting - Institute of Occupational Health, Helsinki, Finland and second department of medicine, University of Helsinki. Subjects - In all, 3490 men born during 1919-34 participated in a health check up in the late 1960s. In 1974, 1815 of these men who were clinically healthy were entered into a primary prevention trial for cardiovascular disease. On clinical examination 1222 of the men were considered at high risk of cardiovascular disease. Of these, 612 received an intervention and were excluded from the study. A total of 593 men were without risk factors. The study comprised all of the men who did not have an intervention (n = 1203). In 1979, 1120 men were re-examined, and in 1986 945 men attended follow up. There were two groups for analysis: one comprising all subjects and the other comprising only men who were normotensive in 1968 and for whom complete information was available. Interventions - By 1979, 103 men were taking antihypertensive drugs, and by 1986, 131 were taking antihypertensive drugs and 12 were taking drugs for hyperglycaemia. Main outcome measures - Blood glucose concentration one hour after a glucose load, blood pressure, and body weight were measured in 1968, 1974, and 1979. In 1986 blood pressure and body weight were recorded. Results - Men who were hypertensive in 1986 had significantly higher blood pressures (p < 0.0001) and (after adjustment for body mass index and alcohol intake) significantly higher blood glucose concentrations one hour after a glucose load at all examinations than those who were normotensive in 1986. Regression analysis showed that the higher the blood glucose concentration after a glucose load in 1968 the higher the blood pressure during the following years. Those men between the second and third tertiles of blood glucose concentration in 1968 had a significantly higher risk of developing hypertension (odds ratio 1.71, 95% confidence interval 1.05 to 2.77) compared with those below the first tertile. Conclusion - In this study men who developed hypertension tended to have shown an increased intolerance to glucose up to 18 years before the clinical manifestation of their disorder. Blood glucose concentration one hour after a glucose load was an independent predictor of future hypertension.	UNIV HELSINKI, DEPT MED 2, SF-00100 HELSINKI 10, FINLAND; JORVI DIST HOSP, DEPT MED, ESPOO, FINLAND; UNIV HELSINKI, DEPT PUBL HLTH SCI, SF-00100 HELSINKI 10, FINLAND	University of Helsinki; University of Helsinki	SALOMAA, VV (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIOL, SF-00510 HELSINKI, FINLAND.			Sarna, Seppo/0000-0003-3458-1627; strandberg, timo/0000-0001-6299-925X				DIXON WJ, 1985, BMDP STATISTICAL SOF; DUVFLOREY C, 1976, BRIT MED J, V1, P1368, DOI 10.1136/bmj.1.6022.1368; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FOSTER DW, 1989, NEW ENGL J MED, V320, P733, DOI 10.1056/NEJM198903163201111; FOURNIER AM, 1986, AM J MED, V80, P861, DOI 10.1016/0002-9343(86)90629-7; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; HULTMAN E, 1959, NATURE, V183, P108, DOI 10.1038/183108a0; JARRETT RJ, 1978, INT J EPIDEMIOL, V7, P15, DOI 10.1093/ije/7.1.15; Kessler G., 1966, AUTOMATION ANALYTICA, P341; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATTILA S, 1980, THESIS U HELSINKI FI; MBANYA JCN, 1988, LANCET, V1, P733; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; NAUKKARINEN VA, 1989, ANN MED, V21, P441, DOI 10.3109/07853898909149236; PORTA M, 1988, NEW ENGL J MED, V318, P383; REAVEN PD, 1990, DIABETES CARE, V13, P119, DOI 10.2337/diacare.13.2.119; STAMLER J, 1975, J CHRON DIS, V28, P527, DOI 10.1016/0021-9681(75)90060-0; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105; 1985, WHO TECH REP SER, V727	20	65	69	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1991	302	6775					493	496		10.1136/bmj.302.6775.493	http://dx.doi.org/10.1136/bmj.302.6775.493			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012844	Green Published, Bronze			2022-12-01	WOS:A1991FB05500016
J	TACHAKRA, SS; PAWSEY, S; BECKETT, M; POTTS, D; IDOWU, A				TACHAKRA, SS; PAWSEY, S; BECKETT, M; POTTS, D; IDOWU, A			OUTCOME OF PATIENTS WITH CHEST PAIN DISCHARGED FROM AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article									W MIDDLESEX HOSP,DEPT ACCID & EMERGENCY,ISLEWORTH TW7 6AF,ENGLAND	Imperial College London	TACHAKRA, SS (corresponding author), CENT MIDDLESEX HOSP,DEPT ACCID & EMERGENCY,LONDON NW10 7NS,ENGLAND.							COLQUHOUN MC, 1989, BMJ-BRIT MED J, V299, P433, DOI 10.1136/bmj.299.6696.433; Slosberg B, 1977, JACEP, V6, P445; TACHAKRA SS, 1987, BRIT J ACCIDENT EMER, V2, P8; WILCOX RG, 1981, BRIT MED J, V282, P431, DOI 10.1136/bmj.282.6262.431; 1985, LANCET, V2, P578	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					504	505		10.1136/bmj.302.6775.504	http://dx.doi.org/10.1136/bmj.302.6775.504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012846	Bronze, Green Published			2022-12-01	WOS:A1991FB05500019
J	VANDIJK, JG; DORRESTEIJN, M; HAAN, J; FERRARI, MD				VANDIJK, JG; DORRESTEIJN, M; HAAN, J; FERRARI, MD			NO CONFIRMATION OF VISUAL EVOKED-POTENTIAL DIAGNOSTIC-TEST FOR MIGRAINE	LANCET			English	Note								We have attempted to replicate the results of studies on a diagnostic test reported to have 90% sensitivity and 89-96% specificity for migraine. The technique is based on peak-to-peak measurements of fast background electroencephalographic activity during a visual evoked potential (VEP) study. VEP latencies and amplitudes did not differ significantly, and showed substantial overlap, between a group of eight migraine patients and ten age-matched healthy controls. We could not recognise previously described fast activity or measure it objectively by peak-to-peak measurements. We cannot confirm that measurement of fast wave activity in the VEP background is useful in diagnosis of migraine.			VANDIJK, JG (corresponding author), LEIDEN UNIV HOSP,DEPT NEUROL CLIN NEUROPHYSIOL,POB 9600,2300 RC LEIDEN,NETHERLANDS.							MARSTERS JB, 1988, HEADACHE, V28, P526, DOI 10.1111/j.1526-4610.1988.hed2808526.x; MORTIMER MJ, 1990, LANCET, V335, P789, DOI 10.1016/0140-6736(90)90903-I; MORTIMER MJ, 1990, HEADACHE, V30, P285, DOI 10.1111/j.1526-4610.1990.hed3005285.x; MORTIMER MJ, 1990, LANCET, V335, P75, DOI 10.1016/0140-6736(90)90541-C; Regan D., 1989, HUMAN BRAIN ELECTROP; VANDIJK JG, 1990, LANCET, V335, P480; VANDIJK JG, 1989, NEW TRENDS CLIN NEUR, P107; WINTER AL, 1987, MIGRAINE CLIN THERAP, P485; 1988, CEPHALALGIA S, V7, P1	9	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 2	1991	337	8740					517	518		10.1016/0140-6736(91)91298-9	http://dx.doi.org/10.1016/0140-6736(91)91298-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ874	1671891				2022-12-01	WOS:A1991EZ87400005
J	CHAKRABORTY, M; CHATTERJEE, D; KELLOKUMPU, S; RASMUSSEN, H; BARON, R				CHAKRABORTY, M; CHATTERJEE, D; KELLOKUMPU, S; RASMUSSEN, H; BARON, R			CELL-CYCLE DEPENDENT COUPLING OF THE CALCITONIN RECEPTOR TO DIFFERENT G-PROTEINS	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; SALMON-CALCITONIN; KINASE-C; ISOLATED OSTEOCLASTS; ADENYLATE-CYCLASE; BINDING-SITES; HEART-CELLS; RAT-BRAIN; K+-ATPASE; PATHWAYS	Calcitonin is a calcium regulating peptide hormone with binding sites in kidney and bone as well as in the central nervous system. The mechanisms of signal transduction by calcitonin receptors were studied in a pig kidney cell line where the hormone was found to regulate sodium pumps. Calcitonin receptors activated the cyclic adenosine monophosphate (cAMP) or the protein kinase C (PKC) pathways. The two transduction pathways required guanosine triphosphate (GTP)-binding proteins (G proteins) (the choleratoxin sensitive G(s) and the pertussis toxin sensitive G(i), respectively) and led to opposite biological responses. Moreover, selective activation of one or the other pathway was cell cycle-dependent. Therefore, calcitonin may induce different biological responses in target cells depending on their positions in the cell cycle. Such a modulation of ligand-induced responses could be of importance in rapidly growing cell populations such as during embryogenesis, growth, and tumor formation.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT ORTHOPED,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004724, R01DE004724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019813, R01DK019813] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-04724] Funding Source: Medline; NIDDK NIH HHS [DK-19813] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL N, 1986, AM J PHYSIOL, V251, pC825, DOI 10.1152/ajpcell.1986.251.5.C825; AITON JF, 1981, BRIT J PHARMACOL, V73, P333, DOI 10.1111/j.1476-5381.1981.tb10426.x; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; AZRIA M, 1989, CALCITONINS, P152; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BARON R, 1986, CELL, V46, P311, DOI 10.1016/0092-8674(86)90748-8; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF370, DOI 10.1152/ajprenal.1989.256.2.F370; BLACK NB, 1980, AM J PHYSIOL, V238, pR406; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; CAMBARDIERE C, 1990, BIOCHEM BIOPH RES CO, V168, P65; CHAKRABORTY M, UNPUB; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104; CHAMBERS TJ, 1983, J CLIN ENDOCR METAB, V57, P819, DOI 10.1210/jcem-57-4-819; CLEMENTI G, 1984, EUR J PHARMACOL, V98, P449, DOI 10.1016/0014-2999(84)90298-X; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DAYER JM, 1981, J CELL BIOL, V91, P195, DOI 10.1083/jcb.91.1.195; DOODS HN, 1987, J PHARMACOL EXP THER, V242, P257; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; ENJALBERT A, 1986, J BIOL CHEM, V261, P4071; FINDLAY DM, 1980, CANCER RES, V40, P1311; FISCHER JA, 1981, LIFE SCI, V29, P663, DOI 10.1016/0024-3205(81)90018-7; FORBUSH B, 1979, BIOCHEMISTRY-US, V18, P2308, DOI 10.1021/bi00578a027; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENKE H, 1985, BRAIN RES, V360, P165, DOI 10.1016/0006-8993(85)91232-6; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUNT NH, 1977, BRIT J CANCER, V35, P777, DOI 10.1038/bjc.1977.119; KRIEGER NS, 1980, PHARMACOL REV, V217, P586; KYTE J, 1976, J CELL BIOL, V68, P287, DOI 10.1083/jcb.68.2.287; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1989, J CELL SCI, V92, P131; MACINTYRE I, 1989, ENDOCRINOLOGY, P892; MARBACH I, 1988, EUR J BIOCHEM, V172, P239, DOI 10.1111/j.1432-1033.1988.tb13879.x; MCCALL D, 1979, AM J PHYSIOL, V236, pC87, DOI 10.1152/ajpcell.1979.236.1.C87; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; MORGAN A, 1990, BIOCHEM J, V269, P521, DOI 10.1042/bj2690521; MUALLEM S, 1989, BIOCHEM J, V263, P769, DOI 10.1042/bj2630769; NAKAMUTA H, 1981, JPN J PHARMACOL, V31, P53, DOI 10.1254/jjp.31.53; NAKAMUTA H, 1987, FOLIA PHARMACOL JPN, V89, P191, DOI 10.1254/fpj.89.191; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PECILE A, 1975, EXPERIENTIA, V31, P332, DOI 10.1007/BF01922569; PRALLET B, 1988, CALCIFIED TISSUE INT, V42, pA14; RIZZO AJ, 1981, ENDOCRINOLOGY, V108, P1672, DOI 10.1210/endo-108-5-1672; SCHOFIELD PR, 1990, TRENDS NEUROSCI, V13, P8, DOI 10.1016/0166-2236(90)90052-C; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TWERY MJ, 1982, PEPTIDES, V3, P749, DOI 10.1016/0196-9781(82)90010-9; TWERY MJ, 1988, EUR J PHARMACOL, V155, P285, DOI 10.1016/0014-2999(88)90515-8; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	57	134	135	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1078	1082		10.1126/science.1847755	http://dx.doi.org/10.1126/science.1847755			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1847755				2022-12-01	WOS:A1991EZ66500053
J	ERICKSON, JW; CLINE, TW				ERICKSON, JW; CLINE, TW			MOLECULAR NATURE OF THE DROSOPHILA SEX DETERMINATION SIGNAL AND ITS LINK TO NEUROGENESIS	SCIENCE			English	Article							SCUTE GENE-COMPLEX; DOSAGE COMPENSATION; N-MYC; MELANOGASTER; ACHAETE; EXPRESSION; LETHAL; PROTEINS; ELEMENT; DAUGHTERLESS	In 1921 it was discovered that the sexual fate of Drosophila is determined by the ratio of X chromosomes to sets of autosomes. Only recently has it been found that the X chromosome to autosome (X:A) ratio is communicated in part by the dose of sisterless-b (sis-b), an X-linked genetic element located within the achaete-scute complex of genes involved in neurogenesis. In this report, the molecular nature of the primary sex determination signal and its relation to these proneural genes was determined by analysis of sis-b+ germline transformants. The sis-b+ function is conferred by protein T4, a member of the helix-loop-helix family of transcription factors. Although T4 is shared by sis-b and scute-alpha, the regulatory regions of sis-b, which control T4 expression in sex determination, are both separable from and simpler than those of scute-alpha, which control T4 expression in neurogenesis. Dose-sensitive cooperative interactions in the assembly or binding of sis-dependent transcription factors may directly determine the activity of the female-specific promoter of Sex-lethal, the master regulator of sexual development. In this model there is no need to invoke the existence of analogous autosomal negative regulators of Sex-lethal.			ERICKSON, JW (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV GENET,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [GM 23468] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023468] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.ge.23.120189.001303; ALONSO LG, 1986, ROUX ARCH DEV BIOL, V195, P259, DOI 10.1007/BF02438959; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELL LR, IN PRESS CELL; BENEZRA R, 1990, CELL, V61, P45; Bridges CB, 1925, AM NAT, V59, P127, DOI 10.1086/280023; Bridges CB, 1921, SCIENCE, V54, P252, DOI 10.1126/science.54.1394.252; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CLINE TL, UNPUB; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P1297; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ENGELS WR, 1987, GENETICS, V117, P745; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARELL J, 1990, CELL, V61, P39; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; KEYES L, UNPUB; LENARDO M, 1989, EMBO J, V8, P3351, DOI 10.1002/j.1460-2075.1989.tb08497.x; LINDSLEY DL, 1985, DROSOPHILA INFO SER, V62; LINDSLEY DL, 1990, DROSOPHILA INFO SER, V68; LINDSLEY DL, 1987, DROSOPHILA INFO SER, V65; LINDSLEY DL, 1986, DROSOPHILA INFO SER, V64; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUIZGOMEZ M, 1987, GENE DEV, V1, P1238, DOI 10.1101/gad.1.10.1238; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SALZ HK, 1987, GENETICS, V117, P221; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STEINMANNZWICKY H, 1990, ADV GENET, V27, P189; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; Villeneuve A.M., 1990, Advances in Genetics, V27, P117	44	75	75	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1071	1074		10.1126/science.1900130	http://dx.doi.org/10.1126/science.1900130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1900130				2022-12-01	WOS:A1991EZ66500050
J	FLORAS, JS; LEGAULT, L; MORALI, GA; HARA, K; BLENDIS, LM				FLORAS, JS; LEGAULT, L; MORALI, GA; HARA, K; BLENDIS, LM			INCREASED SYMPATHETIC OUTFLOW IN CIRRHOSIS AND ASCITES - DIRECT EVIDENCE FROM INTRANEURAL RECORDINGS	ANNALS OF INTERNAL MEDICINE			English	Article						ASCITES; LIVER CIRRHOSIS; SYMPATHETIC NERVOUS SYSTEM; NOREPINEPHRINE; EPINEPHRINE	NERVOUS-SYSTEM ACTIVITY; OUTPUT CARDIAC-FAILURE; BODY NEGATIVE-PRESSURE; PLASMA NOREPINEPHRINE; WATER-RETENTION; DECOMPENSATED CIRRHOSIS; ESSENTIAL-HYPERTENSION; HEPATORENAL-SYNDROME; NEPHROTIC SYNDROME; VOLUME EXPANSION	Objective: To determine if central sympathetic outflow is increased in patients with cirrhosis and ascites. Patients: Eleven patients with cirrhosis and ascites, 8 patients with cirrhosis but without ascites, and 7 age-matched and 8 young healthy volunteers. Methods: With subjects supine, direct microneurographic recordings of efferent post-ganglionic muscle sympathetic nerve activity were obtained from the peroneal nerve, and sympathetic burst frequency was compared with subjects' blood pressure, heart rate, sodium excretion, catecholamines, and plasma renin activity. All patients with cirrhosis were studied at least 5 days after withdrawal from all medications and after 7 days of a 20 mmol/d sodium, 1-L fluid-restricted diet. Age-matched volunteers were studied after 7 days of 20 mmol/d sodium intake and young healthy volunteers after 7 days of 150 mmol/d sodium intake. Results: Sympathetic nerve activity in ascitic patients (65 +/- 15 bursts/min; mean +/- SD) was markedly increased, whether compared with patients with cirrhosis but without ascites (34 +/- 16 bursts/min; p < 0.001), age-matched healthy volunteers on similar sodium intake (27 +/- 22 bursts/min; P < 0.001), or young healthy subjects (21 +/- 10 bursts/min; P < 0.001). The frequency of muscle sympathetic nerve discharge was directly related to plasma norepinephrine and epinephrine concentrations, plasma renin activity, and heart rate, all of which were increased in those patients with cirrhosis and ascites, and inversely related to 24-hour urinary sodium excretion, the fractional excretion of sodium, and subjects' pulse pressures. Sympathetic nerve activity fell from 78 to 6 bursts/min in one patient after liver transplantation. Conclusions: This study provides the first direct evidence that elevated plasma norepinephrine concentrations in patients with cirrhosis and ascites are due to increased central sympathetic outflow. Sympathetic nerve activity is not increased in patients with cirrhosis but without ascites. Because there were direct positive correlations of sympathetic nerve activity with plasma norepinephrine concentrations, plasma epinephrine concentrations, plasma renin activity, and heart rate, the increase in central sympathetic outflow in patients with cirrhosis and ascites appears generalized and not restricted to muscle nerves. The anti-natriuretic effects of parallel increases in renal and muscle sympathetic nerve activity could account for the inverse correlation between muscle sympathetic nerve activity and sodium excretion.			FLORAS, JS (corresponding author), UNIV TORONTO, TORONTO GEN HOSP, DIV CARDIOL, 12 EN-234, 200 ELIZABETH ST, TORONTO M5G 2C4, ONTARIO, CANADA.		Floras, John S./D-4042-2015					ANDERSON EA, 1989, HYPERTENSION, V14, P177, DOI 10.1161/01.HYP.14.2.177; ANDERSON EA, 1987, HYPERTENSION, V9, P114, DOI 10.1161/01.HYP.9.6_Pt_2.III114; ANGELLJAMES JE, 1971, J PHYSIOL-LONDON, V214, P65; BERNARDI M, 1983, HEPATOLOGY, V3, P56; BETTER OS, 1983, KIDNEY INT, V23, P303, DOI 10.1038/ki.1983.20; BICHET DG, 1982, NEW ENGL J MED, V307, P1552, DOI 10.1056/NEJM198212163072504; BLENDIS LM, 1987, HEPATOLOGY, V7, P143, DOI 10.1002/hep.1840070128; DIBONA GF, 1988, AM J PHYSIOL, V254, pR1017, DOI 10.1152/ajpregu.1988.254.6.R1017; DIBONA GF, 1989, MINER ELECTROL METAB, V15, P44; DIBONA GF, 1984, KIDNEY INT, V25, P841, DOI 10.1038/ki.1984.99; ERIKSSON BM, 1982, J CHROMATOGR, V228, P143, DOI 10.1016/S0378-4347(00)80427-2; ESLER M, 1988, HYPERTENSION, V11, P3, DOI 10.1161/01.HYP.11.1.3; FLORAS JS, 1988, J CLIN INVEST, V81, P1265, DOI 10.1172/JCI113444; FLORAS JS, 1990, CIRCULATION, V81, P1860, DOI 10.1161/01.CIR.81.6.1860; HENRIKSEN JH, 1984, GUT, V25, P1034, DOI 10.1136/gut.25.10.1034; KOEPKE JP, 1987, AM J PHYSIOL, V252, pR1019, DOI 10.1152/ajpregu.1987.252.5.R1019; KOSTREVA DR, 1980, AM J PHYSIOL, V238, pR390, DOI 10.1152/ajpregu.1980.238.5.R390; KOWALSKI HJ, 1953, J CLIN INVEST, V32, P1025, DOI 10.1172/JCI102813; LAWTON W, 1986, FASEB J, V45, P522; LEIMBACH WN, 1986, CIRCULATION, V73, P913, DOI 10.1161/01.CIR.73.5.913; MAJEWSKI H, 1983, J AUTON PHARMACOL, V3, P47, DOI 10.1111/j.1474-8673.1983.tb00496.x; MORLIN C, 1983, ACTA PHYSIOL SCAND, V119, P117, DOI 10.1111/j.1748-1716.1983.tb07315.x; NEZU M, 1985, HYPERTENSION, V7, P187, DOI 10.1161/01.HYP.7.2.187; NICHOLLS KM, 1985, CIRC RES, V56, P457, DOI 10.1161/01.RES.56.3.457; OSBORN JL, 1983, CIRC RES, V53, P298, DOI 10.1161/01.RES.53.3.298; PERSSON PB, 1989, AM J PHYSIOL, V256, pF485, DOI 10.1152/ajprenal.1989.256.3.F485; RINGLARSEN H, 1982, HEPATOLOGY, V2, P304; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1127, DOI 10.1056/NEJM198810273191705; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1065, DOI 10.1056/NEJM198810203191606; SKORECKI KL, 1988, AM J MED, V85, P375, DOI 10.1016/0002-9343(88)90590-6; SOLISHERRUZO JA, 1987, J HEPATOL, V5, P167, DOI 10.1016/S0168-8278(87)80569-X; SUNDLOF G, 1978, J PHYSIOL-LONDON, V278, P525, DOI 10.1113/jphysiol.1978.sp012322; SUNDLOF G, 1977, J PHYSIOL-LONDON, V272, P383, DOI 10.1113/jphysiol.1977.sp012050; SUNDLOF G, 1978, J PHYSIOL-LONDON, V274, P621, DOI 10.1113/jphysiol.1978.sp012170; TAGEJENSEN U, 1988, J HEPATOL, V6, P350, DOI 10.1016/S0168-8278(88)80053-9; THULUVATH PJ, 1989, Q J MED, V72, P737; UNIKOWSKY B, 1983, J CLIN INVEST, V72, P1594, DOI 10.1172/JCI111118; VALLBO AB, 1979, PHYSIOL REV, V59, P919, DOI 10.1152/physrev.1979.59.4.919; VICTOR RG, 1987, J APPL PHYSIOL, V63, P2558, DOI 10.1152/jappl.1987.63.6.2558; WEBB DJ, 1988, J HYPERTENS, V6, pS542, DOI 10.1097/00004872-198812040-00170; WEICKER H, 1984, CLIN CHIM ACTA, V141, P17, DOI 10.1016/0009-8981(84)90162-1; WESTFALL TC, 1985, ANNU REV PHARMACOL, V25, P621, DOI 10.1146/annurev.pharmtox.25.1.621; WILLETT I, 1985, J HEPATOL, V1, P639, DOI 10.1016/S0168-8278(85)80007-6; YAMADA Y, 1989, HYPERTENSION, V13, P870, DOI 10.1161/01.HYP.13.6.870; ZIMMERMAN BG, 1978, FED PROC, V37, P199	47	117	118	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					373	380		10.7326/0003-4819-114-5-373	http://dx.doi.org/10.7326/0003-4819-114-5-373			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992879				2022-12-01	WOS:A1991EZ17400005
J	GENBERG, L; RICHARD, L; MCLENDON, G; MILLER, RJD				GENBERG, L; RICHARD, L; MCLENDON, G; MILLER, RJD			DIRECT OBSERVATION OF GLOBAL PROTEIN MOTION IN HEMOGLOBIN AND MYOGLOBIN ON PICOSECOND TIME SCALES	SCIENCE			English	Article							ENERGY RELAXATION PROCESSES; HEME-PROTEINS; GEMINATE RECOMBINATION; RESONANCE RAMAN; LIGAND-BINDING; EXCITED-STATE; SPECTROSCOPY; DYNAMICS; (CARBONMONOXY)HEMOGLOBIN; CARBOXYMYOGLOBIN	Picosecond phase-grating spectroscopy is highly sensitive to density changes and provides a new holographic approach to the study of protein dynamics. Photodissociation of carbon monoxide from heme proteins induces a well-defined transition from a ligated to a deoxy structure that is important to hemoglobin and myoglobin functionality. Grating spectroscopy was used to observe protein-driven density waves on a picosecond time scale after carbon monoxide dissociation. This result demonstrates that global tertiary structure changes of proteins occur on an extremely fast time scale and provides new insight into the biomechanics of deterministic protein motion.	UNIV ROCHESTER,INST OPT,ROCHESTER,NY 14627	University of Rochester	GENBERG, L (corresponding author), UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627, USA.				NIGMS NIH HHS [1 R01 GM41909-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041909] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; ANSARI A, 1986, BIOCHEMISTRY-US, V25, P3139, DOI 10.1021/bi00359a011; CHERNOFF DA, 1980, P NATL ACAD SCI USA, V77, P5606, DOI 10.1073/pnas.77.10.5606; CUSACK S, 1990, BIOPHYS J, V58, P243, DOI 10.1016/S0006-3495(90)82369-9; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; Eichler H. J., 1986, LASER INDUCED DYNAMI; FINDSEN EW, 1985, SCIENCE, V229, P661, DOI 10.1126/science.4023704; FRIEDMAN JM, 1985, SCIENCE, V229, P187, DOI 10.1126/science.4012316; GENBERG L, 1989, CHEM PHYS, V131, P81, DOI 10.1016/0301-0104(89)87082-X; GENBERG L, 1987, J PHYS CHEM-US, V91, P5521, DOI 10.1021/j100306a002; HENRY ER, 1986, P NATL ACAD SCI USA, V83, P8982, DOI 10.1073/pnas.83.23.8982; JANES SM, 1988, BIOPHYS J, V54, P545, DOI 10.1016/S0006-3495(88)82987-4; KOGELNIK H, 1969, AT&T TECH J, V48, P2909, DOI 10.1002/j.1538-7305.1969.tb01198.x; LEUNG WP, 1987, CHEM PHYS LETT, V141, P220, DOI 10.1016/0009-2614(87)85013-3; MILLER RJD, 1989, TIME RESOLVED SPECTR, V18, P1; MURRAY LP, 1988, BIOPHYS CHEM, V29, P63, DOI 10.1016/0301-4622(88)87025-X; NELSON KA, 1982, J CHEM PHYS, V77, P1144, DOI 10.1063/1.443979; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PETRICH JW, 1987, BIOCHEMISTRY-US, V26, P7914, DOI 10.1021/bi00398a056; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; REYNOLDS AH, 1981, P NATL ACAD SCI-BIOL, V78, P2292, DOI 10.1073/pnas.78.4.2292; SIEGMAN AE, 1977, J OPT SOC AM, V67, P545, DOI 10.1364/JOSA.67.000545; WESTRICK JA, 1990, BIOCHEMISTRY-US, V29, P6741, DOI 10.1021/bi00480a026; ZIMMT MB, 1989, CHEM PHYS LETT, V160, P564, DOI 10.1016/0009-2614(89)80064-8	24	99	99	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1051	1054		10.1126/science.1998121	http://dx.doi.org/10.1126/science.1998121			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1998121				2022-12-01	WOS:A1991EZ66500042
J	GREENSON, JK; BELITSOS, PC; YARDLEY, JH; BARTLETT, JG				GREENSON, JK; BELITSOS, PC; YARDLEY, JH; BARTLETT, JG			AIDS ENTEROPATHY - OCCULT ENTERIC INFECTIONS AND DUODENAL MUCOSAL ALTERATIONS IN CHRONIC DIARRHEA	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA, CHRONIC; ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM-AVIUM-INTRACELLULARE INFECTION; MICROSPORIDIA INFECTION	ACQUIRED IMMUNODEFICIENCY SYNDROME; INTESTINAL INFECTIONS; VIRUS HIV; T-CELLS; DISEASE	Objective: To investigate occult enteric infections and morphologic changes in the small intestine in patients with advanced human immunodeficiency virus (HIV) infection and chronic diarrhea of undefined cause. Design: Case-control study. Setting: Referral-based clinic and hospital in tertiary care center. Patients: Twenty-two patients with advanced HIV infection (19 with the acquired immunodeficiency syndrome [AIDS], 3 with AIDS-related complex) with chronic diarrhea, selected because of previously negative stool evaluations for bacterial or parasitic pathogens, were compared with 13 patients with advanced HIV infection (9 with AIDS, 4 with AIDS-related complex) without diarrhea by analysis of endoscopic biopsies using light and electron microscopy, viral culture, and morphometric studies. Both groups were convenience samples and had at least 7 months follow-up. Measurements and main Result: Eleven of twenty-two patients with HIV infection and chronic diarrhea but only 1 of 13 patients without diarrhea showed occult enteric pathogens (that is, undetected by routine studies) after extensive evaluation of duodenal and colorectal biopsies. Mycobacterium avium-intracellulare and microsporidia were the most common occult agents in study patients with diarrhea (5 each). Patients with diarrhea and occult enteric infections had greater weight loss (mean, 14.3 kg compared with 6.2 kg; P < 0.05) and shorter survival (1 of 11 compared with 8 of 11 still alive; P < 0.004) than those with diarrhea but no identified pathogens (defined as "AIDS enteropathy"). Duodenal morphometry showed decreased villus-to-crypt ratios because of villus atrophy and crypt elongation in HIV -infected patients both with and without diarrhea compared with normal controls (P < 0.001 for each). All three groups showed comparable frequencies of epithelial mitoses. Conclusions: Further endoscopic biopsy evaluation of patients with AIDS who had unexplained chronic diarrhea showed an occult infectious cause in half of the cases. However, altered villus and crypt architecture in advanced HIV infection was independent of the presence of diarrhea or enteric infection and therefore did not correlate with AIDS enteropathy. Subnormal epithelial proliferation in response to injury could be a factor, but the underlying cause of the architectural changes remains obscure. We suggest that T-cell dysfunction may play a role.	JOHNS HOPKINS UNIV HOSP, DIV INFECT DIS, BLALOCK 11, 600 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV HOSP, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040618] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 RO1DK4061802] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONY MA, 1988, DIGEST DIS SCI, V33, P1141, DOI 10.1007/BF01535791; BARTELSMAN JFWM, 1989, SCAND J GASTROENTERO, V24, P112, DOI 10.3109/00365528909091381; BATMAN PA, 1989, J CLIN PATHOL, V42, P275, DOI 10.1136/jcp.42.3.275; COLEBUNDERS R, 1988, GUT, V29, P1687, DOI 10.1136/gut.29.12.1687; CONNOLLY GM, 1989, GUT, V30, P195, DOI 10.1136/gut.30.2.195; CUMMINS AG, 1990, GUT, V31, P317, DOI 10.1136/gut.31.3.317; DESPORTES I, 1985, J PROTOZOOL, V32, P250; ELLAKANY S, 1987, AM J CLIN PATHOL, V87, P356, DOI 10.1093/ajcp/87.3.356; FERREIRA RD, 1990, GASTROENTEROLOGY, V98, P1255, DOI 10.1016/0016-5085(90)90342-X; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; JARRY A, 1990, HISTOPATHOLOGY, V16, P133; JOHANSON JF, 1990, ANN INTERN MED, V112, P942, DOI 10.7326/0003-4819-112-12-942; KOTLER DP, 1984, ANN INTERN MED, V101, P421, DOI 10.7326/0003-4819-101-4-421; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; MACDONALD TT, 1977, CELL TISSUE KINET, V10, P301, DOI 10.1111/j.1365-2184.1977.tb00298.x; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MATHIJS JM, 1988, LANCET, V1, P1111; NELSON JA, 1988, LANCET, V1, P259; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; RENE E, 1989, DIGEST DIS SCI, V34, P773, DOI 10.1007/BF01540353; RODGERS VD, 1986, GASTROENTEROLOGY, V90, P552, DOI 10.1016/0016-5085(86)91108-X; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; ULLRICH R, 1989, ANN INTERN MED, V111, P15, DOI 10.7326/0003-4819-111-1-15; 1989, LANCET, V2, P777; 1985, MMWR, V34, P373	26	158	158	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					366	372		10.7326/0003-4819-114-5-366	http://dx.doi.org/10.7326/0003-4819-114-5-366			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992878				2022-12-01	WOS:A1991EZ17400004
J	KOREN, MJ; DEVEREUX, RB; CASALE, PN; SAVAGE, DD; LARAGH, JH				KOREN, MJ; DEVEREUX, RB; CASALE, PN; SAVAGE, DD; LARAGH, JH			RELATION OF LEFT-VENTRICULAR MASS AND GEOMETRY TO MORBIDITY AND MORTALITY IN UNCOMPLICATED ESSENTIAL-HYPERTENSION	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERTENSION; HEART ENLARGEMENT; LEFT VENTRICULAR MASS AND GEOMETRY; CARDIOVASCULAR DISEASES; RISK FACTORS	BLOOD-PRESSURE; ECHOCARDIOGRAPHIC DETERMINATION; ELECTROCARDIOGRAPHIC DETECTION; SYSTEMIC HYPERTENSION; CONSCIOUS DOGS; HYPERTROPHY; CRITERIA; VALIDATION; OCCLUSION; DISEASE	Objective: To assess the prognostic significance of left ventricular mass and geometry in initially healthy persons with essential hypertension. Design: An observational study of a prospectively identified cohort. Setting: University medical center. Patients: Two hundred and eight patients with essential hypertension and pre-existing cardiac disease were evaluated using echocardiography between 1976 and 1981. Two hundred and fifty-three subjects or their family members (90%) were contacted for a follow-up interview an average of 10.2 years after the initial echocardiogram was obtained; the survival status of 27 patients lost to follow-up was ascertained using National Death Index data. Measurements and Main Results: Left ventricular mass exceeded 125 g/m2 in 69 of 253 patients (27%). Cardiovascular events occurred in a higher proportion of patients with than without left ventricular hypertrophy (26% compared with 12%; p = 0.006). Patients with increased ventricular mass were also at higher risk for cardiovascular death (14% compared with 0.5%; P < 0.001) and all-cause mortality (16% compared with 2%; P = 0.001). Electrocardiographic left ventricular hypertrophy did not predict risk. Patients with normal left ventricular geometry had the fewest adverse outcomes (no cardiac deaths; morbid events in 11%), and those with concentric hypertrophy had the most (death in 21%; morbid events in 31%). In a multivariate analysis, only age and left ventricular mass-but not gender, blood pressure, or serum cholesterol level-independently predicted all three outcome measures. Conclusions: Echocardiographically determined left ventricular mass and geometry stratify risk in patients with essential hypertension independently of and more strongly than blood pressure or other potentially reversible risk factors and may help to stratify the need for intensive treatment.	CORNELL UNIV, MED CTR,NEW YORK HOSP,DIV CARDIOL,BOX 222, 525 E 68TH ST, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital					NHLBI NIH HHS [HL 18323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1980, CARDIOLOGY REV REPOR, V1, P509; [Anonymous], 1980, LANCET, V1, P1261; BLAKE J, 1988, AM J CARDIOL, V62, P246, DOI 10.1016/0002-9149(88)90220-2; BLAKE J, 1990, AM J MED, V88, P477, DOI 10.1016/0002-9343(90)90426-E; BRESLIN DJ, 1966, CIRCULATION, V33, P87, DOI 10.1161/01.CIR.33.1.87; CASALE PN, 1985, J AM COLL CARDIOL, V6, P572, DOI 10.1016/S0735-1097(85)80115-7; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CHIKOS PM, 1977, AM J ROENTGENOL, V128, P367, DOI 10.2214/ajr.128.3.367; COOPER RS, 1990, AM J CARDIOL, V65, P441, DOI 10.1016/0002-9149(90)90807-D; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; DEVEREUX RB, 1984, J AM COLL CARDIOL, V3, P82, DOI 10.1016/S0735-1097(84)80433-7; DEVEREUX RB, 1987, HYPERTENSION, V9, P97; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1984, AM J CARDIOL, V54, P592, DOI 10.1016/0002-9149(84)90255-8; DEVEREUX RB, 1983, CIRCULATION, V67, P907, DOI 10.1161/01.CIR.67.4.907; DEVEREUX RB, 1983, CIRCULATION, V68, P470, DOI 10.1161/01.CIR.68.3.470; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEVEREUX RB, 1984, J AM COLL CARDIOL, V4, P1222, DOI 10.1016/S0735-1097(84)80141-2; DEVEREUX RB, 1987, HYPERTENSION, V9, P69; DIXON WJ, 1988, BMDP STATISTICAL SOF; FUJITA M, 1988, J AM COLL CARDIOL, V12, P1048, DOI 10.1016/0735-1097(88)90475-5; GANAU A, 1989, Journal of the American College of Cardiology, V13, p245A; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; HOUGHTON JL, 1990, J AM COLL CARDIOL, V15, P43, DOI 10.1016/0735-1097(90)90173-M; KANNEL WB, 1972, NEW ENGL J MED, V287, P782; KOYANAGI S, 1982, CIRCULATION, V65, P1192, DOI 10.1161/01.CIR.65.6.1192; KOYANAGI S, 1982, CIRC RES, V50, P55, DOI 10.1161/01.RES.50.1.55; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1987, AM J CARDIOL, V59, P836, DOI 10.1016/0002-9149(87)91102-7; MacMahon S., 1989, HYPERTENSION S1, V13, P45; MESSERLI FH, 1990, CIRCULATION, V81, P1128, DOI 10.1161/01.CIR.81.3.1128; MESSERLI FH, 1983, ANN INTERN MED, V99, P757, DOI 10.7326/0003-4819-99-6-757; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; POLESE A, 1990, Journal of the American College of Cardiology, V15, p111A; REICHEK N, 1981, CIRCULATION, V63, P1391, DOI 10.1161/01.CIR.63.6.1391; REICHEK N, 1982, AM HEART J, V103, P202, DOI 10.1016/0002-8703(82)90493-8; REN JF, 1985, J AM COLL CARDIOL, V5, P1224, DOI 10.1016/S0735-1097(85)80029-2; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; SAVAGE DD, 1987, CIRCULATION, V75, P26; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SCHMIEDER RE, 1988, CIRCULATION, V78, P951, DOI 10.1161/01.CIR.78.4.951; SILBERBERG JS, 1989, KIDNEY INT, V36, P286, DOI 10.1038/ki.1989.192; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; SOKOLOW M, 1961, CIRCULATION, V23, P697, DOI 10.1161/01.CIR.23.5.697; 1972, CIRCULATION, V45, P991; 1979, JAMA-J AM MED ASSOC, V242, P2572	51	1992	2076	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					345	352		10.7326/0003-4819-114-5-345	http://dx.doi.org/10.7326/0003-4819-114-5-345			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1825164				2022-12-01	WOS:A1991EZ17400001
J	KUO, HC; NASIM, FUH; GRABOWSKI, PJ				KUO, HC; NASIM, FUH; GRABOWSKI, PJ			CONTROL OF ALTERNATIVE SPLICING BY THE DIFFERENTIAL BINDING OF U1 SMALL NUCLEAR RIBONUCLEOPROTEIN PARTICLE	SCIENCE			English	Article							PRE-MESSENGER RNA; SITE SELECTION; SNRNP PROTEIN; AFFINITY-CHROMATOGRAPHY; COMPLEX; SPLICEOSOME; GENE; IDENTIFICATION; SEQUENCES; INVITRO	Cellular factors controlling alternative splicing of precursor messenger RNA are largely unknown, even though this process plays a central role in specifying the diversity of proteins in the eukaryotic cell. For the identification of such factors, a segment of the rat preprotachykinin gene was used in which differential expression of neuropeptides-gamma and K is dependent on alternative splicing of the fourth exon (E4). Sequence variants of the three-exon segment, (E3-E4-E5) were created, resulting in a sensitive assay for factors mediating the splicing switch between E4-skipping and E4-inclusion. A dinucleotide mutation in the 5' splice site of E4 that increases base-pairing of this site to U1 small nuclear RNA resulted in uniform selection of E4, whereas a control mutation that destroyed base-pairing resulted in uniform E4-skipping. Affinity selection of spliceosomes formed on these functionally distinct substrates revealed that the extreme difference in splicing was mediated by differential binding of the U1 small nuclear ribonucleoprotein particle (snRNP) to the 5' splice site of E4. These data show that, apart from its established role in selecting 5' splice sites, U1 snRNP plays a fundamental role in 3' exon selection and provides insight into possible mechanisms of alternative splicing.	BROWN UNIV, BIOCHEM SECT, PROVIDENCE, RI 02912 USA	Brown University			Nasim, Faiz/F-6397-2015; Nasim, Faiz-ul Hassan/G-5799-2010	Nasim, Faiz-ul Hassan/0000-0001-9107-7449	NIGMS NIH HHS [GM-39695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BONADIO J, 1990, J BIOL CHEM, V265, P2262; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COOPER TA, 1989, NUCLEIC ACIDS RES, V17, P7905, DOI 10.1093/nar/17.19.7905; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; ETZERODT M, 1988, EMBO J, V7, P4311, DOI 10.1002/j.1460-2075.1988.tb03330.x; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FREYER GA, 1989, J BIOL CHEM, V264, P14631; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XY, 1988, EMBO J, V7, P809, DOI 10.1002/j.1460-2075.1988.tb02879.x; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HELFMAN DM, 1989, NUCLEIC ACIDS RES, V17, P5633, DOI 10.1093/nar/17.14.5633; KASHER MS, 1986, MOL CELL BIOL, V6, P3117, DOI 10.1128/MCB.6.9.3117; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAUSE JE, 1987, P NATL ACAD SCI USA, V84, P881, DOI 10.1073/pnas.84.3.881; KUIVANIEMI H, 1988, J BIOL CHEM, V263, P11407; KUO HC, UNPUB; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; NASIM FH, 1990, GENE DEV, V4, P1172, DOI 10.1101/gad.4.7.1172; NASIM FH, UNPUB; NOBLE JCS, 1987, CELL, V50, P227, DOI 10.1016/0092-8674(87)90218-2; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; WEIL D, 1988, J BIOL CHEM, V263, P8561; YUAN ZA, 1987, MOL CELL BIOL, V7, P3018, DOI 10.1128/MCB.7.8.3018; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	63	159	159	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 1	1991	251	4997					1045	1050		10.1126/science.1825520	http://dx.doi.org/10.1126/science.1825520			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1825520				2022-12-01	WOS:A1991EZ66500041
J	LO, SC; TSAI, S; BENISH, JR; SHIH, JWK; WEAR, DJ; WONG, DM				LO, SC; TSAI, S; BENISH, JR; SHIH, JWK; WEAR, DJ; WONG, DM			ENHANCEMENT OF HIV-1 CYTOCIDAL EFFECTS IN CD4+ LYMPHOCYTES BY THE AIDS-ASSOCIATED MYCOPLASMA	SCIENCE			English	Article							INFECTIOUS AGENT VLIA; HTLV-III/LAV ENVELOPE; CELL-FUSION; VIRUS; IDENTIFICATION; INCOGNITUS; INDUCTION	Coinfection with Mycoplasma fermentans (incognitus strain) enhances the ability of human immunodeficiency virus type-1 (HIV-1) to induce cytopathic effects on human T lymphocytes in vitro. Syncytium formation of HIV-infected T cells was essentially eliminated in the presence of M. fermentans (incognitus strain), despite prominent cell death. However, replication and production of HIV-1 particles continued during the coinfection. Furthermore, the supernatant from cultures coinfected with HIV-1 and the mycoplasma contained a factor that inhibited the standard reverse transcriptase enzyme assay. The modification of the biological properties of HIV-1 by coinfection with mycoplasma may be involved in the pathogenesis of acquired immunodeficiency syndrome (AIDS).	BIOTECH RES LABS INC,ROCKVILLE,MD 20852; NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	LO, SC (corresponding author), ARMED FORCES INST PATHOL,DEPT INFECT & PARASIT DIS PATHOL,AMER REGISTRY PATHOL,WASHINGTON,DC 20306, USA.							BALTIMORE D, 1971, P NATL ACAD SCI USA, V68, P1507, DOI 10.1073/pnas.68.7.1507; CHOWDHURY MIH, 1990, LANCET, V336, P247; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; LEMAITRE M, 1990, RES VIROLOGY, V141, P5, DOI 10.1016/0923-2516(90)90052-K; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; LO SC, 1986, AM J TROP MED HYG, V35, P675, DOI 10.4269/ajtmh.1986.35.675; LO SC, 1989, AM J TROP MED HYG, V40, P399, DOI 10.4269/ajtmh.1989.40.399; LO SC, 1989, AM J TROP MED HYG, V41, P364, DOI 10.4269/ajtmh.1989.41.364; LO SC, 1989, AM J TROP MED HYG, V40, P213, DOI 10.4269/ajtmh.1989.40.213; LO SC, 1989, AM J TROP MED HYG, V41, P586, DOI 10.4269/ajtmh.1989.41.586; LO SC, 1989, AM J TROP MED HYG, V41, P601, DOI 10.4269/ajtmh.1989.41.601; LO ST, UNPUB; MARCUS JI, 1990, J CELL PHYSL, V143, P416; SAILLARD C, 1990, RES VIROLOGY, V141, P385, DOI 10.1016/0923-2516(90)90010-G; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SOMASUNDARAN M, 1987, J VIROL, V61, P3114, DOI 10.1128/JVI.61.10.3114-3119.1987; VASNDEVACHARI MB, 1990, AIDS RES HUM RETROV, V6, P411; Wright K, 1990, Science, V248, P682, DOI 10.1126/science.2333519; 1989, 5 INT C AIDS MONTR	20	141	145	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1074	1076		10.1126/science.1705362	http://dx.doi.org/10.1126/science.1705362			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1705362				2022-12-01	WOS:A1991EZ66500051
J	NOREL, R; AGUR, Z				NOREL, R; AGUR, Z			A MODEL FOR THE ADJUSTMENT OF THE MITOTIC CLOCK BY CYCLIN AND MPF LEVELS	SCIENCE			English	Article							CELL-CYCLE; BIOLOGY	A mathematical model of cell cycle progression is presented, which integrates recent biochemical information on the interaction of the maturation promotion factor (MPF) and cyclin. The model retrieves the dynamics observed in early embryos and explains how multiple cycles of MPF activity can be produced and how the internal clock that determines durations and number of cycles can be adjusted by modulating the rate of change in MPF or cyclin concentrations. Experiments are suggested for verifying the role of MPF activity in determining the length of the somatic cell cycle.	WEIZMANN INST SCI,DEPT APPL MATH & COMP SCI,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Norel, Raquel/ABB-3422-2021	Norel, Raquel/0000-0001-7737-4172				CONTE SD, 1965, ELEMENTARY NUMERICAL; LIN CC, 1988, MATH APPLIED DETERMI; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NORTH G, 1989, NATURE, V339, P97, DOI 10.1038/339097a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086	11	80	83	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1076	1078		10.1126/science.1825521	http://dx.doi.org/10.1126/science.1825521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1825521				2022-12-01	WOS:A1991EZ66500052
J	NORTH, CS; ALPERS, DH; HELZER, JE; SPITZNAGEL, EL; CLOUSE, RE				NORTH, CS; ALPERS, DH; HELZER, JE; SPITZNAGEL, EL; CLOUSE, RE			DO LIFE EVENTS OR DEPRESSION EXACERBATE INFLAMMATORY BOWEL-DISEASE - A PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						INFLAMMATORY BOWEL DISEASE; PSYCHIATRIC STATUS RATING SCALES; DEPRESSION; COLITIS, ULCERATIVE; CROHN DISEASE	CROHNS-DISEASE; PSYCHIATRIC-ILLNESS; ULCERATIVE-COLITIS; ASSOCIATION; DISORDERS	Objective: To determine whether depressed mood or life events are associated with an exacerbation of inflammatory bowel disease. Design: A prospective study of a consecutive sample of patients with relapsing inflammatory bowel disease, followed by monthly questionnaires and periodic office visits. Setting: A referral-based gastroenterology clinic at a medical school. Patients: A consecutive sample of 32 patients with inflammatory bowel disease who had had at least one relapse in a 2-year period after entry into the study. Measurements and Main Results: The Social Readjustment Rating Scale (measuring life events), the Beck Depression Inventory (a visual analog scale for depressed mood) and an inventory of intestinal symptoms were completed monthly by each subject with a 78% rate of compliance. A mean of 2.2 exacerbations was seen per subject during the study period. Life events were not temporally associated with changes in intestinal symptoms. Significant associations were found between intestinal symptoms and the two mood scales (P < 0.05 for each), but no directionality in symptom occurrence could be detected in a time-lagged analysis. The results were similar when the months preceding exacerbations of inflammatory bowel disease were analyzed separately. Conclusions: Although these findings suggest that mood changed concurrently with exacerbation of inflammatory bowel disease, no evidence indicated that stressful life events or depressed mood precipitated exacerbations in this study group.	WASHINGTON UNIV, SCH MED, DEPT BIOSTAT, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MATH, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	NORTH, CS (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, 4940 AUDUBON AVE, ST LOUIS, MO 63110 USA.							ANDREWS H, 1987, GUT, V28, P1600, DOI 10.1136/gut.28.12.1600; ARAPAKIS G, 1986, PSYCHOTHER PSYCHOSOM, V46, P171, DOI 10.1159/000287981; BACHMAN JG, 1984, PUBLIC OPIN QUART, V48, P491, DOI 10.1086/268845; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; CAMPBELL D, 1986, GASTROENTEROLOGY, V90, P1364; CREED F, 1988, GUT, V29, P235, DOI 10.1136/gut.29.2.235; DROSSMAN DA, 1986, STRESS MEDICINE, V2, P119, DOI 10.1002/smi.2460020209; DRUSS RG, 1969, ARCH GEN PSYCHIAT, V20, P419; FAVA GA, 1977, PSYCHOTHER PSYCHOSOM, V27, P100; FINLAYJONES R, 1981, AUST NZ J PSYCHIAT, V15, P229, DOI 10.3109/00048678109159440; FREEMAN H, 1986, STRESS MEDICINE, V2, P291, DOI 10.1002/smi.2460020404; GAZZARD BG, 1978, BRIT MED J, V2, P1117, DOI 10.1136/bmj.2.6145.1117; GERBERT B, 1980, Journal of Behavioral Medicine, V3, P41, DOI 10.1007/BF00844913; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; GOLDBERG D, 1970, GUT, V11, P459, DOI 10.1136/gut.11.6.459; HELZER JE, 1982, DIGEST DIS SCI, V27, P513, DOI 10.1007/BF01296730; HELZER JE, 1984, GASTROENTEROLOGY, V86, P324; HELZER JE, 1985, COLON RECTAL ANAL SU, P329; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; LATIMER PR, 1978, PSYCHOL MED, V8, P649, DOI 10.1017/S0033291700018857; Lourens P J, 1973, Ala J Med Sci, V10, P285; MURRAY JB, 1984, J GEN PSYCHOL, V110, P201, DOI 10.1080/00221309.1984.9709964; NORTH CS, 1990, AM J PSYCHIAT, V147, P974; PAYKEL ES, 1976, BRIT J MED PSYCHOL, V49, P237, DOI 10.1111/j.2044-8341.1976.tb02370.x; ROSE JDR, 1986, GUT, V27, P1025, DOI 10.1136/gut.27.9.1025; SCHWARTZ RA, 1982, INT J PSYCHIAT MED, V12, P67, DOI 10.2190/FL8Y-1WU6-1N5L-1FQV; SUDMAN S, 1974, RESPONSE EFFECTS SUR, P93; TARTER RE, 1987, INT J PSYCHIAT MED, V17, P173; WELLS KB, 1988, AM J PSYCHIAT, V145, P976; WHYBROW PC, 1968, PSYCHOSOM MED, V30, P209, DOI 10.1097/00006842-196803000-00006; WHYBROW PC, 1973, EMOTIONAL FACTORS GA, P82; WRIGHT JP, 1987, DIGEST DIS SCI, V32, P164, DOI 10.1007/BF01297104; YOUNG SJ, 1976, GASTROENTEROLOGY, V70, P162	33	135	136	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					381	386		10.7326/0003-4819-114-5-381	http://dx.doi.org/10.7326/0003-4819-114-5-381			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992880				2022-12-01	WOS:A1991EZ17400006
J	WHEELER, DA; KYRIACOU, CP; GREENACRE, ML; YU, Q; RUTILA, JE; ROSBASH, M; HALL, JC				WHEELER, DA; KYRIACOU, CP; GREENACRE, ML; YU, Q; RUTILA, JE; ROSBASH, M; HALL, JC			MOLECULAR TRANSFER OF A SPECIES-SPECIFIC BEHAVIOR FROM DROSOPHILA-SIMULANS TO DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							COURTSHIP SONG RHYTHMS; PERIOD GENE; SPECTRAL-ANALYSIS; MUTANTS; LOCUS; DNA; CYCLES	Drosophila males modulate the interpulse intervals produced during their courtship songs. These song cycles, which are altered by mutations in the clock gene period, exhibit a species-specific variation that facilitates mating. We have used chimeric period gene constructs from Drosophila melanogaster and Drosophila simulans in germline transformation experiments to map the genetic control of their song rhythm difference to a small segment of the amino acid encoding information within this gene.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254; UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,ENGLAND	Brandeis University; Brandeis University; Howard Hughes Medical Institute; University of Leicester					NIGMS NIH HHS [GM-33205, GM-21473] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM033205, R01GM021473] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETCLARK HC, 1969, ANIM BEHAV, V17, P755, DOI 10.1016/S0003-3472(69)80023-0; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; COWLING DE, 1981, ANIM BEHAV, V29, P924, DOI 10.1016/S0003-3472(81)80030-9; CROSSLEY SA, 1988, ANIM BEHAV, V36, P1098, DOI 10.1016/S0003-3472(88)80069-1; EWING AW, 1988, ANIM BEHAV, V36, P1091, DOI 10.1016/S0003-3472(88)80068-X; Hall J.C., 1990, Advances in Insect Physiology, V22, P221, DOI 10.1016/S0065-2806(08)60007-7; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMBLENCOYLE M, 1989, J NEUROGENET, V5, P229, DOI 10.3109/01677068909066210; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KYRIACOU CP, 1982, ANIM BEHAV, V30, P794, DOI 10.1016/S0003-3472(82)80152-8; KYRIACOU CP, 1990, BEHAV GENET, V20, P617, DOI 10.1007/BF01065875; KYRIACOU CP, 1980, P NATL ACAD SCI-BIOL, V77, P6729, DOI 10.1073/pnas.77.11.6729; KYRIACOU CP, 1986, SCIENCE, V232, P494, DOI 10.1126/science.3083506; KYRIACOU CP, 1989, ANIM BEHAV, V37, P850, DOI 10.1016/0003-3472(89)90069-9; LOGAN IG, 1989, ANIM BEHAV, V37, P860, DOI 10.1016/0003-3472(89)90070-5; PETERSEN G, 1988, EMBO J, V7, P3939, DOI 10.1002/j.1460-2075.1988.tb03280.x; RAUP DM, 1988, SCIENCE, V241, P94, DOI 10.1126/science.241.4861.94; RAUP DM, 1984, P NATL ACAD SCI-BIOL, V81, P801, DOI 10.1073/pnas.81.3.801; ROBERTS DH, 1987, ASTRON J, V93, P968, DOI 10.1086/114383; RUTILA JE, 1986, J VIROL, V58, P526, DOI 10.1128/JVI.58.2.526-535.1986; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILCHER FV, 1976, ANIM BEHAV, V24, P622, DOI DOI 10.1016/S0003-3472(76)80076-0; TAJIMA Y, 1990, NEUROSCIENCE, V39, P245, DOI 10.1016/0306-4522(90)90237-X; THACKERAY JR, 1990, J MOL EVOL, V31, P389, DOI 10.1007/BF02106054; WHEELER D, UNPUB; WHEELER DA, 1988, BEHAV GENET, V18, P675, DOI 10.1007/BF01066850; YU Q, 1987, NATURE, V326, P765, DOI 10.1038/326765a0	29	159	163	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1082	1085		10.1126/science.1900131	http://dx.doi.org/10.1126/science.1900131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1900131				2022-12-01	WOS:A1991EZ66500054
J	WILLIAMS, T; TJIAN, R				WILLIAMS, T; TJIAN, R			CHARACTERIZATION OF A DIMERIZATION MOTIF IN AP-2 AND ITS FUNCTION IN HETEROLOGOUS DNA-BINDING PROTEINS	SCIENCE			English	Article							LEUCINE ZIPPER; TRANSCRIPTION FACTOR; ENHANCER-BINDING; SEQUENCE; JUN; SPECIFICITY; ELEMENTS; COMMON; DOMAIN; C/EBP	The mammalian transcription factor AP-2 is a retinoic acid inducible sequence-specific DNA-binding protein that is developmentally regulated. In this report, the functional domains necessary for AP-2 DNA binding were studied. AP-2 required a dimerization domain and an adjacent region of net basic charge to achieve a sequence-specific protein: DNA interaction. The sequences responsible for dimerization consisted of two putative amphipathic alpha helices separated by a large intervening span region. This helix-span-helix (HSH) domain was unable to bind DNA when separated from the basic region, but was still capable of dimerization. The ability of the HSH domain to function as a module that promotes DNA binding through dimerization was further demonstrated by attaching it to the heterologous basic region of the c-Jun proto-oncogene product. The resulting chimeric protein specifically recognized an AP-1 DNA-binding site in the absence of an intact c-Jun leucine repeat and in a manner that was dependent on the presence of a functional AP-2 dimerization domain.			WILLIAMS, T (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.							ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WILLIAMS T, IN PRESS GENES DEV; Williams T. J., UNPUB	31	196	204	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1067	1071		10.1126/science.1998122	http://dx.doi.org/10.1126/science.1998122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1998122				2022-12-01	WOS:A1991EZ66500049
J	WONG, KF; HUI, PK; CHAN, JKC; CHAN, YW; HA, SY				WONG, KF; HUI, PK; CHAN, JKC; CHAN, YW; HA, SY			THE ACUTE LUPUS HEMOPHAGOCYTIC SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						LUPUS ERYTHEMATOSUS, SYSTEMIC; PANCYTOPENIA; LUPUS HEMOPHAGOCYTIC SYNDROME; HISTIOCYTOSIS, NON-LANGERHANS-CELL; STEROIDS	MALIGNANT HISTIOCYTOSIS; ERYTHEMATOSUS	Objective: To characterize an unusual mode of presentation of systemic lupus erythematosus: acute and severe pancytopenia related to reactive hemophagocytosis. Design: Retrospective case series. Setting: Two general community hospitals in Hong Kong. Patients: Six patients presenting with a reactive hemophagocytic syndrome, identified over a 3.5 year period, diagnosed with systemic lupus erythematosus according to the criteria of the American Rheumatism Association. Results: In addition to severe pancytopenia and marrow hemophagocytosis, other characteristic features were fever, hypocomplementemia, high antinuclear antibody titer, and cutaneous and visceral vasculitis. There was no evidence of an underlying infection. The pancytopenia responded dramatically to treatment with steroids. Conclusion: Recognition of the acute lupus hemophagocytic syndrome and distinction from an infection-associated hemophagocytic syndrome is important because it responds well to steroid therapy. The evaluation of patients presenting with a hemophagocytic syndrome should include serologic tests for systemic lupus erythematosus.	KWONG WAH HOSP, CLIN PATHOL UNIT, KOWLOON, HONG KONG; KWONG WAH HOSP, MED UNIT A, KOWLOON, HONG KONG	Kwong Wah Hospital; Kwong Wah Hospital	WONG, KF (corresponding author), QUEEN ELIZABETH HOSP, INST PATHOL, KOWLOON, HONG KONG.			HA, Shau Yin/0000-0002-9191-8743				BUDMAN DR, 1977, ANN INTERN MED, V86, P220, DOI 10.7326/0003-4819-86-2-220; CHAN JKC, 1987, PATHOLOGY, V19, P43, DOI 10.3109/00313028709065134; CHAN JKC, 1987, LANCET, V1, P507; GOLD SC, 1953, Q J MED, V22, P457; HUANG LM, 1990, LANCET, V336, P60, DOI 10.1016/0140-6736(90)91580-4; JAFFE ES, 1983, AM J MED, V75, P741, DOI 10.1016/0002-9343(83)90402-3; KOFFLER D, 1982, ARTHRITIS RHEUM, V25, P858, DOI 10.1002/art.1780250729; Meyerhoff J, 1983, Md State Med J, V32, P935; MICHAEL SR, 1951, BLOOD, V6, P1059, DOI 10.1182/blood.V6.11.1059.1059; REINER AP, 1988, MEDICINE, V67, P369, DOI 10.1097/00005792-198811000-00002; Richert-Boe K E, 1987, Hematol Oncol Clin North Am, V1, P301; RISDALL RJ, 1979, CANCER, V44, P993, DOI 10.1002/1097-0142(197909)44:3<993::AID-CNCR2820440329>3.0.CO;2-5; RISDALL RJ, 1984, CANCER, V54, P2968, DOI 10.1002/1097-0142(19841215)54:12<2968::AID-CNCR2820541226>3.0.CO;2-4; ROSENTHAL NS, 1989, AM J CLIN PATHOL, V92, P650, DOI 10.1093/ajcp/92.5.650; SAKURAI T, 1984, Henry Ford Hospital Medical Journal, V32, P142; SERDULA MK, 1979, ARTHRITIS RHEUM-US, V22, P328, DOI 10.1002/art.1780220403; SIMRELL CR, 1982, B T CELL TUMORS, P247; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WOO J, 1987, ASIAN J CLIN SCI, V7, P77	19	173	178	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					387	390		10.7326/0003-4819-114-5-387	http://dx.doi.org/10.7326/0003-4819-114-5-387			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992881				2022-12-01	WOS:A1991EZ17400007
J	DANESHDOOST, L; GENNARELLI, TA; BASHEY, HM; SAVINO, PJ; SERGOTT, RC; BOSLEY, TM; SNYDER, PJ				DANESHDOOST, L; GENNARELLI, TA; BASHEY, HM; SAVINO, PJ; SERGOTT, RC; BOSLEY, TM; SNYDER, PJ			RECOGNITION OF GONADOTROPH ADENOMAS IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SECRETING PITUITARY-ADENOMAS; THYROTROPIN-RELEASING-HORMONE; CELL ADENOMAS; LUTEINIZING-HORMONE; ALPHA-SUBUNIT; FSH; CULTURE; INVITRO; INVIVO; BROMOCRIPTINE	Background. Pituitary adenomas that arise from the gonadotroph cells are being recognized with increasing frequency in men, but they are still rarely recognized in women. This rarity could be the result of an actual difference in occurrence or of greater difficulty in recognition. The tumors are usually recognized in men more than 50 years old, but elevated serum gonadotropin levels in women of that age could be produced by normal gonadotroph cells. Methods. Because the stimulation of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and the beta subunit of LH (LH-beta) by thyrotropin-releasing hormone (TRH) is a characteristic of gonadotroph adenomas in men, we administered TRH to 16 women with apparently nonsecreting pituitary macroadenomas and measured serum FSH, LH, LH-beta, and the glycoprotein hormone alpha-subunit every 15 minutes for 90 minutes before and 90 minutes after. The results were compared with the responses in 16 healthy women matched for age and in 10 women with macroadenomas secreting prolactin, growth hormone, or corticotropin. The tumors from 12 of the women with nonsecreting adenomas were cultured, and the secretion of FSH, LH, and LH-beta in culture was determined. Results. Eleven of the 16 women with apparently nonsecreting adenomas had significant increases in serum LH-beta in response to TRH, 3 had FSH responses, and 4 had LH responses. None of the 16 healthy women and none of the 10 women with secreting macroadenomas had LH-beta, FSH, or LH responses to TRH. Ten of the 12 adenomas that were cultured secreted readily detectable amounts of FSH, LH, and LH-beta, and their secretion in vitro correlated with the patients' responses to TRH in vivo. Conclusions. Most apparently nonsecreting pituitary macroadenomas in women arise from gonadotroph cells. The majority of these can be recognized, even in postmenopausal women, by the serum LH-beta responses to TRH, and some can be recognized by the responses of serum FSH and LH.	WILLS EYE HOSP & RES INST,NEUROOPHTHALMOL SERV,PHILADELPHIA,PA 19107; UNIV PENN,SCH MED,DEPT MED,ENDOCRINOL SECT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104	Jefferson University; University of Pennsylvania; University of Pennsylvania					NCRR NIH HHS [RR-40] Funding Source: Medline; NIDDK NIH HHS [DK-42139] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042139] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASA SL, 1986, J CLIN ENDOCR METAB, V62, P1011, DOI 10.1210/jcem-62-5-1011; BECKERS A, 1985, J CLIN ENDOCR METAB, V61, P525, DOI 10.1210/jcem-61-3-525; BECKPECCOZ P, 1985, J CLIN ENDOCR METAB, V61, P541, DOI 10.1210/jcem-61-3-541; BLACK PM, 1987, J NEUROSURG, V66, P244, DOI 10.3171/jns.1987.66.2.0244; CUNNINGHAM GR, 1977, J CLIN ENDOCR METAB, V44, P248, DOI 10.1210/jcem-44-2-248; FRIEND JN, 1976, J CLIN ENDOCR METAB, V43, P650, DOI 10.1210/jcem-43-3-650; JAMESON JL, 1987, J CLIN INVEST, V80, P1472, DOI 10.1172/JCI113228; KOVACS K, 1978, FERTIL STERIL, V29, P622; KWEKKEBOOM DJ, 1989, J CLIN ENDOCR METAB, V68, P1128, DOI 10.1210/jcem-68-6-1128; LAMBERTS SWJ, 1987, J CLIN ENDOCR METAB, V64, P524, DOI 10.1210/jcem-64-3-524; MASHITER K, 1981, CLIN ENDOCRINOL, V15, P103, DOI 10.1111/j.1365-2265.1981.tb00643.x; SNYDER PJ, 1980, J CLIN ENDOCR METAB, V51, P744, DOI 10.1210/jcem-51-4-744; SNYDER PJ, 1984, J CLIN ENDOCR METAB, V59, P1169, DOI 10.1210/jcem-59-6-1169; SNYDER PJ, 1985, ENDOCR REV, V6, P552, DOI 10.1210/edrv-6-4-552; SNYDER PJ, 1985, J CLIN ENDOCR METAB, V61, P1061, DOI 10.1210/jcem-61-6-1061; SNYDER PJ, 1976, J CLIN ENDOCR METAB, V42, P544, DOI 10.1210/jcem-42-3-544; TROUILLAS J, 1986, SEMIN DIAGN PATHOL, V3, P42; WHITE MC, 1986, CLIN ENDOCRINOL, V25, P173, DOI 10.1111/j.1365-2265.1986.tb01679.x; WHITE MC, 1990, CLIN ENDOCRINOL, V32, P681, DOI 10.1111/j.1365-2265.1990.tb00914.x; WIDE L, 1981, J CLIN ENDOCR METAB, V53, P923, DOI 10.1210/jcem-53-5-923; WOOLF PD, 1974, J CLIN ENDOCR METAB, V38, P561, DOI 10.1210/jcem-38-4-561	21	109	113	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 28	1991	324	9					589	594		10.1056/NEJM199102283240904	http://dx.doi.org/10.1056/NEJM199102283240904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY886	1899470				2022-12-01	WOS:A1991EY88600004
J	DESHAIES, RJ; SANDERS, SL; FELDHEIM, DA; SCHEKMAN, R				DESHAIES, RJ; SANDERS, SL; FELDHEIM, DA; SCHEKMAN, R			ASSEMBLY OF YEAST SEC PROTEINS INVOLVED IN TRANSLOCATION INTO THE ENDOPLASMIC-RETICULUM INTO A MEMBRANE-BOUND MULTISUBUNIT COMPLEX	NATURE			English	Article							LAMBDA-DNA-REPLICATION; HEAT-SHOCK PROTEIN; NUCLEOPROTEIN STRUCTURES; BACTERIOPHAGE-LAMBDA; INITIATION; GENE; SEQUENCE; ENCODES; MUTANT; ORIGIN	SECRETORY-protein translocation into the endoplasmic reticulum (ER) is thought to be catalysed by integral membrane proteins. Genetic selections uncovered three Saccharomyces cerevisiae genes (SEC61, SEC62 and SEC63), mutations in which block import of precursor proteins into the ER lumen in vivo 1-3 and in vitro 2-4. The DNA sequences of SEC62 (ref. 4) and SEC63 (ref. 5) predict multispanning membrane proteins, and biochemical characterization of the SEC62 protein (Sec62) confirms that it is an integral ER membrane protein6. Here we show that Sec61, Sec62 and Sec63 are assembled with two additional proteins into a multisubunit membrane-associated complex. These results confirm previous predictions, based upon genetic interactions between the SEC genes, that Sec61, Sec62 and Sec63 act together to facilitate protein translocation into the ER.	UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354				ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; BERNSTEIN M, 1985, J CELL BIOL, V101, P2374, DOI 10.1083/jcb.101.6.2374; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DODSON M, 1989, J BIOL CHEM, V264, P10719; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; RAPOPORT TA, 1990, NATO ADV SCI I H-CEL, V40, P231; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	22	276	281	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					806	808		10.1038/349806a0	http://dx.doi.org/10.1038/349806a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	2000150				2022-12-01	WOS:A1991EZ66600061
J	FEATHERSTONE, C; RUSSELL, P				FEATHERSTONE, C; RUSSELL, P			FISSION YEAST P107WEE1 MITOTIC INHIBITOR IS A TYROSINE SERINE KINASE	NATURE			English	Article							EXPRESSION; PROTEINS; MITOSIS	THE fission yeast wee1+ gene product is a dose-dependent, negative regulator of entry into mitosis 1,2. wee1+ encodes a protein of relative molecular mass 107,000 (M(r) 107K), the C-terminal third of which has strong similarities with the serine/threonine protein kinase family 2,3. Here we report that p107wee1 immune complexes phosphorylate p107wee1 equally on serine and tyrosine residues, and also phosphorylate an exogenous substrate, angiotensin II, on tyrosine. Both kinase activities are attributable to p107wee1 because they are also observed when wee1+ is expressed in heterologous systems; both are abolished by a point mutation in the ATP-binding domain, and both behave like an asymmetric monomer of M(r) 114K on gel filtration and density-gradient centrifugation. Thus the wee1+ gene product is representative of a novel class of protein kinase that phosphorylates both serine and tyrosine residues.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Featherstone, Carol/0000-0002-7881-7235				BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MAIZEL JV, 1969, FUNDAMENTAL TECHNIQU, P334; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; Summers MD, 1987, TEXAS AGR EXPT STATI	13	328	340	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 28	1991	349	6312					808	811		10.1038/349808a0	http://dx.doi.org/10.1038/349808a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1825699				2022-12-01	WOS:A1991EZ66600062
J	GANNON, JV; LANE, DP				GANNON, JV; LANE, DP			PROTEIN-SYNTHESIS REQUIRED TO ANCHOR A MUTANT P53 PROTEIN WHICH IS TEMPERATURE-SENSITIVE FOR NUCLEAR TRANSPORT	NATURE			English	Article							TRANSFORMED-CELLS; GENE-PRODUCT; MUTATIONS; EXPRESSION; ANTIGEN; CANCER	THE p53 protein is rendered temperature-sensitive by a point mutation 1. Rat cells transformed by this mutant p53 and an activated ras oncogene grow well at 37-degrees-C but cease DNA synthesis and cell division when shifted to 32-degrees-C (ref. 1). Immunostaining demonstrates that the mutant p53 protein is in the nucleus of the arrested cells at 32-degrees-C but in the cytoplasm of the growing cells at 37-degrees-C. This is the first example of a protein which is temperature-sensitive for nuclear transport. The translocation from cytoplasm to nucleus and vice versa occurs 6 h after temperature shift and is coincident with the inhibition of DNA synthesis; transport from cytoplasm to nucleus does not require protein synthesis. Remarkably, inhibition of protein synthesis at 37-degrees-C also results in the rapid appearance of mutant p53 in the cell nucleus. These results suggest the presence of a short-lived protein responsible for holding p53 in the cytoplasm at 37-degrees-C but not at 32-degrees-C. Analysis of a non-temperature-sensitive mutant p53 protein shows that its cytoplasmic location is sensitive to protein synthesis inhibitors but not to temperature.			GANNON, JV (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ANDENBERG FM, 1989, J PATHOL, V157, P193; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; Crawford L V, 1984, Mol Biol Med, V2, P261; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARLOW E, 1988, ANTIBODIES LABORATOR; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WASEEM NH, 1990, J CELL SCI, V96, P121; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	29	200	203	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					802	806						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	2000149				2022-12-01	WOS:A1991EZ66600060
J	LAWLOR, DA; DICKEL, CD; HAUSWIRTH, WW; PARHAM, P				LAWLOR, DA; DICKEL, CD; HAUSWIRTH, WW; PARHAM, P			ANCIENT HLA GENES FROM 7,500-YEAR-OLD ARCHAEOLOGICAL REMAINS	NATURE			English	Article							MOLECULAR ANALYSIS; CHAIN-REACTION; DNA-SEQUENCES; MUMMY DNA; ALLELES; CLONING; NUMBER; EVOLUTION; FAMILY; BRAIN	IN the past decade there has been increasing interest in cloning DNA from ancient and preserved tissues 1-6. Most studies, however, have focused on mitochondrial or chloroplast genes, present at hundreds to thousands of copies per cell compared with one or two for each nuclear gene 7-9. With a probe containing Alu repeat sequences, Paabo isolated a 3.4-kilobase DNA fragment from a 2,400-year-old Egyptian mummy 10 which was subsequently shown to contain an intron of the nuclear gene HLA-DQA (ref. 11). Here we report a more targeted approach to the characterization of nuclear genes from archaeological specimens. The Windover pond of central Florida has provided skeletal and soft tissue remains from 165 humans, radiocarbon-dated to be 6,990-8,130 years old 12-14. Using DNA obtained from one individual we have characterized segments from six nuclear genes: that for beta-2-microglobulin and five members of the class I HLA heavy chain gene family. Distinctive patterns of nucleotide substitution in the cloned heavy chain gene segments permit tentative assignment of the HLA-A,B type of the ancient individual.	STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; UNIV FLORIDA,COLL MED,DEPT IMMUNOL & MED MICROBIOL,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT OPHTHALMOL,GAINESVILLE,FL 32610	Stanford University; Stanford University; State University System of Florida; University of Florida; State University System of Florida; University of Florida								BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; CHIEWSILP P, 1986, HLA ASIA OCEANIA 198, P40; DELPOZZO G, 1989, NATURE, V339, P431; Doran G.H., 1988, WET SITE ARCHAEOLOGY, P263, DOI 10.1201/9781351077750-17; Doran G.H., 1988, FLORIDA ANTHR, V41, P365; DORAN GH, 1986, NATURE, V323, P803, DOI 10.1038/323803a0; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145; GOLENBERG EM, 1990, NATURE, V344, P656, DOI 10.1038/344656a0; HAGELBERG E, 1989, NATURE, V342, P485, DOI 10.1038/342485a0; HANSEN T, IN PRESS TISSUE ANTI; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; KATO K, 1989, J IMMUNOL, V143, P3371; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LAMPPA GK, 1980, PLANTA, V148, P437, DOI [10.1007/BF00552656, 10.1007/BF02395311]; MAYER WE, 1988, EMBO J, V7, P2765, DOI 10.1002/j.1460-2075.1988.tb03131.x; MICHAELS GS, 1982, DEV BIOL, V94, P246, DOI 10.1016/0012-1606(82)90088-4; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PAABO S, 1985, NATURE, V314, P644, DOI 10.1038/314644a0; PAABO S, 1989, J BIOL CHEM, V264, P9709; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; PAABO S, 1990, J BIOL CHEM, V265, P4718; PAABO S, 1988, NUCLEIC ACIDS RES, V16, P9775, DOI 10.1093/nar/16.20.9775; PARHAM P, 1989, J IMMUNOL, V142, P3937; POHLA H, 1989, IMMUNOGENETICS, V29, P297, DOI 10.1007/BF00352839; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; THOMAS RH, 1989, NATURE, V340, P465, DOI 10.1038/340465a0; THOMAS WK, 1990, J MOL EVOL, V31, P101, DOI 10.1007/BF02109479; ZEMMOUR J, 1990, J IMMUNOL, V144, P3619	30	94	98	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					785	788		10.1038/349785a0	http://dx.doi.org/10.1038/349785a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	2000147				2022-12-01	WOS:A1991EZ66600054
J	PICKER, LJ; KISHIMOTO, TK; SMITH, CW; WARNOCK, RA; BUTCHER, EC				PICKER, LJ; KISHIMOTO, TK; SMITH, CW; WARNOCK, RA; BUTCHER, EC			ELAM-1 IS AN ADHESION MOLECULE FOR SKIN-HOMING T-CELLS	NATURE			English	Article							LEUKOCYTE ADHESION; ENDOTHELIAL ACTIVATION; LYMPH-NODES; LYMPHOCYTES; RECEPTOR; PROTEINS; ANTIGEN; CD2	ENDOTHELIAL cell leukocyte adhesion molecule-1 (ELAM-1) has been described as an inducible endothelial cell-adhesion molecule for neutrophils, and is believed to have a key role in the extravasation of these cells at sites of acute inflammation 1-3. Here we report that ELAM-1-transfected COS cells also bind a unique skin-associated subset of circulating memory T cells defined by the expression of the cutaneous lymphocyte-associated antigen 4,5. T cells expressing this antigen bind at least as well as neutrophils to expressed ELAM-1, whereas other lymphocytes in the peripheral blood bind poorly, or not at all. Immunohistological survey of chronically inflamed tissue specimens revealed that vascular expression of ELAM-1 occurs at cutaneous sites in preference to noncutaneous sites. We conclude that at sites of chronic inflammation, ELAM-1 may function as a skin vascular addressin, a tissue-selective endothelial cell-adhesion molecule for skin-homing memory T lymphocytes.	VET ADM MED CTR,CTR MOLEC MED,PALO ALTO,CA 94304; STANFORD UNIV,MED CTR,SCH MED,CTR DIGEST DIS,STANFORD,CA 94305; BAYLOR UNIV,DEPT PEDIAT,LEUKOCYTE BIOL SECT,HOUSTON,TX 77030	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; Baylor University	PICKER, LJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305, USA.							BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CHIN W, 1980, GASTROENTEROLOGY, V79, P1231; CHIN YH, 1990, J INVEST DERMATOL, V94, P413, DOI 10.1111/1523-1747.ep12874486; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; ISSEKUTZ TB, 1980, CELL IMMUNOL, V54, P79, DOI 10.1016/0008-8749(80)90191-4; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MUNRO JM, 1989, AM J PATHOL, V135, P121; NAKACHE M, 1989, NATURE, V337, P179, DOI 10.1038/337179a0; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1990, AM J PATHOL, V136, P1053; SAKSTEIN R, 1988, J INVEST DERMATOL, V91, P423; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; TERSTAPPEN WMM, 1990, J LEUKOCYTE BIOL, V48, P138; WELLICOME SM, 1990, J IMMUNOL, V144, P2558	23	812	840	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					796	799		10.1038/349796a0	http://dx.doi.org/10.1038/349796a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1705666				2022-12-01	WOS:A1991EZ66600058
J	SHIMIZU, Y; SHAW, S; GRABER, N; GOPAL, TV; HORGAN, KJ; VANSEVENTER, GA; NEWMAN, W				SHIMIZU, Y; SHAW, S; GRABER, N; GOPAL, TV; HORGAN, KJ; VANSEVENTER, GA; NEWMAN, W			ACTIVATION-INDEPENDENT BINDING OF HUMAN-MEMORY T-CELLS TO ADHESION MOLECULE ELAM-1	NATURE			English	Article							HELPER-INDUCER; ENDOTHELIAL-CELLS; LYMPHOCYTES; RECEPTOR; PROTEINS; LFA-1; ADHESIVENESS; ICAM-1	THE induction of an ensemble of adhesion molecules on endothelial cells by inflammatory cytokines is likely to be crucial to the differential migration of T-lymphocyte subsets into inflammatory sites. Two molecular pathways involving the VLA-4 and LFA-1 integrins are known to mediate T-cell adhesion to activated endothelium 1-4. Here we show that a third pathway involving the rapidly inducible endothelial cell-surface adhesion molecule ELAM-1 (refs 5, 6) contributes to the binding of resting CD4+ T cells to IL-1-induced human endothelial cells. All three pathways contribute to the greater adhesion to endothelium of memory T cells than naive T cells. There are two unique features of T-cell adhesion to purified ELAM-1: first, ELAM-1 exclusively mediates adhesion of memory T cells; second, memory T-cell binding to ELAM-1 is independent of acute activation events that regulate integrin-mediated adhesion 7,8. Thus, ELAM-1 may be of primary importance in the initial attachment of memory T cells to inflamed endothelium in vivo and to the preferential migration of memory T cells into tissue and inflammatory sites.	OTSUKA AMER PHARMACEUT INC,DEPT IMMUNOL,ROCKVILLE,MD 20850; OTSUKA AMER PHARMACEUT INC,DEPT MOLEC BIOL,ROCKVILLE,MD 20850		SHIMIZU, Y (corresponding author), NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892, USA.			Shimizu, Yoji/0000-0001-9760-0288; Horgan, Kevin/0000-0003-0647-9078				BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CAVENDER DE, 1988, CELL IMMUNOL, V117, P111, DOI 10.1016/0008-8749(88)90081-0; CLAYBERGER C, 1987, J IMMUNOL, V138, P1510; DAMLE NK, 1990, J IMMUNOL, V144, P1233; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GRABER N, 1990, J IMMUNOL, V145, P819; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HORGAN KJ, 1990, EUR J IMMUNOL, V20, P1111, DOI 10.1002/eji.1830200525; JAMES SP, 1986, GASTROENTEROLOGY, V91, P1483, DOI 10.1016/0016-5085(86)90205-2; JANOSSY G, 1989, IMMUNOLOGY, V66, P517; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUNG TM, 1990, J IMMUNOL, V144, P3130; KINGSLEY G, 1988, SCAND J IMMUNOL, V28, P225, DOI 10.1111/j.1365-3083.1988.tb02435.x; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PITZALIS C, 1988, EUR J IMMUNOL, V18, P1397, DOI 10.1002/eji.1830180915; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TEDDER TF, 1985, J IMMUNOL, V134, P2989; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579	34	395	406	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					799	802		10.1038/349799a0	http://dx.doi.org/10.1038/349799a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1705667				2022-12-01	WOS:A1991EZ66600059
J	WAGNER, JA; COZENS, AL; SCHULMAN, H; GRUENERT, DC; STRYER, L; GARDNER, P				WAGNER, JA; COZENS, AL; SCHULMAN, H; GRUENERT, DC; STRYER, L; GARDNER, P			ACTIVATION OF CHLORIDE CHANNELS IN NORMAL AND CYSTIC-FIBROSIS AIRWAY EPITHELIAL-CELLS BY MULTIFUNCTIONAL CALCIUM CALMODULIN-DEPENDENT PROTEIN-KINASE	NATURE			English	Article							PHOSPHORYLATION; IDENTIFICATION; CONDUCTANCE; GENE	CYSTIC fibrosis is associated with defective regulation of apical membrane chloride channels in airway epithelial cells. These channels in normal cells are activated by cyclic AMP-dependent protein kinase 1,2 and protein kinase C 3,4. In cystic fibrosis these kinases fail to activate otherwise normal Cl- channels 1-4. But Cl- flux in cystic fibrosis cells, as in normal cells, can be activated by raising intracellular Ca2+ (refs 5-10). We report here whole-cell patch clamp studies of normal and cystic fibrosis-derived airway epithelial cells showing that Cl- channel activation by Ca2+ is mediated by multifunctional Ca2+/calmodulin-dependent protein kinase. We find that intracellular application of activated kinase and ATP activates a Cl- current similar to that activated by a Ca2+ ionophore, that peptide inhibitors of either the kinase or calmodulin block Ca2+-dependent activation of Cl- channels, and that a peptide inhibitor of protein kinase C does not block Ca2+-dependent activation. Ca2+/calmodulin activation of Cl- channels presents a pathway with therapeutic potential for circumventing defective regulation of Cl- channels in cystic fibrosis.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,FALK CVRC,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University; Stanford University; University of California System; University of California San Francisco; Stanford University								CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COZENS AL, IN PRESS IDENTIFICAT; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GORMAN ALF, 1982, BIOPHYS J, V38, P319, DOI 10.1016/S0006-3495(82)84565-7; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; GRUENERT DC, 1988, PEDIATR PULMONOL S2, V17, P100; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	24	194	194	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					793	796		10.1038/349793a0	http://dx.doi.org/10.1038/349793a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1705665				2022-12-01	WOS:A1991EZ66600057
J	ENGLISH, TL				ENGLISH, TL			SKEPTICAL OF SKEPTICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	7	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					964	964		10.1001/jama.265.8.964	http://dx.doi.org/10.1001/jama.265.8.964			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY432	1992204				2022-12-01	WOS:A1991EY43200007
J	GREENBERG, DP; VADHEIM, CM; BORDENAVE, N; ZIONTZ, L; CHRISTENSON, P; WATERMAN, SH; WARD, JI				GREENBERG, DP; VADHEIM, CM; BORDENAVE, N; ZIONTZ, L; CHRISTENSON, P; WATERMAN, SH; WARD, JI			PROTECTIVE EFFICACY OF HAEMOPHILUS-INFLUENZAE TYPE-B POLYSACCHARIDE AND CONJUGATE VACCINES IN CHILDREN 18 MONTHS OF AGE AND OLDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPSULAR POLYSACCHARIDE	To evaluate the protective efficacy of polyribosylribitol phosphate (PRP) and polyribosylribitol phosphate-diphtheria toxoid (PRP-D) vaccines in children 18 to 59 months of age, we conducted a case-control study in Los Angeles (Calif) County between July 1, 1988, and July 31, 1989. Seventy-nine children with invasive Haemophilus influenzae type b disease 18 to 59 months of age were identified, and 212 controls were selected by random-digit telephone dialing methods. Cases and controls were stratified by age and month of disease onset of the case. Seventeen PRP vaccine failures and two PRP-D vaccine failures occurred more than 2 weeks after vaccination. The PRP vaccine was shown not to be effective (point estimate -47%; 95% confidence interval, -307% to 47%), but the PRP-D vaccine was 88% protective (95% confidence interval, 42% to 97%). Adjustment of the efficacy estimates for potential confounding variables did not change the results significantly. The PRP-D vaccine provided significantly better protection than the PRP vaccine against invasive H influenzae type b disease in this population.	LOS ANGELES CTY DEPT HLTH SERV,LOS ANGELES,CA		GREENBERG, DP (corresponding author), UNIV CALIF LOS ANGELES,HARBOR MED CTR,SCH MED,CTR VACCINE RES,1124 W CARSON ST,BLDG E-6,TORRANCE,CA 90502, USA.							BERKOWITZ CD, 1987, J PEDIATR-US, V110, P509, DOI 10.1016/S0022-3476(87)80540-1; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; Breslow N, 1980, STAT METHODS CANC RE, P248; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; ESKOLA J, 1989, 29TH INT C ANT AG CH; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; HARRISON LH, 1988, JAMA-J AM MED ASSOC, V260, P1413, DOI 10.1001/jama.260.10.1413; HARRISON LH, 1989, PEDIATRICS, V84, P255; KAYHTY H, 1984, PEDIATRICS, V74, P857; MURPHY TV, 1990, CLIN RES, V38, pA183; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; OSTERHOLM MT, 1989, 29TH INT C ANT AG CH; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; PELTOLA H, 1977, PEDIATRICS, V60, P730; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; SHAPIRO ED, 1990, 30TH INT C ANT AG CH; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; VADHEIM CM, 1990, PEDIATR INFECT DIS J, V9, P555, DOI 10.1097/00006454-199008000-00006; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; WENGER JD, 1990, 30TH INT C ANT AG CH; 1985, MMWR, V34, P201; 1990, MMWR, V39, P925; 1988, MMWR, V37, P13; 1990, MMWR, V39, P698; 1988, HAEMOPHILUS INFLUENZ, V81, P908	25	40	40	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					987	992		10.1001/jama.265.8.987	http://dx.doi.org/10.1001/jama.265.8.987			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY432	1992212				2022-12-01	WOS:A1991EY43200026
J	HIBBS, J; PERPER, J; WINEK, CL				HIBBS, J; PERPER, J; WINEK, CL			AN OUTBREAK OF DESIGNER DRUG RELATED DEATHS IN PENNSYLVANIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								3-Methylfentanyl ("China White") is a "designer" opiate that has caused more than 100 overdose deaths in California since 1979, but that has not been associated previously with deaths east of the Rocky Mountains. During 1988, 3-methylfentanyl was identified in 16 fatal overdose cases in Allegheny County, Pennsylvania, contributing to a fourfold rise in overdose mortality during October of that year. Morphine was detected in the blood of five persons (31%) and cocaine in the blood of three persons (19%) dying of 3-methylfentanyl overdoses; these were demographically similar to 99 other fatal overdose cases investigated by the county coroner from 1986 through 1988. This documents the contribution of 3-methylfentanyl to overdose mortality in an eastern city and the use of 3-methylfentanyl with other illegal drugs. Drug abusers in the northeastern United States should be considered at risk for more "designer drug" overdose outbreaks in the future.	CTR DIS CONTROL, DIV FIELD SERV, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA; ALLEGHENY CTY CORONERS OFF, PITTSBURGH, PA USA; ALLEGHENY CTY DEPT LABS, PITTSBURGH, PA USA	Centers for Disease Control & Prevention - USA								AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; FROEDE RC, 1980, MICROSCOPIC DIAGNOSI, P149; GILLESPIE TJ, 1982, J ANAL TOXICOL, V6, P139, DOI 10.1093/jat/6.3.139; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; Janssen P.A., 1985, OPIOIDS ANESTHESIA, P37; LABARBERA M, 1983, J PSYCHOACTIVE DRUGS, V15, P293, DOI 10.1080/02791072.1983.10471966; MARTIN ML, 1989, ANN EMERG MED, V18, P446; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; RUTTENBER AJ, 1984, SCIENCE, V226, P14, DOI 10.1126/science.6474188; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003	11	50	50	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					1011	1013		10.1001/jama.265.8.1011	http://dx.doi.org/10.1001/jama.265.8.1011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY432	1867667				2022-12-01	WOS:A1991EY43200031
J	MAKI, DG; KLEIN, BS; MCCORMICK, RD; ALVARADO, CJ; ZILZ, MA; STOLZ, SM; HASSEMER, CA; GOULD, J; LIEGEL, AR				MAKI, DG; KLEIN, BS; MCCORMICK, RD; ALVARADO, CJ; ZILZ, MA; STOLZ, SM; HASSEMER, CA; GOULD, J; LIEGEL, AR			NOSOCOMIAL PSEUDOMONAS-PICKETTII BACTEREMIAS TRACED TO NARCOTIC TAMPERING - A CASE FOR SELECTIVE DRUG SCREENING OF HEALTH-CARE PERSONNEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAINING-PROGRAMS; INFECTION; OUTBREAK; DEATHS; ABUSE	Three patients in a university hospital developed nosocomial infusion-related Pseudomonas pickettii bacteremia. Investigation identified six additional patients who had received intravenous fluid contaminated by P pickettii but did not become ill. All nine patients had had surgery, and each of these patients but only nine of 19 operated-on control patients had received intravenous fentanyl citrate in the operating room; the mean dose given to the nine case patients was far greater than that given to control patients. Fentanyl in 20 (40%) of 50 predrawn 30-mL syringes was shown to be contaminated by P pickettii. Contamination was caused by theft of fentanyl from predrawn syringes and replacement by distilled water contaminated by P pickettii. Narcotic theft by health care personnel may cause patients to suffer pain needlessly and can also result in dire unanticipated consequences, such as nosocomial bacteremia. Whereas drug testing in the workplace is highly controversial, we believe that testing of health care personnel is indicated when drug abuse or theft is suspected.	UNIV WISCONSIN HOSP & CLIN,HOSP PHARM,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,DEPT MED,INFECT DIS SECT,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT PEDIAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	MAKI, DG (corresponding author), UNIV WISCONSIN HOSP & CLIN,DEPT INFECT CONTROL,H4-574,MADISON,WI 53792, USA.							ANDERSON HJ, 1986, MOD HEALTHCARE, V16, P46; AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BUEHLER JW, 1985, NEW ENGL J MED, V313, P211, DOI 10.1056/NEJM198507253130402; DURANT W, 1967, AM J HOSP PHARM, V24, P112; GARDNER S, 1984, PEDIATR INFECT DIS J, V3, P420, DOI 10.1097/00006454-198409000-00006; GILARDI GL, 1985, MANUAL CLIN MICROBIO, P350; Goerth C R, 1985, Occup Health Saf, V54, P55; HALL RJ, 1978, INTRO HIGH PERFORMAN, P1; ISTRE GR, 1985, NEW ENGL J MED, V313, P205, DOI 10.1056/NEJM198507253130401; Japp H., 1981, CLIN MICROBIOL NEWSL, V3, P124; KAHAN A, 1983, J INFECTION, V7, P256, DOI 10.1016/S0163-4453(83)97196-7; KING A, 1979, J GEN MICROBIOL, V114, P137, DOI 10.1099/00221287-114-1-137; LABARBERA M, 1984, J PSYCHOACTIVE DRUGS, V15, P293; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; LEWIS DC, 1986, NEW ENGL J MED, V315, P826, DOI 10.1056/NEJM198609253151309; LUNDBERG GD, 1986, JAMA-J AM MED ASSOC, V256, P3003, DOI 10.1001/jama.256.21.3003; MAKI DG, 1982, NEW ENGL J MED, V307, P1562, DOI 10.1056/NEJM198212163072507; MAKI DG, 1987, JAMA-J AM MED ASSOC, V258, P2396, DOI 10.1001/jama.258.17.2396; MAKI DG, 1980, 11TH P INT C CHEM 19, P1089; Maki DG, 1982, CURRENT TOPICS CLIN, P309; MAKI DG, 1981, CRC HDB HOSPITAL ACQ, P371; MAKI DG, 1977, MICROBIOLOGIC HAZARD, P13; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; MORGAN JP, 1984, J PSYCHOACTIVE DRUGS, V16, P305, DOI 10.1080/02791072.1984.10472301; PHILLIPS I, 1972, LANCET, V1, P1258; PICKETT MJ, 1980, J GEN MICROBIOL, V120, P439; RAKATANSKY H, 1987, NEW ENGL J MED, V316, P694; RILEY PS, 1975, J CLIN MICROBIOL, V1, P61, DOI 10.1128/JCM.1.1.61-64.1975; ROBERTS LA, 1990, MED J AUSTRALIA, V152, P652, DOI 10.5694/j.1326-5377.1990.tb125422.x; ROSENBERG M, 1986, J ORAL MAXIL SURG, V44, P458, DOI 10.1016/S0278-2391(86)80011-8; SPIEGELMAN WG, 1981, ANESTHESIOLOGY, V60, P335; VERSCHRAEGEN G, 1985, J CLIN MICROBIOL, V21, P278, DOI 10.1128/JCM.21.2.278-279.1985; WARD CF, 1983, JAMA-J AM MED ASSOC, V250, P922, DOI 10.1001/jama.250.7.922; ZIPORYN T, 1986, JAMA-J AM MED ASSOC, V256, P3061, DOI 10.1001/jama.256.22.3061; 1987, REGULATORY DIGEST	37	53	53	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					981	986		10.1001/jama.265.8.981	http://dx.doi.org/10.1001/jama.265.8.981			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY432	1992211				2022-12-01	WOS:A1991EY43200025
J	ANDERSEN, IB; SORENSEN, TIA; PRENER, A				ANDERSEN, IB; SORENSEN, TIA; PRENER, A			INCREASE IN INCIDENCE OF DISEASE DUE TO DIAGNOSTIC DRIFT - PRIMARY LIVER-CANCER IN DENMARK, 1943-85	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the extent to which changes in diagnostic methods and classification are responsible for the striking increase in incidence of primary liver cancer in Denmark since 1943. Design-Analysis of the time trends in sex specific, age standardised incidence of primary liver cancer and unspecified liver cancer (either secondary without known primary cancer or not specified as primary cancer) in the entire population from 1943 to 1985. By review of the 727 notifications from three periods of 5 years (1948-52, 1963-7, and 1978-82) the changes in histological diagnosis and classification were assessed. Setting-Denmark. Subjects-Notifications of liver cancer to the Danish cancer registry. Results-Concomitant with the increase in primary liver cancer, the incidence of the unspecified liver cancer declined. The proportion of histologically diagnosed primary liver cancer rose from 85% to 98%, whereas the proportion for unspecified liver cancer rose from 12% to 51%. When the proportion of primary versus unspecified liver cancer obtained by histological diagnosis was extrapolated to all cases, the annual incidence of primary liver cancer was 4.4 rather than 1.6 per 100 000 population in 1948-52 and 6.0 rather than 5.5 per 100 000 in 1978-82. Conclusion-The increase in the incidence of primary liver cancer may be much smaller than the numbers of registered cases indicate. This example emphasises the need to consider diagnostic drift in time trend studies of disease incidence.	HVIDOVRE UNIV HOSP,DEPT MED,DIV HEPATOL,DK-2650 COPENHAGEN,DENMARK; DANISH CANC SOC,DANISH CANC REGISTRY,COPENHAGEN,DENMARK	University of Copenhagen; Danish Cancer Society								[Anonymous], 1976, INT CLASSIFICATION D; BASSENDINE MF, 1987, BAILLIERE CLIN GASTR, V1, P1, DOI 10.1016/0950-3528(87)90031-5; FABER M, 1979, ENVIRON RES, V18, P37, DOI 10.1016/0013-9351(79)90135-X; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; HARDELL L, 1984, BRIT J CANCER, V50, P389, DOI 10.1038/bjc.1984.188; JENSEN OM, 1980, CANCER MORBIDITY CAU; KEW MC, 1987, LANCET, V2, P1183; OLSEN JH, 1988, BRIT J CANCER, V58, P392, DOI 10.1038/bjc.1988.226; PRYTZ H, 1981, SCAND J GASTROENTERO, V16, P833; SARACCI R, 1980, J NATL CANCER I, V65, P241; Storm H H, 1986, Ugeskr Laeger, V148, P1110; STORM HH, 1989, CANCER INCIDENCE DEN; TUYNS AJ, 1975, J NATL CANCER I, V54, P61, DOI 10.1093/jnci/54.1.61; WATERHOUSE J, 1982, INT AGENCY RES CANCE, V42; 1957, MANUAL INT STATISTIC; 1986, STATISTICAL YB 1986, P171; 1983, LANCET, V1, P463	17	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					437	440		10.1136/bmj.302.6774.437	http://dx.doi.org/10.1136/bmj.302.6774.437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004170	Green Published, Bronze			2022-12-01	WOS:A1991EZ03300019
J	BRAHAMS, D				BRAHAMS, D			LATE BENOXAPROFEN CLAIMS	LANCET			English	Editorial Material																		1991, TIMES           0213	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					483	484		10.1016/0140-6736(91)93412-3	http://dx.doi.org/10.1016/0140-6736(91)93412-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671484				2022-12-01	WOS:A1991EY88700019
J	DEAN, JD; JONES, CJH; HUTCHISON, SJ; PETERS, JR; HENDERSON, AH				DEAN, JD; JONES, CJH; HUTCHISON, SJ; PETERS, JR; HENDERSON, AH			HYPERINSULINEMIA AND MICROVASCULAR ANGINA (SYNDROME-X)	LANCET			English	Note								Glucose and insulin responses to a glucose load in 11 patients with angina attributed to microvascular coronary dysfunction were compared with those in 11 healthy subjects matched for age, sex, and body mass. Stimulated hyperinsulinaemia was demonstrated in the microvascular angina group. The findings suggest a role for increased concentrations of insulin in coronary microvascular dysfunction.	UNIV COLL CARDIFF,DEPT CARDIOL,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES; UNIV COLL CARDIFF,DEPT MED,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University								CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; FACTOR SM, 1985, PROG CARDIOVASC DIS, V27, P395, DOI 10.1016/0033-0620(85)90002-7; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GELTMAN EM, 1990, J AM COLL CARDIOL, V16, P586, DOI 10.1016/0735-1097(90)90347-R; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; SAX FL, 1987, NEW ENGL J MED, V317, P1366, DOI 10.1056/NEJM198711263172202; STALDER M, 1981, DIABETOLOGIA, V21, P544; 1987, LANCET, V2, P1247	10	120	123	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					456	457						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671472				2022-12-01	WOS:A1991EY88700005
J	ENNALS, S				ENNALS, S			UNDERSTANDING BENEFITS - BENEFITS FOR PEOPLE IN HOSPITAL, NURSING-HOMES, AND RESIDENTIAL CARE HOMES	BRITISH MEDICAL JOURNAL			English	Editorial Material											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					463	465		10.1136/bmj.302.6774.463	http://dx.doi.org/10.1136/bmj.302.6774.463			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004176	Green Published, Bronze			2022-12-01	WOS:A1991EZ03300029
J	GOODBURN, E; MATTOSINHO, S; MONGI, P; WATERSTON, T				GOODBURN, E; MATTOSINHO, S; MONGI, P; WATERSTON, T			MANAGEMENT OF CHILDHOOD DIARRHEA BY PHARMACISTS AND PARENTS - IS BRITAIN LAGGING BEHIND THE THIRD-WORLD	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GASTROENTERITIS; CHILDREN; DRUGS	Objective-To investigate the role of community pharmacists in providing advice and treatment for children with diarrhoea; to investigate mothers' responses to diarrhoea in their children. Design-Cross sectional questionnaire study of a random selection of community pharmacists and of mothers attending child health clinics. Pharmacists were interviewed and given a questionnaire and a separate group was visited by a researcher posing as a parent; mothers were interviewed at the clinic. Setting-Newcastle upon Tyne. Subjects-20 pharmacists were interviewed and visits by a researcher posing as a parent were carried out to 10 different pharmacists; 58 mothers were interviewed. Main outcome measures-Advice given by pharmacists was contrasted with standard advice on management of diarrhoea in children. Results-Half the pharmacists interviewed and 70% of pharmacists visited by a researcher posing as a parent recommended inappropriate treatment of childhood diarrhoea (such as antidiarrhoeal drugs and withholding breast milk), and only 30% at interview stated that they would ask for the age of the child. Mothers' knowledge of home treatment was inadequate. All pharmacists in the posed visits recommended a purchased treatment. Conclusion-Pharmacists are widely used by parents for consultation for children's ailments but their advice is not always appropriate; hence they should be given more consistent training in recognising and managing clinical problems. Medical advice on management of diarrhoea is also inconsistent and should be modified to conform to the guidelines of the World Health Organisation.	NEWCASTLE GEN HOSP, NEWCASTLE UPON TYNE NE4 6BE, TYNE & WEAR, ENGLAND; INST CHILD HLTH, TROP CHILD HLTH UNIT, LONDON WC1N 1EH, ENGLAND	Newcastle General Hospital; University of London; University College London								CONWAY SP, 1989, ARCH DIS CHILD, V64, P87, DOI 10.1136/adc.64.1.87; CUNNINGHAMBURLEY S, 1987, SOC SCI MED, V24, P371, DOI 10.1016/0277-9536(87)90155-9; CUTTING WAM, 1989, LANCET, V1, P1080; EDWARDS C, 1982, MINOR ILLNESS MAJOR; GALLAGER F, 1983, BMJ-BRIT MED J, V287, P397; KHINMAUNGU, 1985, BMJ-BRIT MED J, V290, P587; MOBEY N, 1986, PHARM J, V3, P807; MORRELL DC, 1981, UPDATE, V1, P1187; PAUNCEFOR Z, 1989, PHARM HLTH CARE REPO; RYLANCE GW, 1988, BMJ-BRIT MED J, V297, P445, DOI 10.1136/bmj.297.6646.445; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P917, DOI 10.1136/adc.65.9.917; WATERSTON T, 1981, J MATERNAL CHILD HLT, V1, P34; WHARTON BA, 1988, BMJ-BRIT MED J, V296, P450, DOI 10.1136/bmj.296.6620.450; 1980, WHO CDDSER802; 1989, MED ETHICS GUIDE PHA	15	52	54	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 23	1991	302	6774					440	443		10.1136/bmj.302.6774.440	http://dx.doi.org/10.1136/bmj.302.6774.440			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004171	Bronze, Green Published			2022-12-01	WOS:A1991EZ03300020
J	HARRISON, PJ; MCLAUGHLIN, D; KERWIN, RW				HARRISON, PJ; MCLAUGHLIN, D; KERWIN, RW			DECREASED HIPPOCAMPAL EXPRESSION OF A GLUTAMATE RECEPTOR GENE IN SCHIZOPHRENIA	LANCET			English	Article							HYPOTHESIS	A striking and specific loss of the messenger RNA that encodes a non-N-methyl D-aspartate (non-NMDA) glutamate receptor was found in hippocampal tissue obtained at necropsy from 6 patients with schizophrenia, when compared to specimens from 8 controls without neurological or psychiatric signs or symptoms. These findings support suggestions of aberrant glutamatergic function in schizophrenia. Evidence that gene expression may be abnormal in schizophrenia, with decreased production of an excitatory neurotransmitter receptor, may have therapeutic as well as pathogenetic implications.	INST PSYCHIAT,DEPT NEUROSCI,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT PSYCHIAT,LONDON SE5 8AF,ENGLAND; ST MARYS HOSP,SCH MED,DEPT ANAT,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,SCH MED,DEPT PSYCHIAT,LONDON W2 1PG,ENGLAND	University of London; King's College London; University of London; King's College London; Imperial College London; Imperial College London			McLaughlin, Danny/J-6818-2013	Harrison, Paul/0000-0002-6719-1126; McLaughlin, Daniel/0000-0002-7060-7321	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSHULER LL, 1987, ARCH GEN PSYCHIAT, V44, P1094; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; DEAKIN JFW, 1989, J NEUROCHEM, V52, P1781, DOI 10.1111/j.1471-4159.1989.tb07257.x; DEUTSCH SI, 1989, CLIN NEUROPHARMACOL, V12, P1, DOI 10.1097/00002826-198902000-00001; FALKAI P, 1986, EUR ARCH PSY CLIN N, V236, P154, DOI 10.1007/BF00380943; Harrison P J, 1990, Neuroreport, V1, P149, DOI 10.1097/00001756-199010000-00017; HARRISON PJ, 1990, PROG NEUROBIOL, V34, P271, DOI 10.1016/0301-0082(90)90007-4; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; JESTE DV, 1989, ARCH GEN PSYCHIAT, V46, P1019; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KERWIN R, 1990, NEUROSCIENCE, V39, P25, DOI 10.1016/0306-4522(90)90219-T; KERWIN RW, 1988, LANCET, V1, P583; KERWIN RW, 1990, NEUROSCI LETT, V118, P164, DOI 10.1016/0304-3940(90)90617-I; KIM JS, 1980, NEUROSCI LETT, V20, P379, DOI 10.1016/0304-3940(80)90178-0; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MELDRUM B S, 1987, Journal of Psychopharmacology, V1, P217, DOI 10.1177/026988118700100401; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; OKADA F, IN PRESS J NEURAL TR; ROBERTS GW, 1990, TRENDS NEUROSCI, V13, P207, DOI 10.1016/0166-2236(90)90161-3; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; Spitzer R.L., 1975, RES DIAGNOSTIC CRITE, V2; STORMANN T, 1990, Society for Neuroscience Abstracts, V16, P959; VANTOL HHM, 1990, NEUROSCI LETT, V111, P303, DOI 10.1016/0304-3940(90)90279-I; WACHTEL H, 1990, TRENDS PHARMACOL SCI, V11, P219, DOI 10.1016/0165-6147(90)90243-2	25	217	219	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					450	452		10.1016/0140-6736(91)93392-M	http://dx.doi.org/10.1016/0140-6736(91)93392-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY887	1671470				2022-12-01	WOS:A1991EY88700003
J	JAMJOOM, AB; KANE, N; SANDEMAN, D; CUMMINS, B				JAMJOOM, AB; KANE, N; SANDEMAN, D; CUMMINS, B			EPILEPSY RELATED TO TRAUMATIC EXTRADURAL HEMATOMAS	BRITISH MEDICAL JOURNAL			English	Article									FRENCHAY HOSP,DEPT NEUROSURG,BRISTOL BS16 1LE,AVON,ENGLAND									ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; JENNETT B, 1975, J NEUROL NEUROSUR PS, V38, P378, DOI 10.1136/jnnp.38.4.378; JENNETT B, 1975, EPILEPSY NONMISSILE, P136	3	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					448	448		10.1136/bmj.302.6774.448	http://dx.doi.org/10.1136/bmj.302.6774.448			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	1900725	Bronze, Green Published			2022-12-01	WOS:A1991EZ03300022
J	KEMPLE, TJ; HAYTER, SR				KEMPLE, TJ; HAYTER, SR			AUDIT OF DIABETES IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To complete a first audit cycle of diabetes care in a general practice and to develop a simple method for continuing the audit cycle. Design-Retrospective examination of the medical records of all diabetic patients in a general practice in 1990. Setting-A group general practice in a Bristol health centre with roughly 13 200 patients, which since 1983 has had a protocol for care of its diabetic patients. Patients-223 known diabetic patients in the practice. Main audited measures-Comparison against previously agreed standards of process and outcome of diabetes care in the practice, including number of patients whose care had been reviewed in accordance with the practice protocol, serum fructosamine and blood glucose concentrations in patients aged under 70, and number of newly diagnosed patients given explicit education and referred for diatetic advice. Results-Defined standards were not met for several criteria-for example, percentages of patients aged below 70 (n = 149) with serum fructosamine concentrations < 3.5 mmol/l (62% v 90% defined value) and < 2.8 mmol/l (35% v 70%) and last recorded blood glucose concentrations < 10 mmol/l in insulin dependent patients (n = 48) (23% v 90%) and < 8 mmol/l in non-insulin dependent patients (n = 101) (17% v 90%). Of newly identified diabetic patients (n = 32), 59% and 28% respectively were referred to dieticians and given educational material compared with the 100% standard. Conclusions-The practice has a high prevalence of diabetes (1.7%) but has the resources for their care. The format and implementation of the agreed systematic process of care for diabetic patients needs improvement. Implications-A simple audit suitable for most general practices might record two measures of the process of care-a disease register of all diabetic patients in a practice and an attendance register to determine whether they have regular check ups-and one measure of the outcome of care, such as serum fructosamine concentration (or local equivalent). A practice could establish its own standards for these measures and monitor its performance against them.			KEMPLE, TJ (corresponding author), HORFIELD HLTH CTR,LOCKLEAZE RD,BRISTOL BS7 9RR,ENGLAND.			Kemple, Terence/0000-0002-9217-4598				FLEMING PC, 1985, PRACTICAL DIABETES, V2, P26; FOSTER W, 1989, PRACTITIONER, V233, P1023; GROL R, 1990, BRIT J GEN PRACT, V40, P361; HILL RD, 1986, PRACTICAL DIABETES, V3, P67; HILL RD, 1990, PRACTICAL DIABETES, V7, P149; IRVING JMR, 1988, PRACTICAL DIABETES, V3, P125; MALINS JM, 1971, BRIT MED J, V4, P161, DOI 10.1136/bmj.4.5780.161; SMITH T, 1990, BRIT MED J, V300, P65, DOI 10.1136/bmj.300.6717.65; THORN PA, 1973, BRIT MED J, V2, P534, DOI 10.1136/bmj.2.5865.534; WAINE C, 1990, PRACTICAL DIABETES, V7, P152; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; Wood J, 1990, Health Trends, V22, P39; 1988, DIABETES; 1989, MED AUDIT 1ST REPORT; 1989, 6 SECRE STAT HLTH WO	15	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					451	453		10.1136/bmj.302.6774.451	http://dx.doi.org/10.1136/bmj.302.6774.451			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004174	Green Published, Bronze			2022-12-01	WOS:A1991EZ03300024
J	METCALFE, MA; BAUM, JD				METCALFE, MA; BAUM, JD			INCIDENCE OF INSULIN-DEPENDENT DIABETES IN CHILDREN AGED UNDER 15 YEARS IN THE BRITISH-ISLES DURING 1988	BRITISH MEDICAL JOURNAL			English	Article							INCREASING INCIDENCE; MELLITUS; EPIDEMIOLOGY; SCOTLAND	Objective-To ascertain the annual incidence rate of insulin dependent diabetes diagnosed in children under the age of 15 years in the British Isles during 1988, and to compare the results with an earlier study carried out in 1973-4. Design-Active monthly reporting of cases by consultant paediatricians, with additional input from diabetologists and all specialist diabetes nurses and health visitors. Setting-British Isles (England, Wales, Scotland, Northern Ireland, Republic of Ireland) with a total population at risk of 11 819 000 children. Patients-All children diagnosed under the age of 15 years with primary insulin dependent diabetes from 1 January to 31 December 1988 and resident in the British Isles at diagnosis. Main outcome measures-National incidence rate of insulin dependent diabetes; differences in incidence rates between regions and between three age groups: 4 and under, 5-9, and 10-14 year olds. Results-1600 children (837 boys and 763 girls) had a confirmed diagnosis of insulin dependent diabetes, giving a national incidence rate of 13.5/100 000/year (95% confidence interval 12.9 to 14.2/100 000/year). This was considerably higher than the incidence rate of 7.7/100 000/year in children under the age of 16 years reported in the British Diabetic Association's study of 1973-4. The age-sex adjusted rates varied between regions, ranging from 6.8/100 000/year (Republic of Ireland) to 19.8/100 000/year (Scotland). There were considerable differences in the numbers of cases diagnosed each month, with the 10-14 year age group showing the most seasonal variation. A quarter of the children (404/1600) were under 5 years old. Case ascertainment was estimated as 90%. Conclusions-Insulin dependent diabetes in the British Isles does not seem to occur uniformly over time or geographical area. Even allowing for differences in ascertainment between the 1973-4 and 1988 studies, there seems to have been an increase in the incidence rate of insulin dependent diabetes in children under the age of 15 years during the 15 year time period. If diabetes is becoming more common in this age group, possibly by developing earlier in susceptible children, this would be a matter of considerable public health concern.	ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND	Bristol Royal Hospital For Children; University of Bristol								ARMITAGE P, 1987, JSTATISTICAL METHODS; BARCLAY RPC, 1988, SCOT MED J, V33, P237, DOI 10.1177/003693308803300205; BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BLOOM A, 1975, BRIT MED J, V3, P580, DOI 10.1136/bmj.3.5983.580; BURDEN AC, 1989, DIABETIC MED, V6, P334; DAHLQUIST G, 1985, DIABETOLOGIA, V28, P802, DOI 10.1007/BF00291068; FREEDMAN LS, 1979, J EPIDEMIOL COMMUNIT, V33, P233; Hall S M, 1988, Arch Dis Child, V63, P344; JONER G, 1989, DIABETOLOGIA, V32, P79, DOI 10.1007/BF00505178; JONES C, 1990, POPULATION TRENDS, V60, P31; Lentner C., 1982, GEIGY SCI TABLES, V2; LESLIE PJ, 1990, DIABETIC MED S2, V7, pA24; MATSUURA N, 1981, TOHOKU J EXP MED S, V141, P181; NYSTROM L, 1990, INT J EPIDEMIOL, V19, P141, DOI 10.1093/ije/19.1.141; PATTERSON CC, 1988, DIABETIC MED, V5, P160, DOI 10.1111/j.1464-5491.1988.tb00964.x; PATTERSON CC, 1983, DIABETOLOGIA, V24, P238, DOI 10.1007/BF00282706; REUNANEN A, 1982, ACTA PAEDIATR SCAND, V71, P893, DOI 10.1111/j.1651-2227.1982.tb09545.x; REWERS M, 1987, DIABETES, V36, P106, DOI 10.2337/diabetes.36.1.106; SOLTESZ G, 1990, DIABETIC MED, V7, P111, DOI 10.1111/j.1464-5491.1990.tb01343.x; WILLIAMS DRR, 1989, DIABETIC MED, V6, P320, DOI 10.1111/j.1464-5491.1989.tb01172.x; 1989, 1988 POPULATION ESTI; 1986, ISLE MAN INTERIM CEN; 1987, CENSUS 86 SUMMARY PO; 1987, 1986 EC ADV OFF REP; 1990, KEY POPULATION VIT 5; 1989, 3RD BRIT PAED SURV U; 1990, 67TH REG GEN OFF; 1973, CENSUS POPULATION IR, V2; 1987, GUERNSEY CENSUS 1986; 1975, CENSUS POPULATION 19; 1987, BMJ, V295, P479; 1987, DIRECTORY NURSES SPE; 1973, CENSUS 1971 SUMMARY	34	78	79	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					443	447		10.1136/bmj.302.6774.443	http://dx.doi.org/10.1136/bmj.302.6774.443			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004172	Green Published, Bronze			2022-12-01	WOS:A1991EZ03300021
J	NAVARATNAM, DS; PRIDDLE, JD; MCDONALD, B; ESIRI, MM; ROBINSON, JR; SMITH, AD				NAVARATNAM, DS; PRIDDLE, JD; MCDONALD, B; ESIRI, MM; ROBINSON, JR; SMITH, AD			ANOMALOUS MOLECULAR-FORM OF ACETYLCHOLINESTERASE IN CEREBROSPINAL-FLUID IN HISTOLOGICALLY DIAGNOSED ALZHEIMERS-DISEASE	LANCET			English	Article							CSF ACETYLCHOLINESTERASE; HUMAN NEOCORTEX; NEURONS; HIPPOCAMPUS	The possibility that the different molecular forms of acetylcholinesterase (AChE) in cerebrospinal fluid (CSF) which can be revealed by isoelectric focusing may reflect changes in AChE in pathologically affected neurons in Alzheimer's disease was tested in a retrospective study. CSF samples obtained at necropsy from 33 patients with clinically diagnosed dementia, 9 with possible dementia, and 19 without a diagnosis of dementia were examined by isoelectric focusing. An additional band indicating an anomalous molecular form of AChE was present in CSF from 19 of 23 patients with a histological diagnosis of Alzheimer's disease and no other central nervous system disorder but in none of the 19 non-demented patients (without a histological diagnosis of Alzheimer's disease). The band was also present in 2 of 8 patients with histologically defined Alzheimer's disease plus other neurological disorders and in 4 of 8 patients with possible dementia who did not meet histopathological criteria for Alzheimer's disease. The absence of the anomalous form of AChE from the CSF of non-demented patients and its presence in the CSF of the majority of patients with Alzheimer's disease has implications for our understanding of the biological basis of the disease and might form the basis of an antemortem diagnostic test.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND; LITTLEMORE HOSP,OXFORD,ENGLAND	University of Oxford; Radcliffe Infirmary			Smith, Anthony D./A-4233-2010	Smith, Anthony D./0000-0002-1095-6722	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPLEYARD ME, 1987, NEUROCHEM INT, V11, P397, DOI 10.1016/0197-0186(87)90029-5; APPLEYARD ME, 1983, LANCET, V2, P452; APPLEYARD ME, 1987, BRAIN, V110, P1309, DOI 10.1093/brain/110.5.1309; ARENDT T, 1984, LANCET, V1, P173; CHUBB IW, 1976, NEUROSCIENCE, V1, P57, DOI 10.1016/0306-4522(76)90048-8; CHUBB IW, 1975, PROC R SOC SER B-BIO, V191, P245, DOI 10.1098/rspb.1975.0126; CROSS RB, 1982, MED LAB SCI, V39, P67; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GEULA C, 1989, BRAIN RES, V498, P185, DOI 10.1016/0006-8993(89)90419-8; GIULIAN GG, 1984, ANAL BIOCHEM, V142, P421, DOI 10.1016/0003-2697(84)90486-X; GREENFIELD SA, 1979, BRAIN RES, V177, P445, DOI 10.1016/0006-8993(79)90463-3; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LAMY C, 1989, NEUROPATH APPL NEURO, V15, P563, DOI 10.1111/j.1365-2990.1989.tb01255.x; MESULAM MM, 1988, ANN NEUROL, V24, P765, DOI 10.1002/ana.410240611; NAKAMURA S, 1985, NEUROSCI LETT, V61, P183, DOI 10.1016/0304-3940(85)90422-7; PERRY EK, 1986, BRIT MED BULL, V42, P63, DOI 10.1093/oxfordjournals.bmb.a072100; PERRY EK, 1981, METABOLIC DISORDERS, P382; SMITH AD, 1984, LANCET, V1, P513	18	60	64	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					447	450		10.1016/0140-6736(91)93391-L	http://dx.doi.org/10.1016/0140-6736(91)93391-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671469				2022-12-01	WOS:A1991EY88700002
J	ROBERTS, RG				ROBERTS, RG			CORRECTION	LANCET			English	Correction, Addition													Roberts, Roland G/C-3596-2009					ROBERTS RG, 1990, LANCET, V336, P1523, DOI 10.1016/0140-6736(90)93305-9	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					504	504						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1704092				2022-12-01	WOS:A1991EY88700071
J	RUSKIN, J; LARIVIERE, M				RUSKIN, J; LARIVIERE, M			LOW-DOSE COTRIMOXAZOLE FOR PREVENTION OF PNEUMOCYSTIS-CARINII PNEUMONIA IN HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE	LANCET			English	Article							SULFAMETHOXAZOLE; CHEMOPROPHYLAXIS; PENTAMIDINE; AIDS	The efficacy and tolerability of low, intermittent doses of co-trimoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole given Monday, Wednesday, Friday) for prophylaxis against Pneumocystis carinii pneumonia (PCP) was assessed retrospectively in 116 patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex at high risk of PCP. 92% were receiving concomitant zidovudine. 71 with previous episode(s) of PCP were followed a mean of 18.5 months (range 3-42). 45 without past PCP but with depletion of CD4 cells to < 200/mu-l were observed for a mean of 24.2 months (range 9-40). PCP did not develop in any patient on co-trimoxazole. 33 (28%) had side-effects, mainly rash, pruritus, and nausea. 15 discontinued co-trimoxazole, but only 11 (9%), who withdrew in the first month, were clearly drug-intolerant. Thus, low-dose, thrice weekly cotrimoxazole completely prevents AIDS-associated PCP, is cost-effective, and well tolerated by more than 85% of patients. Controlled comparisons of this regimen with other prophylactic agents are warranted.			RUSKIN, J (corresponding author), KAISER PERMANENTE MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,1505 N EDGEMONT ST,LOS ANGELES,CA 90027, USA.							BERNARD EM, 1989, 5 INT C AIDS MONTR; BIGBY TD, 1986, AM REV RESPIR DIS, V133, P515; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; GIRARD PM, 1989, LANCET, V1, P1348; GLUCKSTEIN D, 1988, 4 INT C AIDS STOCKH; GOLDEN JA, 1989, LANCET, V1, P654; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1979, ANTIMICROB AGENTS CH, V16, P333, DOI 10.1128/AAC.16.3.333; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; NICHOLAS P, 1990, 6 INT C AIDS SAN FRA; PESANTI EL, 1980, J INFECT DIS, V141, P775, DOI 10.1093/infdis/141.6.775; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; TELZAK EE, 1990, REV INFECT DIS, V12, P380; [No title captured]; 1989, AIDS WKLY SURV  0130, P1; 1989, MMWR, V38, P1	20	126	126	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					468	471		10.1016/0140-6736(91)93402-U	http://dx.doi.org/10.1016/0140-6736(91)93402-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671479				2022-12-01	WOS:A1991EY88700013
J	SCOTT, NA; LEINHARDT, DJ; OHANRAHAN, T; FINNEGAN, S; SHAFFER, JL; IRVING, MH				SCOTT, NA; LEINHARDT, DJ; OHANRAHAN, T; FINNEGAN, S; SHAFFER, JL; IRVING, MH			SPECTRUM OF INTESTINAL FAILURE IN A SPECIALIZED UNIT	LANCET			English	Article							HOME PARENTERAL-NUTRITION; FISTULAS; MANAGEMENT; TRACT	300 consecutive admissions over 7 years to a purpose-built intestinal failure unit are reviewed. The commonest underlying condition was Crohn's disease (42%), and the commonest complication precipitating admission was intestinal fistula (42%). Total parenteral nutrition was used in 85% and surgery in 50%. A multidisciplinary approach to management gave a high success rate-90% of patients were discharged from hospital, although nearly 25% needed home parental nutrition. These results suggest that chronic intestinal failure should be managed in specialised units in the same manner as other types of organ failure.	UNIV MANCHESTER, HOPE HOSP, DEPT SURG, NUTR UNIT, ECCLES OLD RD, SALFORD M6 8HD, LANCS, ENGLAND; UNIV MANCHESTER, HOPE HOSP, DEPT MED, SALFORD M6 8HD, LANCS, ENGLAND	University of Manchester; University of Manchester								BURY KD, 1971, AM J SURG, V121, P174, DOI 10.1016/0002-9610(71)90096-1; FISCHER JE, 1976, TOTAL PARENTERAL NUT, P127; FLEMING CR, 1981, CLIN SURGERY INT, P219; IRVING M, 1985, ANN ROY COLL SURG, V67, P2; KETTLEWELL MGW, 1983, BRIT MED J, V286, P1323; LEREBOURS E, 1988, JPEN-PARENTER ENTER, V12, P360, DOI 10.1177/0148607188012004360; LEVY E, 1988, BRIT J SURG, V75, P549, DOI 10.1002/bjs.1800750615; MCINTYRE PB, 1984, BRIT J SURG, V71, P293, DOI 10.1002/bjs.1800710416; MUGHAL M, 1986, LANCET, V2, P383; MUGHAL MM, 1989, BRIT J SURG, V76, P15, DOI 10.1002/bjs.1800760107; PADBERG FT, 1981, ANN SURG, V193, P264, DOI 10.1097/00000658-198103000-00002; PETTIGREW RA, 1985, BRIT J SURG, V72, P52, DOI 10.1002/bjs.1800720121; ROSE D, 1986, SURG GYNECOL OBSTET, V163, P345; STOKES MA, 1988, BRIT J SURG, V75, P481, DOI 10.1002/bjs.1800750524	14	33	33	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 23	1991	337	8739					471	473		10.1016/0140-6736(91)93403-V	http://dx.doi.org/10.1016/0140-6736(91)93403-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671480				2022-12-01	WOS:A1991EY88700014
J	TRAPE, JF; DUPLANTIER, JM; BOUGANALI, H; GODELUCK, B; LEGROS, F; CORNET, JP; CAMICAS, JL				TRAPE, JF; DUPLANTIER, JM; BOUGANALI, H; GODELUCK, B; LEGROS, F; CORNET, JP; CAMICAS, JL			TICK-BORNE BORRELIOSIS IN WEST AFRICA	LANCET			English	Article								Reported cases of tick-borne relapsing fever due to the spirochaete Borrelia crocidurae are rare in West Africa, and few epidemiological data are available. To see how common relapsing fever is in Senegal thick blood smears from cases of fever of unknown origin and from randomly selected clinic outpatients from a rural dispensary were examined for Borrelia. The prevalence of Borrelia infections in small mammals was also assessed. Borrelia was seen in smears of 12 (0.9%) of 1340 children. All children who tested positive had complained of acute fever. Prevalence was 0% (0/496), 0.5% (2/417), 1.6% (5/308), and 4.2% (5/119) at ages 0-1, 2-4, 5-9, and 10-14, respectively. 26 other instances of borreliosis were seen in patients from different regions of Senegal. Blood samples from 7 of these patients were inoculated intraperitoneally into white mice; serious infection developed in all mice. Borrelia was seen in thick smears from 65 of 461 wild rodents or insectivores. Six rodents species were infected. From a sample of 93 rodents, 33.3% were infected, as judged by intraperitoneal inoculation of white mice, compared with 14.1% by direct smear examination. The findings suggest that borreliosis has a wide distribution and a high incidence in Senegal. This disease may be a major cause of morbidity in rural areas throughout much of West Africa.			TRAPE, JF (corresponding author), ORSTOM,BP 1386,DAKAR,SENEGAMBIA.							BALTAZARD M., 1954, BULL SOC PATHOL EXOT, V47, P878; BALTAZARD M., 1948, Bulletin de la Societe de Pathologie Exotique, V41, P399; BOIRON H., 1949, BULL SOC PATH EXOT, V42, P62; COLLIGNON R., 1989, SANTE POPULATION SEN; LEGER Andre, 1917, Bulletin de la Societe de Pathologie Exotique, V10, P280; Mathis C., 1934, Ann Inst Pasteur Paris T, V52, P166; MATHIS C., 1928, BULL SOC PATH EXOT, V21, P472; 1989, WHOVBC89967	8	52	52	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 23	1991	337	8739					473	475		10.1016/0140-6736(91)93404-W	http://dx.doi.org/10.1016/0140-6736(91)93404-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY887	1671481				2022-12-01	WOS:A1991EY88700015
J	AHMED, YF; GILMARTIN, GM; HANLY, SM; NEVINS, JR; GREENE, WC				AHMED, YF; GILMARTIN, GM; HANLY, SM; NEVINS, JR; GREENE, WC			THE HTLV-I REX RESPONSE ELEMENT MEDIATES A NOVEL FORM OF MESSENGER-RNA POLYADENYLATION	CELL			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; POLY(A) POLYMERASE; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; MULTIPLE FACTORS; 3' END; CLEAVAGE	HTLV-I structural gene expression is posttranscriptionally regulated by the Rex protein and the Rex response element (RexRE), a 255 nucleotide RNA stem-loop structure located in the retroviral 3' LTR. Independent of Rex, the RexRE also plays a critical role in the polyadenylation of all HTLV-I transcripts. Folding of the RexRE serves to spatially juxtapose the widely separated AAUAAA hexamer and GU-rich elements that are essential for polyadenylation. In turn, this folding promotes the cooperative and stable binding of two nuclear factors at these elements that commits this poly(A) site to 3' processing. These findings highlight a novel mechanism of 3' end formation in the HTLV family of retroviruses and underscore the general requirement for protein-protein interactions in the polyadenylation reaction.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University	AHMED, YF (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710, USA.							AHMED YF, 1990, GENE DEV, V4, P1014, DOI 10.1101/gad.4.6.1014; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BURNY A, 1980, BOVINE LEUKEMIA VIRU, P231; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHEN ISY, 1983, NATURE, V305, P502, DOI 10.1038/305502a0; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; DERSE D, 1988, J VIROL, V62, P1115, DOI 10.1128/JVI.62.4.1115-1119.1988; GALLO RC, 1985, CANCER RES, V45, P4524; GIL A, 1987, CELL, V49, P399, DOI 10.1016/0092-8674(87)90292-3; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KIM JH, 1991, J VIROL, V65, P405, DOI 10.1128/JVI.65.1.405-414.1991; LE SY, 1988, NUCLEIC ACIDS RES, V16, P5153, DOI 10.1093/nar/16.11.5153; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MCDEVITT MA, 1988, GENE DEV, V2, P588, DOI 10.1101/gad.2.5.588; MCDEVITT MA, 1986, EMBO J, V5, P2907, DOI 10.1002/j.1460-2075.1986.tb04586.x; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MOORE CL, 1986, EMBO J, V5, P1929, DOI 10.1002/j.1460-2075.1986.tb04446.x; OHTA M, 1988, J VIROL, V62, P4445, DOI 10.1128/JVI.62.12.4445-4451.1988; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROSENBLATT JD, 1988, SCIENCE, V240, P916, DOI 10.1126/science.2834826; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; SAGATA N, 1983, GENE, V26, P1, DOI 10.1016/0378-1119(83)90030-6; SAGATA N, 1984, P NATL ACAD SCI-BIOL, V81, P4741, DOI 10.1073/pnas.81.15.4741; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SHIMOTOHNO K, 1984, P NATL ACAD SCI-BIOL, V81, P1079, DOI 10.1073/pnas.81.4.1079; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WONGSTAAL F, 1985, CANCER RES, V45, P4539; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	51	96	96	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					727	737		10.1016/0092-8674(91)90502-P	http://dx.doi.org/10.1016/0092-8674(91)90502-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1671761				2022-12-01	WOS:A1991EZ47800008
J	BARNARD, SM; WALT, DR				BARNARD, SM; WALT, DR			CHEMICAL SENSORS BASED ON CONTROLLED-RELEASE POLYMER SYSTEMS	SCIENCE			English	Article							FIBER	A novel chemical sensor has been developed in which the polymer ethylene-vinyl acetate is used as a controlled-release system to deliver reagents to the sensing region of an optical fiber for a homogeneous competitive immunoassay based on fluorescence energy transfer. A competition reaction is used to enable continuous measurements of the solution antigen concentration. More generally, the technique allows irreversible indicating chemistries to be used in the construction of chemical sensors that can measure continuously for long periods. Although the sensor configuration has not been optimized in all respects, data are presented for a model system in which a fluorescein-labeled antibody and Texas Red-labeled immunoglobulin G (IgG) are used.	TUFTS UNIV,DEPT CHEM,MAX TISHLER LAB ORGAN CHEM,MEDFORD,MA 02155	Tufts University								ANDERSON FP, 1988, CLIN CHEM, V34, P1417; Bawa R., 1985, J CONTR RELEASE, V1, P259, DOI [10.1016/0168-3659(85)90002-1, DOI 10.1016/0168-3659(85)90002-1]; BRIGHT FV, 1990, ANAL CHEM, V62, P1065, DOI 10.1021/ac00209a019; CHRISTIAN LM, 1988, TALANTA, V35, P119, DOI 10.1016/0039-9140(88)80049-3; Forster T., 1959, DISCUSS FARADAY SOC, V27, P7, DOI [10.1039/DF9592700007, DOI 10.1039/DF9592700007]; HELLER J, 1980, BIOMATERIALS, V1, P51, DOI 10.1016/0142-9612(80)90060-5; INMAN SM, 1989, ANAL CHIM ACTA, V217, P249, DOI 10.1016/S0003-2670(00)80407-9; JANATA J, 1990, ANAL CHEM, V62, pR33, DOI 10.1021/ac00211a017; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LUO SF, 1989, ANAL CHEM, V61, P174, DOI 10.1021/ac00177a019; NISONOFF A, 1985, INTRO MOL IMMUNOLOGY, P29; ODONNELL CM, 1979, ANAL CHEM, V51, pA33, DOI 10.1021/ac50037a003; SCHULMAN SG, 1985, MOL LUMINESCENCE S 1, V77, P1; SEITZ WR, 1988, CRC CR REV ANAL CHEM, V19, P135, DOI 10.1080/10408348808542810; SOINI E, 1979, CLIN CHEM, V25, P353; TROMBERG BJ, 1987, ANAL CHEM, V59, P1226, DOI 10.1021/ac00135a033	16	52	55	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					927	929		10.1126/science.2000492	http://dx.doi.org/10.1126/science.2000492			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000492				2022-12-01	WOS:A1991EY62900040
J	BAUMGARTNER, M; DUTRILLAUX, B; LEMIEUX, N; LILIENBAUM, A; PAULIN, D; VIEGASPEQUIGNOT, E				BAUMGARTNER, M; DUTRILLAUX, B; LEMIEUX, N; LILIENBAUM, A; PAULIN, D; VIEGASPEQUIGNOT, E			GENES OCCUPY A FIXED AND SYMMETRICAL POSITION ON SISTER CHROMATIDS	CELL			English	Article							INSITU HYBRIDIZATION; NUCLEOTIDE-SEQUENCE; HUMAN-CHROMOSOMES; HUMAN VIMENTIN; DNA LIBRARIES; SV40 DNA; METAPHASE; CELLS; MICROSCOPY; ASSIGNMENT	A high-resolution fluorescence methodology for non-isotopic in situ hybridization was applied to determine the positions occupied by several single-copy genes, DNA sequences, and integrated viral genomes on sister chromatids. The lateral and longitudinal mapping of the probes was performed on prometaphase and metaphase chromosomes. A fixed lateral position, exterior or median in relation to the longitudinal axis of the chromatids, was observed for a given probe, with a symmetrical position of the double fluorescent spots. This position appears to be independent of chromosome condensation stage from prometaphase to metaphase. These observations suggest an opposite helical-handedness conformation of DNA on both chromatids with a mirror symmetry. They support the model of chromosome packaging recently proposed by Boy de la Tour and Laemmli. Moreover, our results indicate that the last stages of chromosome condensation occur by packing down the coils without further coiling.	UNIV PARIS 07, BIOL MOLEC DIFFERENTIAT LAB, F-75724 PARIS 15, FRANCE	UDICE-French Research Universities; Universite Paris Cite	BAUMGARTNER, M (corresponding author), INST CURIE, CNRS, URA CNRS, BIOL STRUCT & MUTAGENESE CHROMOSOM SECT, 26 RUE ULM, F-75231 PARIS 05, FRANCE.							BAK AL, 1977, P NATL ACAD SCI USA, V74, P1595, DOI 10.1073/pnas.74.4.1595; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DUPRAW EJ, 1965, NATURE, V206, P338, DOI 10.1038/206338a0; DUPRAW EJ, 1966, NATURE, V209, P577, DOI 10.1038/209577a0; FERRARI S, 1987, AM J HUM GENET, V41, P616; FUSCOE JC, 1989, GENOMICS, V5, P100, DOI 10.1016/0888-7543(89)90092-X; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LI ZL, 1989, GENE, V78, P243; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LILIENBAUM A, 1986, EMBO J, V5, P2809, DOI 10.1002/j.1460-2075.1986.tb04572.x; MARLHENS F, 1988, ANN GENET-PARIS, V31, P81; OHNUKI Y, 1968, CHROMOSOMA, V25, P402, DOI 10.1007/BF02327721; PERREAU J, 1988, GENE, V62, P7, DOI 10.1016/0378-1119(88)90575-6; QUAXJEUKEN Y, 1985, CYTOGENET CELL GENET, V40, P727; RUDDLE FH, 1989, CYTOGENET CELL GENET, V51, P1, DOI 10.1159/000132773; SAINTRUF C, 1989, INT J CANCER, V44, P367, DOI 10.1002/ijc.2910440230; SEDAT J, 1977, COLD SPRING HARB SYM, V42, P331, DOI 10.1101/SQB.1978.042.01.035; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; VELLARD M, 1991, IN PRESS ONCOGENE; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582; WRAY W, 1977, COLD SPRING HARB SYM, V42, P361; ZEHNER ZE, 1983, P NATL ACAD SCI-BIOL, V80, P911, DOI 10.1073/pnas.80.4.911	27	52	52	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					761	766		10.1016/0092-8674(91)90505-S	http://dx.doi.org/10.1016/0092-8674(91)90505-S			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997205				2022-12-01	WOS:A1991EZ47800011
J	BELL, MV; HIRST, MC; NAKAHORI, Y; MACKINNON, RN; ROCHE, A; FLINT, TJ; JACOBS, PA; TOMMERUP, N; TRANEBJAERG, L; FROSTERISKENIUS, U; KERR, B; TURNER, G; LINDENBAUM, RH; WINTER, R; PEMBREY, M; THIBODEAU, S; DAVIES, KE				BELL, MV; HIRST, MC; NAKAHORI, Y; MACKINNON, RN; ROCHE, A; FLINT, TJ; JACOBS, PA; TOMMERUP, N; TRANEBJAERG, L; FROSTERISKENIUS, U; KERR, B; TURNER, G; LINDENBAUM, RH; WINTER, R; PEMBREY, M; THIBODEAU, S; DAVIES, KE			PHYSICAL MAPPING ACROSS THE FRAGILE-X - HYPERMETHYLATION AND CLINICAL EXPRESSION OF THE FRAGILE-X SYNDROME	CELL			English	Article							LINKED MENTAL-RETARDATION; CHROMOSOME; DNA; SITE; METHYLATION; LINKAGE; LOCUS; FREQUENCY; REGION; FAMILY	The most common genetic cause of mental retardation after Down's syndrome, the fragile X syndrome, is associated with the occurrence of a fragile site at Xq27.3. This X-linked disease is intriguing because transmission can occur through phenotypically normal males. Theories to explain this unusual phenomenon include genomic rearrangements and methylation changes associated with a local block of reactivation of the X chromosome. Using microdissected markers close to the fragile site, we have been able to test these hypotheses. We present evidence for the association of methylation with the expression of the disease. However, there is no simple relationship between the degree of methylation and either the level of expression of the fragile site or the severity of the clinical phenotype.	GEN HOSP, WESSEX REG GENET LAB, SALISBURY SP2 7SX, WILTS, ENGLAND; ULLEVAL HOSP, DEPT MED GENET, N-0315 OSLO 3, NORWAY; UNIV TROMSO, N-9001 TROMSO, NORWAY; REG HOSP CORK, POLAR INST MED GENET, N-9012 TROMSO, NORWAY; LUBECK MED UNIV, DEPT GYNAECOL & OBSTET, W-2400 LUBECK, GERMANY; PRINCE WALES HOSP, DEPT MED GENET, RANDWICK, NSW 2031, AUSTRALIA; CHURCHILL HOSP, DEPT MED GENET, OXFORD OX3 7LJ, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, CLIN RES INST, NW THAMES REG GENET SERV, HARROW HA1 3UJ, MIDDX, ENGLAND; UNIV LONDON, INST CHILD HLTH, MOTHERCARE UNIT, LONDON WC1, ENGLAND; MAYO CLIN & MAYO FDN, DEPT LAB MED, ROCHESTER, MN 55905 USA	Salisbury District Hospital; University of Oslo; UiT The Arctic University of Tromso; University of Oxford; Imperial College London; University of London; Mayo Clinic	BELL, MV (corresponding author), JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC GENET GRP, OXFORD OX3 9DU, ENGLAND.		Tommerup, Niels/T-8776-2017; MacKinnon, Ruth/E-6202-2011	Tommerup, Niels/0000-0003-2304-0112; MacKinnon, Ruth/0000-0003-0294-5051				BARLOW D P, 1990, Technique (Philadelphia), V2, P79; DAHL N, 1989, AM J HUM GENET, V45, P304; DAVIES KE, 1985, HUM GENET, V70, P249; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRYNS JP, 1989, FRAGILE X SYNDROME, P1; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HARRISON CJ, 1983, J MED GENET, V20, P280, DOI 10.1136/jmg.20.4.280; HIRST MC, 1991, IN PRESS GENOMICS; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; KENWRICK S, 1987, CELL, V48, P351, DOI 10.1016/0092-8674(87)90438-7; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LUBS HA, 1969, AM J HUM GENET, V21, P231; MACKINNON RN, 1990, AM J HUM GENET, V47, P181; Martin JP, 1943, J NEUROL PSYCHIATRY, V6, P154, DOI 10.1136/jnnp.6.3-4.154; NUSSBAUM RL, 1986, AM J MED GENET, V23, P715, DOI 10.1002/ajmg.1320230162; OOSTRA BA, 1990, GENOMICS, V6, P129, DOI 10.1016/0888-7543(90)90457-6; PATTERSON M, 1988, AM J HUM GENET, V43, P684; PEMBREY ME, 1985, AM J MED GENET, V21, P709, DOI 10.1002/ajmg.1320210413; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; SUTHERS GK, 1989, SCIENCE, V246, P1298, DOI 10.1126/science.2573953; TOMMERUP N, 1987, 3RD INT WORKSH FRAG; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; TURKER MS, 1989, J BIOL CHEM, V264, P11632; TURNER G, 1980, J PEDIATR-US, V96, P837, DOI 10.1016/S0022-3476(80)80552-X; VINCENT A, 1991, IN PRESS NATURE; VOELCKEL MA, 1989, HUM GENET, V81, P353, DOI 10.1007/BF00283690; WEBB TP, 1986, J MED GENET, V23, P396, DOI 10.1136/jmg.23.5.396; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; YEN PH, 1984, P NATL ACAD SCI-BIOL, V81, P1759, DOI 10.1073/pnas.81.6.1759	34	307	313	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					861	866		10.1016/0092-8674(91)90514-Y	http://dx.doi.org/10.1016/0092-8674(91)90514-Y			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997211				2022-12-01	WOS:A1991EZ47800020
J	CLEVES, AE; MCGEE, TP; WHITTERS, EA; CHAMPION, KM; AITKEN, JR; DOWHAN, W; GOEBL, M; BANKAITIS, VA				CLEVES, AE; MCGEE, TP; WHITTERS, EA; CHAMPION, KM; AITKEN, JR; DOWHAN, W; GOEBL, M; BANKAITIS, VA			MUTATIONS IN THE CDP CHOLINE PATHWAY FOR PHOSPHOLIPID BIOSYNTHESIS BYPASS THE REQUIREMENT FOR AN ESSENTIAL PHOSPHOLIPID TRANSFER PROTEIN	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; YEAST GOLGI; GENE; CLONING; ACTIN; CELLS; TRANSFORMATION; MUTANTS	SEC14p is the yeast phosphatidylinositol (PI)/phosphatidylcholine (PC) transfer protein, and it effects an essential stimulation of yeast Golgi secretory function. We now report that the SEC14p localizes to the yeast Golgi and that the SEC14p requirement can be specifically and efficiently bypassed by mutations in any one of at least six genes. One of these suppressor genes was the structural gene for yeast choline kinase (CKI), disruption of which rendered the cell independent of the normally essential SEC14p requirement. The antagonistic action of the CKI gene product on SEC14p function revealed a previously unsuspected influence of biosynthetic activities of the CDP-choline pathway for PC biosynthesis on yeast Golgi function and indicated that SEC14p controls the phospholipid content of yeast Golgi membranes in vivo.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225; INDIANA UNIV,WALTHER ONCOL CTR,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	University of Texas System; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	CLEVES, AE (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801, USA.			Cleves, Ann/0000-0002-1622-2770; McGee, Todd/0000-0002-3901-1001	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35143, R01 GM044530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN JF, 1990, J BIOL CHEM, V265, P4711; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; Goldstein A, 1975, Methods Enzymol, V42, P504; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HELMKAMP GM, 1986, J BIOENERG BIOMEMBR, V18, P71, DOI 10.1007/BF00743477; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KREIBICH G, 1973, J CELL BIOL, V58, P436, DOI 10.1083/jcb.58.2.436; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MASON TL, 1973, J BIOL CHEM, V248, P1346; MIMMS LT, 1990, VIROLOGY, V176, P604, DOI 10.1016/0042-6822(90)90031-L; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1989, GENETICS, V121, P659; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHMAN JE, 1990, NATURE, V347, P519, DOI 10.1038/347519a0; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; Sherman F., 1983, METHODS YEAST GENETI; Silhavy T.J., 1984, EXPT GENE FUSIONS; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	36	304	306	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					789	800		10.1016/0092-8674(91)90508-V	http://dx.doi.org/10.1016/0092-8674(91)90508-V			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997207	Green Accepted, Green Submitted			2022-12-01	WOS:A1991EZ47800014
J	DECHIARA, TM; ROBERTSON, EJ; EFSTRATIADIS, A				DECHIARA, TM; ROBERTSON, EJ; EFSTRATIADIS, A			PARENTAL IMPRINTING OF THE MOUSE INSULIN-LIKE GROWTH FACTOR-II GENE	CELL			English	Article							RIBONUCLEIC-ACID; PATERNAL GENOMES; 2 PROMOTERS; EXPRESSION; EMBRYOGENESIS; METHYLATION; RECEPTOR; LOCALIZATION; CHICKEN; FETUS	We are studying mice that carry a targeted disruption of the gene encoding insulin-like growth factor II (IGF-II). Transmission of this mutation through the male germline results in heterozygous progeny that are growth deficient. In contrast, when the disrupted gene is transmitted maternally, the heterozygous offspring are phenotypically normal. Therefore, the difference in growth phenotypes depends on the type of gamete contributing the mutated allele. Homozygous mutants are indistinguishable in appearance from growth-deficient heterozygous siblings. Nuclease protection and in situ hybridization analyses of the transcripts from the wild-type and mutated alleles indicate that only the paternal allele is expressed in embryos, while the maternal allele is silent. An exception is the choroid plexus and leptomeninges, where both alleles are transcriptionally active. These results demonstrate that IGF-II is indispensable for normal embryonic growth and that the IGF-II gene is subject to tissue-specific parental imprinting.			DECHIARA, TM (corresponding author), COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA.							Adams R. L. P., 1985, MOL BIOL DNA METHYLA; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTON SC, 1984, NATURE, V311, P374, DOI 10.1038/311374a0; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BEECHEY CV, 1990, MOUSE GENOME, V87, P64; BELL GI, 1985, P NATL ACAD SCI USA, V82, P6450, DOI 10.1073/pnas.82.19.6450; BONDY CA, 1990, MOL ENDOCRINOL, V4, P1386, DOI 10.1210/mend-4-9-1386; BRILLIANT MH, 1987, J NEUROGENET, V4, P259, DOI 10.3109/01677068709102346; BRISSENDEN JE, 1984, NATURE, V310, P781, DOI 10.1038/310781a0; CANFIELD WM, 1989, J BIOL CHEM, V264, P7100; CATTANACH BM, 1986, J EMBRYOL EXP MORPH, V97, P137; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; CHARD T, 1989, J ENDOCRINOL, V123, P3, DOI 10.1677/joe.0.1230003; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAIRMONT KB, 1989, J BIOL CHEM, V264, P16390; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEPAGTERHOLTHUIZEN P, 1985, HUM GENET, V69, P170, DOI 10.1007/BF00293291; DERCOLE AJ, 1980, DEV BIOL, V75, P315, DOI 10.1016/0012-1606(80)90166-9; EVANS T, 1988, J MOL BIOL, V199, P61, DOI 10.1016/0022-2836(88)90379-8; FRUNZIO R, 1986, J BIOL CHEM, V261, P7138; GAMMELTOFT S, 1989, PEPTIDE HORMONES PRO, P176; GIRARD J, 1989, INTRAUTERINE GROWTH, P23; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; HARPER ME, 1981, P NATL ACAD SCI-BIOL, V78, P4458, DOI 10.1073/pnas.78.7.4458; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IKEJIRI K, 1990, BIOCHIM BIOPHYS ACTA, V1049, P350, DOI 10.1016/0167-4781(90)90110-N; JOHNSON DR, 1974, GENETICS, V76, P795; JOHNSON DR, 1974, GENET RES, V24, P207, DOI 10.1017/S0016672300015226; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LALLEY PA, 1984, CYTOGENET CELL GENET, V37, P515; LEE JE, 1990, DEVELOPMENT, V110, P151; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MCGRATH J, 1984, NATURE, V308, P550, DOI 10.1038/308550a0; MILNER RDG, 1987, EUR J PEDIATR, V146, P113, DOI 10.1007/BF02343214; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; MONK M, 1988, GENE DEV, V2, P921, DOI 10.1101/gad.2.8.921; MOSES AC, 1980, P NATL ACAD SCI-BIOL, V77, P3649, DOI 10.1073/pnas.77.6.3649; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; RAPPOLEE DA, 1990, UCLA SYM BI, V117, P11; REIK W, 1989, TRENDS GENET, V5, P331, DOI 10.1016/0168-9525(89)90138-8; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; Sambrook J., 1989, MOL CLONING LAB MANU; SAPIENZA C, 1989, PROG NUCLEIC ACID RE, V36, P145; SAPIENZA C, 1989, ANN NY ACAD SCI, V564, P24, DOI 10.1111/j.1749-6632.1989.tb25885.x; SAPIENZA C, 1990, SCI AM, V263, P52, DOI 10.1038/scientificamerican1090-52; SEARLE AG, 1989, ANN HUM GENET, V53, P89, DOI 10.1111/j.1469-1809.1989.tb01777.x; SEARLE AG, 1978, CYTOGENET CELL GENET, V20, P282, DOI 10.1159/000130859; SEARLE AG, 1985, ANEUPLOIDY ETIOLOGY, P363; SLACK J, 1991, NATURE, V349, P17, DOI 10.1038/349017a0; SLACK JMW, 1989, DEVELOPMENT, V107, P141; SMITH JC, 1989, DEVELOPMENT, V107, P149; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SOLTER D, 1988, ANNU REV GENET, V22, P127; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; STYLIANOPOULOU F, 1988, DEVELOPMENT, V103, P497; SURANI MA, 1990, PHILOS T ROY SOC B, V326, P313, DOI 10.1098/rstb.1990.0014; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; SURANI MA, 1986, EXPT APPROACHES MAMM, P431; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; SURANI MAH, 1986, J EMBRYOL EXP MORPH, V97, P123; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; SZULMAN AE, 1984, HUMAN TROPHOBLAST NE, P135; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TRICOLI JV, 1984, NATURE, V310, P784, DOI 10.1038/310784a0; UENO T, 1989, BIOCHIM BIOPHYS ACTA, V1009, P27, DOI 10.1016/0167-4781(89)90074-2; UENO T, 1987, BIOCHEM BIOPH RES CO, V148, P344, DOI 10.1016/0006-291X(87)91116-8; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WOLPERT L, 1989, DEVELOPMENT, V107, P3; WYLIE C, 1990, NATURE, V347, P337, DOI 10.1038/347337a0	80	1474	1528	2	87	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					849	859		10.1016/0092-8674(91)90513-X	http://dx.doi.org/10.1016/0092-8674(91)90513-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997210				2022-12-01	WOS:A1991EZ47800019
J	DINSMORE, JH; SOLOMON, F				DINSMORE, JH; SOLOMON, F			INHIBITION OF MAP2 EXPRESSION AFFECTS BOTH MORPHOLOGICAL AND CELL-DIVISION PHENOTYPES OF NEURONAL DIFFERENTIATION	CELL			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; EMBRYONAL CARCINOMA-CELLS; DEPENDENT PHOSPHORYLATION; MAMMALIAN NEURONS; TAU; RNA; INVITRO; LINE; DNA; IDENTIFICATION	Expression of the differentiated neuronal phenotype is typically manifest in several properties: distinct morphologies and organizations of the underlying cytoskeleton; appearance of specific macromolecules; and cessation of cell division. All of these properties are induced in undifferentiated embryonal carcinoma cells exposed to retinoic acid. We show here that the mRNA and protein for the microtubule component MAP2 is also induced by retinoic acid. Stable transfectants of undifferentiated cells, constitutively expressing MAP2 antisense RNA, show significantly reduced levels of MAP2 protein upon induction compared with controls. These cells do express other neuronal markers, but they do not undergo normal morphological differentiation nor do they withdraw from the cell cycle. The results suggest that MAP2 expression may be necessary for both neurite extension and cessation of cell division.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	DINSMORE, JH (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.							ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DINSMORE JH, 1988, CELL, V53, P769, DOI 10.1016/0092-8674(88)90094-3; DOTTI CG, 1987, NEUROSCIENCE, V23, P121, DOI 10.1016/0306-4522(87)90276-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNER CC, 1988, J CELL BIOL, V106, P779, DOI 10.1083/jcb.106.3.779; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAMMANG JP, 1990, NEURON, V4, P775, DOI 10.1016/0896-6273(90)90204-S; HARRIS PJ, 1986, METHOD CELL BIOL, V27, P243, DOI 10.1016/S0091-679X(08)60352-0; HIROKAWA N, 1988, J NEUROSCI, V8, P2769; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KIM S, 1987, J CELL BIOL, V104, P51, DOI 10.1083/jcb.104.1.51; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; LEWIS SA, 1986, J CELL BIOL, V102, P2098, DOI 10.1083/jcb.102.6.2098; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MONARD D, 1973, P NATL ACAD SCI USA, V70, P1894, DOI 10.1073/pnas.70.6.1894; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURPHY DB, 1977, J MOL BIOL, V117, P33, DOI 10.1016/0022-2836(77)90021-3; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; Rudnicki M.A., 1987, TERATOCARCINOMAS EMB; RUDNICKI MA, 1988, MOL CELL BIOL, V8, P406, DOI 10.1128/MCB.8.1.406; SAMBROOK S, 1989, MOL CLONING; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SCHMECHEL D, 1978, SCIENCE, V199, P313, DOI 10.1126/science.339349; SLOBODA RD, 1979, BIOCHEMISTRY-US, V18, P48, DOI 10.1021/bi00568a008; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; TUCKER RP, 1988, J NEUROSCI, V8, P4503; WALLACE DM, 1987, METHOD ENZYMOL, V152, P33	54	197	202	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					817	826		10.1016/0092-8674(91)90510-6	http://dx.doi.org/10.1016/0092-8674(91)90510-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997209				2022-12-01	WOS:A1991EZ47800016
J	HARTMANN, HA; KIRSCH, GE; DREWE, JA; TAGLIALATELA, M; JOHO, RH; BROWN, AM				HARTMANN, HA; KIRSCH, GE; DREWE, JA; TAGLIALATELA, M; JOHO, RH; BROWN, AM			EXCHANGE OF CONDUCTION PATHWAYS BETWEEN 2 RELATED K+ CHANNELS	SCIENCE			English	Article							POTASSIUM CHANNELS; SODIUM-CHANNEL; RAT-BRAIN; TETRAETHYLAMMONIUM; MEMBRANE; NEURONS	The structure of the ion conduction pathway or pore of voltage-gated ion channels is unknown, although the linker between the membrane spanning segments S5 and S6 has been suggested to form part of the pore in potassium channels. To test whether this region controls potassium channel conduction, a 21-amino acid segment of the S5-S6 linker was transplanted from the voltage-activated potassium channel NGK2 to another potassium channel DRK1, which has very different pore properties. In the resulting chimeric channel, the single channel conductance and blockade by external and internal tetraethylammonium (TEA) ion were characteristic of the donor NGK2 channel. Thus, this 21-amino acid segment controls the essential biophysical properties of the pore and may form the conduction pathway of these potassium channels.	BAYLOR UNIV,DEPT ANESTHESIOL,HOUSTON,TX 77030	Baylor University	HARTMANN, HA (corresponding author), BAYLOR UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/A-2062-2019; Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/ABH-4262-2020	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; 	NINDS NIH HHS [NS08805, NS23877, NS28407] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028407, F32NS008805, R01NS023877] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1972, J GEN PHYSIOL, V59, P388, DOI 10.1085/jgp.59.4.388; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Erlich H.A., 1989, PCR TECHNOLOGY; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HERMANN A, 1979, NEUROSCI LETT, V12, P87, DOI 10.1016/0304-3940(79)91485-X; Hille B, 1984, IONIC CHANNELS EXCIT; JOHO RH, 1990, MOL BRAIN RES, V7, P105, DOI 10.1016/0169-328X(90)90087-T; KOPPENHOFER E, 1969, PFLUG ARCH EUR J PHY, V313, P361, DOI 10.1007/BF00593959; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; MOORMAN JR, 1990, SCIENCE, V250, P688; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; TAGLIALATELA M, UNPUB; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; THOMPSON SH, 1977, J PHYSIOL-LONDON, V265, P465, DOI 10.1113/jphysiol.1977.sp011725; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	25	373	377	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					942	944		10.1126/science.2000495	http://dx.doi.org/10.1126/science.2000495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000495				2022-12-01	WOS:A1991EY62900046
J	HIGASHIYAMA, S; ABRAHAM, JA; MILLER, J; FIDDES, JC; KLAGSBRUN, M				HIGASHIYAMA, S; ABRAHAM, JA; MILLER, J; FIDDES, JC; KLAGSBRUN, M			A HEPARIN-BINDING GROWTH-FACTOR SECRETED BY MACROPHAGE-LIKE CELLS THAT IS RELATED TO EGF	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; FACTOR FAMILY; FACTOR-ALPHA; EXPRESSION; AFFINITY; DNA; ATHEROSCLEROSIS; PURIFICATION; AMPHIREGULIN	Macrophage-like U-937 cells secrete a 22-kilodalton heparin-binding growth factor that is mitogenic for BALB-3T3 fibroblasts and smooth muscle cells, but not endothelial cells. The amino acid sequence predicted from complementary DNA clones indicates that the mitogen is a new member of the epidermal growth factor (EGF) family. This heparin-binding EGF-like growth factor (HB-EGF) binds to EGF receptors on A-431 epidermoid carcinoma cells and smooth muscle cells, but is a far more potent mitogen for smooth muscle cells than is EGF. HB-EGF is also expressed in cultured human macrophages and may be involved in macrophage-mediated cellular proliferation.	CHILDRENS HOSP MED CTR,DEPT SURG RES,BOSTON,MA 02115; CALIF BIOTECHNOL INC,MT VIEW,CA 94043; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA37392, CA45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548, R01CA037392, R56CA037392, R37CA037392] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AQEL NM, 1985, J PATHOL, V146, P197, DOI 10.1002/path.1711460306; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GREGORY H, 1975, NATURE, V257, P235; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HIGASHIYAMA S, UNPUB; IBERG N, 1989, J BIOL CHEM, V264, P19951; KIMBALL ES, 1984, BIOCHIM BIOPHYS ACTA, V771, P82, DOI 10.1016/0005-2736(84)90113-5; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MINTA JO, 1985, AM J PATHOL, V119, P111; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SINGH JP, 1987, METHOD ENZYMOL, V147, P13; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	39	1074	1141	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					936	939		10.1126/science.1840698	http://dx.doi.org/10.1126/science.1840698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	1840698				2022-12-01	WOS:A1991EY62900044
J	JACOBS, KM; DONOGHUE, JP				JACOBS, KM; DONOGHUE, JP			RESHAPING THE CORTICAL MOTOR MAP BY UNMASKING LATENT INTRACORTICAL CONNECTIONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; NMDA RECEPTORS; CORTEX; INHIBITION; NEURONS; INVITRO	The primary motor cortex (MI) contains a map organized so that contralateral limb or facial movements are elicited by electrical stimulation within separate medial to lateral MI regions. Within hours of a peripheral nerve transection in adult rats, movements represented in neighboring MI areas are evoked from the cortical territory of the affected body part. One potential mechanism for reorganization is that adjacent cortical regions expand when preexisting lateral excitatory connections are unmasked by decreased intracortical inhibition. During pharmacological blockade of cortical inhibition in one part of the MI representation, movements of neighboring representations were evoked by stimulation in adjacent MI areas. These results suggest that intracortical connections form a substrate for reorganization of cortical maps and that inhibitory circuits are critically placed to maintain or readjust the form of cortical motor representations.			JACOBS, KM (corresponding author), BROWN UNIV,CTR NEURAL SCI,BOX 1953,PROVIDENCE,RI 02912, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022517, R37NS025074, R01NS025074] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25074, NS22517] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKHTAR N D, 1987, Society for Neuroscience Abstracts, V13, P77; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; Brown TG, 1912, P R SOC LOND B-CONTA, V85, P250, DOI 10.1098/rspb.1912.0050; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747, DOI 10.1152/jn.1989.61.4.747; CRAGGS MD, 1976, BRAIN, V99, P575, DOI 10.1093/brain/99.3.575; DONOGHUE JP, 1988, J NEUROSCI, V8, P3221; DONOGHUE JP, 1987, BRAIN RES, V408, P367, DOI 10.1016/0006-8993(87)90407-0; DONOGHUE JP, 1990, EXP BRAIN RES, V79, P492; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; HENDRY SHC, 1986, NATURE, V320, P750, DOI 10.1038/320750a0; IRIKI A, 1989, SCIENCE, V245, P1385, DOI 10.1126/science.2551038; KRNJEVIC K, 1963, J PHYSIOL-LONDON, V166, P296, DOI 10.1113/jphysiol.1963.sp007106; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557, DOI 10.1152/jn.1985.53.2.557; METHERATE R, 1988, J NEUROPHYSIOL, V59, P1231, DOI 10.1152/jn.1988.59.4.1231; STELZER A, 1987, NATURE, V326, P698, DOI 10.1038/326698a0; WELKER E, 1989, EXP BRAIN RES, V74, P441, DOI 10.1007/BF00247346; WHITE EL, 1989, CORTICAL CIRCUITS SY, P46; WIGSTROM H, 1986, J PHYSIOL-PARIS, V81, P228; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V125, P159, DOI 10.1111/j.1748-1716.1985.tb07703.x	19	749	761	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					944	947		10.1126/science.2000496	http://dx.doi.org/10.1126/science.2000496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000496				2022-12-01	WOS:A1991EY62900047
J	KARTNER, N; HANRAHAN, JW; JENSEN, TJ; NAISMITH, AL; SUN, SZ; ACKERLEY, CA; REYES, EF; TSUI, LC; ROMMENS, JM; BEAR, CE; RIORDAN, JR				KARTNER, N; HANRAHAN, JW; JENSEN, TJ; NAISMITH, AL; SUN, SZ; ACKERLEY, CA; REYES, EF; TSUI, LC; ROMMENS, JM; BEAR, CE; RIORDAN, JR			EXPRESSION OF THE CYSTIC-FIBROSIS GENE IN NONEPITHELIAL INVERTEBRATE CELLS PRODUCES A REGULATED ANION CONDUCTANCE	CELL			English	Article							HIGH-LEVEL EXPRESSION; INSECT CELLS; BACULOVIRUS VECTOR; COMPLEMENTARY-DNA; FOREIGN GENES; GLYCOPROTEIN; RECEPTOR; MEMBRANE; PROTEINS; CHANNEL	The nature of involvement of the cystic fibrosis gene product (CFTR) in epithelial anion transport is not yet understood. We have expressed CFTR in Sf9 insect cells using the baculovirus expression vector system. Reactivity with antibodies against 12 different epitopes spanning the entire sequence suggested that the complete polypeptide chain was synthesized. Immunogold labeling showed localization to both cell-surface and intracellular membranes. Concomitant with CFTR expression, these cells exhibited a new cAMP-stimulated anion permeability. This conductance, monitored both by radioiodide efflux and patch clamping, strongly resembled that present in several CFTR-expressing human epithelial cells. These findings demonstrate that CFTR can function in heterologous nonepithelial cells and lend support to the possibility that CFTR may itself be a regulated anion channel.	UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM & CLIN BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3G 1Y6,QUEBEC,CANADA	University of Toronto; University of Toronto; University of Toronto; McGill University	KARTNER, N (corresponding author), HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA.		Tsui, Lap-chee/A-1081-2010; Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039				ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTENSENO, 1989, PFLUGERS ARCH, V415, P37; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; DOMINGO DL, 1988, J BIOL CHEM, V263, P13386; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HWANG TC, 1990, BIOPHYS J, V57, pA88; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHNSON PW, 1989, GENE, V77, P287, DOI 10.1016/0378-1119(89)90076-0; KALIBER K, 1990, NEURON, V5, P221; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MARCEL YL, 1987, ARTERIOSCLEROSIS, V7, P166, DOI 10.1161/01.ATV.7.2.166; POSSEE RD, 1986, VIRUS RES, V5, P43, DOI 10.1016/0168-1702(86)90064-X; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RINGE D, 1990, NATURE, V346, P312, DOI 10.1038/346312a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1990, IDENTIFICATION CF CY; RIORDAN JR, 1991, J PHARM THERAPEUT, V28, P51; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STIERHOF YD, 1986, J ULTRA MOL STRUCT R, V97, P187, DOI 10.1016/S0889-1605(86)80017-9; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	40	517	533	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					681	691		10.1016/0092-8674(91)90498-N	http://dx.doi.org/10.1016/0092-8674(91)90498-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1705179				2022-12-01	WOS:A1991EZ47800004
J	KIRMAIER, C; GAUL, D; DEBEY, R; HOLTEN, D; SCHENCK, CC				KIRMAIER, C; GAUL, D; DEBEY, R; HOLTEN, D; SCHENCK, CC			CHARGE SEPARATION IN A REACTION CENTER INCORPORATING BACTERIOCHLOROPHYLL FOR PHOTOACTIVE BACTERIOPHEOPHYTIN	SCIENCE			English	Article							PHOTOSYNTHETIC REACTION CENTERS; BACTERIAL REACTION CENTERS; INITIAL ELECTRON-TRANSFER; NANOSECOND RECOMBINATION LUMINESCENCE; RHODOPSEUDOMONAS-SPHAEROIDES R-26; RHODOBACTER-SPHAEROIDES; RHODOSPIRILLUM-RUBRUM; FEMTOSECOND SPECTROSCOPY; PURPLE BACTERIA; PRIMARY DONOR	Site-directed mutagenic replacement of M subunit Leu214 by His in the photosynthetic reaction center (RC) from Rhodobacter sphaeroides results in incorporation of a bacteriochlorophyll molecule (BChl) in place of the native bacteriopheophytin (BPh) electron acceptor. Evidence supporting this conclusion includes the ground-state absorption spectrum of the (M)L214H mutant, pigment and metal analyses, and time-resolved optical experiments. The genetically modified RC supports transmembrane charge separation from the photoexcited BChl dimer to the primary quinone through the new BChl molecule, but with a reduced quantum yield of 60 percent (compared to 100 percent in wild-type RCs). These results have important implications for the mechanism of charge separation in the RC, and rationalize the choice (bacterio)pheophytins as electron acceptors in a variety of photosynthetic systems.	COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523	Colorado State University	KIRMAIER, C (corresponding author), WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018650, K04GM000536, R29GM038214] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18650, GM00536, GM38214] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JP, 1986, P NATL ACAD SCI USA, V83, P8589, DOI 10.1073/pnas.83.22.8589; BIXON M, 1989, BIOCHIM BIOPHYS ACTA, V977, P273, DOI 10.1016/S0005-2728(89)80081-7; BIXON M, IN PRESS BIOCH BIOPH; BORISOV AY, 1980, FEBS LETT, V119, P121, DOI 10.1016/0014-5793(80)81012-X; BRESLOW E, 1967, J BIOL CHEM, V242, P4149; BRETON J, 1988, BIOCHEMISTRY-US, V27, P8276, DOI 10.1021/bi00421a043; BUDIL DE, 1987, ANNU REV PHYS CHEM, V38, P561, DOI 10.1146/annurev.pc.38.100187.003021; BYLINA EJ, 1988, P NATL ACAD SCI USA, V85, P7226, DOI 10.1073/pnas.85.19.7226; CALLAHAN PM, 1987, J AM CHEM SOC, V109, P7001, DOI 10.1021/ja00257a016; CHANG CH, 1986, FEBS LETT, V205, P82, DOI 10.1016/0014-5793(86)80870-5; CHIRINO A, UNPUB; COTTON TM, 1979, J AM CHEM SOC, V101, P7605, DOI 10.1021/ja00519a023; DEBEY R, UNPUB; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; FAJER J, 1975, P NATL ACAD SCI USA, V72, P4956, DOI 10.1073/pnas.72.12.4956; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; FRANZEN S, 1990, J PHYS CHEM-US, V94, P5135, DOI 10.1021/j100375a068; FRIESNER RA, 1989, BIOCHIM BIOPHYS ACTA, V977, P99, DOI 10.1016/S0005-2728(89)80062-3; GOLDSTEIN RA, 1989, BIOCHIM BIOPHYS ACTA, V977, P78, DOI 10.1016/S0005-2728(89)80011-8; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HOLZAPFEL W, 1990, P NATL ACAD SCI USA, V87, P5168, DOI 10.1073/pnas.87.13.5168; HOLZAPFEL W, 1989, CHEM PHYS LETT, V160, P1, DOI 10.1016/0009-2614(89)87543-8; HU YM, 1989, CHEM PHYS LETT, V160, P410, DOI 10.1016/0009-2614(89)87619-5; KIRMAIER C, 1988, FEBS LETT, V239, P211, DOI 10.1016/0014-5793(88)80919-0; KIRMAIER C, 1989, CHEM PHYS LETT, V159, P251, DOI 10.1016/0009-2614(89)87419-6; KIRMAIER C, 1987, PHOTOSYNTH RES, V13, P225, DOI 10.1007/BF00029401; KIRMAIER C, 1990, P NATL ACAD SCI USA, V87, P3552, DOI 10.1073/pnas.87.9.3552; KIRMAIER C, 1988, P NATL ACAD SCI USA, V85, P7562, DOI 10.1073/pnas.85.20.7562; KOMIYA H, 1988, P NATL ACAD SCI USA, V85, P9012, DOI 10.1073/pnas.85.23.9012; KOTOVA EA, 1981, FEBS LETT, V131, P51, DOI 10.1016/0014-5793(81)80885-X; LOCKHART DJ, 1990, J PHYS CHEM-US, V94, P6987, DOI 10.1021/j100381a015; LOCKHART DJ, 1988, J CHEM PHYS, V89, P1408, DOI 10.1063/1.455140; MARCUS RA, 1988, CHEM PHYS LETT, V146, P13, DOI 10.1016/0009-2614(88)85041-3; MARTIN JL, 1986, P NATL ACAD SCI USA, V83, P957, DOI 10.1073/pnas.83.4.957; MCDOWELL LM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P239, DOI 10.1016/0005-2728(90)90153-U; MCDOWELL LM, IN PRESS J PHYS CHEM; MCDOWELL LM, UNPUB; NAGARAJAN V, 1990, P NATL ACAD SCI USA, V87, P7888, DOI 10.1073/pnas.87.20.7888; PARSON WW, 1975, BIOCHIM BIOPHYS ACTA, V387, P265, DOI 10.1016/0005-2728(75)90109-7; SARAI A, 1980, BIOCHIM BIOPHYS ACTA, V589, P71, DOI 10.1016/0005-2728(80)90133-4; SCHENCK CC, 1982, BIOCHIM BIOPHYS ACTA, V680, P44, DOI 10.1016/0005-2728(82)90315-2; SCHERER POJ, 1989, CHEM PHYS, V131, P115, DOI 10.1016/0301-0104(89)87084-3; SEBRING ED, 1970, J BIOL CHEM, V245, P5395; SHUVALOV VA, 1981, P NATL ACAD SCI-BIOL, V78, P957, DOI 10.1073/pnas.78.2.957; SISTROM WR, 1977, J BACTERIOL, V131, P526, DOI 10.1128/JB.131.2.526-532.1977; STRALEY SC, 1973, BIOCHIM BIOPHYS ACTA, V305, P597, DOI 10.1016/0005-2728(73)90079-0; VANDERREST M, 1974, J BIOL CHEM, V249, P6446; WARSHEL A, 1988, J PHYS CHEM-US, V92, P2696, DOI 10.1021/j100320a057; WARSHEL A, 1989, SCIENCE, V246, P112, DOI 10.1126/science.2675313; WARSHEL A, 1990, BIOCHIM BIOPHYS ACTA, V1017, P251; WASIELEWSKI MR, 1986, FEBS LETT, V204, P386; WENDT RH, 1965, ANAL CHEM, V37, P920, DOI 10.1021/ac60226a003; WOODBURY N, IN PRESS P FELDAFING; WOODBURY NW, 1985, BIOCHEMISTRY-US, V24, P7516, DOI 10.1021/bi00347a002; WOODBURY NWT, 1984, BIOCHIM BIOPHYS ACTA, V767, P345, DOI 10.1016/0005-2728(84)90205-6; YEATES TO, 1988, P NATL ACAD SCI USA, V85, P7993, DOI 10.1073/pnas.85.21.7993	56	164	168	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					922	927		10.1126/science.2000491	http://dx.doi.org/10.1126/science.2000491			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000491				2022-12-01	WOS:A1991EY62900039
J	KLAMBT, C; JACOBS, JR; GOODMAN, CS				KLAMBT, C; JACOBS, JR; GOODMAN, CS			THE MIDLINE OF THE DROSOPHILA CENTRAL-NERVOUS-SYSTEM - A MODEL FOR THE GENETIC-ANALYSIS OF CELL FATE, CELL-MIGRATION, AND GROWTH CONE GUIDANCE	CELL			English	Article							AXON PATHWAYS; EMBRYONIC-DEVELOPMENT; NEURONAL DEVELOPMENT; LARVAL CUTICLE; ZYGOTIC LOCI; MELANOGASTER; GRASSHOPPER; EXPRESSION; PATTERN; CNS	A row of mesectodermal cells separates the two lateral neurogenic regions in the Drosophila embryo and generates a discrete set of glia and neurons. Most CNS growth cones initially head straight toward the midline, suggesting that these midline cells play a key role in the formation of the axon commissures. We have used antibodies that stain the first axons, beta-galactosidase enhancer trap lines that selectively stain the different midline cells, and electron microscopic studies to elucidate the cells and interactions that mediate the normal formation of the two major commissures in each segment. This analysis has led to a model that proposes a series of sequential cell interactions controlling the development of the axon commissures. A genetic test of this model has utilized a number of mutations that, by either eliminating or altering the differentiation of various midline cells, perturb the development of the axon commissures in a predictable fashion.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	KLAMBT, C (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.			jacobs, j roger/0000-0002-5878-5416	NINDS NIH HHS [NS18366] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BATE CM, 1981, J EMBRYOL EXP MORPH, V61, P317; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; Bridges CB., 1919, CARNEGIE I WASH PUBL, V278, P123; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERDIEU JR, 1989, DEVELOPMENT, V106, P749; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FOE VE, 1989, DEVELOPMENT, V107, P1; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; HOYLE G, 1986, J COMP NEUROL, V246, P85, DOI 10.1002/cne.902460106; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JESSELL TM, 1989, CIBA F SYMP, V144, P255; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KLAMBT C, 1991, IN PRESS GLIA; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MEYER MR, 1987, J NEUROSCI, V7, P512; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONTELL DJ, 1989, J CELL BIOL, V109, P2441, DOI 10.1083/jcb.109.5.2441; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Poulson D. F., 1950, BIOL DROSOPHILA, P168; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; ZAK NB, 1990, DEVELOPMENT, V109, P865	43	457	457	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					801	815		10.1016/0092-8674(91)90509-W	http://dx.doi.org/10.1016/0092-8674(91)90509-W			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997208				2022-12-01	WOS:A1991EZ47800015
J	LECHNER, J; CARBON, J				LECHNER, J; CARBON, J			A 240-KD MULTISUBUNIT PROTEIN COMPLEX, CBF3, IS A MAJOR COMPONENT OF THE BUDDING YEAST CENTROMERE	CELL			English	Article							BASE-PAIR MUTATIONS; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; TRANSCRIPTION FACTOR; DNA; PURIFICATION; INVITRO; CHROMOSOMES; DIGESTION; HISTONES	A key protein component (CBF3) of the budding yeast (S. cerevisiae) centromere/kinetochore has been purified and characterized. CBF3 is a 240 kd multisubunit protein complex that binds specifically to the yeast wild-type centromere DNA (CEN), but not to nonfunctional CEN DNA containing a single base substitution in the critical CDEIII consensus sequence. When purified by affinity chromatography, CBF3 contains three protein components: CBF3A (110 kd), CBF3B (64 kd), and CBF3C (58 kd). Highly purified CBF3 requires the presence of a separate assembly factor or chaperone activity to bind to CEN DNA. Treatment with phosphatase inactivates CBF3, indicating that at least one of the CBF3 subunits must be phosphorylated for DNA binding to occur. A 56 bp region including the 26 bp CDEIII consensus is protected from DNAase I cleavage in the CBF3-CEN DNA complex.			LECHNER, J (corresponding author), UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106, USA.				NATIONAL CANCER INSTITUTE [R01CA011034] Funding Source: NIH RePORTER; NCI NIH HHS [CA-11034] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER RE, 1989, J BIOL CHEM, V264, P10843; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Brinkley B.R., 1989, MITOSIS MOL MECHANIS, P77; CAI MJ, 1989, MOL CELL BIOL, V9, P2544, DOI 10.1128/MCB.9.6.2544; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARBON J, 1990, New Biologist, V2, P10; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CLARKE L, 1983, NATURE, V305, P23, DOI 10.1038/305023a0; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOTAREL G, 1989, MOL CELL BIOL, V9, P3342; CUMBERLEDGE S, 1987, GENETICS, V117, P203; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FUNK M, 1989, MOL GEN GENET, V219, P153, DOI 10.1007/BF00261171; FUTCHER B, 1986, MOL CELL BIOL, V6, P2213, DOI 10.1128/MCB.6.6.2213; GAUDET A, 1987, MOL CELL BIOL, V7, P68, DOI 10.1128/MCB.7.1.68; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; JIANG WD, 1989, MOL CELL BIOL, V9, P5585, DOI 10.1128/MCB.9.12.5585; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCGREW J, 1986, MOL CELL BIOL, V6, P530, DOI 10.1128/MCB.6.2.530; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; NG R, 1987, MOL CELL BIOL, V7, P4522, DOI 10.1128/MCB.7.12.4522; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OW RA, 1987, J BIOL CHEM, V262, P3409; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SINGER MF, 1982, INT REV CYTOL, V76, P67, DOI 10.1016/S0074-7696(08)61789-1; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3	44	277	288	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					717	725		10.1016/0092-8674(91)90501-O	http://dx.doi.org/10.1016/0092-8674(91)90501-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997204				2022-12-01	WOS:A1991EZ47800007
J	NAKABEPPU, Y; NATHANS, D				NAKABEPPU, Y; NATHANS, D			A NATURALLY-OCCURRING TRUNCATED FORM OF FOSB THAT INHIBITS FOS JUN TRANSCRIPTIONAL ACTIVITY	CELL			English	Article							SERUM GROWTH-FACTORS; C-FOS; PROTO-ONCOGENE; MESSENGER-RNAS; FACTOR AP-1; AUTO-REGULATION; LEUCINE ZIPPER; 3T3 CELLS; GENE; EXPRESSION	Fos and Jun transcription factors are induced by a variety of extracellular signaling agents. We describe here an unusual member of the Fos family that is also induced, namely, a truncated form of FosB (DELTA-FosB) missing the C-terminal 101 amino acids of FosB. DELTA-FosB retains the dimerization and DNA-binding activities of FosB but has lost the ability in transfection assays to activate a promoter with an AP-1 site and to repress the c-fos promoter. Rather, DELTA-FosB inhibits gene activation by Jun or Jun + Fos and inhibits repression of the c-fos promoter by FosB or c-Fos, presumably by competing with full-length Fos proteins at the steps of dimerization with Jun and binding to DNA. In stimulated cells DELTA-FosB may act to limit the transcriptional effects of Fos and Jun proteins.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University	NAKABEPPU, Y (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.		Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X	NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [5 PO1 CA16519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAVO R, 1989, GROWTH FACTORS DIFFE; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COLE AJ, 1990, IN PRESS J NEUROCHEM; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; GANTZ R, 1989, SCIENCE, V243, P1695; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARLOW E, 1988, ANTIBODIES LABORATOR; Higgins GM, 1931, ARCH PATHOL, V12, P186; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1991, MOL ASPECTS CELLULAR, V6; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Miller JH., 1972, EXPT MOL GENETICS; MILLER R, 1984, NATURE, V312, P716; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Swinyard E. A., 1972, EXPT MODELS EPILEPSY, P433; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	68	419	427	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					751	759		10.1016/0092-8674(91)90504-R	http://dx.doi.org/10.1016/0092-8674(91)90504-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1900040				2022-12-01	WOS:A1991EZ47800010
J	PARKS, GD; LAMB, RA				PARKS, GD; LAMB, RA			TOPOLOGY OF EUKARYOTIC TYPE-II MEMBRANE-PROTEINS - IMPORTANCE OF N-TERMINAL POSITIVELY CHARGED RESIDUES FLANKING THE HYDROPHOBIC DOMAIN	CELL			English	Article							PARAMYXOVIRUS SIMIAN VIRUS-5; ENDOPLASMIC-RETICULUM MEMBRANE; CLEAVABLE SIGNAL SEQUENCE; INFLUENZA-VIRUS; INVARIANT CHAIN; MESSENGER-RNA; CELL-SURFACE; NH2 TERMINUS; AMINO-ACID; TRANSLOCATION	We have tested the role of different charged residues flanking the sides of the signal/anchor (S/A) domain of a eukaryotic type II (N(cyt)C(exo)) integral membrane protein in determining its topology. The removal of positively charged residues on the N-terminal side of the S/A yields proteins with an inverted topology, while the addition of positively charged residues to only the C-terminal side has very little effect on orientation. Expression of chimeric proteins composed of domains from a type II protein (HN) and the oppositely oriented membrane protein M2 indicates that the HN N-terminal domain is sufficient to confer a type II topology and that the M2 N-terminal ectodomain can direct a type II topology when modified by adding positively charged residues. These data suggest that eukaryotic membrane protein topology is governed by the presence or absence of an N-terminal signal for retention in the cytoplasm that is composed in part of positive charges.	NORTHWESTERN UNIV,HOWARD HUGHES MED INST,EVANSTON,IL 60208	Howard Hughes Medical Institute; Northwestern University	PARKS, GD (corresponding author), NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020201, R01AI023173, R01AI020201] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20201, AI-23173] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GA, 1985, MOL CELL BIOL, V5, P1442, DOI 10.1128/MCB.5.6.1442; AKITA M, 1990, J BIOL CHEM, V265, P8164; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ERICKSON AH, 1979, J BIOL CHEM, V254, P1771; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIEBERT SW, 1985, J VIROL, V55, P744, DOI 10.1128/JVI.55.3.744-751.1985; HIEBERT SW, 1985, J VIROL, V54, P1; HIGH S, 1987, BIOCHEM J, V243, P277, DOI 10.1042/bj2430277; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; LAMB RA, 1982, VIROLOGY, V123, P237, DOI 10.1016/0042-6822(82)90258-6; LAMB RA, 1978, VIROLOGY, V91, P60, DOI 10.1016/0042-6822(78)90355-0; LAMB RA, 1976, VIROLOGY, V74, P504, DOI 10.1016/0042-6822(76)90356-1; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LAMB RA, 1981, VIROLOGY, V112, P746, DOI 10.1016/0042-6822(81)90319-6; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NGDTW, 1989, J CELL BIOL, V109, P3273; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PARKS GD, 1989, J CELL BIOL, V109, P2023, DOI 10.1083/jcb.109.5.2023; PATERSON RG, 1985, P NATL ACAD SCI USA, V82, P7520, DOI 10.1073/pnas.82.22.7520; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STRUBIN M, 1984, EMBO J, V3, P869, DOI 10.1002/j.1460-2075.1984.tb01898.x; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WEINSTEIN JN, 1982, J MEMBRANE BIOL, V66, P203, DOI 10.1007/BF01868495; WILLIAMS MA, 1986, MOL CELL BIOL, V6, P4317, DOI 10.1128/MCB.6.12.4317; ZERIAL M, 1987, CELL, V48, P147, DOI 10.1016/0092-8674(87)90365-5	49	149	152	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					777	787		10.1016/0092-8674(91)90507-U	http://dx.doi.org/10.1016/0092-8674(91)90507-U			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997206				2022-12-01	WOS:A1991EZ47800013
J	PECORA, R				PECORA, R			DNA - A MODEL-COMPOUND FOR SOLUTION STUDIES OF MACROMOLECULES	SCIENCE			English	Article							TRANSIENT ELECTRIC BIREFRINGENCE; DYNAMIC LIGHT-SCATTERING; ROTATIONAL DIFFUSION-COEFFICIENTS; SYMMETRIC TOP MACROMOLECULES; ELASTIC HINGE MODEL; RESTRICTION FRAGMENTS; WORMLIKE CHAINS; CIRCULAR-CYLINDERS; AQUEOUS-SOLUTIONS; STIFF CHAINS	Well-defined, monodisperse, homologous series of oligonucleotides and DNA restriction fragments may now be produced and used as models of rigid and semirigid rodlike molecules in solution. Information from optical experiments on these model systems aids in the formulation and testing of theories of macromolecular dynamics in both dilute and concentrated solution.			PECORA, R (corresponding author), STANFORD UNIV,CHEM,STANFORD,CA 94305, USA.							ALLISON SA, 1990, MACROMOLECULES, V23, P1110, DOI 10.1021/ma00206a033; ARAGON SR, 1987, MACROMOLECULES, V20, P370, DOI 10.1021/ma00168a025; ARGON SR, 1985, MACROMOLECULES, V18, P1868; Berne B. J., 1976, DYNAMIC LIGHT SCATTE; BLOOMFIELD VA, 1985, DYNAMIC LIGHT SCATTE; BOTT SE, 1984, THESIS STANFORD U ST; BRIAN AA, 1981, BIOPOLYMERS, V20, P1305, DOI 10.1002/bip.1981.360200615; DEGIORGIO V, 1990, PHYS REV LETT, V64, P1043, DOI 10.1103/PhysRevLett.64.1043; DELATORRE JG, 1984, BIOPOLYMERS, V23, P611, DOI 10.1002/bip.360230402; DIEKMANN S, 1982, BIOPHYS CHEM, V15, P263, DOI 10.1016/0301-4622(82)80009-4; Doi M., 1986, THEORY POLYM DYNAMIC; EIMER W, 1990, BIOCHEMISTRY-US, V29, P799, DOI 10.1021/bi00455a030; EIMER W, 1987, THESIS BIELEFELD U B; EIMER W, IN PRESS J CHEM PHYS; ELIAS JG, 1981, BIOPOLYMERS, V20, P2369, DOI 10.1002/bip.1981.360201107; ELIAS JG, 1981, MACROMOLECULES, V14, P410, DOI 10.1021/ma50003a034; FRIED MG, 1984, BIOPOLYMERS, V23, P2141, DOI 10.1002/bip.360231104; FULMER AW, 1981, BIOPOLYMERS, V20, P1147, DOI 10.1002/bip.1981.360200606; GOINGA HT, UNPUB; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1503, DOI 10.1002/bip.1981.360200710; HAGERMAN PJ, 1983, BIOPOLYMERS, V22, P811, DOI 10.1002/bip.360220303; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1481, DOI 10.1002/bip.1981.360200709; HARD T, 1986, BIOPOLYMERS, V25, P1519, DOI 10.1002/bip.360250810; HERVET H, 1978, J CHEM PHYS, V68, P2725, DOI 10.1063/1.436110; KITANO T, 1977, POLYM J, V2, P153; LEWIS RJ, 1985, MACROMOLECULES, V18, P1530, DOI 10.1021/ma00150a003; LEWIS RJ, 1985, MACROMOLECULES, V18, P944, DOI 10.1021/ma00147a022; LEWIS RJ, 1988, J CHEM PHYS, V89, P2490, DOI 10.1063/1.455043; LEWIS RJ, 1987, MACROMOLECULES, V20, P2579, DOI 10.1021/ma00176a044; LEWIS RJ, 1981, MACROMOLECULES, V19, P134; LEWIS RJ, 1985, THESIS STANFORD U ST; MANDELKERN M, 1981, J MOL BIOL, V152, P153, DOI 10.1016/0022-2836(81)90099-1; NICOLAI T, 1989, MACROMOLECULES, V22, P2348, DOI 10.1021/ma00195a059; NICOLAI T, 1989, MACROMOLECULES, V22, P438, DOI 10.1021/ma00191a080; PECORA R, 1968, J CHEM PHYS, V49, P1032, DOI 10.1063/1.1670188; PECORA R, 1964, J CHEM PHYS, V40, P1604, DOI 10.1063/1.1725368; PECORA R, 1968, J CHEM PHYS, V48, P4126, DOI 10.1063/1.1669748; Pecora R. E., 1985, DYNAMIC LIGHT SCATTE, DOI DOI 10.1002/BBPC.19870910455; POST CB, 1982, BIOPOLYMERS, V21, P2139, DOI 10.1002/bip.360211105; POST CB, 1982, BIOPOLYMERS, V21, P2123, DOI 10.1002/bip.360211104; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; Roitman D. B., 1987, ROTATIONAL DYNAMICS, P192; ROITMAN DB, 1984, J CHEM PHYS, V81, P6333, DOI 10.1063/1.447542; ROITMAN DB, 1984, J CHEM PHYS, V81, P6348, DOI 10.1063/1.447543; RONDELEZ F, 1980, LASER SCATTERING FLU; SCALETTAR BA, 1989, MACROMOLECULES, V22, P4550, DOI 10.1021/ma00202a030; Schmitz K. S., 1990, INTRO DYNAMIC LIGHT; SCHULZ SF, 1990, J CHEM PHYS, V92, P7087, DOI 10.1063/1.458249; SCHURR JM, 1986, ANNU REV PHYS CHEM, V37, P271; SEILS J, UNPUB; SORLIE SS, 1990, MACROMOLECULES, V23, P487, DOI 10.1021/ma00204a022; SORLIE SS, 1988, MACROMOLECULES, V21, P1437, DOI 10.1021/ma00183a039; STELLWAGEN NC, 1981, BIOPOLYMERS, V20, P399, DOI 10.1002/bip.1981.360200302; STRZELECKA TE, 1990, BIOPOLYMERS, V30, P57, DOI 10.1002/bip.360300108; STRZELECKA TE, 1987, J AM CHEM SOC, V109, P4513, DOI 10.1021/ja00249a014; SZWARC M, 1956, J AM CHEM SOC, V78, P2656, DOI 10.1021/ja01592a101; TIRADO MM, 1979, J CHEM PHYS, V71, P2581, DOI 10.1063/1.438613; TIRADO MM, 1980, J CHEM PHYS, V73, P1986, DOI 10.1063/1.440288; TIRADO MM, 1984, J CHEM PHYS, V81, P2047, DOI 10.1063/1.447827; VENABLE RM, 1988, BIOPOLYMERS, V27, P1001, DOI 10.1002/bip.360270609; VOORDOUW G, 1978, BIOPHYS CHEM, V8, P71; WANG L, IN PRESS MACROMOLECU; WEBSTER OW, 1991, SCIENCE, V251, P887, DOI 10.1126/science.251.4996.887; WIDOM J, 1983, BIOPOLYMERS, V22, P1595, DOI 10.1002/bip.360220612; WIDOM J, 1983, BIOPOLYMERS, V22, P1621, DOI 10.1002/bip.360220613; WILLIAMSON JR, 1989, BIOCHEMISTRY-US, V28, P2819, DOI 10.1021/bi00433a012; YAMAKAWA H, 1976, J CHEM PHYS, V64, P5222, DOI 10.1063/1.432197; Yamakawa H., 1971, MODERN THEORY POLYM; YOSHIZAKI T, 1984, J CHEM PHYS, V81, P982, DOI 10.1063/1.447699; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462	70	64	66	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					893	898		10.1126/science.2000490	http://dx.doi.org/10.1126/science.2000490			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000490				2022-12-01	WOS:A1991EY62900034
J	RAMACHANDRAN, VS				RAMACHANDRAN, VS			FORM, MOTION, AND BINOCULAR-RIVALRY	SCIENCE			English	Article									UNIV CALIF SAN DIEGO,NEUROSCI PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego	RAMACHANDRAN, VS (corresponding author), UNIV CALIF SAN DIEGO,DEPT PSYCHOL,LA JOLLA,CA 92093, USA.							BARINAGA M, 1990, SCIENCE, V249, P856, DOI 10.1126/science.2392677; BLAKE R, 1974, NATURE, V249, P488, DOI 10.1038/249488a0; Crick F., 1990, Seminars in the Neurosciences, V2, P263; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; Kaufman L., 1974, SIGHT MIND, DOI [10.1097/00006324-197411000, DOI 10.1097/00006324-197411000]; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MYERSON J, 1981, BEHAV ANAL LETT, V1, P149; RAMACHANDRAN VS, 1973, NATURE, V242, P412, DOI 10.1038/242412a0; RAMACHANDRAN VS, IN PRESS ARTFUL BRAI; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; TREISMAN A, 1962, Q J EXP PSYCHOL, V14, P23, DOI 10.1080/17470216208416507; VONHELMHOLTZ H, 1925, PHYSL OPTICS	13	10	10	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					950	951		10.1126/science.2000497	http://dx.doi.org/10.1126/science.2000497			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000497				2022-12-01	WOS:A1991EY62900049
J	SAWAGUCHI, T; GOLDMANRAKIC, PS				SAWAGUCHI, T; GOLDMANRAKIC, PS			D1 DOPAMINE-RECEPTORS IN PREFRONTAL CORTEX - INVOLVEMENT IN WORKING MEMORY	SCIENCE			English	Article							CEREBRAL-CORTEX; TYROSINE-HYDROXYLASE; HUMAN-BRAIN; AUTORADIOGRAPHIC DISTRIBUTION; H-3 RACLOPRIDE; RHESUS-MONKEY; D-2 RECEPTORS; SCH 23390; INNERVATION; BINDING	The prefrontal cortex is involved in the cognitive process of working memory. Local injections of SCH23390 and SCH39166, selective antagonists of the D1 dopamine receptor, into the prefrontal cortex of rhesus monkeys induced errors and increased latency in performance on an oculomotor task that required memory-guided saccades. The deficit was dose-dependent and sensitive to the duration of the delay period. These D1 antagonists had no effect on performance in a control task requiring visually guided saccades, indicating that sensory and motor functions were unaltered. Thus, D1 dopamine receptors play a selective role in the mnemonic, predictive functions of the primate prefrontal cortex.			SAWAGUCHI, T (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038546, R37MH038546, P50MH044866] Funding Source: NIH RePORTER; NIMH NIH HHS [MH38546, MH44866] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERGER B, 1989, Society for Neuroscience Abstracts, V15, P428; BERGER B, 1988, J COMP NEUROL, V273, P99, DOI 10.1002/cne.902730109; BISCHOFF S, 1986, EUR J PHARMACOL, V129, P367, DOI 10.1016/0014-2999(86)90449-8; BROWN RM, 1979, BRAIN RES, V168, P133, DOI 10.1016/0006-8993(79)90132-X; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; CAMPS M, 1989, NEUROSCIENCE, V28, P275, DOI 10.1016/0306-4522(89)90179-6; CHIPKIN RE, 1988, J PHARMACOL EXP THER, V247, P1093; CORTES R, 1989, NEUROSCIENCE, V28, P263, DOI 10.1016/0306-4522(89)90178-4; FARDE L, 1988, PSYCHOPHARMACOLOGY, V94, P471, DOI 10.1007/BF00212840; FARDE L, 1987, PSYCHOPHARMACOLOGY, V92, P278, DOI 10.1007/BF00210831; FUNAHASHI S, 1986, Society for Neuroscience Abstracts, V12, P554; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; GASPAR P, 1989, J COMP NEUROL, V279, P249, DOI 10.1002/cne.902790208; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1990, J NEUROSCI, V10, P2125; HALL H, 1988, J NEURAL TRANSM, V73, P7, DOI 10.1007/BF01244618; KEBABIAN JW, 1986, TRENDS PHARMACOL SCI, V7, P96, DOI 10.1016/0165-6147(86)90272-5; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOHLER C, 1985, BIOCHEM PHARMACOL, V34, P2251, DOI 10.1016/0006-2952(85)90778-6; LEVITT P, 1984, J COMP NEUROL, V225, P1; LEWIS DA, 1988, BRAIN RES, V449, P225, DOI 10.1016/0006-8993(88)91040-2; LEWIS DA, 1987, J NEUROSCI, V7, P279; LIDOW MS, 1989, P NATL ACAD SCI USA, V86, P6412, DOI 10.1073/pnas.86.16.6412; MEMO M, 1986, J NEURAL TRANSM-SUPP, V22, P19; MYERS RD, 1966, PHYSIOL BEHAV, V1, P171, DOI 10.1016/0031-9384(66)90064-3; RICHFIELD EK, 1989, J COMP NEUROL, V286, P409, DOI 10.1002/cne.902860402; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1385, DOI 10.1152/jn.1990.63.6.1385; SAWAGUCHI T, 1988, NEUROSCI RES, V5, P465, DOI 10.1016/0168-0102(88)90030-2	28	1065	1080	5	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					947	950		10.1126/science.1825731	http://dx.doi.org/10.1126/science.1825731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	1825731				2022-12-01	WOS:A1991EY62900048
J	SORIANO, P; MONTGOMERY, C; GESKE, R; BRADLEY, A				SORIANO, P; MONTGOMERY, C; GESKE, R; BRADLEY, A			TARGETED DISRUPTION OF THE C-SRC PROTOONCOGENE LEADS TO OSTEOPETROSIS IN MICE	CELL			English	Article							AVIAN-SARCOMA VIRUSES; DEVELOPING RAT-BRAIN; GENE-PRODUCT; STEM-CELLS; HOMOLOGOUS RECOMBINATION; NUCLEOTIDE-SEQUENCE; TYROSINE KINASE; SPLEEN-CELLS; PP60C-SRC; EXPRESSION	To understand the normal, physiological role of the c-src proto-oncogene, a null mutation was introduced into the gene by homologous recombination in mouse embryonic stem cells. Two independent targeted clones were used to generate chimeras that transmitted the mutated allele to their offspring. Intercrossing of heterozygotes gave rise to live born homozygotes, but most of these mice died within the first few weeks of birth. Histological and hematological examination of the homozygous mutants did not reveal detectable abnormalities in the brain or platelets, where src is most highly expressed. However, these mutants were deficient in bone remodeling, indicating impaired osteoclast function, and developed osteopetrosis. These results demonstrate that src is not required for general cell viability (possibly because of functional overlap with other tyrosine kinases related to src) and uncover an essential role for src in bone formation.	BAYLOR UNIV, INST MOLEC GENET, HOUSTON, TX 77030 USA; BAYLOR UNIV, CTR COMPARAT MED, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor University; Baylor University	SORIANO, P (corresponding author), BAYLOR UNIV, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Bradley, Allan/0000-0002-2349-8839	NICHD NIH HHS [HD25326, HD24875] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875, R37HD025326, R01HD025326] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAIR GM, 1989, P NATL ACAD SCI USA, V86, P4574, DOI 10.1073/pnas.86.12.4574; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ANDERSSON GN, 1989, J HISTOCHEM CYTOCHEM, V37, P115, DOI 10.1177/37.1.2461980; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOLDEN A, 1988, ONCOGENE HDB, V7; Green MC., 1989, GENETIC VARIANTS STR, P12; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JONES KL, 1988, SMITHS RECOGNIZABLE, P353; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Luna L.G., 1968, MANUAL HISTOLOGIC ST, Vthird; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WALKER DG, 1975, SCIENCE, V190, P785, DOI 10.1126/science.1198094; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	51	1852	1923	1	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					693	702		10.1016/0092-8674(91)90499-O	http://dx.doi.org/10.1016/0092-8674(91)90499-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997203				2022-12-01	WOS:A1991EZ47800005
J	WEISS, S; BOGEN, B				WEISS, S; BOGEN, B			MHC CLASS-II-RESTRICTED PRESENTATION OF INTRACELLULAR ANTIGEN	CELL			English	Article							TOXIC LYMPHOCYTES-T; B-LYMPHOMA CELLS; SOLUBLE-PROTEIN; LIGHT-CHAINS; INFLUENZA HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; PRESENTING CELLS; IMMUNOGLOBULIN; RECOGNITION; SEQUENCE	An endogenously produced immunoglobulin light chain (lambda-2(315)) is processed and presented to T cells in association with major histocompatibility complex (MHC) class II molecules. Using transfectants producing variant forms of lambda-2(315) that are neither expressed on the cell surface nor secreted, we demonstrate that intracellular lambda-2(315), which has never been exported outside of the cell, is the source of processed lambda-2(315) idiotype. This challenges the currently accepted paradigm that endogenous antigens are only presented by MHC class I molecules. Variants of lambda-2(315) protein that are retained in the endoplasmic recticulum (ER) are also presented. Variants that are expressed in the cytosol as well as those that are transported into the nucleus rather than the ER are not presented. Thus, the ER is likely to be the processing compartment.	INST IMMUNOL & RHEUMATOL,N-0172 OSLO,NORWAY		WEISS, S (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.							BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BARNABA V, 1990, NATURE, V345, P258, DOI 10.1038/345258a0; BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; BIKOFF EK, 1989, EUR J IMMUNOL, V19, P1903, DOI 10.1002/eji.1830191022; BOGEN B, 1989, EMBO J, V8, P1947, DOI 10.1002/j.1460-2075.1989.tb03599.x; BOGEN B, 1990, EUR J IMMUNOL, V20, P2359, DOI 10.1002/eji.1830201030; BOGEN B, 1986, EUR J IMMUNOL, V16, P1373, DOI 10.1002/eji.1830161110; BOGEN B, 1989, SCAND J IMMUNOL, V29, P273, DOI 10.1111/j.1365-3083.1989.tb01125.x; BOGEN B, 1986, EUR J IMMUNOL, V16, P1379, DOI 10.1002/eji.1830161111; BOGEN B, 1983, EUR J IMMUNOL, V13, P353, DOI 10.1002/eji.1830130502; BOGEN B, 1984, THESIS U TROMSO TROM; BOGEN B, 1988, HISTOPHYSIOLOGY IMMU, P877; BOTHWELL ALM, 1982, NATURE, V298, P380, DOI 10.1038/298380a0; BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; BROWNING MJ, 1990, J IMMUNOL, V145, P985; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DICK T, 1989, P NATL ACAD SCI USA, V86, P2316, DOI 10.1073/pnas.86.7.2316; DONERMEYER DL, 1989, J IMMUNOL, V142, P1063; EAGER KB, 1989, J IMMUNOL, V143, P2328; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEE P, 1988, J IMMUNOL, V140, P1063; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROCHE PA, 1990, NATURE, V345, P618; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAERZ UD, 1987, NATURE, V329, P449, DOI 10.1038/329449a0; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; THOMAS DB, 1990, J IMMUNOL, V144, P2789; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WEISS S, 1984, EUR J IMMUNOL, V14, P744, DOI 10.1002/eji.1830140814; WEISS S, 1989, P NATL ACAD SCI USA, V86, P282, DOI 10.1073/pnas.86.1.282; WINBERRY L, 1980, J IMMUNOL, V124, P1174; WINCHESTER G, 1984, IMMUNOGENETICS, V19, P487, DOI 10.1007/BF00403439; WU GE, 1982, NUCLEIC ACIDS RES, V10, P3831, DOI 10.1093/nar/10.13.3831; WU GE, 1983, CELL, V33, P77, DOI 10.1016/0092-8674(83)90336-7; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YURIN VL, 1989, EUR J IMMUNOL, V79, P1685	62	273	278	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					767	776		10.1016/0092-8674(91)90506-T	http://dx.doi.org/10.1016/0092-8674(91)90506-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1847667				2022-12-01	WOS:A1991EZ47800012
J	YAYON, A; KLAGSBRUN, M; ESKO, JD; LEDER, P; ORNITZ, DM				YAYON, A; KLAGSBRUN, M; ESKO, JD; LEDER, P; ORNITZ, DM			CELL-SURFACE, HEPARIN-LIKE MOLECULES ARE REQUIRED FOR BINDING OF BASIC FIBROBLAST GROWTH-FACTOR TO ITS HIGH-AFFINITY RECEPTOR	CELL			English	Article							CAPILLARY ENDOTHELIAL-CELLS; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; PLASMINOGEN-ACTIVATOR PRODUCTION; PROTEIN-TYROSINE KINASE; SULFATE; PROTEOGLYCAN; GLYCOSAMINOGLYCANS; PURIFICATION; STIMULATION; METABOLISM	The role of low affinity, heparin-like binding sites for basic fibroblast growth factor (bFGF) was investigated in CHO cells mutant in their metabolism of glycosaminoglycans. Heparan sulfate-deficient mutants transfected to express a cloned mouse FGF receptor cDNA are not able to bind bFGF. It is demonstrated that free heparin and heparan sulfate can reconstitute a low affinity receptor that is, in turn, required for the high affinity binding of bFGF. These studies suggest that the low affinity receptor is an accessory molecule required for binding of bFGF to the high affinity site. Such an obligatory interaction of low and high affinity FGF receptors suggests a physiological role for heparin-like, low affinity receptors and constitutes a novel mechanism for the regulation of growth factor-receptor interactions.	HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	YAYON, A (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.			Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [R01CA037329, P01CA045548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37329, CA 45548] Funding Source: Medline; NIGMS NIH HHS [GM 33063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZIZKHAN RG, 1980, J EXP MED, V152, P931, DOI 10.1084/jem.152.4.931; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; IMAMURA T, 1987, EXP CELL RES, V172, P92, DOI 10.1016/0014-4827(87)90096-6; KANER RJ, 1990, SCIENCE, V248, P1410, DOI 10.1126/science.2162560; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KINOSHITA S, 1979, EXP CELL RES, V123, P229, DOI 10.1016/0014-4827(79)90463-4; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LATERRA J, 1980, P NATL ACAD SCI-BIOL, V77, P6662, DOI 10.1073/pnas.77.11.6662; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MUELLER SN, 1989, J CELL PHYSIOL, V140, P439, DOI 10.1002/jcp.1041400306; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; NADER HB, 1984, J BIOL CHEM, V259, P1431; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PRESTA M, 1989, CANCER RES, V48, P68; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1990, CANCER METAST REV, V9, P191, DOI 10.1007/BF00046360	47	2303	2379	3	130	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					841	848		10.1016/0092-8674(91)90512-W	http://dx.doi.org/10.1016/0092-8674(91)90512-W			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1847668				2022-12-01	WOS:A1991EZ47800018
J	YELLEN, G; JURMAN, ME; ABRAMSON, T; MACKINNON, R				YELLEN, G; JURMAN, ME; ABRAMSON, T; MACKINNON, R			MUTATIONS AFFECTING INTERNAL TEA BLOCKADE IDENTIFY THE PROBABLE PORE-FORMING REGION OF A K+ CHANNEL	SCIENCE			English	Article							POTASSIUM CHANNELS; GIANT-AXONS; FLUX RATIO; IONS; CHARYBDOTOXIN; DROSOPHILA	The active site of voltage-activated potassium channels is a transmembrane aqueous pore that permits ions to permeate the cell membrane in a rapid yet highly selective manner. A useful probe for the pore of potassium-selective channels is the organic ion tetraethylammonium (TEA), which binds with millimolar affinity to the intracellular opening of the pore and blocks potassium current. In the potassium channel encoded by the Drosophila Shaker gene, an amino acid residue that specifically affects the affinity for intracellular TEA has now been identified by site-directed mutagenesis. This residue is in the middle of a conserved stretch of 18 amino acids that separates two locations that are both near the external opening of the pore. These findings suggest that this conserved region is intimately involved in the formation of the ion conduction pore of voltage-activated potassium channels. Further, a stretch of only eight amino acid residues must traverse 80 percent of the transmembrane electric potential difference.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS CHEM,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Harvard Medical School	YELLEN, G (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.			Yellen, Gary/0000-0003-4228-7866	NIGMS NIH HHS [GM4399] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1972, J GEN PHYSIOL, V59, P388, DOI 10.1085/jgp.59.4.388; BEGENISICH T, 1980, J GEN PHYSIOL, V76, P83, DOI 10.1085/jgp.76.1.83; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; FRENCH RJ, 1981, BIOPHYS J, V34, P271, DOI 10.1016/S0006-3495(81)84849-7; GUY HR, 1989, MONOVALENT CATIONS B; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; HOROWICZ P, 1968, J GEN PHYSIOL, V51, pS193; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KOPPENHOFER E, 1969, PFLUG ARCH EUR J PHY, V313, P361, DOI 10.1007/BF00593959; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MACKINNON R, IN PRESS NATURE; MACKINNON RN, UNPUB; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SPALDING BC, 1981, AM J PHYSIOL, V241, pC68, DOI 10.1152/ajpcell.1981.241.1.C68; STANFIELD PR, 1983, REV PHYSIOL BIOCH P, V97, P1, DOI 10.1007/BFb0035345; STRYER L, 1988, BIOCHEMISTRY; TASAKI I, 1957, J GEN PHYSIOL, V40, P859, DOI 10.1085/jgp.40.6.859; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; VILLARROEL A, 1988, PFLUG ARCH EUR J PHY, V413, P118, DOI 10.1007/BF00582521; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YELLEN G, 1987, ANNU REV BIOPHYS BIO, V16, P227	32	562	569	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					939	942		10.1126/science.2000494	http://dx.doi.org/10.1126/science.2000494			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000494				2022-12-01	WOS:A1991EY62900045
J	ADAMS, SR; HAROOTUNIAN, AT; BUECHLER, YJ; TAYLOR, SS; TSIEN, RY				ADAMS, SR; HAROOTUNIAN, AT; BUECHLER, YJ; TAYLOR, SS; TSIEN, RY			FLUORESCENCE RATIO IMAGING OF CYCLIC-AMP IN SINGLE CELLS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; RESONANCE ENERGY-TRANSFER; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; TRANSFER MICROSCOPY; SKELETAL-MUSCLE; EXPRESSION; COMPARTMENTS; RECEPTOR; PROBES	FLUORESCENCE imaging is perhaps the most powerful technique currently available for continuously observing the dynamic intracellular biochemistry of single living cells 1. However, fluorescent indicator dyes have been available only for simple inorganic ions such as Ca2+, H+, Na+, K+, Mg2+ and Cl-. We now report a fluorescent indicator for the adenosine 3',5'-cyclic monophosphate (cAMP) signalling pathway. The sensor consists of cAMP-dependent protein kinase 2 in which the catalytic (C) and regulatory (R) subunits are each labelled with a different fluorescent dye such as fluorescein or rhodamine capable of fluorescence resonance energy transfer in the holoenzyme complex R2C2. When cAMP molecules bind to the R subunits, the C subunits dissociate, thereby eliminating energy transfer. The change in shape of the fluorescence emission spectrum allows cAMP concentrations and the activation of the kinase to be nondestructively visualized in single living cells microinjected with the labelled holoenzyme.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST M-047, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT CHEM M-054, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego								BEAVO JA, 1974, P NATL ACAD SCI USA, V71, P3580, DOI 10.1073/pnas.71.9.3580; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BRIGHT GR, 1989, METHOD CELL BIOL, V30, P157; BUCHLER W, 1990, EUR J BIOCHEM, V188, P253, DOI 10.1111/j.1432-1033.1990.tb15397.x; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; HAUGLAND RP, 1989, HDB FLUORESCENT PROB, P32; HAYES JS, 1982, J CYCLIC NUCL PROT, V8, P1; HERMAN B, 1989, METHOD CELL BIOL, V30, P219; HUGHES RJ, 1982, MOL PHARMACOL, V22, P258; JOHNSON DA, 1984, J BIOL CHEM, V259, P5717; JOVIN TM, 1989, ANNU REV BIOPHYS BIO, V18, P271, DOI 10.1146/annurev.bb.18.060189.001415; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MURRAY KJ, 1989, MOL CELL BIOCHEM, V89, P175; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SLICE LW, 1989, J BIOL CHEM, V264, P20940; TAYLOR SS, 1978, J BIOL CHEM, V253, P2284; TAYLOR SS, 1990, REV BIOCH, V59, P971; TERASAKI WL, 1977, J BIOL CHEM, V252, P1041; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; USTER PS, 1986, J CELL BIOL, V103, P1221, DOI 10.1083/jcb.103.4.1221; WILLIAMS DA, 1990, CELL CALCIUM, V11, P55, DOI 10.1016/0143-4160(90)90058-3; WU FYH, 1974, BIOCHEMISTRY-US, V13, P2567, DOI 10.1021/bi00709a015; YAMASHITA T, 1986, J BIOL CHEM, V261, P6878	30	549	580	1	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					694	697		10.1038/349694a0	http://dx.doi.org/10.1038/349694a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1847505				2022-12-01	WOS:A1991EY62700047
J	FELLER, DC; DELACRUZ, VF				FELLER, DC; DELACRUZ, VF			IDENTIFYING ANTIGENIC T-CELL SITES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; RECOGNITION; PREDICTION; SEQUENCE				FELLER, DC (corresponding author), MEDLMMUNE INC, 19 FIRSTFIELD RD, GAITHERSBURG, MD 20878 USA.							BERZOFSKY JA, 1988, J CLIN INVEST, V82, P1811, DOI 10.1172/JCI113796; BERZOFSKY JA, 1987, IMMUNOL REV, V98, P9, DOI 10.1111/j.1600-065X.1987.tb00518.x; CORNETTE JL, 1989, METHOD ENZYMOL, V178, P611; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; GREY HM, 1985, IMMUNOL TODAY, V6, P101, DOI 10.1016/0167-5699(85)90025-8; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MATIS LA, 1990, ANNU REV IMMUNOL, V8, P65; REYES VE, 1989, J BIOL CHEM, V264, P12854; REYES VE, 1990, MOL IMMUNOL, V27, P1021, DOI 10.1016/0161-5890(90)90125-J; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTHBARD JB, IN PRESS ANN REV IMM; SCHWARTZ AL, 1990, ANNU REV IMMUNOL, V8, P195, DOI 10.1146/annurev.immunol.8.1.195; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296; SPOUGE JL, 1987, J IMMUNOL, V138, P204; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143	17	68	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					720	721		10.1038/349720a0	http://dx.doi.org/10.1038/349720a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1705016				2022-12-01	WOS:A1991EY62700056
J	GOATE, A; CHARTIERHARLIN, MC; MULLAN, M; BROWN, J; CRAWFORD, F; FIDANI, L; GIUFFRA, L; HAYNES, A; IRVING, N; JAMES, L; MANT, R; NEWTON, P; ROOKE, K; ROQUES, P; TALBOT, C; PERICAKVANCE, M; ROSES, A; WILLIAMSON, R; ROSSOR, M; OWEN, M; HARDY, J				GOATE, A; CHARTIERHARLIN, MC; MULLAN, M; BROWN, J; CRAWFORD, F; FIDANI, L; GIUFFRA, L; HAYNES, A; IRVING, N; JAMES, L; MANT, R; NEWTON, P; ROOKE, K; ROQUES, P; TALBOT, C; PERICAKVANCE, M; ROSES, A; WILLIAMSON, R; ROSSOR, M; OWEN, M; HARDY, J			SEGREGATION OF A MISSENSE MUTATION IN THE AMYLOID PRECURSOR PROTEIN GENE WITH FAMILIAL ALZHEIMERS-DISEASE	NATURE			English	Article							SECONDARY STRUCTURE; LINKAGE; CHROMOSOME-21; CDNA; PREDICTION; MARKERS; DEFECT; LOCUS; DNA	A LOCUS segregating with familial Alzheimer's disease (AD) has been mapped to chromosome 21 (ref. 1), close to the amyloid precursor protein (APP) gene 2-5. Recombinants between the APP gene and the AD locus have been reported 6-8 which seemed to exclude it as the site of the mutation causing familial AD. But recent genetic analysis of a large number of AD families has demonstrated that the disease is heterogeneous 9. Families with late-onset AD do not show linkage to chromosome 21 markers 9,10. Some families with early-onset AD show linkage to chromosome 21 markers, but some do not 8,9,11. This has led to the suggestion that there is non-allelic genetic heterogeneity even within early onset familial AD 8,9. To avoid problems that heterogeneity poses for genetic analysis, we have examined the cosegregation of AD and markers along the long arm of chromosome 21 in a single family with AD confirmed by autopsy. Here we demonstrate that in this kindred, which shows linkage to chromosome 21 markers, there is a point mutation in the APP gene. This mutation causes an amino-acid substitution (Val --> Ile) close to the carboxy terminus of the beta-amyloid peptide. Screening other cases of familial AD revealed a second unrelated family in which this variant occurs. This suggests that some cases of AD could be caused by mutations in the APP gene.	ST MARYS HOSP, SCH MED, DEPT BIOCHEM, ALZHEIMERS DIS RES GRP, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, SCH MED, DEPT NEUROL, LONDON W2 1PG, ENGLAND; YALE UNIV, SCH MED, DEPT HUMAN GENET, NEW HAVEN, CT 06510 USA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; UNIV COLL CARDIFF, DEPT PSYCHOL MED, CARDIFF CF4 4XN, S GLAM, WALES; UNIV COLL CARDIFF, DEPT MED GENET, CARDIFF CF4 4XN, S GLAM, WALES	Imperial College London; Imperial College London; Yale University; Duke University; Cardiff University; Cardiff University			Rossor, Martin/C-1598-2008; Hardy, John/C-2451-2009; Chartier-Harlin, Marie-Christine/L-4527-2018	Hardy, John/0000-0002-3122-0423; Chartier-Harlin, Marie-Christine/0000-0001-6416-6526; Goate, Alison/0000-0002-0576-2472; Rossor, Martin/0000-0001-8215-3120; Mullan, Michael/0000-0002-1473-7527	NIA NIH HHS [AG-05128] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARGOS P, 1982, EUR J BIOCHEM, V128, P565; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE AM, 1989, LANCET, V1, P352; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GUO Z, 1990, NUCLEIC ACIDS RES, V18, P4967, DOI 10.1093/nar/18.16.4967-a; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LEWIS JG, 1990, GENOMICS, V8, P400, DOI 10.1016/0888-7543(90)90300-J; LIM VI, 1974, J MOL BIOL, V88, P857, DOI 10.1016/0022-2836(74)90404-5; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; TANZI R E, 1988, Genomics, V3, P129, DOI 10.1016/0888-7543(88)90143-7; TANZI RE, 1987, NATURE, V329, P156, DOI 10.1038/329156a0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; VAN BROECKHOVEN C, 1987, NATURE, V329, P153; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; WARREN AC, 1989, GENOMICS, V4, P579, DOI 10.1016/0888-7543(89)90282-6; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N; [No title captured]	30	3705	3890	4	498	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					704	706		10.1038/349704a0	http://dx.doi.org/10.1038/349704a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1671712				2022-12-01	WOS:A1991EY62700050
J	GUO, XD; JOHNSON, JJ; KRAMER, JM				GUO, XD; JOHNSON, JJ; KRAMER, JM			EMBRYONIC LETHALITY CAUSED BY MUTATIONS IN BASEMENT-MEMBRANE COLLAGEN OF C-ELEGANS	NATURE			English	Article							CAENORHABDITIS-ELEGANS; IV COLLAGEN; DNA; SEQUENCE; REGION; DOMAIN; GENES; CHAIN	BASEMENT membranes are specialized forms of extracellular matrix with important functions in development 1-3. A major structural component of basement membranes is type IV collagen, a heterotrimer of two alpha-1(IV) and one alpha-2(IV) chains, which forms a complex, polygonal network associated with other basement membrane components 4,5. Here we report that the alpha-1(IV) collagen chain of Caenorhabditis elegans is encoded by the genetic locus emb-9. Mutations in emb-9 cause temperature-sensitive lethality during late embryogenesis. We have identified single nucleotide alterations that substitute glutamic acid for glycine in the triple-helical Gly-X-Y repeat region of the alpha-1(IV) collagen in three emb-9 mutant strains. These results are direct evidence that defects in basement membranes can disrupt embryonic development and form a basis for the genetic analysis of basement membrane function.	UNIV ILLINOIS,DEPT BIOL SCI,MOLEC BIOL LAB,POB 4348,CHICAGO,IL 60680	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; Bernfield M., 1984, ROLE EXTRACELLULAR M, P545; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BONADIO J, 1985, NATURE, V316, P363, DOI 10.1038/316363a0; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; CASADA R, 1981, DEV BIOL, V84, P193; CHEAH KSE, 1985, BIOCHEM J, V229, P287, DOI 10.1042/bj2290287; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GLANVILLE RW, 1985, EUR J BIOCHEM, V152, P213, DOI 10.1111/j.1432-1033.1985.tb09186.x; GREENWALD I, 1987, NUCLEIC ACIDS RES, V15, P2295, DOI 10.1093/nar/15.5.2295; GUO XD, 1989, J BIOL CHEM, V264, P17574; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; ISNENGHI E, 1983, DEV BIOL, V98, P465, DOI 10.1016/0012-1606(83)90376-7; KRAMER JM, 1988, CELL, V55, P555, DOI 10.1016/0092-8674(88)90214-0; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cb.03.110187.000421; MIWA J, 1980, DEV BIOL, V76, P160, DOI 10.1016/0012-1606(80)90369-3; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; PIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SOININEN R, 1987, FEBS LETT, V225, P188; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559	27	90	95	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					707	709		10.1038/349707a0	http://dx.doi.org/10.1038/349707a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1996137				2022-12-01	WOS:A1991EY62700051
J	GURURAJAN, R; PERRYOKEEFE, H; MELTON, DA; WEEKS, DL				GURURAJAN, R; PERRYOKEEFE, H; MELTON, DA; WEEKS, DL			THE XENOPUS LOCALIZED MESSENGER-RNA AN3 MAY ENCODE AN ATP-DEPENDENT RNA HELICASE	NATURE			English	Article							UNWINDING ACTIVITY; FACTOR EIF-4A; PROTEIN; CLONING; EGGS; GENES; VASA	THE maternal messenger RNA An3 was originally identified localized to the animal hemisphere of Xenopus laevis oocytes, eggs and early embryos 1,2. Xenopus embryos depend on mRNA and protein present in the egg before fertilization (maternal molecules) to provide the information needed for early development. Localization of maternal mRNA gives cells derived from different regions of the egg distinctive capacities for protein synthesis. We show here that An3 mRNA encodes a protein with 74% identity to a protein encoded by the testes-specific mRNA PL10 found in mouse 3, which is proposed to have RNA helicase activity. Because the gene encoding An3 mRNA is reactivated after gastrulation and remains active throughout embryogenesis 1,2, we have examined its distribution in embryonic and adult tissues. Unlike PL10 mRNA, which is primarily restricted to the testes, An3 mRNA is broadly distributed in later development.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	University of Iowa; Harvard University			Weeks, Daniel/F-6216-2010; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Weeks, Daniel/0000-0002-4977-2410				BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOER D, 1990, NUCLEIC ACIDS RES, V18, P5489; DUMONT JN, 1972, J MORPHOL, V136, P155; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413; KREIG PA, 1989, DEV BIOL, V133, P93; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; PERRYOKEEFE H, 1990, IN SITU HYBRIDISATIO, P115; RAY BK, 1985, J BIOL CHEM, V260, P7651; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RICHTER JD, 1984, J MOL BIOL, V173, P227, DOI 10.1016/0022-2836(84)90191-8; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WEEKS DL, 1985, COLD SPRING HARB SYM, V50, P21, DOI 10.1101/SQB.1985.050.01.005	25	78	81	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					717	719		10.1038/349717a0	http://dx.doi.org/10.1038/349717a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1996140				2022-12-01	WOS:A1991EY62700055
J	HAN, HQ; NICHOLS, RA; RUBIN, MR; BAHLER, M; GREENGARD, P				HAN, HQ; NICHOLS, RA; RUBIN, MR; BAHLER, M; GREENGARD, P			INDUCTION OF FORMATION OF PRESYNAPTIC TERMINALS IN NEUROBLASTOMA-CELLS BY SYNAPSIN-IIB	NATURE			English	Article							GLIOMA HYBRID-CELLS; PHOSPHOPROTEIN; PROTEIN-1	THE synapsins are a family of closely related phosphoproteins (termed synapsins Ia, Ib, IIa and IIb) associated with synaptic vesicles and implicated in the short-term regulation of neurotransmitter release from nerve endings 1-5. During development, expression of the synapsins correlates temporally with synapse formation 6, but there has been no direct evidence that they are involved in synaptogenesis. Here we report that overexpression of synapsin IIb in the neuroblastoma x glioma hybrid clonal cell line NG108-15 leads, during cell differentiation, to marked increases in the number of neuritic varicosities and in the numbers of small clear vesicles and large dense core vesicles per varicosity, as well as to the appearance of synapse-like cell-cell contacts. Thus, synapsin IIb may be involved in the regulation of synapse formation and, as a result, in long-term neuronal signalling.			HAN, HQ (corresponding author), ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.							BAHLER M, 1990, BIOESSAYS, V12, P259, DOI 10.1002/bies.950120603; CHANDLER CE, 1985, J CELL PHYSIOL, V125, P367, DOI 10.1002/jcp.1041250303; CZERNIK AJ, IN PRESS METH ENZYM; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; FURUYA S, 1983, TISSUE CELL, V15, P903, DOI 10.1016/0040-8166(83)90057-5; GRAY DB, 1990, J NEUROSCI, V10, P2687; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NELSON P, 1976, P NATL ACAD SCI USA, V73, P123, DOI 10.1073/pnas.73.1.123; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; NESTLER EJ, 1982, SCIENCE, V217, P357, DOI 10.1126/science.6124039; NESTLER EJ, 1981, SCIENCE, V212, P1162, DOI 10.1126/science.6785886; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; ROMANO C, 1987, J NEUROSCI, V7, P1294; SAMBROOCK J, 1989, MOL CLONING LABORATO; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642	20	163	167	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					697	700		10.1038/349697a0	http://dx.doi.org/10.1038/349697a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1899916				2022-12-01	WOS:A1991EY62700048
J	JAMIESON, DJ; RAHE, B; PRINGLE, J; BEGGS, JD				JAMIESON, DJ; RAHE, B; PRINGLE, J; BEGGS, JD			A SUPPRESSOR OF A YEAST SPLICING MUTATION (PRP8-1) ENCODES A PUTATIVE ATP-DEPENDENT RNA HELICASE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; GENE REGION; PROTEIN; TRANSFORMATION	FIVE small nuclear RNAs (snRNAs) are required for nuclear pre-messenger RNA splicing: U1, U2, U4, U5 and U6 1,2. The yeast U1 and U2 snRNAs base-pair to the 5' splice site and branch-point sequences of introns respectively 1. The role of the U5 and U4/U6 small nuclear ribonucleoprotein particles (snRNPs) is splicing is not clear, through a catalytic role for the U6 snRNA has be proposed 3. Less is known about yeast splicing factors, but the availability of genetic techniques in Saccharomyces cerevisiae has led to the identification of mutants deficient in nuclear pre-mRNA splicing (prp2-prp27)4,5. Several PRP genes have now been cloned and their protein products characterized. The PRP8 protein is a component of the U5 snRNP and associates with the U4/U6 snRNAs/snRNP to form a multi-snRNP particle believed to be important for spliceosome assembly 6. We have isolated extragenic suppressors of the prp8-1 mutation of S. cerevisiae and present here the preliminary characterization of one of these suppressors, spp81. The predicted amino-acid sequence of the SPP81 protein shows extensive similarity to a recently identified family of proteins thought to possess ATP-dependent RNA helicase activity. The possible role of this putative helicase in nuclear pre-mRNA splicing is discussed.	UNIV MICHIGAN,PROGRAM CELLULAR & MOLEC BIOL,ANN ARBOR,MI 48103; UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48103	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	JAMIESON, DJ (corresponding author), UNIV EDINBURGH,INST CELL & MOLEC BIOL,KINGS BLDG,MAYFIELD RD,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND.		Beggs, Jean/H-4861-2011; , jbeggs/N-9551-2019	Beggs, Jean/0000-0002-8179-6519; 				BELTZER JP, 1986, J BIOL CHEM, V261, P5160; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HIRLING H, 1989, NATURE, V339, P56; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; JAMIESON DJ, IN PRESS MOL MICROBI; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; PEARSON NJ, 1982, MOL CELL BIOL, V2, P571, DOI 10.1128/MCB.2.5.571; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; Sherman F., 1982, METHODS YEAST GENETI; SILICIANO PG, 1987, CELL, V50, P585, DOI 10.1016/0092-8674(87)90031-6; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; STRUHL K, 1980, J MOL BIOL, V136, P309, DOI 10.1016/0022-2836(80)90376-9; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206	30	100	101	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					715	717		10.1038/349715a0	http://dx.doi.org/10.1038/349715a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1996139	Green Published			2022-12-01	WOS:A1991EY62700054
J	PETERS, PJ; NEEFJES, JJ; OORSCHOT, V; PLOEGH, HL; GEUZE, HJ				PETERS, PJ; NEEFJES, JJ; OORSCHOT, V; PLOEGH, HL; GEUZE, HJ			SEGREGATION OF MHC CLASS-II MOLECULES FROM MHC CLASS-I MOLECULES IN THE GOLGI-COMPLEX FOR TRANSPORT TO LYSOSOMAL COMPARTMENTS	NATURE			English	Article							MANNOSE 6-PHOSPHATE; RECEPTORS; ANTIGEN; CHAINS; CELLS; PATHWAYS; ASIALOGLYCOPROTEIN; BIOSYNTHESIS; HEPATOCYTES; ENDOCYTOSIS	Traffic of MHC molecules dictates the source of peptides that are presented to T cells. The intracellular distribution of MHC class I and class II molecules reflects the dichotomy in presentation of antigen from endogenous and exogenous origin, respectively. In human B lymphoblastoid cells, class I molecules are present in compartments constituting the biosynthetic pathway, whereas class II molecules enter structures related to lysosomes during their biosynthesis.	NETHERLANDS CANC INST, DEPT CELLULAR BIOCHEM, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute	PETERS, PJ (corresponding author), STATE UNIV UTRECHT, SCH MED, CELL BIOL LAB, HEIDELBERGLAAN 100, 3584 CX UTRECHT, NETHERLANDS.		Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211				ACTON SL, 1990, J CELL BIOL, V111, P1419, DOI 10.1083/jcb.111.4.1419; ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRODSKY FM, 1984, IMMUNOL TODAY, V5, P350, DOI 10.1016/0167-5699(84)90078-1; CHAIN BM, 1988, IMMUNOL REV, V106, P33, DOI 10.1111/j.1600-065X.1988.tb00772.x; CRESSWELL P, 1987, CRIT REV IMMUNOL, V7, P31; DARNELL J, 1990, MOL CELL BIOL, P596; DAVIS JE, 1990, J IMMUNOL, V144, P990; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1984, EMBO J, V3, P2677, DOI 10.1002/j.1460-2075.1984.tb02193.x; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HAMMERLING GJ, 1990, IMMUNOL TODAY, V11, P337; HOPKINS CR, 1986, TRENDS BIOCHEM SCI, V11, P473, DOI 10.1016/0968-0004(86)90250-1; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; KLAUSNER R D, 1989, New Biologist, V1, P3; KOCH N, 1989, TRENDS BIOCHEM SCI, V14, P383, DOI 10.1016/0968-0004(89)90013-3; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LONG EO, 1989, IMMUNOL TODAY, V10, P232, DOI 10.1016/0167-5699(89)90259-4; MACHY P, 1990, J IMMUNOL, V145, P1350; METZELAAR MJ, IN PRESS J BIOL CHEM; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NGUYEN QV, 1989, HUM IMMUNOL, V24, P153, DOI 10.1016/0198-8859(89)90056-6; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; OTTEN G, 1989, CURR OPIN IMMUNOL, V2, P204, DOI 10.1016/0952-7915(89)90189-1; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROTH J, 1984, J BIOL CHEM, V93, P350; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWARTZ AL, 1990, ANNU REV IMMUNOL, V8, P195, DOI 10.1146/annurev.immunol.8.1.195; SLOT JW, 1989, AM J ANAT, V185, P271, DOI 10.1002/aja.1001850220; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SLOT JW, IN PRESS J CELL BIOL; STAM NJ, 1986, J IMMUNOL, V137, P2299; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; TASSIN MT, 1990, EUR J CELL BIOL, V52, P219; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	51	628	633	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					669	676		10.1038/349669a0	http://dx.doi.org/10.1038/349669a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1847504				2022-12-01	WOS:A1991EY62700038
J	THORPEBEESTON, JG; NICOLAIDES, KH; FELTON, CV; BUTLER, J; MCGREGOR, AM				THORPEBEESTON, JG; NICOLAIDES, KH; FELTON, CV; BUTLER, J; MCGREGOR, AM			MATURATION OF THE SECRETION OF THYROID-HORMONE AND THYROID-STIMULATING HORMONE IN THE FETUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL; PREGNANCY; NEWBORN	Background. Data on human fetal thyroid function have largely been derived from histologic studies or studies of cord-blood samples obtained at hysterotomy or delivery. These data may not represent true normal values. Cordocentesis (ultrasound-guided blood sampling from the umbilical cord) is a technique that allows investigation of physiologic processes in fetuses not under stress. Methods. We measured serum thyroid-stimulating hormone, total and free thyroxine (T4), total and free triiodothyronine (T3), and thyroxine-binding globulin in blood samples from 62 fetuses. The samples were obtained by cordocentesis (n = 58) or cardiocentesis (n = 4) at 12 to 37 weeks of gestation. Maternal serum samples were obtained immediately before fetal blood sampling. Results. Fetal serum thyroid-stimulating hormone, thyroxine-binding globulin, and total and free T4 and T3 concentrations increased significantly with the length of gestation (P < 0.001). The only significant association among these variables, independent of the length of gestation, was between thyroid-stimulating hormone and free T4 (P < 0.0001). Maternal serum concentrations of these variables did not change during gestation, and there was no significant relation between fetal and maternal values. Most fetal serum concentrations of thyroid-stimulating hormone were higher, whereas most serum total and free T3 concentrations were lower than the respective values for normal adults. The fetal serum total T4, free T4, and thyroxine-binding globulin values reached the level of the mean adult values at approximately 36 weeks of gestation. Conclusions. The increases in fetal serum concentrations of thyroid-stimulating hormone, thyroxine-binding globulin, and total and free T4 and T3 during gestation reflect increasing maturation of the pituitary, thyroid, and liver. The finding of increasing fetal serum concentrations of thyroid-stimulating hormone in the presence of increasing thyroid hormone concentrations suggests that the sensitivity of the fetal pituitary gland to negative feedback is limited or is counterbalanced by increasing stimulation by thyrotropin-releasing hormone from the hypothalamus.	KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND; WYNN INST METAB RES,LONDON,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT CLIN BIOCHEM,LONDON WC2R 2LS,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON WC2R 2LS,ENGLAND	University of London; King's College London; Imperial College London; University of London; King's College London; University of London; King's College London				Nicolaides, Kypros/0000-0003-1266-0711				BALLABIO M, 1989, CLIN ENDOCRINOL, V31, P565, DOI 10.1111/j.1365-2265.1989.tb01280.x; DEESCOBAR GM, 1987, HORM RES, V26, P12, DOI 10.1159/000180681; Fisher D A, 1976, Recent Prog Horm Res, V33, P59; FISHER DA, 1981, NEW ENGL J MED, V304, P702, DOI 10.1056/NEJM198103193041205; FISHER DA, 1983, CLIN PERINATOL, V10, P615, DOI 10.1016/S0095-5108(18)30954-0; FISHER DA, 1973, J CLIN ENDOCR METAB, V36, P397, DOI 10.1210/jcem-36-2-397; FISHER DA, 1970, PEDIATRICS, V46, P208; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; GREENBERG AH, 1970, J CLIN INVEST, V49, P1790, DOI 10.1172/JCI106397; KLEIN AH, 1982, EARLY HUM DEV, V6, P321, DOI 10.1016/0378-3782(82)90070-6; LARSEN PR, 1981, ENDOCR REV, V2, P87, DOI 10.1210/edrv-2-1-87; MAN EB, 1969, AM J OBSTET GYNECOL, V103, P338, DOI 10.1016/0002-9378(69)90492-X; MONIZ CF, 1985, J CLIN PATHOL, V38, P468, DOI 10.1136/jcp.38.4.468; MORRISS FH, 1974, BIOL NEONATE, V25, P44; NICOLAIDES KH, 1986, LANCET, V1, P1065; ROSEN F, 1966, J CLIN ENDOCR METAB, V26, P1343, DOI 10.1210/jcem-26-12-1343; SHEPARD TH, 1967, J CLIN ENDOCR METAB, V27, P945, DOI 10.1210/jcem-27-7-945; WU SY, 1978, ENDOCRINOLOGY, V103, P235, DOI 10.1210/endo-103-1-235	18	272	279	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 21	1991	324	8					532	536		10.1056/NEJM199102213240805	http://dx.doi.org/10.1056/NEJM199102213240805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX918	1899469				2022-12-01	WOS:A1991EX91800005
J	YEH, E; DRISCOLL, R; COLTRERA, M; OLINS, A; BLOOM, K				YEH, E; DRISCOLL, R; COLTRERA, M; OLINS, A; BLOOM, K			A DYNAMIN-LIKE PROTEIN ENCODED BY THE YEAST SPORULATION GENE SPO15	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MICROTUBULES	THE tightly centromere-linked gene SPO15 is essential for meiotic cell division in the yeast Saccharomyces cerevisiae. Diploid cells without the intact SPO15 gene product are able to complete premeiotic DNA synthesis and genetic recombination, but are unable to traverse the division cycles. Electron microscopy of blocked cells reveals a duplicated but unseparated spindle-pole body. Thus cells are unable to form a bipolar spindle. Sequence analysis of SPO15 DNA reveals an open reading frame that predicts a protein of 704 amino acids. This protein is identical to VPS1, a gene involved in vacuolar protein sorting in yeast which has significant sequence homology (45% overall, 66% over 300 amino acids) to the microtubule bundling-protein, dynamin. The SPO15 gene product expressed in Escherichia coli can be affinity-purified with microtubules. SPO15 encodes a protein that is likely to be involved in a microtubule-dependent process required for the timely separation of spindle-pole bodies in meiosis	UNIV WASHINGTON,DEPT OTOLARYNGOL,SEATTLE,WA 98195; UNIV TENNESSEE,GRAD SCH BIOMED SCI,DIV BIOL,OAK RIDGE NATL LAB,OAK RIDGE,TN 37831	University of Washington; University of Washington Seattle; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville	YEH, E (corresponding author), UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599, USA.		Bloom, Kerry/AAE-5336-2019	Bloom, Kerry/0000-0002-3457-004X				BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; TABOR S, 1990, CURRENT PROTOCOLS MO; YEH E, 1986, MOL CELL BIOL, V6, P158, DOI 10.1128/MCB.6.1.158	11	78	79	1	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					713	715		10.1038/349713a0	http://dx.doi.org/10.1038/349713a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1825352				2022-12-01	WOS:A1991EY62700053
J	YOOL, AJ; SCHWARZ, TL				YOOL, AJ; SCHWARZ, TL			ALTERATION OF IONIC SELECTIVITY OF A K+ CHANNEL BY MUTATION OF THE H5 REGION	NATURE			English	Article							POTASSIUM CHANNELS; SHAKER LOCUS; XENOPUS OOCYTES; DROSOPHILA; BRAIN; CDNA; EXPRESSION; CATIONS; CLONING	THE high ionic selectivity of K+ channels is a unifying feature of this diverse class of membrane proteins. Though K+ channels differ widely in regulation and kinetics, physiological studies have suggested a common structure: a single file pore containing mulitiple ion-binding sites and having broader vestibules at both ends 1-5. We have used site-directed mutagenesis and single-channel recordings to identify a molecular region that influences ionic selectivity in a cloned A-type K+ channel from Drosophila. Single amino-acid substitutions in H5, the fifth hydrophobic region 6, enhanced the passage of NH4+ and Rb+, ions with diameters larger than K+, without compromising the ability of the channel to exclude the smaller cation, Na+. The mutations that substantially altered selectivity had little effect on the gating properties of the channel. We conclude that the H5 region is likely to line the pore of the K+ channel.			YOOL, AJ (corresponding author), STANFORD UNIV,MED CTR,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.		Yool, Andrea/AAK-9907-2020	Yool, Andrea/0000-0003-1283-585X				ARMSTRONG CM, 1975, QUART REV BIOPH, V7, P179; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P558; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GUY HR, 1989, MONOVALENT CATIONS B; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATTESON DR, 1986, J GEN PHYSIOL, V87, P795, DOI 10.1085/jgp.87.5.795; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TAYLOR PS, 1987, J PHYSIOL-LONDON, V388, P437, DOI 10.1113/jphysiol.1987.sp016623; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; VANDERLEY P, 1986, J BIOL CHEM, V261, P2222; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	25	374	382	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					700	704		10.1038/349700a0	http://dx.doi.org/10.1038/349700a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1899917				2022-12-01	WOS:A1991EY62700049
J	MIRKIN, G				MIRKIN, G			ESTROGEN IN YAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MIRKIN, G (corresponding author), GEORGETOWN UNIV,SCH MED,WASHINGTON,DC 20057, USA.							BLUNDEN G, 1967, J PHARM SCI, V56, P948, DOI 10.1002/jps.2600560804; BLUNDEN G, 1968, J PHARM SCI, V57, P602, DOI 10.1002/jps.2600570411; Chakravarti R N, 1966, Bull Calcutta Sch Trop Med, V14, P45; CURNOW DH, 1954, BIOCHEM J, V58, P283, DOI 10.1042/bj0580283	4	13	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					912	912						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992191				2022-12-01	WOS:A1991EX58700048
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW CONTRACEPTIVE IMPLANT SYSTEM APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					847	847		10.1001/jama.265.7.847	http://dx.doi.org/10.1001/jama.265.7.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899454				2022-12-01	WOS:A1991EX58700010
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SHILEY HEART-VALVE PHYSICIAN AND PATIENT NOTIFICATION PROGRAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					847	847		10.1001/jama.265.7.847	http://dx.doi.org/10.1001/jama.265.7.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899454				2022-12-01	WOS:A1991EX58700011
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW LABELING FOR SODIUM-NITROPRUSSIDE EMPHASIZES RISK OF CYANIDE TOXICITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					847	847		10.1001/jama.265.7.847	http://dx.doi.org/10.1001/jama.265.7.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899454				2022-12-01	WOS:A1991EX58700009
J	PAPADAKIS, MA; MANGIONE, CM; LEE, KK; KRISTOF, M				PAPADAKIS, MA; MANGIONE, CM; LEE, KK; KRISTOF, M			TREATABLE ABDOMINAL PATHOLOGICAL CONDITIONS AND UNSUSPECTED MALIGNANT NEOPLASMS AT AUTOPSY IN VETERANS WHO RECEIVED MECHANICAL VENTILATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Study Objective: To determine, in medical patients who received mechanical ventilation, the frequency and types of major unexpected diagnoses at autopsy that, if known before death, would probably have led to improved survival (class I errors) or substantively changed management but not survival (class IIB errors). Design: Retrospective cohort study. Setting: Six medical intensive care units in a Department of Veterans Affairs Cooperative Study. Patients: One hundred seventy-two autopsied patients of the 401 veterans who received mechanical ventilation and died in the hospital. Results: The class I error rate was 12%. Abdominal pathologic conditions-abscesses, bowel perforations, or infarction-were as frequent as pulmonary emboli as a cause of class I errors. While patients with abdominal pathologic conditions generally complained of abdominal pain, results of examination of the abdomen were considered unremarkable in most patients, and the symptom was not pursued. Six percent of patients had extensive malignant neoplasms (class IIb errors). Conclusions: Atypical presentation of potentially treatable abdominal pathologic conditions is a common cause of class I errors in veterans who receive mechanical ventilation. Conversely, several patients with unrecognized terminal conditions underwent intensive intervention. If the information gained at autopsy had been known before death, management would have probably changed substantively in 18% of patients.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; VET AFFAIRS MED CTR,DEPT BIOSTAT,PALO ALTO,CA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	PAPADAKIS, MA (corresponding author), DEPT VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,4150 CLEMENT ST 111A1,SAN FRANCISCO,CA 94121, USA.							Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANDEFELD CS, 1988, NEW ENGL J MED, V318, P1249, DOI 10.1056/NEJM198805123181906; LUNDBERG GD, 1988, JAMA-J AM MED ASSOC, V260, P3488; MCPHEE SJ, 1985, AM J MED, V78, P107, DOI 10.1016/0002-9343(85)90470-X; Reichert C M, 1985, Health Aff (Millwood), V4, P82, DOI 10.1377/hlthaff.4.2.82; ROBERTS WC, 1978, NEW ENGL J MED, V299, P332, DOI 10.1056/NEJM197808172990704; 1988, MMWR, V37, P191	10	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					885	887		10.1001/jama.265.7.885	http://dx.doi.org/10.1001/jama.265.7.885			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992186	Green Submitted			2022-12-01	WOS:A1991EX58700040
J	RATNER, J; LISBONA, A; ROSENBLOOM, M; PALAYEW, M; SZABOLCSI, S; TUPAZ, T				RATNER, J; LISBONA, A; ROSENBLOOM, M; PALAYEW, M; SZABOLCSI, S; TUPAZ, T			THE PREVALENCE OF GALLSTONE DISEASE IN VERY OLD INSTITUTIONALIZED PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							POPULATION; SYMPTOMS; AUTOPSY	We present the results of a study that was undertaken at a large geriatric nursing home to assess the prevalence of gallstone disease in very old institutionalized persons. One hundred seventeen residents underwent ultrasound examination of the gallbladder. Two thirds of 82 women and half of 35 men had gallstone disease. When stratified for age, 80% of women and men over the age of 90 years were positive for the disease. In summary, the prevalence of gallstone disease in our very old nursing home population was found to be unexpectedly high.	SIR MORTIMER B DAVIS JEWISH HOSP,MONTREAL H3T 1E2,QUEBEC,CANADA	McGill University	RATNER, J (corresponding author), MAIMONIDES HOSP,CTR GERIATR,PROFESS SERV,5795 CALDWELL AVE,MONTREAL H4W 1W3,QUEBEC,CANADA.							BATESON MC, 1975, BMJ-BRIT MED J, V4, P427; CLINCH D, 1984, AGE AGEING, V13, P120, DOI 10.1093/ageing/13.2.120; EINARSSON K, 1985, NEW ENGL J MED, V313, P277, DOI 10.1056/NEJM198508013130501; FENYO G, 1982, AM J SURG, V143, P751, DOI 10.1016/0002-9610(82)90052-6; GILAT T, 1985, AM J CLIN NUTR, V41, P336, DOI 10.1093/ajcn/41.2.336; GLAMBEK I, 1989, SCAND J GASTROENTERO, V24, P277, DOI 10.3109/00365528909093046; GLAMBEK I, 1987, SCAND J GASTROENTERO, V22, P1089, DOI 10.3109/00365528708991963; GRUNDY SM, 1987, HEPATOLOGY, V7, P946, DOI 10.1002/hep.1840070526; JANZON L, 1985, SCAND J GASTROENTERO, V20, P706, DOI 10.3109/00365528509089199; LICHTAROWICZ AM, 1987, J ROY SOC MED, V80, P692, DOI 10.1177/014107688708001111; LONGINO CF, 1988, GERONTOLOGIST, V28, P515, DOI 10.1093/geront/28.4.515; LOWBEER TS, 1985, RECENT ADV GERIATRIC, P37; MOGENSEN NB, 1984, SURG GYNECOL OBSTET, V159, P353; ROSENWAIKE I, 1987, GERONTOLOGIST, V27, P275, DOI 10.1093/geront/27.3.275; Strom BL, 1985, GALLSTONES, P1; VITETTA L, 1988, AUST NZ J SURG, V58, P561; ZAHOR Z, 1974, SCAND J GASTROENTERO, V9, P3	17	36	38	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					902	903		10.1001/jama.265.7.902	http://dx.doi.org/10.1001/jama.265.7.902			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992189				2022-12-01	WOS:A1991EX58700044
J	DIXON, JM; ELTON, RA; RAINEY, JB; MACLEOD, DAD				DIXON, JM; ELTON, RA; RAINEY, JB; MACLEOD, DAD			RECTAL EXAMINATION IN PATIENTS WITH PAIN IN THE RIGHT LOWER QUADRANT OF THE ABDOMEN	BRITISH MEDICAL JOURNAL			English	Article							APPENDICITIS	Objective-To determine whether rectal examination provides any diagnostic information in patients admitted to hospital with pain in the right lower quadrant of the abdomen. Design-Casualty officer or surgical registrar recorded symptoms and signs on admission on detailed forms. Final diagnosis was noted on discharge from hospital. Setting-District general hospital. Patients-1204 Consecutive patients admitted to hospital with pain in the right lower quadrant of the abdomen as their major complaint; 1028 had a rectal examination on admission. Main outcome measures-Odds ratio for each symptom and sign related to final diagnosis. Results of multiple logistic regression analysis for acute appendicitis. Results-Right sided rectal tenderness, present in 309 of those examined, was more common in patients with acute appendicitis (odds ratio 1.34, p < 0.05). This odds ratio was considerably less than that for other clinical signs-namely, tenderness in the right lower quadrant (odds ratio 5.09), rebound tenderness (3.34), guarding (3.07), and muscular rigidity in the abdomen (5.03). In the logistic regression analysis of patients with acute appendicitis, when allowance was made for the presence or absence of rebound tenderness, rectal tenderness on the right lost its significance. Six patients had masses palpable rectally, of which three were palpable on abdominal examination; the other three patients had acute appendicitis. No other unexpected diagnoses were established, and no useful additional diagnostic information was obtained by routine rectal examination. Conclusion-If patients presenting with pain in the right lower quadrant of the abdomen are tested for rebound tenderness then rectal examination does not give any further diagnostic information.	UNIV EDINBURGH,MED STAT UNIT,EDINBURGH,SCOTLAND; ST JOHNS HOSP HOWDEN,DEPT SURG,LIVINGSTON,W LOTHIAN,SCOTLAND	University of Edinburgh	DIXON, JM (corresponding author), UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							Armitage P., 1987, STATISTICAL METHODS, P386; BONNELLO JC, 1979, DIS COLON RECTUM, V22, P97; CAIN A, 1986, H BAILEYS DEMONSTRAT, P297; CONDON R, 1986, TXB SURG, P971; DICKSON AP, 1985, ARCH DIS CHILD, V60, P666, DOI 10.1136/adc.60.7.666; KAZARIAN KK, 1970, AM J SURG, V119, P681, DOI 10.1016/0002-9610(70)90239-4; LEWIS FR, 1975, ARCH SURG-CHICAGO, V110, P677; Magee R B, 1967, Pa Med, V70, P47; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; NAUTA RJ, 1986, AM J SURG, V151, P746, DOI 10.1016/0002-9610(86)90057-7; OSLER W, 1901, PRINCIPLES PRACTICES, P525; SMITH PH, 1965, POSTGRAD MED J, V41, P2, DOI 10.1136/pgmj.41.471.2; TEICHER I, 1983, ANN SURG, V198, P753, DOI 10.1097/00000658-198312000-00014	13	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					386	388		10.1136/bmj.302.6773.386	http://dx.doi.org/10.1136/bmj.302.6773.386			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	2004144	Bronze, Green Published			2022-12-01	WOS:A1991EX85800027
J	ENNALS, S				ENNALS, S			UNDERSTANDING BENEFITS - INDUSTRIAL INJURIES BENEFITS	BRITISH MEDICAL JOURNAL			English	Article											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					400	401		10.1136/bmj.302.6773.400	http://dx.doi.org/10.1136/bmj.302.6773.400			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	1825930	Green Published, Bronze			2022-12-01	WOS:A1991EX85800032
J	HELFGOTT, SM; MOSCISCKI, RA; MARTIN, JS; LORENZO, C; KIEVAL, R; MCKENNA, M; NADOL, J; TRENTHAM, DE				HELFGOTT, SM; MOSCISCKI, RA; MARTIN, JS; LORENZO, C; KIEVAL, R; MCKENNA, M; NADOL, J; TRENTHAM, DE			CORRELATION BETWEEN ANTIBODIES TO TYPE-II COLLAGEN AND TREATMENT OUTCOME IN BILATERAL PROGRESSIVE SENSORINEURAL HEARING-LOSS	LANCET			English	Article							INNER-EAR DISEASE; RELAPSING POLYCHONDRITIS; RHEUMATOID-ARTHRITIS; SERUM ANTIBODIES; AUTOIMMUNITY	Our aim was to assess whether "idiopathic" bilateral progressive sensorineural hearing loss (BPSHL) has an immunological cause in some patients; antibodies to native type II collagen were sought by an ELISA in eighteen patients with BPSHL, before and after corticosteroid treatment, and in twelve patients with Meniere's disease, fifteen with otosclerosis, eighteen with rheumatoid arthritis, nine with fibrositis, and nine healthy controls. A positive result was defined as a mean dilution titre of 2 or more. Eight of eighteen BPSHL patients had positive titres - significantly (p < 0.005) more than in any other group (one Meniere's disease, two otosclerosis, and no others). The mean antibody titre was higher in the BPSHL group than in any other group (2.02[SEM 0.62] vs 0.17 [0.17]) Meniere's disease, 0.44 [0.32] otosclerosis, 0 all others; p < 0.005). The nine BPSHL patients who showed a clinical response to corticosteroids (improvement in at least one tone by audiogram or 25 db in speech discrimination score) had the highest mean antibody titre (3.46 [0.88] vs 0.59 [0.59] for the nine non-responsive patients; p < 0.04). We suggest that in some patients with BPSHL, immunity to type II collagen, a major constituent of the inner ear, may be important in the pathogenesis of the disorder.	MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; MASSACHUSETTS EYE & EAR HOSP,DIV OTORHINOLARYNGOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	HELFGOTT, SM (corresponding author), BETH ISRAEL HOSP,DEPT MED,RES E,ROOM 319,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							ADAMS RD, 1985, PRINCIPLES NEUROLOGY, P211; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; ARNOLD W, 1985, ACTA OTO-LARYNGOL, V99, P437, DOI 10.3109/00016488509108935; BOWMAN CA, 1987, LARYNGOSCOPE, V97, P7; CLAGUE RB, 1983, ANN RHEUM DIS, V42, P537, DOI 10.1136/ard.42.5.537; FOIDART JM, 1978, NEW ENGL J MED, V299, P1203, DOI 10.1056/NEJM197811302992202; HARRIS JP, 1986, ANN OTO RHINOL LARYN, V95, P176, DOI 10.1177/000348948609500214; HUGHES GB, 1986, LARYNGOSCOPE, V96, P502, DOI 10.1288/00005537-198605000-00006; HUGHES GB, 1984, LARYNGOSCOPE, V94, P758; KAKANI RS, 1990, J OTOLARYNGOL, V19, P100; LEUTJE CM, 1989, LARYNGOSCOPE, V99, P1137; MARKUSSE HM, 1988, ANN RHEUM DIS, V47, P600, DOI 10.1136/ard.47.7.600; MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501; MOLONEY JR, 1978, J LARYNGOL OTOL, V92, P9, DOI 10.1017/S0022215100084875; MOSCICKI R, 1990, Journal of Allergy and Clinical Immunology, V85, P149; PLESTER D, 1989, AM J OTOL, V10, P188; TRENTHAM DE, 1983, J IMMUNOL, V130, P2684; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; YOO TJ, 1985, AM J OTOLARYNG, V6, P209, DOI 10.1016/S0196-0709(85)80087-9; YOO TJ, 1983, SCIENCE, V222, P65, DOI 10.1126/science.6623056; YOO TJ, 1982, SCIENCE, V217, P1153, DOI 10.1126/science.7112122; YOO TJ, 1984, J LARYNGOL OTOL, V9, P220; YOO TJ, 1985, AM J OTOL, V6, P95	23	48	48	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					387	389		10.1016/0140-6736(91)91165-Q	http://dx.doi.org/10.1016/0140-6736(91)91165-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671423				2022-12-01	WOS:A1991EX60500003
J	IRELAND, A; HARTLEY, L; RYLEY, N; MCGEE, JOD; TROWELL, JM; CHAPMAN, RW				IRELAND, A; HARTLEY, L; RYLEY, N; MCGEE, JOD; TROWELL, JM; CHAPMAN, RW			RAISED GAMMA-GLUTAMYL-TRANSFERASE ACTIVITY AND THE NEED FOR LIVER-BIOPSY	BRITISH MEDICAL JOURNAL			English	Article									JOHN RADCLIFFE HOSP,DEPT GASTROENTEROL & HISTOPATHOL,OXFORD OX3 9DU,ENGLAND	University of Oxford								ATTERBURY CE, 1988, J CLIN GASTROENTEROL, V10, P605, DOI 10.1097/00004836-198812000-00003; LATCHAM RW, 1986, BRIT J PSYCHIAT, V149, P353, DOI 10.1192/bjp.149.3.353; NAKANO M, 1982, GASTROENTEROLOGY, V83, P777; TALLEY NJ, 1988, J CLIN GASTROENTEROL, V10, P647, DOI 10.1097/00004836-198812000-00015; WHITEHEAD TP, 1978, LANCET, V1, P978	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					388	389		10.1136/bmj.302.6773.388	http://dx.doi.org/10.1136/bmj.302.6773.388			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	1672259	Bronze, Green Published			2022-12-01	WOS:A1991EX85800028
J	JAMES, MR; MARSHALL, H; CAREWMCCOLL, M				JAMES, MR; MARSHALL, H; CAREWMCCOLL, M			PULSE OXIMETRY DURING APPARENT TONIC-CLONIC SEIZURES	LANCET			English	Note								A pulse oximeter was used to monitor arterial oxygen saturations in 11 patients during apparent tonic-clonic seizures. 8 had a clinical diagnosis of genuine fits, 6 of whom showed striking falls in oxygen saturation during the seizures. 3 had a clinical diagnosis of pseudoseizures, none of whom had hypoxia during these episodes. Pulse oximetry during apparent tonic-clonic seizures may help to identify patients with low arterial oxygen tension who need immediate intervention.	HOPE HOSP,DEPT ACCID & EMERGENCY,SALFORD M6 8HD,LANCS,ENGLAND		JAMES, MR (corresponding author), ROYAL PRESTON HOSP,DEPT ACCID & EMERGENCY,PRESTON PR2 4HT,ENGLAND.							SADEH M, 1983, J NEUROL NEUROSUR PS, V46, P566, DOI 10.1136/jnnp.46.6.566	1	29	32	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					394	395						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671426				2022-12-01	WOS:A1991EX60500006
J	MCELVANEY, NG; HUBBARD, RC; BIRRER, P; CHERNICK, MS; CAPLAN, DB; FRANK, MM; CRYSTAL, RG				MCELVANEY, NG; HUBBARD, RC; BIRRER, P; CHERNICK, MS; CAPLAN, DB; FRANK, MM; CRYSTAL, RG			AEROSOL ALPHA-1-ANTITRYPSIN TREATMENT FOR CYSTIC-FIBROSIS	LANCET			English	Note							HUMAN NEUTROPHIL ELASTASE	In cystic fibrosis neutrophil-dominated inflammation on the respiratory epithelial surface results in a chronic epithelial burden of the destructive enzyme, neutrophil elastase. Alpha-1-antitrypsin (alpha-1AT), the main inhibitor of neutrophil elastase in lung, was given in aerosol form to 12 cystic fibrosis patients. It suppressed neutrophil elastase in the respiratory epithelial lining fluid (ELF) and restored the ELF anti-neutrophil elastase capacity when ELF alpha-1AT reached 8-mu-mol/l. This treatment also reversed the inhibitory effect of cystic fibrosis ELF on pseudomonas killing by neutrophils, which suggests that it may augment host defence in cystic fibrosis.	NHLBI,PULM BRANCH,BLDG 10,ROOM 6DO3,BETHESDA,MD 20892; NIDDKD,PEDIAT METAB BRANCH,BETHESDA,MD; NIAID,CLIN INVEST LAB,BETHESDA,MD 20892; EMORY UNIV,SCH MED,DEPT PEDIAT,DIV GASTROENTEROL & CYST FIBROSIS,ATLANTA,GA 30322	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emory University			McElvaney, Noel/A-6809-2010	mcelvaney, Noel/0000-0002-0152-4370				BERGER M, 1989, J CLIN INVEST, V84, P1302, DOI 10.1172/JCI114298; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BREUER R, 1989, AM REV RESPIR DIS, V139, P779, DOI 10.1164/ajrccm/139.3.779; FICK RB, 1984, J CLIN INVEST, V74, P236, DOI 10.1172/JCI111407; LUCEY EC, 1988, EXP LUNG RES, V14, P671, DOI 10.3109/01902148809087836; SUTER S, 1989, PSEUDOMONAS AERUGINO, P158; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	7	297	307	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					392	394		10.1016/0140-6736(91)91167-S	http://dx.doi.org/10.1016/0140-6736(91)91167-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671425				2022-12-01	WOS:A1991EX60500005
J	MCKEIGUE, PM; SHAH, B; MARMOT, MG				MCKEIGUE, PM; SHAH, B; MARMOT, MG			RELATION OF CENTRAL OBESITY AND INSULIN RESISTANCE WITH HIGH DIABETES PREVALENCE AND CARDIOVASCULAR RISK IN SOUTH ASIANS	LANCET			English	Article							CORONARY HEART-DISEASE; FAT DISTRIBUTION; NORTHWEST LONDON; ADIPOSE-TISSUE; SERUM-LIPIDS; MORTALITY; MEN; ADULTS; WOMEN; DIET	The hypothesis that the high mortality from coronary heart disease (CHD) in South Asians settled overseas compared with other populations is due to metabolic disturbances related to insulin resistance was tested in a population survey of 3193 men and 561 women aged 40-69 years in London, UK. The sample was assembled from industrial workforces and general practitioners' lists. In comparison with the European group, the South Asian group had a higher prevalence of diabetes (19% vs 4%), higher blood pressures, higher fasting and post-glucose serum insulin concentrations, higher plasma triglyceride, and lower HDL cholesterol concentrations. Mean waist-hip girth ratios and trunk skinfolds were higher in the South Asian than in the European group. Within each ethnic group waist-hip ratio was correlated with glucose intolerance, insulin, blood pressure, and triglyceride. These results confirm the existence of an insulin resistance syndrome, prevalent in South Asian populations and associated with a pronounced tendency to central obesity in this group. Control of obesity and greater physical activity offer the best chances for prevention of diabetes and CHD in South Asian people.	UNIV COLL & MIDDLESEX SCH MED,DEPT COMMUNITY MED,LONDON,ENGLAND	University of London; University College London			Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		[Anonymous], 1985, WHO TECH REP SER, V727, P1; BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; BECKLES GLA, 1986, LANCET, V1, P1298; BOLINDER J, 1983, DIABETES, V32, P117, DOI 10.2337/diabetes.32.2.117; DONAHUE RP, 1987, LANCET, V1, P821; DUCIMETIERE P, 1986, INT J OBESITY, V10, P229; Duncan I.W., 1982, PROCEDURE PROPOSED C; ELLIOTT P, 1988, CONTROL CLIN TRIALS, V9, pS1, DOI 10.1016/0197-2456(88)90028-1; HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1985, LANCET, V2, P1086; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; MORRISON JA, 1981, JAMA-J AM MED ASSOC, V245, P939, DOI 10.1001/jama.245.9.939; OLEFSKY J, 1974, J CLIN INVEST, V53, P64, DOI 10.1172/JCI107560; PEEPLES LH, 1989, METABOLISM, V38, P1029, DOI 10.1016/0026-0495(89)90017-6; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SEIDELL JC, 1988, EUR J CLIN INVEST, V18, P243, DOI 10.1111/j.1365-2362.1988.tb01253.x; SLACK J, 1977, BRIT MED J, V2, P353, DOI 10.1136/bmj.2.6083.353; STERN MP, 1981, AM J EPIDEMIOL, V113, P546, DOI 10.1093/oxfordjournals.aje.a113131; YKIJARVINEN H, 1988, DIABETES, V37, P1271, DOI 10.2337/diabetes.37.9.1271; ZIMMET P, 1977, DIABETOLOGIA, V13, P111, DOI 10.1007/BF00745137; 1989, LANCET, V1, P589; 1990, MORTALITY GEOGRAP DS	30	1184	1189	0	53	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 16	1991	337	8738					382	386		10.1016/0140-6736(91)91164-P	http://dx.doi.org/10.1016/0140-6736(91)91164-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671422				2022-12-01	WOS:A1991EX60500002
J	PHILLIPS, AN; LEE, CA; ELFORD, J; JANOSSY, G; TIMMS, A; BOFILL, M; KERNOFF, PBA				PHILLIPS, AN; LEE, CA; ELFORD, J; JANOSSY, G; TIMMS, A; BOFILL, M; KERNOFF, PBA			SERIAL LYMPHOCYTE-CD4 COUNTS AND DEVELOPMENT OF AIDS	LANCET			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; NATURAL-HISTORY; HOMOSEXUAL MEN; HIV INFECTION; LYMPHADENOPATHY; SUBSETS; FOLLOW; COHORT	Low CD4 lymphocyte counts are associated with increased risk of progression to AIDS in human immunodeficiency virus (HIV) infection. We investigated the extent to which the timing of progression to AIDS can be explained solely in terms of decline of the CD4 lymphocyte count in 111 haemophiliacs followed for up to 11 years since infection with HIV. A median of 10 CD4 lymphocyte counts were made per patient. By applying a simple linear model for the decline in CD4 lymphocyte counts over time, we estimated the date of development of AIDs in 96 patients who had at least 5 determinations. 84% (81 of 96) of patients were correctly classified as to development of AIDS before Jan 1, 1990 (p < 0.0001), with this model. The results suggest that differences in the time at which patients with HIV will progress to AIDS can largely be explained by differences in rates of decline of CD4 lymphocyte counts.	ROYAL FREE HOSP, SCH MED, CTR HAEMOPHILIA, LONDON NW3 2PF, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT IMMUNOL, LONDON NW3 2PF, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	PHILLIPS, AN (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PUBL HLTH & PRIMARY CARE, ROWLAND HILL ST, LONDON NW3 2PF, ENGLAND.		Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807				CAMPANA D, 1987, J IMMUNOL, V138, P648; CROWE S, 1990, 6 INT C AIDS SAN FRA; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FABIO G, 1990, BRIT J HAEMATOL, V75, P531, DOI 10.1111/j.1365-2141.1990.tb07794.x; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GARDENER MJ, 1989, STATISTICS CONFIDENC; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; JANOSSY G, 1985, CLIN EXP IMMUNOL, V59, P257; KAPLAN JE, 1988, JAMA-J AM MED ASSOC, V260, P2694, DOI 10.1001/jama.260.18.2694; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LANGE JMA, 1989, AIDS, V3, pS153, DOI 10.1097/00002030-198901001-00023; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LEE CA, 1990, BRIT J HAEMATOL, V75, P623, DOI 10.1111/j.1365-2141.1990.tb07813.x; LEIBOVITZ E, 1990, NEW ENGL J MED, V323, P531, DOI 10.1056/NEJM199008233230807; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MOSS AR, 1989, AIDS, V3, P55, DOI 10.1097/00002030-198902000-00001; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PEDERSEN C, 1989, BRIT MED J, V299, P154, DOI 10.1136/bmj.299.6692.154; PHILLIPS A, 1989, AIDS, V3, P737, DOI 10.1097/00002030-198911000-00008; PHILLIPS AN, 1990, 6 INT C AIDS SAN FRA; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; VISSCHER B, 1990, 6 INT C AIDS SAN FRA; WAYNE WF, 1988, CYTOMETRY, V3, P23; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017	28	319	322	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 16	1991	337	8738					389	392						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX605	1671424				2022-12-01	WOS:A1991EX60500004
J	BOTTARO, DP; RUBIN, JS; FALETTO, DL; CHAN, AML; KMIECIK, TE; VANDEWOUDE, GF; AARONSON, SA				BOTTARO, DP; RUBIN, JS; FALETTO, DL; CHAN, AML; KMIECIK, TE; VANDEWOUDE, GF; AARONSON, SA			IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT	SCIENCE			English	Article							MOLECULAR-CLONING; TYROSINE KINASE; CELL-LINE; PURIFICATION; GENE; PHOSPHORYLATION; ACTIVATION; SEQUENCE; SUBUNIT; CDNA	Hepatocyte growth factor (HGF) is a plasminogen-like protein thought to be a humoral mediator of liver regeneration. A 145-kilodalton tyrosyl phosphoprotein observed in rapid response to HGF treatment of intact target cells was identified by immunoblot analysis as the beta-subunit of the c-met proto-oncogene product, a membrane-spanning tyrosine kinase. Covalent cross-linking of I-125-labeled ligand to cellular proteins of appropriate size that were recognized by antibodies to c-met directly established the c-met product as the cell-surface receptor for HGF.	NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	BOTTARO, DP (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020; Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464; Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Kmiecik, Thomas/0000-0002-1367-443X				BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOTTARO DP, UNPUB; Chan A. H. Y., UNPUB; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FALETTO DL, UNPUB; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HORJUP P, 1985, FEBS LETT, V184, P333; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; KUROSKY A, 1980, P NATL ACAD SCI-BIOL, V77, P3388, DOI 10.1073/pnas.77.6.3388; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RUBIN J, UNPUB; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; WHITE MF, 1988, INSULIN RECEPTORS A, P125; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1989, CANCER RES, V49, P3314	35	2163	2306	1	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					802	804		10.1126/science.1846706	http://dx.doi.org/10.1126/science.1846706			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1846706				2022-12-01	WOS:A1991EX57500047
J	CREUZET, F; MCDERMOTT, A; GEBHARD, R; VANDERHOEF, K; SPIJKERASSINK, MB; HERZFELD, J; LUGTENBURG, J; LEVITT, MH; GRIFFIN, RG				CREUZET, F; MCDERMOTT, A; GEBHARD, R; VANDERHOEF, K; SPIJKERASSINK, MB; HERZFELD, J; LUGTENBURG, J; LEVITT, MH; GRIFFIN, RG			DETERMINATION OF MEMBRANE-PROTEIN STRUCTURE BY ROTATIONAL RESONANCE NMR - BACTERIORHODOPSIN	SCIENCE			English	Article							MAGIC-ANGLE; POLYCRYSTALLINE SOLIDS; SPIN DIFFUSION; SPECTRA	Rotationally resonant magnetization exchange, a new nuclear magnetic resonance (NMR) technique for measuring internuclear distances between like spins in solids, was used to determine the distance between the C-8 and C-18 carbons of retinal in two model compounds and in the membrane protein bacteriorhodopsin. Magnetization transfer between inequivalent spins with an isotropic shift separation, delta, is driven by magic angle spinning at a speed omega-r that matches the rotational resonance condition delta = n-omega-r, where n is a small integer. The distances measured in this way for both the 6-s-cis- and 6-s-trans-retinoic acid model compounds agreed well with crystallographically known distances. In bacteriorhodopsin the exchange trajectory between C-8 and C-18 was in good agreement with the internuclear distance for a 6-s-trans configuration [4.2 angstroms (angstrom)] and inconsistent with that for a 6-s-cis configuration (3.1 angstrom). The results illustrate that rotational resonance can be used for structural studies in membrane proteins and in other situations where diffraction and solution NMR techniques yield limited information.	MIT,FRANCIS BITTER NATL MAGNET LAB,CAMBRIDGE,MA 02139; LEIDEN STATE UNIV,GORLAEUS LABS,2300 RA LEIDEN,NETHERLANDS; BRANDEIS UNIV,DEPT CHEM,WALTHAM,MA 02254; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Leiden University; Leiden University - Excl LUMC; Brandeis University; Massachusetts Institute of Technology (MIT)			Levitt, Malcolm/B-3746-2010	Levitt, Malcolm/0000-0001-9878-1180; McDermott, Ann/0000-0002-9249-1649	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036920, R01GM023403, R37GM023403, R01GM036810] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-23403, GM-36920, GM-36810] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREW ER, 1963, PHYS LETT, V4, P99, DOI 10.1016/0031-9163(63)90123-9; ANDREW ER, 1966, PHYS LETT, V21, P505, DOI 10.1016/0031-9163(66)91274-1; ANDREW ER, 1958, NATURE, V182, P1659, DOI 10.1038/1821659a0; COLUMBO MG, 1988, CHEM PHYS LETT, V146, P189; CREUZET F, UNPUB; DEGRIP WJ, 1988, PHOTOCHEM PHOTOBIOL, V48, P799, DOI 10.1111/j.1751-1097.1988.tb02895.x; GAN ZH, 1990, MOL PHYS, V67, P1419; GRIFFIN RG, 1988, PHYSICS NMR SPECTROS, P203; HARBISON G S, 1985, Journal of the American Chemical Society, V107, P4809, DOI 10.1021/ja00303a001; HARBISON GS, 1985, BIOCHEMISTRY-US, V24, P6955, DOI 10.1021/bi00345a031; HERZFELD J, 1980, J CHEM PHYS, V73, P6021, DOI 10.1063/1.440136; HONIG B, 1971, P NATL ACAD SCI USA, V68, P1289, DOI 10.1073/pnas.68.6.1289; HONIG B, 1976, BIOCHEMISTRY-US, V15, P4593, DOI 10.1021/bi00666a008; KUBO A, 1988, J CHEM SOC FARAD T 1, V84, P3713, DOI 10.1039/f19888403713; LEVITT MH, 1990, J CHEM PHYS, V92, P6347, DOI 10.1063/1.458314; LOWE IJ, 1959, PHYS REV LETT, V2, P285, DOI 10.1103/PhysRevLett.2.285; MAAS WEJR, 1988, CHEM PHYS LETT, V149, P170, DOI 10.1016/0009-2614(88)87216-6; Mathies R. A., 1987, BIOL APPLICATIONS RA, P59; MCDERMOTT AE, 1990, BIOCHEMISTRY-US, V29, P5767, DOI 10.1021/bi00476a018; MEHRING M, 1983, PRINCIPLES HIGH RESO, P250; PINES A, 1973, J CHEM PHYS, V59, P569, DOI 10.1063/1.1680061; RALEIGH DP, 1989, J AM CHEM SOC, V111, P4502, DOI 10.1021/ja00194a057; RALEIGH DP, 1988, CHEM PHYS LETT, V146, P71, DOI 10.1016/0009-2614(88)85051-6; REDFIELD AG, 1971, COLD SPRING HARB SYM, V36, P405, DOI 10.1101/SQB.1972.036.01.052; RODMANGILSON HS, 1988, J AM CHEM SOC, V110, P1943; SCHAEFER J, 1976, J AM CHEM SOC, V98, P1031, DOI 10.1021/ja00420a036; STAM CH, 1972, ACTA CRYSTALL B-STRU, VB 28, P2936, DOI 10.1107/S0567740872007253; STAM CH, 1963, ACTA CRYSTALLOGR, V16, P62, DOI 10.1107/S0365110X63000104; WOLFF EK, 1977, J CHEM PHYS, V67, P2387, DOI 10.1063/1.435081; Wuthrich K., 1986, NMR PROTEINS NUCL AC; [No title captured]	31	185	187	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					783	786		10.1126/science.1990439	http://dx.doi.org/10.1126/science.1990439			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990439				2022-12-01	WOS:A1991EX57500040
J	CYBULSKY, MI; GIMBRONE, MA				CYBULSKY, MI; GIMBRONE, MA			ENDOTHELIAL EXPRESSION OF A MONONUCLEAR LEUKOCYTE ADHESION MOLECULE DURING ATHEROGENESIS	SCIENCE			English	Article							CHEMOTACTIC FACTOR; INTERFERON-GAMMA; ATHEROSCLEROSIS; CELL; ACTIVATION; PROTEINS; LESION; RABBIT; PATHOGENESIS; CHOLESTEROL	An inducible rabbit endothelial adhesion molecule that is selective for mononuclear leukocytes has been identified. This adhesion protein was expressed on the surface of activated cultured endothelium in two forms, 118 and 98 kilodaltons, the amino-terminal sequence of each being highly homologous to human VCAM-1. In dietary hypercholesterolemic and Watanabe heritable hyperlipidemic rabbit models of atherosclerosis, this adhesion molecule was found to be expressed in a localized fashion by aortic endothelium that overlies early foam cell lesions. This lesion-localized expression suggests a potential endothelium-dependent mechanism for mononuclear leukocyte recruitment during atherogenesis and may provide a molecular marker for early atherosclerosis.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	CYBULSKY, MI (corresponding author), BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV VASC RES,BOSTON,MA 02115, USA.		Cybulsky, Myron I./AAD-6539-2019	Cybulsky, Myron/0000-0002-1696-2867	NHLBI NIH HHS [P01-HL-36028] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036028] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER JA, 1986, ARTERIOSCLEROSIS, V6, P254, DOI 10.1161/01.ATV.6.3.254; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BUJA LM, 1983, ARTERIOSCLEROSIS, V3, P87, DOI 10.1161/01.ATV.3.1.87; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; COTRAN RS, 1988, J IMMUNOL, V140, P1883; CYBULSKY MI, UNPUB; CYBULSKY MI, IN PRESS AM J PATHOL; DUSTIN ML, 1986, J IMMUNOL, V137, P245; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAULL RJ, 1989, TRANSPLANTATION, V48, P226, DOI 10.1097/00007890-198908000-00009; GERRITY RG, 1985, ARTERIOSCLEROSIS, V5, P55, DOI 10.1161/01.ATV.5.1.55; Gimbrone M., 1986, VASCULAR ENDOTHELIUM, P1; GIMBRONE MA, 1980, ATHEROSCLEROSIS, V5, P415; GRYGLEWSKI RJ, 1988, HYPERTENSION, V12, P530, DOI 10.1161/01.HYP.12.6.530; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE L, 1989, PRODUCTIVITY OCEAN P, P49; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MUNRO JA, COMMUNICATION; MUNRO JM, 1989, AM J PATHOL, V135, P121; MUNRO JM, 1988, LAB INVEST, V58, P249; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; POLTE T, 1990, NUCLEIC ACIDS RES, V18, P5901, DOI 10.1093/nar/18.19.5901; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V7, P9, DOI 10.1161/01.ATV.7.1.9; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; VALENTE AJ, 1988, BIOCHEMISTRY-US, V27, P4162, DOI 10.1021/bi00411a039; WALKER LN, 1986, AM J PATHOL, V125, P450; WATANABE T, 1985, LAB INVEST, V53, P80	39	1365	1441	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					788	791		10.1126/science.1990440	http://dx.doi.org/10.1126/science.1990440			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990440				2022-12-01	WOS:A1991EX57500042
J	ESCALANTE, B; ERLIJ, D; FALCK, JR; MCGIFF, JC				ESCALANTE, B; ERLIJ, D; FALCK, JR; MCGIFF, JC			EFFECT OF CYTOCHROME-P450 ARACHIDONATE METABOLITES ON ION-TRANSPORT IN RABBIT KIDNEY LOOP OF HENLE	SCIENCE			English	Article							THICK ASCENDING LIMB; ACID METABOLISM; ATPASE; SODIUM; CELLS; SUSPENSION; PUMP	In the medullary segment of the thick ascending limb of the loop of Henle (mTALH), arachidonic acid (AA) is metabolized by a cytochrome P450-dependent monooxygenase to products that affect ion transport. The linkage between changes in ion transport and AA metabolism in isolated cells of the mTALH was examined. AA produced a concentration-dependent inhibition of Rb-86 uptake - an effect that was prevented by selective blockade of cytochrome P450 monooxygenases. Inhibition by cytochrome P450 blockade of the effect of AA on Rb-86 uptake could be circumvented by addition of the principal products of AA metabolism in the mTALH.	SUNY DOWNSTATE MED CTR,DEPT PHYSIOL,BROOKLYN,NY 11203; UNIV TEXAS,HLTH SCI CTR,DEPT MOLEC GENET,DALLAS,TX 75235	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Texas System; University of Texas Dallas	ESCALANTE, B (corresponding author), NEW YORK MED COLL,DEPT PHARMACOL,VALHALLA,NY 10595, USA.			Falck, John/0000-0002-9219-7845	NHLBI NIH HHS [HL34300, R01 HL25394] Funding Source: Medline; NIDDK NIH HHS [R01 DK33612] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025394, P01HL034300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033612] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN ML, 1988, AM J PHYSIOL, V255, pF704, DOI 10.1152/ajprenal.1988.255.4.F704; CANTIELLO HF, 1988, AM J PHYSIOL, V255, pF574, DOI 10.1152/ajprenal.1988.255.4.F574; CHAMBERLIN ME, 1984, AM J PHYSIOL, V247, pF955, DOI 10.1152/ajprenal.1984.247.6.F955; DOWNING DT, 1970, BIOCHEM BIOPH RES CO, V40, P218, DOI 10.1016/0006-291X(70)91069-7; EVELOFF J, 1981, PFLUG ARCH EUR J PHY, V389, P263, DOI 10.1007/BF00584788; FERRERI NR, 1984, J PHARMACOL EXP THER, V231, P441; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; KATZ AI, 1982, AM J PHYSIOL, V242, pF207, DOI 10.1152/ajprenal.1982.242.3.F207; KINNE R, 1985, RENAL BIOCH CELLS ME, P99; MAINES MD, 1977, J BIOL CHEM, V252, P5900; Overbeck HW, 1976, CIRC RES, V38, P48, DOI 10.1161/01.RES.38.6.48; ROMERO MF, 1990, ADV PROSTAGLANDIN TH, P205; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; SCHWARTZMAN ML, 1986, BIOCHEM J, V238, P283, DOI 10.1042/bj2380283; SERI I, 1988, AM J PHYSIOL, V255, pF666, DOI 10.1152/ajprenal.1988.255.4.F666; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781	16	223	225	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					799	802		10.1126/science.1846705	http://dx.doi.org/10.1126/science.1846705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1846705				2022-12-01	WOS:A1991EX57500046
J	FODOR, SPA; READ, JL; PIRRUNG, MC; STRYER, L; LU, AT; SOLAS, D				FODOR, SPA; READ, JL; PIRRUNG, MC; STRYER, L; LU, AT; SOLAS, D			LIGHT-DIRECTED, SPATIALLY ADDRESSABLE PARALLEL CHEMICAL SYNTHESIS	SCIENCE			English	Article								Solid-phase chemistry, photolabile protecting groups, and photolithography have been combined to achieve light-directed, spatially addressable parallel chemical synthesis to yield a highly diverse set of chemical products. Binary masking, one of many possible combinatorial synthesis strategies, yields 2n compounds in n chemical steps. An array of 1024 peptides was synthesized in ten steps, and its interaction with a monoclonal antibody was assayed by epifluorescence microscopy. High-density arrays formed by light-directed synthesis are potentially rich sources of chemical diversity for discovering new ligands that bind to biological receptors and for elucidating principles governing molecular interactions. The generality of this approach is illustrated by the light-directed synthesis of a dinucleotide. Spatially directed synthesis of complex compounds could also be used for microfabrication of devices.			FODOR, SPA (corresponding author), AFFYMAX RES INST,3180 PORTER DR,PALO ALTO,CA 94304, USA.							CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GELB MH, 1985, BIOCHEMISTRY-US, V24, P1813, DOI 10.1021/bi00329a001; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1986, CIBA F S, V119, P131; KHRAPKO KR, 1989, FEBS LETT, V256, P118, DOI 10.1016/0014-5793(89)81730-2; LATT SA, 1972, ANAL BIOCHEM, V50, P56, DOI 10.1016/0003-2697(72)90485-X; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; McGillis D. A., 1983, VLSI technology, P267; MEO T, 1983, P NATL ACAD SCI-BIOL, V80, P4084, DOI 10.1073/pnas.80.13.4084; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; NESTOR JJ, 1988, J MED CHEM, V31, P65, DOI 10.1021/jm00396a011; NEWMAN TH, 1987, J VAC SCI TECHNOL B, V5, P88, DOI 10.1116/1.583934; OHTSUKA E, 1977, SYNTHESIS-STUTTGART, P453; PATCHORNIK CA, 1970, J AM CHEM SOC, V92, P6333; PILLAI VNR, 1980, SYNTHESIS-STUTTGART, P1; ROGET A, 1989, NUCLEIC ACIDS RES, V17, P7643, DOI 10.1093/nar/17.19.7643; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	20	2203	3247	5	274	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					767	773		10.1126/science.1990438	http://dx.doi.org/10.1126/science.1990438			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990438				2022-12-01	WOS:A1991EX57500036
J	FU, LN; YE, RQ; BROWDER, LW; JOHNSTON, RN				FU, LN; YE, RQ; BROWDER, LW; JOHNSTON, RN			TRANSLATIONAL POTENTIATION OF MESSENGER-RNA WITH SECONDARY STRUCTURE IN XENOPUS	SCIENCE			English	Article							5' NONCODING REGION; C-MYC; UNWINDING ACTIVITY; MAMMALIAN-CELLS; OOCYTE MATURATION; PROTEIN-SYNTHESIS; GENE-EXPRESSION; POLIOVIRUS RNA; ANTISENSE RNA; POLY(A) RNAS	Differential translation of messenger RNA (mRNA) with stable secondary structure in the 5' untranslated leader may contribute to the dramatic changes in protein synthetic patterns that occur during oogenesis and early development. Plasmids that contained the bacterial gene chloramphenicol acetyltransferase and which encoded mRNA with (hpCAT) or without (CAT) a stable hairpin secondary structure in the 5' noncoding region were transcribed in vitro, and the resulting mRNAs were injected into Xenopus oocytes, eggs, and early embryos. During early oogenesis, hpCAT mRNA was translated at less than 3 percent of the efficiency of CAT mRNA. The relative translational potential of hpCAT reached 100 percent in the newly fertilized egg and returned to approximately 3 percent after the midblastula transition.	UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,ALBERTA,CANADA	University of Calgary			Johnston, Randal/B-9247-2009					ADAMSON ED, 1977, DEV BIOL, V57, P136, DOI 10.1016/0012-1606(77)90360-8; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; CAPASSO O, 1987, EMBO J, V6, P1825, DOI 10.1002/j.1460-2075.1987.tb02437.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ETKIN LD, 1985, DEV BIOL, V108, P173, DOI 10.1016/0012-1606(85)90019-3; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FLYNN JM, 1980, DEV BIOL, V75, P222, DOI 10.1016/0012-1606(80)90157-8; GALILI G, 1988, J BIOL CHEM, V263, P5764; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HARSAKING ML, 1979, EUCARYOTIC GENE REGU, P239; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; KOZAK M, 1983, MICROBIOL REV, V47, P1; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LAZARUS P, 1988, ONCOGENE, V3, P517; LEE G, 1984, CELL, V36, P729, DOI 10.1016/0092-8674(84)90353-2; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MCGREW LL, 1989, DEV BIOL, V134, P267, DOI 10.1016/0012-1606(89)90097-3; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; NAJITA L, 1990, P NATL ACAD SCI USA, V87, P5846, DOI 10.1073/pnas.87.15.5846; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PARKIN NT, 1989, ONCOGENE, V4, P815; PATRICK TD, 1989, DEVELOPMENT, V106, P1; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RICHTER JD, 1984, J MOL BIOL, V173, P227, DOI 10.1016/0022-2836(84)90191-8; ROLLER RJ, 1989, DEVELOPMENT, V106, P251; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WAGNER RW, 1990, P NATL ACAD SCI USA, V10, P5586; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	52	46	46	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					807	810		10.1126/science.1990443	http://dx.doi.org/10.1126/science.1990443			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990443				2022-12-01	WOS:A1991EX57500049
J	KLEIN, CB; CONWAY, K; WANG, XW; BHAMRA, RK; LIN, XH; COHEN, MD; ANNAB, L; BARRETT, JC; COSTA, M				KLEIN, CB; CONWAY, K; WANG, XW; BHAMRA, RK; LIN, XH; COHEN, MD; ANNAB, L; BARRETT, JC; COSTA, M			SENESCENCE OF NICKEL-TRANSFORMED CELLS BY AN X-CHROMOSOME - POSSIBLE EPIGENETIC CONTROL	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENES; CHINESE-HAMSTER; RETINOBLASTOMA; LOCALIZATION; CANCER; REGION; MOUSE; DNA	Transfer of a normal Chinese hamster X chromosome (carried in a mouse A9 donor cell line) to a nickel-transformed Chinese hamster cell line with an Xq chromosome deletion resulted in senescence of these previously immortal cells. At early passages of the A9/CX donor cells, the hamster X chromosome was highly active, inducing senescence in 100% of the colonies obtained after its transfer into the nickel-transformed cells. However, senescence was reduced to 50% when Chinese hamster X chromosomes were transferred from later passage A9 cells. Full senescing activity of the intact hamster X chromosome was restored by treatment of the donor mouse cells with 5-azacytidine, which induced demethylation of DNA. These results suggest that a senescence gene or genes, which may be located on the Chinese hamster X chromosome, can be regulated by DNA methylation, and that escape from senescence and possibly loss of tumor suppressor gene activity can occur by epigenetic mechanisms.	NYU MED CTR,INST ENVIRONM MED,NEW YORK,NY 10016; UNIV N CAROLINA,SCH MED,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	New York University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			costa, max/H-1754-2012; Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Klein, Catherine/0000-0001-8588-3751	NIEHS NIH HHS [ES 04715, ES 04895, ES 05512] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004895, R01ES004715] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIGGART NW, 1986, MUTAT RES, V175, P209, DOI 10.1016/0165-7992(86)90056-4; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BROWN CJ, 1990, AM J HUM GENET, V46, P273; CONWAY K, 1989, CANCER RES, V49, P6032; CONWAY K, 1989, THESIS NEW YORK U GR; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FENWICK RG, 1980, SOMAT CELL GENET, V6, P477, DOI 10.1007/BF01539151; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOCKEY AJ, 1989, SOMAT CELL MOLEC GEN, V15, P421, DOI 10.1007/BF01534893; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HUEBNER K, 1986, AM J HUM GENET, V38, P819; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOI M, 1989, P NATL ACAD SCI USA, V86, P8733; LIMON J, 1986, CANCER GENET CYTOGEN, V23, P87, DOI 10.1016/0165-4608(86)90152-4; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NISHIOKA H, 1975, MUTAT RES, V31, P185, DOI 10.1016/0165-1161(75)90088-6; PERIERASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SEN P, 1986, TOXICOL APPL PHARM, V84, P278, DOI 10.1016/0041-008X(86)90135-3; SEN P, 1985, CANCER RES, V45, P2320; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; STENMAN G, 1987, P NATL ACAD SCI USA, V84, P9099, DOI 10.1073/pnas.84.24.9099; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WANG X, UNPUB; YAMADA H, 1990, ONCOGENE, V5, P141	35	167	168	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					796	799		10.1126/science.1990442	http://dx.doi.org/10.1126/science.1990442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990442				2022-12-01	WOS:A1991EX57500045
J	MOSIER, DE; GULIZIA, RJ; BAIRD, SM; WILSON, DB; SPECTOR, DH; SPECTOR, SA				MOSIER, DE; GULIZIA, RJ; BAIRD, SM; WILSON, DB; SPECTOR, DH; SPECTOR, SA			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION OF HUMAN-PBL-SCID MICE	SCIENCE			English	Article							HUMAN CYTOMEGALO-VIRUS; HU MOUSE; SEQUENCES; CLONES; PROBES	Severe combined immunodeficient (SCID) mice reconstituted with human peripheral blood leukocytes (hu-PBL-SCID mice) have inducible human immune function and may be useful as a small animal model for acquired immunodeficiency syndrome (AIDS) research. Hu-PBL-SCID mice infected with human immunodeficiency virus-1 (HIV-1) contained virus that was recoverable by culture from the peritoneal cavity, spleen, peripheral blood, and lymph nodes for up to 16 weeks after infection; viral sequences were also detected by in situ hybridization and by amplification with the polymerase chain reaction (PCR). Mice could be infected with multiple strains of HIV-1, including LAV-1/Bru, IIIB, MN, SF2, and SF13. HIV-1 infection affected the concentration of human immunoglobulin and the number of CD4+ T cells in the mice. These results support the use of the hu-PBL-SCID mouse for studies of the pathogenesis and treatment of AIDS.	VET ADM MED CTR, LA JOLLA, CA 92161 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PEDIAT, LA JOLLA, CA 92093 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	MOSIER, DE (corresponding author), MED BIOL INST, DIV IMMUNOL, LA JOLLA, CA 92037 USA.			Spector, Deborah/0000-0002-7605-6348	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI029182, R01AI027703, R01AI029182] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27703, AI-29182] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; LUSSO P, 1990, SCIENCE, V247, P848, DOI 10.1126/science.2305256; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MOSIER DE, 1989, NATURE, V338, P211, DOI 10.1038/338211b0; MOSIER DE, 1989, CURR TOP MICROBIOL, V152, P195; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MOSIER DE, UNPUB; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SPECTOR SA, 1989, CLIN CHEM, V35, P1581; SPECTOR SA, 1985, CLIN CHEM, V31, P1514	15	252	264	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 15	1991	251	4995					791	794		10.1126/science.1990441	http://dx.doi.org/10.1126/science.1990441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990441				2022-12-01	WOS:A1991EX57500043
J	READ, AE; DONEGAN, E; LAKE, J; FERRELL, L; GALBRAITH, C; KURAMOTO, IK; ZELDIS, JB; ASCHER, NL; ROBERTS, J; WRIGHT, TL				READ, AE; DONEGAN, E; LAKE, J; FERRELL, L; GALBRAITH, C; KURAMOTO, IK; ZELDIS, JB; ASCHER, NL; ROBERTS, J; WRIGHT, TL			HEPATITIS-C IN PATIENTS UNDERGOING LIVER-TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; HEPATOCELLULAR-CARCINOMA; NON-A; VIRUS; ANTIBODIES; RECIPIENTS; PREVALENCE; ASSAY	Objective: To determine the prevalence of antibodies to hepatitis C virus (anti-HCV) among patients undergoing liver transplantation and the relation between anti-HCV and post-transplant hepatitis. Design: Retrospective cohort. Patients: Serum samples from 128 patients who underwent liver transplantation. Sixty-six patients who had 6 months of follow-up and for whom both pretransplant and post-transplant serum samples were available were included in a study to assess the relation between anti-HCV and post-transplant hepatitis. Measurements: Sera were tested for anti-HCV using an enzyme-linked immunosorbent assay (ELISA) and, if positive, two confirmatory tests were done. Patients had a biopsy every week until two specimens showed no abnormal findings. Main Results: Only patients with chronic non-A, non-B hepatitis (15 of 30; 50%), alcoholic cirrhosis (7 of 19; 37%), and chronic hepatitis B infection (3 of 11; 27%) were anti-HCV positive. No patient with another form of chronic liver disease or with acute liver failure due to non-A, non-B hepatitis was anti-HCV positive. After transplantation, loss of anti-HCV was frequent and acquisition rare. Hepatitis developed in the graft in 17% of patients, but the incidence was similar among anti-HCV negative and anti-HCV-positive patients. Conclusions: Hepatitis C virus is a common cause of chronic liver disease in patients requiring liver transplantation, but anti-HCV is rarely found in patients with acute liver failure. Previous HCV infection, based on detection of anti-HCV, is not an independent risk factor for post-transplant hepatitis.	VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA; UNIV CALIF DAVIS, DAVIS, CA 95616 USA; SACRAMENTO MED FDN, CTR BLOOD, SACRAMENTO, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Davis	READ, AE (corresponding author), UNIV CALIF SAN FRANCISCO, GASTROENTEROL UNIT 1120 HSW, SAN FRANCISCO, CA 94143 USA.			Lake, John/0000-0002-4332-0528	NIDDK NIH HHS [DK-26743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRUIX J, 1989, LANCET, V2, P1004; COLOMBO M, 1989, LANCET, V2, P1006; DEMETRIS AJ, 1986, AM J PATHOL, V125, P161; ESTEBAN JI, 1989, LANCET, V2, P294; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; PAYA CV, 1987, J CLIN MICROBIOL, V25, P755, DOI 10.1128/JCM.25.5.755-757.1987; ZELDIS JB, 1990, ANN INTERN MED, V112, P958, DOI 10.7326/0003-4819-112-12-958	8	93	93	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					282	284		10.7326/0003-4819-114-4-282	http://dx.doi.org/10.7326/0003-4819-114-4-282			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1846278				2022-12-01	WOS:A1991EX52100005
J	SMRCKA, AV; HEPLER, JR; BROWN, KO; STERNWEIS, PC				SMRCKA, AV; HEPLER, JR; BROWN, KO; STERNWEIS, PC			REGULATION OF POLYPHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C ACTIVITY BY PURIFIED GQ	SCIENCE			English	Article							PROTEIN ALPHA-SUBUNIT; BETA-GAMMA-SUBUNITS; GUANINE-NUCLEOTIDE; PERTUSSIS TOXIN; BOVINE BRAIN; MEMBRANES; AFFINITY; CALCIUM; CELLS	The hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C yields the second messengers inositol 1,4,5-trisphosphate (InsP3) and 1,2-diacylglycerol. This activity is regulated by a variety of hormones through G protein pathways. However, the specific G protein or proteins involved has not been identified. The alpha-subunit of a newly discovered pertussis toxin-insensitive G protein (G(q)) has recently been isolated and is now shown to stimulate the activity of polyphosphoinositide-specific phospholipase C (PI-PLC) from bovine brain. Both the maximal activity and the affinity of PI-PLC for calcium ion were affected. These results identify G(q) as a G protein that regulates PI-PLC.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM34497, GM31954] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954, R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOYER JL, 1989, J BIOL CHEM, V264, P13917; BRADFORD PG, 1986, BIOCHEM J, V239, P97, DOI 10.1042/bj2390097; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GUTOWSKI S, UNPUB; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HARDENTK, 1989, INOSITOL LIPIDS CELL, P113; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MARTIN TFJ, 1989, INOSITOL LIPIDS CELL, P81; MARTIN TFJ, 1986, J BIOL CHEM, V261, P10041; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SHAFFNER W, 1973, ANAL BIOCHEM, V56, P502; SMRCKA AV, UNPUB; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; Taylor Suzanne, COMMUNICATION; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254	34	841	847	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					804	807		10.1126/science.1846707	http://dx.doi.org/10.1126/science.1846707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1846707				2022-12-01	WOS:A1991EX57500048
J	TREMOLADA, F; CASARIN, C; TAGGER, A; RIBERO, ML; REALDI, G; ALBERTI, A; RUOL, A				TREMOLADA, F; CASARIN, C; TAGGER, A; RIBERO, ML; REALDI, G; ALBERTI, A; RUOL, A			ANTIBODY TO HEPATITIS-C VIRUS IN POSTTRANSFUSION HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; BLOOD	Objective: To evaluate the prevalence of antibodies to hepatitis C virus (anti-HCV), their relation to outcome, and the seroconversion rate in patients with post-transfusion non-A, non-B hepatitis. Design: Retrospective analysis of prospectively collected serum specimens. Setting: A referral-based university hospital. Patients: Sixty-three consecutive patients who developed non-A, non-B post-transfusion hepatitis after open-heart surgery. All patients had follow-up with serial serum testing and clinical evaluation. The mean ( +/- SD) duration of follow-up after hepatitis onset was 81 +/- 33 months (range, 13 to 132 months). Seventeen patients recovered after acute-phase illness, whereas 46 developed chronic disease which, in 30 cases, was confirmed histologically. Main Results: Of 32 patients tested before transfusion, 1 (3.1%) had anti-HCV. Fifty-nine (93%) patients were anti-HCV positive during acute-phase hepatitis: Patients with "early" seroconversion ( < 15 days after hepatitis onset) did not differ from those with "late" seroconversion ( > 60 days after onset) in epidemiologic, clinical, and biochemical features. The rate of anti-HCV positivity during acute-phase illness was not significantly different among patients who recovered (76%) compared with those who developed chronic disease (95%). At 6 to 12 months, patients whose disease resolved had lower antibody activity than those with progressive disease. Further, during long-term follow-up (1 to 9 years), 53% of patients whose disease resolved but only 6.9% of patients who had progressive disease became anti-HCV negative. Conclusions: Hepatitis C virus is the major cause of post-transfusion hepatitis in Italy. The time to anti-HCV seroconversion varies widely after hepatitis onset and is not significantly associated with acute-phase features or outcome of disease.	UNIV PADUA, I-35100 PADUA, ITALY; UNIV MILAN, I-20122 MILAN, ITALY	University of Padua; University of Milan				ALBERTI, ALFREDO/0000-0001-9926-2382				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1975, LANCET, V2, P838, DOI 10.1016/S0140-6736(75)90234-2; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DIENSTAG JL, 1986, SEMIN LIVER DIS, V6, P67, DOI 10.1055/s-2008-1040795; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; SEEFF LB, 1988, GASTROENTEROLOGY, V95, P530; TREMOLADA F, 1988, J CLIN GASTROENTEROL, V10, P413, DOI 10.1097/00004836-198808000-00014; TREMOLADA F, 1983, VOX SANG, V44, P25, DOI 10.1111/j.1423-0410.1983.tb04099.x	8	117	117	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					277	281		10.7326/0003-4819-114-4-277	http://dx.doi.org/10.7326/0003-4819-114-4-277			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1846277				2022-12-01	WOS:A1991EX52100004
J	VEENSTRA, RJ; GLUCK, JC				VEENSTRA, RJ; GLUCK, JC			ACCESS TO INFORMATION ABOUT AIDS	ANNALS OF INTERNAL MEDICINE			English	Article								Medical information related to human immunodeficiency virus (HIV) infection is highly diverse, and the practicing physician or researcher may find specific information difficult to locate. To provide timely access to medical information on topics related to the acquired immunodeficiency syndrome (AIDS), several computer-based products have recently been developed. Some are available from vendors of online information systems, whereas others are available only on CD-ROM or floppy disk. We review several computer-based products. AIDSLINE is the most comprehensive bibliographic index, AIDSTRIALS contain specific information about ongoing unpublished investigational studies, and AIDS Knowledge Base from San Francisco General Hospital is an up-to-date electronic textbook covering all aspects of AIDS. COMPACT LIBRARY: AIDS operates on a microcomputer and combines several database, including full-text AIDS-related articles from nine major medical journals. AIDS References from the Bureau of Hygiene and Tropical Diseases provides critical analysis of publications worldwide. Although smaller in size than AIDSLINE, about one third of the publications covered by this resource are not covered by AIDSLINE.	MANCHESTER MEM HOSP, MANCHESTER, CT 06040 USA		VEENSTRA, RJ (corresponding author), HARTFORD HOSP, HLTH SCI LIB, 80 SEYMOUR ST, HARTFORD, CT 06115 USA.							BIND N, 1990, ONLINE 89 LOGON, V13, P9; CLANCY S, 1988, ONLINE, V12, P93; DUPONT G, 1989, NLM TECH B, V242, P1; DUPONT G, 1989, NLM TECH B, V242, P4; DUTCHER GA, 1989, NLM TECH B, V243, P17; Gottlieb M. S., 1981, MMWR-MORBID MORTAL W, V30, P250; MARMION D, 1990, LIBR SOFTWARE REV, V9, P139; SHORT R, 1989, BRIT J HOSP MED, V42, P166; 1989, CURRENT AIDS LIT, V2, P594	9	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					320	324		10.7326/0003-4819-114-4-320	http://dx.doi.org/10.7326/0003-4819-114-4-320			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1888346				2022-12-01	WOS:A1991EX52100012
J	BUDRENE, EO; BERG, HC				BUDRENE, EO; BERG, HC			COMPLEX PATTERNS FORMED BY MOTILE CELLS OF ESCHERICHIA-COLI	NATURE			English	Article							CHEMOTAXIS; MIGRATION; MOVEMENT	WHEN chemotactic strains of the bacterium Escherichia coli are inoculated on semi-solid agar containing mixtures of amino acids or sugars, the cells swarm outwards in a series of concentric rings: they respond to spatial gradients of attractants generated by uptake and catabolism 1-3. Cells also drift up gradients generated artificially, for example by diffusion from the tip of a capillary tube 4 or by mixing 5. Here we describe conditions under which cells aggregate in response to gradients of attractant which they excrete themselves. When cells are grown in semi-solid agar on intermediates of the tricarboxylic acid cycle, they form symmetrical arrays of spots or stripes that arise sequentially. When cells in a thin layer of liquid culture are exposed to these compounds, spots appear synchronously, more randomly arrayed. In either case, the patterns are stationary. The attractant is a chemical sensed by the aspartate receptor. Its excretion can be triggered by oxidative stress. As oxygen is limiting at high cell densities, aggregation might serve as a mechanism for collective defence.	ROWLAND INST SCI INC,CAMBRIDGE,MA 02142		BUDRENE, EO (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ADLER J, 1969, SCIENCE, V166, P1588, DOI 10.1126/science.166.3913.1588; BERG HC, 1979, NATURE, V278, P349, DOI 10.1038/278349a0; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BERG HC, 1990, BIOPHYS J, V58, P919, DOI 10.1016/S0006-3495(90)82436-X; BERG HC, 1990, COLD SH Q B, V55, P539; DAHLQUIS.FW, 1972, NATURE-NEW BIOL, V236, P120, DOI 10.1038/newbio236120a0; GERHART J, 1989, TRENDS GENET, V5, P233, DOI 10.1016/0168-9525(89)90093-0; Halliwell B., 1985, BRIT J EXP PATHOL, DOI 10.1016/0748-5514(85)90140-0; LOSICK R, 1984, MICROBIAL DEV; MACNAB RM, 1987, ESCHERICHIA COLI SAL, V1, P732; MESIBOV R, 1972, J BACTERIOL, V112, P315, DOI 10.1128/JB.112.1.315-326.1972; Miller J. H., 1972, EXPT MOL GENETICS, P431; NEIDHARDT FC, 1990, PHYSL BACTERIAL CELL, pCH7; NOSSAL R, 1972, EXP CELL RES, V75, P138, DOI 10.1016/0014-4827(72)90529-0; OSTER GF, 1989, J EXP ZOOL, V251, P186, DOI 10.1002/jez.1402510207; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; QU Y, 1989, P NATL ACAD SCI USA, V86, P8358; SHIMKETS LJ, 1982, J BACTERIOL, V152, P451; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOLFE AJ, 1989, P NATL ACAD SCI USA, V86, P6973, DOI 10.1073/pnas.86.18.6973	22	426	430	5	60	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					630	633		10.1038/349630a0	http://dx.doi.org/10.1038/349630a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	2000137				2022-12-01	WOS:A1991EX57000066
J	DAVIES, CH; STARKEY, SJ; POZZA, MF; COLLINGRIDGE, GL				DAVIES, CH; STARKEY, SJ; POZZA, MF; COLLINGRIDGE, GL			GABA-B AUTORECEPTORS REGULATE THE INDUCTION OF LTP	NATURE			English	Article							D-ASPARTATE RECEPTORS; COLLATERAL-COMMISSURAL PATHWAY; SYNAPTIC TRANSMISSION; RAT HIPPOCAMPUS; DEPENDENT DEPRESSION; POTENTIATION; INHIBITION; INVITRO; NEURONS; CULTURE	UNDERSTANDING the mechanisms involved in long-term potentiation (LTP) should provide insights into the cellular and molecular basis of learning and memory in vertebrates 1. It has been established that in the CA1 region of the hippocampus the induction of LTP requires the transient activation of the N-methyl-D-aspartate (NMDA) receptor system 21. During low-frequency transmission, significant activation of this system is prevented by gamma-aminobutyric acid (GABA) mediated synaptic inhibition 3,4 which hyperpolarizes neurons into a region where NMDA receptor-operated channels are substantially blocked by Mg2+ (refs. 5, 6). But during high-frequency transmission, mechanisms are evoked that provide sufficient depolarization of the postsynaptic membrane to reduce this block 7 and thereby permit the induction of LTP. We now report that this critical depolarization is enabled because during high-frequency transmission GABA depresses its own release by an action on GABA(B) autoreceptors, which permits sufficient NMDA receptor activation for the induction of LTP. These findings demonstrate a role for GABA(B) receptors in synaptic plasticity.	UNIV BIRMINGHAM, SCH MED, DEPT INTERNAL MED, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV BRISTOL, SCH MED SCI, DEPT PHARMACOL, BRISTOL BS8 1TD, AVON, ENGLAND	University of Birmingham; University of Bristol			collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015	Collingridge, Graham L/0000-0002-9572-5359				ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BENARI Y, 1979, CAN J PHYSIOL PHARM, V57, P1462, DOI 10.1139/y79-218; BLISS TVP, 1988, NEUROLOGY NEUROBIOLO, V35, P3; COAN EJ, 1985, NEUROSCI LETT, V53, P21, DOI 10.1016/0304-3940(85)90091-6; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P283; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P301; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; DINGLEDINE R, 1986, J PHYSIOL-LONDON, V380, P175, DOI 10.1113/jphysiol.1986.sp016279; DUTAR P, 1988, NEURON, V1, P585, DOI 10.1016/0896-6273(88)90108-0; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; LANTHORN TH, 1981, BRAIN RES, V225, P171, DOI 10.1016/0006-8993(81)90326-7; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557, DOI 10.1152/jn.1985.53.2.557; MOTT DD, 1990, NEUROSCI LETT, V113, P222, DOI 10.1016/0304-3940(90)90307-U; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; OLPE HR, 1990, N-S ARCH PHARMACOL, V342, P194, DOI 10.1007/BF00166964; OLPE HR, 1990, EUR J PHARMACOL, V187, P27, DOI 10.1016/0014-2999(90)90337-6; RANDALL AD, 1990, J PHYSIOL-LONDON, V426, pP51; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0	25	491	495	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 14	1991	349	6310					609	611		10.1038/349609a0	http://dx.doi.org/10.1038/349609a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1847993				2022-12-01	WOS:A1991EX57000059
J	FLETCHER, JA; KOZAKEWICH, HP; HOFFER, FA; LAGE, JM; WEIDNER, N; TEPPER, R; PINKUS, GS; MORTON, CC; CORSON, JM				FLETCHER, JA; KOZAKEWICH, HP; HOFFER, FA; LAGE, JM; WEIDNER, N; TEPPER, R; PINKUS, GS; MORTON, CC; CORSON, JM			DIAGNOSTIC RELEVANCE OF CLONAL CYTOGENETIC ABERRATIONS IN MALIGNANT SOFT-TISSUE TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHROMOSOME-ABNORMALITIES; EWINGS-SARCOMA; SOLID TUMORS; RHABDOMYOSARCOMA; TRANSLOCATION; EXPERIENCE; CHILDHOOD; LEUKEMIA	Background. Malignant soft-tissue tumors often present substantial diagnostic challenges. Chromosome aberrations that might be diagnostic have been identified in some types of soft-tissue tumors, but the overall frequency and diagnostic relevance of these aberrations have not been established. Methods. We attempted to determine the karyotypes of a series of 62 consecutive, unselected malignant spindle-cell or small round-cell soft-tissue tumors (from 46 adults and 16 children) after direct harvesting of cells or short-term culture. All tumors were examined independently by immunohistochemical staining in addition to routine light-microscopical evaluation, and all but two tumors were examined by electron microscopy. Results. Metaphases were obtained from 61 of the 62 tumors, and clonal chromosome aberrations were identified in 55 (89 percent). In the six tumors that yielded metaphases but lacked apparent clonal aberrations, the normal metaphases were found to originate from non-neoplastic stromal elements within the tumor specimens. Thus, all tumors in which karyotyping was successful contained clonal chromosome aberrations. Forty of 62 tumors (65 percent) contained clonal chromosome aberrations that either suggested or confirmed a specific diagnosis; in 15 of these tumors (24 percent of all tumors), the aberrations were important in establishing the final diagnosis. Cytogenetic analyses were particularly informative about small round-cell tumors from children: 8 of 14 round-cell tumors contained diagnostically important chromosome aberrations. Using the combined approaches of light and electron microscopy, immunohistochemistry, and cytogenetics, we established an unambiguous diagnosis for 60 of 62 tumors. Conclusions. Cytogenetic analyses reveal clonal chromosome aberrations in virtually all malignant soft-tissue tumors. These clonal chromosome aberrations, particularly in small round-cell tumors in children, often have diagnostic relevance.	CHILDRENS HOSP MED CTR,DIV HEMATOL ONCOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	FLETCHER, JA (corresponding author), BRIGHAM & WOMENS HOSP,DEPT PATHOL,75 FRANCIS ST,BOSTON,MA 02115, USA.				NCI NIH HHS [1-K11-CA-01498-01] Funding Source: Medline; NIA NIH HHS [AG-00294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABELL MR, 1975, CANCER, V36, P2206, DOI 10.1002/cncr.2820360938; BECHER R, 1984, J NATL CANCER I, V72, P823; CHEN TR, 1988, CANCER GENET CYTOGEN, V33, P77, DOI 10.1016/0165-4608(88)90052-0; CRIST W, 1990, BLOOD, V76, P489; DOUGLASS EC, 1990, GENE CHROMOSOME CANC, V2, P210, DOI 10.1002/gcc.2870020308; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; FLETCHER J A, 1990, Current Opinion in Oncology, V2, P467; FLETCHER JA, 1989, CANCER GENET CYTOGEN, V41, P224, DOI 10.1016/0165-4608(89)90263-X; FLETCHER JA, 1990, CANCER RES, V50, P4092; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; HOROWITZ ME, 1986, J CLIN ONCOL, V4, P559, DOI 10.1200/JCO.1986.4.4.559; LIMON J, 1986, CANCER GENET CYTOGEN, V23, P305, DOI 10.1016/0165-4608(86)90013-0; MANDAHL N, 1989, GENE CHROMOSOME CANC, V1, P9, DOI 10.1002/gcc.2870010104; MIETTINEN M, 1988, CANCER, V62, P2060, DOI 10.1002/1097-0142(19881101)62:9<2060::AID-CNCR2820620932>3.0.CO;2-Y; MOLENAAR WM, 1989, LAB INVEST, V60, P266; MUGNERET F, 1988, CANCER GENET CYTOGEN, V32, P239, DOI 10.1016/0165-4608(88)90286-5; NILBERT M, 1988, CANCER GENET CYTOGEN, V34, P209, DOI 10.1016/0165-4608(88)90262-2; NILBERT M, 1988, CANCER GENET CYTOGEN, V36, P141; PRESANT CA, 1986, J CLIN ONCOL, V4, P1658, DOI 10.1200/JCO.1986.4.11.1658; RICCARDI VM, 1986, CANCER GENET CYTOGEN, V23, P199, DOI 10.1016/0165-4608(86)90179-2; SANDBERG AA, 1988, CANCER RES, V48, P1049; SEABRIGH.M, 1971, LANCET, V2, P971; SHENG WW, 1988, CANCER RES, V48, P983; SHIRAKI M, 1989, CANCER-AM CANCER SOC, V64, P484, DOI 10.1002/1097-0142(19890715)64:2<484::AID-CNCR2820640223>3.0.CO;2-T; TRENT J, 1985, CANCER GENET CYTOGEN, V16, P189, DOI 10.1016/0165-4608(85)90045-7; TRICHE TJ, 1989, PRINCIPLES PRACTICE, P93; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V23, P291, DOI 10.1016/0165-4608(86)90011-7; WHANGPENG J, 1986, CANCER GENET CYTOGEN, V21, P185, DOI 10.1016/0165-4608(86)90001-4; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; WILLIAMS DL, 1985, NEW ENGL J MED, V313, P640; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002; YUNIS JJ, 1981, NEW ENGL J MED, V305, P135, DOI 10.1056/NEJM198107163050304	34	278	280	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 14	1991	324	7					436	442		10.1056/NEJM199102143240702	http://dx.doi.org/10.1056/NEJM199102143240702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX363	1988828				2022-12-01	WOS:A1991EX36300002
J	GERARD, NP; GERARD, C				GERARD, NP; GERARD, C			THE CHEMOTACTIC RECEPTOR FOR HUMAN-C5A ANAPHYLATOXIN	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; C5A RECEPTOR; CLONING; CDNA; C3A	HOST defence and inflammatory responses are controlled and amplified by receptor-mediated events often initiated by a chemotactic factor that directs the approach of phagocytic cells 1. Complement receptors CR1 and CR3 are responsible for the phagocytic and adhesive properties of neutrophils 2,3, whereas the C5a receptor mediates the pro-inflammatory and chemotactic actions of the complement anaphylatoxin C5a 4-6. In addition stimulating chemotaxis, granule enzyme release and superoxide anion production, this receptor stimulates upregulation of expression and activity of the adhesion molecule MAC-1, and of CR1, and a decrease in cell-surface glycoprotein 100MEL-14 on neutrophils 7-9. In vivo, the C5a receptor may participate in anaphylactoid and septic shock. The human C5a receptor was cloned from U937 and HL-60 cells and identified by high affinity binding when expressed in COS-7 cells. The deduced amino-acid sequence of the receptor reveals the expected motifs befitting its interaction with cellular GTP-binding proteins.	BETH ISRAEL HOSP, DIV PULM, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	GERARD, NP (corresponding author), CHILDRENS HOSP MED CTR, INA SUE PERLMUTTER RES LAB, BOSTON, MA 02115 USA.							AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ARUFFO A, 1990, P NATL ACAD SCI USA, V265, P20455; BIRNBAUMER L, 1990, AM REV RESPIR DIS, V141, pS106, DOI 10.1164/ajrccm/141.3_Pt_2.S106; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; COTECCHIA S, 1985, LIFE SCI, V37, P2389, DOI 10.1016/0024-3205(85)90106-7; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DELBALZO U, 1989, CIRC RES, V65, P847, DOI 10.1161/01.RES.65.3.847; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FELTNER DE, 1986, J IMMUNOL, V137, P1961; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; GERARD NP, 1990, J BIOL CHEM, V265, P20455; HACK CE, 1989, AM J MED, V86, P20, DOI 10.1016/0002-9343(89)90224-6; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; JOHNSON RJ, 1985, J BIOL CHEM, V260, P7161; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; ROLLINS TE, 1985, J BIOL CHEM, V260, P7157; SNYDERMAN R, 1986, MED CLIN N AM, V70, P217, DOI 10.1016/S0025-7125(16)30951-8; STIMLERGERARD NP, 1980, AM J PATHOL, V100, P1057; WARD PA, 1974, AM J PATHOL, V77, P519	23	628	662	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 14	1991	349	6310					614	617		10.1038/349614a0	http://dx.doi.org/10.1038/349614a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1847994				2022-12-01	WOS:A1991EX57000061
J	GREGORY, CD; DIVE, C; HENDERSON, S; SMITH, CA; WILLIAMS, GT; GORDON, J; RICKINSON, AB				GREGORY, CD; DIVE, C; HENDERSON, S; SMITH, CA; WILLIAMS, GT; GORDON, J; RICKINSON, AB			ACTIVATION OF EPSTEIN-BARR-VIRUS LATENT GENES PROTECTS HUMAN B-CELLS FROM DEATH BY APOPTOSIS	NATURE			English	Article							ENDEMIC BURKITTS-LYMPHOMA; DEPENDENCE; EXPRESSION; PHENOTYPE; LINES; EBV	EPSTEIN-Barr virus (EBV), a human herpesvirus, establishes a persistent asymptomatic infection of the circulating B-lymphocyte pool 1-3. The mechanism of virus persistence is not understood but, given the limited lifespan of most B cells in vivo, it seems most likely that EBV-infected cells must gain access to the long-lived memory B-cell pool. Here we show in an in vitro system that EBV, through expression of the full set of eight virus-coded 'latent' proteins, can protect human B cells from programmed cell death (apoptosis), the deletion mechanism which normally restricts entry into memory 4. We have found that EBV-positive Burkitt's lymphoma (BL) cell clones 5 retaining the original tumour cell phenotype and expressing only one of the virus latent proteins, the nuclear antigen EBNA 1, are extremely sensitive to apoptosis; in this respect they resemble the tumour's normal cell of origin found in the germinal centres of lymphoid tissue. By contrast, isogenic BL cell clones which have activated expression of all eight EBV latent proteins are resistant to the induction of apoptosis. The EBV latent proteins should therefore be seen not just as activators of B-cell proliferation but, perhaps more importantly, as mediators of enhanced B-cell survival.	UNIV BIRMINGHAM, SCH MED, DEPT CANC STUDIES, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV BIRMINGHAM, DEPT ANAT, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV ASTON, INST PHARMACEUT SCI, BIRMINGHAM B4 7ET, W MIDLANDS, ENGLAND	University of Birmingham; University of Birmingham; Aston University	GREGORY, CD (corresponding author), UNIV BIRMINGHAM, SCH MED, DEPT IMMUNOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND.			Hope, Sheila/0000-0002-3608-4379; Williams, Gwyn/0000-0003-4556-9930; Dive, Caroline/0000-0002-1726-8850				ARENDS MJ, 1990, AM J PATHOL, V136, P593; Berard C W, 1985, IARC Sci Publ, P31; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1987, J IMMUNOL, V139, P313; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MANN RB, 1976, NEW ENGL J MED, V295, P685, DOI 10.1056/NEJM197609232951301; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; PENNELL CA, 1986, EUR J IMMUNOL, V16, P1577, DOI 10.1002/eji.1830161217; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	23	510	525	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 14	1991	349	6310					612	614		10.1038/349612a0	http://dx.doi.org/10.1038/349612a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1705663				2022-12-01	WOS:A1991EX57000060
J	MIRANKER, A; RADFORD, SE; KARPLUS, M; DOBSON, CM				MIRANKER, A; RADFORD, SE; KARPLUS, M; DOBSON, CM			DEMONSTRATION BY NMR OF FOLDING DOMAINS IN LYSOZYME	NATURE			English	Article							EGG-WHITE LYSOZYME; MOLTEN GLOBULE STATE; ALPHA-LACTALBUMIN; RIBONUCLEASE-A; PROTEIN; INTERMEDIATE; EXCHANGE; KINETICS	ALTHOUGH there has been much speculation on the pathways of protein folding, only recently have experimental data on the topic been available. The study of proteins under conditions where species intermediate between the fully folded and unfolded states are stable has provided important information, for example about the disulphide intermediates in BPTI 1,2, cis/trans proline isomers of RNase A3 and the molten globule state of alpha-lactalbumin 4. An alternative approach to investigating folding pathways has involved detection and characterization of transient conformers in refolding studies using stopped-flow methods coupled with NMR measurements of hydrogen exchange 5,6. The formation of intermediate structures has been detected in the early stages of folding of cytochrome c (ref. 7), RNaseA 8 and barnase 9. For alpha-lactalbumin, hydrogen exchange kinetics monitored by NMR proved to be crucial for identifying native-like molten globule state 10. An analogous partially folded protein stable under equilibrium conditions has not been observed for the structurally homologous protein hen egg-white lysozyme, although there is evidence that a similar but transient state is formed during refolding. Here we describe NMR experiments based on competition between hydrogen exchange and the refolding process which not only support the existence of such a transient species for lysozyme, but enable its structural characteristics to be defined. The results indicate that the two structural domains of lysozyme are distinct folding domains, in that they differ significantly in the extent to which compact, probably native-like, structure is present in the early stages of folding.	UNIV OXFORD,INORGAN CHEM LAB,OXFORD OX1 3QR,ENGLAND; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; UNIV OXFORD,OXFORD CTR MOLEC SCI,OXFORD OX1 3QR,ENGLAND	University of Oxford; Harvard University; University of Oxford	MIRANKER, A (corresponding author), HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,7 DIVIN ST,CAMBRIDGE,MA 02138, USA.			Radford, Sheena/0000-0002-3079-8039				BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P365, DOI 10.1098/rspb.1967.0034; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DOBSON CM, 1984, BIOCHEMISTRY-US, V23, P4267, DOI 10.1021/bi00314a001; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; Imoto T., 1972, ENZYMES, V7, P665; JANIN J, 1983, PROG BIOPHYS MOL BIO, V42, P21, DOI 10.1016/0079-6107(83)90003-2; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KATO S, 1982, BIOCHEMISTRY-US, V21, P38, DOI 10.1021/bi00530a007; KATO S, 1981, BIOCHEMISTRY-US, V20, P1080, DOI 10.1021/bi00508a006; Kim P S, 1986, Methods Enzymol, V131, P136; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.bi.59.070190.003215; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; MCCAMMON JA, 1976, NATURE, V262, P325, DOI 10.1038/262325a0; PEDERSEN TG, 1987, J MOL BIOL, V197, P111; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; REDFIELD C, 1988, BIOCHEMISTRY-US, V27, P122, DOI 10.1021/bi00401a020; RODER H, 1986, Proteins Structure Function and Genetics, V1, P34, DOI 10.1002/prot.340010107; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SCHMID FX, 1983, BIOCHEMISTRY-US, V22, P4690, DOI 10.1021/bi00289a013; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; STATES DJ, 1987, J MOL BIOL, V195, P731, DOI 10.1016/0022-2836(87)90192-6; TANFORD C, 1973, J MOL BIOL, V73, P185, DOI 10.1016/0022-2836(73)90322-7; TOPPING KD, 1988, THESIS U OXFORD; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0	29	240	240	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					633	636		10.1038/349633a0	http://dx.doi.org/10.1038/349633a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	2000138				2022-12-01	WOS:A1991EX57000067
J	NIGGLI, E; LEDERER, WJ				NIGGLI, E; LEDERER, WJ			MOLECULAR OPERATIONS OF THE SODIUM CALCIUM EXCHANGER REVEALED BY CONFORMATION CURRENTS	NATURE			English	Article							GUINEA-PIG; VOLTAGE DEPENDENCE; VENTRICULAR CELLS; MECHANISM; VESICLES; PUMPS	THE sodium-calcium exchanger is critical in the normal functioning of many cells 1,2. In heart muscle, it is the principal way by which the cells keep the concentration of intracellular calcium low, pumping out the Ca2+ that enters the cytosol through L-type Ca2+ channels 3,4. The exchanger may also contribute to the triggering of Ca2+ release during voltage-activated excitation-contraction coupling in heart 5,6. Time resolved examination of the conformational changes of macromolecules in living cells has so far been largely restricted to ion-channel proteins whose gating is voltage-dependent 7,8. We have now directly measured electrical currents arising from the molecular rearrangements of the sarcolemmal Na-Ca exchanger. Changes in the conformation of the exchanger protein were activated by a rapid increase in the intracellular calcium concentration produced by flash photolysis of caged calcium 9 in voltage-clamped heart cells. Two components of membrane current were produced, reflecting a calcium-dependent conformational change of the transporter proteins and net transport of ions by the exchanger. The properties of these components provide evidence that the Na-Ca exchanger protein undergoes two consecutive membrane-crossing molecular transitions that each move charge, and that there are at least 250 exchangers per mu-m2 turning over up to 2,500 times per second.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; MED BIOTECHNOL CTR,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Niggli, Ernst/C-4884-2015; Lederer, William/B-1285-2010; Niggli, Ernst/AAL-4351-2020	Niggli, Ernst/0000-0003-4670-4903; Niggli, Ernst/0000-0003-4670-4903				ALLEN TJA, 1989, SODIUM CALCIUM EXCHA; Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BLAUSTEIN MP, 1977, BIOPHYS J, V20, P79, DOI 10.1016/S0006-3495(77)85538-0; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CALLEWAERT G, 1986, PFLUG ARCH EUR J PHY, V406, P424, DOI 10.1007/BF00590947; CHEON J, 1988, J BIOL CHEM, V263, P2309; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; DIFRANCESCO D, 1985, PHILOS T ROY SOC B, V307, P353, DOI 10.1098/rstb.1985.0001; EHARA T, 1989, J PHYSIOL-LONDON, V410, P227, DOI 10.1113/jphysiol.1989.sp017530; EHARA T, 1988, J PHYSIOL-LONDON, V403, P117, DOI 10.1113/jphysiol.1988.sp017242; EISNER DA, 1985, AM J PHYSIOL, V248, pC189, DOI 10.1152/ajpcell.1985.248.3.C189; HILGEMANN DW, 1988, PROG BIOPHYS MOL BIO, V51, P1, DOI 10.1016/0079-6107(88)90009-0; HODGKIN AL, 1987, J PHYSIOL-LONDON, V391, P371, DOI 10.1113/jphysiol.1987.sp016743; HOROWICZ P, 1981, J PHYSIOL-LONDON, V314, P595, DOI 10.1113/jphysiol.1981.sp013726; KAPLAN JH, 1990, REV PHYSL, V52, P897; KHANANSHVILI D, 1990, BIOCHEMISTRY-US, V29, P2437, DOI 10.1021/bi00462a001; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; LAUGER P, 1984, BIOCHIM BIOPHYS ACTA, V779, P307, DOI 10.1016/0304-4157(84)90015-7; LAUGER P, 1987, J MEMBRANE BIOL, V99, P1, DOI 10.1007/BF01870617; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LIPP P, 1988, J PHYSIOL-LONDON, V403, P355, DOI 10.1113/jphysiol.1988.sp017253; MULLINS LJ, 1977, J GEN PHYSIOL, V70, P681, DOI 10.1085/jgp.70.6.681; REUTER H, 1968, J PHYSL, V218, P908; SLAUGHTER RS, 1988, BIOCHEMISTRY-US, V27, P2403, DOI 10.1021/bi00407a023	27	130	132	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					621	624		10.1038/349621a0	http://dx.doi.org/10.1038/349621a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	2000135				2022-12-01	WOS:A1991EX57000063
J	VINCENT, A; HEITZ, D; PETIT, C; KRETZ, C; OBERLE, I; MANDEL, JL				VINCENT, A; HEITZ, D; PETIT, C; KRETZ, C; OBERLE, I; MANDEL, JL			ABNORMAL PATTERN DETECTED IN FRAGILE-X PATIENTS BY PULSED-FIELD GEL-ELECTROPHORESIS	NATURE			English	Article							MENTAL-RETARDATION; MUTATION; INHERITANCE; EXPRESSION; MARKERS; MALES	THE fragile-X syndrome is the most frequent inherited form of mental retardation, with an incidence of 1 in 1,500 males. It is characterized by the presence of a fragile site at Xq27.3 induced in vitro by folate deprivation or by inhibitors of deoxynucleotide synthesis 1. Its mode of inheritance is unusual for an X-linked trait, with incomplete penetrance in both males and females. Some phenotypically normal males transmit the mutation to all their daughters who rarely express any symptoms, but penetrance is high in sons and daughters of these carrier women 2. Genetic and physical mapping of the Xq27-q28 region has confirmed that the disease locus is located at or very near the fragile site 3-6. Hypotheses proposed to account for the abnormalities in the inheritance of the disease include sequence rearrangements by meiotic recombination 1,7,8 or a mutation that affects reactivation of an inactive X chromosome during differentiation of female germ cells 9,10. To detect such rearrangements, or methylation changes that may reflect a locally inactive X chromosome, we used pulsed-field gel analysis of DNA from fragile-X patients with probes close to the fragile-X locus. The probe Do33 (DXS465) detected abnormal patterns in fragile-X patients, but not in normal controls or in non-expressing male transmitters.	FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE; INST PASTEUR,UNITE RECOMBINAISON & EXPRESS GENET,F-75724 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Petit, Christine/0000-0002-9069-002X				BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; LAIRD CD, 1990, AM J HUM GENET, V46, P696; LAIRD CD, 1987, GENETICS, V117, P587; LEDBETTER DH, 1986, NATURE, V324, P161, DOI 10.1038/324161a0; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; OBERLE I, 1986, P NATL ACAD SCI USA, V83, P1016, DOI 10.1073/pnas.83.4.1016; PEMBREY ME, 1985, AM J MED GENET, V21, P709, DOI 10.1002/ajmg.1320210413; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SOUTHERN EM, 1987, NUCLEIC ACIDS RES, V15, P5925, DOI 10.1093/nar/15.15.5925; SUTHERS GK, 1990, AM J HUM GENET, V47, P187; SUTHERS GK, 1989, SCIENCE, V246, P1298, DOI 10.1126/science.2573953; SUTHERS GK, IN PRESS AM J HUM GE; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856	14	195	198	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					624	626		10.1038/349624a0	http://dx.doi.org/10.1038/349624a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1672039				2022-12-01	WOS:A1991EX57000064
J	WHITLEY, R; ARVIN, A; PROBER, C; COREY, L; BURCHETT, S; PLOTKIN, S; STARR, S; JACOBS, R; POWELL, D; NAHMIAS, A; SUMAYA, C; EDWARDS, K; ALFORD, C; CADDELL, G; SOONG, SJ				WHITLEY, R; ARVIN, A; PROBER, C; COREY, L; BURCHETT, S; PLOTKIN, S; STARR, S; JACOBS, R; POWELL, D; NAHMIAS, A; SUMAYA, C; EDWARDS, K; ALFORD, C; CADDELL, G; SOONG, SJ			PREDICTORS OF MORBIDITY AND MORTALITY IN NEONATES WITH HERPES-SIMPLEX VIRUS-INFECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECURRENT GENITAL HERPES; VIDARABINE THERAPY; ENCEPHALITIS; HISTORY; MOTHERS	Background. In a controlled trial comparing acyclovir with vidarabine in the treatment of neonatal herpes simplex virus (HSV) infection, we found no significant difference between the treatments in adjusted mortality and morbidity. Hence, we sought to define for the entire cohort (n = 202) the clinical characteristics that best predicted the eventual outcome in these neonates. Methods. Data were gathered prospectively at 27 centers between 1981 and 1988 in infants less than one months of age who had virologically confirmed HSV infection. We examined the outcomes by multivariate analyses of 24 variables. Disease was classified in one of three categories based on the extent of the involvement at entry into the trial: infection confined to skin, eyes, or mouth; encephalitis; or disseminated infection. Results and Conclusions. There were no deaths among the 85 infants with localized HSV infection. The mortality rate was significantly higher in the 46 neonates with disseminated infection (57 percent) than in the 71 with encephalitis (15 percent). In addition, the risk of death was increased in neonates who were in or near coma at entry (relative risk, 5.2), had disseminated intravascular coagulopathy (relative risk, 3.8), or were premature (relative risk, 3.7). In babies with disseminated disease, HSV pneumonitis was also associated with greater mortality (relative risk, 3.6). In the survivors, morbidity was most frequent in infants with encephalitis (relative risk, 4.4), disseminated infection (relative risk, 2.1), seizures (relative risk, 3.0), or infection with HSV type 2 (relative risk, 4.9). With HSV infection limited to the skin, eyes, or mouth, the presence of three or more recurrences of vesicles was associated with an increased risk of neurologic impairment as compared with two or fewer recurrences.	UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT BIOSTAT,BIRMINGHAM,AL 35294; STANFORD UNIV,DEPT PEDIAT,STANFORD,CA 94305; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; JOSEPH STOKES JR RES INST,DEPT PEDIAT,PHILADELPHIA,PA; UNIV ARKANSAS,DEPT PEDIAT,LITTLE ROCK,AR 72204; OHIO STATE UNIV,DEPT PEDIAT,COLUMBUS,OH 43210; EMORY UNIV,DEPT PEDIAT,ATLANTA,GA 30322; UNIV TEXAS,DEPT PEDIAT,SAN ANTONIO,TX 78285; VANDERBILT UNIV,DEPT PEDIAT,NASHVILLE,TN 37240	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Stanford University; University of Washington; University of Washington Seattle; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; University System of Ohio; Ohio State University; Emory University; University of Texas System; Vanderbilt University	WHITLEY, R (corresponding author), UNIV ALABAMA,DEPT PEDIAT,BIRMINGHAM,AL 35294, USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI062554] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-032] Funding Source: Medline; NIAID NIH HHS [N01-AI-62554] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COREY L, 1988, LANCET, V1, P1; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; STONE KM, 1989, SEX TRANSM DIS, V16, P152, DOI 10.1097/00007435-198907000-00007; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107; SULLIVANBOLYAI J, 1983, JAMA-J AM MED ASSOC, V250, P3059, DOI 10.1001/jama.250.22.3059; SULLIVANBOLYAI JZ, 1986, PEDIATR INFECT DIS J, V5, P309, DOI 10.1097/00006454-198605000-00007; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; WHITLEY RJ, 1980, PEDIATRICS, V66, P489; WHITLEY RJ, 1977, NEW ENGL J MED, V297, P289, DOI 10.1056/NEJM197708112970601; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; WHITLEY RJ, 1986, NEW ENGL J MED, V314, P144, DOI 10.1056/NEJM198601163140303; WHITLEY RJ, 1981, NEW ENGL J MED, V304, P313, DOI 10.1056/NEJM198102053040602; WHITLEY RJ, 1983, PEDIATRICS, V72, P778; WHITLEY RJ, 1980, PEDIATRICS, V66, P495; YEAGER AS, 1984, PEDIATRICS, V73, P188; [No title captured]; 1985, NEW VACCINE DEV ESTA, V1, P280	20	269	272	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 14	1991	324	7					450	454		10.1056/NEJM199102143240704	http://dx.doi.org/10.1056/NEJM199102143240704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX363	1988830				2022-12-01	WOS:A1991EX36300004
J	HANZLICK, R; GOWITT, GT				HANZLICK, R; GOWITT, GT			COCAINE METABOLITE DETECTION IN HOMICIDE VICTIMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							COUNTY; DEATHS; EPIDEMIC; HUMANS; ABUSE	We analyzed the blood of homicide victims for the presence of cocaine's major metabolite, benzoylecgonine. During 1989 in Fulton County, Georgia, 81% of 275 homicide victims were tested for benzoylecgonine; 40% tested positive. The proportions of blacks and victims of firearm injuries who tested positive for benzoylecgonine were significantly larger than the respective proportions for whites and victims of injuries not involving firearms. The data show overall proportions of benzoylecgonine positivity much larger than those previously reported in the literature. The relationships between homicide, race, firearms, and cocaine use deserve further study.			HANZLICK, R (corresponding author), OFF MED EXAMINER FULTON CTY,50 COCA COLA PL SE,ATLANTA,GA 30303, USA.							BAILEY DN, 1989, J FORENSIC SCI, V34, P407; BASELT RC, 1982, DISPOSITION TOXIC DR, P193; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; FAIRBANKS DNF, 1983, ANN PLAS SURG, V10, P452, DOI 10.1097/00000637-198306000-00003; HAMILTON HE, 1977, J FORENSIC SCI, V22, P697; HARRUFF RC, 1988, J FORENSIC SCI, V33, P1231; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JEFFCOAT AR, 1989, DRUG METAB DISPOS, V17, P153; LOWRY PW, 1988, AM J EPIDEMIOL, V128, P1130; ROGERS JN, 1986, J FORENSIC SCI, V31, P1404; SANDER R, 1985, J FORENSIC SCI, V30, P478; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; WETLI CV, 1985, J FORENSIC SCI, V30, P873; 1988, DATA DRUG ABUSE WARN, V7, P26	14	22	23	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					760	761		10.1001/jama.265.6.760	http://dx.doi.org/10.1001/jama.265.6.760			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EW479	1990194				2022-12-01	WOS:A1991EW47900030
J	KITZMILLER, JL; GAVIN, LA; GIN, GD; JOVANOVICPETERSON, L; MAIN, EK; ZIGRANG, WD				KITZMILLER, JL; GAVIN, LA; GIN, GD; JOVANOVICPETERSON, L; MAIN, EK; ZIGRANG, WD			PRECONCEPTION CARE OF DIABETES - GLYCEMIC CONTROL PREVENTS CONGENITAL-ANOMALIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RAT-EMBRYO CULTURE; EARLY-PREGNANCY; SPONTANEOUS-ABORTION; EARLY EMBRYOGENESIS; ARACHIDONIC-ACID; INFANTS; MALFORMATIONS; MOTHERS; ORGANOGENESIS; HYPERGLYCEMIA	To test the value of intensive management of diabetes before and during early pregnancy, 84 women recruited prior to conception were compared with 110 women who were already pregnant referred at 6 to 30 weeks' gestation. All underwent daily measurement of fasting and postprandial capillary blood glucose levels. Mean blood glucose levels during embryogenesis and organogenesis were within 3.3 to 7.8 mmol/L in 50% of preconception subjects and exceeded 10 mmol/L in 6.5%. One major congenital anomaly occurred in 84 infants (1.2%) of women treated before conception compared with 12 anomalies in 110 infants (10.9%) of mothers in the postconception group. Transient symptomatic hypoglycemia occurred during embryogenesis in 60% of women in the preconception group, with a median frequency of 2.7 episodes per week, but was not associated with excess malformations. We conclude that education and intensive management for glycemic control of diabetic women before and during early pregnancy will prevent excess rates of congenital anomalies in their infants.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; CHILDRENS HOSP,SAN FRANCISCO,CA 94119	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	KITZMILLER, JL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,ROOM M-1489,SAN FRANCISCO,CA 94143, USA.							AKAZAWA M, 1989, DIABETES, V38, P1573, DOI 10.2337/diabetes.38.12.1573; BUCHANAN TA, 1986, J CLIN INVEST, V78, P643, DOI 10.1172/JCI112622; BUCHANAN TA, 1989, DIABETES, V38, P1063, DOI 10.2337/diabetes.38.8.1063; COUSINS L, 1983, AM J OBSTET GYNECOL, V147, P333, DOI 10.1016/0002-9378(83)91122-5; CROCKROFT DL, 1977, TERATOLOGY, V16, P141; DAMM P, 1989, AM J OBSTET GYNECOL, V161, P1163, DOI 10.1016/0002-9378(89)90656-X; ERIKSSON UJ, 1988, TERATOLOGY, V37, P365, DOI 10.1002/tera.1420370410; FREINKEL N, 1986, AM J CLIN NUTR, V44, P986, DOI 10.1093/ajcn/44.6.986; FREINKEL N, 1984, NEW ENGL J MED, V310, P223, DOI 10.1056/NEJM198401263100404; FUHRMANN K, 1983, DIABETES CARE, V6, P219, DOI 10.2337/diacare.6.3.219; Gabbe S G, 1977, Obstet Gynecol Surv, V32, P125, DOI 10.1097/00006254-197703000-00001; GOLDMAN AS, 1985, P NATL ACAD SCI USA, V82, P8227, DOI 10.1073/pnas.82.23.8227; GOLDMAN JA, 1986, AM J OBSTET GYNECOL, V155, P293, DOI 10.1016/0002-9378(86)90812-4; GREENE MF, 1989, TERATOLOGY, V39, P225, DOI 10.1002/tera.1420390303; HARE JW, 1980, DIABETES CARE, V3, P294; HOD M, 1986, BIOCHEM BIOPH RES CO, V140, P974, DOI 10.1016/0006-291X(86)90731-X; HORTON WE, 1983, DIABETES, V32, P610, DOI 10.2337/diabetes.32.7.610; HUNTER ES, 1987, AM J PHYSIOL, V253, pE72, DOI 10.1152/ajpendo.1987.253.1.E72; KARLSSON K, 1972, AM J OBSTET GYNECOL, V112, P213, DOI 10.1016/0002-9378(72)90118-4; KEY TC, 1987, AM J OBSTET GYNECOL, V156, P1096, DOI 10.1016/0002-9378(87)90117-7; KITZMILLER JL, 1978, AM J OBSTET GYNECOL, V131, P560, DOI 10.1016/0002-9378(78)90120-5; KITZMILLER JL, 1988, CURR PROBL OBSTET GY, V11, P107; KITZMILLER JL, 1985, OBSTET GYNECOL, V66, P1177; LESLIE RDG, 1978, LANCET, V2, P958; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MILLS JL, 1979, DIABETES, V28, P292, DOI 10.2337/diabetes.28.4.292; MILLS JL, 1988, NEW ENGL J MED, V319, P1617, DOI 10.1056/NEJM198812223192501; MILLS JL, 1988, NEW ENGL J MED, V318, P671, DOI 10.1056/NEJM198803173181104; MIODOVNIK M, 1988, DIABETES CARE, V11, P713, DOI 10.2337/diacare.11.9.713; PEDERSEN J, 1977, PREGNANT DIABETIC HE; PIAQUADI K, 1990, DIABETES S1, V39, pA123; PINTER E, 1986, AM J OBSTET GYNECOL, V155, P691, DOI 10.1016/S0002-9378(86)80001-1; SADLER TW, 1980, TERATOLOGY, V21, P349, DOI 10.1002/tera.1420210311; SADLER TW, 1989, DIABETES, V38, P70, DOI 10.2337/diabetes.38.1.70; SOSENKO JM, 1982, DIABETES CARE, V5, P566, DOI 10.2337/diacare.5.6.566; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; SUSSMAN I, 1988, DIABETES, V37, P974, DOI 10.2337/diabetes.37.7.974; YLINEN K, 1984, BRIT MED J, V289, P345, DOI 10.1136/bmj.289.6441.345	38	350	358	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					731	736		10.1001/jama.265.6.731	http://dx.doi.org/10.1001/jama.265.6.731			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW479	1990188				2022-12-01	WOS:A1991EW47900024
J	LONGAKER, MT; GOLBUS, MS; FILLY, RA; ROSEN, MA; CHANG, SW; HARRISON, MR				LONGAKER, MT; GOLBUS, MS; FILLY, RA; ROSEN, MA; CHANG, SW; HARRISON, MR			MATERNAL OUTCOME AFTER OPEN FETAL SURGERY - A REVIEW OF THE 1ST 17 HUMAN CASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGENITAL DIAPHRAGMATIC-HERNIA; EXPERIMENTAL PULMONARY HYPOPLASIA; HYDRONEPHROSIS INUTERO; NATURAL-HISTORY; SACROCOCCYGEAL TERATOMA; HYDROCEPHALUS INUTERO; PRENATAL-DIAGNOSIS; RENAL DYSPLASIA; URINARY-TRACT; MANAGEMENT	A few fetal diseases may benefit from surgical treatment before birth, but hysterotomy and subsequent delivery by cesarean section pose a risk to the otherwise unaffected mother. To assess maternal risk of mortality, morbidity, and reproductive potential after fetal surgery, we reviewed our experience with 17 highly selected women who underwent fetal surgery. Fifteen of these procedures were performed for one of two congenital anomalies: severe bilateral hydronephrosis and congenital diaphragmatic hernia. There were no deaths or serious maternal injuries. In the 14 women who continued pregnancy after hysterotomy, uterine irritability and preterm labor were frequent complications, requiring early confinement in most cases. There has been no detectable effect on future fertility, as indicated by eight subsequent normal pregnancies. We conclude that hysterotomy for fetal surgery can be accomplished without unduly endangering the mother's life or her future reproductive potential. However, morbidity related to premature labor remains a serious problem, and our ability to control uterine contractions after hysterotomy remains the limiting factor in human fetal surgery.	UNIV CALIF SAN FRANCISCO, DEPT SURG,FETAL TREATMENT PROGRAM, 3RD & PARNASSUS AVE,ROOM 585 HSE, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT OBSTET GYNECOL & REPROD SCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Harrison, Michael/GYD-8608-2022					ADZICK NS, 1985, J PEDIATR SURG, V20, P673, DOI 10.1016/S0022-3468(85)80022-1; ADZICK NS, 1985, J PEDIATR SURG, V20, P315; ADZICK NS, 1984, J PEDIATR SURG, V19, P658, DOI 10.1016/S0022-3468(84)80349-8; ADZICK NS, 1986, J PEDIATR SURG, V21, P477, DOI 10.1016/S0022-3468(86)80215-9; ADZICK NS, 1985, J PEDIATR SURG, V20, P483; BOND SJ, 1989, OBSTET GYNECOL, V74, P25; CHINN DH, 1983, RADIOLOGY, V148, P119, DOI 10.1148/radiology.148.1.6856820; CROMBLEHOLME TM, 1988, J PEDIATR SURG, V23, P1114, DOI 10.1016/S0022-3468(88)80325-7; DUMESIC DA, 1982, NEW ENGL J MED, V307, P1128, DOI 10.1056/NEJM198210283071806; FLAKE AW, 1986, J PEDIATR SURG, V21, P563, DOI 10.1016/S0022-3468(86)80404-3; GLICK PL, 1984, J PEDIATR-US, V105, P97, DOI 10.1016/S0022-3476(84)80371-6; GLICK PL, 1983, J PEDIATR SURG, V18, P681, DOI 10.1016/S0022-3468(83)80003-7; GLICK PL, 1984, J PEDIATR SURG, V19, P870, DOI 10.1016/S0022-3468(84)80387-5; GLICK PL, 1984, J PEDIATR SURG, V19, P649, DOI 10.1016/S0022-3468(84)80348-6; GRANNUM PA, 1986, NEW ENGL J MED, V314, P1431, DOI 10.1056/NEJM198605293142207; HARRIGAN JT, 1981, NEW ENGL J MED, V304, P1527, DOI 10.1056/NEJM198106183042506; Harrison M.R., 1990, UNBORN PATIENT PRENA; HARRISON MR, 1990, J PEDIATR SURG, V25, P47, DOI 10.1016/S0022-3468(05)80163-0; HARRISON MR, 1982, J PEDIATR SURG, V17, P115, DOI 10.1016/S0022-3468(82)80193-0; HARRISON MR, 1981, J PEDIATR SURG, V16, P934, DOI 10.1016/S0022-3468(81)80849-4; HARRISON MR, 1980, SURGERY, V88, P174; HARRISON MR, 1980, SURGERY, V88, P260; HARRISON MR, 1982, J PEDIATR SURG, V17, P728, DOI 10.1016/S0022-3468(82)80437-5; HARRISON MR, 1981, JAMA-J AM MED ASSOC, V246, P774, DOI 10.1001/jama.246.7.774; HARRISON MR, 1987, J PEDIATR SURG, V22, P556, DOI 10.1016/S0022-3468(87)80221-X; HARRISON MR, 1982, J PEDIATR SURG, V17, P965, DOI 10.1016/S0022-3468(82)80476-4; HARRISON MR, 1982, NEW ENGL J MED, V306, P591, DOI 10.1056/NEJM198203113061006; HARRISON MR, 1982, NEW ENGL J MED, V307, P1651, DOI 10.1056/NEJM198212233072623; HARRISON MR, 1983, J PEDIATR SURG, V18, P247, DOI 10.1016/S0022-3468(83)80094-3; HARRISON MR, 1986, CLIN OBSTET GYNECOL, V29, P490, DOI 10.1097/00003081-198609000-00005; HARRISON MR, 1981, JAMA-J AM MED ASSOC, V246, P635, DOI 10.1001/jama.246.6.635; HOLZGREVE W, 1985, PRENATAL DIAG, V5, P245, DOI 10.1002/pd.1970050402; JEFFCOATE TNA, 1959, AM J OBSTET GYNECOL, V77, P475, DOI 10.1016/S0002-9378(16)36717-5; KUHLMANN R S, 1987, Fetal Therapy, V2, P95; LANGER JC, 1989, AM J OBSTET GYNECOL, V160, P1145, DOI 10.1016/0002-9378(89)90177-4; LONGAKER MT, 1989, J PEDIATR SURG, V24, P573, DOI 10.1016/S0022-3468(89)80509-3; NAKAYAMA DK, 1985, J PEDIATR SURG, V20, P118, DOI 10.1016/S0022-3468(85)80282-7; NAKAYAMA DK, 1983, J PEDIATR SURG, V18, P331, DOI 10.1016/S0022-3468(83)80177-8; NAKAYAMA DK, 1983, J PEDIATR SURG, V18, P347, DOI 10.1016/S0022-3468(83)80179-1; NAKAYAMA DK, 1984, J PEDIATR SURG, V19, P333, DOI 10.1016/S0022-3468(84)80248-1; NICOLAIDES K H, 1986, Fetal Therapy, V1, P185; NISULA BC, 1980, AM J OBSTET GYNECOL, V138, P77, DOI 10.1016/0002-9378(80)90014-9; RODECK CH, 1988, NEW ENGL J MED, V319, P1135, DOI 10.1056/NEJM198810273191706; RODECK CH, 1984, AM J OBSTET GYNECOL, V150, P769, DOI 10.1016/0002-9378(84)90683-5	44	115	120	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					737	741		10.1001/jama.265.6.737	http://dx.doi.org/10.1001/jama.265.6.737			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW479	1990189				2022-12-01	WOS:A1991EW47900025
J	RAUB, W				RAUB, W			NEW CONJUGATE VACCINE PROTECTS YOUNGER CHILDREN AGAINST MENINGITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					706	706						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW479	1990184				2022-12-01	WOS:A1991EW47900007
J	RAUB, W				RAUB, W			RISK OF OCCUPATIONAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS EVALUATED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1990, ANN INTERN MED, V113, P740	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					706	706						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW479	1990184				2022-12-01	WOS:A1991EW47900009
J	RAUB, W				RAUB, W			SALIVARY-GLAND FUNCTION NOT AFFECTED BY MENOPAUSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, J GERONTOL, V46, pM11	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					706	706						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EW479	1990184				2022-12-01	WOS:A1991EW47900008
J	DENTON, M; MORGAN, MS; WHITE, RR				DENTON, M; MORGAN, MS; WHITE, RR			QUALITY OF PRESCRIBING OF INTRAVENOUS ANTIBIOTICS IN A DISTRICT GENERAL-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article									WALTON HOSP,DEPT MICROBIOL,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND	University of Liverpool; Walton Centre				morgan, marina/0000-0002-9336-481X				BAIN PG, 1990, BRIT MED J, V300, P1463; BAKKERWOUDENBERG IAJM, 1988, J ANTIMICROB CHEMOTH, V21, P145, DOI 10.1093/jac/21.2.145; BROWN B, 1989, ANN INTERN MED, V110, P247, DOI 10.7326/0003-4819-110-3-247; ZALIN AM, 1989, BRIT MED J, V299, P1279, DOI 10.1136/bmj.299.6710.1279	4	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					327	328		10.1136/bmj.302.6772.327-a	http://dx.doi.org/10.1136/bmj.302.6772.327-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	2001508	Bronze, Green Published			2022-12-01	WOS:A1991EX56900024
J	HANKEY, GJ; WARLOW, CP				HANKEY, GJ; WARLOW, CP			LACUNAR TRANSIENT ISCHEMIC ATTACKS - A CLINICALLY USEFUL CONCEPT	LANCET			English	Article							COMMUNITY STROKE PROJECT; ISCHEMIC ATTACKS; BASAL GANGLIA; INFARCTION; LESIONS; TOMOGRAPHY; OCCLUSION; FEATURES; ARTERY; RISK	Lacunar ischaemic stroke syndromes are clinically, pathophysiologically, and prognostically distinguishable from cortical ischaemic stroke syndromes. Could cerebrovascular transient ischaemic attacks (TIAs) share similar heterogeneity? 130 patients with TIAs were prospectively studied, 71 of whom underwent carotid angiography. Symptoms were associated with a 50% or greater stenosis of the ipsilateral internal carotid artery in 36 (67%) of 54 patients with presumed cortical TIAs, but in only 1 (6%) of 17 patients with presumed lacunar TIAs (p < 0.0001). These findings support the view that cortical TIAs are associated with ipsilateral extracranial internal carotid artery atheromatous disease, whereas patients with lacunar TIAs may have absent or insignificant large-vessel disease, and probably intracranial small-vessel disease. Accurate distinction between lacunar and cortical events may have implications for investigation and treatment of patients with TIAs.			HANKEY, GJ (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				ADAMS HP, 1983, STROKE, V14, P948, DOI 10.1161/01.STR.14.6.948; ALEKSIC SN, 1973, J NEUROL SCI, V19, P331, DOI 10.1016/0022-510X(73)90096-8; [Anonymous], 1989, Stroke, V20, P1407; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BOGOUSSLAVSKY J, 1986, ARCH NEUROL-CHICAGO, V43, P223, DOI 10.1001/archneur.1986.00520030015005; DAMASIO AR, 1982, ARCH NEUROL-CHICAGO, V39, P15, DOI 10.1001/archneur.1982.00510130017003; DEBONO DP, 1981, LANCET, V1, P343; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DONNAN GA, 1987, STROKE, V18, P296; DONNAN GA, 1982, NEUROLOGY, V32, P49, DOI 10.1212/WNL.32.1.49; FISHER CM, 1965, ARCH NEUROL-CHICAGO, V13, P30, DOI 10.1001/archneur.1965.00470010034005; FISHER CM, 1969, ACTA NEUROPATHOL, V12, P1, DOI 10.1007/BF00685305; GARDNER MJ, 1989, STATISTICS CONFIDENC; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HART RG, 1986, ARCH NEUROL-CHICAGO, V43, P71; HUANG CY, 1984, J NEUROL NEUROSUR PS, V47, P84, DOI 10.1136/jnnp.47.1.84; KAPPELLE LJ, 1988, STROKE, V19, P1093, DOI 10.1161/01.STR.19.9.1093; KASE CS, 1988, HDB CLIN NEUROLOGY, P353; LODDER J, 1990, STROKE, V21, P375, DOI 10.1161/01.STR.21.3.375; MILLER VT, 1983, ARCH NEUROL-CHICAGO, V40, P129, DOI 10.1001/archneur.1983.04050030023002; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; MORI E, 1985, STROKE, V16, P454, DOI 10.1161/01.STR.16.3.454; NELSON RF, 1980, STROKE, V11, P256, DOI 10.1161/01.STR.11.3.256; NORRVING B, 1989, STROKE, V20, P59, DOI 10.1161/01.STR.20.1.59; PESSIN MS, 1977, NEW ENGL J MED, V296, P358, DOI 10.1056/NEJM197702172960703; ROTHROCK JF, 1987, STROKE, V18, P781, DOI 10.1161/01.STR.18.4.781; ROTHROCK JF, 1988, NEUROLOGY, V38, P198, DOI 10.1212/WNL.38.2.198; SANTAMARIA J, 1983, STROKE, V14, P911, DOI 10.1161/01.STR.14.6.911; STILLER J, 1982, ARCH NEUROL-CHICAGO, V39, P660, DOI 10.1001/archneur.1982.00510220058014; WARLOW CP, 1982, TRANSIENT ISCHAEMIC, pR7; WIEBERS DO, 1982, NEUROLOGY, V32, P459, DOI 10.1212/WNL.32.5.459; WOLF PA, 1981, JAMA-J AM MED ASSOC, V245, P1442, DOI 10.1001/jama.245.14.1442	34	41	41	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 9	1991	337	8737					335	338		10.1016/0140-6736(91)90953-M	http://dx.doi.org/10.1016/0140-6736(91)90953-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671240				2022-12-01	WOS:A1991EX36200012
J	HERXHEIMER, A				HERXHEIMER, A			HOW MUCH DRUG IN THE TABLET	LANCET			English	Editorial Material								Many recommended drug doses are higher than necessary, for two reasons. Drugs are often introduced at a dose that will be effective in around 90% of the target population, because this helps market penetration. Doses are also partly determined by an irrational preference for round numbers. The dose excess due to such digit preference may be as much as 70% of the correct dose and on average is probably 25%. Needlessly high doses are bound to cause avoidable unwanted effects in a proportion of patients. Rigorous methods must be used to determine the doses recommended and the amount of drug to be put into a tablet or other dosage form.			HERXHEIMER, A (corresponding author), CHARING CROSS HOSP,CHARING CROSS & WESTMINSTER MED SCH,DEPT CLIN PHARMACOL & THERAPEUT,LONDON W6 8RF,ENGLAND.							ALEXANDER GR, 1989, AM J PUBLIC HEALTH, V79, P600, DOI 10.2105/AJPH.79.5.600; HERXHEIMER A, 1987, LANCET, V1, P32; ROSE GA, 1964, LANCET, V1, P296; 1990, BRIT NATIONAL FORMUL; 1990, DRUG THER B, V28, P71	5	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					346	348		10.1016/0140-6736(91)90958-R	http://dx.doi.org/10.1016/0140-6736(91)90958-R			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EX362	1671244				2022-12-01	WOS:A1991EX36200016
J	MARSDEN, PD				MARSDEN, PD			AIDS - IT CAME FOR THE CARNIVAL	BRITISH MEDICAL JOURNAL			English	Editorial Material											MARSDEN, PD (corresponding author), UNIV BRASILIA,CP153121,BR-70010 BRASILIA,DF,BRAZIL.								0	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					337	337		10.1136/bmj.302.6772.337	http://dx.doi.org/10.1136/bmj.302.6772.337			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	2001511	Bronze, Green Published			2022-12-01	WOS:A1991EX56900028
J	PALLESEN, G; HAMILTONDUTOIT, SJ; ROWE, M; YOUNG, LS				PALLESEN, G; HAMILTONDUTOIT, SJ; ROWE, M; YOUNG, LS			EXPRESSION OF EPSTEIN-BARR-VIRUS LATENT GENE-PRODUCTS IN TUMOR-CELLS OF HODGKINS-DISEASE	LANCET			English	Article							ESTABLISHED RODENT CELLS; MEMBRANE-PROTEIN; NASOPHARYNGEAL CARCINOMA; MALIGNANT-LYMPHOMAS; INFECTION; TRANSFORMATION; PATTERNS; TAMARINS; TISSUES; GENOMES	The Epstein-Barr virus (EBV)-encoded latent gene products, latent membrane protein (LMP) and EBV nuclear antigen 2 (EBNA 2), seem to have important roles in EBV-induced cell transformation in vitro, and have been implicated as important effector molecules in EBV-associated lymphomagenesis. Because up to 35% of Hodgkin's disease (HD) samples have been reported to contain EBV genomes, the expression of LMP and EBNA 2 in these tumours was investigated. 84 cases of HD were studied with monoclonal antibodies and immunohistochemical labelling of acetone-fixed cryostat sections. LMP, but not EBNA 2 was demonstrated in Reed-Sternberg (RS) cells of 40 cases (48%); the two proteins were easily detected in transformed lymphocytes of positive control acute infectious mononucleosis tonsils. LMP expression in RS cells varied according to the histological subtype of HD (1/10 cases [10%] of lymphocyte predominance subtype, 16/50 cases [32%] of nodular sclerosis, 23/24 [96%] cases of mixed cellularity type). That the LMP antibodies showed no substantial cross-reactivity with negative control tissues shows that they are useful probes for the diagnosis of latent EBV infection in tissue sections. The finding suggest that EBV is associated with more cases of HD than was previously recognised, that in positive cases RS cells express a latent infection protein phenotype (LMP +, EBNA 2-) which differs from that of other EBV-associated lymphomas, and the LMP expression is related to histologically aggressive subtypes of HD.	UNIV BIRMINGHAM,DEPT CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	PALLESEN, G (corresponding author), AARHUS UNIV,AARHUS KOMMUNE HOSP,INST PATHOL,IMMUNOHISTOL LAB,FINSENSGADE 12,DK-8000 AARHUS,DENMARK.		Dutoit, Stephen Hamilton/E-1815-2013; Rowe, Martin/B-2880-2009; Young, Lawrence S/B-7213-2009	Rowe, Martin/0000-0003-4139-7326; Young, Lawrence S/0000-0003-3919-4298; Hamilton-Dutoit, Stephen/0000-0003-2158-3885	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; CLEARY ML, 1985, SCIENCE, V228, P722, DOI 10.1126/science.2986287; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; EPSTEIN MA, 1986, LANCET, V1, P1425; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GUTENSOHN N, 1981, NEW ENGL J MED, V304, P135, DOI 10.1056/NEJM198101153040302; HARABUCHI Y, 1990, LANCET, V335, P128, DOI 10.1016/0140-6736(90)90002-M; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; JOHANSSO.B, 1970, INT J CANCER, V6, P450, DOI 10.1002/ijc.2910060316; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; LEVINE PH, 1971, CANCER-AM CANCER SOC, V27, P416, DOI 10.1002/1097-0142(197102)27:2<416::AID-CNCR2820270227>3.0.CO;2-W; MASIH A, 1990, LAB INVEST, V62, pA64; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; PALLESEN G, 1990, ORD M EUR ASS HAEM W, P1; PALLESEN G, 1990, 3RD M EUR ASS HAEM W, P1; POPPEMA S, 1985, AM J CLIN PATHOL, V84, P385, DOI 10.1093/ajcp/84.3.385; ROSDAHL N, 1974, BMJ-BRIT MED J, V2, P253, DOI 10.1136/bmj.2.5913.253; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; STAAL SP, 1989, AM J CLIN PATHOL, V91, P1; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEISS LM, 1987, AM J PATHOL, V129, P86; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; WOLF BC, 1990, AM J PATHOL, V136, P717; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; YOUNG LS, 1989, J VIROL, V63, P1967, DOI 10.1128/JVI.63.5.1967-1974.1989	30	658	663	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					320	322		10.1016/0140-6736(91)90943-J	http://dx.doi.org/10.1016/0140-6736(91)90943-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671232				2022-12-01	WOS:A1991EX36200003
J	WIKTOR, SZ; JACOBSON, S; WEISS, SH; SHAW, GM; REUBEN, JS; SHORTY, VJ; MCFARLIN, DE; BLATTNER, WA				WIKTOR, SZ; JACOBSON, S; WEISS, SH; SHAW, GM; REUBEN, JS; SHORTY, VJ; MCFARLIN, DE; BLATTNER, WA			SPONTANEOUS LYMPHOCYTE-PROLIFERATION IN HTLV-II INFECTION	LANCET			English	Note								We measured lymphocyte proliferation in the absence of antigenic stimulation in 45 HTLV-II infected, 9 HTLV-I infected, and 19 HTLV-I seronegative intravenous drug users (IVDU). Lymphocyte proliferation was higher in IVDUs infected with HTLV-II than in seronegative IVDUs but lower than among those infected with HTLV-I. Higher rates of proliferation were also associated with needle sharing, CD4+ and IL2R+ lymphocyte counts, and HTLV-I antibody titres.	NIH,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; DESIRE NARCOT REHABIL CTR,NEW ORLEANS,LA; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PREVENT MED & COMMUNITY HLTH,NEWARK,NJ 07103; UNIV ALABAMA,SCH MED,DEPT MED,BIRMINGHAM,AL 35233	National Institutes of Health (NIH) - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Alabama System; University of Alabama Birmingham	WIKTOR, SZ (corresponding author), NCI,VIRAL EPIDEMIOL SECT,6130 EXECUT BLVD,EPN 434,ROCKVILLE,MD 20852, USA.		Reuben, Jayne/GWQ-6664-2022	Weiss, Stanley/0000-0002-5485-551X				BLATTNER WA, 1989, VIRAL INFECTIONS HUM, P545; GRIFFIN DE, 1989, NEW ENGL J MED, V320, P1667, DOI 10.1056/NEJM198906223202506; JACOBSON S, 1990, ANN NEUROL, V27, P149, DOI 10.1002/ana.410270209; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LILLEHOJ EP, IN PRESS J CLIN MICR; SOOP M, 1988, SCAND J IMMUNOL, V28, P659, DOI 10.1111/j.1365-3083.1988.tb01499.x	6	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 9	1991	337	8737					327	328		10.1016/0140-6736(91)90947-N	http://dx.doi.org/10.1016/0140-6736(91)90947-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX362	1671234				2022-12-01	WOS:A1991EX36200006
J	ALIFANO, P; RIVELLINI, F; LIMAURO, D; BRUNI, CB; CARLOMAGNO, MS				ALIFANO, P; RIVELLINI, F; LIMAURO, D; BRUNI, CB; CARLOMAGNO, MS			A CONSENSUS MOTIF COMMON TO ALL RHO-DEPENDENT PROKARYOTIC TRANSCRIPTION TERMINATORS	CELL			English	Article							ESCHERICHIA-COLI K-12; RIBOSOMAL-RNA TRANSCRIPTION; SALMONELLA-TYPHIMURIUM; HISTIDINE OPERON; BACTERIOPHAGE-LAMBDA; INTERCISTRONIC REGION; REGULATORY REGION; GENE-EXPRESSION; BINDING DOMAIN; SITES	We have characterized at the molecular level several polar mutations in four different cistrons of the his operon of S. typhimurium. An analysis of the his-specific transcripts produced in vivo in the mutant strains, together with in vitro transcription assays, led to the identification of several cryptic Rho-dependent transcription termination elements within the his operon that are activated by the uncoupling of transcription and translation. Common features of these elements were sought and found with a computer program. We have identified a consensus motif, consisting of a cytosine-rich and guanosine-poor region, that is located upstream of the heterogeneous 3' endpoints of the prematurely terminated in vivo transcripts and that is present in all the Rho-dependent transcription terminators described thus far.			ALIFANO, P (corresponding author), NAPLES UNIV,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY.							ADHYA S, 1978, ANNU REV BIOCHEM, V47, P967, DOI 10.1146/annurev.bi.47.070178.004535; AKSOY S, 1984, J BACTERIOL, V159, P260, DOI 10.1128/JB.159.1.260-264.1984; ALIFANO P, 1988, CELL, V55, P351, DOI 10.1016/0092-8674(88)90058-X; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRUNI CB, 1980, J BACTERIOL, V142, P32, DOI 10.1128/JB.142.1.32-42.1980; BURGIN AB, 1990, CELL, V60, P405, DOI 10.1016/0092-8674(90)90592-3; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; CARLOMAGNO MS, 1985, J BACTERIOL, V163, P362, DOI 10.1128/JB.163.1.362-368.1985; CARLOMAGNO MS, 1988, J MOL BIOL, V203, P585, DOI 10.1016/0022-2836(88)90194-5; CERUZZI MAF, 1985, J BIOL CHEM, V260, P9412; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CIAMPI MS, 1989, J BACTERIOL, V171, P4472, DOI 10.1128/JB.171.8.4472-4478.1989; CIAMPI MS, 1988, GENETICS, V218, P193; CLEWELL DB, 1972, J BACTERIOL, V110, P667, DOI 10.1128/JB.110.2.667-676.1972; COURT D, 1980, J MOL BIOL, V138, P231, DOI 10.1016/0022-2836(80)90285-5; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; Favaloro J, 1980, Methods Enzymol, V65, P718; FINK GR, 1967, J MOL BIOL, V30, P97, DOI 10.1016/0022-2836(67)90246-X; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GARRICKS.L, 1970, GENETICS, V66, P231; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; GOODMAN HM, 1980, METHOD ENZYMOL, V75, P63; GOTTESMAN M, 1982, CELL, V29, P727, DOI 10.1016/0092-8674(82)90434-2; GRISOLIA V, 1982, J BACTERIOL, V151, P692, DOI 10.1128/JB.151.2.692-700.1982; HARTMAN PE, 1971, ADV GENET, V16, P1, DOI 10.1016/S0065-2660(08)60352-1; HIGGINS CF, 1986, SOC GENERAL MICROBIO, V39, P179; HOLBEN WE, 1984, P NATL ACAD SCI-BIOL, V81, P6789, DOI 10.1073/pnas.81.21.6789; HOPPE I, 1979, GENETICS, V92, P17; HYMAN HC, 1986, J MOL BIOL, V189, P131, DOI 10.1016/0022-2836(86)90386-4; JOHNSTON HM, 1979, GENETICS, V92, P1; KASAI T, 1974, NATURE, V249, P523, DOI 10.1038/249523a0; KIESER T, 1988, GENE, V65, P83, DOI 10.1016/0378-1119(88)90419-2; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; Maniatis T., 1982, MOL CLONING; MARTIN RG, 1966, J MOL BIOL, V21, P357, DOI 10.1016/0022-2836(66)90104-5; MATSUMOTO Y, 1986, J BACTERIOL, V166, P945, DOI 10.1128/jb.166.3.945-958.1986; Maxam A M, 1980, Methods Enzymol, V65, P499; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; Miller J. H., 1972, EXPT MOL GENETICS, P433; MORGAN EA, 1986, J BACTERIOL, V168, P1; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; NEWTON WA, 1965, J MOL BIOL, V14, P290, DOI 10.1016/S0022-2836(65)80250-9; RECHLER MM, 1972, J MOL BIOL, V69, P427, DOI 10.1016/0022-2836(72)90256-2; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROSENTHAL ER, 1987, J MOL BIOL, V194, P443, DOI 10.1016/0022-2836(87)90673-5; ROSSI J, 1981, CELL, V26, P305, DOI 10.1016/0092-8674(81)90199-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMEISSNER U, 1984, J MOL BIOL, V176, P39, DOI 10.1016/0022-2836(84)90381-4; STANSSENS P, 1986, CELL, V44, P711, DOI 10.1016/0092-8674(86)90837-8; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; STITT BL, 1988, J BIOL CHEM, V263, P11130; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VERDE P, 1981, NUCLEIC ACIDS RES, V9, P2075, DOI 10.1093/nar/9.9.2075; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; VOLL MJ, 1967, J MOL BIOL, V30, P109, DOI 10.1016/0022-2836(67)90247-1; WEK RC, 1987, J BIOL CHEM, V262, P15256; WHITFIELD HJ, 1966, J MOL BIOL, V21, P335, DOI 10.1016/0022-2836(66)90103-3; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; YAGER TD, 1987, ESCHERICHIA COLI SAL, V1, P1241; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0	72	123	124	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					553	563						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1703923				2022-12-01	WOS:A1991EX36100011
J	ANDERSON, MP; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ				ANDERSON, MP; RICH, DP; GREGORY, RJ; SMITH, AE; WELSH, MJ			GENERATION OF CAMP-ACTIVATED CHLORIDE CURRENTS BY EXPRESSION OF CFTR	SCIENCE			English	Article							CYSTIC-FIBROSIS HETEROZYGOTES; RECOMBINANT VACCINIA VIRUS; DEPENDENT PROTEIN-KINASE; ATP SYNTHASE; AIRWAY CELLS; CHANNELS; IDENTIFICATION; EPITHELIUM; TRANSPORT; SYSTEM	Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis. In order to evaluate its function, CFTR was expressed in HeLa, Chinese hamster ovary (CHO), and NIH 3T3 fibroblast cells, and anion permeability was assessed with a fluorescence microscopic assay and the whole-cell patch-clamp technique. Adenosine 3',5'-monophosphate (cAMP) increased anion permeability and chloride currents in cells expressing CFTR, but not in cells expressing a mutant CFTR (DELTA-F508) or in nontransfected cells. The simplest interpretation of these observations is that CFTR is itself a cAMP-activated chloride channel. The alternative interpretation, that CFTR directly or indirectly regulates chloride channels, requires that these cells have endogenous cryptic, chloride channels that are stimulated by cAMP only in the presence of CFTR.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Sanofi-Aventis; Genzyme Corporation				Welsh, Michael/0000-0002-1646-6206; Anderson, Matthew/0000-0003-4602-1811				ANDERSON M P, 1990, Journal of Cell Biology, V111, p63A; ANDERSON MW, UNPUB; BEHM JK, 1987, PEDIATR RES, V22, P271, DOI 10.1203/00006450-198709000-00007; BOAT TF, 1989, METABOLIC BASIS INHE; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHAO AC, 1990, J MEMBRANE BIOL, V113, P193, DOI 10.1007/BF01870071; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CRYSTAL RA, 1990, PEDIATR PULM S, V5, P59; CULLEN JJ, 1987, J CLIN INVEST, V79, P73, DOI 10.1172/JCI112811; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ERLICH HA, 1989, PRC TECHNOLOGY PRINC; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANRAHAN JW, 1989, BICARBONATE CHLORIDE; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; JEFFERSON DM, 1990, AM J PHYSIOL, V249, pL496; KUNZELMANN K, 1989, PFLUG ARCH EUR J PHY, V415, P172, DOI 10.1007/BF00370589; LEONARD RJ, 1989, P NATL ACAD SCI USA, V86, P7629, DOI 10.1073/pnas.86.19.7629; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LIN PY, 1987, J BIOL CHEM, V262, P15345; MADARA JL, 1987, GASTROENTEROLOGY, V92, P1133, DOI 10.1016/S0016-5085(87)91069-9; MASTROCOLA T, 1990, LIFE SCI, V46, P1661, DOI 10.1016/0024-3205(90)90381-Z; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; MCCANN JL, UNPUB; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROMMENS JM, 1989, SCIENCE, V245, P1073; SATO K, 1988, J LAB CLIN MED, V111, P511; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; WAGNER R, 1989, EMBO J, V8, P2827, DOI 10.1002/j.1460-2075.1989.tb08429.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	43	536	546	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					679	682		10.1126/science.1704151	http://dx.doi.org/10.1126/science.1704151			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	EW399	1704151				2022-12-01	WOS:A1991EW39900047
J	BOYLE, WJ; SMEAL, T; DEFIZE, LHK; ANGEL, P; WOODGETT, JR; KARIN, M; HUNTER, T				BOYLE, WJ; SMEAL, T; DEFIZE, LHK; ANGEL, P; WOODGETT, JR; KARIN, M; HUNTER, T			ACTIVATION OF PROTEIN-KINASE-C DECREASES PHOSPHORYLATION OF C-JUN AT SITES THAT NEGATIVELY REGULATE ITS DNA-BINDING ACTIVITY	CELL			English	Article							LEUCINE ZIPPER; TRANSCRIPTION FACTOR; ONCOGENE JUN; METALLOTHIONEIN GENE; GROWTH-FACTORS; FOS PROTEINS; 3T3 CELLS; V-JUN; AP-1; PRODUCT	In resting human epithelial and fibroblastic cells, c-Jun is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by glycogen synthase kinase 3 (GSK-3). These three sites are nested within a single tryptic peptide located just upstream of the basic region of the c-Jun DNA-binding domain (residues 227-252). Activation of protein kinase C results in rapid, site-specific dephosphorylation of c-Jun at one or more of these three sites and is coincident with increased AP-1-binding activity. Phosphorylation of recombinant human c-Jun proteins in vitro by GSK-3 decreases their DNA-binding activity. Mutation of serine 243 to phenylalanine blocks phosphorylation of all three sites in vivo and increases the inherent trans-activation ability of c-Jun at least 10-fold. We propose that c-Jun is present in resting cells in a latent, phosphorylated form that can be activated by site-specific dephosphorylation in response to protein kinase C activation.	SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Ludwig Institute for Cancer Research			Woodgett, Jim/F-1087-2010; Messier, Claude/A-2322-2008	Woodgett, Jim/0000-0003-3731-5797; Messier, Claude/0000-0002-4791-1763	NATIONAL CANCER INSTITUTE [P01CA050528, P30CA014195, R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA14195, CA39780, CA50528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, IN PRESS METH ENZYMO; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1984, CELL, V36, P259; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MULLER R, 1987, ONCOGENE RES, V2, P19; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SATAKE M, 1989, J VIROL, V63, P3669, DOI 10.1128/JVI.63.9.3669-3677.1989; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; YANG-YEN H-F, 1990, New Biologist, V2, P351; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	70	1016	1025	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					573	584		10.1016/0092-8674(91)90241-P	http://dx.doi.org/10.1016/0092-8674(91)90241-P			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1846781				2022-12-01	WOS:A1991EX36100013
J	BRUGGEMEIER, U; KALFF, M; FRANKE, S; SCHEIDEREIT, C; BEATO, M				BRUGGEMEIER, U; KALFF, M; FRANKE, S; SCHEIDEREIT, C; BEATO, M			UBIQUITOUS TRANSCRIPTION FACTOR OTF-1 MEDIATES INDUCTION OF THE MMTV PROMOTER THROUGH SYNERGISTIC INTERACTION WITH HORMONE RECEPTORS	CELL			English	Article							MAMMARY-TUMOR VIRUS; RNA POLYMERASE-II; HEAVY-CHAIN PROMOTER; HISTONE H2B GENE; GLUCOCORTICOID RECEPTOR; BINDING-PROTEIN; ADENOVIRUS ORIGIN; STEROID-HORMONES; DNA-REPLICATION; OCTAMER MOTIF	Steroid hormones induce transcription from the mouse mammary tumor virus (MMTV) promoter by complex mechanisms requiring binding of the hormone receptors to the hormone responsive element (HRE) of the long terminal repeat region. Here we show that the MMTV promoter contains two degenerated octamer motifs immediately upstream of the TATA box that together bind OTF-1 (Oct-1, NFIII) with an affinity similar to the octamer consensus. In transfection experiments, mutation of these octamer motifs interferes with the hormonal response of the MMTV promoter. In vitro, these mutations do not influence basal transcription but completely abolish the stimulatory effect of purified progesterone receptor. Progesterone receptor and glucocorticoid receptor bound to the HRE facilitate binding of OTF-1 to the two octamer motifs. Thus, OTF-1 is a natural mediator of hormonal induction of the MMTV promoter and acts through cooperation with the hormone receptors for binding to DNA.	MAX PLANCK INST MOLEC GENET, W-1000 BERLIN, GERMANY	Max Planck Society	BRUGGEMEIER, U (corresponding author), INST MOLEK BIOL & TUMORFORSCH, EMIL MANNKOPFF STR 2, W-3550 MARBURG, GERMANY.		Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GODING CR, 1989, VIROLOGY, V173, P363; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	49	207	209	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					565	572		10.1016/0092-8674(91)90240-Y	http://dx.doi.org/10.1016/0092-8674(91)90240-Y			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1846780				2022-12-01	WOS:A1991EX36100012
J	BURBULYS, D; TRACH, KA; HOCH, JA				BURBULYS, D; TRACH, KA; HOCH, JA			INITIATION OF SPORULATION IN BACILLUS-SUBTILIS IS CONTROLLED BY A MULTICOMPONENT PHOSPHORELAY	CELL			English	Article							GTP-BINDING PROTEIN; BACILLUS-SUBTILIS; REGULATORY PROTEINS; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; RESPONSE REGULATOR; DEDUCED PRODUCT; GENE; PHOSPHORYLATION; SPO0A	Stage 0 sporulation (spo0) mutants of Bacillus subtilis are defective in the signal transduction system initiating sporulation. Two of the products of these genes, Spo0A and Spo0F, are related to response regulator components of two-component regulatory systems used to control environmental responses in bacteria. The Spo0F response regulator was found to be the primary substrate for phosphorylation by the sporulation-specific protein kinase, KinA. Phosphorylated Spo0F was the phosphodonor for a phosphotransferase, Spo0B, which transferred the phosphate group to the second response regulator, the transcription regulatory protein Spo0A. This phosphorelay provides a mechanism for signal gathering from several protein kinases using Spo0F as a secondary messenger. These divergent signals are integrated through Spo0B phosphotransferase to activate the Spo0A transcription factor. This system provides for many levels of control to prevent capricious induction of sporulation.			BURBULYS, D (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, DIV CELLULAR BIOL, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019416, R01GM039442, R01GM019416] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39442, GM19416] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; ANTONIEWSKI C, 1990, J BACTERIOL, V172, P86, DOI 10.1128/JB.172.1.86-93.1990; BOUVIER J, 1984, P NATL ACAD SCI-BIOL, V81, P7012, DOI 10.1073/pnas.81.22.7012; FERRARI FA, 1985, P NATL ACAD SCI USA, V82, P2647, DOI 10.1073/pnas.82.9.2647; FERRARI FA, 1985, J BACTERIOL, V161, P556, DOI 10.1128/JB.161.2.556-562.1985; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HOCH JA, 1985, J BACTERIOL, V161, P552, DOI 10.1128/JB.161.2.552-555.1985; HOCH JA, 1976, ADV GENET, V18, P69, DOI 10.1016/S0065-2660(08)60437-X; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOSHLAND DE, 1952, J AM CHEM SOC, V74, P2286, DOI 10.1021/ja01129a035; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANDELSTAM J, 1974, J BACTERIOL, V120, P38, DOI 10.1128/JB.120.1.38-42.1974; MARCH PE, 1988, ONCOGENE, V2, P539; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; PEREGO M, 1989, J BACTERIOL, V171, P6187, DOI 10.1128/jb.171.11.6187-6196.1989; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; PEREGO M, 1987, MOL MICROBIOL, V1, P125, DOI 10.1111/j.1365-2958.1987.tb00536.x; RONSON CW, 1987, CELL, V49, P579, DOI 10.1016/0092-8674(87)90530-7; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SPIEGELMAN G, 1990, J BACTERIOL, V172, P5011, DOI 10.1128/jb.172.9.5011-5019.1990; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; TRACH KA, 1985, P NATL ACAD SCI USA, V82, P7260, DOI 10.1073/pnas.82.21.7260; WEINRAUCH Y, 1990, GENE DEV, V4, P860, DOI 10.1101/gad.4.5.860; ZAIN-UL-ABEDIN, 1983, Nucleosides and Nucleotides, V2, P257, DOI 10.1080/07328318308078860; ZUBER P, 1987, J BACTERIOL, V169, P2223, DOI 10.1128/jb.169.5.2223-2230.1987	35	726	744	2	58	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					545	552		10.1016/0092-8674(91)90238-T	http://dx.doi.org/10.1016/0092-8674(91)90238-T			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1846779				2022-12-01	WOS:A1991EX36100010
J	CHAROENVIT, Y; COLLINS, WE; JONES, TR; MILLET, P; YUAN, L; CAMPBELL, GH; BEAUDOIN, RL; BRODERSON, JR; HOFFMAN, SL				CHAROENVIT, Y; COLLINS, WE; JONES, TR; MILLET, P; YUAN, L; CAMPBELL, GH; BEAUDOIN, RL; BRODERSON, JR; HOFFMAN, SL			INABILITY OF MALARIA VACCINE TO INDUCE ANTIBODIES TO A PROTECTIVE EPITOPE WITHIN ITS SEQUENCE	SCIENCE			English	Article							PLASMODIUM-VIVAX; CIRCUMSPOROZOITE PROTEIN; IMMUNODOMINANT EPITOPE; MONOCLONAL-ANTIBODIES; PEPTIDE-SYNTHESIS; FALCIPARUM; ANTIGEN; SPOROZOITES; INFECTION; EFFICACY	Saimiri monkeys immunized with a recombinant protein containing 20 copies of the nine amino acid repeat of the Plasmodium vivax circumsporozoite (CS) protein developed high concentrations of antibodies to the repeat sequence and to sporozoites, but were not protected against challenge. After intravenous injection of an immunoglobulin G3 monoclonal antibody (NVS3) against irradiated P. vivax sporozoites, four of six monkeys were protected against sporozoite-induced malaria, and the remaining two animals took significantly longer to become parasitemic. Epitope mapping demonstrated that NVS3 recognizes only four (AGDR) of the nine amino acids within the repeat region of the P. vivax CS protein. The monkeys immunized with (DRA(D)(A)GQPAG)20 did not produce antibodies to the protective epitope AGDR. Thus, determination of the fine specificity of protective immune responses may be critical to the construction of successful subunit vaccines.	USN,MED RES INST,DEPT INFECT DIS,BETHESDA,MD 20889; CTR DIS CONTROL,MALARIA BRANCH,ATLANTA,GA 30333	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Centers for Disease Control & Prevention - USA								ALVING CR, UNPUB; ARNOT DE, 1985, SCIENCE, V230, P815, DOI 10.1126/science.2414847; ARNOT DE, 1988, P NATL ACAD SCI USA, V85, P8102, DOI 10.1073/pnas.85.21.8102; BALLOU WR, 1987, LANCET, V1, P1277; BARR PJ, 1987, J EXP MED, V165, P1160, DOI 10.1084/jem.165.4.1160; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; CHAROENVIT Y, IN PRESS J IMMUNOL; COLLINS WE, 1989, AM J TROP MED HYG, V40, P455, DOI 10.4269/ajtmh.1989.40.455; COLLINS WE, 1986, AM J TROP MED HYG, V35, P56, DOI 10.4269/ajtmh.1986.35.56; EGAN JE, 1987, SCIENCE, V236, P453, DOI 10.1126/science.3551073; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GORDON DM, 1990, AM J TROP MED HYG, V42, P527, DOI 10.4269/ajtmh.1990.42.527; HALL T, 1984, J IMMUNOL, V132, P2059; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HJELM H, 1976, IMMUNOADSORBENTS PRO, P51; MCCUTCHAN TF, 1985, SCIENCE, V230, P1381, DOI 10.1126/science.2416057; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLET P, 1988, AM J TROP MED HYG, V38, P340; NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; RICKMAN LS, 1990, CLIN RES, V38, pA352; ROSENBERG R, 1989, SCIENCE, V245, P973, DOI 10.1126/science.2672336	25	88	97	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					668	671		10.1126/science.1704150	http://dx.doi.org/10.1126/science.1704150			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1704150				2022-12-01	WOS:A1991EW39900044
J	CLEMMER, CR; BEEBE, TP				CLEMMER, CR; BEEBE, TP			GRAPHITE - A MIMIC FOR DNA AND OTHER BIOMOLECULES IN SCANNING TUNNELING MICROSCOPE STUDIES	SCIENCE			English	Article							TUNNELLING MICROSCOPY; NUCLEIC-ACIDS	Highly ordered pyrolytic graphite (HOPG) is the substrate often used in scanning tunneling microscope (STM) studies of biomolecules such as DNA. All of the images presented in this article are of freshly cleaved HOPG surfaces upon which no deposition has occurred. These images illustrate features previously thought to be due to biological molecules, such as periodicity and meandering of "molecules" over steps. These features can no longer be used to distinguish real molecules from features of the native substrate. The feasibility of the continued use of HOPG as a substrate for biological STM studies is discussed.	UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,CTR BIOPOLYMERS INTERFACES,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NCRR NIH HHS [S07RR07092] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007092] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBRECHT TR, 1988, APPL PHYS LETT, V52, P362, DOI 10.1063/1.99465; AMREIN M, 1989, SCIENCE, V243, P1708, DOI 10.1126/science.2928803; ARSCOTT PG, 1989, NATURE, V339, P484, DOI 10.1038/339484a0; BEEBE TP, 1989, SCIENCE, V243, P370, DOI 10.1126/science.2911747; Binnig G., 1984, TRENDS PHYSICS, P38; BINNING G, 1982, PHYS REV LETT, V49, P57, DOI 10.1103/PhysRevLett.49.57; CHANG H, UNPUB; CLEMMER CR, UNPUB; CRICENTI A, IN PRESS J VAC SCI A; DEROSE JA, IN PRESS J VAC SCI A; DRISCOLL RJ, 1990, NATURE, V346, P294, DOI 10.1038/346294a0; DUNLAP DD, 1989, NATURE, V342, P204, DOI 10.1038/342204a0; HEBEN MJ, 1989, J MICROSC-OXFORD, V152, P651; KELLER D, 1989, P NATL ACAD SCI USA, V86, P5356, DOI 10.1073/pnas.86.14.5356; KUWABARA M, 1990, APPL PHYS LETT, V56, P2396, DOI 10.1063/1.102906; LEE G, 1989, SCIENCE, V244, P475, DOI 10.1126/science.2470146; LINDSAY SM, 1988, J VAC SCI TECHNOL A, V6, P543; Liu C.-P., UNPUB; LYDING JW, 1988, J MICROSC-OXFORD, V152, P371, DOI 10.1111/j.1365-2818.1988.tb01398.x; MARTI O, 1987, SURF SCI, V181, P230, DOI 10.1016/0039-6028(87)90163-4; MOORE AW, 1981, CHEM PHYS CARBON, V17, P233; SALEMINK HWM, 1987, SURF SCI, V181, P139, DOI 10.1016/0039-6028(87)90150-6; SALMERON M, 1990, J VAC SCI TECHNOL A, V8, P635, DOI 10.1116/1.576361; SOTO MR, 1990, SURF SCI, V225, P190, DOI 10.1016/0039-6028(90)90437-D; Thrower P.A., 1969, CHEM PHYS CARBON, V5, P217; THUNDAT T, IN PRESS J VAC SCI A; WILSON TE, IN PRESS J VAC SCI A; YOUNGQUIST MG, IN PRESS J VAC SCI A; ZEGLINSKI DM, IN PRESS REV SCI INS; IN PRESS J VAC SCI A	30	288	294	1	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					640	642		10.1126/science.1992517	http://dx.doi.org/10.1126/science.1992517			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1992517				2022-12-01	WOS:A1991EW39900036
J	CROSTON, GE; KERRIGAN, LA; LIRA, LM; MARSHAK, DR; KADONAGA, JT				CROSTON, GE; KERRIGAN, LA; LIRA, LM; MARSHAK, DR; KADONAGA, JT			SEQUENCE-SPECIFIC ANTIREPRESSION OF HISTONE HL-MEDIATED INHIBITION OF BASAL RNA POLYMERASE-II TRANSCRIPTION	SCIENCE			English	Article							HIGHER-ORDER STRUCTURE; DNA-BINDING PROTEINS; MAJOR LATE PROMOTER; CHROMATIN STRUCTURE; INVITRO TRANSCRIPTION; FUNCTIONAL STEPS; NUCLEOSOMES; GENE; INITIATION; YEAST	To understand the principles of control and selectivity in gene expression, the biochemical mechanisms by which promoter- and enhancer-binding factors regulate transcription by RNA polymerase II were analyzed. A general observed repressor of transcription was purified and identified as histone H-1. Since many aspects of H-1 binding to naked DNA resemble its interaction with chromatin, purified H-1 bound to naked DNA was used as a model for the repressed state of the DNA template. Three sequence-specific transcription factors, Spl, GAL4-VP16, and GAGA factor, were shown to counteract H-1-mediated repression (antirepression). In addition, Spl and GAL4-VP16, but not the GAGA factor, activated transcription in the absence of H-1. Therefore, true activation and antirepression appear to be distinct activities of sequence-specific factors. Furthermore, transcription antirepression by GAL4-VP16 was sustained for several rounds of transcription. These findings, together with previous studies on H-1, suggest that H-1 participates in repression of the genome in the ground state and that sequence-specific transcription factors induce selected genes by a combination of true activation and release of basal repression that is mediated at least in part by H-1.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Cold Spring Harbor Laboratory								ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CARTWRIGHT IL, 1987, EMBO J, V6, P3097, DOI 10.1002/j.1460-2075.1987.tb02618.x; CARTWRIGHT IL, 1982, NUCLEIC ACIDS RES, V10, P5835, DOI 10.1093/nar/10.19.5835; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CLARK DJ, 1988, EUR J BIOCHEM, V178, P225, DOI 10.1111/j.1432-1033.1988.tb14447.x; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; CROSTON GE, UNPUB; DEBERNARDIN W, 1986, J MOL BIOL, V189, P503, DOI 10.1016/0022-2836(86)90320-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GOLDBERG ML, 1979, THESIS STANFORD U; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAMAKAKA RT, IN PRESS P NATL ACAD; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KUMAR NM, 1980, NUCLEIC ACIDS RES, V8, P3535, DOI 10.1093/nar/8.16.3535; LAYBOURN PJ, UNPUB; LENNARD AC, 1985, EMBO J, V4, P3455, DOI 10.1002/j.1460-2075.1985.tb04104.x; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY TJ, 1986, NUCLEIC ACIDS RES, V14, P5563, DOI 10.1093/nar/14.13.5563; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SCHLISSEL MS, 1989, EMBO J, V8, P527; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; THOMAS JO, 1983, EUR J BIOCHEM, V134, P109, DOI 10.1111/j.1432-1033.1983.tb07538.x; THOMAS JO, 1980, EUR J BIOCHEM, V112, P501; van Holde K E, 1988, CHROMATIN; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WOLFFE A P, 1990, New Biologist, V2, P211; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	67	344	347	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 8	1991	251	4994					643	649		10.1126/science.1899487	http://dx.doi.org/10.1126/science.1899487			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1899487				2022-12-01	WOS:A1991EW39900037
J	FARNSWORTH, CL; MARSHALL, MS; GIBBS, JB; STACEY, DW; FEIG, LA				FARNSWORTH, CL; MARSHALL, MS; GIBBS, JB; STACEY, DW; FEIG, LA			PREFERENTIAL INHIBITION OF THE ONCOGENIC FORM OF RASH BY MUTATIONS IN THE GAP BINDING EFFECTOR DOMAIN	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIVATING PROTEIN; P21; PRODUCT; MUTANT; GTPASE; RAS-P21; GENES	The double mutation, D33H/P34S, reduced the transforming activity of oncogenic Ras(H) proteins, G12V and Q61L, 400- and 20-fold, respectively. Remarkably, this same mutation did not reduce the transforming activity of normal Ras(H), nor did it impair the ability of the protein to restore a functional Ras pathway in cells whose endogenous Ras proteins were inhibited. Another mutation in this region, D38N, had similar effects. The mutations reduced downstream coupling efficiency of normal Ras as assessed by yeast adenylyl cyclase stimulation. However, this was offset by decreased GTPase activating protein (GAP) binding, since the latter resulted in elevated GTP-bound mutant Ras in cells. The mutations produced a similar decrease in downstream coupling efficiency of oncogenic Ras, but decreased GAP binding did not compensate because the GTPase activity of oncogenic Ras is not stimulated by GAP. These results imply that preferential inactivation of oncogenic Ras in human tumors may be achieved by reagents designed to inhibit the GAP-binding/"effector" domain of Ras proteins.	MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486; CLEVELAND CLIN EDUC FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44106	Merck & Company; Cleveland Clinic Foundation	FARNSWORTH, CL (corresponding author), TUFTS UNIV,DEPT BIOCHEM,HLTH SCI CAMPUS,BOSTON,MA 02111, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1987, MOL ENDOCRINOL, V1, P127, DOI 10.1210/mend-1-2-127; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HATA Y, 1990, J BIOL CHEM, V265, P7104; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOLFMAN A, 1990, SCIENCE, V248, P247; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	40	80	80	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					625	633		10.1016/0092-8674(91)90246-U	http://dx.doi.org/10.1016/0092-8674(91)90246-U			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1899358				2022-12-01	WOS:A1991EX36100018
J	GLAICHENHAUS, N; SHASTRI, N; LITTMAN, DR; TURNER, JM				GLAICHENHAUS, N; SHASTRI, N; LITTMAN, DR; TURNER, JM			REQUIREMENT FOR ASSOCIATION OF P56LCK WITH CD4 IN ANTIGEN-SPECIFIC SIGNAL TRANSDUCTION IN T-CELLS	CELL			English	Article							TYROSINE-PROTEIN-KINASE; MAJOR HISTOCOMPATIBILITY COMPLEX; PHORBOL-MYRISTATE ACETATE; CLASS-I MOLECULES; LYMPHOCYTES-T; TRANSGENIC MICE; GENE-TRANSFER; MOUSE CD4; RECEPTOR; ACTIVATION	The T cell-specific transmembrane glycoprotein CD4 interacts with class II MHC molecules via its external domain and is associated with the tyrosine kinase p56lck via a cysteine motif in its cytoplasmic domain. We have assessed the ability of CD4 to synergize with the antigen-specific T cell receptor (TCR) for induction of transmembrane signals that result in lymphokine production. Mutant CD4 molecules were introduced into T cells that lacked endogenous CD4 but expressed TCRs specific for lysozyme peptides or the superantigen SEA bound to A(b) or A(bm12) class II MHC molecules. With either ligand, T cell activation occurred only when CD4 was associated with p56lck. These results demonstrate that residues within the cytoplasmic domain of CD4 are required for its coreceptor function in TCR-mediated signal transduction and strongly support the notion that the association of CD4 with p56lck is critical in this process.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	GLAICHENHAUS, N (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.							ACRES RB, 1986, J BIOL CHEM, V261, P6210; ACRES RB, 1987, J IMMUNOL, V139, P2268; ANDERSON P, 1988, J IMMUNOL, V140, P1732; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BIDDISON WE, 1984, J EXP MED, V159, P783, DOI 10.1084/jem.159.3.783; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; CHUCK RS, 1990, P NATL ACAD SCI USA, V87, P5021, DOI 10.1073/pnas.87.13.5021; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; JANEWAY CA, 1989, TODAY, V10, P234; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; MACDONALD HR, 1990, J EXP MED, V171, P1381, DOI 10.1084/jem.171.4.1381; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARNES JR, 1989, ADV IMMUNOL, V44, P265; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; RONCHESE F, 1987, J IMMUNOL, V139, P629; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHASTRI N, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P249; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONHOEGEN P, 1989, J EXP MED, V170, P1879, DOI 10.1084/jem.170.6.1879; WASSMER P, 1985, J IMMUNOL, V135, P2237; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	53	447	462	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					511	520		10.1016/0092-8674(91)90235-Q	http://dx.doi.org/10.1016/0092-8674(91)90235-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1671341				2022-12-01	WOS:A1991EX36100007
J	GOTTFRIED, DS; STEFFEN, MA; BOXER, SG				GOTTFRIED, DS; STEFFEN, MA; BOXER, SG			LARGE PROTEIN-INDUCED DIPOLES FOR A SYMMETRICAL CAROTENOID IN A PHOTOSYNTHETIC ANTENNA COMPLEX	SCIENCE			English	Article							ELECTROCHROMIC ABSORBANCE CHANGES; RHODOPSEUDOMONAS-SPHAEROIDES; RHODOBACTER-SPHAEROIDES; ABSORPTION-SPECTRUM; REACTION CENTERS; ELECTRIC-FIELDS; DYE MOLECULES; LIPID LAYERS; STATE; MEMBRANES	Unusually large electric field effects have been measured for the absorption spectra of carotenoids (spheroidene) in the B800-850 light-harvesting complex from the photosynthetic bacterium Rhodobacter sphaeroides. Quantitative analysis shows that the difference in the permanent dipole moment between the ground state and excited states in this protein complex is substantially larger than for pure spheroidene extracted from the protein. The results demonstrate the presence of a large perturbation on the electronic structure of this nearly symmetric carotenoid due to the organized environment in the protein. This work also provides an explanation for the seemingly anomalous dependence of carotenoid band shifts on transmembrane potential and a generally useful approach for calibrating electric field-sensitive dyes that are widely used to probe potentials in biological systems.			GOTTFRIED, DS (corresponding author), STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305, USA.			Boxer, Steven/0000-0001-9167-4286; Gottfried, David/0000-0002-2729-2504	NIGMS NIH HHS [GM07365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JP, 1985, ANTENNAS REACTION CT, P82; BOXER SG, 1989, J PHYS CHEM-US, V93, P8280, DOI 10.1021/j100363a004; BRETON J, 1987, TOP PHOTOSYNTH, V8, P159; CHANCE B, 1955, NATURE, V175, P803, DOI 10.1038/175803b0; CHANCE BRITTON, 1958, BROOKHAVEN SYMPOSIA IN BIOL, V11, P74; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; COGDELL RJ, 1978, BIOCHIM BIOPHYS ACTA, V502, P409, DOI 10.1016/0005-2728(78)90074-9; COGDELL RJ, 1985, ANTENNAS REACTION CT, P85; CRIELAARD W, 1988, BIOCHIM BIOPHYS ACTA, V973, P505; DEGROOTH BG, 1977, BIOCHIM BIOPHYS ACTA, V462, P237, DOI 10.1016/0005-2728(77)90122-0; DEGROOTH BG, 1980, BIOCHIM BIOPHYS ACTA, V589, P299, DOI 10.1016/0005-2728(80)90046-8; EVANS MB, 1988, BIOCHIM BIOPHYS ACTA, V935, P292, DOI 10.1016/0005-2728(88)90224-1; Goodwin T. W., 1988, Plant pigments., P61; GOTTFRIED DS, UNPUB; HAYASHI H, 1989, PHOTOCHEM PHOTOBIOL, V49, P337, DOI 10.1111/j.1751-1097.1989.tb04116.x; JACKSON JB, 1969, FEBS LETT, V4, P185, DOI 10.1016/0014-5793(69)80230-9; JUNGE W, 1982, PHOTOSYNTHESIS ENERG, V1, P589; KAKITANI T, 1982, BIOPHYS J, V39, P57, DOI 10.1016/S0006-3495(82)84490-1; KRAMER HJM, 1984, BIOCHIM BIOPHYS ACTA, V765, P156, DOI 10.1016/0005-2728(84)90009-4; LIPTAY W, 1988, CHEM PHYS, V120, P439, DOI 10.1016/0301-0104(88)87230-6; LIPTAY W, 1974, EXCITED STATES, P129; LOCKHART DJ, 1987, BIOCHEMISTRY-US, V26, P2958; LOCKHART DJ, 1988, P NATL ACAD SCI USA, V85, P107, DOI 10.1073/pnas.85.1.107; LOCKHART DJ, 1987, BIOCHEMISTRY-US, V26, P664, DOI 10.1021/bi00377a001; LOCKHART DJ, UNPUB; MANTELE W, 1985, ANTENNAS REACTION CT, P88; MATHIES R, 1976, P NATL ACAD SCI USA, V73, P2169, DOI 10.1073/pnas.73.7.2169; MYERS AB, 1981, J AM CHEM SOC, V103, P1881, DOI 10.1021/ja00398a001; PONDER M, 1983, J PHYS CHEM-US, V87, P5090, DOI 10.1021/j150643a010; Rau W., 1988, PLANT PIGMENTS, P231; REICH R, 1972, BERICH BUNSEN GESELL, V76, P589; REICH R, 1976, BIOCHIM BIOPHYS ACTA, V449, P285, DOI 10.1016/0005-2728(76)90140-7; SIEFERMANNHARMS D, 1985, BIOCHIM BIOPHYS ACTA, V811, P325, DOI 10.1016/0304-4173(85)90006-0; SYMONS M, 1977, BIOCHIM BIOPHYS ACTA, V462, P706, DOI 10.1016/0005-2728(77)90112-8; SYMONS M, 1983, BIOCHIM BIOPHYS ACTA, V723, P454, DOI 10.1016/0005-2728(83)90052-X; TRAUTMAN JK, 1990, P NATL ACAD SCI USA, V87, P215, DOI 10.1073/pnas.87.1.215; WRAIGHT CA, 1978, PHOTOSYNTHETIC BACTE, P471; ZUBER H, 1986, TRENDS BIOCHEM SCI, V11, P414, DOI 10.1016/0968-0004(86)90175-1	38	68	69	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					662	665		10.1126/science.1992518	http://dx.doi.org/10.1126/science.1992518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1992518				2022-12-01	WOS:A1991EW39900042
J	HOU, JZ; KAN, M; MCKEEHAN, K; MCBRIDE, G; ADAMS, P; MCKEEHAN, WL				HOU, JZ; KAN, M; MCKEEHAN, K; MCBRIDE, G; ADAMS, P; MCKEEHAN, WL			FIBROBLAST GROWTH-FACTOR RECEPTORS FROM LIVER VARY IN 3 STRUCTURAL DOMAINS	SCIENCE			English	Article							COMPLEMENTARY-DNA; BINDING; CELL; PURIFICATION; PROTEINS; CLONING; GENE	Changes in heparin-binding fibroblast growth factor gene expression and receptor phenotype occur during liver regeneration and in hepatoma cells. The nucleotide sequence of complementary DNA predicts that three amino-terminal domain motifs, two juxtamembrane motifs, and two intracellular carboxyl-terminal domain motifs combine to form a minimum of 6 and potentially 12 homologous polypeptides that constitute the growth factor receptor family in a single human liver cell population. Amino-terminal variants consisted of two transmembrane molecules that contained three and two immunoglobulin-like disulfide loops, as well as a potential intracellular form of the receptor. The two intracellular juxtamembrane motifs differed in a potential serine-threonine kinase phosphorylation site. One carboxyl-terminal motif was a putative tyrosine kinase that contained potential tyrosine phosphorylation sites. The second carboxyl-terminal motif was probably not a tyrosine kinase and did not exhibit the same candidate carboxyl-terminal tyrosine phosphorylation sites.	W ALTON JONES CELL SCI CTR,10 OLD BARN RD,LAKE PLACID,NY 12946									BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; HOSHI H, 1988, FASEB J, V2, P2797, DOI 10.1096/fasebj.2.12.2457532; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KAN M, 1988, J BIOL CHEM, V263, P11306; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	10	223	231	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					665	668		10.1126/science.1846977	http://dx.doi.org/10.1126/science.1846977			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1846977				2022-12-01	WOS:A1991EW39900043
J	KAELIN, WG; PALLAS, DC; DECAPRIO, JA; KAYE, FJ; LIVINGSTON, DM				KAELIN, WG; PALLAS, DC; DECAPRIO, JA; KAYE, FJ; LIVINGSTON, DM			IDENTIFICATION OF CELLULAR PROTEINS THAT CAN INTERACT SPECIFICALLY WITH THE T/E1A-BINDING REGION OF THE RETINOBLASTOMA GENE-PRODUCT	CELL			English	Article							SV40 LARGE-T; SUSCEPTIBILITY GENE; DNA-BINDING; ADENOVIRUS E1A; RB GENE; SV40-TRANSFORMED CELLS; ENCODED PROTEIN; OSTEO-SARCOMA; 1A PROTEINS; EXPRESSION	The SV40 T antigen (T)/adenovirus E1A-binding domain of the retinoblastoma gene product (pRB) has been fused to S. japonicum glutathione S-transferase, and the chimera, bound to insoluble glutathione, was used to search for cellular proteins that can interact specifically with pRB. At least seven such proteins were detected in extracts of multiple human tumor cell lines. These proteins failed to bind to a family of pRB fusion proteins that harbor inactivating mutations in the T/E1A-binding domain and to the wild-type fusion protein in the presence of a peptide replica of the pRB-binding domain of T. Therefore, the binding of one or more of these proteins may contribute to the growth-suppressing function of pRB.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; NCI,USN,MED ONCOL BRANCH,BETHESDA,MD 20814; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA	KAELIN, WG (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.		kaye, frederic/E-2437-2011		NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIGGE J, 1988, NATURE, V334, P109, DOI 10.1038/334109a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HYTE P, 1989, CELL, V56, P67; JENSEN RH, 1977, J HISTOCHEM CYTOCHEM, V25, P573, DOI 10.1177/25.7.70448; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P357; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PALLAS D, 1982, CELL, V30, P407, DOI 10.1016/0092-8674(82)90238-0; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; REISSMANN PT, 1989, ONCOGENE, V4, P839; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHEN JY, 1990, CELL GROWTH DIFF, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; VARLEY JM, 1989, ONCOGENE, V4, P725; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YOKOTA J, 1988, ONCOGENE, V3, P471	66	545	563	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					521	532		10.1016/0092-8674(91)90236-R	http://dx.doi.org/10.1016/0092-8674(91)90236-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1825028				2022-12-01	WOS:A1991EX36100008
J	LEE, VMY; BALIN, BJ; OTVOS, L; TROJANOWSKI, JQ				LEE, VMY; BALIN, BJ; OTVOS, L; TROJANOWSKI, JQ			A68 - A MAJOR SUBUNIT OF PAIRED HELICAL FILAMENTS AND DERIVATIZED FORMS OF NORMAL-TAU	SCIENCE			English	Article							ALZHEIMERS-DISEASE; PROTEIN-TAU; NEUROFIBRILLARY TANGLES; MONOCLONAL-ANTIBODY; NERVOUS-SYSTEM; HUMAN-BRAIN; IDENTIFICATION; LOCALIZATION; ANTIGEN; MICROTUBULES	Putative Alzheimer disease (AD)-specific proteins (A68) were purified to homogeneity and shown to be major subunits of one form of paired helical filaments (PHFs). The amino acid sequence and immunological data indicate that the backbone of A68 is indistinguishable from that of the protein-tau (tau), but A68 could be distinguished from normal human-tau by the degree to which A68 was phosphorylated and by the specific residues in A 68 that served as phosphate acceptors. The larger apparent relative molecular mass (M(r)) of A68, compared to normal human-tau, was attributed to abnormal phosphorylation of A68 because enzymatic dephosphorylation of A68 reduced its M(r) to close to that of normal-tau. Moreover, the LysSerProVal motif in normal human-tau appeared to be an abnormal phosphorylation site in A68 because the Ser in this motif was a phosphate acceptor site in A68, but not in normal human-tau. Thus, the major subunits of a class of PHFs are A68 proteins and the excessive or inappropriate phosphorylation of normal-tau may change its apparent M(r), thus transforming-tau into A68.	WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute	LEE, VMY (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.							ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; CHUI HC, 1989, ARCH NEUROL-CHICAGO, V46, P806, DOI 10.1001/archneur.1989.00520430102025; CLEVELAND DW, 1990, CELL, V60, P701, DOI 10.1016/0092-8674(90)90083-Q; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P816; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; KSIEZAKREDING H, 1988, J BIOL CHEM, V263, P7943; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEE VY, UNPUB; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MCKEE AC, 1989, ANN NEUROL, V26, P652, DOI 10.1002/ana.410260511; MIYAKAWA T, 1989, VIRCHOWS ARCH B, V57, P267, DOI 10.1007/BF02899091; NUKINA N, 1988, NEUROSCI LETT, V87, P240, DOI 10.1016/0304-3940(88)90455-7; OTVOS L, 1989, INT J PEPT PROT RES, V34, P129; PRICE DL, 1989, BIOESSAYS, V10, P69, DOI 10.1002/bies.950100208; SCHMIDT ML, 1990, AM J PATHOL, V136, P1069; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; STERN RA, 1989, AM J PATHOL, V134, P973; Trojanowski J Q, 1990, Annu Rev Gerontol Geriatr, V10, P167; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; Wischik CM, 1989, CURR OPIN CELL BIOL, V1, P115, DOI 10.1016/S0955-0674(89)80047-X; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOLOZIN B, 1988, P NATL ACAD SCI USA, V85, P6202, DOI 10.1073/pnas.85.16.6202; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509	35	1331	1397	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					675	678		10.1126/science.1899488	http://dx.doi.org/10.1126/science.1899488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1899488				2022-12-01	WOS:A1991EW39900046
J	NIGRO, JM; CHO, KR; FEARON, ER; KERN, SE; RUPPERT, JM; OLINER, JD; KINZLER, KW; VOGELSTEIN, B				NIGRO, JM; CHO, KR; FEARON, ER; KERN, SE; RUPPERT, JM; OLINER, JD; KINZLER, KW; VOGELSTEIN, B			SCRAMBLED EXONS	CELL			English	Article							MESSENGER-RNA PRECURSORS; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; ENZYMATIC AMPLIFICATION; SPLICING INVITRO; LEADER SEQUENCE; DNA-POLYMERASES; CDNA LIBRARIES; EVOLUTION; GENES; INTERMEDIATE	Using a sensitive assay for RNA expression, we identified several abnormally spliced transcripts in which exons from a candidate tumor suppressor gene (DCC) were scrambled during the splicing process in vivo. Cloning and sequencing of PCR-amplified segments of the abnormally spliced transcripts showed that exons were joined accurately at consensus splice sites, but in an order different from that present in the primary transcript. Four scrambled transcripts were identified, each involving a different pair of exons. The scrambled transcripts were found at relatively low levels in a variety of normal and neoplastic cells of rodent and human origin, primarily in the nonpolyadenylated component of cytoplasmic RNA. These results demonstrate that the splicing process does not always pair sequential exons in the order predicted from their positions in genomic DNA, thus creating a novel type of RNA product.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,PROGRAM HUMAN GENET,BALTIMORE,MD 21231	Johns Hopkins University; Johns Hopkins University	NIGRO, JM (corresponding author), JOHNS HOPKINS UNIV,CTR ONCOL,SCH MED,BALTIMORE,MD 21231, USA.			Cho, Kathleen/0000-0003-0500-9998	NATIONAL CANCER INSTITUTE [R37CA043460, R01CA043460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER; NCI NIH HHS [CA43460] Funding Source: Medline; NIGMS NIH HHS [GM07184, GM07309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGET SM, 1977, P NATL ACAD SCI USA, V74, P3171, DOI 10.1073/pnas.74.8.3171; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CECH TR, 1985, INT REV CYTOL, V93, P3, DOI 10.1016/S0074-7696(08)61370-4; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW LT, 1977, CELL, V12, P1, DOI 10.1016/0092-8674(77)90180-5; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; EDELMANN P, 1977, CELL, V10, P131, DOI 10.1016/0092-8674(77)90147-7; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GONZALEZ IL, 1990, J MOL BIOL, V212, P27, DOI 10.1016/0022-2836(90)90302-3; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAUER A, 1983, NUCLEIC ACIDS RES, V11, P3503, DOI 10.1093/nar/11.11.3503; HAYMERLE H, 1986, NUCLEIC ACIDS RES, V14, P8615, DOI 10.1093/nar/14.21.8615; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KOLLER B, 1987, CELL, V48, P111, DOI 10.1016/0092-8674(87)90361-8; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; REANNEY D, 1979, NATURE, V277, P598, DOI 10.1038/277598b0; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; VAESSEN RTMJ, 1987, SCIENCE, V235, P1486, DOI 10.1126/science.3823900; VANDOREN K, 1988, NATURE, V335, P556; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.biochem.55.1.631	41	698	748	6	68	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					607	613		10.1016/0092-8674(91)90244-S	http://dx.doi.org/10.1016/0092-8674(91)90244-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991322				2022-12-01	WOS:A1991EX36100016
J	WILKIE, AOM; HIGGS, DR; RACK, KA; BUCKLE, VJ; SPURR, NK; FISCHELGHODSIAN, N; CECCHERINI, I; BROWN, WRA; HARRIS, PC				WILKIE, AOM; HIGGS, DR; RACK, KA; BUCKLE, VJ; SPURR, NK; FISCHELGHODSIAN, N; CECCHERINI, I; BROWN, WRA; HARRIS, PC			STABLE LENGTH POLYMORPHISM OF UP TO 260 KB AT THE TIP OF THE SHORT ARM OF HUMAN CHROMOSOME-16	CELL			English	Article							GLOBIN GENE-CLUSTER; MOUSE ERYTHROLEUKEMIA-CELLS; REPETITIVE DNA-SEQUENCE; SACCHAROMYCES-CEREVISIAE; PSEUDOAUTOSOMAL REGION; RECOMBINATION NODULES; HUMAN TELOMERE; HUMAN MEIOSIS; HUMAN GENOME; LINKAGE MAP	We have completed a long-range restriction map of the terminal region of the short arm of human chromosome 16 (16p13.3) by physically linking a distal genetic locus (alpha-globin) with two recently isolated probes to telomere-associated repeats (TelBam3.4 and TelBam-11). Comparison of 47 chromosomes has revealed major polymorphic length variation in this region: we have identified three alleles in which the alpha-globin genes lie 170 kb, 350 kb, or 430 kb from the telomere. The two most common alleles contain different terminal segments, starting 145 kb distal to the alpha-globin genes. Beyond this boundary these alleles are nonhomologous, yet each contains sequences related to other (different) chromosome termini. This chromosome size polymorphism has probably arisen by occasional exchanges between the subtelomeric regions of nonhomologous chromosomes; analogous length variation is likely to be present at other human telomeres.	IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND; CEDARS SINAI MED CTR,LOS ANGELES,CA 90048; INST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	Cedars Sinai Medical Center; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Oxford	WILKIE, AOM (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MRC,MOLEC HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.		Wilkie, Andrew/AAC-3820-2020; Ceccherini, Isabella/P-8195-2014	Wilkie, Andrew/0000-0002-2972-5481; Ceccherini, Isabella/0000-0001-8732-1955; Brown, William RA/0000-0001-5340-3645	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALTHERR MR, 1989, GENOMICS, V5, P581, DOI 10.1016/0888-7543(89)90026-8; BATES GP, 1990, AM J HUM GENET, V46, P762; BERNARDI G, 1989, ANNU REV GENET, V23, P637, DOI 10.1146/annurev.ge.23.120189.003225; BOJKO M, 1983, CARLSBERG RES COMMUN, V48, P457, DOI 10.1007/BF02911920; Bond D, 1983, OXFORD MONOGRAPHS ME, P198; BROWN WRA, 1990, J CELL SCI, V95, P521; BROWN WRA, 1988, EMBO J, V7, P2377, DOI 10.1002/j.1460-2075.1988.tb03082.x; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; BUCAN M, 1990, GENOMICS, V6, P1; BUCKLE VJ, 1989, NEURON, V3, P647, DOI 10.1016/0896-6273(89)90275-4; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CHANDLEY AC, 1989, J MED GENET, V26, P546, DOI 10.1136/jmg.26.9.546; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHENG JF, 1989, NUCLEIC ACIDS RES, V17, P6109, DOI 10.1093/nar/17.15.6109; CORCORAN LM, 1988, CELL, V53, P807, DOI 10.1016/0092-8674(88)90097-9; DANIEL A, 1989, AM J MED GENET, V31, P14; DEISSEROTH A, 1978, CELL, V15, P55, DOI 10.1016/0092-8674(78)90082-X; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P6197, DOI 10.1093/nar/15.15.6197; GERMINO GG, 1990, AM J HUM GENET, V46, P925; HARRIS PC, 1990, GENOMICS, V7, P195, DOI 10.1016/0888-7543(90)90541-2; HATTON CSR, 1990, BLOOD, V76, P221; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HELDER J, 1987, P NATL ACAD SCI USA, V84, P2387, DOI 10.1073/pnas.84.8.2387; HIGGS DR, 1989, BLOOD, V73, P1081; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; JARMAN AP, 1988, AM J HUM GENET, V43, P249; JARMAN AP, 1986, EMBO J, V5, P1857, DOI 10.1002/j.1460-2075.1986.tb04437.x; JEFFREYS AJ, 1984, NUCLEIC ACIDS RES, V12, P3235, DOI 10.1093/nar/12.7.3235; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LAMB J, 1989, LANCET, V2, P819; LAURIE DA, 1985, ANN HUM GENET, V49, P203, DOI 10.1111/j.1469-1809.1985.tb01694.x; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; MARCUS M, 1976, NATURE, V262, P63, DOI 10.1038/262063a0; MATTEI MG, 1982, HUM GENET, V61, P295; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURRAY AW, 1986, MOL CELL BIOL, V6, P3166, DOI 10.1128/MCB.6.9.3166; Old JM., 1983, METHODS HEMATOLOGY T, V6, P74; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; RAPPOLD GA, 1988, NUCLEIC ACIDS RES, V16, P5361, DOI 10.1093/nar/16.12.5361; RASMUSSEN SW, 1978, CARLSBERG RES COMMUN, V43, P275, DOI 10.1007/BF02906106; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; ROUYER F, 1990, EMBO J, V9, P505, DOI 10.1002/j.1460-2075.1990.tb08137.x; ROYLE NJ, 1988, GENOMICS, V3, P352, DOI 10.1016/0888-7543(88)90127-9; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SPEED RM, 1988, HUM GENET, V78, P260, DOI 10.1007/BF00291673; SPEED RM, 1990, HUM GENET, V84, P547; SPURR NK, 1988, HUM GENET, V78, P333, DOI 10.1007/BF00291730; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; WEBER B, 1990, NUCLEIC ACIDS RES, V18, P3353, DOI 10.1093/nar/18.11.3353; WELLS RA, 1990, GENOMICS, V8, P699, DOI 10.1016/0888-7543(90)90257-U; WELLS RA, 1989, GENOMICS, V5, P761, DOI 10.1016/0888-7543(89)90118-3; WILKIE AOM, 1990, AM J HUM GENET, V46, P1127; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILKIE AOM, 1990, AM J HUM GENET, V46, P1112; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; ZAKIAN VA, 1988, MOL CELL BIOL, V8, P2257, DOI 10.1128/MCB.8.5.2257; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; Zeitlin H C, 1983, Mol Biol Med, V1, P489	64	157	157	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					595	606		10.1016/0092-8674(91)90243-R	http://dx.doi.org/10.1016/0092-8674(91)90243-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991321				2022-12-01	WOS:A1991EX36100015
J	WORKMAN, JL; TAYLOR, ICA; KINGSTON, RE				WORKMAN, JL; TAYLOR, ICA; KINGSTON, RE			ACTIVATION DOMAINS OF STABLY BOUND GAL4 DERIVATIVES ALLEVIATE REPRESSION OF PROMOTERS BY NUCLEOSOMES	CELL			English	Article							RNA POLYMERASE-II; TRANSCRIPTIONALLY ACTIVE CHROMATIN; IMMEDIATE EARLY PROTEIN; DNA-BINDING; GLUCOCORTICOID RECEPTOR; HYPERSENSITIVE SITES; REGULATORY PROTEIN; MAJOR LATE; TATA-BOX; YEAST	GAL4 derivatives containing an activation domain alleviated repression of a promoter during nucleosome assembly. A GAL4 derivative lacking an activation domain stably bound the promoter during nucleosome assembly but was not sufficient to preserve promoter function. The activation domain of GAL4 derivatives was essential for preserving promoter function, and thus the transcriptional stimulatory activity attributable to these activation domains increased dramatically during nucleosome assembly. Furthermore, promoter-bound activation domains allowed the formation of preinitiation complexes after nucleosome assembly. Finally, GAL4 derivatives containing activation domains significantly stimulated transcription through bacterially produced yeast TFIID only from nucleosome-assembled templates. These data indicate that acidic activation domains stimulate transcription by enhancing the ability of basal transcription factors to compete with nucleosomes for occupancy of the promoter.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	WORKMAN, JL (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FELTS SJ, 1990, MOL CELL BIOL, V10, P2390, DOI 10.1128/MCB.10.5.2390; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GOTTESFELD J, 1982, CELL, V28, P781, DOI 10.1016/0092-8674(82)90057-5; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAZVI F, 1983, GENE, V23, P175, DOI 10.1016/0378-1119(83)90049-5; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4349; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SHURE M, 1976, CELL, V8, P215, DOI 10.1016/0092-8674(76)90005-2; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; YANIV M, 1986, CRIT REV BIOCHEM MOL, V21, P1, DOI 10.3109/10409238609113607	66	213	213	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					533	544		10.1016/0092-8674(91)90237-S	http://dx.doi.org/10.1016/0092-8674(91)90237-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991320				2022-12-01	WOS:A1991EX36100009
J	XIAO, H; PERISIC, O; LIS, JT				XIAO, H; PERISIC, O; LIS, JT			COOPERATIVE BINDING OF DROSOPHILA HEAT-SHOCK FACTOR TO ARRAYS OF A CONSERVED 5 BP UNIT	CELL			English	Article							HSP 70 GENE; TRANSCRIPTION FACTOR; PROTEIN-SYNTHESIS; DNA-BINDING; CONSENSUS SEQUENCE; ACTIVATOR PROTEIN; ELEMENTS; YEAST; MELANOGASTER; EXPRESSION	Drosophila heat shock factor (HSF) exists as a multimer in solution and when bound to its regulatory element (HSE). We have previously reported evidence that subunits of HSF associate to form homotrimers and that each subunit contacts a conserved 5 bp DNA sequence repeated within an HSE. Here we show that HSF binding is highly cooperative at two distinct levels: between subunits of the HSF multimer, and between multimers. The binding of HSF to one of a pair of adjacent trimeric binding sites facilitates HSF binding to the second by over 2000-fold. This cooperativity is particularly important in binding HSF at 37-degrees-C, and could account for the requirement for multiple binding sites in vivo and, in part, for the differential expression of heat shock genes.			XIAO, H (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853, USA.			Perisic, Olga/0000-0002-3842-2896	NIGMS NIH HHS [GM25232] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025232, R37GM025232] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; AMIN J, 1985, MOL CELL BIOL, V5, P197, DOI 10.1128/MCB.5.1.197; BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COHEN RS, 1988, NATURE, V332, P856, DOI 10.1038/332856a0; DUDLER R, 1984, CELL, V38, P391, DOI 10.1016/0092-8674(84)90494-X; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LINDQUIST S, 1980, DEV BIOL, V77, P463, DOI 10.1016/0012-1606(80)90488-1; Lis J.T., 1990, STRESS PROTEINS BIOL, P411; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; NOVER L, 1987, ENZYME MICROB TECH, V9, P130, DOI 10.1016/0141-0229(87)90066-4; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Ptashne M., 1986, A GENETIC SWITCH; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLEIF R, 1988, SCIENCE, V240, P127, DOI 10.1126/science.3353710; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SHUEY DJ, 1986, J BIOL CHEM, V261, P7934; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WEI R, 1986, NUCLEIC ACIDS RES, V14, P8183, DOI 10.1093/nar/14.20.8183; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; XIAO H, 1989, MOL CELL BIOL, V9, P1746, DOI 10.1128/MCB.9.4.1746; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	36	215	220	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					585	593		10.1016/0092-8674(91)90242-Q	http://dx.doi.org/10.1016/0092-8674(91)90242-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1899357				2022-12-01	WOS:A1991EX36100014
J	YAMADA, T; PLACZEK, M; TANAKA, H; DODD, J; JESSELL, TM				YAMADA, T; PLACZEK, M; TANAKA, H; DODD, J; JESSELL, TM			CONTROL OF CELL PATTERN IN THE DEVELOPING NERVOUS-SYSTEM - POLARIZING ACTIVITY OF THE FLOOR PLATE AND NOTOCHORD	CELL			English	Article							CHICK LIMB BUD; NEURAL-TUBE; HOMEOBOX GENES; RETINOIC ACID; SPINAL-CORD; EMBRYO; MORPHOGENESIS; NEUROBLASTS; GUIDANCE	Individual classes of neural cells differentiate at distinct locations in the developing vertebrate nervous system. We provide evidence that the pattern of cell differentiation along the dorsoventral axis of the chick neural tube is regulated by signals derived from two ventral midline cell groups, the notochord and floor plate. Grafting an additional notochord or floor plate to ectopic positions, or deleting both cell groups, resulted in changes in the fate and position of neural cell types, defined by expression of specific antigens. These results suggest that the differentiation of neural cells is controlled, in part, by their position with respect to the notochord and floor plate.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10032 USA; GUNMA UNIV, SCH MED, DEPT PHARMACOL, MAEBASHI, GUNMA 371, JAPAN	Columbia University; Columbia University; Gunma University	YAMADA, T (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.		Placzek, Marysia/E-6172-2010	Placzek, Marysia/0000-0002-4106-9229				Ahlborn Friedrich, 1883, Z WISS ZOOL, V39, P191; ALTABA AR, 1989, NATURE, V341, P33; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; BOVOLENTA P, 1988, Society for Neuroscience Abstracts, V14, P271; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; DODD J, 1986, J EXP BIOL, V124, P225; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FONTAINEPERUS JC, 1989, DEVELOPMENT, V107, P413; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, IN PRESS COMMUNICATI; HATTA K, 1991, IN PRESS NATURE; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HOMMA S, 1990, Society for Neuroscience Abstracts, V16, P836; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; HORSTADIUS S, 1944, ACTA ZOOLOGICA, V25, P257; Hutchinson C, 1936, J COMP NEUROL, V63, P465, DOI 10.1002/cne.900630305; JACOBSON CO, 1964, ZOOL BIDR UPPS, V36, P73; JESSELL TM, 1989, CIBA F SYMP, V144, P255; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KITCHIN IC, 1949, J EXP ZOOL, V112, P393, DOI 10.1002/jez.1401120303; KUWADA JY, 1990, J NEUROSCI, V10, P1299; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEBER SM, 1990, J NEUROSCI, V10, P2451; MADEN M, 1989, DEV BIOL, V135, P124, DOI 10.1016/0012-1606(89)90163-2; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MELTON DA, 1989, CIBA F SYMP, V144, P16; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; ROACH FC, 1945, J EXP ZOOL, V99, P53, DOI 10.1002/jez.1400990203; ROSENQUIST GLENN C., 1966, CARNEGIE INST WASH PUBL, V38, P71; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; Spemann H., 1938, EMBRYONIC DEV INDUCT; STEDING G, 1962, ACTA ANAT, V49, P199; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VANSTRAATEN HWM, 1989, DEVELOPMENT, V107, P793; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VANSTRAATEN HWM, 1985, DEV BIOL, V110, P247, DOI 10.1016/0012-1606(85)90081-8; VANSTRAATEN HWM, 1987, NATO ASI, V5, P153; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WALLACE JA, 1985, J COMP NEUROL, V236, P443, DOI 10.1002/cne.902360403; WATTERSON RL, 1955, ANAT REC, V122, P539, DOI 10.1002/ar.1091220405; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WATTERSON RL, 1965, ORGANOGENESIS, P129; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; YAGINUMA H, 1990, DEVELOPMENT, V108, P705	54	647	659	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					635	647		10.1016/0092-8674(91)90247-V	http://dx.doi.org/10.1016/0092-8674(91)90247-V			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991324				2022-12-01	WOS:A1991EX36100019
J	ZHOU, RP; OSKARSSON, M; PAULES, RS; SCHULZ, N; CLEVELAND, D; VANDEWOUDE, GF				ZHOU, RP; OSKARSSON, M; PAULES, RS; SCHULZ, N; CLEVELAND, D; VANDEWOUDE, GF			ABILITY OF THE C-MOS PRODUCT TO ASSOCIATE WITH AND PHOSPHORYLATE TUBULIN	SCIENCE			English	Article							PROTO-ONCOGENE PRODUCT; CELL-CYCLE; MEIOTIC MATURATION; XENOPUS OOCYTES; GERM-CELLS; EXPRESSION; EGGS; OOGENESIS; CLEAVAGE; PROTEINS	The mos proto-oncogene product, pp39mos, is a protein kinase and has been equated with cytostatic factor (CSF), an activity in unfertilized eggs that is thought to be responsible for the arrest of meiosis at metaphase II. The biochemical properties and potential substrates of pp39mos were examined in unfertilized eggs and in transformed cells in order to study how the protein functions both as CSF and in transformation. The pp39mos protein associated with polymers under conditions that favor tubulin oligomerization and was present in an approximately 500-kilodalton "core" complex under conditions that favor depolymerization. beta-Tubulin was preferentially coprecipitated in pp39mos immunoprecipitates and was the major phosphorylated product in a pp39mos-dependent immune complex kinase assay. Immunofluorescence analysis of NIH 3T3 cells transformed with Xenopus c-mos showed that pp39mos colocalizes with tubulin in the spindle during metaphase and in the midbody and asters during telophase. Disruption of microtubules with nocodazole affected tubulin and pp39mos organization in the same way. It therefore appears that pp39mos is a tubulin-associated protein kinase and may thus participate in the modification of microtubules and contribute to the formation of the spindle. This activity expressed during interphase in somatic cells may be responsible for the transforming activity of pp39mos.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University	ZHOU, RP (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702, USA.		Cleveland, Don/AAN-9783-2021	Paules, Richard S/0000-0001-9106-7486	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BORISY GG, 1975, ANN NY ACAD SCI, V253, P107, DOI 10.1111/j.1749-6632.1975.tb19196.x; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FISCHINGER PJ, 1971, J GEN VIROL, V13, P203, DOI 10.1099/0022-1317-13-2-203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GRAETTA G, 1989, CELL, V56, P829; HEIDEMANN SR, 1980, DEV BIOL, V80, P489, DOI 10.1016/0012-1606(80)90421-2; KATZ W, 1990, MOL CELL BIOL, V10, P5286, DOI 10.1128/MCB.10.10.5286; KLOETZER WS, 1984, VIROLOGY, V138, P143, DOI 10.1016/0042-6822(84)90154-5; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEYERHOF PG, 1977, DEV BIOL, V61, P214, DOI 10.1016/0012-1606(77)90293-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAULES RS, 1988, ONCOGENE, V3, P59; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHIFF PB, 1979, NATURE, V277, P605; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; YEW N, IN PRESS MOL CELL BI	40	137	139	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					671	675		10.1126/science.1825142	http://dx.doi.org/10.1126/science.1825142			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1825142				2022-12-01	WOS:A1991EW39900045
J	BRENNAN, TA; LEAPE, LL; LAIRD, NM; HEBERT, L; LOCALIO, AR; LAWTHERS, AG; NEWHOUSE, JP; WEILER, PC; HIATT, HH				BRENNAN, TA; LEAPE, LL; LAIRD, NM; HEBERT, L; LOCALIO, AR; LAWTHERS, AG; NEWHOUSE, JP; WEILER, PC; HIATT, HH			INCIDENCE OF ADVERSE EVENTS AND NEGLIGENCE IN HOSPITALIZED-PATIENTS - RESULTS OF THE HARVARD MEDICAL-PRACTICE STUDY-I	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MALPRACTICE	Background. As part of an interdisciplinary study of medical injury and malpractice litigation, we estimated the incidence of adverse events, defined as injuries caused by medical management, and of the subgroup of such injuries that resulted from negligent or substandard care. Methods. We reviewed 30, 121 randomly selected records from 51 randomly selected acute care, nonpsychiatric hospitals in New York State in 1984. We then developed population estimates of injuries and computed rates according to the age and sex of the patients as well as the specialties of the physicians. Results. Adverse events occurred in 3.7 percent of the hospitalizations (95 percent confidence interval, 3.2 to 4.2), and 27.6 percent of the adverse events were due to negligence (95 percent confidence interval, 22.5 to 32.6). Although 70.5 percent of the adverse events gave rise to disability lasting less than six months, 2.6 percent caused permanently disabling injuries and 13.6 percent led to death. The percentage of adverse events attributable to negligence increased in the categories of more severe injuries (Wald test chi-2 = 21.04, P < 0.0001). Using weighted totals, we estimated that among the 2,671,863 patients discharged from New York hospitals in 1984 there were 98,609 adverse events and 27,179 adverse events involving negligence. Rates of adverse events rose with age (P < 0.0001). The percentage of adverse events due to negligence was markedly higher among the elderly (P < 0.01). There were significant differences in rates of adverse events among categories of clinical specialties (P < 0.0001), but no differences in the percentage due to negligence. Conclusions. There is a substantial amount of injury to patients from medical management, and many injuries are the result of substandard care.	HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard University	BRENNAN, TA (corresponding author), BRIGHAM & WOMENS HOSP,DIV GEN MED,75 FRANCIS ST,BOSTON,MA 02115, USA.		Newhouse, Joseph/AGJ-5632-2022					BRENNAN TA, 1990, ANN INTERN MED, V112, P221, DOI 10.7326/0003-4819-112-3-221; BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; BRENNAN TA, IN PRESS JUST DOCTOR; COUCH NP, 1981, NEW ENGL J MED, V304, P634, DOI 10.1056/NEJM198103123041103; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; NADER R, 1987, GONZAGA LAW REV, V22, P15; PEAR T, 1990, NY TIMES        0923, P1; PRIEST, 1987, VAL UL REV, V22, P1; ROBINSON GO, 1986, LAW CONTEMP PROBL, V49, P5, DOI 10.2307/1191413; SHAH BV, 1981, SESUDAAN STANDARD ER; SIEGEL DR, 1986, NEW YORK STATE J MED, V86, P377; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; 1986, GAO HRD86112 GEN ACC; 1985, STATEWIDE PLANNING R; 1987, DHHS19041270133 DEP; 1977, REPORT MED INSURANCE; 1986, GAO HRD8755 GEN ACC; 1987, PRELIMINARY FACT FIN; 1986, GAO HRD8721 GEN ACC; 1990, PATIENTS DOCTORS LAW	20	2974	3070	0	67	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 7	1991	324	6					370	376		10.1056/NEJM199102073240604	http://dx.doi.org/10.1056/NEJM199102073240604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW296	1987460				2022-12-01	WOS:A1991EW29600004
J	COMPANY, M; ARENAS, J; ABELSON, J				COMPANY, M; ARENAS, J; ABELSON, J			REQUIREMENT OF THE RNA HELICASE-LIKE PROTEIN PRP22 FOR RELEASE OF MESSENGER-RNA FROM SPLICEOSOMES	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; NUCLEOTIDE-SEQUENCE; RIBOSOMAL PROTEIN-S1; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; PUTATIVE HELICASES; YEAST; GENE; CLONING; ATP	The product of the yeast PRP22 gene acts late in the splicing of yeast pre-messenger RNA, mediating the release of the spliced mRNA from the spliceosome. The predicted PRP22 protein sequence shares extensive homology with that of PRP2 and PRP16 proteins, which are also involved in nuclear pre-mRNA splicing. The homologous region contains sequence elements characteristic of several demonstrated or putative ATP-dependent RNA helicases. A putative RNA-binding motif originally identified in bacterial ribosomal protein S1 and Escherichia coli polynucleotide phosph orylase has also been found in PRP22.			COMPANY, M (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							ANDERSON GJ, 1989, NATURE, V342, P819, DOI 10.1038/342819a0; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BJORN SP, 1989, MOL CELL BIOL, V9, P3698, DOI 10.1128/MCB.9.9.3698; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHANG TH, 1990, P NATL ACAD SCI USA, V87, P1571, DOI 10.1073/pnas.87.4.1571; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; COLLETT MS, 1988, VIROLOGY, V165, P191, DOI 10.1016/0042-6822(88)90672-1; COUTO JR, 1987, GENE DEV, V1, P445, DOI 10.1101/gad.1.5.445; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; ERNST H, 1987, J BIOL CHEM, V262, P1206; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAIN S, 1989, GENE, V82, P357, DOI 10.1016/0378-1119(89)90063-2; LAIN S, 1990, NUCLEIC ACIDS RES, V18, P7003, DOI 10.1093/nar/18.23.7003; LAIN S, 1989, VIRUS RES, V13, P157, DOI 10.1016/0168-1702(89)90013-0; LAIN S, 1991, J VIROL, V65, P1, DOI 10.1016/0042-6822(91)90641-N; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LANE D, 1988, NATURE, V334, P478, DOI 10.1038/334478a0; LIN RJ, 1987, GENE DEV, V1, P7, DOI 10.1101/gad.1.1.7; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; LUSTIG AJ, 1986, CELL, V47, P953, DOI 10.1016/0092-8674(86)90810-X; MACKOW E, 1987, VIROLOGY, V159, P217, DOI 10.1016/0042-6822(87)90458-2; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; RAY BK, 1985, J BIOL CHEM, V260, P7651; REGNIER P, 1987, J BIOL CHEM, V262, P63; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUBY SW, 1991, TRENDS GENET, V7, P79; SANDS JF, 1987, NUCLEIC ACIDS RES, V15, P5157, DOI 10.1093/nar/15.13.5157; SAWA H, 1988, NUCLEIC ACIDS RES, V16, P3157; SCHNIER J, 1988, NUCLEIC ACIDS RES, V16, P3075, DOI 10.1093/nar/16.7.3075; SCHNIER J, 1982, P NATL ACAD SCI-BIOL, V79, P1008, DOI 10.1073/pnas.79.4.1008; SCHNIER J, 1985, MOL GEN GENET, V200, P476, DOI 10.1007/BF00425734; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SIJBENMULLER G, 1986, NUCLEIC ACIDS RES, V14, P1029, DOI 10.1093/nar/14.2.1029; SIKORSKI RS, 1989, GENETICS, V122, P19; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; SUBRAMANIAN AR, 1985, ESSAYS BIOCHEM, V21, P45; UMESONO K, 1984, NUCLEIC ACIDS RES, V12, P9551, DOI 10.1093/nar/12.24.9551; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VIJAYRAGHAVAN U, 1990, MOL CELL BIOL, V10, P324, DOI 10.1128/MCB.10.1.324; VIJAYRAGHAVAN U, 1989, NUCLEIC ACIDS MOL BI, V3, P197; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604	67	302	306	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 7	1991	349	6309					487	493		10.1038/349487a0	http://dx.doi.org/10.1038/349487a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992352				2022-12-01	WOS:A1991EW57100055
J	COVERLEY, D; KENNY, MK; MUNN, M; RUPP, WD; LANE, DP; WOOD, RD				COVERLEY, D; KENNY, MK; MUNN, M; RUPP, WD; LANE, DP; WOOD, RD			REQUIREMENT FOR THE REPLICATION PROTEIN SSB IN HUMAN DNA EXCISION REPAIR	NATURE			English	Article							HUMAN CELL-EXTRACTS; SIMIAN VIRUS-40 DNA; PURIFIED PROTEINS; POLYMERASE-DELTA; HELICASE-II; INVITRO; COMPLEX; ALPHA	REPLICATION and repair are essential processes that maintain the continuity of the genetic material. Dissection of simian virus 40 (SV40) DNA replication has resulted in the identification of many eukaryotic replication proteins, but the biochemistry of the multienzyme process of DNA excision repair is less well defined. One protein that is absolutely required for semiconservative replication of SV40 DNA in vitro is human single-stranded DNA-binding protein (SSB, also called RF-A and RP-A) 1-3. SSB consists of three polypeptides of relative molecular mass 70,000, 34,000 and 13,000, and acts with T antigen and topoisomerases to unwind DNA, allowing the access of other replication proteins. Human SSB can also stimulate the activity of polymerases- alpha and delta, suggesting a further role in elongation during DNA replication 4-6. We have now found a role for human SSB in DNA excision repair using a cell-free system that can carry out nucleotide excision repair in vitro 7. Monoclonal antibodies against human SSB caused extensive inhibition of DNA repair in plasmid molecules damaged by ultraviolet light or acetylaminofluorene. Addition of purified SSB reversed this inhibition and further stimulated repair synthesis by increasing the number of repair events. These results show that a mammalian DNA replication protein is also essential for repair.	YALE UNIV, SCH MED, RADIOBIOL LABS, NEW HAVEN, CT 06510 USA	Yale University	COVERLEY, D (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, BLANCHE LANE, S MIMMS EN6 3LD, HERTS, ENGLAND.		Lane, David P/C-4920-2008; Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892; Lane, David/0000-0003-0551-3545; Coverley, Dawn/0000-0001-8262-7023				CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; IKEDA JE, 1981, P NATL ACAD SCI-BIOL, V78, P884, DOI 10.1073/pnas.78.2.884; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; MANLEY JL, 1988, P NATN ACAD SCI US, V77; NISHIDA C, 1988, J BIOL CHEM, V263, P501; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TOULME JJ, 1983, EMBO J, V2, P505, DOI 10.1002/j.1460-2075.1983.tb01454.x; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOOD RD, 1988, MECHANISMS CONSEQUEN, P57	23	233	234	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					538	541		10.1038/349538a0	http://dx.doi.org/10.1038/349538a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992355				2022-12-01	WOS:A1991EW57100072
J	DYSON, PJ; KNIGHT, AM; FAIRCHILD, S; SIMPSON, E; TOMONARI, K				DYSON, PJ; KNIGHT, AM; FAIRCHILD, S; SIMPSON, E; TOMONARI, K			GENES ENCODING LIGANDS FOR DELETION OF V-BETA-11 T-CELLS COSEGREGATE WITH MAMMARY-TUMOR VIRUS GENOMES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLONAL DELETION; ENTEROTOXIN-B; TOLERANCE; PRODUCTS; REACTIVITY; ANTIGENS; MARKERS; MLS	THE T-cell receptor (TCR) repertoire is selected in the thymus after rearrangement of genes encoding TCR alpha and beta chains 1. Selection is based on the recognition by newly emergent T cells of self-ligands associated with molecules of the major histocompatibility complex: some combinations result in positive selection, others in negative selection. Negative selection, or clonal deletion, is an important mechanism for eliminating autoreactive T cells. A group of self-ligands involved in clonal deletion was identified because they, like exogenous superantigens 2, were recognized by almost all T cells expressing particular TCR V-beta genes. V-beta-17a T cells are deleted by a tissue-specific ligand 3,4; V-beta-6, V-beta-7, V-beta-8.1 and V-beta-9 T cells are deleted by the minor lymphocyte-stimulating (Mls) determinant Mls-1a (refs 5-8); V-beta-3 T cells by Mls-2a and Mls-3a (refs 9,10); V-beta-11 T cells 11 by ligands encoded by independently segregating genes; and V-beta-5 T cells by ligands encoded by two genes 12. Chromosomes mapping using recombinant inbred strains of mice and classic backcrosses show that Mls-1a in DBA/2 mice is encoded on chromosome 1, that one of the two ligand genes for deletion of V-beta-5 T cells maps to chromosome 12 (ref. 12) and that a ligand gene for V-beta-11 deletion is linked to the CD8 locus on chromosome 6 (ref. 11). Here we present evidence from three sets of backcross mice for concordance between V-beta-11 deletion ligand genes on chromosomes 6, 12 and 14 and endogenous mouse mammary tumour virus integrant (Mtv) genomes. Our results indicate that the V-beta-11 deletion ligands are products of Mtv genomes.			DYSON, PJ (corresponding author), CLIN RES CTR,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.			Simpson, Elizabeth/0000-0002-2118-3139				ABE R, 1989, J EXP MED, V170, P1059, DOI 10.1084/jem.170.4.1059; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; DAVISSON MT, 1989, GENETIC VARIANTS STR, P416; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GEBHARD W, 1983, J MOL BIOL, V170, P567, DOI 10.1016/S0022-2836(83)80161-2; GIBSON DM, 1983, IMMUNOGENETICS, V18, P111, DOI 10.1007/BF00368538; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KING LB, 1990, J IMMUNOL, V144, P3218; KNIGHT AM, 1990, MOL CELL PROBE, V4, P497, DOI 10.1016/0890-8508(90)90008-N; LAWLOR DA, 1990, ANNU REV IMMUNOL, V8, P23, DOI 10.1146/annurev.iy.08.040190.000323; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; Maniatis T., 1982, MOL CLONING; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MOLLICK JA, 1989, SCIENCE, V244, P817, DOI 10.1126/science.2658055; OKADA CY, 1990, J IMMUNOL, V144, P3473; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; TOMONARI K, 1990, IMMUNOL REV, V116, P139, DOI 10.1111/j.1600-065X.1990.tb00808.x; TOMONARI K, 1988, IMMUNOGENETICS, V28, P445, DOI 10.1007/BF00355377; TOMONARI K, 1990, IMMUNOGENETICS, V32, P60, DOI 10.1007/BF01787331; TOMONARI K, IN PRESS IMMUNOGENET; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YANG JN, 1987, IMMUNOGENETICS, V25, P222, DOI 10.1007/BF00404691	32	329	329	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					531	532		10.1038/349531a0	http://dx.doi.org/10.1038/349531a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846950				2022-12-01	WOS:A1991EW57100069
J	FRANKEL, WN; RUDY, C; COFFIN, JM; HUBER, BT				FRANKEL, WN; RUDY, C; COFFIN, JM; HUBER, BT			LINKAGE OF MLS GENES TO ENDOGENOUS MAMMARY-TUMOR VIRUSES OF INBRED MICE	NATURE			English	Article							INDUCED IMMUNODEFICIENCY SYNDROME; CHROMOSOMAL DISTRIBUTION; MOUSE CHROMOSOME-1; RETROVIRUS; LOCI; GR; DETERMINANTS; SEGREGATION; EXPRESSION; INDUCTION	T CELLS that recognize self antigen are clonally deleted in the thymus-a maturation process that occurs in the context of histocompatibility molecules and the T-cell receptor. The minor lymphocyte stimulation antigens (Mls) effect these deletions through interactions with the V-beta portion of the T-cell receptor, thus mimicking bacterial 'superantigens'. Intrigued by the fact that each known Mls gene maps to the same chromosomal region as an endogenous mouse mammary tumour virus (Mtv), we reevaluated the linkage relationships between the two gene families. Here we report perfect concordance in inbred and recombinant inbred mice between the presence of four Mtv proviruses with the expression of Mls gene products. These data suggest a general model in which mammary tumour virus gene products themselves are the ligands that shape a considerable portion of the immunological repertoire of common laboratory mice.	TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MOLEC BIOL,BOSTON,MA 02111	Tufts University; Tufts University								ABE R, 1987, J EXP MED, V165, P1113, DOI 10.1084/jem.165.4.1113; ABE R, IN PRESS IMMUNOGENET; ABROMSONLEEMAN SR, 1988, J IMMUNOL, V140, P1726; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BALL JK, 1985, VIROLOGY, V140, P159, DOI 10.1016/0042-6822(85)90455-6; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CHO M, IN PRESS MAMM GENOME; DUDLEY J, 1984, J VIROL, V49, P92, DOI 10.1128/JVI.49.1.92-101.1984; EICHER EM, 1990, GENETICS, V125, P431; FESTENSTEIN H, 1977, IMMUNOGENETICS, V5, P357, DOI 10.1007/BF01570493; FRANKEL WN, 1990, GENETICS, V124, P221; GRAY DA, 1986, VIROLOGY, V148, P237, DOI 10.1016/0042-6822(86)90421-6; JANEWAY CA, 1990, CELL, V63, P659, DOI 10.1016/0092-8674(90)90130-7; KAPPLER JW, 1989, COLD SPRING HARB SYM, V54, P401; KING LB, 1990, J IMMUNOL, V144, P3218; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MACINNES JI, 1984, VIROLOGY, V132, P12, DOI 10.1016/0042-6822(84)90087-4; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; Maniatis T., 1982, MOL CLONING; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MICHALIDES R, 1985, VIROLOGY, V142, P278, DOI 10.1016/0042-6822(85)90336-8; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; MORSE HC, 1989, J IMMUNOL, V143, P844; MORSE HC, 1981, MOUSE BIOMEDICAL RES; PAULEY RJ, 1984, VIRUS RES, V1, P381, DOI 10.1016/0168-1702(84)90025-X; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PROCHAZKA M, 1990, MOUSE GENOME, V87, P111; PULLEN AM, 1989, J IMMUNOL, V142, P3033; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RYAN JJ, 1990, J IMMUNOL, V144, P2506; SELDIN MF, 1988, J IMMUNOGENET, V15, P59; Seldin MF, 1988, GENOMICS, V2, P48, DOI 10.1016/0888-7543(88)90108-5; SILVER J, 1985, J HERED, V76, P436, DOI 10.1093/oxfordjournals.jhered.a110140; STOYE J, 1985, RNA TUMOR VIRUSES, P357; TRAINA VL, 1981, J VIROL, V40, P735, DOI 10.1128/JVI.40.3.735-744.1981; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	41	367	368	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					526	528		10.1038/349526a0	http://dx.doi.org/10.1038/349526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846948				2022-12-01	WOS:A1991EW57100067
J	HABER, HL; LEAVY, JA; KESSLER, PD; KUKIN, ML; GOTTLIEB, SS; PACKER, M				HABER, HL; LEAVY, JA; KESSLER, PD; KUKIN, ML; GOTTLIEB, SS; PACKER, M			THE ERYTHROCYTE SEDIMENTATION-RATE IN CONGESTIVE-HEART-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; CLINICAL-RESPONSE; BLOOD-VISCOSITY; SURVIVAL; SYSTEM; PLASMA	Background and Methods. Physicians have long believed that the erythrocyte sedimentation rate is low in patients with congestive heart failure, but this concept is based on a misinterpretation of the results in a single report published in 1936. To reevaluate this concept in the modern era, we measured the sedimentation rate in 242 patients who were referred for treatment of chronic heart failure. Results. The sedimentation rate was low (less than 5 mm per hour) in only 24 patients (10 percent) but was increased (above 25 mm per hour) in 50 percent. Patients with low or normal sedimentation rates (less-than-or-equal-to 25 mm per hour) had more severe hemodynamic abnormalities than patients with elevated rates: lower cardiac index (mean +/- SEM, 1.7 +/- 0.1 vs. 2.0 +/- 0.1 liters per minute per square meter of body-surface area) and higher mean right atrial pressure (mean +/- SEM, 12 +/- 1 vs. 9 +/- 1 mm Hg)(both P < 0.0001). New York Heart Association functional class IV symptoms were present in 66 percent of the patients with a low or normal sedimentation rate, as compared with 42 percent of those with elevated rates (P < 0.0001). After one to three months of therapy, patients whose sedimentation rates decreased showed little hemodynamic or clinical response to treatment, whereas both cardiac performance and functional status improved in patients whose rates increased (P < 0.02 for the comparison between groups). The sedimentation rate was correlated with the plasma fibrinogen level (r = 0.64, P = 0.0025), and changes in the sedimentation rate during treatment were correlated inversely with changes in mean right atrial pressure (r = -0.57, P = 0.0002). During long-term follow-up, patients with low or normal sedimentation rates had a worse one-year survival than patients with elevated rates (41 vs. 66 percent, P = 0.01). Conclusions. These data indicate that the erythrocyte sedimentation rate is correlated with the severity of illness in patients with chronic heart failure. Because of its lack of discriminatory power, however, the test is of limited value in the clinical management of this disorder.	CUNY MT SINAI SCH MED,DIV CARDIOL,1 GUSTAVE LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,DIV CARDIOL,CTR HEART FAILURE RES,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NHLBI NIH HHS [R01-HL-25055, T32-HL-07347, K04-HL-01229] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025055, K04HL001229, T32HL007347] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEDELL SE, 1985, AM J MED, V78, P1001, DOI 10.1016/0002-9343(85)90224-4; BOTTIGER LE, 1967, BRIT MED J, V2, P85, DOI 10.1136/bmj.2.5544.85; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; Coburn AF, 1936, J CLIN INVEST, V15, P715, DOI 10.1172/JCI100825; CREAGER MA, 1982, AM HEART J, V104, P1147, DOI 10.1016/0002-8703(82)90043-6; EISENBERG S, 1964, CIRCULATION, V30, P686, DOI 10.1161/01.CIR.30.5.686; ELSTER SK, 1956, AM HEART J, V51, P533, DOI 10.1016/0002-8703(56)90099-0; FABRY TL, 1987, BLOOD, V70, P1572; FLINT FJ, 1954, BRIT MED J, V2, P1018, DOI 10.1136/bmj.2.4895.1018; GAMBINO S R, 1965, Tech Bull Regist Med Technol, V35, P1; Gilligan DR, 1934, AM J MED SCI, V187, P552, DOI 10.1097/00000441-193404000-00012; GOLDSMITH RL, 1988, CIRCULATION S2, V78, P56; GRIFFITHS RA, 1984, BRIT MED J, V289, P724, DOI 10.1136/bmj.289.6447.724; Ham TH, 1938, MEDICINE, V17, P447, DOI 10.1097/00005792-193812000-00003; HAMILTON PJ, 1974, J CLIN PATHOL, V27, P326, DOI 10.1136/jcp.27.4.326; HENRY DP, 1975, LIFE SCI, V16, P375, DOI 10.1016/0024-3205(75)90258-1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kugel MA, 1933, ARCH INTERN MED, V52, P16, DOI 10.1001/archinte.1933.00160010023002; LEE WH, 1985, J AM COLL CARDIOL, V5, P461; LEE WH, 1986, CIRCULATION, V73, P257, DOI 10.1161/01.CIR.73.2.257; LOWE GD, 1986, DIABETES RES CLIN EX, V3, P67; LOWE GDO, 1980, BRIT MED J, V280, P673, DOI 10.1136/bmj.280.6215.673; MCGINNIS AE, 1953, AM J MED SCI, V225, P599, DOI 10.1097/00000441-195306000-00002; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; PACKER M, 1985, CIRCULATION, V71, P761, DOI 10.1161/01.CIR.71.4.761; PARRY EH, 1961, ACTA MED SCAND, V169, P79; RAINER C, 1987, CIRCULATION, V76, P15, DOI 10.1161/01.CIR.76.1.15; SANGHVI L M, 1960, Postgrad Med J, V36, P620; SANGHVI LM, 1963, GERIATRICS, V18, P382; SANGHVI LM, 1962, BRIT HEART J, V24, P180; SEALEY JE, 1972, KIDNEY INT, V1, P240, DOI 10.1038/ki.1972.34; WOOD P, 1936, Q J MED, V5, P1; ZANNAD F, 1988, J HYPERTENS, V6, P293	33	54	56	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 7	1991	324	6					353	358		10.1056/NEJM199102073240601	http://dx.doi.org/10.1056/NEJM199102073240601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW296	1987458				2022-12-01	WOS:A1991EW29600001
J	HALLER, RG; LEWIS, SF				HALLER, RG; LEWIS, SF			GLUCOSE-INDUCED EXERTIONAL FATIGUE IN MUSCLE PHOSPHOFRUCTOKINASE DEFICIENCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUCLEAR MAGNETIC-RESONANCE; MCARDLES DISEASE; CARDIAC-OUTPUT; EXERCISE; METABOLISM; SPECTROSCOPY	Background. The exercise capacity of patients with muscle phosphofructokinase deficiency is low and fluctuates from day to day. The basis of this variable exercise tolerance is unknown, but out patients with this disorder report that fatigue of active muscles is more rapid after a high-carbohydrate meal. Methods and Results. To determine the effect of carbohydrate on exercise performance, we asked four patients with muscle phosphofructokinase deficiency to perform cycle exercise under conditions of differing availability of substrate - i.e., after an overnight fast, and during an infusion of glucose or triglyceride (with 10 U of heparin per kilogram of body weight) after an overnight fast. As compared with fasting and the infusion of triglyceride with heparin, the glucose infusion lowered plasma levels of free fatty acids and ketones, reduced maximal work capacity by 60 to 70 percent, and lowered maximal oxygen consumption by 30 to 40 percent. Glucose also increased the relative intensity of submaximal exercise, as indicated by a higher heart rate at a given workload during exercise. The maximal cardiac output (i.e., oxygen delivery) was not affected by varying substrate availability, but the maximal systemic arteriovenous oxygen difference was significantly lower during glucose infusion (mean +/- SE, 5.5 +/- 0.3 ml per deciliter) than after fasting (7.6 +/- 0.4 ml per deciliter, P < 0.05) or during the infusion of triglyceride with heparin (8.9 +/- 1.3 ml per deciliter, P < 0.05). Conclusions. In muscle phosphofructokinase deficiency, the oxidative capacity of muscle and the capacity for aerobic exercise vary according to the availability of blood-borne fuels. We believe that glucose infusion lowers exercise tolerance by inhibiting lipolysis and thus depriving muscle of oxidative substrate (plasma free fatty acids and ketones); this impairs the capacity of working muscle to extract oxygen and lowers maximal oxygen consumption.	DEPT VET AFFAIRS MED CTR, DEPT PHYSIOL, DALLAS, TX USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75230 USA; DEPT VET AFFAIRS MED CTR, DEPT NEUROL, DALLAS, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL001581, P01HL006296] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-00633] Funding Source: Medline; NHLBI NIH HHS [HL-01581, HL-06296] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGAMANOLIS DP, 1980, MUSCLE NERVE, V3, P456, DOI 10.1002/mus.880030602; ARGOV Z, 1987, ANN NEUROL, V22, P46, DOI 10.1002/ana.410220112; DIMAURO S, 1986, MYOLOGY, P1585; DUBOC D, 1987, NEUROLOGY, V37, P663, DOI 10.1212/WNL.37.4.663; EDWARDS RHT, 1982, LANCET, V1, P725; GOLLNICK PD, 1985, FED PROC, V44, P353; HALLER RG, 1986, NEUROLOGY, V36, P716, DOI 10.1212/WNL.36.5.716; HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135; HALLER RG, 1985, ANN NEUROL, V17, P196, DOI 10.1002/ana.410170216; LAUWERYS RR, 1969, ANAL BIOCHEM, V32, P331, DOI 10.1016/0003-2697(69)90093-1; LAYZER RB, 1967, ARCH NEUROL-CHICAGO, V17, P512, DOI 10.1001/archneur.1967.00470290066009; LEWIS SF, 1985, J APPL PHYSIOL, V59, P1991, DOI 10.1152/jappl.1985.59.6.1991; LEWIS SF, 1986, J APPL PHYSIOL, V61, P391, DOI 10.1152/jappl.1986.61.2.391; LEWIS SF, 1984, J APPL PHYSIOL, V57, P1749, DOI 10.1152/jappl.1984.57.6.1749; LEWIS SF, 1989, EXERCISE SPORT SCI R, V17, P67; MINEO I, 1984, MUSCLE NERVE, V7, P552, DOI 10.1002/mus.880070706; PEARSON CM, 1961, AM J MED, V30, P502, DOI 10.1016/0002-9343(61)90075-4; PERNOW BB, 1967, ACTA MED SCAND, VS, P294; PORTE D, 1966, NEW ENGL J MED, V275, P406, DOI 10.1056/NEJM196608252750802; ROWLAND LP, 1986, MYOLOGY, P1603; Sahlin K., 1986, BIOCH EXERCISE, VVI, P323; SCHMID R, 1959, J CLIN INVEST, V38, P2044, DOI 10.1172/JCI103983; TARUI S, 1984, NEUROMUSCULAR DISEAS, P71; TRIEBWASSER JH, 1977, AVIAT SPACE ENVIR MD, V48, P203; VORA S, 1983, J CLIN INVEST, V72, P1995, DOI 10.1172/JCI111164; WILLIAMSON DH, 1962, BIOCHEM J, V82, P90, DOI 10.1042/bj0820090	26	62	62	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 7	1991	324	6					364	369		10.1056/NEJM199102073240603	http://dx.doi.org/10.1056/NEJM199102073240603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW296	1824792				2022-12-01	WOS:A1991EW29600003
J	LAWSON, DM; ARTYMIUK, PJ; YEWDALL, SJ; SMITH, JMA; LIVINGSTONE, JC; TREFFRY, A; LUZZAGO, A; LEVI, S; AROSIO, P; CESARENI, G; THOMAS, CD; SHAW, WV; HARRISON, PM				LAWSON, DM; ARTYMIUK, PJ; YEWDALL, SJ; SMITH, JMA; LIVINGSTONE, JC; TREFFRY, A; LUZZAGO, A; LEVI, S; AROSIO, P; CESARENI, G; THOMAS, CD; SHAW, WV; HARRISON, PM			SOLVING THE STRUCTURE OF HUMAN H-FERRITIN BY GENETICALLY ENGINEERING INTERMOLECULAR CRYSTAL CONTACTS	NATURE			English	Article							HORSE SPLEEN APOFERRITIN; SUBUNIT GENE; ESCHERICHIA-COLI; CHAIN FERRITINS; IRON; EXPRESSION; RESOLUTION; IDENTIFICATION; CONSERVATION; PSEUDOGENE	FERRITIN is important in iron homeostasis. Its twenty-four chains of two types, H and L, assemble as a hollow shell providing an iron-storage cavity 1-3. Ferritin molecules in cells containing high levels of iron tend to be rich in L chains, and may have a long-term storage function, whereas H-rich ferritins are more active in iron metabolism 3-7. The molecular basis for the greater activity of H-rich ferritins has until now been obscure, largely because the structure of H-chain ferritin has remained unknown owing to the difficulties in obtaining crystals ordered enough for X-ray crystallographic analysis. Here we report the three-dimensional structure of a human ferritin H-chain homopolymer. By genetically engineering a change in the sequence of the intermolecular contact region, we obtained crystals isomorphous with the homologous rat L ferritin 8,9 and of high enough quality for X-ray diffraction analysis. The X-ray structure of human H ferritin shows a novel metal site embedded within each of its four-helix bundles and we suggest that ferroxidase activity associated with this site accounts for its rapid uptake of iron 10.	UNIV SHEFFIELD,KREBS INST BIOMOLEC RES,DEPT MOLEC BIOL & BIOTECHNOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY; UNIV MILANO,OSPED SAN RAFFAELE,DIPARTIMENTO SCI & TECNOL BIOMED,I-20132 MILAN,ITALY; UNIV ROMA TOR VERGATA,DIPARTIMENTO BIOL,I-00173 ROME,ITALY; UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7HR,ENGLAND	University of Sheffield; European Molecular Biology Laboratory (EMBL); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Rome Tor Vergata; University of Leicester			arosio, paolo/S-3272-2019; arosio, paolo/E-6817-2010; Thomas, Christopher D./E-1236-2015; Cesareni, Gianni/AAW-1382-2020; levi, sonia/A-3161-2015; Lawson, David M/D-1810-2009	arosio, paolo/0000-0002-5343-8992; Thomas, Christopher D./0000-0003-0316-6391; levi, sonia/0000-0002-5092-0847; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AROSIO P, 1978, J BIOL CHEM, V253, P4451; AROSIO P, 1983, BIOCHIM BIOPHYS ACTA, V774, P230; BAKKER GR, 1986, J BIOL CHEM, V261, P3182; BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; BAUMINGER ER, 1989, BIOCHEMISTRY-US, V28, P5486, DOI 10.1021/bi00439a025; BOYD D, 1985, J BIOL CHEM, V260, P1755; CHASTEEN ND, 1982, J BIOL CHEM, V257, P7672; CONNOLLY MJ, 1983, J APPL CRYSTALLOGR, V16, P23; DANIELSMCQUEEN S, 1988, NUCLEIC ACIDS RES, V16, P7741, DOI 10.1093/nar/16.15.7741; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; FRASER RDB, 1978, J APPL CRYSTALLOGR, V11, P693, DOI 10.1107/S0021889878014296; HARRISON PM, 1989, BIOMINERALIZATION CH, P257; HEUSTERSPREUTE M, 1981, FEBS LETT, V129, P322, DOI 10.1016/0014-5793(81)80193-7; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1990, THESIS SHEFFIELD U; LEIBOLD EA, 1987, J BIOL CHEM, V262, P7335; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; MURRAY MT, 1987, P NATL ACAD SCI USA, V84, P7438, DOI 10.1073/pnas.84.21.7438; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; STENKAMP RE, 1984, J AM CHEM SOC, V106, P618, DOI 10.1021/ja00315a027; STEVENS PW, 1987, MOL CELL BIOL, V7, P1751, DOI 10.1128/MCB.7.5.1751; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.bi.56.070187.001445; THOMAS CD, 1988, BIOCHEM SOC T, V16, P838, DOI 10.1042/bst0160838; TREFFRY A, 1984, J INORG BIOCHEM, V21, P9, DOI 10.1016/0162-0134(84)85035-7; TREFFRY A, 1989, FEBS LETT, V247, P268, DOI 10.1016/0014-5793(89)81350-X	30	667	689	5	92	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					541	544		10.1038/349541a0	http://dx.doi.org/10.1038/349541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992356				2022-12-01	WOS:A1991EW57100073
J	LEAPE, LL; BRENNAN, TA; LAIRD, N; LAWTHERS, AG; LOCALIO, AR; BARNES, BA; HEBERT, L; NEWHOUSE, JP; WEILER, PC; HIATT, H				LEAPE, LL; BRENNAN, TA; LAIRD, N; LAWTHERS, AG; LOCALIO, AR; BARNES, BA; HEBERT, L; NEWHOUSE, JP; WEILER, PC; HIATT, H			THE NATURE OF ADVERSE EVENTS IN HOSPITALIZED-PATIENTS - RESULTS OF THE HARVARD MEDICAL-PRACTICE STUDY-II	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE; PREVENTION; MANAGEMENT; QUALITY	Background. In a sample of 30,195 randomly selected hospital records, we identified 1133 patients (3.7 percent) with disabling injuries caused by medical treatment. We report here an analysis of these adverse events and their relation to error, negligence, and disability. Methods. Two physician-reviewers independently identified the adverse events and evaluated them with respect to negligence, errors in management, and extent of disability. One of the authors classified each event according to type of injury. We tested the significance of differences in rates of negligence and disability among categories with at least 30 adverse events. Results. Drug complications were the most common type of adverse event (19 percent), followed by wound infections (14 percent) and technical complications (13 percent). Nearly half the adverse events (48 percent) were associated with an operation. Adverse events during surgery were less likely to be caused by negligence (17 percent) than nonsurgical ones (37 percent). The proportion of adverse events due to negligence was highest for diagnostic mishaps (75 percent), noninvasive therapeutic mishaps ("errors of omission") (77 percent), and events occurring in the emergency room (70 percent). Errors in management were identified for 58 percent of the adverse events, among which nearly half were attributed to negligence. Conclusions. Although the prevention of many adverse events must await improvements in medical knowledge, the high proportion that are due to management errors suggests that many others are potentially preventable now. Reducing the incidence of these events will require identifying their causes and developing methods to prevent error or reduce its effects.	HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard Medical School	LEAPE, LL (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Newhouse, Joseph/AGJ-5632-2022; Newhouse, Joseph/AAD-9763-2019					BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1990, ANN INTERN MED, V112, P221, DOI 10.7326/0003-4819-112-3-221; BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; DEARDEN CH, 1985, INJURY, V16, P249, DOI 10.1016/S0020-1383(85)80013-9; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; PERROW C, 1984, NORMAL ACCIDENTS LIV; RICKETSON DS, 1980, AVIAT SPACE ENVIR MD, V51, P1036; SHAH BV, 1981, SESUDAAN STANDARD ER; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; VINCENT CA, 1989, BMJ-BRIT MED J, V299, P1150, DOI 10.1136/bmj.299.6708.1150; 1977, REPORT MED INSURANCE	16	2448	2530	0	105	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 7	1991	324	6					377	384		10.1056/NEJM199102073240605	http://dx.doi.org/10.1056/NEJM199102073240605			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW296	1824793	Green Published, Green Submitted			2022-12-01	WOS:A1991EW29600005
J	LUSSO, P; DEMARIA, A; MALNATI, M; LORI, F; DEROCCO, SE; BASELER, M; GALLO, RC				LUSSO, P; DEMARIA, A; MALNATI, M; LORI, F; DEROCCO, SE; BASELER, M; GALLO, RC			INDUCTION OF CD4 AND SUSCEPTIBILITY TO HIV-1 INFECTION IN HUMAN CD8+ LYMPHOCYTES-T BY HUMAN HERPESVIRUS-6	NATURE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; CELLS; VIRUS; EXPRESSION; ANTIGEN; GENE; DIFFERENTIATION; CYTOMEGALOVIRUS; INDIVIDUALS; RETROVIRUS	DURING intrathymic T-cell ontogenesis, functionally competent CD3+CD4+CD8- and CD3+CD4-CD8+ T lymphocytes develop from immature CD4-CD8- thymocytes after transiently acquiring a double-positive CD4+CD8+ phenotype 1-3. The partition between CD4+CD8- and CD4-CD8+ T cells is generally considered to be irreversible, although a small percentage of circulating CD3+ T lymphocytes coexpressing CD4 and CD8 molecules has been identified 4. It has been suggested that in CD8+ T cells the CD4 genes may be methylated and thus highly repressed 5, whereas in CD4+ T cells the CD8 genes are unmethylated 6 and their transcription can be induced by physiological stimuli such as interleukin-4 (ref. 7). Here, we demonstrate that infection with human herpesvirus 6 (HHV-6) (ref. 8), a virus proposed as a potential cofactor in AIDS (ref. 9), dramatically upregulates the expression of CD4-the receptor for human immunodeficiency virus type-1 (HIV-1) (refs 10-12)-in a human neoplastic T-cell line. More importantly, HHV-6 induces de novo expression of CD4 messenger RNA and protein in normal mature CDE8+ T lymphocytes, rendering them susceptible to infection with HIV-1. These findings demonstrate that human CD3+CD4-CD8+ T lymphocytes can reacquire CD4 in the post-thymic life and elucidate a novel mechanism-receptor regulation-through which HHV-6 may positively interact with HIV-1 in coinfected patients.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; NCI,FREDERICK CANC RES FACIL,PROGRAM RESOURCES INC,FREDERICK,MD 21701; NIAID,IMMUNOGENET LAB,BETHESDA,MD 20892; ADV BIOSCI LABS,DEPT CELL BIOL,KENSINGTON,MD 20895	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	LUSSO, P (corresponding author), NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892, USA.		de maria, andrea/F-7116-2016; Malnati, Mauro/AAN-4207-2020	de maria, andrea/0000-0001-5782-333X; Malnati, mauro/0000-0001-5355-1680				BACH MA, 1984, J IMMUNOL, V132, P735; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; BIASSONI R, 1988, J IMMUNOL, V140, P1685; BLUE ML, 1986, J IMMUNOL, V137, P1202; BLUE ML, 1985, J IMMUNOL, V134, P2281; CARBONE AM, 1988, SCIENCE, V242, P1174, DOI 10.1126/science.2460926; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERSTOFT J, 1985, SCAND J IMMUNOL, V22, P463, DOI 10.1111/j.1365-3083.1985.tb01904.x; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MORETTA A, 1983, J EXP MED, V157, P743, DOI 10.1084/jem.157.2.743; PAGANO JS, 1988, J VIROL METHODS, V21, P229, DOI 10.1016/0166-0934(88)90069-9; PALIARD X, 1988, NATURE, V335, P642, DOI 10.1038/335642a0; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134; RICHARDSON B, 1986, J IMMUNOL, V137, P35; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SHARMA B, 1985, CLIN EXP IMMUNOL, V62, P296; SHEARER GM, 1985, J CLIN INVEST, V76, P1699, DOI 10.1172/JCI112158; SOLBACH W, 1982, J EXP MED, V156, P1250, DOI 10.1084/jem.156.4.1250; STINSKI MF, 1977, J VIROL, V23, P751, DOI 10.1128/JVI.23.3.751-767.1977; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933	30	244	246	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					533	535		10.1038/349533a0	http://dx.doi.org/10.1038/349533a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846951				2022-12-01	WOS:A1991EW57100070
J	MARRACK, P; KUSHNIR, E; KAPPLER, J				MARRACK, P; KUSHNIR, E; KAPPLER, J			A MATERNALLY INHERITED SUPERANTIGEN ENCODED BY A MAMMARY-TUMOR VIRUS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NUCLEOTIDE-SEQUENCE; EXPRESSION; GENE; REACTIVITY; TOLERANCE; PRODUCTS; REGION; MLS	A COLLECTION of superantigens, molecules which in combination with class II major histocompatibility complex (MHC) engage T cells bearing particular V-beta chains as part of their alpha-beta receptors, have recently been described 1,2. The mouse self superantigen, Mls-1a, for example, in conjunction with many MHC class II proteins, engages mouse T cells bearing V-beta-6, 7, 8.1 and 9, almost regardless of the sequences of the other variable components of the receptors on the T cells 3-5. Two types of superantigen have been identified so far: first, superantigens encoded in the mouse genome, such as mls-1a; second, superantigens produced by bacteria, such as the staphylococcal enterotoxins 1,2. Although the latter type of super-antigens are in many cases known to be proteins of about 220 amino acids 6,7, nothing is known about the structures of any of the superantigens encoded in mouse. Here we describe the properties of a new mouse superantigen. The antigen is maternally transmitted in milk and is probably encoded by a mammary tumour virus (MTV). Given the known genetic linkage between at least one of the mouse genomic superantigens and endogenous MTV integration sites 8, it is tempting to speculate that the superantigen described here and some of the endogenous mouse superantigens are encoded by MTVs.			MARRACK, P (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,HOWARD HUGHES MED INST,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687				ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; Andervont HB, 1940, J NATL CANCER I, V1, P147; BETLEY MJ, 1988, J BACTERIOL, V170, P34, DOI 10.1128/jb.170.1.34-41.1988; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JONES CL, 1986, J BACTERIOL, V166, P29, DOI 10.1128/jb.166.1.29-33.1986; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAPPLER JW, 1989, J EXP MED, V169, P1533, DOI 10.1084/jem.169.5.1533; KING LB, 1990, J IMMUNOL, V144, P3218; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; OLTER AD, 1988, MOL ENDOCRINOL, V2, P143; ONEILL HC, 1987, CELL, V49, P143, DOI 10.1016/0092-8674(87)90764-1; PARKS WP, 1974, SCIENCE, V184, P158, DOI 10.1126/science.184.4133.158; RINGOLD GM, 1983, CURR TOP MICROBIOL, V106, P79; SOLTER D, 1988, ANNU REV GENET, V22, P127; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; 1987, JAX430 NOT	20	345	354	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					524	526		10.1038/349524a0	http://dx.doi.org/10.1038/349524a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846947				2022-12-01	WOS:A1991EW57100066
J	OHOLLAREN, MT; YUNGINGER, JW; OFFORD, KP; SOMERS, MJ; OCONNELL, EJ; BALLARD, DJ; SACHS, MI				OHOLLAREN, MT; YUNGINGER, JW; OFFORD, KP; SOMERS, MJ; OCONNELL, EJ; BALLARD, DJ; SACHS, MI			EXPOSURE TO AN AEROALLERGEN AS A POSSIBLE PRECIPITATING FACTOR IN RESPIRATORY ARREST IN YOUNG-PATIENTS WITH ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-ZEALAND; ALTERNARIA ALLERGENS; FATAL ASTHMA; ALT-I; MORTALITY; DEATHS; IMMUNOTHERAPY; PATHOGENESIS; INCREASES; RESPONSES	Background. Exposure to airborne spores of the common mold Alternaria alternata has been implicated in asthma attacks. Such exposure is particularly frequent in the Midwest during the summer and fall months. To determine the role of A. alternata in triggering severe asthma attacks, we investigated the cases of 11 patients with asthma who had sudden respiratory arrest and determined the frequency of sensitivity to this allergen in these patients. Methods. The 11 patients (age range, 11 to 25 years) with initial episodes of respiratory arrest, which was fatal in 2 patients, were identified in the course of their care in our pediatric and adult clinical allergy practice and by a retrospective review of all Mayo Clinic records of patients with severe asthma cared for between 1980 and 1989. Skin-test reactivity to A. alternata and levels of IgE antibody against this mold in the 11 patients were compared with those in 99 matched controls with asthma who had no history of respiratory arrest. Results. All the patients came from the upper Mid-West, and the episodes of respiratory arrest occurred in the summer or early fall. Ten of the 11 patients with asthma who had respiratory arrest (91 percent) had positive skin-puncture tests for sensitivity to alternaria, as compared with 31 percent of the controls (P < 0.001), and the serum levels of IgE antibodies to alternaria were elevated in all 9 patients tested. Among the covariates we examined (age, sex, and distance from the Mayo Clinic), only age was a significant confounder. After adjustment for age, alternaria skin-test reactivity was found to be associated with an increase of approximately 200-fold in the risk of respiratory arrest (adjusted odd ratio, 189.5; 95 percent confidence interval, 6.5 to 5535.8). Conclusions. Exposure to the aeroallergen A. alternata is a risk factor for respiratory arrest in children and young adults with asthma.	MAYO CLIN & MAYO FDN,DIV ALLERG DIS & INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,GEN PEDIAT & PEDIAT ALLERGY & IMMUNOL SECT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic			Ballard, David J/H-1062-2018					AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V72, P40, DOI 10.1016/0091-6749(83)90050-7; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1987, J ALLERGY CLIN IMMUN, V80, P379, DOI 10.1016/0091-6749(87)90054-6; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DRAZEN JM, 1987, J ALLERGY CLIN IMMUN, V80, P428, DOI 10.1016/0091-6749(87)90069-8; EVANS R, 1987, J ALLERGY CLIN IMMUN, V80, P377, DOI 10.1016/0091-6749(87)90053-4; HOGG JC, 1987, J ALLERGY CLIN IMMUN, V80, P417, DOI 10.1016/0091-6749(87)90065-0; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; KRAVIS LP, 1985, AM J DIS CHILD, V139, P558, DOI 10.1001/archpedi.1985.02140080028026; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; MARKHAM D, 1986, J ALLERGY CLIN IMMUN, V77, P161; METZGER WJ, 1983, J ALLERGY CLIN IMMUN, V71, P119, DOI 10.1016/0091-6749(83)90245-2; MILES RM, 1983, J ALLERGY CLIN IMMUN, V71, P36, DOI 10.1016/0091-6749(83)90544-4; NYHOLM L, 1983, J ALLERGY CLIN IMMUN, V71, P461, DOI 10.1016/0091-6749(83)90462-1; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; PICCOLO MC, 1988, ANN ALLERGY, V60, P107; PLATTSMILLS TAE, 1982, LANCET, V2, P675; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; Richerson H B, 1986, Iowa Med, V76, P212; RICHERSON HB, 1986, ASTHMA CLIN PHARM TH, P23; RUBINSTEIN S, 1984, ANN ALLERGY, V53, P311; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P477, DOI 10.1016/0091-6749(87)90079-0; SEARS MR, 1988, J ALLERGY CLIN IMMUN, V82, P957, DOI 10.1016/0091-6749(88)90130-3; SEARS MR, 1985, NEW ZEAL MED J, V98, P271; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P383, DOI 10.1016/0091-6749(87)90055-8; SIEGEL SC, 1987, J ALLERGY CLIN IMMUN, V80, P458, DOI 10.1016/0091-6749(87)90075-3; SLY RM, 1984, ANN ALLERGY, V53, P20; SLY RM, 1986, ANN ALLERGY, V56, P207; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; SOLOMON WR, 1988, ALLERGY PRINCIPLES P, V1, P312; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; STRUNK RC, 1989, J ALLERGY CLIN IMMUN, V83, P477, DOI 10.1016/0091-6749(89)90137-1; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; WOOLCOCK AJ, 1986, CHEST, V90, pS40, DOI 10.1378/chest.90.5_Supplement.40S; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; CAUSES DEATH AUSTR 1; 1982, BMJ, V285, P1251	43	500	508	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 7	1991	324	6					359	363		10.1056/NEJM199102073240602	http://dx.doi.org/10.1056/NEJM199102073240602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW296	1987459				2022-12-01	WOS:A1991EW29600002
J	WOOD, WB				WOOD, WB			EVIDENCE FROM REVERSAL OF HANDEDNESS IN C-ELEGANS EMBRYOS FOR EARLY CELL-INTERACTIONS DETERMINING CELL FATES	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; LINEAGES; GLP-1	MANY animals with overall bilateral symmetry also exhibit some left-right asymmetries with generally invariant handedness. Therefore, the left-right embryonic axis must have a consistent polarity, whose origins and subsequent effects on development are not understood (reviewed in ref. 1). Caenorhabditis elegans exhibits such left-right asymmetries at all developmental stages. The embryonic cell lineage is asymmetric as well: although the animal is generally bilaterally symmetric, many of its contralaterally analogous cells arise from different lineages on the two sides of the embryo 2,3. I accomplished reversal of embryonic handedness by micromanipulation at the 6-cell stage, which resulted in mirror-image but otherwise normal development into healthy, fertile animals with all the usual left-right asymmetries reversed. This result demonstrates that in the 6-cell embryo the pair of anterior (AB) blastomeres on the right is equivalent to the pair on the left, and that the extensive differences in fates between lineally homologous derivatives of these cells on the two sides of the animals must be dictated by cell interactions, most of which are likely to occur early in embryogenesis.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	WOOD, WB (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOX 347,BOULDER,CO 80309, USA.							Bonfig R, 1925, Z WISS ZOOL ABT A, V124, P407; BROWN NA, 1990, DEVELOPMENT, V109, P1; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; DEPPE U, 1978, P NATL ACAD SCI USA, V75, P376, DOI 10.1073/pnas.75.1.376; Dunschen F., 1929, Archiv fuer Entwicklungsmechanik der Organismen Berlin, V115, P237; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; STRASSEN OZ, 1896, ARCH ENTWICKLUNGSMEC, V3, P27; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1983, COLD SPRING HARB SYM, V48, P443, DOI 10.1101/SQB.1983.048.01.049; White J., 1988, NEMATODE CAENORHABDI, V17, P81; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	18	147	148	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					536	538		10.1038/349536a0	http://dx.doi.org/10.1038/349536a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992354				2022-12-01	WOS:A1991EW57100071
J	WOODLAND, DL; HAPP, MP; GOLLOB, KJ; PALMER, E				WOODLAND, DL; HAPP, MP; GOLLOB, KJ; PALMER, E			AN ENDOGENOUS RETROVIRUS MEDIATING DELETION OF ALPHA-BETA T-CELLS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODIES; IMPARTS REACTIVITY; I-E; TOLERANCE; DIFFERENTIATION; EXPRESSION; ANTIGENS; TRANSCRIPTS; MOLECULE	A SPECIAL class of self-antigens (endogenous superantigens) is capable of deleting many murine T cells on the basis of their expression of particular T-cell receptor V-beta gene segments. In mice that endogenously express these antigens, tolerance is mediated in part by the clonal deletion of the relevant V-beta-bearing T cells 1-17. The deletion of I-E-reactive V-beta-5.2-bearing T cells is dependent on the coexpression of an I-E tolerogenic coligand (Etc) 14 and the gene for one of these coligands, Etc-1, maps to chromosome 12, near the mouse mammary tumour viral integrant, Mtv-9. Here we report a perfect genetic linkage between Etc-1 and Mtv-9 and show that Etc-1 is also involved in the I-E-dependent deletion of T cells bearing V-beta-5.1 and V-beta-11 domains. We also demonstrate that Mtv-9 transcripts are present in B cells expressing Etc-1 and suggest that the coligand recognized by roughly 15% of all T lymphocytes is encoded by the Mtv-9 genome.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WOODLAND, DL (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.		Gollob, Kenneth J/C-1341-2008; Gollob, Kenneth J/GPX-8434-2022	Gollob, Kenneth J/0000-0003-4184-3867; 				BILL J, 1988, P NATL ACAD SCI USA, V85, P9184, DOI 10.1073/pnas.85.23.9184; BILL J, 1989, J EXP MED, V169, P115, DOI 10.1084/jem.169.1.115; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BILL J, 1990, J MOL CELL IMMUNOL, V4, P269; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; EICHER EM, 1990, GENETICS, V125, P431; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KING LB, 1989, P NATL ACAD SCI USA, V86, P2814, DOI 10.1073/pnas.86.8.2814; KING LB, 1990, J IMMUNOL, V144, P3218; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KUMAGAI N, 1987, J IMMUNOL, V139, P1393; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; OKADA CY, 1990, J IMMUNOL, V144, P3473; OKADA CY, 1989, J EXP MED, V169, P1703, DOI 10.1084/jem.169.5.1703; PALMER E, 1989, COLD SPRING HARB SYM, V54, P135; PENNELL CA, 1985, P NATL ACAD SCI USA, V82, P3799, DOI 10.1073/pnas.82.11.3799; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; SHARMA S, 1988, J IMMUNOL, V141, P2510; TAYLOR BA, 1987, ORIGIN INBRED MICE, P423; TOMONARI K, 1990, IMMUNOL REV, V116, P139, DOI 10.1111/j.1600-065X.1990.tb00808.x; TOMONARI K, 1988, IMMUNOGENETICS, V28, P445, DOI 10.1007/BF00355377; VACCHIO MS, 1990, J EXP MED, V172, P802; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289	30	318	323	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					529	530		10.1038/349529a0	http://dx.doi.org/10.1038/349529a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846949				2022-12-01	WOS:A1991EW57100068
J	XIE, XM; SMART, TG				XIE, XM; SMART, TG			A PHYSIOLOGICAL-ROLE FOR ENDOGENOUS ZINC IN RAT HIPPOCAMPAL SYNAPTIC NEUROTRANSMISSION	NATURE			English	Article							PYRAMIDAL CELLS; BRAIN; LOCALIZATION; RELEASE; NEURONS; ZN-2+; RESPONSES	THE mammalian central nervous system (CNS) contains an abundance of the transition metal zinc, which is highly localized in the neuronal parenchyma 1-4. Zinc is actively taken up 5,6 and stored in synaptic vesicles in nerve terminals 7-10, and stimulation of nerve fibre tracts that contain large amounts of zinc, such as the hippocampal mossy fibre system 4, can induce its release 11-13, suggesting that it may act as a neuromodulator. The known interaction of zinc with the major excitatory and inhibitory amino-acid neurotransmitter receptors in the CNS supports this notion 14-16. That zinc has a role in CNS synaptic transmission, however, has so far not been shown. Here we report a physiological role for zinc in the young rat hippocampus (postnatal, P3-P14 days). Our results indicate that naturally occurring spontaneous giant depolarizing synaptic potentials (GDPs) in young CA3 pyramidal neurones, mediated by the release of GABA (gamma-aminobutyric acid) 17, are induced by endogenously released zinc. These synaptic potentials are inhibited by specific zinc-chelating agents. GDPs are apparently generated by an inhibitory action of zinc on both pre- and postsynaptic GABA(B) receptors in the hippocampus. Our study implies that zinc modulates synaptic transmission in the immature hippocampus, a finding that may have implications for understanding benign postnatal seizures in young children suffering with acute zinc deficiency 18.	UNIV LONDON, DEPT PHARMACOL, 29-39 BRUNSWICK SQ, LONDON WC1N 1AX, ENGLAND	University of London				Xie, Xinmin Simon/0000-0002-4049-6499	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; CHARTON G, 1985, EXP BRAIN RES, V58, P202; CRAWFORD IL, 1975, J ORTHOMOL MED, V4, P39; CRAWFORD IL, 1972, J NEUROCHEM, V19, P1451, DOI 10.1111/j.1471-4159.1972.tb05088.x; DANSCHER G, 1975, BRAIN RES, V85, P522, DOI 10.1016/0006-8993(75)90825-2; DANSCHER G, 1984, NEUROBIOLOGY ZINC, VA, P227; DOLLER HJ, 1984, NEUROBIOLOGY ZINC, VB, P163; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FRIEDMAN B, 1984, J COMP NEUROL, V223, P88, DOI 10.1002/cne.902230108; GOLDBERG HJ, 1982, ARCH DIS CHILD, V57, P633, DOI 10.1136/adc.57.8.633; HESSE GW, 1979, SCIENCE, V205, P1005, DOI 10.1126/science.224456; HIDER RC, 1990, BIOCHEM PHARMACOL, V39, P1005, DOI 10.1016/0006-2952(90)90278-S; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HOLM IE, 1988, HISTOCHEMISTRY, V89, P289, DOI 10.1007/BF00493154; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; IBATA Y, 1969, J HISTOCHEM CYTOCHEM, V17, P171, DOI 10.1177/17.3.171; MCLAUGHLIN BJ, 1975, BRAIN RES, V85, P355, DOI 10.1016/0006-8993(75)90813-6; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; SCHWARTZKROIN PA, 1981, DEV BRAIN RES, V2, P469, DOI 10.1016/0165-3806(81)90017-1; SMART TG, 1990, BRIT J PHARMACOL, V99, P643, DOI 10.1111/j.1476-5381.1990.tb12984.x; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; WENSINK J, 1988, J NEUROCHEM, V50, P782, DOI 10.1111/j.1471-4159.1988.tb02982.x; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WOLF G, 1984, NEUROSCI LETT, V51, P277, DOI 10.1016/0304-3940(84)90564-0	30	372	381	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 7	1991	349	6309					521	524		10.1038/349521a0	http://dx.doi.org/10.1038/349521a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846946				2022-12-01	WOS:A1991EW57100065
J	CHASE, HP; GARG, SK; MARSHALL, G; BERG, CL; HARRIS, S; JACKSON, WE; HAMMAN, RE				CHASE, HP; GARG, SK; MARSHALL, G; BERG, CL; HARRIS, S; JACKSON, WE; HAMMAN, RE			CIGARETTE-SMOKING INCREASES THE RISK OF ALBUMINURIA AMONG SUBJECTS WITH TYPE-I DIABETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RETINOPATHY; NEPHROPATHY; MELLITUS	The effect of cigarette smoking on diabetic renal and retinal complications was evaluated in 359 young subjects with insulin-dependent diabetes mellitus. The prevalence of increased albumin excretion rates was 2.8 times higher in smokers than nonsmokers. Mean glycohemoglobin levels and duration of diabetes were also significant factors in the development of diabetic nephropathy and retinopathy in a logistic regression model. Smoking remained a significant factor in the logistic regression model for albuminuria (but not retinopathy) when controlled for glycohemoglobin level, duration of diabetes, age, gender, and blood pressure. The progression of albuminuria and of retinopathy was also greater in smokers. Albuminuria improved significantly when subjects ceased smoking. It is concluded that cigarette smoking is an independent risk factor and is associated with the development and progression of early diabetic renal damage (albuminuria) and with the worsening of retinal disease in young subjects with diabetes.	UNIV COLORADO,HLTH SCI CTR,DEPT PREVENT MED & BIOMETR,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT OPHTHALMOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	CHASE, HP (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,BARBARA DAVIS CTR CHILDHOOD DIABET,4200 E 9TH AVE,DENVER,CO 80262, USA.		Marshall, Guillermo/F-2302-2011		NCRR NIH HHS [RR69] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGRESTI A, 1990, CATEGORICAL DATA ANA, P306; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; CHASE HP, 1990, OPHTHALMOLOGY, V97, P155; CHASE HP, 1990, ARCH INTERN MED, V150, P639, DOI 10.1001/archinte.150.3.639; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P10; KLEIN R, 1983, AM J EPIDEMIOL, V118, P228, DOI 10.1093/oxfordjournals.aje.a113630; LUNDMAN BM, 1990, J INTERN MED, V227, P101, DOI 10.1111/j.1365-2796.1990.tb00126.x; MCCANCE DR, 1989, LANCET, V2, P824; MOGENSEN CE, 1985, HYPERTENSION, V7, P64; MUHLHAUSER I, 1986, DIABETOLOGIA, V29, P500, DOI 10.1007/BF00453501; NORDEN G, 1984, ACTA MED SCAND, V215, P257; ORCHARD TJ, 1990, DIABETES CARE, V13, P741, DOI 10.2337/diacare.13.7.741; OSBERG I, 1990, CLIN CHEM, V36, P1428; ROSE GA, 1968, CARDIOVASCULAR SURVE, P160; RUDEHILL A, 1989, CLIN PHYSIOL, V9, P243, DOI 10.1111/j.1475-097X.1989.tb00976.x; VIBERTI GC, 1982, LANCET, V1, P1430; VOORS AW, 1976, CIRCULATION, V54, P319, DOI 10.1161/01.CIR.54.2.319; 1987, SAS STAT GUIDE PERSO; 1989, MMWR, V38, P543; 1981, INVEST OPHTHALMOL VI, V21, P210	21	215	222	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	1991	265	5					614	617		10.1001/jama.265.5.614	http://dx.doi.org/10.1001/jama.265.5.614			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV718	1987411				2022-12-01	WOS:A1991EV71800018
J	GATES, G				GATES, G			SUBMANDIBULAR CALCULI	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GATES, G (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	1991	265	5					650	650						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV718	1987419				2022-12-01	WOS:A1991EV71800027
J	KLAG, MJ; WHELTON, PK; CORESH, J; GRIM, CE; KULLER, LH				KLAG, MJ; WHELTON, PK; CORESH, J; GRIM, CE; KULLER, LH			THE ASSOCIATION OF SKIN COLOR WITH BLOOD-PRESSURE IN UNITED-STATES BLACKS WITH LOW SOCIOECONOMIC-STATUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GEOGRAPHIC DIFFERENCES; STROKE MORTALITY; PUERTO-RICO; HYPERTENSION; POPULATION; WHITES; LIGHT; MEN	To determine the association of skin color, measured by a reflectometer, with blood pressure in US blacks, we studied a community sample of 457 blacks from three US cities. Persons taking antihypertensive medications were excluded. Both systolic and diastolic blood pressure were higher in darker persons and increased by 2 mm Hg for every 1-SD increase in skin darkness. However, the association was dependent on socioeconomic status, whether measured by education or an index consisting of education, occupation, and ethnicity, being present only in persons with lower levels of either indicator. Using multiple linear regression, both systolic and diastolic blood pressure remained significantly associated with darker skin color in the lower levels of socioeconomic status, independent of age, body mass index, and concentrations of blood glucose, serum urea nitrogen, serum uric acid, and urinary sodium and potassium. The association of skin color with blood pressure only in low socioeconomic strata may be due to the lesser ability of such groups to deal with the psychosocial stress associated with darker skin color. However, these findings also are consistent with an interaction between an environmental factor associated with low socioeconomic status and a susceptible gene that has a higher prevalence in persons with darker skin color.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21218 USA; CHARLES R DREW UNIV, SCH MED, DEPT MED, LOS ANGELES, CA USA; UNIV PITTSBURGH, SCH PUBL HLTH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Charles R. Drew University of Medicine & Science; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BOYLE E, 1970, J AMER MED ASSOC, V213, P1637, DOI 10.1001/jama.213.10.1637; Cavalli-Sforza Luigi., 1971, GENETICS HUMAN POPUL; COMSTOCK GW, 1957, AM J HYG, V65, P271, DOI 10.1093/oxfordjournals.aje.a119870; COSTAS R, 1981, AM J PUBLIC HEALTH, V71, P614, DOI 10.2105/AJPH.71.6.614; DRIZD R, 1986, VITAL HLTH STAT, V11, P31; GILLUM RF, 1979, HYPERTENSION, V1, P468, DOI 10.1161/01.HYP.1.5.468; GREEN LW, 1970, PUBLIC HEALTH REP, V85, P815, DOI 10.2307/4593972; GRIM CE, 1984, AUST NZ J MED, V14, P453, DOI 10.1111/j.1445-5994.1984.tb03614.x; HARBURG E, 1978, AM J PUBLIC HEALTH, V68, P1177, DOI 10.2105/AJPH.68.12.1177; HARBURG E, 1982, HUM BIOL, V54, P283; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; JAMES SA, 1987, AM J EPIDEMIOL, V126, P664, DOI 10.1093/oxfordjournals.aje.a114706; KEIL JE, 1981, AM J PUBLIC HEALTH, V71, P532, DOI 10.2105/AJPH.71.5.532; KEIL JE, 1977, AM J PUBLIC HEALTH, V67, P634, DOI 10.2105/AJPH.67.7.634; LUFT FC, 1977, J LAB CLIN MED, V90, P555; MACLEAN CJ, 1974, AM J HUM GENET, V26, P614; MILLER JM, 1985, AM J PUBLIC HEALTH, V75, P558, DOI 10.2105/AJPH.75.5.558; NEFZGER MD, 1977, STROKE, V8, P546, DOI 10.1161/01.STR.8.5.546; SORLIE PD, 1988, AM HEART J, V116, P777, DOI 10.1016/0002-8703(88)90337-7; STOLLEY PD, 1977, STROKE, V8, P551, DOI 10.1161/01.STR.8.5.551; TYROLER HA, 1978, AM J PUBLIC HEALTH, V68, P1170, DOI 10.2105/AJPH.68.12.1170; 1985, SAS USERS GUIDE BASI	22	131	133	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	1991	265	5					599	602		10.1001/jama.265.5.599	http://dx.doi.org/10.1001/jama.265.5.599			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV718	1987409				2022-12-01	WOS:A1991EV71800015
J	MIRKIN, G				MIRKIN, G			EXERCISE-ASSOCIATED URTICARIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							INDUCED ANAPHYLAXIS; CHOLINERGIC URTICARIA				MIRKIN, G (corresponding author), GEORGETOWN UNIV,SCH MED,WASHINGTON,DC 20057, USA.							BLACK AK, 1988, ACTA DERM-VENEREOL, V68, P541; CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; HARRIES MG, 1979, CLIN ALLERGY, V9, P437, DOI 10.1111/j.1365-2222.1979.tb02506.x; HATTY S, 1983, POSTGRAD MED J, V59, P586, DOI 10.1136/pgmj.59.695.586; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P319, DOI 10.1016/0091-6749(81)90158-5; KIVITY S, 1988, J ALLERGY CLIN IMMUN, V81, P1155, DOI 10.1016/0091-6749(88)90884-6; KUSHIMOTO H, 1985, ARCH DERMATOL, V121, P355, DOI 10.1001/archderm.121.3.355; MCCLEAN SP, 1989, J ALLERGY CLIN IMMUN, V83, P738, DOI 10.1016/0091-6749(89)90008-0; SHEFFER AL, 1984, J ALLERGY CLIN IMMUN, V73, P699, DOI 10.1016/0091-6749(84)90309-9; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SHEFFER AL, 1988, NEW ENGL REG ALLERGY, V9, P215	11	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	1991	265	5					650	650						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV718	1987418				2022-12-01	WOS:A1991EV71800026
J	MURPH, JR; BARON, JC; BROWN, CK; EBELHACK, CL; BALE, JF				MURPH, JR; BARON, JC; BROWN, CK; EBELHACK, CL; BALE, JF			THE OCCUPATIONAL RISK OF CYTOMEGALOVIRUS-INFECTION AMONG DAY-CARE PROVIDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS INFECTION; MOLECULAR EPIDEMIOLOGY; CHILDREN; TRANSMISSION; PREGNANCY; CENTERS; PARENTS	We prospectively studied day-care providers at six day-care centers in southeastern Iowa to determine their occupational risk for primary cytomegalovirus infection and to define epidemiologic risk factors. Ninety-six (38%) of 252 day-care providers were seropositive for cytomegalovirus by latex agglutination at entry into the study. Among 82 seronegative providers available for follow-up, seven seroconversions occurred at only two of the six participating centers, yielding an annualized seroconversion rate of 7.9%. Median time to seroconversion among these providers was 13 months. Using Kaplan-Meier estimates of risk, we determined that the overall risk of seroconversion among providers at various centers ranged from 0% to 22% by 12 months and from 0% to 40% by 16 months. Risk of cytomegalovirus acquisition by providers was independent of race, age, education, the presence of a child at home, or caring for children younger than 2 or 3 years in the day-care center. However, the risk of seroconversion among day-care providers appeared to parallel rates of cytomegalovirus excretion and acquisition among children at each center.	UNIV IOWA,COLL MED,DIV GEN PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DIV PEDIAT NEUROL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PREVENT MED & ENVIRONM HLTH,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa	MURPH, JR (corresponding author), UNIV IOWA HOSP & CLIN,DIV GEN PEDIAT,2474 JCP,IOWA CITY,IA 52242, USA.				NICHD NIH HHS [HD 22136] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022136] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADLER SP, 1985, J INFECT DIS, V152, P760, DOI 10.1093/infdis/152.4.760; ADLER SP, 1988, J PEDIATR-US, V112, P366, DOI 10.1016/S0022-3476(88)80314-7; ADLER SP, 1989, NEW ENGL J MED, V321, P1290, DOI 10.1056/NEJM198911093211903; AHLFORS K, 1982, ACTA PAEDIATR SCAND, V71, P109, DOI 10.1111/j.1651-2227.1982.tb09380.x; BALCAREK KB, 1990, JAMA-J AM MED ASSOC, V263, P840, DOI 10.1001/jama.263.6.840; BALFOUR CL, 1986, JAMA-J AM MED ASSOC, V256, P1909, DOI 10.1001/jama.256.14.1909; BLACKMAN JA, 1987, PEDIATR INFECT DIS J, V6, P725, DOI 10.1097/00006454-198708000-00006; GRIFFITHS PD, 1984, BRIT J OBSTET GYNAEC, V91, P307, DOI 10.1111/j.1471-0528.1984.tb05915.x; HUTTO C, 1985, PEDIATR INFECT DIS J, V4, P149, DOI 10.1097/00006454-198503000-00008; JONES LA, 1985, J INFECT DIS, V151, P953, DOI 10.1093/infdis/151.5.953; KALBFLEISH JD, 1980, STATISTICAL ANAL FAI, P143; MCHUGH TM, 1985, J CLIN MICROBIOL, V22, P1014, DOI 10.1128/JCM.22.6.1014-1019.1985; MURPH JR, 1988, AM J DIS CHILD, V142, P843, DOI 10.1001/archpedi.1988.02150080049020; MURPH JR, 1986, J PEDIATR-US, V109, P35, DOI 10.1016/S0022-3476(86)80568-6; PASS RF, 1990, PEDIATR INFECT DIS J, V9, P465, DOI 10.1097/00006454-199007000-00003; PASS RF, 1984, PEDIATRICS, V74, P121; PASS RF, 1986, NEW ENGL J MED, V314, P1414, DOI 10.1056/NEJM198605293142204; PASS RF, 1982, NEW ENGL J MED, V307, P477, DOI 10.1056/NEJM198208193070804; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; 1987, USERS MANUAL STAT LI, P371	20	78	78	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	1991	265	5					603	608		10.1001/jama.265.5.603	http://dx.doi.org/10.1001/jama.265.5.603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV718	1846215				2022-12-01	WOS:A1991EV71800016
J	SATO, K				SATO, K			HYPERHIDROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SATO, K (corresponding author), UNIV IOWA,SCH MED,IOWA CITY,IA 52242, USA.							FEALEY RD, 1989, MAYO CLIN PROC, V64, P617, DOI 10.1016/S0025-6196(12)65338-5; GOBBI PG, 1990, CANCER, V65, P2074, DOI 10.1002/1097-0142(19900501)65:9<2074::AID-CNCR2820650931>3.0.CO;2-O; KENNEY MJ, 1986, CLIN EXP DERMATOL, V11, P543, DOI 10.1111/j.1365-2230.1986.tb00506.x; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; SATO K, 1989, J AM ACAD DERMATOL, V20, P713, DOI 10.1016/S0190-9622(89)70081-5; SATO KT, 1988, AM J MED SCI, V295, P528, DOI 10.1097/00000441-198806000-00006	6	9	13	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	1991	265	5					651	651		10.1001/jama.265.5.651	http://dx.doi.org/10.1001/jama.265.5.651			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV718	1987421				2022-12-01	WOS:A1991EV71800029
J	SPOOR, TC				SPOOR, TC			SUDDEN VISUAL-LOSS FOLLOWING CATARACT REMOVAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SPOOR, TC (corresponding author), WAYNE STATE UNIV,SCH MED,KRESGE EYE INST,DETROIT,MI 48201, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	1991	265	5					650	651						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV718	1987420				2022-12-01	WOS:A1991EV71800028
J	BARLOW, DH; BROCKIE, JA; REES, CMP				BARLOW, DH; BROCKIE, JA; REES, CMP			STUDY OF GENERAL-PRACTICE CONSULTATIONS AND MENOPAUSAL PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT THERAPY	Objective-To investigate the nature of work related to the menopause in general practice. Design-Questionnaire study over six months among general practitioners after each consultation with a woman aged 40-69 at which issues related to the climacteric had been discussed. Setting-9 General practices in the Oxford area. Subjects-416 Women who had 572 consultations. Main outcome measures-Age, menopausal state, and first or subsequent consultation. Symptoms were classified together with the treatment and the outcome of the consultation. Results-The consultation rate varied greatly between practices, the overall rate being 4.4%. There were many premenopausal women and women in their 60s presenting; women with hysterectomies presented more often-36% (37/103) of women with hysterectomies had more than one consultation compared with 26% (38/144) for premenopausal women and 24% (38/155) for postmenopausal women. 409 women had symptoms and 218 were prescribed oestrogen treatment. 156 of the consultations involved discussion and advice only. Only four women were referred to a local specialist clinic. Conclusion-There is a low overall use of hormone replacement therapy in the general postmenopausal population despite the recent media coverage of its benefits in the prevention of osteoporosis and subsequent fractures.			BARLOW, DH (corresponding author), UNIV OXFORD,JOHN RADCLIFFE MATERN HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.		Barlow, David/F-8738-2011					AITKEN JM, 1973, BMJ-BRIT MED J, V3, P515, DOI 10.1136/bmj.3.5879.515; BALLINGER CB, 1975, BRIT MED J, V3, P344, DOI 10.1136/bmj.3.5979.344; BARLOW DH, 1989, BRIT J OBSTET GYNAEC, V96, P1192, DOI 10.1111/j.1471-0528.1989.tb03195.x; BELCHETZ P, 1989, BMJ-BRIT MED J, V298, P1467, DOI 10.1136/bmj.298.6686.1467; DRAPER J, 1990, BRIT MED J, V300, P786, DOI 10.1136/bmj.300.6727.786; SHEARS MR, 1989, PRACTITIONER, V233, P146; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434; THOMPSON B, 1973, J BIOSOC SCI, V5, P71, DOI 10.1017/S0021932000008956	8	41	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					274	276		10.1136/bmj.302.6771.274	http://dx.doi.org/10.1136/bmj.302.6771.274			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998795	Green Published, Bronze			2022-12-01	WOS:A1991EX91900023
J	BROWN, P; GAJDUSEK, DC				BROWN, P; GAJDUSEK, DC			SURVIVAL OF SCRAPIE VIRUS AFTER 3 YEARS INTERNMENT	LANCET			English	Note								Supernatant fluid from a scrapie-infected hamster brain homogenate was mixed with soil, packed into perforated petri dishes that were then embedded within soil-containing pots, and buried in a garden for 3 years. Between 2 and 3 log units of the input infectivity of nearly 5 log units survived this exposure, with little leaching of virus into deeper soil layers. These results have implications for environmental contamination by scrapie and by similar agents, including those of bovine spongiform encephalopathy and Creutzfeldt-Jakob disease.			BROWN, P (corresponding author), NINCDS,CENT NERVOUS SYST STUDIES LAB,BETHESDA,MD 20892, USA.							BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; Brown P, 1980, Epidemiol Rev, V2, P113; Palsson P. A., 1979, Slow transmissible diseases of the nervous system. Volume 1., P357; TATEISHI J, 1987, PRIONS NOVEL INFECTI, P424; [No title captured]	5	177	179	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					269	270		10.1016/0140-6736(91)90873-N	http://dx.doi.org/10.1016/0140-6736(91)90873-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671114				2022-12-01	WOS:A1991EV71900006
J	CRAVIOTO, A; TELLO, A; NAVARRO, A; RUIZ, J; VILLAFAN, H; URIBE, F; ESLAVA, C				CRAVIOTO, A; TELLO, A; NAVARRO, A; RUIZ, J; VILLAFAN, H; URIBE, F; ESLAVA, C			ASSOCIATION OF ESCHERICHIA-COLI HEP-2 ADHERENCE PATTERNS WITH TYPE AND DURATION OF DIARRHEA	LANCET			English	Article							DIFFUSE ADHERENCE; CELL ADHERENCE; ADHESION; PATHOGENS; CHILDREN; STRAINS; CULTURE; ASSAY	373 (59%) out of 636 faecal specimens obtained during the first 2 years of life of 72 Mexican children yielded adherent Escherichia coli (HEp-2 cells). Strains with localised adherence were significantly associated with acute non-bloody diarrhoea, whereas strains with aggregative adherence were significantly associated with persistent diarrhoea. Half the strains with localised adherence were not enteropathogenic E coli serotypes nor did they hybridise with an enteropathogenic E coli adherence factor DNA probe. All strains with localised adherence gave a positive fluorescent actin staining (FAS) assay, irrespective of serotype. One-third of children colonised by aggregative strains had bloody diarrhoea. Isolation of strains with diffuse adherence was not related to type or duration of diarrhoea but was generally associated with isolation of another pathogenic organism.			CRAVIOTO, A (corresponding author), INST NACL SALUD PUBL, CTR RES INFECT DIS, APARTADO POSTAL 16-116, MEXICO CITY 02000, DF, MEXICO.		Navarro, Armando/AAE-3832-2022; NAVARRO, ARMANDO/AAO-7368-2020	NAVARRO, ARMANDO/0000-0002-6693-7168				BAUDRY B, 1990, J INFECT DIS, V161, P1249, DOI 10.1093/infdis/161.6.1249; BENZ I, 1989, INFECT IMMUN, V57, P1506, DOI 10.1128/IAI.57.5.1506-1511.1989; BHAN MK, 1989, PEDIATR INFECT DIS J, V8, P499, DOI 10.1097/00006454-198908000-00005; BHAN MK, 1989, J INFECT DIS, V158, P70; BILGE SS, 1989, J BACTERIOL, V171, P4281, DOI 10.1128/JB.171.8.4281-4289.1989; CHATKAEOMORAKOT A, 1987, J INFECT DIS, V156, P669, DOI 10.1093/infdis/156.4.669; COBELJIC M, 1989, EPIDEMIOL INFECT, V103, P53, DOI 10.1017/S0950268800030351; CRAVIOTO A, 1988, EPIDEMIOL INFECT, V101, P123, DOI 10.1017/S0950268800029289; CRAVIOTO A, 1990, AM J EPIDEMIOL, V131, P886, DOI 10.1093/oxfordjournals.aje.a115579; CRAVIOTO A, 1979, CURR MICROBIOL, V3, P95, DOI 10.1007/BF02602439; FLEISS JL, 1973, STATISTICAL METHODS, P155; GOMES TAT, 1989, J CLIN MICROBIOL, V27, P266, DOI 10.1128/JCM.27.2.266-269.1989; KNUTTON S, 1987, INFECT IMMUN, V55, P78, DOI 10.1128/IAI.55.1.78-85.1987; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; KNUTTON S, 1987, INFECT IMMUN, V55, P69, DOI 10.1128/IAI.55.1.69-77.1987; LEVINE MM, 1988, J INFECT DIS, V158, P224, DOI 10.1093/infdis/158.1.224; LEVINE MM, 1987, J INFECT DIS, V155, P377, DOI 10.1093/infdis/155.3.377; MATHEWSON JJ, 1989, J INFECT DIS, V159, P1057, DOI 10.1093/infdis/159.6.1057; NATARO JP, 1985, J INFECT DIS, V152, P560, DOI 10.1093/infdis/152.3.560; ORSKOV F, 1975, AMPIS B, V83, P565; SAVARINO SJ, 1990, 90TH ANN M AM SOC MI, P45; SCOTLAND SM, 1989, J INFECTION, V19, P237, DOI 10.1016/S0163-4453(89)90729-9; VIAL PA, 1987, J INFECT DIS, V155, P377	23	262	266	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 2	1991	337	8736					262	264		10.1016/0140-6736(91)90868-P	http://dx.doi.org/10.1016/0140-6736(91)90868-P			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671111				2022-12-01	WOS:A1991EV71900003
J	CRAWFORD, CL; HOBBS, MJ				CRAWFORD, CL; HOBBS, MJ			INFANTILE PARALYSIS IN DEVELOPING-COUNTRIES - IS IT POLIOMYELITIS OR DIPLEGIA	LANCET			English	Editorial Material							SERIOUS PROBLEM				CRAWFORD, CL (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND.							ALLBROOK D, 1960, LANCET, V1, P459; BANNISTER R, 1985, BRAINS CLIN NEUROLOG, P328; BAZIN M, 1980, NATURE, V285, P7; BURNETT M, 1962, NATURAL HIST INFECTI, P91; CRAWFORD C L, 1968, Leprosy Review, V39, P9; HARRIES JR, 1973, TROPICAL NEUROLOGY, P213; HUCKSTEP RL, 1975, POLIOMYELITIS, P6; LAFORCE FM, 1980, B WORLD HEALTH ORGAN, V58, P609; MIMS CA, 1976, PATHOGENESIS INFECTI, P202; MODLIN JF, 1990, PRINCIPLES PRACTICE, P1359; NICHOLAS DD, 1977, BRIT MED J, V1, P1009, DOI 10.1136/bmj.1.6067.1009; OFOSUAMAAH S, 1977, BRIT MED J, V1, P1012, DOI 10.1136/bmj.1.6067.1012; POSKANZER DC, 1963, LANCET, V2, P917; SHARRARD WJW, 1955, J BONE JOINT SURG BR, V37, P540, DOI 10.1302/0301-620X.37B4.540; WALKER A J, 1956, East Afr Med J, V33, P169; WILSON SAK, 1954, NEUROLOGY, V2, P891; 1990, B WORLD HEALTH ORGAN, V68, P115	17	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					284	286		10.1016/0140-6736(91)90883-Q	http://dx.doi.org/10.1016/0140-6736(91)90883-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671124				2022-12-01	WOS:A1991EV71900016
J	EELES, RA; TAN, S; WILTSHAW, E; FRYATT, I; AHERN, RP; SHEPHERD, JH; HARMER, CL; BLAKE, PR; CHILVERS, CED				EELES, RA; TAN, S; WILTSHAW, E; FRYATT, I; AHERN, RP; SHEPHERD, JH; HARMER, CL; BLAKE, PR; CHILVERS, CED			HORMONE REPLACEMENT THERAPY AND SURVIVAL AFTER SURGERY FOR OVARIAN-CANCER	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT; POSTMENOPAUSAL WOMEN; MENOPAUSE; EPIDEMIOLOGY; CARCINOMA; RISK	Objective - To evaluate whether hormone replacement therapy affects survival in women who have undergone bilateral salpingo-oophorectomy because of epithelial ovarian cancer. Design - Retrospective analysis by review of patients' notes and questionnaires completed by general practitioners to compare the overall survival and disease free survival in patients with ovarian cancer who did or did not receive hormone replacement therapy after diagnosis. Data were analysed by Cox regression, with hormone replacement therapy as a time dependent covariate because patients who received hormone replacement did so at different times after diagnosis. Setting - Gynaecological oncology unit of Royal Marsden Hospital. Patients - 373 patients aged 50 years or younger who attended the hospital from 1972 to 1988. All of the women had undergone bilateral salpingo-oophorectomy for epithelial ovarian cancer. In all, 78 had received hormone replacement therapy, starting at a median of four months after diagnosis. Intervention - A questionnaire was sent to the general practitioners of all patients who were not recorded as having received hormone replacement therapy. Main outcome measures - Overall survival and disease free survival. Results - There was no significant difference in survival between women receiving hormone replacement therapy and those not receiving it after accounting for the effects of other known prognostic factors (stage of cancer, differentiation of tumour, histological results, and time to relapse). The relative risk of dying in those who received hormone replacement therapy was 0.73 (95% confidence interval 0.44 to 1.20). In addition, there was no significant difference in disease free survival (relative risk in those receiving hormone replacement therapy was 0.90; 95% confidence interval 0.52 to 1.54). Conclusions - This study shows that hormone replacement therapy is unlikely to have a detrimental effect on the prognosis of patients with ovarian cancer, but this would be shown conclusively only by a randomised controlled trial.	ROYAL MARSDEN HOSP,DEPT MED,GYNAECOL ONCOL UNIT,LONDON SW3 6JJ,ENGLAND; ROYAL MARSDEN HOSP,DEPT COMP,LONDON SW3 6JJ,ENGLAND; UNIV NOTTINGHAM,SCH MED,DEPT PUBL HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2RD,ENGLAND	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Nottingham				Eeles, Rosalind/0000-0002-3698-6241; A'Hern, Roger/0000-0003-0593-8391				ANDERSON JR, 1985, CANCER TREAT REP, V69, P1139; BARRETTCONNOR E, 1989, NEW ENGL J MED, V321, P319, DOI 10.1056/NEJM198908033210510; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COOPE J, 1975, BRIT MED J, V4, P139, DOI 10.1136/bmj.4.5989.139; COX DR, 1972, J R STAT SOC B, V34, P187; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; HARTGE P, 1988, AM J EPIDEMIOL, V127, P990, DOI 10.1093/oxfordjournals.aje.a114902; HENDERSON BE, 1988, FERTIL STERIL, V49, pS9; HILDRETH NG, 1981, AM J EPIDEMIOL, V114, P398, DOI 10.1093/oxfordjournals.aje.a113207; HORSMAN A, 1977, BRIT MED J, V2, P789, DOI 10.1136/bmj.2.6090.789; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KUHNEL R, 1987, INT J GYNECOL PATHOL, V6, P248; LAVECCHIA C, 1982, J NATL CANCER I, V69, P1207; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; TOBIAS JS, 1976, NEW ENGL J MED, V294, P818, DOI 10.1056/NEJM197604082941506; TZONOU A, 1984, EUR J CANCER CLIN ON, V20, P1045, DOI 10.1016/0277-5379(84)90107-X; WEISS NS, 1982, J NATL CANCER I, V68, P95; WHITEHEAD M, 1988, LANCET, V2, P1243	20	104	123	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					259	262		10.1136/bmj.302.6771.259	http://dx.doi.org/10.1136/bmj.302.6771.259			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998789	Green Published, Bronze			2022-12-01	WOS:A1991EX91900017
J	MORTIMER, PP				MORTIMER, PP			THE FALLIBILITY OF HIV WESTERN-BLOT	LANCET			English	Editorial Material							RETROVIRUSES HTLV-III; AIDS				MORTIMER, PP (corresponding author), CENT PUBL HLTH LAB,VIRUS REFERENCE LAB,61 COLINDALE AVE,LONDON NW9 5HT,ENGLAND.							BENENSON AS, 1989, JAMA-J AM MED ASSOC, V262, P3435; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; EPSTEIN J, 1990, DIAGN CLIN TEST, V28, P50; GENESCA J, 1989, LANCET, V2, P1023; JORGENSEN A, 1990, SCAND J INFECT DIS, V22, P283, DOI 10.3109/00365549009027049; LEPINE DG, 1990, J CLIN MICROBIOL, V28, P1169, DOI 10.1128/JCM.28.6.1169-1171.1990; MORTIMER PP, 1985, LANCET, V2, P873; PARRY JV, 1990, STD9027 DEP HLTH; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937; SPIELBERG S, 1990, J CLIN MICROBIOL, V28, P303; 1990, MMWR, V39, P380; 1990, WEEK EPIDEMIOL REC; 1989, MMWR, V38, pS7	14	52	55	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 2	1991	337	8736					286	287						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV719	1671125				2022-12-01	WOS:A1991EV71900017
J	RAVN, P; LUNDGREN, JD; KJAELDGAARD, P; HOLTENANDERSON, W; HOJLYNG, N; NIELSEN, JO; GAUB, J				RAVN, P; LUNDGREN, JD; KJAELDGAARD, P; HOLTENANDERSON, W; HOJLYNG, N; NIELSEN, JO; GAUB, J			NOSOCOMIAL OUTBREAK OF CRYPTOSPORIDIOSIS IN AIDS PATIENTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIARRHEA	Objective-To describe a nosocomial outbreak of cryptosporidiosis during four months after June 1989. Setting-A department of infectious diseases in Copenhagen, seeing about half the patients with AIDS in Denmark. Subjects-73 HIV antibody negative subjects and 60 antibody positive subjects admitted as inpatients during the transmission period of the outbreak (20 June-14 August), of whom 18 (17 with AIDS, one with AIDS related complex), developed cryptosporidiosis. Two further HIV negative subjects (one departmental secretary, one visiting relative) developed cryptosporidiosis. Main outcome measures-Cryptosporidia in stool samples, clinical symptoms, CD4 cell count, HIV antigen concentration, chemotherapeutic treatment. Results-The source of the outbreak was identified as ice from an ice machine in the ward, contaminated by an incontinent, psychotic patient with cryptosporidiosis picking out ice for cold drinks. The mean incubation time was at least 13 days-that is, twice that in HIV-negative patients. Of the 18 patients with AIDS who developed cryptosporidiosis, five recovered, two were symptomless carriers, three died of unrelated causes, and eight died after prolonged diarrhoea. Among the 57 exposed HIV antibody positive inpatients (excluding two patients and the index case with cryptosporidiosis diagnosed elsewhere), significantly more of those who developed symptomatic cryptosporidiosis received oral sulphonamides than those who did not (91%, 10/11-upsilon-48%, 21/44, p < 0.05). Conclusions-The clinical and epidemiological findings indicate that infection was the consequence of very small inocula. Increased sensitivity to cryptosporidiosis may be an unrecognised side effect of oral sulphonamide treatment in patients with AIDS.	HVIDOVRE UNIV HOSP, DEPT INFECT DIS, 144, DK-2650 HVIDOVRE, DENMARK; HVIDOVRE UNIV HOSP, DEPT CLIN MICROBIOL, DK-2650 HVIDOVRE, DENMARK; STATENS SERUM INST, DEPT TOXOPLASMOSIS, DK-2300 COPENHAGEN, DENMARK	University of Copenhagen; University of Copenhagen; Statens Serum Institut			Lundgren, Jens/AAE-6876-2019	Lundgren, Jens/0000-0001-8901-7850				CASEMORE DP, 1990, EPIDEMIOL INFECT, V104, P1, DOI 10.1017/S0950268800054480; CONNOLLY GM, 1988, GUT, V29, P593, DOI 10.1136/gut.29.5.593; CURRENT WL, 1988, AM SOC MICROBIOLOGY, V54, P604; HENRIKSEN SA, 1981, ACTA VET SCAND, V22, P594; HOJLYNG N, 1986, J CLIN MICROBIOL, V23, P1109; HOLTENANDERSEN W, 1984, J INFECTION, V9, P277, DOI 10.1016/S0163-4453(84)90618-2; HORNICK RB, 1970, NEW ENGL J MED, V283, P686, DOI 10.1056/NEJM197009242831306; JANOFF EN, 1990, ANN INTERN MED, V112, P75, DOI 10.7326/0003-4819-112-1-75; JOKIPII AMM, 1985, LANCET, V2, P487; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; MARTINO P, 1988, J INFECT DIS, V158, P647, DOI 10.1093/infdis/158.3.647; NAVIN TR, 1987, J INFECT DIS, V155, P150, DOI 10.1093/infdis/155.1.150; NIME FA, 1976, GASTROENTEROLOGY, V70, P592; PEDERSEN C, 1990, AIDS, V4, P233, DOI 10.1097/00002030-199003000-00009; ROLSTON KVI, 1989, J ACQ IMMUN DEF SYND, V2, P426; UNGAR BLP, 1990, GASTROENTEROLOGY, V98, P486, DOI 10.1016/0016-5085(90)90842-O; ZAR F, 1985, J INFECT DIS, V151, P195, DOI 10.1093/infdis/151.1.195	17	61	66	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 2	1991	302	6771					277	280		10.1136/bmj.302.6771.277	http://dx.doi.org/10.1136/bmj.302.6771.277			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998796	Green Published, Bronze			2022-12-01	WOS:A1991EX91900024
J	SEATON, D; YOGANATHAN, K; COADY, T; BARKER, R				SEATON, D; YOGANATHAN, K; COADY, T; BARKER, R			SPONTANEOUS PNEUMOTHORAX - MARKER GAS TECHNIQUE FOR PREDICTING OUTCOME OF MANUAL ASPIRATION	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether in a patient with spontaneous pneumothorax the presence or absence of a pleural leak can be shown at the time of manual aspiration by use of a marker gas. Also, to find out if the technique can predict whether manual aspiration will be successful, hence avoiding the need for intercostal tube drainage. Design-Prospective study of 25 episodes of pneumothorax during which patients breathed air from a Douglas bag that contained chlorofluorocarbon gases from a metered dose inhaler while the pneumothorax was aspirated. Setting-Medical unit of a district general hospital. Patients-22 patients who presented over nine months with acute pneumothorax. Main outcome measures-Presence or absence of chlorofluorocarbon marker gases in the aspirate. Presence or absence of sustained re-expansion of the affected lung in the chest radiograph. Results-Marker gas was detected in the aspirate from 16 out of 25 pneumothoraces. Of these, 13 required intercostal tube drainage because of failure of the lung to re-expand. Marker gas was not detected in nine cases, and in all of these cases manual aspiration resulted in sustained re-expansion of the lung. Conclusions-The presence or absence of a pleural leak during manual aspiration of spontaneous pneumothorax can be shown by using this technique. The absence of marker gas in the aspirate implies that manual aspiration will be successful, whereas its presence predicts, in most cases, either failure of manual aspiration to expand the lung or early recollapse of the lung.			SEATON, D (corresponding author), IPSWICH HOSP,DEPT THORAC MED,IPSWICH IP4 5PD,SUFFOLK,ENGLAND.							BEVELAQUA FA, 1982, CHEST, V81, P693, DOI 10.1378/chest.81.6.693; COADY TJ, 1988, LANCET, V2, P1286; CUMMINGS JH, 1988, RECENT ADV GASTROENT, V7, P328; HAMILTON AAD, 1983, THORAX, V38, P934, DOI 10.1136/thx.38.12.934; JONES JS, 1985, THORAX, V40, P66, DOI 10.1136/thx.40.1.66; RAJA OG, 1981, BR J DIS CHEST, V75, P27; Seaton A, 1989, CROFTON DOUGLASS RES, P761	7	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					262	265		10.1136/bmj.302.6771.262	http://dx.doi.org/10.1136/bmj.302.6771.262			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998790	Green Published, Bronze			2022-12-01	WOS:A1991EX91900018
J	TIERNEY, AJ; LEONARD, RCF; TAYLOR, J; CLOSS, SJ; CHETTY, U; RODGER, A				TIERNEY, AJ; LEONARD, RCF; TAYLOR, J; CLOSS, SJ; CHETTY, U; RODGER, A			SIDE-EFFECTS EXPECTED AND EXPERIENCED BY WOMEN RECEIVING CHEMOTHERAPY FOR BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									LONGMORE HOSP,BREAST UNIT,EDINBURGH,SCOTLAND; WESTERN GEN HOSP,CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	TIERNEY, AJ (corresponding author), UNIV EDINBURGH,DEPT NURSING STUDIES,NURSING RES UNIT,EDINBURGH EH8 9JT,SCOTLAND.			Closs, Susan Jose/0000-0002-3257-5277				TIERNEY AJ, 1989, STUDY INFORM NURSING	1	28	28	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					272	272		10.1136/bmj.302.6771.272	http://dx.doi.org/10.1136/bmj.302.6771.272			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998793	Bronze, Green Published			2022-12-01	WOS:A1991EX91900021
J	COCKRELL, JL; SCHEINMAN, MM; TITUS, C; HELMY, I; LANGBERG, JJ; LEE, MA; GRIFFIN, JC				COCKRELL, JL; SCHEINMAN, MM; TITUS, C; HELMY, I; LANGBERG, JJ; LEE, MA; GRIFFIN, JC			SAFETY AND EFFICACY OF ORAL FLECAINIDE THERAPY IN PATIENTS WITH ATRIOVENTRICULAR REENTRANT TACHYCARDIA	ANNALS OF INTERNAL MEDICINE			English	Article							PARKINSON-WHITE SYNDROME; SUPRAVENTRICULAR ARRHYTHMIAS; JUNCTIONAL TACHYCARDIAS; ATRIAL-FIBRILLATION; CLINICAL EFFICACY; ACETATE; ENCAINIDE; PATHWAYS; ISOPROTERENOL	Objective: To assess the short- and long-term safety and efficacy of oral flecainide therapy in patients with symptomatic tachycardia and an extranodal accessory pathway. Design: Open-label, uncontrolled trial with a mean follow-up of 24 months. Setting: Referral-based, teaching medical center. Patients: Sixty-three patients with symptomatic tachycardia and an extranodal accessory pathway. Interventions: Patients had electrophysiologic testing before and after the initiation of oral flecainide therapy and were followed long-term for the presence of symptoms, new physical limitations, and adverse effects of therapy. Measurements and Main Results: Flecainide therapy prevented or slowed (324 +/- 59 ms to 398 +/- 55 ms; P < 0.001) inducible sustained atrioventricular reciprocating tachycardia in 44 of 63 patients (70%). Of the 44 patients discharged from the hospital, 33 (75%) have continued to receive flecainide therapy and have shown no adverse effects (mean follow-up, 24 +/- 10 months). Adverse cardiac reactions (proarrhythmia or sinus node suppression) attributable to flecainide occurred in 11 of 63 patients (17%); in 9 (82%) of these 11 patients, events were detected during either in-hospital monitoring or the electrophysiologic study done before discharge. Structural heart disease was detected by two-dimensional echocardiography in 8 of 11 patients who had adverse cardiac events and in 6 of 52 patients who did not have such events (P < 0.001). Isoproterenol reversed the effects of flecainide therapy in 11 of 21 patients; 7 of the 11 patients had spontaneous clinical recurrences of tachycardia or palpitations during the follow-up period, but these symptoms occurred in only 1 of 10 patients who did not show isoproterenol-induced reversal (P = 0.02). Conclusions: Oral flecainide therapy was effective in 33 of 63 patients who had tachycardia and an extranodal accessory connection. Hospital monitoring during initial therapy is recommended, and flecainide should be used with caution, if at all, in patients with structural heart disease. An isoproterenol challenge appears to be helpful in predicting late recurrence of tachycardia.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	COCKRELL, JL (corresponding author), LETTERMAN ARMY MED CTR, DEPT MED, CARDIOL SERV, SAN FRANCISCO, CA 94129 USA.							ABDOLLAH H, 1984, AM J CARDIOL, V54, P544, DOI 10.1016/0002-9149(84)90245-5; AKHTAR M, 1988, AM J CARDIOL, V62, pL45, DOI 10.1016/0002-9149(88)90015-X; ANDERSON JL, 1988, AM J CARDIOL, V62, pD62; [Anonymous], 1989, NEW ENGL J MED, V321, P406; BEXTON RS, 1983, EUR HEART J, V4, P92, DOI 10.1093/oxfordjournals.eurheartj.a061432; BREMBILLAPERROT B, 1985, EUR HEART J, V6, P1074, DOI 10.1093/oxfordjournals.eurheartj.a061812; CRIJNS HJGM, 1988, AM HEART J, V115, P1317, DOI 10.1016/0002-8703(88)90032-4; FAUCHIER JP, 1985, ARCH MAL COEUR VAISS, V78, P81; GOY JJ, 1985, EUR HEART J, V6, P518, DOI 10.1093/oxfordjournals.eurheartj.a061897; HAISSAGUERRE M, 1987, ARCH MAL COEUR VAISS, V80, P357; HELLESTRAND KJ, 1983, AM J CARDIOL, V51, P770, DOI 10.1016/S0002-9149(83)80131-3; HELMY I, 1991, IN PRESS J AM COLL C; KAPPENBERGER LJ, 1985, CLIN CARDIOL, V8, P321, DOI 10.1002/clc.4960080603; KIM SS, 1986, AM J CARDIOL, V58, P80, DOI 10.1016/0002-9149(86)90245-6; NEUSS H, 1988, AM J CARDIOL, V62, pD56; NEUSS H, 1983, EUR HEART J, V4, P347, DOI 10.1093/oxfordjournals.eurheartj.a061472; PRYSTOWSKY EN, 1984, CIRCULATION, V69, P278, DOI 10.1161/01.CIR.69.2.278; TILL JA, 1987, ARCH DIS CHILD, V62, P247, DOI 10.1136/adc.62.3.247; WARD DE, 1986, AM J CARDIOL, V57, P787, DOI 10.1016/0002-9149(86)90614-4; WELLENS HJJ, 1980, AM J CARDIOL, V46, P665, DOI 10.1016/0002-9149(80)90518-4; WREN C, 1987, BRIT HEART J, V57, P171; ZEECHENG CS, 1988, AM J CARDIOL, V62, pD23	22	25	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1991	114	3					189	194		10.7326/0003-4819-114-3-189	http://dx.doi.org/10.7326/0003-4819-114-3-189			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV339	1898629				2022-12-01	WOS:A1991EV33900003
J	DESIMONE, G; DEVEREUX, RB; ROMAN, MJ; SCHLUSSEL, Y; ALDERMAN, MH; LARAGH, JH				DESIMONE, G; DEVEREUX, RB; ROMAN, MJ; SCHLUSSEL, Y; ALDERMAN, MH; LARAGH, JH			ECHOCARDIOGRAPHIC LEFT-VENTRICULAR MASS AND ELECTROLYTE INTAKE PREDICT ARTERIAL-HYPERTENSION	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-PRESSURE; CARDIAC SIZE; HYPERTROPHY; POTASSIUM; SALT; RECOMMENDATIONS; POPULATION; RESPONSES; STRESS; TWINS	Objective: To identify predictors of arterial hypertension. Patients: One hundred thirty-two normotensive adults from a large employed population. Methods: Echocardiography, standard blood tests, and 24-hour urine collection, at baseline and after an interval of 3 to 6 years (mean, 4.7 +/- 0.8 years). Results: At follow-up, 15 subjects (11%; 7 men, 8 women) had a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg or both (mean, 143 +/- 7 and 87 +/- 6 mm Hg, respectively). At baseline, subjects who developed hypertension had a greater left ventricular mass index than those who did not (92 +/- 25 compared with 77 +/- 19 g/m2 body surface area; P < 0.005) and higher 24-hour urinary sodium/potassium excretion ratio (3.6 +/- 1.7 compared with 2.6 +/- 1.4; P < 0.04); there were no differences in race, initial age, systolic or diastolic blood pressure, coronary risk factors, or plasma renin activity. The likelihood of developing hypertension rose from 3% in the lowest quartile of sex-adjusted left ventricular mass index to 24% in the highest quartile (P < 0.005); a parallel trend was less regular for quartiles of the sodium/potassium excretion ratio (P < 0.04). In multivariate analyses, follow-up systolic pressures in all subjects and in the 117 who remained normotensive were predicted by initial age, systolic blood pressure, black race, and sex-adjusted left ventricular mass index; final diastolic blood pressure was predicted by its initial value, plasma triglyceride levels, urinary sodium/potassium ratio, low renin activity, black race, and plasma glucose level. Conclusions: Echocardiographic left ventricular mass in normotensive adults is directly related to the risk for developing subsequent hypertension. Left ventricular mass improves prediction of future systolic pressure, whereas diastolic pressure is more related to initial metabolic status. Black race is also an independent determinant of higher subsequent blood pressure.	CORNELL UNIV, MED CTR,NEW YORK HOSP,DIV CARDIOL,BOX 222, 525 E 68TH ST, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital			de Simone, Giovanni/D-1767-2011	de Simone, Giovanni/0000-0001-8567-9881	NHLBI NIH HHS [HL 18323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABERNATHY JR, 1988, AM J CARDIOL, V61, P1071, DOI 10.1016/0002-9149(88)90128-2; ADAMS TD, 1985, CIRCULATION, V71, P39, DOI 10.1161/01.CIR.71.1.39; BLAUSTEIN MP, 1977, AM J PHYSIOL, V232, pC165, DOI 10.1152/ajpcell.1977.232.5.C165; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CELENTANO A, 1988, J HYPERTENS, V6, pS107, DOI 10.1097/00004872-198812040-00030; CHIANG BN, 1969, CIRCULATION, V39, P403, DOI 10.1161/01.CIR.39.3.403; CHIEN S, 1965, P SOC EXP BIOL MED, V119, P1155; DAHL LK, 1972, AM J CLIN NUTR, V25, P231; DELEONARDIS V, 1988, AM J HYPERTENS, V1, P305, DOI 10.1093/ajh/1.3.305; DESIMONE G, 1990, CIRCULATION, V81, P107, DOI 10.1161/01.CIR.81.1.107; DESIMONE G, 1988, AM J NONINVAS CARD, V2, P217; DEVEREUX RB, 1989, AM J HYPERTENS, V2, pS186, DOI 10.1093/ajh/2.6.186S; DEVEREUX RB, 1987, HYPERTENSION, V9, P97; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1983, CIRCULATION, V68, P470, DOI 10.1161/01.CIR.68.3.470; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEVEREUX RB, 1984, J AM COLL CARDIOL, V4, P1222, DOI 10.1016/S0735-1097(84)80141-2; DEVEREUX RB, 1988, AM HEART J, V116, P1124, DOI 10.1016/0002-8703(88)90176-7; DITTO B, 1989, HYPERTENSION, V13, P181, DOI 10.1161/01.HYP.13.2.181; FAGARD R, 1987, AM J CARDIOL, V60, P1362, DOI 10.1016/0002-9149(87)90620-5; GANAU A, 1989, J AM COLL CARDIOL, V14, P715, DOI 10.1016/0735-1097(89)90116-2; GANAU A, 1990, CIRCULATION, V81, P25, DOI 10.1161/01.CIR.81.1.25; GOSSE P, 1986, J HYPERTENS, V4, pS297; GOTTDIENER JS, 1990, ANN INTERN MED, V112, P161, DOI 10.7326/0003-4819-112-3-161; GUDMUNDSSON O, 1984, ACTA MED SCAND, V688, P31; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; HARSHFIELD GA, 1990, AM J HYPERTENS, V3, P538, DOI 10.1093/ajh/3.7.538; KESTELOOT H, 1984, ANN CLIN RES, V16, P72; KOREN MJ, 1991, IN PRESS ANN INTERN; KRISHNA GG, 1987, J LAB CLIN MED, V109, P724; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LIU K, 1979, AM J EPIDEMIOL, V110, P219, DOI 10.1093/oxfordjournals.aje.a112806; MACGREGOR GA, 1985, HYPERTENSION, V7, P628, DOI 10.1161/01.HYP.7.4.628; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAHONEY LT, 1988, HYPERTENSION, V12, P206, DOI 10.1161/01.HYP.12.2.206; NATHWANI D, 1985, AM HEART J, V109, P386, DOI 10.1016/0002-8703(85)90622-2; Nielsen J R, 1985, Acta Med Scand Suppl, V693, P61; Pickering G, 1968, HIGH BLOOD PRESSURE, P236; RADICE M, 1986, AM HEART J, V111, P115, DOI 10.1016/0002-8703(86)90562-4; RAVOGLI A, 1990, IN PRESS HYPERTENSIO; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SEALEY JE, 1977, CARDIOVASC MED, V2, P1079; SEALEY JE, 1970, J CLIN INVEST, V49, P2119, DOI 10.1172/JCI106429; STAESSEN J, 1981, J EPIDEMIOL COMMUN H, V35, P256, DOI 10.1136/jech.35.4.256; TANNEN RL, 1983, ANN INTERN MED, V98, P773, DOI 10.7326/0003-4819-98-5-773; WALLERSON DC, 1987, HYPERTENSION, V9, P6; WEDER AB, 1985, PSYCHOSOM MED, V47, P406, DOI 10.1097/00006842-198509000-00001; WOOD DL, 1984, HYPERTENSION, V6, P301, DOI 10.1161/01.HYP.6.3.301; YOUNG DB, 1976, CIRC RES, V38, P84, DOI 10.1161/01.RES.38.6.84; ZAR JH, 1984, BIOSTAT ANAL, P346	51	105	105	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1991	114	3					202	209		10.7326/0003-4819-114-3-202	http://dx.doi.org/10.7326/0003-4819-114-3-202			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV339	1984744				2022-12-01	WOS:A1991EV33900006
J	LADIAS, JAA; KARATHANASIS, SK				LADIAS, JAA; KARATHANASIS, SK			REGULATION OF THE APOLIPOPROTEIN-A-I GENE BY ARP-1, A NOVEL MEMBER OF THE STEROID-RECEPTOR SUPERFAMILY	SCIENCE			English	Article							COUP TRANSCRIPTION FACTOR; MESSENGER-RNA; HORMONE RECEPTOR; THYROID-HORMONE; INVITRO TRANSCRIPTION; ESTROGEN-RECEPTOR; EXPRESSION; RAT; ELEMENT; BINDS	Apolipoprotein AI (apoAI) is a lipid-binding protein that participates in the transport of cholesterol and other lipids in the plasma. A complementary DNA clone for a protein that bound to regulatory elements of the apoAI gene was isolated. This protein, designed apoAI regulatory protein-1 (ARP-1), is a novel member of the steroid hormone receptor superfamily. ARP-1 bound to DNA as a dimer, and its dimerization domain was localized to the COOH-terminal region. ARP-1 also bound to a thyroid hormone-responsive element and to regulatory regions of the apoB, apoCIII, insulin, and ovalbumin genes. In cotransfection experiments, ARP-1 down-regulated the apoAI gene. The involvement of ARP-1 in the regulation of apoAI gene expression suggests that it may participate in lipid metabolism and cholesterol homeostasis.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	LADIAS, JAA (corresponding author), CHILDRENS HOSP MED CTR,DEPT CARDIOL,MOLEC & CELLULAR CARDIOL LAB,BOSTON,MA 02115, USA.							ARCHER TK, 1986, J BIOL CHEM, V261, P5067; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRESLOW JL, 1989, METABOLIC BASIS INHE, P1251; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LADIAS JAA, UNPUB; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER JCE, 1983, P NATL ACAD SCI-BIOL, V80, P1511, DOI 10.1073/pnas.80.6.1511; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; REUE K, 1988, J BIOL CHEM, V263, P6857; REUE K, 1988, J BIOL CHEM, V263, P11452; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; STAELS B, 1989, J LIPID RES, V30, P1137; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677	41	378	400	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					561	565		10.1126/science.1899293	http://dx.doi.org/10.1126/science.1899293			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1899293				2022-12-01	WOS:A1991EV45900052
J	MARTIN, LG				MARTIN, LG			POPULATION AGING POLICIES IN EAST-ASIA AND THE UNITED-STATES	SCIENCE			English	Article								As a result of successful efforts to reduce fertility and mortality, East Asian populations are beginning to age, in some cases rapidly. Policies in response to population aging range from attempts in Singapore to reverse it by encouraging more births to efforts in Japan to accommodate it by increasing employment opportunities for older workers. The populations of the United States, which had a longer postwar baby boom, is aging more slowly than these two countries and may be able to learn from the East Asian experience with aging policies.			MARTIN, LG (corresponding author), NATL ACAD SCI,NATL RES COUNCIL,COMM POPULAT,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.							BURKHAUSER RV, IN PRESS RES LABOR E; BUTLER RN, 1990, WASHINGTON POST 0605, P6; Chen A.J., 1988, ELDERLY SINGAPORE; CHEUNG PL, 1989, 1989 INT POP C NEW D, P133; CHEUNG PPL, 1989, ASIA PAC POP J, V4, P41; Clark Robert, 1990, RETIREMENT SYSTEMS J; FAWCETT JT, 1980, POPUL DEV REV, V6, P549, DOI 10.2307/1972926; FRIES JF, 1989, MILBANK Q, V67, P208, DOI 10.2307/3350138; GOLDSTEIN C, 1990, FAR E EC REV, V148, P49; HOON SJ, 1990, FAR E EC REV, V148, P19; KOJIMA H, 1990, AUG ANN M AM SOC ASS; KOTKIN J, 1988, 3RD CENTURY AM RESUR; LIANG J, 1989, CARING AGING WORLD, P278; MAEDA N, 1989, CARING AGING WORLD, P253; MANTON KG, 1989, MILBANK Q, V67, P13, DOI 10.2307/3350235; MARTIN LG, 1990, ANN AM ACAD POLIT SS, V510, P102, DOI 10.1177/0002716290510001008; MARTIN LG, 1988, J GERONTOL, V43, pS99, DOI 10.1093/geronj/43.4.S99; MARTIN LG, 1989, POP B, V44; MOORE J, 1990, FAR E EC REV, V148, P19; OGAWA N, 1988, EC SOCIAL IMPLICATIO, P272; OSAKO M, 1988, PROD AGING NEWS, V25, P1; Phua KH, 1987, WORLD HEALTH FORUM, V8, P38; ROBINSON WC, 1989, 1989 INT POP C NEW D, P143; ROGERS RG, 1989, MILBANK Q, V67, P370, DOI 10.2307/3350221; SALEM E, 1988, FAR E EC REV, V141, P141; Sanger David, 1990, NEW YORK TIMES  0707, pA9; SANGER DE, 1990, NY TIMES        0619, pA2; Schulz J., 1989, LIFETIME EMPLOYMENT; SEIKE A, 1989, 2862 RAND NOT; TASKER R, 1990, FAR E EC REV, V148, P18; WATTENBERG BJ, 1990, COMMENTARY, V23; YU YC, 1987, APR ANN M POP ASS AM; 1989, WORLD POPULATION PRO; 1988, EMPLOY EARN, V35, P160; 1987, REPORT INT COMP SURV; 1987, HLTH STATISTICS OLDE, P64; 1989, FAR E EC REV, V145, P14; 1987, EMPLOYMENT MANAGERME; 1988, 1987 JAP STAT BUR AN, P23; 1990, SCOPE CTR IMMIGRATIO, P8	40	24	24	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					527	531		10.1126/science.1990428	http://dx.doi.org/10.1126/science.1990428			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EV459	1990428				2022-12-01	WOS:A1991EV45900041
J	MEINWALD, J; THOMPSON, WR; PEARSON, DL; KONIG, WA; RUNGE, T; FRANCKE, W				MEINWALD, J; THOMPSON, WR; PEARSON, DL; KONIG, WA; RUNGE, T; FRANCKE, W			INHALATIONAL ANESTHETICS STEREOCHEMISTRY - OPTICAL RESOLUTION OF HALOTHANE, ENFLURANE, AND ISOFLURANE	SCIENCE			English	Article							GENERAL-ANESTHETICS; GAS-CHROMATOGRAPHY; STEREOISOMERS; BINDING	Halothane (I), enflurane (II), and isoflurane (III), which are among the most important inhalation anesthetics, are currently administered as racemic mixtures. The pure enantiomers have not been described, and no analytical method for resolving the commercially available racemic mixtures has been reported. Complete optical resolution of (+/-)-I and (+/-)-III on per-n-pentylated alpha-cyclodextrin (Lipodex A) and of (+/-)-II and (+/-)-III on octakis(6-O-methyl-2,3-di-O-pentyl)-gamma-cyclodextrin capillary columns has been achieved, making rapid and convenient determination of enantiomeric ratios in samples of all three of these anesthetics possible.	PARK PLAZA HOSP,DEPT ANESTHESIOL,HOUSTON,TX 77004; UNIV HAMBURG,INST ORGAN CHEM,W-2000 HAMBURG 13,GERMANY	University of Hamburg	MEINWALD, J (corresponding author), CORNELL UNIV,DEPT CHEM,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM37018] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORMAN S, 1990, CHEM ENG NEWS, V68, P9, DOI 10.1021/cen-v068n028.p009; BOUCHE J, 1968, J GAS CHROMATOGR, V6, P501, DOI 10.1093/chromsci/6.10.501; CALVERLEY RK, 1989, CLIN ANESTH, P3; Calverley RK, 1986, SURV ANESTHESIA, V29, P170; DECAMP WH, 1989, CHIRALITY, V1, P2, DOI 10.1002/chir.530010103; DLUZEWSKI AR, 1983, MOL ASPECTS MED, V6, P459, DOI 10.1016/0098-2997(83)90001-8; EVERS AS, 1987, NATURE, V328, P157, DOI 10.1038/328157a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; KENDIG JJ, 1973, ANESTHESIOLOGY, V39, P518, DOI 10.1097/00000542-197311000-00011; Konig W. A., 1990, J HIGH RES CHROMATOG, V13, P702; KONIG WA, 1983, J CHROMATOGR, V280, P135, DOI 10.1016/S0021-9673(00)91548-6; KONIG WA, 1988, ANGEW CHEM INT EDIT, V27, P979, DOI 10.1002/anie.198809791; KONIG WA, 1988, ANGEW CHEM, V100, P989; PEARSON DL, 1990, THESIS CORNELL U ITH; STEVENS WC, 1989, CLIN ANESTH, P293; SUCKLING CW, 1957, BRIT J ANAESTH, V29, P466, DOI 10.1093/bja/29.10.466; TERRELL RC, 1971, J MED CHEM, V14, P517, DOI 10.1021/jm00288a014	17	59	61	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					560	561		10.1126/science.1846702	http://dx.doi.org/10.1126/science.1846702			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1846702				2022-12-01	WOS:A1991EV45900051
J	MEYER, B; HANSEN, T; NUTE, D; ALBERSHEIM, P; DARVILL, A; YORK, W; SELLERS, J				MEYER, B; HANSEN, T; NUTE, D; ALBERSHEIM, P; DARVILL, A; YORK, W; SELLERS, J			IDENTIFICATION OF THE H-1-NMR SPECTRA OF COMPLEX OLIGOSACCHARIDES WITH ARTIFICIAL NEURAL NETWORKS	SCIENCE			English	Article								Artificial neural networks can be used to identify hydrogen nuclear magnetic resonance (H-1-NMR) spectra of complex oligosaccharides. Feed-forward neural networks with back-propagation of errors can distinguish between spectra of oligosaccharides that differ by only one glycosyl residue in twenty. The artificial neural networks use features of the strongly overlapping region of the spectra (hump region) as well as features of the resolved regions of the spectra (structural reporter groups) to recognize spectra and efficiently recognized H-1-NMR spectra even when the spectra were perturbed by minor variations in their chemical shifts. Identification of spectra by neural network-based on pattern recognition techniques required less than 0.1 second. It is anticipated that artificial neural networks can be used to identify the structures of any complex carbohydrate that has been previously characterized and for which a H-1-NMR spectrum is available.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,ARTIFICIAL INTELLIGENCE PROGRAM,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	MEYER, B (corresponding author), UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602, USA.		Meyer, Bernd/A-8828-2008					GOUX WJ, 1989, J MAGN RESON, V85, P457, DOI 10.1016/0022-2364(89)90237-0; HISAMATSU M, UNPUB; KIEFER LL, 1990, CARBOHYD RES, V197, P139, DOI 10.1016/0008-6215(90)84137-J; McClelland J. L., 1988, EXPLORATIONS PARALLE; Rumelhart DE., 1986, ENCY DATABASE SYST, P45; SELLERS J, IN PRESS CARBOHYDR R; THOMSEN JU, 1989, J MAGN RESON, V84, P212, DOI 10.1016/0022-2364(89)90021-8; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YORK WS, 1990, CARBOHYD RES, V200, P9, DOI 10.1016/0008-6215(90)84179-X	9	85	92	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					542	544		10.1126/science.1990429	http://dx.doi.org/10.1126/science.1990429			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1990429				2022-12-01	WOS:A1991EV45900044
J	NELSON, DE				NELSON, DE			A NEW METHOD FOR CARBON ISOTOPIC ANALYSIS OF PROTEIN	SCIENCE			English	Article							ACCELERATOR MASS-SPECTROMETRY; BONE-COLLAGEN; RADIOCARBON; RATIOS; MARINE; C-13	The reaction of ninhydrin with amino acids can be used in carbon isotopic studies of protein. The reaction can be applied to extract as carbon dioxide only peptide-bonded carbon in proteinaceous material, thus avoiding most, if not all, contaminants. Test radiocarbon dates on ancient bone indicate that the method provides reliable ages, and stable carbon isotopic data suggest that our understanding of isotopic dietary reconstruction needs detailed examination. The technique should also be useful in biochemical tracing experiments and in global carbon budget studies, and the underlying principle may be applicable to other isotopes and molecules.	UNIV CALIF LAWRENCE LIVERMORE NATL LAB,CTR ACCELERATOR MASS SPECT,LIVERMORE,CA 94550	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System								BROWN TA, 1988, RADIOCARBON, V30, P171, DOI 10.1017/S0033822200044118; CHISHOLM BS, 1982, SCIENCE, V216, P1131, DOI 10.1126/science.216.4550.1131; DENIRO MJ, 1985, NATURE, V317, P806, DOI 10.1038/317806a0; GILLESPIE R, 1984, J ARCHAEOL SCI, V11, P165, DOI 10.1016/0305-4403(84)90051-7; HARE PE, 1983, CARNEGIE I WASHINGTO, V82, P410; Hedges R.E.M., 1980, P35; HOWE EE, 1951, AMINO ACIDS PROTEINS, P30; LEHNINGER AL, 1978, BIOCHEMISTRY-US, P85; LOGIN R, 1971, NATURE, V320, P241; LOVELL NC, 1986, ARCHAEOMETRY, V28, P51, DOI 10.1111/j.1475-4754.1986.tb00373.x; LOY TH, 1990, ANTIQUITY, V64, P110, DOI 10.1017/S0003598X00077346; Morlan R.E., 1990, CANADIAN J ARCHAEOLO, V14, P75; NELSON DE, 1986, RADIOCARBON, V28, P170, DOI 10.1017/S0033822200060082; NELSON DL, COMMUNICATION; NELSON DR, UNPUB; SCHOENINGER MJ, 1984, GEOCHIM COSMOCHIM AC, V48, P625, DOI 10.1016/0016-7037(84)90091-7; SOUTHON JR, IN PRESS NUCL INSTRU; STAFFORD TW, 1988, GEOCHIM COSMOCHIM AC, V52, P2257, DOI 10.1016/0016-7037(88)90128-7; STAFFORD TW, 1987, RADIOCARBON, V29, P24; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; Van SLYKE DONALD D., 1941, JOUR BIOL CHEM, V141, P627; Van SLYKE DONALD D., 1941, JOUR BIOL CHEM, V141, P671; VANDERMERWE NJ, 1978, NATURE, V276, P815, DOI 10.1038/276815a0; VANKLINKEN GJ, 1990, RADIOCARBON, V32, P155, DOI 10.1017/S0033822200040157; VOGEL JS, 1987, RADIOCARBON, V29, P323; VOGEL JS, IN PRESS NUCL INSTRU; WILLIAMS PM, 1987, NATURE, V330, P246, DOI 10.1038/330246a0	27	54	54	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					552	554		10.1126/science.1990430	http://dx.doi.org/10.1126/science.1990430			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1990430				2022-12-01	WOS:A1991EV45900048
J	NOSSENT, HC; SWAAK, TJG; BERDEN, JHM				NOSSENT, HC; SWAAK, TJG; BERDEN, JHM			SYSTEMIC LUPUS-ERYTHEMATOSUS AFTER RENAL-TRANSPLANTATION - PATIENT AND GRAFT-SURVIVAL AND DISEASE-ACTIVITY	ANNALS OF INTERNAL MEDICINE			English	Article							KIDNEY-TRANSPLANTS; CLINICAL COURSE; EXPERIENCE; RATES	Objective: To determine the outcome of renal transplantation in patients with systemic lupus erythematosus and end-stage renal failure and to compare disease activity after transplantation with disease activity before transplantation. Design: Retrospective case finding using data for an 8-year period from the central registry for renal replacement therapy in The Netherlands. Setting: Tertiary care hospitals with facilities for renal transplantation in The Netherlands. Patients: Twenty-eight patients who fulfilled at least four of the American Rheumatology Association's criteria for the classification of systemic lupus erythematosus and who received a renal transplant. Measurements: Acturial survival rates for grafts and patients after transplantation, maximal nonrenal scores on the Systemic Lupus Erythematosus Disease Activity Index, and time-adjusted disease exacerbation rates in all patients before and after transplantation. Results: The actuarial graft survival rate at 1 year and 5 years was 68% (95% CI, 47% to 82%) and 54% (CI, 25% to 77%), respectively, whereas the acturial patient survival rate was 87% (CI, 69% to 96%) at 1 and 5 years. High disease activity was not found to affect graft survival adversely before the start of renal replacement therapy or during dialysis. After transplantation, disease activity per patient and the overall incidence of disease exacerbations decreased. One case of recurrent lupus nephritis was seen. Conclusions: Patients with systemic lupus erythematosus and end-stage renal failure are excellent candidates for renal transplantation; disease activity after transplantation is sporadic and low, and the recurrence of lupus nephritis is rare.	DR DANIEL DENHOED CLIN, POB 5201, 3008 AE ROTTERDAM, NETHERLANDS; UNIV HOSP NIJMEGEN, NIJMEGEN, NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Radboud University Nijmegen			Berden, J.H.M./H-8009-2014	Nossent, Johannes/0000-0002-2833-7997				AMEND WJC, 1981, ANN INTERN MED, V94, P444, DOI 10.7326/0003-4819-94-4-444; CAMERON JS, 1982, TRANSPLANTATION, V34, P237; CANTAROVICH M, 1988, ANN INTERN MED, V109, P254, DOI 10.7326/0003-4819-109-3-254; CATS S, 1984, TRANSPLANTATION, V37, P575, DOI 10.1097/00007890-198406000-00010; CHANG C, 1986, ARTHRITIS RHEUM, V29, P593; COPLON NS, 1983, NEW ENGL J MED, V308, P186, DOI 10.1056/NEJM198301273080403; DUBOIS EL, 1952, JAMA-J AM MED ASSOC, V149, P995, DOI 10.1001/jama.1952.02930280017006; GOLDBLUM SE, 1980, ANN INTERN MED, V93, P597, DOI 10.7326/0003-4819-93-4-597; HELLERSTEDT WL, 1984, MAYO CLIN PROC, V59, P776, DOI 10.1016/S0025-6196(12)65589-X; JARRETT MP, 1983, ARCH INTERN MED, V143, P1353, DOI 10.1001/archinte.143.7.1353; Klemperer P, 1941, ARCH PATHOL, V32, P569; KUMANO K, 1987, CLIN NEPHROL, V27, P94; LIANG MH, 1989, ARTHRITIS RHEUM, V32, P1107, DOI 10.1002/anr.1780320909; LIANG MH, 1989, 2ND P INT C SYST LUP, P64; MEJIA G, 1983, ARCH INTERN MED, V143, P2089, DOI 10.1001/archinte.143.11.2089; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; MOARTY AV, 1989, ARTHRITIS RHEUM, V31, P464; OPELZ G, 1973, TRANSPLANT P, V5, P253; POLLAK VE, 1961, J LAB CLIN MED, V57, P495; ROTH D, 1987, AM J NEPHROL, V7, P367, DOI 10.1159/000167615; ROTHFIELD NF, 1963, NEW ENGL J MED, V269, P537, DOI 10.1056/NEJM196309122691101; SINGH YN, 1989, 2ND P INT C SYST LUP, P59; SOHMIYA S, 1986, JPN J TRANSPLANT, V21, P18; SWAAK AJG, 1989, ANN RHEUM DIS, V48, P455, DOI 10.1136/ard.48.6.455; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; YAKUB YN, 1981, NEPHRON, V27, P197; ZWEIMAN B, 1968, ANN INTERN MED, V69, P441, DOI 10.7326/0003-4819-69-3-441; 1975, JAMA-J AM MED ASSOC, V232, P148	28	80	82	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1991	114	3					183	188		10.7326/0003-4819-114-3-183	http://dx.doi.org/10.7326/0003-4819-114-3-183			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV339	1984742				2022-12-01	WOS:A1991EV33900002
J	OTTE, AP; KRAMER, IM; DURSTON, AJ				OTTE, AP; KRAMER, IM; DURSTON, AJ			PROTEIN-KINASE-C AND REGULATION OF THE LOCAL COMPETENCE OF XENOPUS ECTODERM	SCIENCE			English	Article							DIFFERENTIAL DOWN-REGULATION; NEURAL INDUCTION; CELLULAR SUBSTRATE; PROSPECTIVE AREAS; LAEVIS; EXPRESSION; GASTRULA; PHOSPHORYLATION; HETEROGENEITY; SPECIFICITY	The limited competence of embryonic tissue to respond to an inductive signal has an essential, regulatory function in embryonic induction. The molecular basis for the competence of Xenopus ectoderm to differentiate into neural tissue was investigated. Dorsal mesoderm or 12-O-tetradecanoyl phorbol-13-acetate (TPA) caused in vivo activation of protein kinase C (PKC) and neural differentiation mainly in dorsal ectoderm and to a lesser extent in ventral ectoderm. These data correlate with the observations that PKC preparations from dorsal and ventral ectoderm differ, the dorsal PKC preparation being more susceptible to activation by TPA and diolein than is the ventral PKC preparation. Monoclonal antibodies against the bovine PKC alpha plus beta or gamma isozymes immunostained dorsal and ventral ectoderm, respectively, which suggests different localizations of PKC isozymes. The results suggest that PKC participates in the establishment of embryonic competence.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)								ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P5002, DOI 10.1021/bi00390a018; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BROOKS SF, 1990, FEBS LETT, V268, P291, DOI 10.1016/0014-5793(90)81030-R; CAZAUBON S, 1989, EUR J BIOCHEM, V182, P401, DOI 10.1111/j.1432-1033.1989.tb14845.x; COOKE J, 1987, DEVELOPMENT, V99, P197; DAVIDS M, 1987, ROUX ARCH DEV BIOL, V196, P137, DOI 10.1007/BF00402036; DENT JA, 1989, DEVELOPMENT, V105, P61; GIMLICH RL, 1983, NATURE, V306, P471, DOI 10.1038/306471a0; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; GURDON JB, 1987, DEVELOPMENT, V99, P285; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUANG KP, 1988, J BIOL CHEM, V263, P14839; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NIEDEL J E, 1986, P47; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; NIEUWKOOP PD, 1969, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1985, EPIGENETIC NATURE EA; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OTTE AP, 1990, DEVELOPMENT, V110, P461; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; OTTE AP, 1988, NATURE, V334, P618, DOI 10.1038/334618a0; OTTE AP, UNPUB; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SCHARF SR, 1989, DEV BIOL, V134, P175, DOI 10.1016/0012-1606(89)90087-0; SHARPE CR, 1988, DEVELOPMENT, V103, P269; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SHEU FS, 1990, BIOCHEM BIOPH RES CO, V171, P1236, DOI 10.1016/0006-291X(90)90818-8; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x	41	63	63	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					570	573		10.1126/science.1990433	http://dx.doi.org/10.1126/science.1990433			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1990433				2022-12-01	WOS:A1991EV45900055
J	PHILLIPS, WD; KOPTA, C; BLOUNT, P; GARDNER, PD; STEINBACH, JH; MERLIE, JP				PHILLIPS, WD; KOPTA, C; BLOUNT, P; GARDNER, PD; STEINBACH, JH; MERLIE, JP			ACH RECEPTOR RICH MEMBRANE DOMAINS ORGANIZED IN FIBROBLASTS BY RECOMBINANT 43-KILDALTON PROTEIN	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; MOUSE NEUROMUSCULAR-JUNCTIONS; TORPEDO-MARMORATA; ALKALINE TREATMENT; ELECTRIC ORGAN; MUSCLE FIBERS; BETA-SUBUNIT; BINDING; CELLS; CHANNELS	Neurotransmitter receptors are generally clustered in the postsynaptic membrane. The mechanism of clustering was analyzed with fibroblast cell lines that were stably transfected with the four subunits for fetal (alpha, beta, gamma, delta) or adult (alpha, beta, epsilon, delta) type mouse muscle nicotinic acetylcholine receptors (AChRs). Immunofluorescent staining indicated that AChRs were dispersed on the surface of these cells. When transiently transfected with an expression construct encoding a 43-kilodalton protein that is normally concentrated under the postsynaptic membrane, AChRs expressed in these cells became aggregated in large cell-surface clusters, colocalized with the 43-kilodalton protein. This suggests that 43-kilodalton protein can induce AChR clustering and that cluster induction involves direct contact between AChR and 43-kilodalton protein.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT BIOCHEM,HANOVER,NH 03756	Washington University (WUSTL); Dartmouth College	PHILLIPS, WD (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.			Phillips, William/0000-0002-5405-8422	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022356] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS022356] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; BARRANTES FJ, 1980, FEBS LETT, V112, P73, DOI 10.1016/0014-5793(80)80131-1; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BREHM P, 1987, P NATL ACAD SCI USA, V84, P2550, DOI 10.1073/pnas.84.8.2550; BUONANNO A, 1989, J BIOL CHEM, V264, P7611; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; CARTAUD J, 1981, J CELL BIOL, V90, P418, DOI 10.1083/jcb.90.2.418; COVARRUBIAS M, 1990, PFLUG ARCH EUR J PHY, V416, P385, DOI 10.1007/BF00370744; COVARRUBIAS M, 1989, J GEN PHYSIOL, V93, P765, DOI 10.1085/jgp.93.5.765; ELLIOTT J, 1980, BIOCHEM J, V185, P667, DOI 10.1042/bj1850667; FAMBROUGH DM, 1972, SCIENCE, V176, P189, DOI 10.1126/science.176.4031.189; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; FISCHBACH GD, 1973, DEV BIOL, V31, P147, DOI 10.1016/0012-1606(73)90326-6; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FRAIL DE, 1987, P NATL ACAD SCI USA, V84, P6302, DOI 10.1073/pnas.84.17.6302; FROEHNER SC, 1986, TRENDS NEUROSCI, V9, P37, DOI 10.1016/0166-2236(86)90013-5; GARDNER PJ, UNPUB; HAMILL OP, 1981, NATURE, V294, P462, DOI 10.1038/294462a0; HARTZELL HC, 1973, DEV BIOL, V30, P153, DOI 10.1016/0012-1606(73)90054-7; HEUSER JE, 1979, J CELL BIOL, V82, P150, DOI 10.1083/jcb.82.1.150; KULLBERG R, 1990, P NATL ACAD SCI USA, V87, P2067, DOI 10.1073/pnas.87.6.2067; LAROCHELLE WJ, 1986, J BIOL CHEM, V261, P5270; LO MMS, 1980, FEBS LETT, V111, P407, DOI 10.1016/0014-5793(80)80838-6; MATTHEWSBELLINGER JA, 1983, J NEUROSCI, V3, P644; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUSIL LS, 1989, J CELL BIOL, V108, P1833, DOI 10.1083/jcb.108.5.1833; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; ROUSSELET A, 1982, EMBO J, V1, P439, DOI 10.1002/j.1460-2075.1982.tb01188.x; SAKMANN B, 1978, NATURE, V276, P401, DOI 10.1038/276401a0; SCHUETZE SM, 1978, P NATL ACAD SCI USA, V75, P520, DOI 10.1073/pnas.75.1.520; SLATER CR, 1982, DEV BIOL, V94, P11, DOI 10.1016/0012-1606(82)90063-X; SOBEL A, 1978, P NATL ACAD SCI USA, V75, P510, DOI 10.1073/pnas.75.1.510; STEINBACH JH, 1981, DEV BIOL, V84, P367; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180	36	202	204	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					568	570		10.1126/science.1703661	http://dx.doi.org/10.1126/science.1703661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1703661				2022-12-01	WOS:A1991EV45900054
J	RIQUIMAROUX, H; GAIONI, SJ; SUGA, N				RIQUIMAROUX, H; GAIONI, SJ; SUGA, N			CORTICAL COMPUTATIONAL MAPS CONTROL AUDITORY-PERCEPTION	SCIENCE			English	Article							CF-FM BAT; FINE FREQUENCY-ANALYSIS; MUSTACHED BAT; RHINOLOPHUS-FERRUMEQUINUM; CORTEX; REPRESENTATION; VOCALIZATIONS; ECHOLOCATION; MACAQUES; COCHLEA	Mustached bats orient and find insects by emitting ultrasonic pulses and analyzing the returning echoes. Neurons in the Doppler-shifted constant-frequency (DSCF) and frequency-modulated (FM-FM) areas of the auditory cortex form maps of echo frequency (target velocity) and echo delay (target range), respectively. Bats were trained to discriminate changes in echo frequency or delay, and then these areas were selectively inactivated with muscimol. Inactivation of the DSCF area disrupted frequency but not delay discriminations; inactivation of the FM-FM area disrupted delay but not frequency discriminations. Thus, focal inactivation of specific cortical maps produces specific disruptions in the perception of biosonar signals.	WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Washington University (WUSTL)					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017333] Funding Source: NIH RePORTER; NINDS NIH HHS [NS17333] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN WF, 1945, AM J PHYSIOL, V144, P415, DOI 10.1152/ajplegacy.1945.144.3.415; Bekhterev V, 1913, PSYCHOL OBJECTIVE; BRUNS V, 1976, J COMP PHYSIOL, V106, P77, DOI 10.1007/BF00606573; BRUNS V, 1976, J COMP PHYSIOL, V106, P87, DOI 10.1007/BF00606574; BUTLER RA, 1957, J NEUROPHYSIOL, V20, P108, DOI 10.1152/jn.1957.20.1.108; CRANFORD JL, 1976, J NEUROPHYSIOL, V39, P143, DOI 10.1152/jn.1976.39.1.143; DIAMOND IT, 1962, J NEUROPHYSIOL, V25, P223, DOI 10.1152/jn.1962.25.2.223; EVARTS EV, 1952, J NEUROPHYSIOL, V15, P443, DOI 10.1152/jn.1952.15.6.443; GAIONI SJ, 1988, ABSTR SOC NEUROSCI, V14, P1100; GAIONI SJ, IN PRESS J NEUROPHYS; GOLDBERG JM, 1961, J NEUROPHYSIOL, V24, P119, DOI 10.1152/jn.1961.24.2.119; HEFFNER HE, 1986, J NEUROPHYSIOL, V56, P683, DOI 10.1152/jn.1986.56.3.683; HEFFNER HE, 1984, SCIENCE, V226, P75, DOI 10.1126/science.6474192; HEFNER HE, 1987, 10TH MIDW M ASS RES, P87; Henson OW., 1980, ANIMAL SONAR SYSTEMS, P913, DOI [10.1007/978-1-4684-7254-7_56, DOI 10.1007/978-1-4684-7254-7_56]; HIKOSAKA O, 1985, BRAIN RES, V325, P375, DOI 10.1016/0006-8993(85)90344-0; KRNJEVIC K, 1967, EXP BRAIN RES, V3, P320, DOI 10.1007/BF00237558; KRNJEVIC K, 1963, J PHYSIOL-LONDON, V165, P274, DOI 10.1113/jphysiol.1963.sp007057; Mackintosh NJ., 1974, PSYCHOL ANIMAL LEARN; MEYER DR, 1952, J NEUROPHYSIOL, V15, P149, DOI 10.1152/jn.1952.15.2.149; ONEILL WE, 1979, SCIENCE, V203, P69, DOI 10.1126/science.758681; Schnitzler H., 1980, ANIMAL SONAR SYSTEMS, V28, P109, DOI [10.10007/978-1-4684-7254-7_6, DOI 10.1007/978-1-4684-7254-7_6]; SCHNITZLER HU, 1970, Z VERGL PHYSIOL, V68, P25, DOI 10.1007/BF00297809; SUGA N, 1987, J NEUROPHYSIOL, V58, P643, DOI 10.1152/jn.1987.58.4.643; SUGA N, 1982, J NEUROPHYSIOL, V47, P225, DOI 10.1152/jn.1982.47.2.225; SUGA N, 1985, J NEUROPHYSIOL, V53, P1109, DOI 10.1152/jn.1985.53.4.1109; SUGA N, 1986, J NEUROPHYSIOL, V55, P776, DOI 10.1152/jn.1986.55.4.776; SUGA N, 1976, SCIENCE, V194, P542, DOI 10.1126/science.973140; SUGA N, 1975, J EXP BIOL, V63, P161; Suga N, 1984, DYNAMIC ASPECTS NEOC, P315; THOMPSON RF, 1960, J NEUROPHYSIOL, V23, P321, DOI 10.1152/jn.1960.23.3.321	31	96	96	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					565	568		10.1126/science.1990432	http://dx.doi.org/10.1126/science.1990432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1990432				2022-12-01	WOS:A1991EV45900053
J	SARTORI, S; NIELSEN, I; INDELLI, M; TREVISANI, L; PAZZI, P; GRANDI, E				SARTORI, S; NIELSEN, I; INDELLI, M; TREVISANI, L; PAZZI, P; GRANDI, E			BARRETT-ESOPHAGUS AFTER CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL (CMF) - AN IATROGENIC INJURY	ANNALS OF INTERNAL MEDICINE			English	Note							COLUMNAR-LINED ESOPHAGUS; AGENTS	Methotrexate and 5-fluorouracil can provoke oral mucosal erosions and ulceration that may extend throughout the esophagus. This study was conducted to determine whether prolonged chemotherapy-induced esophageal damage may cause the development of Barrett esophagus. Sixteen women who had breast cancer and had been selected to receive at least six breast cancer and had been selected to receive at least six courses of chemotherapy with cyclophosphamide, methotrexate, and 5-flourouracil were included in the study. They had esophagoscopy, and several biopsy specimens were taken from the lower esophagus (3, 6, and 9 cm above the lower esophageal sphincter) before chemotherapy was begun and 1 month after the sixth course of chemotherapy. All patients had a normal esophagus at the first examination. After finishing chemotherapy, 10 (63%) had developed Barrett esophagus. One patient had the junctional type, 2 patients had the fundic type, 4 patients had a combination of the junctional and fundic types, and 3 patients had the intestinal type. These results suggest that chemotherapy-induced esophageal injury may have been responsible for the development of Barrett esophagus in our patients.	UNIV FERRARA, SCH MED, I-44100 FERRARA, ITALY	University of Ferrara	SARTORI, S (corresponding author), ST ANNA GEN HOSP, CORSO GIOVECCA 230, I-44100 FERRARA, ITALY.		sartori, samantha/AAL-8884-2020					ADRIAN RM, 1980, CA-CANCER J CLIN, V30, P143, DOI 10.3322/canjclin.30.3.143; DAHMS BB, 1987, CANCER, V60, P2896, DOI 10.1002/1097-0142(19871215)60:12<2896::AID-CNCR2820601208>3.0.CO;2-P; LEWIS JH, 1986, AM J GASTROENTEROL, V81, P819; MCCLAVE SA, 1987, GASTROINTEST ENDOSC, V33, P413, DOI 10.1016/S0016-5107(87)71676-9; ROTHERY GA, 1986, GUT, V27, P1062, DOI 10.1136/gut.27.9.1062; SARTORI S, 1989, HEPATO-GASTROENTEROL, V36, P304; SAVARY M, 1985, ESOPHAGEAL DISORDERS, P101; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; TYTGAT GNJ, 1989, ENDOSCOPY, V21, P177, DOI 10.1055/s-2007-1012937	9	53	54	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1991	114	3					210	211		10.7326/0003-4819-114-3-210	http://dx.doi.org/10.7326/0003-4819-114-3-210			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV339	1984745				2022-12-01	WOS:A1991EV33900007
J	ZHUKOVSKY, EA; ROBINSON, PR; OPRIAN, DD				ZHUKOVSKY, EA; ROBINSON, PR; OPRIAN, DD			TRANSDUCIN ACTIVATION BY RHODOPSIN WITHOUT A COVALENT BOND TO THE 11-CIS-RETINAL CHROMOPHORE	SCIENCE			English	Article							VISUAL PIGMENTS; BOVINE RHODOPSIN; SCHIFF-BASE; PROTEINS; FAMILY; BACTERIORHODOPSIN; RECEPTORS	Rhodopsin and the visual pigments are a distinct group within the family of G-protein-linked receptors in that they have as covalently bound ligand, the 11-cis-retinal chromophore, whereas all of the other receptors bind their agonists through noncovalent interactions. The retinal chromophore in rhodopsin is bound by means of a protonated Schiff base linkage to the epsilon-amino group of Lys-296. Two rhodopsin mutants have been constructed, K296G and K296A, in which the covalent linkage to the chromophore is removed. Both mutants form a pigment with an absorption spectrum close to that of the wild type when reconstituted with the Schiff base of an n-alkylamine and 11-cis-retinal. In addition, the pigment formed from K296G and the n-propylamine Schiff base of 11-cis-retinal was found to activate transducin in a light-dependent manner, with 30 to 40% of the specific activity measured for the wild-type protein. It appears that the covalent bond is not essential for binding of the chromophore or for catalytic activation of transducin.			ZHUKOVSKY, EA (corresponding author), BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254, USA.		Zhukovsky, Eugene/Q-3218-2019	Zhukovsky, Eugene/0000-0003-1822-8946	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007044] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007596] Funding Source: NIH RePORTER; NCRR NIH HHS [S07 RR07044] Funding Source: Medline; NEI NIH HHS [R01 EY007965, EY07965] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07596-11] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BLATZ PE, 1972, BIOCHEMISTRY-US, V11, P848, DOI 10.1021/bi00755a026; COOPER A, 1979, NATURE, V282, P531, DOI 10.1038/282531a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HONG K, 1973, BIOCHEMISTRY-US, V12, P4517, DOI 10.1021/bi00746a033; HONIG B, 1979, P NATL ACAD SCI USA, V76, P2503, DOI 10.1073/pnas.76.6.2503; HONIG B, 1976, BIOCHEMISTRY-US, V15, P4593, DOI 10.1021/bi00666a008; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; MORTON RA, 1955, BIOCHEM J, V59, P128, DOI 10.1042/bj0590128; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHRECKENBACH T, 1977, EUR J BIOCHEM, V76, P499, DOI 10.1111/j.1432-1033.1977.tb11620.x; STRADER CD, 1988, J BIOL CHEM, V263, P10267; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	20	129	130	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					558	560		10.1126/science.1990431	http://dx.doi.org/10.1126/science.1990431			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1990431				2022-12-01	WOS:A1991EV45900050
J	BERRY, MJ; BANU, L; LARSEN, PR				BERRY, MJ; BANU, L; LARSEN, PR			TYPE-I IODOTHYRONINE DEIODINASE IS A SELENOCYSTEINE-CONTAINING ENZYME	NATURE			English	Article							SELENIUM GLUTATHIONE-PEROXIDASE; PROTEIN DISULFIDE ISOMERASE; RAT-LIVER; NUCLEOTIDE-SEQUENCE; ACTIVE-SITE; EXPRESSION; THYROXINE; TRIIODOTHYRONINE; INHIBITION; DEFICIENCY	ALTHOUGH thyroxine (3,5,3',5'-tetraiodonthyroine, T4) is the principal secretory product of the vertebrate thyroid, its essential metabolic and developmental effects are all mediated by 3,5,3'-triiodothyronine (T3), which is produced from the prohormone by 5'-deiodination. The type-I iodothyronine deiodinase, a thiol-requiring propylthiouracil-sensitive oxidoreductase, is found mainly in liver and kidney and provides most of the circulating T3(1) but so far this enzyme has not been purified. Using expression cloning in the Xenopus oocyte, we have isolated a 2.1-kilobase complementary DNA of this deiodinase from a rat liver cDNA library. The kinetic properties of the protein expressed in transient assay systems, the tissue distribution of the messenger RNA, and its changes with thyroid status, all confirm its identity. We find that the mRNA for this enzyme contains a UGA codon for selenocysteine which is necessary for maximal enzyme activity. This explains why conversion to T4 to T3 is impaired in experimental selenium deficiency 2-6 and identifies an essential role for this trace element in thyroid hormone action.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV THYROID,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	BERRY, MJ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,HOWARD HUGHES MED INST LAB,75 FRANCIS ST,BOSTON,MA 02115, USA.							ARTHUR JR, 1988, RES VET SCI, V45, P122, DOI 10.1016/S0034-5288(18)30906-8; ARTHUR JR, 1990, J INORG BIOCHEM, V39, P101, DOI 10.1016/0162-0134(90)80018-S; ARTHUR JR, 1990, CLIN CHEM ENZYMOL CO, V3, P209; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BECKETT GJ, 1987, BIOCHEM J, V248, P443, DOI 10.1042/bj2480443; BECKETT GJ, 1989, BIOCHEM J, V259, P887, DOI 10.1042/bj2590887; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BEHNE D, 1990, BIOCHIM BIOPHYS ACTA, V1033, P219, DOI 10.1016/0304-4165(90)90124-F; BERRY MJ, 1990, MOL ENDOCRINOL, V4, P743, DOI 10.1210/mend-4-5-743; BOADO RJ, 1988, BIOCHEM BIOPH RES CO, V155, P1297, DOI 10.1016/S0006-291X(88)81282-8; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHAUDIERE J, 1984, J INORG BIOCHEM, V20, P313, DOI 10.1016/0162-0134(84)85030-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FORSTROM JW, 1978, BIOCHEMISTRY-US, V17, P2639, DOI 10.1021/bi00606a028; FRUMESS RD, 1975, METABOLISM, V24, P547, DOI 10.1016/0026-0495(75)90079-7; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; ISHIDA K, 1987, NUCLEIC ACIDS RES, V15, P10051, DOI 10.1093/nar/15.23.10051; KOHRLE J, 1990, J BIOL CHEM, V265, P6146; LARSEN PR, 1981, ENDOCR REV, V2, P87, DOI 10.1210/edrv-2-1-87; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; Leonard JL., 1986, THYROID HORMONE META, P189; MENON NK, 1987, J BACTERIOL, V169, P5401, DOI 10.1128/jb.169.12.5401-5407.1987; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; OPPENHEI.JH, 1972, J CLIN INVEST, V51, P2493, DOI 10.1172/JCI107063; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENMAKERS CHH, 1989, BIOCHEM BIOPH RES CO, V162, P857, DOI 10.1016/0006-291X(89)92389-9; STGERMAIN DL, 1989, J BIOL CHEM, V264, P3054; TAPPEL AL, 1984, CURR TOP CELL REGUL, V24, P87; VISSER TJ, 1983, MOL CELL ENDOCRINOL, V33, P321, DOI 10.1016/0303-7207(83)90177-6; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	31	808	844	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					438	440		10.1038/349438a0	http://dx.doi.org/10.1038/349438a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1825132				2022-12-01	WOS:A1991EV51400059
J	BROEK, D; BARTLETT, R; CRAWFORD, K; NURSE, P				BROEK, D; BARTLETT, R; CRAWFORD, K; NURSE, P			INVOLVEMENT OF P34CDC2 IN ESTABLISHING THE DEPENDENCY OF S-PHASE ON MITOSIS	NATURE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; CELL-DIVISION CYCLE; FISSION YEAST; PROTEIN-KINASE; DNA-REPLICATION; TYROSINE PHOSPHORYLATION; CHROMOSOME CONDENSATION; COLORIMETRIC METHOD; MOLECULAR-CLONING; MITOTIC CONTROL	Mutants of cdc2+ can disrupt the dependency of S phase on completion of the previous mitosis. By changing the state of p34cdc2 it is possible to reprogramme a cell from entering mitosis to undergoing S phase. This leads to the proposal that the cell cycle can be considered a p34cdc2 cycle, and has implications for the evolution of life cycles.	UNIV OXFORD,IMPERIAL CANC RES FUND,DEPT BIOCHEM,MICROBIOL UNIT,OXFORD OX1 3QU,ENGLAND	University of Oxford								BARTLETT R, 1990, BIOESSAYS, V10, P457; BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; BEERMANN W, 1972, DEV STUDIES GIANT CH, P1; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BOSTOCK CJ, 1970, EXP CELL RES, V60, P16, DOI 10.1016/0014-4827(70)90484-2; BREWER EN, 1968, EXP CELL RES, V49, P79, DOI 10.1016/0014-4827(68)90521-1; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; Crandall M, 1977, Adv Microb Physiol, V15, P307, DOI 10.1016/S0065-2911(08)60319-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; EGEL R, 1973, MOL GEN GENET, V122, P339, DOI 10.1007/BF00269434; Egel R., 1989, MOL BIOL FISSION YEA, P31; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; GENDIMENICO GJ, 1988, ANAL BIOCHEM, V173, P45, DOI 10.1016/0003-2697(88)90156-X; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAGAN I, 1988, J CELL SCI, V91, P587; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KAI R, 1986, MOL CELL BIOL, V6, P2027, DOI 10.1128/MCB.6.6.2027; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KOHLI J, 1977, GENETICS, V87, P471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; Mitchison J.M., 1971, BIOLOGY CELL CYCLE, P201; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORENO S, 1990, METHOD ENZYMOL, V194, P793; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROBERTS J, 1988, CELL, V452, P397; ROMAN H, 1955, GENETICS, V40, P546; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SAZER S, 1990, J CELL SCI, V97, P509; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SLUDER G, 1986, J EXP ZOOL, V238, P325, DOI 10.1002/jez.1402380307; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	59	325	330	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					388	393		10.1038/349388a0	http://dx.doi.org/10.1038/349388a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992340				2022-12-01	WOS:A1991EV51400040
J	CHERNEVSKAYA, NI; OBUKHOV, AG; KRISHTAL, OA				CHERNEVSKAYA, NI; OBUKHOV, AG; KRISHTAL, OA			NMDA RECEPTOR AGONISTS SELECTIVELY BLOCK N-TYPE CALCIUM CHANNELS IN HIPPOCAMPAL-NEURONS	NATURE			English	Article							EXCITATORY AMINO-ACIDS; CHICK SENSORY NEURONS; GUINEA-PIG INVITRO; SYNAPTIC TRANSMISSION; OMEGA-CONOTOXIN; RAT HIPPOCAMPUS; CA1 NEURONS; CURRENTS; MODULATION; ACTIVATION	THE modulation of voltage-dependent calcium channels by various neurotransmitters had been demonstrated in many neurons 1-4,. Because of the critical role of Ca2+ in transmitter release and, more generally, in transmembrane signalling, this modulation has important functional implications. Hippocampal neurons posses low-threshold (T-type) Ca2+ channels and both L- and N-type high voltage-activated Ca2+ channels. 5-7 N-type Ca2+ channels are blocked selectively by omega-conotoxin 8, 9 and adenosine 10, 11. These substances both block excitatory synaptic transmission in the hippocampus 12-13, whereas dihydropyridines, which selectively block L-type channels 14, are ineffective 12. Excitatory synaptic transmission in the hippocampus displays a number of plasticity phenomena that are initiated by Ca2+ entry through ionic channels operated by N-methyl-D-aspartate (NMDA) receptors 15, 16. Here we report that NMDA receptor agonists selectively and effectively depress N-type Ca2+ channels which are involved in neurotransmitter release from presynaptic sites. The inhibitory effect is eliminated by the competitive NMDA antagonist D-2-amino-5-phosphonovalerate, does not require Ca2+ entry into the cell, and is probably receptor-mediated. This phenomenon may provide a negative feedback between the liberation of excitatory transmitter and entry of Ca2+ into the cell, and could be important in presynaptic inhibition and in the regulation of synaptic plasticity.	AA BOGOMOLETZ PHYSIOL INST,BOGOMOLETZ STR 4,KIEV 252024,UKRAINE,USSR	National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology			Obukhov, Alexander G/C-7246-2008; Krishtal, Oleg A/C-7739-2016	Obukhov, Alexander G/0000-0002-3862-6004; Krishtal, Oleg A/0000-0003-3342-9930				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BERTOLINO M, 1989, NEUROPHARMACOLOGY, V28, P453, DOI 10.1016/0028-3908(89)90078-6; CHIZHMAKOV IV, 1989, NEUROSCI LETT, V99, P131, DOI 10.1016/0304-3940(89)90277-2; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DEISZ RA, 1985, NEUROSCI LETT, V56, P205, DOI 10.1016/0304-3940(85)90130-2; DOCHERTY RJ, 1986, NEUROSCI LETT, V70, P110, DOI 10.1016/0304-3940(86)90447-7; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; GAHWILER BH, 1987, NEUROSCIENCE, V20, P731, DOI 10.1016/0306-4522(87)90236-3; GROSS RA, 1989, J PHYSIOL-LONDON, V411, P585, DOI 10.1113/jphysiol.1989.sp017592; HONORE T, 1982, J NEUROCHEM, V38, P173, DOI 10.1111/j.1471-4159.1982.tb10868.x; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; KASAI H, 1987, Neuroscience Research, V4, P228, DOI 10.1016/0168-0102(87)90014-9; KRISHTAL OA, 1988, NEUROSCI LETT, V85, P82, DOI 10.1016/0304-3940(88)90433-8; KRISHTAL OA, 1989, NEUROSCI LETT, V102, P197, DOI 10.1016/0304-3940(89)90078-5; KRISTAL SM, 1983, NEUROSCI LETT, V35, P41; OKADA Y, 1980, EUR J PHARMACOL, V68, P483; OZAWA S, 1989, BRAIN RES, V495, P329, DOI 10.1016/0006-8993(89)90225-4; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; SARVEY JM, 1989, J NEUROSCI METH, V28, P109, DOI 10.1016/0165-0270(89)90016-2; TAKAHASHI K, 1989, NEUROSCI LETT, V104, P229, DOI 10.1016/0304-3940(89)90359-5; TOSELLI M, 1989, PFLUG ARCH EUR J PHY, V415, P255, DOI 10.1007/BF00370874; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; ZORUMSKI CF, 1988, J NEUROSCI, V8, P4277	26	63	66	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					418	420		10.1038/349418a0	http://dx.doi.org/10.1038/349418a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1671527				2022-12-01	WOS:A1991EV51400052
J	KAWAMURA, S; MURAKAMI, M				KAWAMURA, S; MURAKAMI, M			CALCIUM-DEPENDENT REGULATION OF CYCLIC-GMP PHOSPHODIESTERASE BY A PROTEIN FROM FROG RETINAL RODS	NATURE			English	Article							OUTER SEGMENT; PHOTORECEPTOR-MEMBRANES; CGMP PHOSPHODIESTERASE; GUANYLATE-CYCLASE; PLASMA-MEMBRANE; SALAMANDER RODS; BINDING PROTEIN; ACTIVATION; CONDUCTANCE; SEQUENCE	IN vertebrate photoreceptors, light reduces cyclic GMP concentration and closes cGMP-activated channels to induce a hyperpolarizing response 1. As Ca2+ can permeate the channels and the Na+ - CA2+ exchanger continuously extrudes Ca2+, closure of the channel results in a reduction of the inter-rod Ca2+ concentration 2-4. This is believed to be one of the mechanisms of light adaptation produced by activation of guanylate cyclase 5-9. Effects of Ca2+ on the cGMP phosphodiesterase (PDE) have been reported 10-15, but their physiological significance has remained unclear. We have perfused the inside-out preparation of a frog rod outer segment (I/O ROS (ref. 16), originally termed truncated ROS (ref. 17)), and find that Ca2+ in a physiological range regulates the light-activation of PDE. Therefore, PDE regulation by Ca2+ must be involved in light-adaptation in rods. The effect is mediated by a newly found protein which binds to disk membranes at high Ca2+ concentrations and prolongs PDE activation.			KAWAMURA, S (corresponding author), KEIO UNIV,SCH MED,DEPT PHYSIOL,SHINANOMACHI 35,SHINJUKU KU,TOKYO 160,JAPAN.							BARKDOLL AE, 1989, J GEN PHYSIOL, V93, P1091, DOI 10.1085/jgp.93.6.1091; BUZDYGON BE, 1984, J BIOL CHEM, V259, P4567; DELPRIORE LV, 1983, BIOCHEM BIOPH RES CO, V113, P317, DOI 10.1016/0006-291X(83)90468-0; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; HODGKIN AL, 1988, J PHYSIOL-LONDON, V403, P439, DOI 10.1113/jphysiol.1988.sp017258; KAWAMURA S, 1986, BIOCHIM BIOPHYS ACTA, V870, P256, DOI 10.1016/0167-4838(86)90230-X; KAWAMURA S, 1981, J GEN PHYSIOL, V77, P571, DOI 10.1085/jgp.77.5.571; KAWAMURA S, 1989, J GEN PHYSIOL, V94, P649, DOI 10.1085/jgp.94.4.649; KAWAMURA S, 1989, NEUROSCI RES       S, V10, pS15; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; RATTO GM, 1988, J NEUROSCI, V8, P3240; ROBINSON PR, 1980, J GEN PHYSIOL, V76, P631, DOI 10.1085/jgp.76.5.631; TORRE V, 1986, P NATL ACAD SCI USA, V83, P7109, DOI 10.1073/pnas.83.18.7109; WAGNER R, 1989, FEBS LETT, V242, P249, DOI 10.1016/0014-5793(89)80479-X; WILSON PW, 1985, NUCLEIC ACIDS RES, V13, P8867, DOI 10.1093/nar/13.24.8867; YAMAGATA K, 1990, NEURON, V2, P469; YAMAKUNI T, 1986, NUCLEIC ACIDS RES, V14, P6768, DOI 10.1093/nar/14.16.6768; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0	22	210	212	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					420	423		10.1038/349420a0	http://dx.doi.org/10.1038/349420a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1846944				2022-12-01	WOS:A1991EV51400053
J	KOLCH, W; HEIDECKER, G; LLOYD, P; RAPP, UR				KOLCH, W; HEIDECKER, G; LLOYD, P; RAPP, UR			RAF-1 PROTEIN-KINASE IS REQUIRED FOR GROWTH OF INDUCED NIH/3T3 CELLS	NATURE			English	Article							SIGNAL TRANSDUCTION; V-RAF; ONCOGENE; PHOSPHORYLATION	MANY growth factors regulate the cytoplasmic RAF-1 protein kinase 1-10, consistent with its having a central role in transduction of growth signals. The kinase is ubiquitously expressed 11 and can promote proliferation 12, presumably in a manner dependent on growth-factor receptors and membrane-associated oncogenes 13-15. We have now examined the dependence of serum- and TPa (12-O-tetradecanoylphorbol-13-acetate)-regulated NIH/3T3 cell growth on RAF-1 kinase to determine whether Raf-1 is essential for receptor signalling. We inhibited Raf-1 function by expressing c-raf-1 antisense RNA or kinase-defective c-raf-1 mutants. Antisense RNA for c-raf-1 interferes with proliferation of normal NIH/3T3 cells and reverts raf-transformed cells. In revertant cells, DNA replication induced by serum or TPA was eliminated or reduced proportionately to the reduction in Raf protein levels. Expression of a kinase-defective Raf-1 mutant (craf301) or a regulatory domain fragment (HCR) inhibited serum-induced NIH/3T3-cell proliferation and raf transformation even more efficiently. Inhibition by antisense RNA or craf301 blocked proliferation and transformation by Ki- and Ha-ras oncogenes. We conclude that raf functions as an essential signal transducer downstream of serum growth factor receptors, protein kinase C and ras.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Kolch, Walter/ABF-2102-2021	Kolch, Walter/0000-0001-5777-5016				APP H, IN PRESS MOLEC CELL; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; KOLCH W, 1990, ONCOGENE, V5, P713; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, HDB ONCOGENES, P213; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STORM SM, 1990, ONCOGENE, V5, P345; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TURNER BC, IN PRESS P NATN ACAD; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	26	472	512	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					426	428		10.1038/349426a0	http://dx.doi.org/10.1038/349426a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992343	Green Published			2022-12-01	WOS:A1991EV51400055
J	MOLFINO, NA; NANNINI, LJ; MARTELLI, AN; SLUTSKY, AS				MOLFINO, NA; NANNINI, LJ; MARTELLI, AN; SLUTSKY, AS			RESPIRATORY ARREST IN NEAR-FATAL ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-ADRENERGIC AGONISTS; ORAL THEOPHYLLINE; MORTALITY; DEATH; FENOTEROL; VENTILATION; EXPERIENCE; ZEALAND; RATES	Background and Methods. The majority of asthma-related deaths occur outside the hospital, and therefore the exact factors leading to the terminal event are difficult to ascertain. To examine the mechanisms by which patients might die during acute exacerbations of asthma, we studied 10 such patients who arrived at the hospital in respiratory arrest or in whom it developed soon (within 20 minutes) after admission. Results. The characteristics of the group were similar to those associated in the literature with a high risk of death from asthma, including a long history of the disease in young to middle-aged patients, previous life-threatening attacks or hospitalizations, delay in obtaining medical aid, and sudden onset of a rapidly progressive crisis. Extreme hypercapnia (mean [+/- SD] partial pressure of arterial carbon dioxide, 97.1 +/- 31.1 mm Hg) and acidosis (mean [+/- SD] pH, 7.01 +/- 0.11) were found before mechanical ventilation was begun, and four patients had hypokalemia on admission. Despite the severe respiratory acidosis, no patient had a serious cardiac arrhythmia during the resuscitation maneuvers or during hospitalization. We observed systemic hypertension and sinus tachycardia in eight patients, atrial fibrillation in one, and sinus bradycardia in another. In both patients with arrhythmia the heart reverted to sinus rhythm immediately after manual ventilation with 100 percent oxygen was begun. The median duration of mechanical ventilation was 12 hours, and all patients had normocapnia on discharge from the hospital. Conclusions. We conclude that at least in this group of patients, the near-fatal nature of the exacerbations was the result of severe asphyxia rather than cardiac arrhythmias. These results suggest that undertreatment rather than overtreatment may contribute to an increase in mortality from asthma.	HOSP NACL MARIA FERRER,BUENOS AIRES,ARGENTINA; UNIV TORONTO,MT SINAI HOSP,DEPT MED,DIV RESP,TORONTO M5G 1X5,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Slutsky, Arthur S/A-6013-2008; Slutsky, Arthur/M-3325-2019	Slutsky, Arthur S/0000-0002-6063-3876; 				[Anonymous], 1984, Thorax, V39, P505; BARGER LW, 1988, ANN ALLERGY, V60, P31; BARRIOT P, 1987, CHEST, V92, P460, DOI 10.1378/chest.92.3.460; BATEMAN JRM, 1979, THORAX, V34, P40, DOI 10.1136/thx.34.1.40; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BUIST AS, 1988, CHEST, V93, P449, DOI 10.1378/chest.93.3.449; COCHRANE GM, 1975, THORAX, V30, P300, DOI 10.1136/thx.30.3.300; COLEMAN JJ, 1986, CHEST, V90, P45, DOI 10.1378/chest.90.1.45; CRANE J, 1989, LANCET, V1, P917; CROMPTON G, 1987, BRIT J DIS CHEST, V81, P321, DOI 10.1016/0007-0971(87)90179-3; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; DRISLANE FW, 1987, AM REV RESPIR DIS, V135, P498; FLATT A, 1989, CHEST, V96, P1317, DOI 10.1378/chest.96.6.1317; HAALBOOM JRE, 1985, LANCET, V1, P1125; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; Joseph X, 1981, Fundam Appl Toxicol, V1, P443, DOI 10.1016/S0272-0590(81)80025-5; KEMP JP, 1984, J ALLERGY CLIN IMMUN, V73, P32, DOI 10.1016/0091-6749(84)90481-0; KNOCHEL JP, 1982, AM J MED, V72, P521, DOI 10.1016/0002-9343(82)90522-8; LUKSZA AR, 1986, THORAX, V41, P459, DOI 10.1136/thx.41.6.459; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; MANNING P, 1987, IRISH MED J, V80, P406; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; MUSK AW, 1987, MED J AUSTRALIA, V147, P423, DOI 10.5694/j.1326-5377.1987.tb133582.x; NICKLAS RA, 1984, J ALLERGY CLIN IMMUN, V73, P20, DOI 10.1016/0091-6749(84)90479-2; NICKLAS RA, 1982, NEW ENGL J MED, V307, P557; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; REBUCK AS, 1971, AM J MED, V51, P788, DOI 10.1016/0002-9343(71)90307-X; ROBIN ED, 1988, CHEST, V93, P614, DOI 10.1378/chest.93.3.614; ROTHWELL RPG, 1987, NEW ZEAL MED J, V100, P199; SEARS MR, 1986, BRIT MED J, V293, P1342, DOI 10.1136/bmj.293.6558.1342; SHEFFER AL, 1987, J ALLERGY CLIN IMMUN, V80, P361, DOI 10.1016/0091-6749(87)90047-9; SIEGEL SC, 1987, J ALLERGY CLIN IMMUN, V80, P458, DOI 10.1016/0091-6749(87)90075-3; SLY RM, 1988, ANN ALLERGY, V60, P433; SWENSON E R, 1985, American Review of Respiratory Disease, V131, pA99; WESTERMAN DE, 1979, AM J MED, V66, P565, DOI 10.1016/0002-9343(79)91165-3; WILSON JD, 1981, LANCET, V1, P1235; WOOLCOCK AJ, 1986, CHEST, V90, pS40, DOI 10.1378/chest.90.5_Supplement.40S; 1987, AM REV RESPIR DIS, V136, P225; 1987, BR J DIS CHEST, V81, P30; 1982, BMJ, V285, P1251	42	173	175	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 31	1991	324	5					285	288		10.1056/NEJM199101313240502	http://dx.doi.org/10.1056/NEJM199101313240502			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU922	1986288				2022-12-01	WOS:A1991EU92200002
J	PELLICCIA, A; MARON, BJ; SPATARO, A; PROSCHAN, MA; SPIRITO, P				PELLICCIA, A; MARON, BJ; SPATARO, A; PROSCHAN, MA; SPIRITO, P			THE UPPER LIMIT OF PHYSIOLOGICAL CARDIAC-HYPERTROPHY IN HIGHLY TRAINED ELITE ATHLETES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR HYPERTROPHY; M-MODE ECHOCARDIOGRAPHY; NON-INVASIVE EVALUATION; DOPPLER ECHOCARDIOGRAPHY; CLINICAL MANIFESTATIONS; CARDIOVASCULAR-DISEASE; DIASTOLIC FUNCTION; DISTANCE RUNNERS; PATHO-PHYSIOLOGY; CARDIOMYOPATHY	Background. In some highly trained athletes, the thickness of the left ventricular wall may increase as a consequence of exercise training and resemble that found in cardiac diseases associated with left ventricular hypertrophy, such as hypertrophic cardiomyopathy. In these athletes, the differential diagnosis between physiologic and pathologic hypertrophy may be difficult. Methods. To address this issue, we measured left ventricular dimensions with echocardiography in 947 elite, highly trained athletes who participated in a wide variety of sports. Results. The thickest left ventricular wall among the athletes measured 16 mm. Wall thicknesses within a range compatible with the diagnosis of hypertrophic cardiomyopathy (greater-than-or-equal-to 13 mm) were identified in only 16 of the 947 athletes (1.7 percent); 15 were rowers or canoeists, and 1 was a cyclist. Therefore, the wall was greater-than-or-equal-to 13 mm thick in 7 percent of 219 rowers, canoeists, and cyclists but in none of 728 participants in 22 other sports. All athletes with walls greater-than-or-equal-to 13 mm thick also had enlarged left ventricular end-diastolic cavities (dimensions, 55 to 63 mm). Conclusions. On the basis of these data, a left-ventricular-wall thickness of greater-than-or-equal-to 13 mm is very uncommon in highly trained athletes, virtually confined to athletes training in rowing sports, and associated with an enlarged left ventricular cavity. In addition, the upper limit to which the thickness of the left ventricular wall may be increased by athletic training appears to be 16 mm. Therefore, athletes with a wall thickness of more than 16 mm and a nondilated left ventricular cavity are likely to have primary forms of pathologic hypertrophy, such as hypertrophic cardiomyopathy.	NHLBI,CARDIOL BRANCH,BETHESDA,MD 20892; NHLBI,BIOSTAT RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	PELLICCIA, A (corresponding author), COMITATO OLIMPICO NAZL ITALIANO,INST SPORTS SCI,DEPT MED,VIA CAMPI SPORTIVI 46,I-00197 ROME,ITALY.			Spataro, Antonio/0000-0002-7727-665X				BEKAERT I, 1981, BRIT HEART J, V45, P213; BLAIR NL, 1980, AUST NZ J MED, V10, P540, DOI 10.1111/j.1445-5994.1980.tb04973.x; DEMARIA AN, 1978, CIRCULATION, V57, P237, DOI 10.1161/01.CIR.57.2.237; DEVEREUX RB, 1987, HYPERTENSION, V9, P19; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; EHSANI AA, 1978, AM J CARDIOL, V42, P52, DOI 10.1016/0002-9149(78)90984-0; FAGARD R, 1983, CIRCULATION, V67, P896, DOI 10.1161/01.CIR.67.4.896; FAGARD R, 1984, BRIT HEART J, V52, P124; FAGARD R, 1987, J AM COLL CARDIOL, V9, P1250, DOI 10.1016/S0735-1097(87)80463-1; FISHER AG, 1989, AM J CARDIOL, V63, P337, DOI 10.1016/0002-9149(89)90342-1; GILBERT CA, 1977, AM J CARDIOL, V40, P528, DOI 10.1016/0002-9149(77)90067-4; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; IKAHEIMO MJ, 1979, AM J CARDIOL, V44, P24, DOI 10.1016/0002-9149(79)90246-7; KEREN G, 1985, CIRCULATION, V71, P45, DOI 10.1161/01.CIR.71.1.45; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; LONGHURST JC, 1981, CIRC RES, V48, P171; LOUIE EK, 1987, ANN INTERN MED, V106, P663, DOI 10.7326/0003-4819-106-5-663; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1983, AM J CARDIOL, V51, P189, DOI 10.1016/S0002-9149(83)80034-4; MARON BJ, 1986, J AM COLL CARDIOL, V7, P190, DOI 10.1016/S0735-1097(86)80282-0; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1987, J AM COLL CARDIOL, V10, P733, DOI 10.1016/S0735-1097(87)80264-4; MARTIN WH, 1986, J AM COLL CARDIOL, V7, P982, DOI 10.1016/S0735-1097(86)80215-7; MORGANROTH J, 1975, ANN INTERN MED, V82, P521, DOI 10.7326/0003-4819-82-4-521; NETER J, 1984, APPLIED LINEAR STATI, P214; NISHIMURA T, 1980, CIRCULATION, V61, P832, DOI 10.1161/01.CIR.61.4.832; OAKLEY D, 1984, BRIT HEART J, V52, P121; PARKER BM, 1978, CHEST, V73, P376, DOI 10.1378/chest.73.3.376; ROST R, 1982, EUR HEART J, V3, P193, DOI 10.1093/eurheartj/3.suppl_A.193; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SHAPIRO LM, 1985, EUR HEART J, V6, P967, DOI 10.1093/oxfordjournals.eurheartj.a061796; SNOECKX LHEH, 1983, EUR J APPL PHYSIOL O, V52, P20, DOI 10.1007/BF00429020; SPIRITO P, 1988, ANN INTERN MED, V109, P122, DOI 10.7326/0003-4819-109-2-122; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; SPIRITO P, 1990, J AM COLL CARDIOL, V15, P1521, DOI 10.1016/0735-1097(90)92820-R; Underwood R H, 1977, Ann N Y Acad Sci, V301, P297, DOI 10.1111/j.1749-6632.1977.tb38208.x; WIELING W, 1981, BRIT HEART J, V46, P190; YAMAGUCHI H, 1979, AM J CARDIOL, V44, P401, DOI 10.1016/0002-9149(79)90388-6	42	690	703	1	35	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 31	1991	324	5					295	301		10.1056/NEJM199101313240504	http://dx.doi.org/10.1056/NEJM199101313240504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU922	1824720	Bronze			2022-12-01	WOS:A1991EU92200004
J	POTTER, E; BEHAN, DP; FISCHER, WH; LINTON, EA; LOWRY, PJ; VALE, WW				POTTER, E; BEHAN, DP; FISCHER, WH; LINTON, EA; LOWRY, PJ; VALE, WW			CLONING AND CHARACTERIZATION OF THE CDNAS FOR HUMAN AND RAT CORTICOTROPIN RELEASING FACTOR-BINDING PROTEINS	NATURE			English	Article							AMINO-ACID SEQUENCE; HUMAN-PLASMA; MATERNAL PLASMA; HUMAN-PLACENTA; PREGNANCY; HORMONE; ACTH; ADRENALECTOMY; SECRETION; OXYTOCIN	CORTICOTROPIN-releasing factor (CRF)1, is a potent stimulator of synthesis and secretion of preopiomelanocortin-derived peptides. Although CRF concentrations in the human peripheral circulation are normally low 2-4, they increase throughout pregnancy 4-8 and fall rapidly after parturition. Maternal plasma CRF probably originates from the placenta, which responds to the bioactive peptide 5, 9, 10 and produces the peptide 9 and its messenger RNA 11. Even though CRF concentrations in late gestational maternal plasma are similar to those in rat hypothalamic portal blood 12,13 and to those that can stimulate release of adrenocorticotropic hormone (ACTH) in vitro, maternal plasma ACTH concentrations increase only slightly with advancing gestation and remain within the normal range 14. Several groups have now reported the existence of a CRF-binding protein in human plasma which inactivates CRF 15-20 and which has been proposed to prevent inappropriate pituitary-adrenal stimulation in pregnancy. The binding protein was recently purified from human plasma 19. We have now isolated and partially sequenced the binding protein, allowing us to clone and characterize its complementary DNA from human liver and rat brain. Expression of the cDNAs for human and rat binding protein in COS7 cells showed that these proteins bind CRF with the same affinity as the native human protein 15. Both rat and human recombinant binding proteins inhibit CRF binding to a CRF antibody and inhibit CRF-induced ACTH release by pituitary cells in vitro.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92037; UNIV READING,SCH ANIM & MICROBIAL SCI,DEPT BIOCHEM & PHYSIOL,READING RG6 2AJ,BERKS,ENGLAND	University of California System; University of California San Diego; University of Reading	POTTER, E (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN PEPTIDE BIOL,LA JOLLA,CA 92138, USA.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BEHAN DP, 1989, J ENDOCRINOL, V122, P23, DOI 10.1677/joe.0.1220023; CAMPBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054, DOI 10.1210/jcem-64-5-1054; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNAH D, 1987, J ENDOCRINOL, V113, P123, DOI 10.1677/joe.0.1130123; DESOUZA EB, 1990, CORTICOTROPIN RELEAS; ELLIS MJ, 1988, J ENDOCRINOL, V117, P299, DOI 10.1677/joe.0.1170299; FINK G, 1988, J PHYSIOL-LONDON, V401, P329, DOI 10.1113/jphysiol.1988.sp017165; FISCHER WH, IN PRESS METH NEUROS; GOLAND RS, 1986, J CLIN ENDOCR METAB, V63, P1199, DOI 10.1210/jcem-63-5-1199; GRINO M, 1987, BIOCHEM BIOPH RES CO, V148, P1208, DOI 10.1016/S0006-291X(87)80261-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAATIKAINEN T, 1987, NEUROPEPTIDES, V10, P343, DOI 10.1016/S0143-4179(87)90101-6; LINTON EA, 1987, J CLIN ENDOCR METAB, V64, P1047, DOI 10.1210/jcem-64-5-1047; LINTON EA, 1988, CLIN ENDOCRINOL, V28, P315, DOI 10.1111/j.1365-2265.1988.tb01218.x; LINTON EA, 1989, J CLIN ENDOCR METAB, V70, P174; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; ORTH DN, 1987, BIOCHEM BIOPH RES CO, V143, P411, DOI 10.1016/0006-291X(87)91369-6; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; PLOTSKY PM, 1987, ENDOCRINOLOGY, V120, P1361, DOI 10.1210/endo-120-4-1361; REES LH, 1975, NATURE, V254, P620, DOI 10.1038/254620b0; Sambrook J., 1989, MOL CLONING LAB MANU; SASAKI A, 1984, J CLIN ENDOCR METAB, V59, P812; SHIBASAKI T, 1982, J CLIN ENDOCR METAB, V55, P384, DOI 10.1210/jcem-55-2-384; SUDA T, 1988, J CLIN ENDOCR METAB, V67, P1278, DOI 10.1210/jcem-67-6-1278; SUDA T, 1985, J CLIN INVEST, V76, P2026, DOI 10.1172/JCI112204; SUDA T, 1989, BIOCHEM BIOPH RES CO, V165, P703, DOI 10.1016/S0006-291X(89)80023-3; Vale W, 1986, Methods Enzymol, V124, P389; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699	33	320	328	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					423	426		10.1038/349423a0	http://dx.doi.org/10.1038/349423a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1846945				2022-12-01	WOS:A1991EV51400054
J	ROBLES, L; RUGGERO, MA; RICH, NC				ROBLES, L; RUGGERO, MA; RICH, NC			2-TONE DISTORTION IN THE BASILAR-MEMBRANE OF THE COCHLEA	NATURE			English	Article							MECHANICS; NONLINEARITY; RESPONSES; 2F1-F2; MOTION; TONES; NERVE	WHEN humans listen to pairs of thnes they hear additional tones, or distortion products, that are not present in the stimulus 1. Two-tone distortion products are also known as combination tones, because their pitches match combinations of the primary frequencies (f1 and f2,f2 > f1), such as f2 - f1, (n+1)f1 - nf2 and (n + 1)f2 - nf1 (n = 1,2,3...) (refs 2-4). Physiological correlates of the perceived distortion products exist in responses of auditory-nerve fibres 5-8 and inner hair cells 9 and in otoacoustic emissions (sounds generated by the cochlea, recordable at the ear canal) 7, 10-12. Because the middle ear responds linearly to sound 13, 14 and neural responses to distortion products can be abolished by damage to hair cells at cochlear sites preferentially tuned to the frequencies of the primary tones 8, it was hypothesized that distortion products are generated at these sites and propagate mechanically along the basilar membrane to the location tuned to the distortion-product frequency 7,8. But until now, efforts to confirm this hypothesis have failed 15,16. Here we report the use of a new laser-velocimetry technique 17 to demonstrate two-tone distortion in basilar-membrane motion at low and moderate stimulus intensities.	UNIV CHILE,FAC MED,DEPT FISIOL & BIOFIS,SANTIAGO,CHILE	Universidad de Chile	ROBLES, L (corresponding author), UNIV MINNESOTA,DEPT OTOLARYNGOL,2630 UNIV AVE SE,MINNEAPOLIS,MN 55414, USA.		Ruggero, Mario A/A-9860-2009	Ruggero, Mario A/0000-0001-8240-3644	NIDCD NIH HHS [R01 DC000419] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000419] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BUUNEN TJF, 1978, J ACOUST SOC AM, V64, P772, DOI 10.1121/1.382042; BUUNEN TJF, 1981, J ACOUST SOC AM, V69, P744, DOI 10.1121/1.385574; GOLDSTEI.JL, 1968, PR INST ELECTR ELECT, V56, P981, DOI 10.1109/PROC.1968.6449; GOLDSTEIN JL, 1967, J ACOUST SOC AM, V41, P676, DOI 10.1121/1.1910396; GUINAN JJ, 1967, J ACOUST SOC AM, V41, P1237, DOI 10.1121/1.1910465; Jones AT., 1935, AM J PHYS, V3, P49, DOI [10.1119/1.1992920, DOI 10.1119/1.1992920]; KEMP DT, 1979, ARCH OTO-RHINO-LARYN, V224, P37, DOI 10.1007/BF00455222; KIM DO, 1980, J ACOUST SOC AM, V67, P1704, DOI 10.1121/1.384297; MOUNTAIN DC, 1980, SCIENCE, V210, P71, DOI 10.1126/science.7414321; NUTTALL AL, 1990, J ACOUST SOC AM, V87, P782, DOI 10.1121/1.398890; NUTTALL AL, IN PRESS MECHANICS B; PATUZZI R, 1984, HEARING RES, V13, P19, DOI 10.1016/0378-5955(84)90091-1; Rhode WS., 1977, PSYCHOPHYSICS PHYSL, P27; ROBLES L, 1986, J ACOUST SOC AM, V80, P1364, DOI 10.1121/1.394389; ROBLES L, IN PRESS MECHANICS B; Robles L, 1989, COCHLEAR MECHANISMS, P369; RUGGERO MA, IN PRESS HEAR RES; RUGGERO MA, IN PRESS J NEUROSCI; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; SIEGEL JH, 1982, J NEUROPHYSIOL, V47, P303, DOI 10.1152/jn.1982.47.2.303; SIEGEL JH, 1982, HEARING RES, V6, P171, DOI 10.1016/0378-5955(82)90052-1; SMOORENBURG GF, 1972, J ACOUST SOC AM, V52, P615, DOI 10.1121/1.1913152; WILSON JP, 1973, NATURE, V241, P206, DOI 10.1038/241206a0; ZUREK PM, 1979, SCIENCE, V205, P600, DOI 10.1126/science.451625	24	136	145	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					413	414		10.1038/349413a0	http://dx.doi.org/10.1038/349413a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992342	Green Accepted			2022-12-01	WOS:A1991EV51400050
J	SHIBUTANI, S; TAKESHITA, M; GROLLMAN, AP				SHIBUTANI, S; TAKESHITA, M; GROLLMAN, AP			INSERTION OF SPECIFIC BASES DURING DNA-SYNTHESIS PAST THE OXIDATION-DAMAGED BASE 8-OXODG	NATURE			English	Article							POLYMERASE-DELTA; CALF THYMUS; 8-HYDROXY-2'-DEOXYGUANOSINE	OXIDATIVE damage to DNA, reflected in the formation of 8-oxo-7-hydrodeoxyguanosine (8-oxodG) 1, 2, may be important in mutagenesis, carcinogenesis and the ageing process 3,4. Kuchino et al. studied DNA synthesis on oligodeoxynucleotide templates containing 8-oxodG, concluding that the modified base lacked base pairing specificity and directed misreading of pyrimidine residues neighbouring the lesion 5. Here we report different results, using an approach in which the several products of a DNA polymerase reaction can be measured. In contrast to the earlier report 5, we find that dCMP and dAMP are incorporated selectively opposite 8-oxodG with transient inhibition of chain extension occurring 3' to the modified base. The potentially mutagenic insertion of dAMP is targeted exclusively to the site of the lesion. The ratio of dCMP to dAMP incorporated varies, depending on the DNA polymerase involved. Chain extension from the dA . 8-oxodG pair was efficiently catalysed by all polymerases tested.			SHIBUTANI, S (corresponding author), SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.			Shibutani, Shinya/0000-0003-4190-9512				ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; AIDA M, 1987, MUTAT RES, V192, P83, DOI 10.1016/0165-7992(87)90101-1; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BODEPUDI V, IN PRESS NUCLEOSIDES; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; KARAWYA EM, 1982, J BIOL CHEM, V257, P3129; KASAI H, 1987, B CHEM SOC JPN, V60, P3799, DOI 10.1246/bcsj.60.3799; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KOUCHAKDIJAN M, IN PRESS J BIOCH; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; Maxam A M, 1980, Methods Enzymol, V65, P499; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MORIYA M, IN PRESS MUT RES; Sambrook J., 1989, MOL CLONING; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; TAN CK, 1986, J BIOL CHEM, V261, P2310; UESUGI S, 1977, J AM CHEM SOC, V99, P3250, DOI 10.1021/ja00452a008; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011	23	2042	2071	1	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					431	434		10.1038/349431a0	http://dx.doi.org/10.1038/349431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992344				2022-12-01	WOS:A1991EV51400057
J	SMALL, PM; SCHECTER, GF; GOODMAN, PC; SANDE, MA; CHAISSON, RE; HOPEWELL, PC				SMALL, PM; SCHECTER, GF; GOODMAN, PC; SANDE, MA; CHAISSON, RE; HOPEWELL, PC			TREATMENT OF TUBERCULOSIS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HAITIAN PATIENTS; PULMONARY TUBERCULOSIS; THERAPY; CHEMOTHERAPY; FLORIDA; HIV	Background and Methods. Infection with the human immunodeficiency virus (HIV) increases the risk of tuberculosis and may interfere with the effectiveness of antituberculosis chemotherapy. To examine the outcomes in patients with both diagnoses, we conducted a retrospective study of all 132 patients listed in both the acquired immunodeficiency syndrome (AIDS) and tuberculosis case registries in San Francisco from 1981 through 1988. Results. At the time of the diagnosis of tuberculosis, 78 patients (59 percent) did not yet have a diagnosis of AIDS, 18 patients (14 percent) were given a concomitant diagnosis of AIDS (as determined by the presence of an AIDS-defining disease other than tuberculosis), and the remaining 36 patients (27 percent) already had AIDS. The manifestations of tuberculosis were entirely pulmonary in 50 patients (38 percent), entirely extrapulmonary in 40 patients (30 percent), and both pulmonary and extrapulmonary in 42 patients (32 percent). The treatment regimens were as follows: isoniazid and rifampin supplemented by ethambutol for the first two months, 52 patients; isoniazid and rifampin supplemented by pyrazinamide and ethambutol for the first two months, 39 patients; isoniazid and rifampin, 13 patients; isoniazid and rifampin supplemented by pyrazinamide for the first two months, 4 patients; and other drug regimens, 17 patients. The intended duration of treatment for patients whose regimen included pyrazinamide was six months, and for patients who did not receive pyrazinamide, nine months. Seven patients received no treatment because tuberculosis was first diagnosed after death. Sputum samples became clear of acid-fast organisms after a median of 10 weeks of therapy. Abnormalities on all chest radiographs taken after three months of treatment were stable or improved except for those of patients who had new nontuberculous infections. The only treatment failure occurred in a man infected with multiple drug-resistant organisms who did not comply with therapy. Adverse drug reactions occurred in 23 patients (18 percent). For all 125 treated patients, median survival was 16 months from the diagnosis of tuberculosis. Tuberculosis was a major contributor to death in 5 of the 7 untreated patients and 8 of the 125 treated patients. Three of 58 patients who completed therapy had a relapse (5 percent); compliance was poor in all 3. Conclusions. Tuberculosis causes substantial mortality in patients with advanced HIV infection. In patients who comply with the regimen, conventional therapy results in rapid sterilization of sputum, radiographic improvement, and low rates of relapse.	SAN FRANCISCO GEN HOSP,MED CTR,MED SERV,SAN FRANCISCO,CA 94110; SAN FRANCISCO GEN HOSP,MED CTR,DEPT RADIOL,SAN FRANCISCO,CA 94110; DEPT PUBL HLTH,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [5-T32-GM07546] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUDNEY K, 1989, 5TH INT C AIDS MONTR; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DUTT AK, 1981, CHEST, V80, P724, DOI 10.1378/chest.80.6.724; FARER LS, 1979, AM J EPIDEMIOL, V109, P205, DOI 10.1093/oxfordjournals.aje.a112675; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; ISEMAN MD, 1987, AM REV RESPIR DIS, V136, P1326, DOI 10.1164/ajrccm/136.6.1325; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LOUIE E, 1986, CHEST, V90, P542, DOI 10.1378/chest.90.4.542; PERRIENS J, 1989, 5 INT C AIDS MONTR; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SLUTKIN G, 1988, AM REV RESPIR DIS, V138, P1622, DOI 10.1164/ajrccm/138.6.1622; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; WURTZ RM, 1989, LANCET, V1, P955; 1987, AM REV RESPIR DIS, V136, P492; 1989, MMWR, V38, P236	20	448	454	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 31	1991	324	5					289	294		10.1056/NEJM199101313240503	http://dx.doi.org/10.1056/NEJM199101313240503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU922	1898769				2022-12-01	WOS:A1991EU92200003
J	TURSKI, L; BRESSLER, K; RETTIG, KJ; LOSCHMANN, PA; WACHTEL, H				TURSKI, L; BRESSLER, K; RETTIG, KJ; LOSCHMANN, PA; WACHTEL, H			PROTECTION OF SUBSTANTIA-NIGRA FROM MPP+ NEUROTOXICITY BY N-METHYL-D-ASPARTATE ANTAGONISTS	NATURE			English	Article							EXCITATORY AMINO-ACIDS; MOUSE-BRAIN; PARKINSONS-DISEASE; RAT; GLUTAMATE; NEURONS; MPTP; N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM	INTAKE of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) leads to symptoms of Parkinson's disease and produces degeneration of nigrostriatal dopaminergic neurons in humans, giving rise to the hypothesis that this disorder may be caused by endogenous or environmental toxins 1-3. Excitation mediated by dicarboxylic amino acids such as L-glutamate or L-aspartate, has been claimed to be involved in pathogenesis of neurodegenerative disorders 4. We therefore sought to determine whether antagonists active at the NMDA or quisqualate subtypes of L-glutamate receptors prevent toxicity of either MPP+ (1-m ethyl-4-phenyl-pyridinium ion 5, the active metabolite of MPTP 6) or the selective dopaminergic neurotoxin 6-OHDA in the rat substantia nigra pars compacta. We report here that certain selective NMDA antagonists (AP7, CPP, MK-801) 7, but not the preferential quisqualate antagonists CNQX and NBQX, 8 provided short-term (up to 24 h) protection against MPP+ toxicity when coadministered into the substantia nigra. Systemic administration of CPP or MK-801 also offered temporary protection for up to 4 h against MPP+ toxicity. Repeated systemic administration of either compound prolonged protection against MPP+ challenge. Repeated administration for at least 24 h also led to permanent protection, still evident 7 days after intranigral administration of MPP+.			TURSKI, L (corresponding author), SCHERING AG,RES LABS,W-1000 BERLIN 65,GERMANY.							BORMANN J, 1989, EUR J PHARMACOL, V166, P591, DOI 10.1016/0014-2999(89)90385-3; BRADBURY AJ, 1986, NATURE, V319, P56, DOI 10.1038/319056a0; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CALNE DB, 1986, LANCET, V2, P1067, DOI 10.1016/S0140-6736(86)90469-1; CHAPMAN AG, 1983, NEUROSCI LETT, V37, P75, DOI 10.1016/0304-3940(83)90507-4; CHRISTIEPOPE BC, 1989, EXP NEUROL, V104, P235, DOI 10.1016/0014-4886(89)90035-6; COMPTON RP, 1988, NEUROSCI LETT, V84, P339, DOI 10.1016/0304-3940(88)90532-0; DIMONTE D, 1988, REV NEUROSCI, V2, P67; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FALLON JH, 1985, RAT NERVOUS SYSTEM H, V1, P353; FINK ROBERT P., 1967, BRAIN RES, V4, P369, DOI 10.1016/0006-8993(67)90166-7; GIBB WRG, 1988, BRAIN RES, V461, P361, DOI 10.1016/0006-8993(88)90268-5; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; IRWIN I, 1989, NEUROSCI LETT, V101, P83, DOI 10.1016/0304-3940(89)90445-X; JOHANNESSEN JN, 1985, LIFE SCI, V36, P219, DOI 10.1016/0024-3205(85)90062-1; Konig JFR, 1963, RAT BRAIN STEREOTAXI; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; MARKEY SP, 1984, NATURE, V311, P464, DOI 10.1038/311464a0; MAWDSLEY C, 1963, LANCET, V2, P795; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OHYA Y, 1989, NEUROSCI LETT, V105, P221, DOI 10.1016/0304-3940(89)90041-4; OLNEY JW, 1987, EUR J PHARMACOL, V142, P319, DOI 10.1016/0014-2999(87)90123-3; OLNEY JW, 1988, FRONTIERS EXCITATORY, P589; OLVERMAN HJ, 1984, NATURE, V307, P460, DOI 10.1038/307460a0; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V134, P743, DOI 10.1016/S0006-291X(86)80483-1; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SONSALLA PK, 1989, SCIENCE, V243, P398, DOI 10.1126/science.2563176; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; SUN CJ, 1988, J NEURAL TRANSM, V74, P75, DOI 10.1007/BF01245141; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; VEZZANI A, 1989, J PHARMACOL EXP THER, V249, P278; WEISS JH, 1988, SCIENCE, V241, P973, DOI 10.1126/science.3136549	35	539	563	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					414	418		10.1038/349414a0	http://dx.doi.org/10.1038/349414a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1846943				2022-12-01	WOS:A1991EV51400051
J	WILCOCK, D; LANE, DP				WILCOCK, D; LANE, DP			LOCALIZATION OF P53, RETINOBLASTOMA AND HOST REPLICATION PROTEINS AT SITES OF VIRAL REPLICATION IN HERPES-INFECTED CELLS	NATURE			English	Article							SIMPLEX VIRUS TYPE-1; DNA-BINDING-PROTEIN; LARGE TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; GENE-PRODUCT; SV40-TRANSFORMED CELLS; SUSCEPTIBILITY GENE; AUXILIARY PROTEIN; POLYMERASE-DELTA; NUCLEAR ANTIGEN	REPLICATION of DNA occurs at DNA occurs at discrete sites in eukaryotic cell nuclei, where replication proteins are clustered into large complexes, or 'replicases' 1-3. Similarly, viral DNA replication is a highly structured process, notably in herpes simplex virus type-1 (HSV-1; reviewed in ref. 4) in which large globular "replication compartments' containing the viral replication machinery exist. Replicating cellular DNA redistributes to these compartments upon HSV-1 infection 5. We have now used antibodies raised against several cellular proteins to detect changes in their subnuclear localization on HSV-1 infection. We found that various proteins involved in cellular DNA replication move to sites of viral DNA synthesis, whereas a selection of non-replication proteins do not. The retinoblastoma protein and p53 (the products of two putative anti-oncogenes 6.7) relocate to the same sites as known DNA replication proteins, suggesting that they may be associated with DNA replication complexes in normal, uninfected cells.			WILCOCK, D (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BERNS KI, 1978, REPLICATION MAMMALIA, P13; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BROWN SM, 1973, J GEN VIROL, V18, P329, DOI 10.1099/0022-1317-18-3-329; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2187; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOX E, 1990, VIROLOGY, V176, P403, DOI 10.1016/0042-6822(90)90010-O; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KNIPE DM, 1987, J VIROL, V61, P276, DOI 10.1128/JVI.61.2.276-284.1987; KNIPE DM, 1989, ADV VIRUS RES, V37, P85; KOPS AD, 1988, CELL, V55, P857, DOI 10.1016/0092-8674(88)90141-9; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LERNER MR, 1980, NATURE, V283; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAO JCH, 1975, BIOCHEMISTRY-US, V14, P5475, DOI 10.1021/bi00696a015; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; OCHS R, 1983, EXP CELL RES, V146, P139, DOI 10.1016/0014-4827(83)90332-4; OLIVO PD, 1989, J VIROL, V63, P196, DOI 10.1128/JVI.63.1.196-204.1989; POWELL KL, 1981, J VIROL, V39, P894, DOI 10.1128/JVI.39.3.894-902.1981; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; QUINLAN MP, 1984, CELL, V36, P857, DOI 10.1016/0092-8674(84)90035-7; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; WALTON TH, 1989, J VIROL, V63, P3651, DOI 10.1128/JVI.63.9.3651-3660.1989; WASEEM NH, 1990, J CELL SCI, V96, P121; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLTER S, 1980, BIOCHIM BIOPHYS ACTA, V607, P420, DOI 10.1016/0005-2787(80)90152-5; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	42	249	252	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					429	431		10.1038/349429a0	http://dx.doi.org/10.1038/349429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1671528				2022-12-01	WOS:A1991EV51400056
J	ADAMS, S				ADAMS, S			PRESCRIBING OF PSYCHOTROPIC-DRUGS TO CHILDREN AND ADOLESCENTS	BRITISH MEDICAL JOURNAL			English	Article									SOUTHAMPTON ROTAT TRAINING SCHEME,ADOLESCENT UNIT,SOUTHAMPTON,ENGLAND									Bradley C, 1937, AM J PSYCHIAT, V94, P577, DOI 10.1176/ajp.94.3.577; RAPOPORT JL, 1983, DEV NEUROPSYCHIATRY, P385; SHAFFER D, 1968, ARCH DIS CHILD, V43, P665, DOI 10.1136/adc.43.232.665; STEINBERG D, 1985, CHILD ADOLESCENT PSY, P567; VARANKA TM, 1988, AM J PSYCHIAT, V145, P1557	5	26	26	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					217	217		10.1136/bmj.302.6770.217	http://dx.doi.org/10.1136/bmj.302.6770.217			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EV228	1998763	Green Published, Bronze			2022-12-01	WOS:A1991EV22800027
J	AURELIUS, E; JOHANSSON, B; SKOLDENBERG, B; STALAND, A; FORSGREN, M				AURELIUS, E; JOHANSSON, B; SKOLDENBERG, B; STALAND, A; FORSGREN, M			RAPID DIAGNOSIS OF HERPES-SIMPLEX ENCEPHALITIS BY NESTED POLYMERASE CHAIN-REACTION ASSAY OF CEREBROSPINAL-FLUID	LANCET			English	Article							LINKED IMMUNOSORBENT-ASSAY; ENZYMATIC AMPLIFICATION; VIRUS ENCEPHALITIS; SERODIAGNOSIS; VIDARABINE; ACYCLOVIR; THERAPY; DNA	With the aim of improving early diagnosis of herpes simplex encephalitis a polymerase chain reaction (PCR) assay with two "nested" primer pairs was developed for the amplification of herpes simplex virus DNA in cerebrospinal fluid (CSF). Southern blotting was used to confirm the specificity of the amplification. The assay was applied to 151 CSF samples from 43 consecutive patients with herpes simplex encephalitis verified by the finding of herpes simplex virus/viral antigen in a brain biopsy sample or at necropsy (13) and/or intrathecal production of IgG antibody to the virus (40). As controls, 87 CSF samples from 60 patients with acute febrile focal encephalopathy (initially suspected to be herpes simplex encephalitis but excluded by the absence of intrathecal antibody synthesis) were tested. PCR detected herpes simplex virus DNA in 42 of the 43 patients with proven herpes simplex encephalitis; all but 1 were positive in the first CSF sample taken. The 1 PCR-negative patient had been treated with acyclovir from 20 h after the onset of symptoms. All the control subjects were PCR negative, as were 270 internal contamination controls. The PCR result remained positive in samples drawn up to 27 days after the onset of neurological symptoms. This method is a rapid and non-invasive means to diagnose herpes simplex encephalitis; it is highly sensitive and specific.	CENT MICROBIOL LAB,DEPT VIROL,STOCKHOLM,SWEDEN		AURELIUS, E (corresponding author), KAROLINSKA INST,DANDERYD HOSP,DEPT INFECT DIS,S-18288 DANDERYD,SWEDEN.							ANDERSON N E, 1989, Australian and New Zealand Journal of Medicine, V19, P635; AURELIUS E, 1989, SERODIAG IMMUN INF D, V3, P249, DOI 10.1016/0888-0786(89)90005-X; BOERMAN RH, 1989, J VIROL METHODS, V25, P189, DOI 10.1016/0166-0934(89)90032-3; BOS CA, 1987, J MED VIROL, V21, P169, DOI 10.1002/jmv.1890210209; FORSGREN M, 1989, SERODIAG IMMUN INF D, V3, P259, DOI 10.1016/0888-0786(89)90006-1; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; HIGUCHI R, 1989, AMPLIFICATIONS; JOHNSON RT, 1968, ARCH NEUROL-CHICAGO, V18, P260, DOI 10.1001/archneur.1968.00470330050004; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAKEMAN FD, 1987, J INFECT DIS, V155, P1172, DOI 10.1093/infdis/155.6.1172; LEVINE DP, 1978, JAMA-J AM MED ASSOC, V240, P356, DOI 10.1001/jama.240.4.356; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PORTERJORDAN K, 1990, J MED VIROL, V30, P85, DOI 10.1002/jmv.1890300202; POWELL KF, 1990, LANCET, V335, P357, DOI 10.1016/0140-6736(90)90648-O; ROWLEY AH, 1990, LANCET, V335, P440, DOI 10.1016/0140-6736(90)90667-T; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SKOLDENBERG B, 1984, LANCET, V2, P707; WHITLEY RJ, 1977, NEW ENGL J MED, V297, P289, DOI 10.1056/NEJM197708112970601; WHITLEY RJ, 1986, NEW ENGL J MED, V314, P144, DOI 10.1056/NEJM198601163140303	21	476	483	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					189	192		10.1016/0140-6736(91)92155-U	http://dx.doi.org/10.1016/0140-6736(91)92155-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670839				2022-12-01	WOS:A1991EU92400001
J	HOFMEYR, GJ; WILKINS, T; REDMAN, CWG				HOFMEYR, GJ; WILKINS, T; REDMAN, CWG			C4 AND PLASMA-PROTEIN IN HYPERTENSION DURING PREGNANCY WITH AND WITHOUT PROTEINURIA	BRITISH MEDICAL JOURNAL			English	Article							PRE-ECLAMPSIA		JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV WITWATERSRAND,PARKTOWN 2193,SOUTH AFRICA	University of Oxford; University of Witwatersrand								BERGE LN, 1988, ACTA OBSTET GYN SCAN, V67, P499, DOI 10.3109/00016348809029860; BUYON JP, 1986, AM J MED, V81, P194, DOI 10.1016/0002-9343(86)90251-2; MASSOBRIO M, 1985, AM J OBSTET GYNECOL, V152, P578, DOI 10.1016/0002-9378(85)90631-3; REDMAN CWG, 1986, CLIN OBSTET GYNAECOL, V13, P469; ROSIC B, 1988, Clinical and Experimental Obstetrics and Gynecology, V15, P157	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					218	218		10.1136/bmj.302.6770.218	http://dx.doi.org/10.1136/bmj.302.6770.218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998764	Green Published, Bronze			2022-12-01	WOS:A1991EV22800028
J	KAWAMOTO, F				KAWAMOTO, F			RAPID DIAGNOSIS OF MALARIA BY FLUORESCENCE MICROSCOPY WITH LIGHT-MICROSCOPE AND INTERFERENCE FILTER	LANCET			English	Article							PARASITES; PROBES	Fluorochrome staining to detect malaria parasites in bloodfilms is more sensitive, is easier to do, and is less time-consuming than Giemsa staining. However, standard epi-illuminated, mercury vapour, fluorescence microscopes are expensive, especially for tropical countries where malaria is endemic. Fluorescence microscopy with a standard light microscope and a new interference filter specially designed for the fluorochrome stain, acridine orange, was used to detect malaria parasites in thick and thin bloodfilms. In this system two fluorescence colours, green (nuclei) and red (cytoplasm), were emitted from stained parasites. Thick and thin bloodfilms from patients with malaria were examined with this system. Bloodfilms had been fixed and stored for 1-5 years. Rapid scanning of both thick and thin bloodfilms was possible at a magnification of x 200 with standard lenses, indicating that this may be a useful economic system for rapid diagnosis of malarias.			KAWAMOTO, F (corresponding author), NAGOYA UNIV,SCH MED,DEPT MED ZOOL,NAGOYA,AICHI 466,JAPAN.							BARKER RH, 1986, SCIENCE, V231, P1434, DOI 10.1126/science.3513309; BRUCECHWATT LJ, 1987, LANCET, V2, P1509; KAWAMOTO F, 1987, PARASITOL TODAY, V3, P284, DOI 10.1016/0169-4758(87)90110-4; KAWAMOTO F, 1987, JPN J MED SCI BIOL, V40, P35, DOI 10.7883/yoken1952.40.35; RICKMAN LS, 1989, LANCET, V1, P68; ROST FWD, 1980, HISTOCHEMISTRY THEOR, V1, P346; RYGAARD J, 1969, ACTA PATHOL MIC SC, V76, P146; SPIELMAN A, 1988, AM J TROP MED HYG, V39, P337, DOI 10.4269/ajtmh.1988.39.337; VOLLER A, 1982, BRIT MED BULL, V38, P173, DOI 10.1093/oxfordjournals.bmb.a071755; 1977, FLUORESCENT ANTIBODY, P95	10	98	112	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 26	1991	337	8735					200	202		10.1016/0140-6736(91)92159-Y	http://dx.doi.org/10.1016/0140-6736(91)92159-Y			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU924	1670842				2022-12-01	WOS:A1991EU92400004
J	MESSINEZY, M; AUBRY, S; OCONNELL, G; TREACHER, DF; PEARSON, TC				MESSINEZY, M; AUBRY, S; OCONNELL, G; TREACHER, DF; PEARSON, TC			OXYGEN DESATURATION IN APPARENT AND RELATIVE POLYCYTHEMIA	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,SLEEP LAB,LONDON SE1 7EH,ENGLAND; ST THOMAS HOSP,DEPT MED,LUNG FUNCT LAB,LONDON SE1 7EH,ENGLAND	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	MESSINEZY, M (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DIV HAEMATOL,ST THOMASS CAMPUS,LONDON SE1 7EH,ENGLAND.							BERLIN NI, 1975, SEMIN HEMATOL, V12, P339; ECKSTEIN JW, 1960, J LAB CLIN MED, V56, P847; MESSINEZY M, 1990, CLIN LAB HAEMATOL, V12, P121, DOI 10.1111/ijlh.1990.12.2.121; MOOREGILLON JC, 1986, BRIT MED J, V293, P588, DOI 10.1136/bmj.293.6547.588; PEARSON TC, 1984, CLIN LAB HAEMATOL, V6, P207	5	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					216	217		10.1136/bmj.302.6770.216	http://dx.doi.org/10.1136/bmj.302.6770.216			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998762	Green Published, Bronze			2022-12-01	WOS:A1991EV22800026
J	PETERS, BS; BECK, EJ; COLEMAN, DG; WADSWORTH, MJH; MCGUINNESS, O; HARRIS, JRW; PINCHING, AJ				PETERS, BS; BECK, EJ; COLEMAN, DG; WADSWORTH, MJH; MCGUINNESS, O; HARRIS, JRW; PINCHING, AJ			CHANGING DISEASE PATTERNS IN PATIENTS WITH AIDS IN A REFERRAL CENTER IN THE UNITED-KINGDOM - THE CHANGING FACE OF AIDS	BRITISH MEDICAL JOURNAL			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; TRIMETHOPRIM; EXPERIENCE; EFFICACY; SURVIVAL	Objective-To study the changes in morbidity, mortality, and survival patterns in a population of patients with AIDS in the United Kingdom from 1982 to 1989. Design-A retrospective analysis of inpatient and outpatient records of patients with AIDS. Subjects-347 Patients with AIDS, predominantly homosexual or bisexual men. Setting-Department of immunology and genitourinary medicine, St Mary's Hospital, London. Main outcome measures-Presenting diagnosis of AIDS, occurrence of other opportunist diseases, cause of death, and survival since AIDS was diagnosed, in particular for those patients with Pneumocystis carinii pneumonia or Kaposi's sarcoma. Results-The overall proportion of patients who developed P carinii pneumonia dropped from 56% (20/36) in 1984 to 24% (46/194) in 1989, although it has remained the index diagnosis in about half of new patients. Kaposi's sarcoma has decreased as index diagnosis from 30% (20/67) to 20% (15/74) over the same period, though the prevalance has remained constant at around 35%. P carinii pneumonia accounted for 46% (16/35) of known causes of death in 1986 but only 3% (1/31) in 1989. Conversely, deaths due to Kaposi's sarcoma rose from 14% (1/7) to 32% (10/31) between 1984 and 1989. Lymphoma accounted for an increased proportion of deaths among these patients with 16% (5/31) of deaths in 1989. Their median survival increased from 10 months in 1984-6 to 20 months in 1987. Conclusions-The changing patterns of disease in patients with AIDS have important implications both for health care provision and future medical research. Medical and nursing provision must be made for the increased morbidity of these diseases and the increased survival of these patients. Research should now be directed towards developing effective treatments for the opportunist infections which are currently more difficult to treat, the secondary malignancies of AIDS, as well as more effective immunorestorative treatments. Future changes in disease patterns must be recognised at an early stage so that resources can be adequately planned and allocated.	ST MARYS HOSP,SCH MED,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED,LONDON W2 1PG,ENGLAND	Imperial College London; Imperial College London	PETERS, BS (corresponding author), ST MARYS HOSP,SCH MED,DEPT IMMUNOL,LONDON W2 1PG,ENGLAND.							ARMITAGE P, 1987, STATISTICAL METHODS, P429; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GARDNER TD, 1989, J INFECTION, V18, P111, DOI 10.1016/S0163-4453(89)91038-4; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; LEOUNG GS, 1986, ANN INTERN MED, V105, P45, DOI 10.7326/0003-4819-105-1-45; MACFADDEN DK, 1987, LANCET, V1, P1477, DOI 10.1016/S0140-6736(87)92219-7; PENN I, 1986, PROG ALLERGY, V37, P259; PETERS BS, 1990, LANCET, V335, P545, DOI 10.1016/0140-6736(90)90782-Z; PETERS BS, 1990, AIDS, V4, P367, DOI 10.1097/00002030-199004000-00016; PETERS BS, IN PRESS Q J MED; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; RUTHERFORD GW, 1989, J INFECT DIS, V159, P567; SELIK RM, 1987, AIDS, V1, P175; STAMBUK D, 1989, Q J MED, V262, P161; SWART AM, 1990, BRIT MED J, V301, P825, DOI 10.1136/bmj.301.6756.825; THOMAS S, 1990, BRIT MED J, V300, P211, DOI 10.1136/bmj.300.6719.211; 1987, MMWR S1S, V36, pS1	21	160	160	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					203	207		10.1136/bmj.302.6770.203	http://dx.doi.org/10.1136/bmj.302.6770.203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998759	Bronze, Green Published			2022-12-01	WOS:A1991EV22800023
J	THOMAS, KJ; CARR, J; WESTLAKE, L; WILLIAMS, BT				THOMAS, KJ; CARR, J; WESTLAKE, L; WILLIAMS, BT			USE OF NON-ORTHODOX AND CONVENTIONAL HEALTH-CARE IN GREAT-BRITAIN	BRITISH MEDICAL JOURNAL			English	Article							MEDICINE	Objective-To describe the characteristics of patients using non-orthodox health care and their pattern of use of conventional health care with respect to a particular problem. Design-Postal survey of all 2152 practitioners of acupuncture, chiropractic, homoeopathy, naturopathy, and osteopathy identified from 11 national professional association registers. Patients attending a representative sample of 101 responding practitioners completed questionnaires covering demographic characteristics, presenting problems, and use of the health service. Setting-Practices of practitioners of non-orthodox health care in England, Scotland, and Wales. Subjects-Qualified, non-medical practitioners of non-orthodox health care working in Great Britian and 2473 patients who had attended one of the sampled practitioners in an allocated time period between August 1987 and July 1988. Results-An estimated 1909 practitioners were actively practising one of the study treatments in Great Britian in 1987. Of the estimated 70 600 patients seen by this group of practitioners in an average week, most (78%) were attending with a musculoskeletal problem. Two thirds of the patients were women. Only 2% were aged under 16, but 15% were aged 65 or over. One in three patients had not received previous conventional care for their main problem; 18% were receiving concurrent non-orthodox and conventional care. Twenty two per cent of the patients reported having seen their general practitioner for any reason in the two weeks before the surveyed consultation. Conclusions-Patients of non-orthodox health care, as provided by this group of practitioners, had not turned their backs on conventional health care. Non-orthodox treatment was sought for a limited range of problems and used most frequently as a supplement to orthodox medicine.			THOMAS, KJ (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PUBL HLTH MED,MED CARE RES UNIT,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							DAVIES P, 1987, REPORT TRENDS COMPLE; FULDER SJ, 1986, LANCET, V2, P542; INGLIS B, 1985, LANCET, V1, P95; MURRAY J, 1988, J ROY COLL GEN PRACT, V38, P511; Wood M, 1987, ICPC INT CLASSIFICAT; 1984, GENERAL HOUSEHOLD SU; 1987, PROFESSIONAL CONDUCT; 1986, WHICH            OCT, P443; 1986, ALTERNATIVE THERAPIE	9	159	160	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					207	210		10.1136/bmj.302.6770.207	http://dx.doi.org/10.1136/bmj.302.6770.207			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EV228	1998760	Green Published, Bronze			2022-12-01	WOS:A1991EV22800024
J	CELANDER, DW; CECH, TR				CELANDER, DW; CECH, TR			VISUALIZING THE HIGHER-ORDER FOLDING OF A CATALYTIC RNA MOLECULE	SCIENCE			English	Article							SELF-SPLICING RNA; GROUP-I INTRONS; NUCLEAR MAGNETIC-RESONANCE; PHENYLALANINE TRANSFER-RNA; TETRAHYMENA RIBOZYME; ENDORIBONUCLEASE ACTIVITY; INTERVENING SEQUENCE; TERTIARY STRUCTURE; BINDING-SITE; PROTEIN	The higher order folding process of the catalytic RNA derived from the self-splicing intron of Tetrahymena thermophila was monitored with the use of Fe(II)-EDTA-induced free radical chemistry. The overall tertiary structure of the RNA molecule forms cooperatively with the uptake of at least three magnesium ions. Local folding transitions display different metal ion dependencies, suggesting that the RNA tertiary structure assembles through a specific folding intermediate before the catalytic core is formed. Enzymatic activity, assayed with an RNA substrate that is complementary to the catalytic RNA active site, coincides with the cooperative structural transition. The higher order RNA foldings produced by Mg(II), Ca(II), and Sr(II) are similar; however, only the Mg(II)-stabilized RNA is catalytically active. Thus, these results directly demonstrate that divalent metal ions participate in general folding of the ribozyme tertiary structure, and further indicate a more specific involvement of Mg(II) in catalysis.			CELANDER, DW (corresponding author), UNIV COLORADO, DEPT CHEM & BIOCHEM, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA.							ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; [Anonymous], COMMUNICATION; BEAUDRY AA, 1990, BIOCHEMISTRY-US, V29, P6534, DOI 10.1021/bi00479a027; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEEN MD, 1987, COLD SPRING HARB SYM, V52, P147, DOI 10.1101/SQB.1987.052.01.019; BOGUSKI MS, 1980, J BIOL CHEM, V255, P2160; BOYLE J, 1980, J MOL BIOL, V139, P601, DOI 10.1016/0022-2836(80)90051-0; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; BURKE JM, 1988, GENE, V73, P273, DOI 10.1016/0378-1119(88)90493-3; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, UNPUB; CHANDRY S, COMMUNICATION; Creighton TE, 1983, PROTEINS STRUCTURES; CROTHERS DM, 1979, COLD SPRING HARBOR A, V9, P163; DANCHIN A, 1972, BIOCHIMIE, V54, P333, DOI 10.1016/S0300-9084(72)80212-8; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; DOUDNA JA, 1989, MOL CELL BIOL, V9, P5480, DOI 10.1128/MCB.9.12.5480; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; FLOR PJ, 1989, EMBO J, V8, P3391, DOI 10.1002/j.1460-2075.1989.tb08503.x; FRESCO JR, 1966, COLD SPRING HARB SYM, V31, P527, DOI 10.1101/SQB.1966.031.01.068; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERSCHLAG D, COMMUNICATION; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HEUER T, UNPUB; HOLBROOK SR, 1977, NUCLEIC ACIDS RES, V4, P2811, DOI 10.1093/nar/4.8.2811; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; JAEGER JA, 1990, BIOCHEMISTRY-US, V29, P10147, DOI 10.1021/bi00496a002; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JEZEWSKA MJ, 1990, BIOCHEMISTRY-US, V29, P5220, DOI 10.1021/bi00473a032; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; KAYNE MS, 1972, BIOCHEM BIOPH RES CO, V46, P1285; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.bi.59.070190.003215; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; NAZAR RN, COMMUNICATION; PACE NR, 1990, J BIOL CHEM, V265, P3587; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; QUIGLEY GJ, 1978, P NATL ACAD SCI USA, V75, P64, DOI 10.1073/pnas.75.1.64; ROBILLARD GT, 1977, BIOCHEMISTRY-US, V16, P5261, DOI 10.1021/bi00643a016; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; SZOSTAK JW, 1986, NATURE, V322, P83, DOI 10.1038/322083a0; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; TULLIUS TD, 1985, SCIENCE, V230, P679, DOI 10.1126/science.2996145; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANDERHORST G, IN PRESS P NATL ACAD; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WILLIAMS AP, 1989, BIOCHEMISTRY-US, V28, P4283, DOI 10.1021/bi00436a025; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	69	346	355	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 25	1991	251	4992					401	407		10.1126/science.1989074	http://dx.doi.org/10.1126/science.1989074			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1989074				2022-12-01	WOS:A1991EU50400034
J	GOBER, JW; CHAMPER, R; REUTER, S; SHAPIRO, L				GOBER, JW; CHAMPER, R; REUTER, S; SHAPIRO, L			EXPRESSION OF POSITIONAL INFORMATION DURING CELL-DIFFERENTIATION IN CAULOBACTER	CELL			English	Article							GRAM-NEGATIVE BACTERIA; GENE-EXPRESSION; FLAGELLAR GENE; BACILLUS-SUBTILIS; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; PROTOPLAST FUSION; ESCHERICHIA-COLI; SPATIAL CONTROL; CRESCENTUS	The asymmetric targeting of proteins to the Caulobacter predivisional cell poles yields dissimilar progeny. We show that the products of transcriptional reporter gene fusions to a flagellin gene and to the flagellar hook operon are segregated to the progeny swarmer cell. This segregation does not depend on sequences within the mRNA, but on the upstream regulatory region. The subset of developmentally regulated flagellar genes that exhibit mRNA segregation has the same upstream cis-acting elements: an activator-binding site known as the ftr sequence and an IHF-binding site. We propose that these genes are preferentially transcribed from the chromosome in the incipient swarmer cell pole of the predivisional cell.			GOBER, JW (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032506, R01GM032506] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32506] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLOFATTO V, 1984, P NATL ACAD SCI-BIOL, V81, P1035, DOI 10.1073/pnas.81.4.1035; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; CHAMPER R, 1985, COLD SPRING HARB SYM, V50, P831, DOI 10.1101/SQB.1985.050.01.101; CHAMPER R, 1987, J MOL BIOL, V194, P71, DOI 10.1016/0022-2836(87)90716-9; CHEN LS, 1986, P NATL ACAD SCI USA, V83, P2860, DOI 10.1073/pnas.83.9.2860; CONTRERAS I, 1978, J BACTERIOL, V135, P1130, DOI 10.1128/JB.135.3.1130-1136.1978; COOK WR, 1986, J BACTERIOL, V168, P1430, DOI 10.1128/jb.168.3.1430-1438.1986; DINGWALL A, 1990, J BACTERIOL, V172, P6066, DOI 10.1128/jb.172.10.6066-6076.1990; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; EVINGER M, 1979, P NATL ACAD SCI USA, V76, P175, DOI 10.1073/pnas.76.1.175; EVINGER M, 1977, J BACTERIOL, V132, P294, DOI 10.1128/JB.132.1.294-301.1977; FUJITA Y, 1977, J BACTERIOL, V132, P282, DOI 10.1128/JB.132.1.282-293.1977; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOBER JW, 1990, IN PRESS J MOL BIOL; GOMES SL, 1990, J BACTERIOL, V172, P3051, DOI 10.1128/jb.172.6.3051-3059.1990; GOMES SL, 1984, J MOL BIOL, V178, P551, DOI 10.1016/0022-2836(84)90238-9; GUILLEN N, 1982, MOL GEN GENET, V185, P69, DOI 10.1007/BF00333792; HIROOKA T, 1987, J BACTERIOL, V169, P1529, DOI 10.1128/jb.169.4.1529-1536.1987; HOTCHKISS RD, 1980, P NATL ACAD SCI-BIOL, V77, P3553, DOI 10.1073/pnas.77.6.3553; KAPLAN JB, 1989, J MOL BIOL, V205, P71, DOI 10.1016/0022-2836(89)90365-3; KARMAZYNCAMPELLI C, 1989, GENE DEV, V3, P150, DOI 10.1101/gad.3.2.150; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; KUNKEL B, 1990, GENE DEV, V4, P525, DOI 10.1101/gad.4.4.525; KUNKEL B, 1988, J BACTERIOL, V170, P3513, DOI 10.1128/jb.170.8.3513-3522.1988; KUNKEL B, 1989, GENE DEV, V3, P1735, DOI 10.1101/gad.3.11.1735; LEHEGARAT E, 1978, SPORES, V7, P193; LOEWY ZG, 1987, GENE DEV, V1, P626, DOI 10.1101/gad.1.6.626; MACALISTER TJ, 1983, P NATL ACAD SCI-BIOL, V80, P1372, DOI 10.1073/pnas.80.5.1372; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; Maniatis T., 1982, MOL CLONING; MARCZYNSKI GT, 1990, J MOL BIOL, V212, P709, DOI 10.1016/0022-2836(90)90232-B; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MILHAUSEN M, 1983, NATURE, V302, P630, DOI 10.1038/302630a0; MINNICH SA, 1987, P NATL ACAD SCI USA, V84, P1142, DOI 10.1073/pnas.84.5.1142; MULLIN D, 1987, J MOL BIOL, V195, P939, DOI 10.1016/0022-2836(87)90497-9; MULLIN DA, 1989, J BACTERIOL, V171, P3218, DOI 10.1128/jb.171.6.3218-3227.1989; NATHAN P, 1986, J MOL BIOL, V191, P433, DOI 10.1016/0022-2836(86)90138-5; NICHOLSON WL, 1990, J BACTERIOL, V172, P7, DOI 10.1128/JB.172.1.7-14.1990; OHTA N, 1985, J MOL BIOL, V186, P107, DOI 10.1016/0022-2836(85)90261-X; POINDEXTER JS, 1964, BACTERIOL REV, V28, P231, DOI 10.1128/MMBR.28.3.231-295.1964; RATHER PN, 1988, J BACTERIOL, V170, P5086, DOI 10.1128/jb.170.11.5086-5092.1988; REUTER SH, 1987, J MOL BIOL, V194, P653, DOI 10.1016/0022-2836(87)90242-7; SHAPIRO L, 1982, J MOL BIOL, V159, P303, DOI 10.1016/0022-2836(82)90497-1; SHAPIRO L, 1989, J CELL SCI, P85; SHEFFERY M, 1981, CELL, V24, P49, DOI 10.1016/0092-8674(81)90500-6; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; SWOBODA UK, 1982, J GEN MICROBIOL, V128, P291; WADA M, 1988, J MOL BIOL, V204, P581, DOI 10.1016/0022-2836(88)90357-9; XU H, 1989, P NATL ACAD SCI USA, V86, P6656, DOI 10.1073/pnas.86.17.6656	50	63	63	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	1991	64	2					381	391		10.1016/0092-8674(91)90646-G	http://dx.doi.org/10.1016/0092-8674(91)90646-G			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1988153				2022-12-01	WOS:A1991EV33600014
J	HANES, SD; BRENT, R				HANES, SD; BRENT, R			A GENETIC MODEL FOR INTERACTION OF THE HOMEODOMAIN RECOGNITION HELIX WITH DNA	SCIENCE			English	Article							DROSOPHILA EMBRYO; TRANSCRIPTIONAL ACTIVATOR; ANTENNAPEDIA HOMEODOMAIN; BINDING-SPECIFICITY; ANTERIOR PATTERN; LAMBDA-REPRESSOR; BICOID PROTEIN; AMINO-ACID; SEQUENCE; OPERATOR	The Bicoid homeodomain protein controls anterior development in the Drosophila embryo by binding to DNA and regulating gene expression. With the use of genetic assays in yeast, the interaction between the Bicoid homeodomain and a series of mutated DNA sites was studied. These experiments defined important features of homeodomain binding sites, identified specific amino acid-base pair contacts, and suggested a model for interaction of the recognition alpha-helices of Bicoid and Antennapedia-class homeodomain proteins with DNA. The model is in general agreement with results of crystallographic and magnetic resonance studies, but differs in important details. It is likely that genetic studies of protein-DNA interaction will continue to complement conventional structural approaches.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	HANES, SD (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HANES SD, UNPUB; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HOCHSCHILD A, 1986, CELL, V44, P925, DOI 10.1016/0092-8674(86)90015-2; HOCHSCHILD A, 1986, CELL, V47, P807, DOI 10.1016/0092-8674(86)90523-4; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HORTON RM, 1990, BIOTECHNIQUES, V8, P538; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEHMING N, 1987, EMBO J, V6, P3145, DOI 10.1002/j.1460-2075.1987.tb02625.x; LEHMING N, 1990, NATURE, V9, P615; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; OHLENDORF DH, 1982, NATURE, V298, P718, DOI 10.1038/298718a0; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; SAMSON ML, 1989, CELL, V57, P1145; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STAACKE D, 1990, EMBO J, V9, P1963, DOI 10.1002/j.1460-2075.1990.tb08324.x; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TREISMAN J, 1989, CELL, V59, P553; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0	41	201	206	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					426	430		10.1126/science.1671176	http://dx.doi.org/10.1126/science.1671176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1671176				2022-12-01	WOS:A1991EU50400040
J	HARDING, CV; COLLINS, DS; SLOT, JW; GEUZE, HJ; UNANUE, ER				HARDING, CV; COLLINS, DS; SLOT, JW; GEUZE, HJ; UNANUE, ER			LIPOSOME-ENCAPSULATED ANTIGENS ARE PROCESSED IN LYSOSOMES, RECYCLED, AND PRESENTED TO T-CELLS	CELL			English	Article							PH-SENSITIVE LIPOSOMES; MACROPHAGE ENDOSOMES; PINOCYTOSED FLUID; PROTEIN; ENDOCYTOSIS; EXCHANGE; MEMBRANE; BINDING; PEPTIDE; IA	Antigen processing required intracellular antigen catabolism to generate immunogenic peptides that bind to class II MHC molecules (MHC-II) for presentation to T-cells. We now provide direct evidence that these peptides are produced within dense lysosomes, as opposed to earlier endocytic compartments. The protein antigen hen egg lysozyme was targeted to endosomes or lysosomes by encapsulating it in liposomes of different membrane composition. Acid-sensitive liposomes released their contents in early endosomes, whereas acid-resistant liposomes sequestered their contents from potential endosomal processing events and released their contents only after delivery to lysosomes. Antigen encapsulated in acid-resistant liposomes was processed in a chloroquine-sensitive manner and presented more efficiently than soluble antigen or antigen encapsulated in acid-sensitive liposomes. Thus, peptides may be recycled from lysosomes, transported to endosomes to bind MHC-II, and then expressed at the cell surface.	STATE UNIV UTRECHT, SCH MED, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS	Utrecht University	HARDING, CV (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA.							ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; ALLEN PM, 1984, J IMMUNOL, V132, P1077; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BUCKMASTER MJ, 1987, CELL BIOL INT REP, V11, P501, DOI 10.1016/0309-1651(87)90011-7; COLLINS D, 1989, BIOCHIM BIOPHYS ACTA, V987, P47, DOI 10.1016/0005-2736(89)90453-7; CONNOR J, 1984, P NATL ACAD SCI-BIOL, V81, P1715, DOI 10.1073/pnas.81.6.1715; DALEKE DL, 1990, BIOCHIM BIOPHYS ACTA, V1024, P352, DOI 10.1016/0005-2736(90)90365-U; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DONERMEYER DL, 1989, J IMMUNOL, V142, P1063; DUZGUNES N, 1985, BIOCHEMISTRY-US, V24, P3091, DOI 10.1021/bi00334a004; FERRIS AL, 1987, J CELL BIOL, V105, P2703, DOI 10.1083/jcb.105.6.2703; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARDING CV, 1990, CELL REGUL, V1, P499, DOI 10.1091/mbc.1.7.499; HARDING CV, 1990, EUR J IMMUNOL, V20, P323, DOI 10.1002/eji.1830200214; HARDING CV, 1989, J IMMUNOL, V142, P12; LEYVACOBIAN F, 1988, J IMMUNOL, V141, P1445; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; MAYORGA LS, 1989, J BIOL CHEM, V264, P5392; MONTE PD, 1989, J IMMUNOL, V142, P1437; MULLER WA, 1983, J CELL BIOL, V96, P29, DOI 10.1083/jcb.96.1.29; ROOF RW, 1990, P NATL ACAD SCI USA, V87, P1735, DOI 10.1073/pnas.87.5.1735; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; STRAUBINGER RM, 1983, CELL, V32, P1069, DOI 10.1016/0092-8674(83)90291-X; STRUCK O, 1981, BIOCHEMISTRY-US, V23, P1532; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; YATVIN MB, 1980, SCIENCE, V210, P1253, DOI 10.1126/science.7434025	32	257	263	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	1991	64	2					393	401		10.1016/0092-8674(91)90647-H	http://dx.doi.org/10.1016/0092-8674(91)90647-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1899049				2022-12-01	WOS:A1991EV33600015
J	HARDY, SJS; RANDALL, LL				HARDY, SJS; RANDALL, LL			A KINETIC PARTITIONING MODEL OF SELECTIVE BINDING OF NONNATIVE PROTEINS BY THE BACTERIAL CHAPERONE SECB	SCIENCE			English	Article							ESCHERICHIA-COLI SECB; MEMBRANE TRANSLOCATION; TRYPTOPHAN-SYNTHETASE; TRIGGER FACTOR; EXPORT; SEQUENCE; INVITRO; PRECURSOR; GROEL; GENE	An in vitro assay for the interaction of SecB, a molecular chaperone from Escherichia coli, with polypeptide ligands was established based on the ability of SecB to block the refolding of denatured maltose-binding protein. Competition experiments show that SecB binds selectively to nonnative proteins with high affinity and without specificity for a particular sequence of amino acids. It is proposed that selectivity in binding is due to a kinetic partitioning of polypeptides between folding and association with SecB.	WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164	Washington State University								ADACHI O, 1974, J BIOL CHEM, V249, P7756; ANDERER FA, 1966, J BIOL CHEM, V241, P1568; BAGSHAW CR, 1987, SPECTROPHOTOMETRY SP, P109; BEASTY AM, 1985, BIOCHEMISTRY-US, V24, P3547, DOI 10.1021/bi00335a024; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUPLAY P, 1984, J BIOL CHEM, V259, P606; ELLIS RJ, 1988, PHOTOSYNTH RES, V16, P101, DOI 10.1007/BF00039488; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; Fersht A., 1985, ENZYME STRUCTURE MEC; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GANNON PM, 1989, J BACTERIOL, V171, P813, DOI 10.1128/jb.171.2.813-818.1989; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GROARKE JM, 1983, J BIOL CHEM, V258, P2952; HAGERMAN PJ, 1976, BIOCHEMISTRY-US, V15, P1462, DOI 10.1021/bi00652a017; HARTL FU, IN PRESS CELL; HIRS CHW, 1960, J BIOL CHEM, V235, P633; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1989, GENE, V75, P167, DOI 10.1016/0378-1119(89)90393-4; KUMAMOTO CA, 1989, J BIOL CHEM, V264, P2242; KUMAMOTO CA, UNPUB; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LAMINET AA, IN PRESS EMBO J; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LI SH, 1972, J BIOL CHEM, V247, P1031; LIU G, 1988, J BIOL CHEM, V263, P14790; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; Randall L., UNPUB; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; TESCHKE CM, UNPUB; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; WEIS SJB, 1990, J BACTERIOL, V172, P3023; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1989, TRENDS BIOCHEM SCI, V14, P280, DOI 10.1016/0968-0004(89)90064-9; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	56	202	205	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					439	443		10.1126/science.1989077	http://dx.doi.org/10.1126/science.1989077			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1989077				2022-12-01	WOS:A1991EU50400045
J	LEE, TH; SOLOMON, MJ; MUMBY, MC; KIRSCHNER, MW				LEE, TH; SOLOMON, MJ; MUMBY, MC; KIRSCHNER, MW			INH, A NEGATIVE REGULATOR OF MPF, IS A FORM OF PROTEIN PHOSPHATASE-2A	CELL			English	Article							MATURATION-PROMOTING FACTOR; XENOPUS-LAEVIS OOCYTES; RABBIT SKELETAL-MUSCLE; CYCLIN MESSENGER-RNA; CELL-CYCLE; OKADAIC ACID; CDC2 PROTEIN; CYTOPLASMIC FACTOR; KINASE; PURIFICATION	MPF, a protein kinase complex consisting of cyclin and p34cdc2 subunits, promotes the G2 to M phase transition in eukaryotic cells. The pathway of activation and inactivation of MPF is not well understood, although there is strong evidence that removal of phosphate from a tyrosine residue on p34cdc2 is part of the activation process. INH was originally identified as an activity that could inhibit the posttranslational activation of a latent form of MPF, called pre-MPF, in immature (G2 phase-arrested) Xenopus oocytes. We have purified INH and demonstrated that it is a form of protein phosphatase 2A. Both INH and the catalytic subunit of protein phosphatase 2A can directly inactivate an isolated p34cdc2-cyclin complex. Both cyclin and p34cdc2 become dephosphorylated; the rate of inactivation closely parallels the removal of phosphate from a specific site on p34cdc2. We propose that INH opposes MPF activation by reversing this critical phosphorylation.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LEE, TH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31107] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HERMANN J, 1988, EUR J BIOCHEM, V173, P17, DOI 10.1111/j.1432-1033.1988.tb13961.x; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MEIJER L, 1986, EXP CELL RES, V163, P489, DOI 10.1016/0014-4827(86)90079-0; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORIA AO, 1989, CELL, V58, P193; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PONDAVEN P, 1989, CR ACAD SCI III-VIE, V309, P563; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1	41	227	230	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 25	1991	64	2					415	423		10.1016/0092-8674(91)90649-J	http://dx.doi.org/10.1016/0092-8674(91)90649-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1846321				2022-12-01	WOS:A1991EV33600017
J	MARGOTTIN, F; DUJARDIN, G; GERARD, M; EGLY, JM; HUET, J; SENTENAC, A				MARGOTTIN, F; DUJARDIN, G; GERARD, M; EGLY, JM; HUET, J; SENTENAC, A			PARTICIPATION OF THE TATA FACTOR IN TRANSCRIPTION OF THE YEAST U6 GENE BY RNA POLYMERASE-C	SCIENCE			English	Article							III TRANSCRIPTION; UPSTREAM PROMOTER; BINDING-PROTEIN; SEQUENCES; SNRNA; DNA; BOX; SUBSTITUTE; ELEMENTS; INVITRO	Fractionation of transcription extracts has led to the identification of multiple transcription factors specific for each form of nuclear RNA polymerase. Accurate transcription in vitro of the yeast U6 RNA gene by RNA polymerase C requires at least two factors. One of them was physically and functionally indistinguishable from transcription factor IID (TFIID or BTFI), a pivotal component of polymerase B transcription complexes, which binds to the TATA element. Purified yeast TFIID (yIID) or bacterial extracts that contained recombinant yIID were equally competent to direct specific transcription of the U6 gene by RNA polymerase C. The results suggest the formation of a hybrid transcription machinery, which may imply an evolutionary relation between class B and class C transcription factors.	CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	MARGOTTIN, F (corresponding author), CENS,DEPT BIOL,SERV BIOCHIM,F-91191 GIF SUR YVETTE,FRANCE.		Margottin-Goguet, Florence/F-9272-2013; GERARD, Matthieu/D-2235-2014	Margottin-Goguet, Florence/0000-0002-3124-6690; GERARD, Matthieu/0000-0001-8956-0597				BARK C, 1987, NATURE, V328, P356, DOI 10.1038/328356a0; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KLEINERT H, 1988, NUCLEIC ACIDS RES, V16, P1319, DOI 10.1093/nar/16.4.1319; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KUNKEL GR, 1989, NUCLEIC ACIDS RES, V17, P7371, DOI 10.1093/nar/17.18.7371; LEE DI, 1989, J BIOCHEM-TOKYO, V105, P526, DOI 10.1093/oxfordjournals.jbchem.a122700; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; MANIATIS T, 1983, MOL CLONING; MARGOTTIN F, UNPUB; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MEMET S, 1988, J BIOL CHEM, V263, P10048; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SOLLNERWEBB B, 1988, CELL, V52, P153, DOI 10.1016/0092-8674(88)90500-4; WAIBEL G, 1990, NUCLEIC ACIDS RES, V18, P3451; WAIBEL G, 1990, NATURE, V346, P199	33	162	163	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					424	426		10.1126/science.1989075	http://dx.doi.org/10.1126/science.1989075			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1989075				2022-12-01	WOS:A1991EU50400039
J	MCLEAN, S; GANONG, AH; SEEGER, TF; BRYCE, DK; PRATT, KG; REYNOLDS, LS; SIOK, CJ; LOWE, JA; HEYM, J				MCLEAN, S; GANONG, AH; SEEGER, TF; BRYCE, DK; PRATT, KG; REYNOLDS, LS; SIOK, CJ; LOWE, JA; HEYM, J			ACTIVITY AND DISTRIBUTION OF BINDING-SITES IN BRAIN OF A NONPEPTIDE SUBSTANCE-P (NK1) RECEPTOR ANTAGONIST	SCIENCE			English	Article							LOCUS COERULEUS NEURONS; SPINAL-CORD; RAT; RELEASE; EXCITATION; NIGRA	CP-96,345, a nonpeptide substance P antagonist, is selective for the tachykinin NK1 receptor. The compound binds to a single population of sites in guinea pig brain and potently inhibits substance P-induced excitation of locus ceruleus neurons. CP-96,345 should be a useful tool for studying the action of substance P in the central nervous system.			MCLEAN, S (corresponding author), PFIZER INC,CENT RES DIV,DEPT NEUROSCI,GROTON,CT 06340, USA.							BANNON MJ, 1986, BRAIN RES, V381, P393, DOI 10.1016/0006-8993(86)90097-1; CHEESEMAN HJ, 1983, EUR J PHARMACOL, V94, P93, DOI 10.1016/0014-2999(83)90445-4; DAM TV, 1986, PEPTIDES, V7, P855, DOI 10.1016/0196-9781(86)90106-3; DAVIES J, 1976, BRAIN RES, V107, P623, DOI 10.1016/0006-8993(76)90150-5; DEUTCH AY, 1985, PEPTIDES, V6, P113, DOI 10.1016/0196-9781(85)90143-3; EGAN TM, 1983, J PHYSIOL-LONDON, V345, P477, DOI 10.1113/jphysiol.1983.sp014990; ELLIOTT PJ, 1986, BRAIN RES, V385, P379, DOI 10.1016/0006-8993(86)91087-5; GRAY EG, 1962, J ANAT, V96, P79; GUYENET PG, 1977, BRAIN RES, V136, P178, DOI 10.1016/0006-8993(77)90144-5; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HENRY JL, 1976, BRAIN RES, V114, P439, DOI 10.1016/0006-8993(76)90965-3; INNIS RB, 1985, BRAIN RES, V335, P381, DOI 10.1016/0006-8993(85)90499-8; LEMBECK F, 1979, N-S ARCH PHARMACOL, V310, P175, DOI 10.1007/BF00500282; LOWE J, UNPUB; LUNBERG JM, 1984, ACTA PHYSL SCAND, V120, P217; OTSUKA M, 1976, NATURE, V264, P83, DOI 10.1038/264083a0; PAYAN DG, 1989, ANNU REV MED, V40, P341; PERNOW B, 1983, PHARMACOL REV, V35, P85; RANDIC M, 1977, BRAIN RES, V128, P164, DOI 10.1016/0006-8993(77)90245-1; REGOLI D, 1987, LIFE SCI, V40, P109, DOI 10.1016/0024-3205(87)90349-3; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; TAKANO Y, 1985, LIFE SCI, V37, P2507, DOI 10.1016/0024-3205(85)90608-3; TITELER M, 1987, BIOCHEM PHARMACOL, V36, P3265, DOI 10.1016/0006-2952(87)90643-5; WORMSER U, 1986, EMBO J, V5, P2805, DOI 10.1002/j.1460-2075.1986.tb04571.x; YAKSH TL, 1980, NATURE, V286, P155, DOI 10.1038/286155a0	25	206	211	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					437	439		10.1126/science.1703324	http://dx.doi.org/10.1126/science.1703324			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1703324				2022-12-01	WOS:A1991EU50400044
J	OFFNER, H; HASHIM, GA; VANDENBARK, AA				OFFNER, H; HASHIM, GA; VANDENBARK, AA			T-CELL RECEPTOR PEPTIDE THERAPY TRIGGERS AUTOREGULATION OF EXPERIMENTAL ENCEPHALOMYELITIS	SCIENCE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; VACCINATION; RAT; SUPPRESSION; DISEASES; GENES	Encephalitogenic T cells specific for myelin basic protein share common V-beta-8 peptide sequences in their T cell receptor (TCR) that can induce autoregulatory T cells and antibodies that prevent clinical signs of experimental autoimmune encephalomyelitis (EAE). It is not known, however, if TCR peptides can treat established disease. To test its therapeutic value, TCR-V-beta-8-39-59 peptide was injected into rats with clinical signs of EAE. This treatment reduced disease severity and speeded recovery, apparently by boosting anti-V-beta-8 T cells and antibodies raised naturally in response to encephalitogenic V-beta-8+ T cells. These results demonstrate that synthetic TCR be used therapeutically, and implicate the TCR-V-beta-8-39-59 sequence as a natural idiotope involved in EAE recovery. Similarly, human TCR peptides may be effective in enhancing natural regulation of autoreactive T cells that share common V genes.	ST LUKES ROOSEVELT HOSP,DEPT MICROBIOL & SURG,NEW YORK,NY 10025; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MICROBIOL & IMMUNOL AAV,PORTLAND,OR 97201; COLUMBIA UNIV,NEW YORK,NY 10027	Mount Sinai St. Luke's; Mount Sinai West; Oregon Health & Science University; Oregon Health & Science University; Columbia University	OFFNER, H (corresponding author), VET ADM MED CTR,PORTLAND,OR 97201, USA.				NINDS NIH HHS [NS23444, NS21466, NS23221] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021466, R01NS023221, R01NS023444] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHAORBEA H, 1989, ANNU REV IMMUNOL, V7, P371, DOI 10.1146/annurev.iy.07.040189.002103; ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BERNARD CCA, 1977, CLIN EXP IMMUNOL, V29, P100; BURNS FR, 1989, J EXP MED, V169, P27, DOI 10.1084/jem.169.1.27; CHLUBA J, 1989, EUR J IMMUNOL, V19, P279, DOI 10.1002/eji.1830190210; CHOU YK, IN PRESS J NEUROSCI; ELLERMAN KE, 1988, NATURE, V331, P265, DOI 10.1038/331265a0; HASHIM GA, 1981, NEUROCHEM RES, V6, P699, DOI 10.1007/BF00963886; HASHIM GA, 1990, J IMMUNOL, V144, P4621; HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; KUMAR V, 1989, ANNU REV IMMUNOL, V7, P657, DOI 10.1146/annurev.iy.07.040189.003301; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; LOHSE AW, 1989, SCIENCE, V244, P820, DOI 10.1126/science.2471264; LYMAN WD, 1984, CELL IMMUNOL, V85, P542, DOI 10.1016/0008-8749(84)90266-1; OFFNER H, 1989, J NEUROIMMUNOL, V21, P13, DOI 10.1016/0165-5728(89)90154-9; OFFNER H, 1988, J IMMUNOL, V141, P3828; OFFNER H, 1984, J NEUROIMMUNOL, V9, P147; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; OWHASHI M, 1988, J EXP MED, V168, P2153, DOI 10.1084/jem.168.6.2153; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; VARRIALE S, 1989, J IMMUNOL, V125, P186; WELCH AM, 1980, J IMMUNOL, V125, P186; WHITHAM RH, 1990, CELL IMMUNOL, V126, P290, DOI 10.1016/0008-8749(90)90322-I; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015	28	236	271	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					430	432		10.1126/science.1989076	http://dx.doi.org/10.1126/science.1989076			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1989076				2022-12-01	WOS:A1991EU50400041
J	SILVA, LR; AMITAI, Y; CONNORS, BW				SILVA, LR; AMITAI, Y; CONNORS, BW			INTRINSIC OSCILLATIONS OF NEOCORTEX GENERATED BY LAYER-5 PYRAMIDAL NEURONS	SCIENCE			English	Article							RAT CEREBRAL-CORTEX; CAT VISUAL-CORTEX; HIPPOCAMPAL SLICE; N-METHYLASPARTATE; INVITRO; RESPONSES; RECEPTOR; TRANSMITTERS; POTENTIALS; CELLS	Rhythmic activity in the neocortex varies with different behavioral and pathological states and in some cases may encode sensory information. However, the neural mechanisms of these oscillations are largely unknown. Many pyramidal neurons in layer 5 of the neocortex showed prolonged, 5- to 12-hertz rhythmic firing patterns at threshold. Rhythmic firing was due to intrinsic membrane properties, sodium conductances were essential for rhythmicity, and calcium-dependent conductances strongly modified rhythmicity. Isolated slices of neocortex generated epochs of 4- to 10-hertz synchronized activity when N-methyl-D-aspartate receptor-mediated channels were facilitated. Layer 5 was both necessary and sufficient to produce these synchronized oscillations. Thus, synaptic networks of intrinsically rhythmic neurons in layer 5 may generate or promote certain synchronized oscillations of the neocortex.	BROWN UNIV,DIV BIOL & MED,NEUROBIOL SECT,PROVIDENCE,RI 02912	Brown University			Connors, Barry/AAX-1975-2020; Amitai, Yael/G-2791-2013	Connors, Barry/0000-0002-3739-3157; Amitai, Yael/0000-0001-6664-8705				AGMON A, 1989, NEUROSCI LETT, V99, P137, DOI 10.1016/0304-3940(89)90278-4; ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; ALVING BO, 1968, J GEN PHYSIOL, V51, P29, DOI 10.1085/jgp.51.1.29; ANDERSON WW, 1986, BRAIN RES, V398, P215, DOI 10.1016/0006-8993(86)91274-6; ARMSTRONGJAMES M, 1988, BRAIN RES, V451, P189, DOI 10.1016/0006-8993(88)90763-9; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149, DOI 10.1152/jn.1989.62.5.1149; CHAGNACAMITAL Y, 1990, J COMP NEUROL, V296, P598, DOI 10.1002/cne.902960407; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; CONNORS BW, 1984, NATURE, V310, P685, DOI 10.1038/310685a0; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FREEMAN WJ, 1985, BRAIN RES REV, V10, P147, DOI 10.1016/0165-0173(85)90022-0; FREEMAN WJ, 1988, BRAIN RES, V422, P627; GETTING PA, 1989, METHODS NEURONAL MOD, P171; GORMAN ALF, 1982, J PHYSIOL-LONDON, V333, P681, DOI 10.1113/jphysiol.1982.sp014475; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GRILLNER S, 1987, TRENDS NEUROSCI, V10, P34, DOI 10.1016/0166-2236(87)90123-8; GUTNICK MJ, 1982, J NEUROPHYSIOL, V48, P1321, DOI 10.1152/jn.1982.48.6.1321; HAGIWARA S, 1983, TRENDS NEUROSCI, V6, P189, DOI 10.1016/0166-2236(83)90084-X; HEGSTAD E, 1989, EPILEPSY RES, V3, P174, DOI 10.1016/0920-1211(89)90046-6; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; JONES KA, 1988, J NEUROSCI, V8, P3522; Kooi K., 1978, FUNDAMENTALS ELECTRO; KRISTIANSEN K, 1949, ELECTROEN CLIN NEURO, V1, P265, DOI 10.1016/0013-4694(49)90191-1; LLINAS R, 1989, Society for Neuroscience Abstracts, V15, P660; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; Lopes da Silva F.H., 1978, ARCHITECTONICS CEREB, P319; LOTURCO JJ, 1990, NEUROSCI LETT, V114, P265, DOI 10.1016/0304-3940(90)90574-S; MASON A, 1990, J NEUROSCI, V10, P1415; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; SCHWINDT PC, 1989, J NEUROPHYSIOL, V61, P233, DOI 10.1152/jn.1989.61.2.233; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P424, DOI 10.1152/jn.1988.59.2.424; STANTON PK, 1987, EPILEPSY RES, V1, P53, DOI 10.1016/0920-1211(87)90051-9; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; SUTOR B, 1987, PFLUG ARCH EUR J PHY, V410, P102, DOI 10.1007/BF00581902; SUTOR B, 1989, J NEUROPHYSIOL, V61, P621, DOI 10.1152/jn.1989.61.3.621; THOMSON AM, 1986, J PHYSIOL-LONDON, V370, P531, DOI 10.1113/jphysiol.1986.sp015949; THOMSON AM, 1985, NATURE, V313, P479, DOI 10.1038/313479a0; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; YAROM Y, 1989, EXPT BRAIN RES SERIE, V17, P209	43	535	540	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					432	435		10.1126/science.1824881	http://dx.doi.org/10.1126/science.1824881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1824881				2022-12-01	WOS:A1991EU50400042
J	SNIDER, RM; CONSTANTINE, JW; LOWE, JA; LONGO, KP; LEBEL, WS; WOODY, HA; DROZDA, SE; DESAI, MC; VINICK, FJ; SPENCER, RW; HESS, HJ				SNIDER, RM; CONSTANTINE, JW; LOWE, JA; LONGO, KP; LEBEL, WS; WOODY, HA; DROZDA, SE; DESAI, MC; VINICK, FJ; SPENCER, RW; HESS, HJ			A POTENT NONPEPTIDE ANTAGONIST OF THE SUBSTANCE-P (NK1) RECEPTOR	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; SELECTIVE AGONISTS; TACHYKININS; ACTIVATION; SECRETION; NEURONS; BINDING; TISSUE	CP-96,345 [(2S, 3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-azabicyclo[2.2.2]octan-3-amine] is a potent neopeptide antagonist of the substance P (NK1) receptor. CP-96,345 inhibited H-3-labeled substance P binding and was a classical competitive antagonist in the NK1 monoreceptor dog carotid artery preparation. CP-96,345 inhibited substance P-induced salivation in the rat, a classical in vivo bioassay, but did not inhibit NK2, NK3, or numerous other receptors; it is thus a selective NK1 antagonist. This compound may prove to be a powerful tool for investigation of the physiological properties of substance P and exploration of its role in diseases.			SNIDER, RM (corresponding author), PFIZER INC,CENT RES DIV,DEPT EXPLORATORY MED CHEM,GROTON,CT 06340, USA.							ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BUCK SH, 1986, TRENDS PHARMACOL SCI, V7, P65, DOI 10.1016/0165-6147(86)90256-7; CHANG MM, 1970, J BIOL CHEM, V245, P4784; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONSTANTINE JW, IN PRESS NAUNYNSCHMI; ENBERG G, 1981, NATURE, V293, P222; GIULIANI S, 1988, EUR J PHARMACOL, V150, P377, DOI 10.1016/0014-2999(88)90022-2; HARTUNG HP, 1986, J IMMUNOL, V136, P3856; HOKFELT T, 1975, SCIENCE, V190, P889, DOI 10.1126/science.242075; LEEMAN SE, 1967, ENDOCRINOLOGY, V81, P803, DOI 10.1210/endo-81-4-803; LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MANTYH PW, 1984, NATURE, V309, P795, DOI 10.1038/309795a0; MELCHIORRI P, 1977, NOBEL S, V37, P311; NICOLL RA, 1980, ANNU REV NEUROSCI, V3, P227, DOI 10.1146/annurev.ne.03.030180.001303; NILSSON G, 1974, MED BIOL, V52, P424; PAYAN DG, 1984, J CLIN INVEST, V74, P1532, DOI 10.1172/JCI111567; PERIANIN A, 1989, BIOCHEM BIOPH RES CO, V161, P520, DOI 10.1016/0006-291X(89)92630-2; PERNOW B, 1975, ACTA PHYSIOL SCAND, V93, P139, DOI 10.1111/j.1748-1716.1975.tb05800.x; PERNOW B, 1983, PHARMACOL REV, V35, P85; PERNOW B, 1953, Acta Physiol Scand Suppl, V29, P1; PERRONE MH, 1983, EUR J PHARMACOL, V95, P131, DOI 10.1016/0014-2999(83)90277-7; REGOLI D, 1988, TRENDS PHARMACOL SCI, V9, P290, DOI 10.1016/0165-6147(88)90013-2; SNIDER RS, UNPUB; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P392, DOI 10.1073/pnas.86.1.392; VOGLER K, 1963, ANN NY ACAD SCI, V104, P378, DOI 10.1111/j.1749-6632.1963.tb17682.x; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74, DOI 10.1113/jphysiol.1931.sp002763; WARAWA EJ, 1974, J MED CHEM, V17, P479; WOMACK MD, 1988, NATURE, V334, P351, DOI 10.1038/334351a0	29	925	947	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					435	437		10.1126/science.1703323	http://dx.doi.org/10.1126/science.1703323			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1703323				2022-12-01	WOS:A1991EU50400043
J	VASSAR, R; COULOMBE, PA; DEGENSTEIN, L; ALBERS, K; FUCHS, E				VASSAR, R; COULOMBE, PA; DEGENSTEIN, L; ALBERS, K; FUCHS, E			MUTANT KERATIN EXPRESSION IN TRANSGENIC MICE CAUSES MARKED ABNORMALITIES RESEMBLING A HUMAN GENETIC SKIN-DISEASE	CELL			English	Article							EPIDERMOLYSIS BULLOSA SIMPLEX; INTERMEDIATE-SIZED FILAMENTS; CULTURED EPIDERMAL-CELLS; CYTOKERATIN EXPRESSION; DOWLING-MEARA; MOLECULAR MARKERS; NORMAL EPITHELIA; DIFFERENTIATION; COMPLEX; FAMILY	To explore the relationship between keratin gene mutations and genetic disease, we made transgenic mice expressing a mutant keratin in the basal layer of their stratified squamous epithelia. These mice exhibited abnormalities in epidermal architecture and often died prematurely. Blistering occurred easily, and basal cell cytolysis was evident at the light and electron microscopy levels. Keratin filament formation was markedly altered, with keratin aggregates in basal cells. In contrast, terminally differentiating cells made keratin filaments and formed a stratum corneum. Recovery of outer layer cells was attributed to down-regulation of mutant keratin expression and concomitant induction of differentiation-specific keratins as cells terminally differentiate, and the fact that these cells arose from basal cells developing at a time when keratin expression was relatively low. Collectively, the pathobiology and biochemistry of the transgenic mice and their cultured keratinocytes bore a resemblance to a group of genetic disorders known as epidermolysis bullosa simplex.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	University of Chicago	VASSAR, R (corresponding author), UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA.		Fuchs, Elaine/G-1565-2016	Albers, Kathryn/0000-0003-4597-9323	NIAMS NIH HHS [AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027883, R01AR027883] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1982, DERMATOLOGICA, V164, P221, DOI 10.1159/000250096; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBINDER LH, 1986, ARCH DERMATOL, V122, P190, DOI 10.1001/archderm.122.2.190; BURGE SM, 1989, J ROY SOC MED, V82, P673, DOI 10.1177/014107688908201113; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; COULOMBE PA, 1989, J CELL BIOL, V109, P2295, DOI 10.1083/jcb.109.5.2295; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COULOMBE PA, 1990, IN PRESS J CELL BIOL; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; FINE JD, 1986, INT J DERMATOL, V25, P143, DOI 10.1111/j.1365-4362.1986.tb02206.x; FITZPATRICK TB, 1987, DERMATOLOGY GENERAL, V1; FRANKE WW, 1983, P NATL ACAD SCI-BIOL, V80, P7113, DOI 10.1073/pnas.80.23.7113; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1978, CELL, V15, P887, DOI 10.1016/0092-8674(78)90273-8; FUCHS EV, 1981, CELL, V27, P75, DOI 10.1016/0092-8674(81)90362-7; HEDBERG KK, 1986, EXP CELL RES, V163, P509, DOI 10.1016/0014-4827(86)90081-9; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; JACKSON BW, 1981, DIFFERENTIATION, V20, P203, DOI 10.1111/j.1432-0436.1981.tb01177.x; KERO M, 1986, INT J DERMATOL, V25, P75, DOI 10.1111/j.1365-4362.1986.tb04542.x; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; KOPAN R, 1989, GENE DEV, V3, P1, DOI 10.1101/gad.3.1.1; KOPAN R, 1989, J CELL BIOL, V109, P295, DOI 10.1083/jcb.109.1.295; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MOLL R, 1982, DIFFERENTIATION, V23, P170, DOI 10.1111/j.1432-0436.1982.tb01280.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NADEAU JH, 1989, GENOMICS, V5, P454, DOI 10.1016/0888-7543(89)90009-8; NAGLE RB, 1985, DIFFERENTIATION, V30, P130, DOI 10.1111/j.1432-0436.1985.tb00524.x; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PEARSON RW, 1961, J INVEST DERMATOL, V36, P213, DOI 10.1038/jid.1961.35; POPESCU NC, 1989, HUM GENET, V82, P109, DOI 10.1007/BF00284039; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; SANCHEZ G, 1983, J INVEST DERMATOL, V81, P576, DOI 10.1111/1523-1747.ep12523269; SAVOLAINEN ER, 1981, NEW ENGL J MED, V304, P197, DOI 10.1056/NEJM198101223040403; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; STROMER MH, 1988, CELL MOTIL CYTOSKEL, V11, P117, DOI 10.1002/cm.970110205; Sun TT, 1984, CANCER CELLS, V1, P169; TIDMAN MJ, 1988, ACTA DERM-VENEREOL, V68, P15; TYNER AL, 1986, J CELL BIOL, V103, P1945, DOI 10.1083/jcb.103.5.1945; VANMUIJEN GNP, 1986, EXP CELL RES, V162, P97, DOI 10.1016/0014-4827(86)90429-5; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VENETIANER A, 1983, NATURE, V305, P730, DOI 10.1038/305730a0; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; WU YJ, 1982, CELL, V31, P693, DOI 10.1016/0092-8674(82)90324-5	54	368	370	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	1991	64	2					365	380		10.1016/0092-8674(91)90645-F	http://dx.doi.org/10.1016/0092-8674(91)90645-F			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1703046				2022-12-01	WOS:A1991EV33600013
J	WAGNER, DD; SAFFARIPOUR, S; BONFANTI, R; SADLER, JE; CRAMER, EM; CHAPMAN, B; MAYADAS, TN				WAGNER, DD; SAFFARIPOUR, S; BONFANTI, R; SADLER, JE; CRAMER, EM; CHAPMAN, B; MAYADAS, TN			INDUCTION OF SPECIFIC STORAGE ORGANELLES BY VON-WILLEBRAND FACTOR PROPOLYPEPTIDE	CELL			English	Article							HUMAN-ENDOTHELIAL CELLS; VONWILLEBRAND ANTIGEN-II; WEIBEL-PALADE BODIES; VIII-RELATED ANTIGEN; GRANULE MEMBRANE-PROTEIN; INTRACELLULAR-LOCALIZATION; PLASMINOGEN-ACTIVATOR; FUNCTIONAL DOMAINS; MULTIMER FORMATION; SECRETION	Endothelial cells store the multimeric adhesive glycoprotein von Willebrand factor (vWf), which promotes the formation of a platelet plug at the site of vessel injury. To investigate the packaging of vWf into the granules called Weibel-Palade bodies, we expresed pro-vWf cDNA and cDNA lacking the prosequence in a variety of cell lines. Storage granules formed only in cells that contain a regulated pathway of secretion. Furthermore, packaging required the prosequence. Pro-vWf, lacking the C-terminal region involved in interchain disulfide bonding, formed granules. We conclude that the signal for storage is universal in that an adhesive glycoprotein can be stored by a hormone-secreting cell; the storage of vWf is independent of its covalent multimeric structure; the unusual rod shape of Weibel-Palade bodies is due to vWf; and the vWf propolypeptide is necessary for the formation of vWf storage granules.	TUFTS UNIV, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, DEPT ANAT, BOSTON, MA 02111 USA; TUFTS UNIV, DEPT CELLULAR BIOL, BOSTON, MA 02111 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; HOP LARIBOISIERE, INST VAISSEAUX & SANG, F-75475 PARIS 10, FRANCE; HOP LARIBOISIERE, INSERM, U150, F-75475 PARIS 10, FRANCE; CHIRON CORP, EMERYVILLE, CA 94608 USA	Tufts University; Tufts University; Howard Hughes Medical Institute; Washington University (WUSTL); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Novartis	WAGNER, DD (corresponding author), NEW ENGLAND MED CTR HOSP, BOSTON, MA 02111 USA.		Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X; Cramer Borde, Elisabeth/0000-0001-7595-0885	NHLBI NIH HHS [R01 HL41002] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONFANTI R, 1989, BLOOD, V73, P1109; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURKE RL, 1986, J BIOL CHEM, V261, P2574; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; CRAMER EM, 1985, BLOOD, V66, P710; EWENSTEIN BM, 1987, J CELL BIOL, V104, P1423, DOI 10.1083/jcb.104.5.1423; FAY PJ, 1986, SCIENCE, V232, P995, DOI 10.1126/science.3486471; FRETTO LJ, 1986, J BIOL CHEM, V261, P5679; FUMAGALLI G, 1985, J CELL BIOL, V100, P2019, DOI 10.1083/jcb.100.6.2019; GIDDINGS JC, 1982, BRIT J HAEMATOL, V52, P79, DOI 10.1111/j.1365-2141.1982.tb03863.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAIGWOOD NL, 1989, PROTEIN ENG, V2, P611, DOI 10.1093/protein/2.8.611; HAMBURGER SA, 1990, BLOOD, V75, P550; HAMILTON KK, 1987, J CLIN INVEST, V79, P600, DOI 10.1172/JCI112853; HANSS M, 1987, J LAB CLIN MED, V109, P97; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HORMIA M, 1984, EUR J CELL BIOL, V33, P217; IKAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KEMMLER W, 1973, J BIOL CHEM, V248, P4544; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LEVINE JD, 1982, BLOOD, V60, P531; LOESBERG C, 1983, BIOCHIM BIOPHYS ACTA, V763, P160, DOI 10.1016/0167-4889(83)90039-3; LYNCH DC, 1983, P NATL ACAD SCI-BIOL, V80, P2738, DOI 10.1073/pnas.80.9.2738; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MATSUDA H, 1970, INVEST OPHTH VISUAL, V9, P919; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; MCCARROLL DR, 1985, J CLIN INVEST, V75, P1089, DOI 10.1172/JCI111802; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; NACHMAN R, 1977, J CLIN INVEST, V60, P914, DOI 10.1172/JCI108846; POWELL SK, 1988, J CELL BIOL, V106, P1843, DOI 10.1083/jcb.106.6.1843; REINDERS JH, 1985, BIOCHIM BIOPHYS ACTA, V844, P306, DOI 10.1016/0167-4889(85)90131-4; REINDERS JH, 1988, HAEMOSTASIS, V18, P246; RIBES JA, 1987, J CLIN INVEST, V79, P117, DOI 10.1172/JCI112771; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; RUGGERI ZM, 1987, BLOOD, V70, P895; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SENGEL A, 1970, J CELL BIOL, V44, P223, DOI 10.1083/jcb.44.1.223; SEVARINO KA, 1987, J BIOL CHEM, V262, P4987; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SHELTONINLOES BB, 1987, BIOCHEM BIOPH RES CO, V144, P657, DOI 10.1016/S0006-291X(87)80016-5; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; STEINER DF, 1974, FED PROC, V33, P2105; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; Tarentino A L, 1978, Methods Enzymol, V50, P574; TOOZE J, 1986, J CELL BIOL, V103, P839, DOI 10.1083/jcb.103.3.839; VERWEIJ CL, 1987, EMBO J, V6, P2885, DOI 10.1002/j.1460-2075.1987.tb02591.x; VERWEIJ CL, 1988, J BIOL CHEM, V263, P7921; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; WAGNER DD, 1987, P NATL ACAD SCI USA, V84, P1955, DOI 10.1073/pnas.84.7.1955; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320; WAGNER DD, 1987, BLOOD, V69, P27; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; WAGNER DD, 1984, J CELL BIOL, V99, P2123, DOI 10.1083/jcb.99.6.2123; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cb.06.110190.001245; WAGNER DD, 1983, J BIOL CHEM, V258, P2065; WAGNER DD, 1989, COAGULATION BLEEDING, P161; WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101; WENCELDRAKE JD, 1984, AM J PATHOL, V115, P156; WHITE JG, 1968, BLOOD, V32, P148, DOI 10.1182/blood.V32.1.148.148; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; ZIMMERMAN TS, 1983, PROG HEMATOL, V13, P279; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	67	231	235	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	1991	64	2					403	413		10.1016/0092-8674(91)90648-I	http://dx.doi.org/10.1016/0092-8674(91)90648-I			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1988154				2022-12-01	WOS:A1991EV33600016
J	WEINSTEIN, IB				WEINSTEIN, IB			MITOGENESIS IS ONLY ONE FACTOR IN CARCINOGENESIS	SCIENCE			English	Editorial Material							HUMAN CANCER; LECTURE		COLUMBIA UNIV,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY 10032	Columbia University; Columbia University	WEINSTEIN, IB (corresponding author), COLUMBIA UNIV,DEPT MED,CTR COMPREHENS CANC,NEW YORK,NY 10032, USA.							ABELSON PH, 1990, SCIENCE, V249, P1357, DOI 10.1126/science.2402628; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; AMES BN, 1979, SCIENCE, V204, P587, DOI 10.1126/science.373122; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7782, DOI 10.1073/pnas.87.19.7782; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7777, DOI 10.1073/pnas.87.19.7777; BLUM A, 1978, SCIENCE, V201, P1020, DOI 10.1126/science.684422; BOYD JA, 1990, GENETIC PHARM THER, V46, P469; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; COLBURN NH, 1989, GENES SIGNAL TRANSDU; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HENDERSON BE, 1988, CANCER RES, V48, P246; HERRLICH P, 1986, ADV ENZYME REGUL, V25, P485, DOI 10.1016/0065-2571(86)90030-0; HOEL DG, 1988, CARCINOGENESIS, V9, P2045, DOI 10.1093/carcin/9.11.2045; HUFF J, IN PRESS MAXCYROSENA; IVANOVIC V, 1981, NATURE, V293, P404, DOI 10.1038/293404a0; MELNICK R, COMMUNICATION; RAO GN, 1987, FUND APPL TOXICOL, V9, P329, DOI 10.1016/0272-0590(87)90055-8; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; TOMATIS L, 1989, JPN J CANCER RES, V80, P795, DOI 10.1111/j.1349-7006.1989.tb01717.x; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEINSTEIN IB, 1990, ADV 2ND MESSENGERS P; 1988, MONOGRAPHS EVALUA S7, V1	23	123	126	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					387	388		10.1126/science.1989073	http://dx.doi.org/10.1126/science.1989073			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1989073				2022-12-01	WOS:A1991EU50400031
J	AHRINGER, J; KIMBLE, J				AHRINGER, J; KIMBLE, J			CONTROL OF THE SPERM-OOCYTE SWITCH IN CAENORHABDITIS-ELEGANS HERMAPHRODITES BY THE FEM-3 3' UNTRANSLATED REGION	NATURE			English	Article							SEX-DETERMINATION GENE; C-ELEGANS; SPERMATOGENESIS; SEQUENCES	IN the Caenorhabditis elegans hermaphrodite germ line, sperm and then oocytes are made from a common pool of germ-cell precursors. The decision to differentiate as a sperm or an oocyte is regulated by the sex-determining gene, fem-3. Expression of fem-3 in the hermaphrodite germ line directs spermatogenesis and must be negatively regulated to allow the switch to oogenesis1,2. In adult hermaphrodites (which are producing oocytes), most fem-3 RNA is found in the germ line3, consistent with both the requirement for fem-3 in hermaphrodite spermatogenesis and the maternal effects of fem-3 on embryonic sex determination1,2. Whereas loss-of-function mutants in fem-3 produce only oocytes, hermaphrodites carrying any of nine fem-3 gain-of-function (gf) mutations make none; instead sperm are produced continuously and in vast excess over wild-type amounts1. Genetic analyses suggest that fem-3(gf) mutations have escaped a negative control required for the switch to oogenesis1. Here we report that all nine fem-3(gf) mutants carry sequence alterations in the fem-3 3' untranslated region (3' UTR). There is no increase in the steady-state level of fem-3(gf) RNA over wild-type, but there is an increase in the polyadenylation of fem-3(gf) RNA that is coincident with the unregulated fem-3 activity. Results of a titration experiment support the hypothesis that a regulatory factory may bind the fem-3 3' UTR. We speculate that fem-3 RNA is regulated through its 3' UTR by binding a factor that inhibits translation, and discuss the idea that this control may be part of a more general regulation of maternal RNAs.	UNIV WISCONSIN, GRAD SCH, MOLEC BIOL LAB, 1525 LINDEN DR, MADISON, WI 53706 USA; UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Ahringer, Julie/0000-0002-7074-4051				BARTON MK, 1987, GENETICS, V115, P107; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; DONIACH T, 1986, GENETICS, V114, P53; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; HODGKIN J, 1986, GENETICS, V114, P15; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; ROSENQUIST TA, 1988, GENE DEV, V2, P606, DOI 10.1101/gad.2.5.606; SCHEDL T, 1988, GENETICS, V119, P43; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; VOURNAKIS JN, 1975, P NATL ACAD SCI USA, V72, P2959, DOI 10.1073/pnas.72.8.2959; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4	16	193	198	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 24	1991	349	6307					346	348		10.1038/349346a0	http://dx.doi.org/10.1038/349346a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1702880				2022-12-01	WOS:A1991EU50100058
J	BALLOU, LM; LUTHER, H; THOMAS, G				BALLOU, LM; LUTHER, H; THOMAS, G			MAP2 KINASE AND 70K-S6 KINASE LIE ON DISTINCT SIGNALING PATHWAYS	NATURE			English	Article							RIBOSOMAL-PROTEIN S6; SERINE-THREONINE KINASE; SWISS MOUSE 3T3-CELLS; 3T3 CELLS; INSULIN; ACTIVATION; SERUM; PHOSPHORYLATION; PURIFICATION; IDENTIFICATION	ACTIVATION of protein synthesis is required for quiescent cells to transit the cell cycle1, and seems to be mediated in part by phosphorylation of the 40S ribosomal protein, S6 (ref. 2). A mitogen-activated S6 kinase of relative molecular mass 70,000 (70K) has been isolated from mouse fibroblasts3,4 as well as from avian, rat and rabbit tissues5-9. Comparison of complementary DNA sequences shows that this enzyme10 is distinct from S6 kinase II (92K)11 found in Xenopus eggs12 and fibroblasts13,14. Both kinases are activated by serine/threonine phosphorylation3,15-18, suggesting that at least one serine/threonine kinase links receptor tyrosine kinases with S6 kinases. A candidate for this link is MAP2 kinase, which is rapidly activated by tyrosine/threonine phosphorylation following mitogenic stimulation19-23. Incubation of MAP2 kinase from insulin-treated 3T3-L1 adipocytes with phosphatase-inactivated S6 kinase II from Xenopus leads to partial reactivation and phosphorylation of the enzyme17. These and other findings8 have led to the suggestion that MAP2 kinase also activates the 70K S6 kinase. Here we refute this idea by showing that the two kinases lie on distinct signalling pathways.	FRIEDRICH MIESCHER INST,POSTFACH 2543,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BLENIS J, 1984, P NATL ACAD SCI-BIOL, V81, P6408, DOI 10.1073/pnas.81.20.6408; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HOSHI M, 1988, J BIOL CHEM, V263, P5396; JENO P, 1989, J BIOL CHEM, V264, P1293; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KOZMA SC, 1989, EMBO J, V8, P4125, DOI 10.1002/j.1460-2075.1989.tb08597.x; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LANE HA, IN PRESS METH ENZYM; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1988, ARCH BIOCHEM BIOPHYS, V262, P307, DOI 10.1016/0003-9861(88)90193-2; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; SWEET LJ, 1990, MOL CELL BIOL, V10, P2787, DOI 10.1128/MCB.10.6.2787; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0	28	204	204	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					348	350		10.1038/349348a0	http://dx.doi.org/10.1038/349348a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1702881				2022-12-01	WOS:A1991EU50100059
J	BIRCH, LL; JOHNSON, SL; ANDRESEN, G; PETERS, JC; SCHULTE, MC				BIRCH, LL; JOHNSON, SL; ANDRESEN, G; PETERS, JC; SCHULTE, MC			THE VARIABILITY OF YOUNG CHILDRENS ENERGY-INTAKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOOD-INTAKE; CALORIC COMPENSATION; SELF-REGULATION	Background. Research conducted in the 1930s showed that, given nutritious choices, children can select an adequate diet without adult supervision. Paradoxically, children grew well and were healthy despite patterns of intake at individual meals that were unpredictable and highly variable. Methods. To investigate in more detail the energy intake of young children, we measured 24-hour food intake for 15 children, from two to five years of age, on six days. For each of the six days of the study, coefficients of variation were calculated for each child for each of the six meals and snacks (breakfast, lunch, dinner, and morning, afternoon, and evening snacks) and for total daily energy intake. Results. The children's intake at individual meals was highly variable, but total daily energy intake was relatively constant for each child. The mean coefficient of variation for each child's energy intake at individual meals was 33.6 percent; in contrast, the mean coefficient of variation for each child's total daily energy intake was 10.4 percent. In most cases, high energy intake at one meal was followed by low energy intake at the next meal, or vice versa. Conclusions. Although children's food consumption is highly variable from meal to meal, daily energy intake is relatively constant, because children adjust their energy intake at successive meals.	PROCTER & GAMBLE CO,MIAMI VALLEY LABS,CINCINNATI,OH 45247	Procter & Gamble	BIRCH, LL (corresponding author), UNIV ILLINOIS,SCH HUMAN RESOURCES & FAMILY STUDIES,CHILD DEV LAB,URBANA,IL 61801, USA.							BIRCH LL, 1980, CHILD DEV, V51, P856, DOI 10.2307/1129474; BIRCH LL, 1986, APPETITE, V7, P323, DOI 10.1016/S0195-6663(86)80001-0; BIRCH LL, 1985, LEARN MOTIV, V16, P341, DOI 10.1016/0023-9690(85)90020-7; BIRCH LL, 1989, PHYSIOL BEHAV, V45, P387, DOI 10.1016/0031-9384(89)90145-5; BIRCH LL, 1984, CHILD DEV, V55, P431, DOI 10.2307/1129954; Costanzo P. R., 1984, J SOC CLIN PSYCHOL, V2, P305; Davis CM, 1928, AM J DIS CHILD, V36, P651; Davis CM, 1939, CAN MED ASSOC J, V41, P257; FOLTIN RW, 1990, AM J CLIN NUTR, V52, P969, DOI 10.1093/ajcn/52.6.969; FOMON SJ, 1974, INFANT NUTRITION; HARRIES JM, 1962, P NUTR SOC, V21, P157, DOI 10.1079/PNS19620027; PELLETT PL, 1990, AM J CLIN NUTR, V51, P711, DOI 10.1093/ajcn/51.5.711	12	253	257	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 24	1991	324	4					232	235		10.1056/NEJM199101243240405	http://dx.doi.org/10.1056/NEJM199101243240405			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU022	1985244				2022-12-01	WOS:A1991EU02200005
J	BIX, M; LIAO, NS; ZIJLSTRA, M; LORING, J; JAENISCH, R; RAULET, D				BIX, M; LIAO, NS; ZIJLSTRA, M; LORING, J; JAENISCH, R; RAULET, D			REJECTION OF CLASS-I MHC-DEFICIENT HEMATOPOIETIC-CELLS BY IRRADIATED MHC-MATCHED MICE	NATURE			English	Article							BONE-MARROW ALLOGRAFTS; NATURAL-KILLER CELLS; EMBRYONIC STEM-CELLS; GRAFT-REJECTION; T-CELLS; HISTOCOMPATIBILITY ANTIGENS; HOMOLOGOUS RECOMBINATION; EXPRESSION; SUSCEPTIBILITY; DIFFERENTIATION	IRRADIATED MHC-heterozygous mice often reject bone marrow cells transplanted from one of the homozygous parental strains, a phenomenon ('hybrid resistance') that appears to violate the laws of transplantation 1,2. Rejection of parental and allogeneic marrow cells also differs from conventional T cell-mediated rejection mechanisms as it is effected by NK1.1+ cells 3-5. To account for the unusual specificity of bone marrow rejection, it has been proposed that NK1.1+ cells destroy marrow cells that fail to express the full complement of self MHC class I (MHC-I) molecules 5. We show here that NK1.1+ cells in normal mice reject haemopoietic transplants from mice that are deficient for normal cell-surface MHC-I expression because of a targeted mutation in the beta-2-microglobulin gene 6-9. These findings demonstrate that deficient expression of MHC-I molecules renders marrow cells susceptible to rejection.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute			Liao, Nan-Shih/ABE-7580-2020; Loring, Jeanne F/A-1620-2011	Liao, Nan-Shih/0000-0003-3707-4145; Loring, Jeanne F/0000-0001-6226-9767; Bix, Mark/0000-0003-4617-0497; Raulet, David/0000-0002-1257-8649				CUDKOWICZ G, 1964, NATURE, V204, P450, DOI 10.1038/204450a0; CUDKOWICZ G, 1971, J EXP MED, V134, P1513, DOI 10.1084/jem.134.6.1513; CUDKOWICZ G, 1973, TRANSPLANT P, V4, P1399; DENNERT G, 1990, IMMUNOGENETICS, V31, P161; FOWLKES BJ, 1985, J EXP MED, V162, P802, DOI 10.1084/jem.162.3.802; HARELBELLAN A, 1986, P NATL ACAD SCI USA, V83, P5688, DOI 10.1073/pnas.83.15.5688; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; HOGLUND P, 1988, J EXP MED, V168, P1469, DOI 10.1084/jem.168.4.1469; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KIESSLING R, 1977, EUR J IMMUNOL, V7, P655, DOI 10.1002/eji.1830070915; KLEIN J, 1978, IMMUNOGENETICS, V6, P489, DOI 10.1007/BF01563941; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOO GC, 1986, J IMMUNOL, V137, P3742; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MURPHY WJ, 1987, J EXP MED, V166, P1499, DOI 10.1084/jem.166.5.1499; MURPHY WJ, 1987, J EXP MED, V165, P1212, DOI 10.1084/jem.165.4.1212; OHLEN C, 1989, SCIENCE, V246, P666, DOI 10.1126/science.2814488; REMBECKI RM, 1987, J IMMUNOL, V138, P2734; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHIMIZU Y, 1989, EUR J IMMUNOL, V19, P447, DOI 10.1002/eji.1830190306; STALLCUP KC, 1981, J IMMUNOL, V127, P923; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; STUMHOFEL K, 1990, EUR J IMMUNOL, V20, P171; YANKELEVICH B, 1989, J IMMUNOL, V142, P3423; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	27	357	382	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					329	331		10.1038/349329a0	http://dx.doi.org/10.1038/349329a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1987491				2022-12-01	WOS:A1991EU50100052
J	ERIKSON, J; RADIC, MZ; CAMPER, SA; HARDY, RR; CARMACK, C; WEIGERT, M				ERIKSON, J; RADIC, MZ; CAMPER, SA; HARDY, RR; CARMACK, C; WEIGERT, M			EXPRESSION OF ANTI-DNA IMMUNOGLOBULIN TRANSGENES IN NON-AUTOIMMUNE MICE	NATURE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; LYMPHOCYTES-B; ANTIBODIES; AUTOANTIBODIES; MOUSE; ACTIVATION; GENES; CELLS	SELF-REACTIVE B cells can be regulated by either deletion or inactivation 1. These manifestations of self-tolerance have been dramatically shown in transgenic mice in which the number of self-reactive cells has been artificially expanded 2,3. We have now extended these models to ask if B-cell tolerance as described for non-disease-associated antigens also operates for the targets of autoimmunity. The target we have chosen is DNA. Anti-DNA antibodies are diagnostic of certain autoimmune syndromes in humans and are a characteristic of the murine model of systemic autoimmunity, the MRI/Ipr mouse4. Antibodies to both single-stranded and double-stranded DNA have been implicated in disease 5,6. By generating anti-DNA transgenic mice, we have addressed the question of whether DNA-specific B cells are regulated in normal (non-autoimmune) mice. We indeed found that most transgenic B cells bind DNA, yet we failed to detect secreted anti-DNA. We suggest that as a consequence of their self-reactivity these B cells are developmentally arrested.	UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	ERIKSON, J (corresponding author), FOX CHASE CANC INST, INST CANC RES, 7701 BURHOLME AVE, PHILADELPHIA, PA 19111 USA.			Radic, Marko/0000-0002-8004-282X; Camper, Sally/0000-0001-8556-3379				BASTEN A, 1989, PROGR IMMUNOLOGY, V7, P377; BENNETT RM, 1987, J EXP MED, V166, P850, DOI 10.1084/jem.166.4.850; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPER SA, 1987, BIOTECHNIQUES, V5, P638; CHACE JH, 1988, J IMMUNOL, V141, P3258; COLECLOUGH C, 1981, NATURE, V290, P372, DOI 10.1038/290372a0; EATON RB, 1983, ARTHRITIS RHEUM, V26, P52, DOI 10.1002/art.1780260109; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARDY RR, 1982, NATURE, V297, P589, DOI 10.1038/297589a0; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HOLMBERG D, 1986, IMMUNOL REV, V93, P147, DOI 10.1111/j.1600-065X.1986.tb01506.x; KUROSAWA Y, 1982, J EXP MED, V155, P201, DOI 10.1084/jem.155.1.201; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1989, SCIENCE, V245, P147, DOI 10.1126/science.2526369; PANKEWYCZ OG, 1987, J IMMUNOL, V139, P3287; PERRY RP, 1979, CELL, V18, P1333, DOI 10.1016/0092-8674(79)90243-5; RADIC MZ, 1989, COLD SPRING HARB SYM, V54, P933; RADIC MZ, IN PRESS J IMMUN; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150; SOUROUJON M, 1988, J IMMUNOL, V140, P4173; STALL AM, 1984, J IMMUNOL, V132, P787; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; VANSNICK JL, 1982, J EXP MED, V155, P219, DOI 10.1084/jem.155.1.219; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YANCOPOULOS GD, 1988, J EXP MED, V168, P417, DOI 10.1084/jem.168.1.417	30	453	455	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 24	1991	349	6307					331	334		10.1038/349331a0	http://dx.doi.org/10.1038/349331a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1898987	Green Published			2022-12-01	WOS:A1991EU50100053
J	FELGNER, PL; RHODES, G				FELGNER, PL; RHODES, G			GENE THERAPEUTICS	NATURE			English	Article							FOREIGN GENE; EXPRESSION; INVIVO; DNA; DELIVERY; TRANSFECTION; VIRUS; LIVER; MICE				FELGNER, PL (corresponding author), VICAL INC,DIV GENE THERAPEUT,9373 TOWNE CTR DR,SAN DIEGO,CA 92121, USA.							BENVENISTY N, 1986, P NATL ACAD SCI USA, V83, P9551, DOI 10.1073/pnas.83.24.9551; BEVIN MJ, 1987, NATURE, V325, P192; BOUCHARD L, 1984, VIROLOGY, V135, P53, DOI 10.1016/0042-6822(84)90116-8; BRIGHAM KL, 1989, AM J MED SCI, V298, P278, DOI 10.1097/00000441-198910000-00013; DUBENSKY TW, 1984, P NATL ACAD SCI-BIOL, V81, P7529, DOI 10.1073/pnas.81.23.7529; FELGNER P L, 1990, Advanced Drug Delivery Reviews, V5, P163, DOI 10.1016/0169-409X(90)90015-K; FUNG YKT, 1983, P NATL ACAD SCI-BIOL, V80, P353, DOI 10.1073/pnas.80.2.353; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; ISRAEL MA, 1979, J VIROL, V29, P990, DOI 10.1128/JVI.29.3.990-996.1979; JOHNSTON SA, 1990, NATURE, V346, P776, DOI 10.1038/346776a0; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; MALONE RW, 1989, FOCUS, V11, P4; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NICOLAU C, 1983, P NATL ACAD SCI-BIOL, V80, P1068, DOI 10.1073/pnas.80.4.1068; ONO T, 1990, NEUROSCI LETT, V117, P259, DOI 10.1016/0304-3940(90)90673-W; SEEGER C, 1984, P NATL ACAD SCI-BIOL, V81, P5849, DOI 10.1073/pnas.81.18.5849; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WANG CY, 1987, P NATL ACAD SCI USA, V84, P7851, DOI 10.1073/pnas.84.22.7851; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1988, J BIOL CHEM, V263, P14621; YANG NS, 1990, P NATL ACAD SCI USA, V87, P9568, DOI 10.1073/pnas.87.24.9568	24	201	241	2	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					351	352		10.1038/349351a0	http://dx.doi.org/10.1038/349351a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1987492				2022-12-01	WOS:A1991EU50100060
J	FINGERHUT, MA; HALPERIN, WE; MARLOW, DA; PIACITELLI, LA; HONCHAR, PA; SWEENEY, MH; GREIFE, AL; DILL, PA; STEENLAND, K; SURUDA, AJ				FINGERHUT, MA; HALPERIN, WE; MARLOW, DA; PIACITELLI, LA; HONCHAR, PA; SWEENEY, MH; GREIFE, AL; DILL, PA; STEENLAND, K; SURUDA, AJ			CANCER MORTALITY IN WORKERS EXPOSED TO 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOFT-TISSUE SARCOMA; NON-HODGKINS LYMPHOMA; PHENOXYACETIC ACIDS; MALIGNANT-LYMPHOMA; ORGANIC-SOLVENTS; CHEMICAL WORKERS; COHORT MORTALITY; CASE-REFERENT; CHLOROPHENOLS; PROMOTION	Background. In both animal and epidemiologic studies, exposure to dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, or TCDD) has been associated with an increased risk of cancer. Methods. We conducted a retrospective cohort study of mortality among the 5172 workers at 12 plants in the United States that produced chemicals contaminated with TCDD. Occupational exposure was documented by reviewing job descriptions and by measuring TCDD in serum from a sample of 253 workers. Causes of death were taken from death certificates. Results. Mortality from several cancers previously associated with TCDD (stomach, liver, and nasal cancers, Hodgkin's disease, and non-Hodgkin's lymphoma) was not significantly elevated in this cohort. Mortality from soft-tissue sarcoma was increased, but not significantly (4 deaths; standardized mortality ratio [SMR], 338; 95 percent confidence interval, 92 to 865). In the subcohort of 1520 workers with greater-than-or-equal-to 1 year of exposure and greater-than-or-equal-to 20 years of latency, however, mortality was significantly increased for soft-tissue sarcoma (3 deaths; SMR, 922;95 percent confidence interval, 190 to 2695) and for cancers of the respiratory system (SMR, 142; 95 percent confidence interval, 103 to 192). Mortality from all cancers combined was slightly but significantly elevated in the overall cohort (SMR, 115; 95 percent confidence interval, 102 to 130) and was higher in the subcohort with greater-than-or-equal-to 1 year of exposure and greater-than-or-equal-to 20 years of latency (SMR, 146; 95 percent confidence interval, 121 to 176). Conclusions. This study of mortality among workers with occupational exposure to TCDD does not confirm the high relative risks reported for many cancers in previous studies. Conclusions about an increase in the risk of soft-tissue sarcoma are limited by small numbers and misclassification on death certificates. Excess mortality from all cancers combined, cancers of the respiratory tract, and soft-tissue sarcoma may result from exposure to TCDD, although we cannot exclude the possible contribution of factors such as smoking and occupational exposure to other chemicals.			FINGERHUT, MA (corresponding author), CTR DIS CONTROL, DIV SURVEILLANCE HAZARD EVALUAT & FIELD STUDIES, IND WIDE STUDIES BRANCH, CINCINNATI, OH 45226 USA.							AXELSON O, 1978, SCAND J WORK ENV HEA, V4, P98, DOI 10.5271/sjweh.2720; AXELSON O, 1980, SCAND J WORK ENV HEA, V6, P73, DOI 10.5271/sjweh.2631; ERIKSSON M, 1981, BRIT J IND MED, V38, P27; ERIKSSON M, 1990, J NATL CANCER I, V82, P486, DOI 10.1093/jnci/82.6.486; ESPOSITO M, 1980, EPA600280197 PUBL; FINGERHUT M, 1990, PB91125971; FINGERHUT MA, 1984, SCAND J WORK ENV HEA, V10, P299, DOI 10.5271/sjweh.2325; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; HARDELL L, 1979, BRIT J CANCER, V39, P711, DOI 10.1038/bjc.1979.125; HARDELL L, 1984, BRIT J CANCER, V50, P389, DOI 10.1038/bjc.1984.188; HARDELL L, 1981, BRIT J CANCER, V43, P169, DOI 10.1038/bjc.1981.25; HARDELL L, 1988, CANCER, V62, P652, DOI 10.1002/1097-0142(19880801)62:3<652::AID-CNCR2820620334>3.0.CO;2-4; HARDELL L, 1983, BRIT J CANCER, V48, P217, DOI 10.1038/bjc.1983.177; HARDELL L, 1982, American Journal of Industrial Medicine, V3, P247, DOI 10.1002/ajim.4700030304; KOCIBA RJ, 1978, TOXICOL APPL PHARM, V46, P279, DOI 10.1016/0041-008X(78)90075-3; MONSON RR, 1990, OCCUPATIONAL EPIDEMI, P100; OLSEN JH, 1984, LANCET, V2, P47; OTT MG, 1987, J OCCUP ENVIRON MED, V29, P422; PATTERSON DG, 1989, AM J IND MED, V16, P135, DOI 10.1002/ajim.4700160205; PEARCE NE, 1987, INT J CANCER, V39, P155, DOI 10.1002/ijc.2910390206; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; PERSSON B, 1989, BRIT J IND MED, V46, P516; PITOT HC, 1980, CANCER RES, V40, P3616; POLAND A, 1982, NATURE, V300, P271, DOI 10.1038/300271a0; RAO MS, 1988, CARCINOGENESIS, V9, P1677, DOI 10.1093/carcin/9.9.1677; ROTHMAN KJ, 1979, DHEW NIH791649 PUBL, P30; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P229; SIEMIATYCKI J, 1988, J OCCUP ENVIRON MED, V30, P617, DOI 10.1097/00043764-198808000-00004; SMITH AH, 1984, J NATL CANCER I, V73, P1111; STEENLAND K, 1990, J OCCUP ENVIRON MED, V32, P1091, DOI 10.1097/00043764-199011000-00008; STEENLAND K, 1984, SCAND J WORK ENV HEA, V10, P143, DOI 10.5271/sjweh.2349; SUIT HD, 1978, CA-CANCER J CLIN, V28, P284, DOI 10.3322/canjclin.28.5.284; SUSKIND RR, 1984, JAMA-J AM MED ASSOC, V251, P2372, DOI 10.1001/jama.251.18.2372; SWEENEY MH, 1989, CHEMOSPHERE, V19, P973, DOI 10.1016/0045-6535(89)90443-8; THIESS A M, 1982, American Journal of Industrial Medicine, V3, P179, DOI 10.1002/ajim.4700030209; WIKLUND K, 1987, BRIT J CANCER, V56, P505, DOI 10.1038/bjc.1987.234; WIKLUND K, 1986, J NATL CANCER I, V76, P229; WIKLUND K, 1984, BRIT J CANCER, V2, P47; WOODS JS, 1987, J NATL CANCER I, V78, P899; ZACK JA, 1980, J OCCUP ENVIRON MED, V22, P11, DOI 10.1097/00043764-198001000-00005; Zack Judith A., 1983, HUMAN ENV RISKS CHLO, P575; ZOBER A, 1990, INT ARCH OCC ENV HEA, V62, P139, DOI 10.1007/BF00383591; 1977, INT CLASSIFICATION D; 1982, DHHS NIH821765 PUBL	44	467	476	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 24	1991	324	4					212	218		10.1056/NEJM199101243240402	http://dx.doi.org/10.1056/NEJM199101243240402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU022	1985242				2022-12-01	WOS:A1991EU02200002
J	LEE, CC; PEARLMAN, JA; CHAMBERLAIN, JS; CASKEY, CT				LEE, CC; PEARLMAN, JA; CHAMBERLAIN, JS; CASKEY, CT			EXPRESSION OF RECOMBINANT DYSTROPHIN AND ITS LOCALIZATION TO THE CELL-MEMBRANE	NATURE			English	Article							PROTEIN PRODUCT; MUSCLE; GENE; MYOFIBERS; EFFICIENT; MICE	DUCHENNE'S muscular dystrophy (DMD) is an X-linked progressive myopathy caused by a defect in the DMD gene locus 1,2. The gene corresponding to the DMD locus produces a 14-kilobase (kb) messenger RNA that codes for a large cytoskeletal membrane protein, dystrophin 3,4. DMD and Becker's muscular dystrophy are the consequences of dystrophin mutations 4,5. The exact biological function of dystrophin remains unknown but it has been demonstrated that it is localized to the cytoplasmic face of the cell membrane and has direct interaction with several other membrane proteins 6,7. We report here the synthesis of a 14-kb full-length complementary DNA for the mouse muscle dystrophin mRNA and the expression of this cDNA in COS cells. The recombinant dystrophin is indistinguishable from mouse muscle dystrophin by western blot analysis with anti-dystrophin antibodies and was shown by an immunofluorescent technique to be localized in the cell membrane. Our successful construction of a functional full-length cDNA opens opportunities for the study of structure and function of dystrophin and provides an opportunity to initiate gene therapy studies.	BAYLOR UNIV,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR UNIV,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor University; Baylor University; Howard Hughes Medical Institute				Chamberlain, Jeffrey/0000-0001-5299-0059				CHAMBERLAIN JS, 1990, CURRENT NEUROLOGY, V10, pCH2; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; EMERGY AEH, 1987, OXFORD MONOGRAPHS ME, V15; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; MONACO AP, 1989, TRENDS BIOCHEM SCI, V14, P412, DOI 10.1016/0968-0004(89)90290-9; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MONGINI T, 1988, NEUROLOGY, V38, P476, DOI 10.1212/WNL.38.3.476; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	20	78	80	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					334	336		10.1038/349334a0	http://dx.doi.org/10.1038/349334a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1824797				2022-12-01	WOS:A1991EU50100054
J	MANASCO, PK; GIRTON, ME; DIGGS, RL; DOPPMAN, JL; FEUILLAN, PP; BARNES, KM; CUTLER, GB; LORIAUX, DL; ALBERTSON, BD				MANASCO, PK; GIRTON, ME; DIGGS, RL; DOPPMAN, JL; FEUILLAN, PP; BARNES, KM; CUTLER, GB; LORIAUX, DL; ALBERTSON, BD			A NOVEL TESTIS-STIMULATING FACTOR IN FAMILIAL MALE PRECOCIOUS PUBERTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LUTEINIZING-HORMONE; SEXUAL PRECOCITY; LEYDIG; RADIOIMMUNOASSAY; GONADOTROPIN; TESTOSTERONE; THERAPY	Background. Familial male precocious puberty is a gonadotropin-independent form of precocious puberty that occurs only in males. The cause of the disorder is unknown. To examine the hypothesis that the plasma of boys with familial male precocious puberty contains a novel stimulator of testicular testosterone production, we developed a bioassay using adult male cynomolgus monkeys. Methods. We collected plasma from 12 boys with familial male precocious puberty, 7 normal prepubertal boys of similar ages and with similar plasma gonadotropin levels, and 1 boy with hypogonadotropic hypogonadism and infused it into the testicular artery of adult male cynomolgus monkeys that had been pretreated with gonadotropin-releasing-hormone antaganist to inhibit the endogenous secretion of gonadotropins. Testicular venous effluent was collected at 15-minute intervals for 3 to 5 hours for the measurement of testosterone. Results. The mean (+/- SE) peak testosterone response, as compared with base line, was significantly greater in the monkeys infused with plasma from the 12 boys with familial male precocious puberty than in the monkeys infused with plasma from the 7 normal prepubertal boys and the boy with hypogonadotropic hypogonadism (385 +/- 51 vs. 184 +/- 25 percent, P < 0.005) in the three-hour studies. Plasma from 92 percent of the boys with familial male precocious puberty and 12.5 percent of the normal prepubertal boys stimulated a response greater than 195 percent of base-line values. In the animals studied for five hours after receiving a second dose of antagonist, the mean peak testosterone response, as compared with base line, was significantly greater in the monkeys infused with plasma from three boys with familial male precocious puberty than in the monkeys infused with plasma from three normal prepubertal boys (363 +/- 81 vs. 115 +/- 6 percent, P < 0.01). The mean area under the testosterone-response curve wa significantly larger in the monkeys infused with plasma from the boys with familial male precocious puberty in the five-hour studies (154 +/- 34 vs. -58 +/- 10 percent, P < 0.005), but not in the three-hour studies. Conclusions. These findings support the presence of a circulating testis-stimulating factor in the plasma of boys with familial male precocious puberty. The production of such a factor would explain the biologic nature of the disorder.	NICHHD,DEV ENDOCRINOL BRANCH,BLDG 10,RM 10N262,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT RADIOL,BETHESDA,MD 20892; GEORGETOWN UNIV HOSP,DEPT RADIOL,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Georgetown University								ADAMS LA, 1986, J CLIN ENDOCR METAB, V62, P58, DOI 10.1210/jcem-62-1-58; DUFAU ML, 1974, J CLIN ENDOCR METAB, V39, P610, DOI 10.1210/jcem-39-3-610; Greulich WW., 1971, RADIOGRAPHIC ATLAS S; HOLLAND F J, 1988, Pediatric Research, V23, p278A; LAUE L, 1989, NEW ENGL J MED, V320, P496, DOI 10.1056/NEJM198902233200805; NIESCHLAG E, 1972, Z KLIN CHEM KLIN BIO, V10, P164; NISWENDER GD, 1971, ENDOCRINOLOGY, V88, P1327, DOI 10.1210/endo-88-6-1327; ODELL WD, 1967, J LAB CLIN MED, V70, P973; ODELL WD, 1967, J CLIN INVEST, V46, P248, DOI 10.1172/JCI105527; PESCOVITZ OH, 1986, J PEDIATR-US, V108, P47, DOI 10.1016/S0022-3476(86)80767-3; REITER EO, 1984, NEW ENGL J MED, V311, P515, DOI 10.1056/NEJM198408233110807; ROSENTHAL SM, 1983, J CLIN ENDOCR METAB, V57, P571, DOI 10.1210/jcem-57-3-571; SCHEDEWIE HK, 1981, J CLIN ENDOCR METAB, V52, P271, DOI 10.1210/jcem-52-2-271; WIERMAN ME, 1985, NEW ENGL J MED, V312, P65, DOI 10.1056/NEJM198501103120201	14	20	20	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 24	1991	324	4					227	231		10.1056/NEJM199101243240404	http://dx.doi.org/10.1056/NEJM199101243240404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU022	1898671				2022-12-01	WOS:A1991EU02200004
J	ROTZLER, S; SCHRAMEK, H; BRENNER, HR				ROTZLER, S; SCHRAMEK, H; BRENNER, HR			METABOLIC STABILIZATION OF END-PLATE ACETYLCHOLINE-RECEPTORS REGULATED BY CA2+ INFLUX ASSOCIATED WITH MUSCLE-ACTIVITY	NATURE			English	Article							MAMMALIAN SKELETAL-MUSCLE; CA-2+ CHANNELS; CALCIUM CURRENTS; MEMBRANE; DEGRADATION; RYANODINE; CELLS; ENANTIOMERS; DENERVATION; FRACTION	DURING formation of the neuromuscular junction, acetylcholine receptors in the endplate membrane become matabolically stabilized under neural control, their half-life increasing from about 1 day to about 10 days (see ref. 1 for review). The metabolic stability of the receptors is regulated by the electrical activity induced in the muscle by innervation 2-4. We report here that metabolic stabilization of endplate receptors but not of extrajunctional receptors can be induced in the absence of muscle activity if muscles are treated with the calcium ionophore A23187. Acetylcholine receptor stabilization was also induced by culturing non-stimulated muscle in elevated K+ with the Ca2+ channel activator (+)-SDZ202-791. Conversely, activity-dependent receptor stabilization is prevented in muscle stimulated in the presence of the Ca2+ channel blockers (+)-PN200-110 or D-600. Treatment of muscles with ryanodine, which induces Ca2+ release from the sarcoplasmic reticulum in the absence of activity, does not cause stabilization of junctional receptors. Evidently, muscle activity induces metabolic acetylcholine receptor stabilization by way of an influx of Ca2+ ions through dihydropyridine-sensitive Ca2+ channels in the endplate membrane, whereas Ca2+ released from the sarcoplasmic reticulum is ineffective in this developmental process.	UNIV BASEL,DEPT PHYSIOL,VESALGASSE 1,CH-4051 BASEL,SWITZERLAND	University of Basel								BEAM KG, 1988, J GEN PHYSIOL, V91, P799, DOI 10.1085/jgp.91.6.799; BEAM KG, 1988, J GEN PHYSIOL, V91, P781, DOI 10.1085/jgp.91.6.781; BEVAN S, 1983, J PHYSIOL-LONDON, V336, P159, DOI 10.1113/jphysiol.1983.sp014574; BRENNER HR, 1989, J PHYSIOL-LONDON, V410, P501, DOI 10.1113/jphysiol.1989.sp017546; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P517, DOI 10.1073/pnas.83.2.517; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P1518, DOI 10.1073/pnas.83.5.1518; FAIRHURST AS, 1970, EUR J BIOCHEM, V13, P504, DOI 10.1111/j.1432-1033.1970.tb00953.x; FAIRHURST AS, 1974, AM J PHYSIOL, V227, P1124, DOI 10.1152/ajplegacy.1974.227.5.1124; FUMAGALLI G, 1990, NEURON, V4, P563, DOI 10.1016/0896-6273(90)90114-U; HARRIS JB, 1971, ACTA PHYSIOL SCAND, V83, P382, DOI 10.1111/j.1748-1716.1971.tb05091.x; HOF RP, 1985, J CARDIOVASC PHARM, V7, P689, DOI 10.1097/00005344-198507000-00012; JENDEN DJ, 1969, PHARMACOL REV, V21, P1; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; KOKUBUN S, 1986, MOL PHARMACOL, V30, P571; LEVITT TA, 1981, NATURE, V291, P239, DOI 10.1038/291239a0; LINDEN DC, 1979, NEUROSCIENCE, V4, P527, DOI 10.1016/0306-4522(79)90129-5; MCCLESKEY EW, 1985, J PHYSIOL-LONDON, V361, P231, DOI 10.1113/jphysiol.1985.sp015643; MILEDI R, 1980, J PHYSIOL-LONDON, V300, P197, DOI 10.1113/jphysiol.1980.sp013158; PAPPONE PA, 1980, J PHYSIOL-LONDON, V306, P377, DOI 10.1113/jphysiol.1980.sp013403; PEZZEMENTI L, 1981, J BIOL CHEM, V256, P2651; ROTZLER S, 1990, J CELL BIOL, V111, P655, DOI 10.1083/jcb.111.2.655; SALPETER MM, 1986, J CELL BIOL, V103, P1399, DOI 10.1083/jcb.103.4.1399; SALPETER MM, 1985, PROG NEUROBIOL, V25, P297, DOI 10.1016/0301-0082(85)90018-8; SCHMID A, 1984, FEBS LETT, V172, P114, DOI 10.1016/0014-5793(84)80885-6; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0	26	58	58	5	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					337	339		10.1038/349337a0	http://dx.doi.org/10.1038/349337a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1846230				2022-12-01	WOS:A1991EU50100055
J	SHIBUKI, K; OKADA, D				SHIBUKI, K; OKADA, D			ENDOGENOUS NITRIC-OXIDE RELEASE REQUIRED FOR LONG-TERM SYNAPTIC DEPRESSION IN THE CEREBELLUM	NATURE			English	Article							PURKINJE-CELLS; ACTIVATION; RAT	CONJUNCTIVE stimulation of climbing and parallel fibres in the cerebellum evokes a long-term depression of parallel-fibre Purkinje-cell transmission 1,2, a phenomenon implicated as the cellular mechanism for cerebellar motor learning 3. It is suspected that the increase in cyclic GMP concentration that occurs after activation of climbing fibres 4 is required to evoke long-term depression 3. Excitatory amino acids are known to cause the release of nitric oxide (NO), resulting in elevation of the cGMP level in the cerebellum 5. Here we report that endogenous NO is released after stimulation of climbing fibres, that long-term depression evoked by conjunctive stimulation of parallel and climbing fibres is blocked by haemoglobin (which strongly binds NO) or L-N(G)-monomethyl-arginine (an inhibitor of NO synthase), and that exogenous NO or cGMP can substitute for the stimulation of climbing fibres to cause long-term depression in rat cerebellar slices. These results demonstrate that the release of endogenous NO is essential for the induction of synaptic plasticity in the cerebellum.			SHIBUKI, K (corresponding author), INST PHYS & CHEM RES,FRONTIER RES PROGRAM,NEURAL NETWORKS LAB,WAKO,SAITAMA 35101,JAPAN.							BIGGIO G, 1976, BRAIN RES, V107, P365, DOI 10.1016/0006-8993(76)90233-X; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; DECAMILLI P, 1984, NEUROSCIENCE, V11, P761, DOI 10.1016/0306-4522(84)90193-3; DEVENTE J, 1989, BRAIN RES, V504, P332, DOI 10.1016/0006-8993(89)91380-2; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; Ito M, 1990, Neuroreport, V1, P129; KARACHOT L, 1987, EXP BRAIN RES, V66, P229; KNOPFEL T, 1990, EUR J NEUROSCI, V2, P726, DOI 10.1111/j.1460-9568.1990.tb00463.x; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; SHIBUKI K, 1990, NEUROSCI LETT, V113, P34, DOI 10.1016/0304-3940(90)90490-Z	18	836	848	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					326	328		10.1038/349326a0	http://dx.doi.org/10.1038/349326a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1702879				2022-12-01	WOS:A1991EU50100051
J	TANAKA, K; OSHIMURA, M; KIKUCHI, R; SEKI, M; HAYASHI, T; MIYAKI, M				TANAKA, K; OSHIMURA, M; KIKUCHI, R; SEKI, M; HAYASHI, T; MIYAKI, M			SUPPRESSION OF TUMORIGENICITY IN HUMAN COLON-CARCINOMA CELLS BY INTRODUCTION OF NORMAL CHROMOSOME-5 OR CHROMOSOME-18	NATURE			English	Article							FAMILIAL POLYPOSIS COLI; COLORECTAL CARCINOMAS; CONSTITUTIONAL HETEROZYGOSITY; GENE; ASSIGNMENT; TUMORS; ARM	DEVELOPMENT of colon carcinomas can be associated with allelic deletions on several chromosomes, including 5q and 18q (refs 1-10). The APC gene11-13 on 5q and the DCC gene14 on 18q have been identified as potential tumor suppressor genes, whose suppression contributes to colon carcinogenesis. To investigate the role of genes in these deleted regions, we have now introduced a single normal human chromosome into a human colon carcinoma cell line, COKFu, through microcell hybridization15-20. Several clones of hybrid cells containing normal chromosome 5, and others containing normal chromosome 18, were obtained. The morphology of the hybrid cells was markedly altered: the hybrids with chromosome 5 exhibited a closely packed polygonal morphology, and the hybrid cells with chromosome 18 were flattened. The cloning efficiency of the hybrid cells in soft agar was reduced from 0.46 to 0% of that of the parental carcinoma cells, and the tumorigenicity of these hybrid cells in athymic nude mice was completely suppressed. The growth properties of the hybrid cells with chromosome 11 were not substantially changed. These results strongly suggest that the genes on normal chromosome 5 and 18 function as tumor suppressors in colon carcinogenesis.	TOTTORI UNIV,FAC MED,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN	Tottori University	TANAKA, K (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,3-18-22 HONKOMAGOME,BUNKYO KU,TOKYO 113,JAPAN.							ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DIETZSCH E, 1986, NUCLEIC ACIDS RES, V14, P1923, DOI 10.1093/nar/14.4.1923; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1989, CARCINOGENESIS, V2, P12; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MIYAKI M, 1990, CANCER RES, V50, P7166; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; NISHISHO I, 1987, JPN J HUM GENET, V32, P1, DOI 10.1007/BF01876521; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; SASAKI M, 1989, CANCER RES, V49, P4402; SAXSON PJ, 1986, EMBO J, V5, P3461; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	25	183	191	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					340	342		10.1038/349340a0	http://dx.doi.org/10.1038/349340a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1670965				2022-12-01	WOS:A1991EU50100056
J	GARRARD, J; MAKRIS, L; DUNHAM, T; HESTON, LL; COOPER, S; RATNER, ER; ZELTERMAN, D; KANE, RL				GARRARD, J; MAKRIS, L; DUNHAM, T; HESTON, LL; COOPER, S; RATNER, ER; ZELTERMAN, D; KANE, RL			EVALUATION OF NEUROLEPTIC DRUG-USE BY NURSING-HOME ELDERLY UNDER PROPOSED MEDICARE AND MEDICAID REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSYCHOACTIVE MEDICATION; CARE; RESIDENTS; FACILITIES	Federal regulations for use of neuroleptic drugs in Medicare- and Medicaid-certified nursing homes throughout the United States were implemented October 1, 1990. These regulations constitute the first time that prescription drugs are required, by law, to be justified by indications documented in the medical chart. This study used extant data to estimate ineligible neuroleptic use at the individual and nursing home levels had these regulations been in effect in 1976 through 1985. Subjects, randomly sampled admissions (N = 5752) and residents (N = 3191), were followed up for up to 24 months in 60 nursing homes. One half of neuroleptic use in each cohort could be considered ineligible under the regulations; all but one of the nursing homes had one or more individuals who were treated with the ineligible use of neuroleptics. Improvements in documentation and/or prescription of neuroleptic drugs for nursing home elderly will be needed to ensure compliance with these new regulations.	UNIV MINNESOTA,SCH STAT,DEPT APPL STAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,COLL EDUC,DEPT EDUC PSYCHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,COLL PHARM,DEPT PHARM PRACTICE,MINNEAPOLIS,MN 55455; ST PAUL RAMSEY MED CTR,DEPT CLIN PHARM,ST PAUL,MN 55101; UNIV MINNESOTA,DIV BIOSTAT,MINNEAPOLIS,MN 55455; ABBOTT NW HOSP,MINNEAPOLIS,MN; UNIV WASHINGTON,WASHINGTON INST MENTAL ILLNESS TRAINING & RES,SEATTLE,WA 98195	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Saint Paul Ramsey Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle	GARRARD, J (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV HLTH SERV RES & POLICY,420 DELAWARE ST SE,BOX 729 MAYO,MINNEAPOLIS,MN 55455, USA.			Zelterman, Daniel/0000-0003-0711-8688	NATIONAL INSTITUTE ON AGING [K01AG000434] Funding Source: NIH RePORTER; NIA NIH HHS [1KO1-AG 000434-02] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1978, INT CLASSIFICATION D; AVORN J, 1989, NEW ENGL J MED, V320, P227, DOI 10.1056/NEJM198901263200406; BEARDSLEY RS, 1989, J AM GERIATR SOC, V37, P327, DOI 10.1111/j.1532-5415.1989.tb05499.x; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BUCK JA, 1988, J AM GERIATR SOC, V36, P409, DOI 10.1111/j.1532-5415.1988.tb02379.x; BUCK JA, 1989, AM J MENT RETARD, V93, P618; BURNS BJ, 1988, J FAM PRACTICE, V26, P155; DOANE KW, 1989, CONSULTANT PHARM, V4, P367; Goodman L.S., 1980, PHARM BASIS THERAPEU, V6th; HILL BK, 1985, PSYCHOPHARMACOL BULL, V21, P279; Institute of Medicine report, 1986, IMPROVING QUALITY CA; KANE RL, 1989, AM J PUBLIC HEALTH, V79, P1271, DOI 10.2105/AJPH.79.9.1271; KANE RL, 1989, NURSING HOMES NURSIN, P37; Kepferle L, 1983, J Long Term Care Adm, V11, P54; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; 1976, US DHEW MONOGRAPH, V2; 1988, ADVERSE DRUG REACT, P100; 1989, FED REG         0202, V54, P5316; 1986, DRUG EVALUATIONS	20	82	82	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	1991	265	4					463	467		10.1001/jama.265.4.463	http://dx.doi.org/10.1001/jama.265.4.463			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET377	1670645				2022-12-01	WOS:A1991ET37700023
J	MOSER, M; BLAUFOX, MD; FREIS, E; GIFFORD, RW; KIRKENDALL, W; LANGFORD, H; SHAPIRO, A; SHEPS, S				MOSER, M; BLAUFOX, MD; FREIS, E; GIFFORD, RW; KIRKENDALL, W; LANGFORD, H; SHAPIRO, A; SHEPS, S			WHO REALLY DETERMINES YOUR PATIENTS PRESCRIPTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FOLLOW-UP; HYPERTENSION; DIURETICS; GLUCOSE; LIPIDS; TRIAL		YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; VET ADM,WASHINGTON,DC 20420; CLEVELAND CLIN EDUC FDN,CLEVELAND,OH 44106; UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225; UNIV MISSISSIPPI,MED CTR,SCH MED,JACKSON,MS 39216; UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15261; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905	Yale University; Yeshiva University; Albert Einstein College of Medicine; Cleveland Clinic Foundation; University of Texas System; University of Texas Health Science Center Houston; University of Mississippi; University of Mississippi Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Mayo Clinic			Blaufox, MDonald/AAF-6965-2020	Blaufox, MDonald/0000-0002-4148-6866				AMES RP, 1986, DRUGS, V32, P260, DOI 10.2165/00003495-198632030-00003; [Anonymous], 1981, LANCET, V2, P539; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CURB JD, 1986, PROG CARDIOVASC DIS, V29, P73; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FREIS ED, 1989, ARCH INTERN MED, V149, P2649; GREENBERG G, 1984, AM J MED, V76, P45, DOI 10.1016/0002-9343(84)90956-2; MACMAHON S, 1989, HYPERTENSION S1, V13, P145; MOSER M, 1989, CARDIOVASC DRUG THER, V3, P743, DOI 10.1007/BF01857624; MOSER M, 1989, AM HEART J, V118, P1362, DOI 10.1016/0002-8703(89)90059-8; MOSER M, 1985, J HYPERTENS, V3, P437; MOSER M, 1989, AM FAM PHYSICIAN, V40, P213; MURPHY MB, 1982, LANCET, V2, P1293; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; SHAPIRO AP, 1961, NEW ENGL J MED, V265, P1028, DOI 10.1056/NEJM196111232652102; SHEKELLE RB, 1984, ATHER REV, V12, P113; 1980, LANCET, V1, P1261; 1985, AM J CARDIOL, V56, P913; 1979, JAMA-J AM MED ASSOC, V242, P2562; 1980, AM J MED, V69, P725; 1988, JAMA-J AM MED ASSOC, V259, P2113; 1990, CIRCULATION, V82, P1616; 1985, JAMA-J AM MED ASSOC, V291, P97; 1985, LANCET, V1, P1349; 1982, JAMA-J AM MED ASSOC, V248, P1996	26	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	1991	265	4					498	500		10.1001/jama.265.4.498	http://dx.doi.org/10.1001/jama.265.4.498			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET377	1985236				2022-12-01	WOS:A1991ET37700031
J	APPLEBY, L				APPLEBY, L			SUICIDE DURING PREGNANCY AND IN THE 1ST POSTNATAL YEAR	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDER	Objectives-To calculate age adjusted mortality ratios for suicide by women in the first year after childbirth and during pregnancy, and to identify characteristics of postnatal suicide in childbearing women. Design-Retrospective study based on population data for England and Wales from 1973 to 1984. Subjects-Women aged 15-44 who committed suicide in the year after childbirth or during pregnancy. Main outcome measures-Observed to expected mortality ratios for the total postnatal sample, for five year age groups, for unmarried mothers, and for suicide after stillbirth; observed to expected mortality ratios for all suicides during pregnancy and for five year age groups; the timing of suicides in relation to delivery; and the frequency of the various methods of suicide. Results-The standardised mortality ratio for postnatal suicide was calculated to be 0.17-that is, the actual total was only one sixth of that expected. The low ratio was not found after stillbirth, which was associated with a rate six times that in all women after childbirth. The low ratio was less pronounced, but still present, in teenage mothers and in unmarried mothers. Women who committed suicide after childbirth most often did so in the first month, and there was a tendency to use violent methods. The standardised mortality ratio for suicide during pregnancy was calculated to be 0.05 of all pregnant women. Teenagers were at substantially increased risk. Conclusions-Women in the first year after childbirth and during pregnancy have a low risk of suicide despite their high rate of psychiatric morbidity. Underreporting of maternal suicides is unlikely to explain the findings, though it may affect their magnitude. Motherhood seems to protect against suicide. Concern for dependants may be an important focus for suicide prevention in clinical practice.			APPLEBY, L (corresponding author), INST PSYCHIAT,DEPT PSYCHIAT,LONDON SE5 8AF,ENGLAND.							BECK AT, 1979, COGNITIVE THERAPY DE; Breslow N. E., 1987, STATISTICAL METHODS, VII; COOPER PJ, 1988, BRIT J PSYCHIAT, V152, P799, DOI 10.1192/bjp.152.6.799; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; KLEINER GJ, 1984, SUICIDE PREGNANCY; KUMAR R, 1984, BRIT J PSYCHIAT, V144, P35, DOI 10.1192/bjp.144.1.35; LINEHAN MM, 1983, J CONSULT CLIN PSYCH, V51, P276, DOI 10.1037/0022-006X.51.2.276; O'Hara M. W., 1988, MOTHERHOOD MENTAL IL, P17; PAFFENBARGER RS, 1964, BRIT J PREV SOC MED, V18, P189; WATSON JP, 1984, BRIT J PSYCHIAT, V144, P453, DOI 10.1192/bjp.144.5.453; 1990, REPORT CONFIDENTIAL; [No title captured]; 1982, REPORT CONFIDENTIAL; ANN PUBLICATION OFFI; 1979, REPORT CONFIDENTIAL; 1973, ANN PUBLICATION OFFI; 1986, REPORT CONFDENTIAL E	17	184	188	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					137	140		10.1136/bmj.302.6769.137	http://dx.doi.org/10.1136/bmj.302.6769.137			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU020	1995132	Bronze, Green Published			2022-12-01	WOS:A1991EU02000018
J	CHART, H; SMITH, HR; SCOTLAND, SM; ROWE, B; MILFORD, DV; TAYLOR, CM				CHART, H; SMITH, HR; SCOTLAND, SM; ROWE, B; MILFORD, DV; TAYLOR, CM			SEROLOGICAL IDENTIFICATION OF ESCHERICHIA-COLI O157-H7 INFECTION IN HEMOLYTIC UREMIC SYNDROME	LANCET			English	Article							HEMOLYTIC UREMIC SYNDROME; CYTOTOXIN-PRODUCING STRAINS; POLYACRYLAMIDE GELS; ANTIBODIES; PROTEINS; PROBES	To test the value of serological tests as an adjunct to bacteriological methods and toxin testing in haemolytic uraemic syndrome (HUS), 60 patients with the disorder were examined for evidence of faecal Escherichia coli producing verocytotoxin (VTEC), particularly of serogroup O157. They were also tested for serum antibodies reacting with the lipopolysaccharide of E coli O157 by means of an enzyme-linked immunosorbent assay (ELISA) and immunoblotting; for faecal VTEC by means of DNA probes hybridising with the genes encoding verocytotoxins VT1 and VT2; and for "free" faecal VT. Strains of E coli serotype O157:H7 were isolated from 9 patients, and faecal VT2 was detected in 3 of them. Strains of E coli of serotypes O5:H -, O55:H10, O105ac:H18, and O163:H19 were isolated from 4 patients, but faecal VT was not detected. Faecal VT2 was present in 1 patient from whom VTEC were not isolated. Antibodies to the lipopolysaccharide of E coli O157 were detected in serum samples from 44 patients. The 9 patients with faecal O157:H7 all had high titres of these antibodies, but serum samples from 16 healthy control children were negative. Serological testing of patients with HUS for antibodies to the lipopolysaccharide of E coli O157 provides evidence of infection with E coli O157 when faecal bacteria or VT cannot be detected.	CHILDRENS HOSP,DEPT NEPHROL,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND		CHART, H (corresponding author), CENT PUBL HLTH LAB,DIV ENTER PATHOGENS,61 COLINDALE AVE,LONDON NW9 5HT,ENGLAND.							CHART H, 1989, J CLIN MICROBIOL, V27, P285, DOI 10.1128/JCM.27.2.285-290.1989; CHART H, 1989, J CLIN PATHOL, V42, P973, DOI 10.1136/jcp.42.9.973; Gross R. J., 1985, SPECIAL PUBLICATION, V13, P345; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KLEANTHOUS H, 1988, EPIDEMIOL INFECT, V101, P327, DOI 10.1017/S0950268800054261; KLEANTHOUS H, 1990, ARCH DIS CHILD, V65, P722, DOI 10.1136/adc.65.7.722; KONOWALCHUK J, 1977, INFECT IMMUN, V18, P775, DOI 10.1128/IAI.18.3.775-779.1977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN M, 1984, ARCH DIS CHILD, V59, P397, DOI 10.1136/adc.59.5.397; MILFORD DV, 1990, ARCH DIS CHILD, V65, P716, DOI 10.1136/adc.65.7.716; SCOTLAND SM, 1987, EPIDEMIOL INFECT, V99, P613, DOI 10.1017/S0950268800066462; SCOTLAND SM, 1985, LANCET, V2, P885; SCOTLAND SM, 1988, J MED MICROBIOL, V25, P237, DOI 10.1099/00222615-25-4-237; SMITH HR, 1984, LANCET, V1, P1242; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Von Gasser C, 1955, SCHWEIZ MED WOCHENSC, V85, P905; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WILLSHAW GA, 1987, J GEN MICROBIOL, V133, P1309; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	19	136	146	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					138	140		10.1016/0140-6736(91)90801-U	http://dx.doi.org/10.1016/0140-6736(91)90801-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670788				2022-12-01	WOS:A1991ET67900004
J	FLEISSIG, A				FLEISSIG, A			UNINTENDED PREGNANCIES AND THE USE OF CONTRACEPTION - CHANGES FROM 1984 TO 1989	BRITISH MEDICAL JOURNAL			English	Article											FLEISSIG, A (corresponding author), INSTITUTE SOCIAL STUDIES MED CARE,14 S HILL PK,LONDON NW3 2SB,ENGLAND.							CARTWRIGHT A, 1988, SOC SCI MED, V27, P249, DOI 10.1016/0277-9536(88)90128-1; Griffiths M, 1990, BRIT J FAM PLANN, V16, P16; Guillebaud J, 2017, CONTRACEPTION YOUR Q; SMITH T, 1990, BRIT MED J, V300, P1154, DOI 10.1136/bmj.300.6733.1154	4	50	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					147	147		10.1136/bmj.302.6769.147	http://dx.doi.org/10.1136/bmj.302.6769.147			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU020	1995134	Green Published, Bronze			2022-12-01	WOS:A1991EU02000021
J	GORE, SM; TAYLOR, RMR; WALLWORK, J				GORE, SM; TAYLOR, RMR; WALLWORK, J			AVAILABILITY OF TRANSPLANTABLE ORGANS FROM BRAIN-STEM DEAD DONORS IN INTENSIVE-CARE UNITS	BRITISH MEDICAL JOURNAL			English	Article								Objective-By audit from January to June 1989 to quantify, separately for hearts, kidneys, liver, lungs and corneas, the possible increases in transplantable organs from brain stem dead potential donors in intensive care units and to compare them with the increases achieved in October-November 1989, during intense, national publicity about transplantation. Design-Prospective audit of all deaths in intensive care units in England from 1 January to 30 June 1989 and subsequent case study of the impact of publicity on offers and donations during October-November 1989. Setting-15 regional and special health authorities in England. Patients-5803 patients dying in intensive care units, of whom 497 were confirmed as brain stem dead and had no general medical contraindication to organ donation. Main outcome measures-Organ specific suitability for transplantation (as reported by intensive care units); consent for donation of specific suitable organs; and procurement of specific organs reported as suitable for transplantation and offered. Results-In the 497 (8.6%) brain stem dead potential donors we estimated the organ specific suitability for heart as 63%, kidneys 95%, liver 70%, lungs 29%, and corneas 91%. Refusal of relatives (30%) accounted for major losses of suitable organs of all types. For kidneys the loss was equivalent to 44% of brain stem dead actual kidney donors. No discussion of organ donation was the second most important reason for missed kidney donors, the loss being equivalent to 10% of brain stem dead actual donors. Non-procurement or difficulties with allocating organs was the second most notable cause of missed suitable liver and lung donors; 29% (55) of the offered total of 189 liver donors and 27% (21) of 78 offered suitable lung donors in six months. Non-procurement of suitable, offered organs was rare for kidneys and modest, of the order of 13% and 10% respectively, for heart and corneas. Corneal donation from brain stem dead potential donors might be improved nearly as much (that is, a 78% increase in brain stem dead actual corneal donors) by specific measures to promote corneal donation when other organs are offered as by reducing the overall refusal rate. Restricted offers, non-procurement, and no discussion of donation accounted for nearly equal numbers of lost donations of hearts (each equivalent to 15% of donated hearts). During October-November 1989 when there was intense, positive publicity about transplantation the rates of refusal and non-discussion fell compared with during January-June (22%, 36/163 upsilon 30%, 138/460; 7%, 33/497 upsilon 2%, 4/167 respectively). Offers of suitable donors increased significantly (p < 0.02) compared with the first six months of 1989, most notably for heart donors (80 upsilon 60.1 expected) and kidney donors (122 upsilon 102.1 expected) but only for kidneys was there a noticeable 17% increase in actual donors (118 actual audited donors upsilon 100.8 expected donors; p = 0.09). Conclusions-Four strategies to increase the supply of transplantable organs from brain stem dead potential donors in intensive care units were identified: (a) reducing refusal of relatives (b) avoiding non-procurement of actually suitable organs (by logistical initiatives) and deterioration of initially suitable organs (by donor care initiatives); (c) converting restricted offers to unrestricted offers; and (d) ensuring discussion with families. Early referral to the transplant team or coordinator gives time for discussion about donor care and agreement on medical suitability for donation of specific organs. Solving some of the logistical problems of non-procurement may be a prerequisite for increased offers to be translated into increased donations. The impact of publicity therefore needs to be measured on offers of suitable donors as well as by actual donations.	ROYAL VICTORIA INFIRM,ORGAN GRAFTING UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; PAPWORTH HOSP,THORAC SURG UNIT,CAMBRIDGE CB3 8RE,ENGLAND	Newcastle University - UK; Papworth Hospital	GORE, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND.							GORE SM, 1989, BRIT MED J, V299, P1193, DOI 10.1136/bmj.299.6709.1193; GREBENCK CR, 1987, BR J HOSP MED    JUL, P62; JENNETT B, 1981, BRIT J ANAESTH, V53, P1111, DOI 10.1093/bja/53.11.1111; KEMP G, 1989, SUNDAY EXPRESS  0827, P1; ODOM NJ, 1990, BMJ-BRIT MED J, V300, P1571, DOI 10.1136/bmj.300.6739.1571; WALLWORK J, 1989, BRIT MED J, V299, P1291, DOI 10.1136/bmj.299.6711.1291; 1987, REPORT	7	54	55	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					149	153		10.1136/bmj.302.6769.149	http://dx.doi.org/10.1136/bmj.302.6769.149			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1995135	Green Published, Bronze			2022-12-01	WOS:A1991EU02000023
J	GRANDA, H; GISPERT, S; DORTICOS, A; MARTIN, M; CUADRAS, Y; CALVO, M; MARTINEZ, G; ZAYAS, MA; OLIVA, JA; HEREDERO, L				GRANDA, H; GISPERT, S; DORTICOS, A; MARTIN, M; CUADRAS, Y; CALVO, M; MARTINEZ, G; ZAYAS, MA; OLIVA, JA; HEREDERO, L			CUBAN PROGRAM FOR PREVENTION OF SICKLE-CELL DISEASE	LANCET			English	Article							DNA ANALYSIS; HEMOGLOBIN; DIAGNOSIS; ANEMIA	The percentage of carriers of the sickle cell gene in Cuba ranges from 3 to 7% in different regions. In 1983 the National Medical Genetics Centre initiated a programme for the control of sickle cell disease, which was started in Havana and later extended nationwide. The programme is based on mass education, screening and supportive genetic counselling, care of affected individuals, and availability of prenatal diagnosis. 806 935 pregnant women had been screened by the end of 1989: 29 913 (3.7%) were heterozygous, homozygous or doubly heterozygous for abnormal haemoglobin. 19 686 fathers (67%) were also tested: 1268 at-risk couples were detected. 531 elected to have prenatal diagnosis; 404 results were obtained and 98 affected fetuses (SS or SC) found. In 72 cases the pregnancy was terminated.	S PAEDIAT HOSP, DEPT PROV GENET, Santiago De Cuba, CUBA; MINIST PUBL HLTH CUBA, NATL INST HAEMATOL & IMMUNOL, HAVANA, CUBA; GYNECO OBSTET HOSP RAMON GONZALEZ CORO, PROV DEPT PRENATAL DIAG, HAVANA, CUBA; PAEDIAT HOSP GUANTANAMO, DEPT PROV GENET, GUANTANAMO, CUBA		GRANDA, H (corresponding author), NATL CTR MED GENET, HIGHER INST MED SCI,DEPT BIOCHEM,31 AVE,3102, PLAYA 16, HAVANA, CUBA.							BASSET P, 1978, BLOOD, V51, P971; CHANG JC, 1982, NEW ENGL J MED, V307, P30, DOI 10.1056/NEJM198207013070105; GRANDA-I H, 1987, American Journal of Human Genetics, V41, pA276; HEREDERO L, 1974, HUMANGENETIK, V21, P167, DOI 10.1007/BF00281035; HEREDERO L, 1976, CLIN CHIM ACTA, V71, P515; HEREDERO L, 1974, REV CUB PEDIATRIA, V46; KAN YW, 1978, LANCET, V2, P910; ORKIN SH, 1982, NEW ENGL J MED, V307, P32, DOI 10.1056/NEJM198207013070106; WAIKAN Y, 1978, P NATL ACAD SCI USA, V75, P5631, DOI 10.1073/pnas.75.11.5631	9	31	35	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 19	1991	337	8734					152	153						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670797				2022-12-01	WOS:A1991ET67900013
J	GRAZIANO, JH; BLUM, C				GRAZIANO, JH; BLUM, C			LEAD-EXPOSURE FROM LEAD CRYSTAL	LANCET			English	Note								In a study of the elution of lead (Pb) from crystal decanters and glasses, port containing 89-mu-g Pb/l was placed in decanters and the Pb content of the wine rose steadily to 3518-mu-g/l after 4 months. Wines and spirits stored in crystal decanters for a long time contained Pb at concentrations up to 21 530-mu-g/l. In a short-term experiment white wine eluted small amounts of Pb from crystal glasses within minutes.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University	GRAZIANO, JH (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032, USA.							DELEACY EA, 1987, MED J AUSTRALIA, V147, P622; Elias RW, 1985, DIETARY ENV LEAD HUM, P79; Fernandez F., 1982, ATOM SPECTROSC, V3, P130; Nriagu J.O., 1985, DIETARY ENV LEAD HUM, P1; PLANCHES LTD, 1848, LEAD DISEASES TREATI, P37; 1988, NATURE EXTENT LEAD P, pI28	6	41	41	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					141	142						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670790				2022-12-01	WOS:A1991ET67900006
J	KENDELL, RE				KENDELL, RE			CHRONIC FATIGUE, VIRUSES, AND DEPRESSION	LANCET			English	Editorial Material							POSTVIRAL FATIGUE; MAGNETIC-RESONANCE; MUSCLE; INFECTION; SYMPTOMS; PATIENT				KENDELL, RE (corresponding author), UNIV EDINBURGH,ROYAL EDINBURGH HOSP,DEPT PSYCHIAT,EDINBURGH EH10 5HF,SCOTLAND.							ANDREASEN NC, 1986, ARCH GEN PSYCHIAT, V43, P246; [Anonymous], 1989, ANN REPORT; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARNOLD DL, 1984, LANCET, V1, P1367; Beard GM, 1869, BOSTON MED SURG J, V80, P217; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; CALDER BD, 1987, J ROY COLL GEN PRACT, V37, P11; CHURCH AJ, 1980, MED J AUSTRALIA, V1, P307, DOI 10.5694/j.1326-5377.1980.tb134875.x; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JAMAL GA, 1985, J NEUROL NEUROSUR PS, V48, P961; KENDELL RE, 1983, HDB PSYCHIATRY, V4, P232; KENDLER KS, 1986, ARCH GEN PSYCHIAT, V43, P213; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; KRUESI MJP, 1989, J CLIN PSYCHIAT, V50, P53; MANU P, 1988, ANN INTERN MED, V109, P554, DOI 10.7326/0003-4819-109-7-554; SCHLEIFER SJ, 1983, JAMA-J AM MED ASSOC, V250, P374, DOI 10.1001/jama.250.3.374; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; YONGE RP, 1988, J ROY SOC MED, V81, P322, DOI 10.1177/014107688808100607; YOUSEF GE, 1988, LANCET, V1, P146; 1987, HLTH LIFESTYLE SURVE; 1989, WHO ICD10 DIV MENT H, pCH5	25	44	47	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					160	162						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ET679	1670800				2022-12-01	WOS:A1991ET67900016
J	LINDBERG, G; EKLUND, GA; GULLBERG, B; RASTAM, L				LINDBERG, G; EKLUND, GA; GULLBERG, B; RASTAM, L			SERUM SIALIC-ACID CONCENTRATION AND CARDIOVASCULAR MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							CANCER; CHOLESTEROL; FIBRINOGEN	Objective - To determine whether serum sialic acid concentration may be used to predict short and long term cardiovascular mortality. Design - Prospective study on all men and women who had their serum sialic acid concentration measured as part of a general health survey in 1964 or in 1965. All were followed up for an average of 20.5 years. Setting - Geographical part of the county of Varmland, Sweden. Subjects - Residents in the area participating in a health check up in 1964-5 (27 065 men and 28 037 women), of whom 372 men (169 with incomplete data and 203 lost to follow up) and 345 women (143 and 202 respectively) were excluded; thus 26 693 men and 27 692 women entered the study. The study sample was restricted to subjects aged 40-74 during any of the 20 years' follow up. Main outcome measures - Serum sialic acid concentration, serum cholesterol concentration, diastolic blood pressure, body mass index at the general health survey visit; cardiovascular and noncardiovascular deaths during three periods of follow up (0-6 years, 7-13 years, and 14-20 years), according to the Swedish mortality register, in subjects aged 45-74. Results - Mean serum sialic acid concentration (mg/100 ml) was 68.8 (SD 8.0) for men and 69.2 (8.0) for women; the average concentration increasing with age in both sexes. A total of 5639 (21%) men and 3307 (12%) women died during the follow up period, in whom death in 3052 (54%) men and 1368 (41%) women was from cardiovascular causes. During short (0-6 years), medium (7-13 years), and long (14-20 years) term follow up the relative risk of death from cardiovascular disease increased with increasing serum sialic acid concentration. The relative risk (95% confidence interval) associated with the highest quartile of sialic acid concentration compared with the lowest quartile was 2.38 (2.01 to 2.83) in men and 2.62 (1.93 to 3.57) in women. Similar results were found for deaths from noncardiovascular disease with relative risks of 1.50 (1.34 to 2.68) in men and 1.89 (1.57 to 2.28) in women, but these relative risks were significantly lower than those for deaths from cardiovascular disease (p < 0.001 and p < 0.005 respectively). In multivariate analysis of total mortality and of cardiovascular mortality with sialic acid concentration, serum cholesterol concentration, diastolic blood pressure, and body mass index as independent variables the impact of sialic acid concentration was virtually the same as in univariate analysis. Conclusion - Serum sialic acid concentration is a strong predictor of cardiovascular mortality. A possible explanation of these findings is that the serum sialic acid concentration may reflect the existence or the activity of an atherosclerotic process, and this may warrant further investigation.	KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN; UNIV LUND,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Lund University	LINDBERG, G (corresponding author), CTR PUBL HLTH RES,S-65182 KARLSTAD,SWEDEN.							BOLANDER AM, 1981, MED ASPECTS MORTALIT, P236; Hrncir Z, 1975, Vnitr Lek, V21, P436; KROLIKOWSKI FJ, 1976, PHARMACOLOGY, V14, P47, DOI 10.1159/000136578; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; MEADE TW, 1980, LANCET, V1, P1050; Ng S.-S., 1976, BIOL ROLES SIALIC AC, P59; PETREN S, 1989, BIOCHIM BIOPHYS ACTA, V994, P161, DOI 10.1016/0167-4838(89)90155-6; RADHAKRISHNAMURTHY B, 1976, LAB INVEST, V34, P159; SCHWICK HG, 1986, BEHRING I MITT, V80, P1; SHANBERGER RJ, 1984, J CLIN CHEM CLIN BIO, V22, P647; SHVARTS L S, 1971, Problemy Endokria, V17, P37; STUART J, 1981, J CLIN PATHOL, V34, P464, DOI 10.1136/jcp.34.5.464; SUCCARI M, 1982, PATHOL BIOL, V30, P151; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SWAHN E, 1989, SCAND J CLIN LAB INV, V49, P49, DOI 10.3109/00365518909089077; TANIUCHI K, 1981, Kobe Journal of Medical Sciences, V27, P91; TORNBERG SA, 1986, NEW ENGL J MED, V315, P1629, DOI 10.1056/NEJM198612253152601; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VARMA R, 1983, J CLIN CHEM CLIN BIO, V21, P273; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; ZAK B, 1954, AM J CLIN PATHOL, V24, P1307, DOI 10.1093/ajcp/24.11_ts.1307; 1967, MANUAL INT STATISTIC; 1955, MANUAL INT STATISTIC; 1971, VARMLAND SURVEY	24	205	209	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					143	146		10.1136/bmj.302.6769.143	http://dx.doi.org/10.1136/bmj.302.6769.143			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1995133	Bronze, Green Published			2022-12-01	WOS:A1991EU02000020
J	MASTRO, TD; GHAFOOR, A; NOMANI, NK; ISHAQ, Z; ANWAR, F; GRANOFF, DM; SPIKA, JS; THORNSBERRY, C; FACKLAM, RR				MASTRO, TD; GHAFOOR, A; NOMANI, NK; ISHAQ, Z; ANWAR, F; GRANOFF, DM; SPIKA, JS; THORNSBERRY, C; FACKLAM, RR			ANTIMICROBIAL RESISTANCE OF PNEUMOCOCCI IN CHILDREN WITH ACUTE LOWER RESPIRATORY-TRACT INFECTION IN PAKISTAN	LANCET			English	Article							STREPTOCOCCUS-PNEUMONIAE; CO-TRIMOXAZOLE; DEVELOPING-COUNTRIES; NEW-GUINEA; ETIOLOGY; VACCINE; PENICILLIN; SEROTYPES	87 strains of Streptococcus pneumoniae isolated during three winter seasons (1986-89) from the blood of children with acute lower respiratory tract infection (ALRI) in Pakistan were serotyped and tested for susceptibility to a range of antimicrobial agents. 97% of isolates were resistant to at least one antimicrobial drug. 62% had decreased susceptibility to co-trimoxazole (trimethoprim/sulphamethoxazole) (31% were fully resistant) and 39% were resistant to chloramphenicol. All isolates were susceptible to erythromycin, cefaclor, cephalothin, ceftriaxone, cefuroxime, rifampicin, vancomycin, and clindamycin. 29% of isolates were neither vaccine types nor vaccine-related types. Serotype distribution and antimicrobial susceptibility varied significantly during the three winter seasons. No single serotype was found in all three winters. The findings highlight the need for surveillance of antimicrobial resistance and serotype distribution of S pneumoniae in developing countries as a guide both to the choice of agent for treatment of pneumococcal infections, especially ALRI, and to the formulation of new pneumococcal conjugate vaccines for use in young children.	NATL INST HLTH,ISLAMABAD,PAKISTAN; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,DIV INFECT DIS,ST LOUIS,MO 63110; CTR DIS CONTROL,CTR INFECT DIS,HOSP INFECT PROGRAM,ANTIMICROB INVEST BRANCH,ATLANTA,GA 30333	Washington University (WUSTL); Centers for Disease Control & Prevention - USA	MASTRO, TD (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV BACTERIAL DIS,RESP DIS BRANCH,MAILSTOP C-09,ATLANTA,GA 30333, USA.		Anwar, Farooq/K-8137-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024332] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24332] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPELBAUM PC, 1987, EUR J CLIN MICROBIOL, V6, P367, DOI 10.1007/BF02013089; BROOME CV, 1981, REV INFECT DIS, V3, P277; CAMPBELL H, 1988, LANCET, V2, P1182; CHRETIEN J, 1984, NEW ENGL J MED, V310, P982, DOI 10.1056/NEJM198404123101509; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; ELMOUZAN MI, 1988, TROP GEOGR MED, V40, P213; GHAFOOR A, 1990, REV INFECT DIS, V12, pS907; GREENWOOD BM, 1970, LANCET, V1, P360; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; KEELEY DJ, 1990, B WORLD HEALTH ORGAN, V68, P185; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; LINARES J, 1983, EUR J CLIN MICROBIOL, V2, P473, DOI 10.1007/BF02013907; LINARES J, 1984, J ANTIMICROB CHEMOTH, V13, P353, DOI 10.1093/jac/13.4.353; MONTO AS, 1989, REV INFECT DIS, V11, P498; ONYEMELUKWE GC, 1982, J INFECTION, V5, P157, DOI 10.1016/S0163-4453(82)91772-8; OTIN CL, 1988, J ANTIMICROB CHEMOTH, V22, P659, DOI 10.1093/jac/22.5.659; PALLARES R, 1988, NEW ENGL J MED, V318, P124; RILEY ID, 1981, ARCH DIS CHILD, V56, P354, DOI 10.1136/adc.56.5.354; RILEY ID, 1986, LANCET, V2, P877; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005; SHANN F, 1984, LANCET, V2, P537; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553; WARD J, 1981, REV INFECT DIS, V3, P254; WEINBERG GA, 1990, B WORLD HEALTH ORGAN, V68, P179; WEINBERG GA, 1989, J INFECT DIS, V160, P634, DOI 10.1093/infdis/160.4.634; 1986, WHORSD85; 1986, B WORLD HEALTH ORGAN, V64, P929; 1988, WHOARI893; 1985, LANCET, V2, P699; 1988, LANCET, V1, P1142; 1986, WHORSD8626; 1988, METHODS DILUTION ANT	34	109	109	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					156	159		10.1016/0140-6736(91)90813-5	http://dx.doi.org/10.1016/0140-6736(91)90813-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670799				2022-12-01	WOS:A1991ET67900015
J	MILLER, NA; CARMICHAEL, HA; CALDER, BD; BEHAN, PO; BELL, EJ; MCCARTNEY, RA; HALL, FC				MILLER, NA; CARMICHAEL, HA; CALDER, BD; BEHAN, PO; BELL, EJ; MCCARTNEY, RA; HALL, FC			ANTIBODY TO COXSACKIE-B VIRUS IN DIAGNOSING POSTVIRAL FATIGUE SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYALGIC ENCEPHALOMYELITIS; INFECTIOUS-MONONUCLEOSIS; GENERAL-PRACTICE; PERSISTENT; EPIDEMIC; ILLNESS; DISEASE; MUSCLE	Objective-To study the association between coxsackie B virus infection and the postviral fatigue syndrome and to assess the immunological abnormalities associated with the syndrome. Design - Case-control study of patients with the postviral fatigue syndrome referred by local general practitioners over one year. Setting - General practioner referrals in Dunbartonshire, Scotland. Patients - 254 Patients referred with the postviral fatigue syndrome (exhaustion, myalgia, and other symptoms referable to postviral fatigue syndrome of fairly recent onset - that is, several months) and age and sex matched controls obtained from same general practitioner; 11 patients were rejected because of wrong diagnoses, resolution of symptoms, and refusal to participate, leaving 243 patients and matched controls. Main outcome measures - Detailed questionnaire (patients and controls) and clinical examination (patients) and blind analysis of blood sample at entry and after six months for determination of coxsackie B virus IgM and IgG antibodies and other variables (including lymphocyte protein synthesis, lymphocyte subsets, and immune complexes). Results - Percentage positive rates for coxsackie B virus IgM at entry were 24.4% for patients and 22.6% for controls and for coxsackie B virus IgG 56.2% and 55.3% respectively; there were no significant differences between different categories of patients according to clinical likelihood of the syndrome nor any predictive value in a fourfold rise or fall in the coxsackie B virus IgG titre in patients between entry and review at six months. The rates of positive antibody test results in patients and controls showed a strong seasonal variation. Of the numerous immunological tests performed, only a few detected significant abnormalities; in particular the mean value for immune complex concentration was much higher in 35 patients and 35 controls compared with the normal range and mean value for total IgM was also raised in 227 patients and 35 controls compared with the normal range. Conclusions - Serological tests available for detecting coxsackie B virus antibodies do not help diagnose the postviral fatigue syndrome. Percentage positive rates of the antibodies in patients simply reflect the background in the population as probably do the raised concentrations of total IgM and immune complexes.	VALE LEVEN HOSP, ALEXANDRIA G83 0UA, DUNBARTON, SCOTLAND; UNIV GLASGOW, NEUROL, GLASGOW G12 8QQ, SCOTLAND; RUCHILL HOSP, REG VIRUS LAB, GLASGOW G20 9NB, SCOTLAND	University of Glasgow								ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARCHARD LC, 1988, J EXP CLIN CANC RES, V7, P3; ARNOLD DL, 1984, LANCET, V1, P1367; BARNES DM, 1986, SCIENCE, V234, P541, DOI 10.1126/science.3020689; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BELL EJ, 1983, SCOT MED J, V28, P157, DOI 10.1177/003693308302800212; BORYSIEWICZ LK, 1986, Q J MED, V58, P111; CALDER BD, 1984, J ROY COLL GEN PRACT, V34, P15; CALDER BD, 1987, J ROY COLL GEN PRACT, V37, P11; DILLON MJ, 1974, BRIT MED J, V1, P301, DOI 10.1136/bmj.1.5903.301; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; FEGAN KG, 1983, J ROY COLL GEN PRACT, V33, P335; Grist N. R., 1979, DIAGNOSTIC METHODS C; HAMBLIN TJ, 1983, BRIT MED J, V287, P85, DOI 10.1136/bmj.287.6385.85; HENDERSON DA, 1959, NEW ENGL J MED, V260, P814, DOI 10.1056/NEJM195904162601606; HENDERSON DA, 1959, NEW ENGL J MED, V260, P757, DOI 10.1056/NEJM195904092601506; JAMAL GA, 1985, J NEUROL NEUROSUR PS, V48, P691, DOI 10.1136/jnnp.48.7.691; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; KADIRY WA, 1983, PROG BRAIN RES, V59, P61; KEIGHLEY BD, 1983, J ROY COLL GEN PRACT, V33, P339; MCCARTNEY RA, 1986, J MED VIROL, V19, P205, DOI 10.1002/jmv.1890190302; POOLE M, 1984, NZ MED J, V97, P351; Ramsay AM, 1986, POSTVIRAL FATIGUE SY, V1st; RICE GPA, 1984, J NEUROIMMUNOL, V6, P75, DOI 10.1016/0165-5728(84)90028-6; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; TOBI M, 1982, LANCET, V1, P61; YOUSEF GE, 1988, LANCET, V1, P146	29	70	71	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 19	1991	302	6769					140	143		10.1136/bmj.302.6769.140	http://dx.doi.org/10.1136/bmj.302.6769.140			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1847316	Green Published, Bronze			2022-12-01	WOS:A1991EU02000019
J	PICARDO, M; SCHOR, SL; GREY, AM; HOWELL, A; LAIDLAW, I; REDFORD, J; SCHOR, AM				PICARDO, M; SCHOR, SL; GREY, AM; HOWELL, A; LAIDLAW, I; REDFORD, J; SCHOR, AM			MIGRATION STIMULATING ACTIVITY IN SERUM OF BREAST-CANCER PATIENTS	LANCET			English	Article							FIBROBLAST PHENOTYPE; SKIN FIBROBLASTS; SCATTER FACTOR; FETAL; COLLAGEN; PURIFICATION; CELLS	An assay to measure the ability to stimulate migration of fibroblasts into collagen gel was carried out on serum from treated and untreated breast cancer patients and from healthy controls. Migration stimulating activity was found in the serum of 10 (83%) of 12 untreated breast cancer patients immediately before surgical resection of the primary tumour and in 9 (75%) of them 4 days after resection; in 13 (93%) of 14 patients 1-13 years after tumour resection who had received adjuvant treatment; and in 2 (10%) of 20 healthy women matched for age. The migration stimulating activity in cancer patients' serum was indistinguishable from the migration stimulating factor produced in vitro by fetal and cancer patient skin fibroblasts in its behaviour in various biochemical fractionation procedures. The presence of this activity in the serum of treated breast cancer patients clearly distinguishes it from other oncofetal proteins, which all seem to be produced by tumours.	UNIV MANCHESTER,DEPT CELL & STRUCT BIOL,COUPLAND 3 BLDG,MANCHESTER M13 9PL,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND	University of Manchester; Christie NHS Foundation Trust; Christie Hospital				Howell, Anthony/0000-0002-6233-719X				AZZARONE B, 1984, INT J CANCER, V33, P759, DOI 10.1002/ijc.2910330608; DECKER M, 1989, CANCER RES, V49, P3499; DURNING P, 1984, LANCET, V1, P890; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; HAGGIE J, 1987, LANCET, V1, P1477; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; OTTMAN R, 1983, LANCET, V2, P556; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P1079; SCHOR SL, 1985, J CELL SCI, V73, P235; SCHOR SL, 1979, J CELL SCI, V38, P267; SCHOR SL, 1987, BIOESSAYS, V7, P200, DOI 10.1002/bies.950070503; SCHOR SL, 1988, J CELL SCI, V90, P391; SCHOR SL, 1980, J CELL SCI, V41, P159; SCHOR SL, 1987, EXP CELL BIOL, V55, P11; SCHOR SL, 1986, INT J CANCER, V37, P831, DOI 10.1002/ijc.2910370606; SCHOR SL, 1987, BREAST CANCER SCI CL, P142; SCHOR SL, 1988, IN VITRO CELL DEV, V25, P137; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WARN RM, 1989, NATURE, V340, P186, DOI 10.1038/340186a0	20	19	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					130	133		10.1016/0140-6736(91)90798-T	http://dx.doi.org/10.1016/0140-6736(91)90798-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670786				2022-12-01	WOS:A1991ET67900002
J	RAVINE, D; WALKER, RG; GIBSON, RN; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM				RAVINE, D; WALKER, RG; GIBSON, RN; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM			TREATABLE COMPLICATIONS IN UNDIAGNOSED CASES OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE	LANCET			English	Article							INTRACRANIAL ANEURYSMS; BLOOD-PRESSURE; PROGRESSION; DIAGNOSIS; ONSET	In a study to determine the proportion of unrecognised cases and the prevalence of treatable complications of autosomal dominant polycystic kidney disease (ADPKD), 46 probands were identified through genetics and renal clinics in Melbourne, Australia. 321 offspring of the probands who were older than 15 years and had not been previously diagnosed as having ADPKD were identified. 68 (21%) had ultrasound evidence of polycystic kidney disease. Of this previously undiagnosed group, 25 (37%) had one or more treatable complications at the time of diagnosis. The complications included 20 cases of hypertension (diastolic blood pressure 95 mm Hg or above), 7 cases of impaired renal function (serum creatinine 0.12 mmol/l or above), and 4 cases of bacterial urinary tract infection. 8 people had several complications. ADPKD has an important treatable component which is not being treated in a substantial proportion of affected individuals, because the disease is not being diagnosed despite the presence of a positive family history.	UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT RADIOL,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT NEPHROL,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; University of Melbourne	RAVINE, D (corresponding author), ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA.		Ravine, David/A-6797-2008					BALDWIN DS, 1985, HYPERTENSION KIDNEY, pA57; BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BERGSTROM J, 1986, CLIN NEPHROL, V25, P1; CHURCHILL DN, 1984, KIDNEY INT, V26, P190, DOI 10.1038/ki.1984.154; COLEMAN AJ, 1966, J CLIN INVEST, V45, P1116, DOI 10.1172/JCI105418; DALGAARD O. Z., 1957, ACTA MED SCAND SUPPL, V158, P1; DISNEY APS, 1990, 13TH AUSTR NZ COMB D, P22; GARDNER KD, 1984, KIDNEY INT, V25, P244; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; KANNEL WB, 1976, STROKE, V7, P327, DOI 10.1161/01.STR.7.4.327; LEVEY AS, 1983, NEW ENGL J MED, V308, P986, DOI 10.1056/NEJM198304283081702; MCNAMARA JJ, 1965, AM J SURG, V109, P178; MILUTINOVIC J, 1980, AM J CLIN PATHOL, V73, P740; REEDERS ST, 1989, CLIN CHEM, V35, pB13; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; RYU SJ, 1990, STROKE, V21, P291, DOI 10.1161/01.STR.21.2.291; SIMON HB, 1955, JAMA-J AM MED ASSOC, V159, P657, DOI 10.1001/jama.1955.02960240023006; Tufveson G, 1989, NEPHROL DIAL TRAN S4, V4, P5; WAKABAYASHI T, 1983, J NEUROSURG, V58, P488, DOI 10.3171/jns.1983.58.4.0488; WERDER AA, 1984, J LAB CLIN MED, V103, P399; ZEIER M, 1988, NEPHRON, V49, P177, DOI 10.1159/000185052	22	22	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					127	129		10.1016/0140-6736(91)90797-S	http://dx.doi.org/10.1016/0140-6736(91)90797-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670785				2022-12-01	WOS:A1991ET67900001
J	SAVIC, I; WIDEN, L; STONEELANDER, S				SAVIC, I; WIDEN, L; STONEELANDER, S			FEASIBILITY OF REVERSING BENZODIAZEPINE TOLERANCE WITH FLUMAZENIL	LANCET			English	Article							POSITRON EMISSION TOMOGRAPHY; RECEPTOR OCCUPANCY; RO 15-1788; ANTAGONIST; RO-15-1788; INVIVO; MICE; BINDING; BRAIN	To examine whether the benzodiazepine antagonist flumazenil can reverse tolerance to benzodiazepines but without precipitating withdrawal seizures, the antiepileptic effect of flumazenil itself and its ability to reverse tolerance at a dose that would leave sufficient receptors free for the binding of benzodiazepines were investigated. Electroencephalographic studies in 6 patients with partial and 6 with generalised seizures showed that flumazenil had a short (20 min) non-dose-dependent suppressant effect on epileptic discharges in those with partial seizures. Receptor occupancy studies in 12 patients showed that 1.5 mg flumazenil given intravenously occupied 55% receptors, whereas 15 mg occupied nearly all receptors. When 3 patients with partial seizures who had become tolerant to clonazepam were given 1.5 mg flumazenil, they were seizure-free for 6-21 days after the injection. The value of intermittent therapy with a benzodiazepine antagonist for preventing or reversing tolerance to benzodiazepine agonists ought to be investigated further.	KAROLINSKA PHARM,STOCKHOLM,SWEDEN	Karolinska Institutet	SAVIC, I (corresponding author), KAROLINSKA HOSP,DEPT CLIN NEUROPHYSIOL,POB 60500,S-10401 STOCKHOLM 60,SWEDEN.							BORMANN J, 1988, CHLORIDE CHANNELS TH, P47; ERIKSSON L, 1988, IEEE T NUCL SCI, V35, P703, DOI 10.1109/23.12815; GALLAGER DW, 1984, NATURE, V308, P74, DOI 10.1038/308074a0; GASTAUT H, 1985, J CLIN NEUROPHYSIOL, V2, P313, DOI 10.1097/00004691-198510000-00001; GELLER E, 1985, ANESTHESIOLOGY, V63, pA157; GLOOR P, 1982, H GASTAUT MARSEILLES, P45; GONSALVES SF, 1987, BRAIN RES, V405, P94, DOI 10.1016/0006-8993(87)90993-0; GONSALVES SF, 1985, EUR J PHARMACOL, V110, P163, DOI 10.1016/0014-2999(85)90208-0; GRECKSCH G, 1983, LIFE SCI, V32, P2579, DOI 10.1016/0024-3205(83)90241-2; Haefley W, 1988, CHLORIDE CHANNELS TH, P275; HAIGH JRM, 1988, TRENDS PHARMACOL SCI, V9, P361, DOI 10.1016/0165-6147(88)90255-6; HALLDIN C, 1988, APPL RADIAT ISOTOPES, V39, P993; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; JENSEN LH, 1983, LIFE SCI, V33, P393, DOI 10.1016/S0024-3205(83)80014-9; LUKAS SE, 1982, SCIENCE, V217, P1161, DOI 10.1126/science.6287579; MENNINI T, 1982, LIFE SCI, V31, P2025, DOI 10.1016/0024-3205(82)90094-7; MILLER LG, 1987, J PHARMACOL EXP THER, V240, P516; NUTT DJ, 1988, LIFE SCI, V43, P1045, DOI 10.1016/0024-3205(88)90199-3; PERSSON A, 1989, Human Psychopharmacology, V4, P215, DOI 10.1002/hup.470040307; POTIER MC, 1988, LIFE SCI, V43, P1287, DOI 10.1016/0024-3205(88)90583-8; ROBERTSON HA, 1983, BRAIN RES, V270, P380, DOI 10.1016/0006-8993(83)90619-4; SAVIC I, 1988, LANCET, V2, P863, DOI 10.1016/S0140-6736(88)92468-3; SAVIC I, IN PRESS EPILEPSIA; SCOLLOLAVIZZARI G, 1984, EUR NEUROL, V23, P1, DOI 10.1159/000115669; SHINOTOH H, 1989, PSYCHOPHARMACOLOGY, V99, P202, DOI 10.1007/BF00442808; SWAHN C-G, 1989, Human Psychopharmacology, V4, P297, DOI 10.1002/hup.470040410; THEODORSSON E, 1988, COMPUT METH PROG BIO, V26, P207, DOI 10.1016/0169-2607(88)90046-6	27	82	83	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					133	137		10.1016/0140-6736(91)90799-U	http://dx.doi.org/10.1016/0140-6736(91)90799-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670787				2022-12-01	WOS:A1991ET67900003
J	[Anonymous]				[Anonymous]			SURGEONS AND HIV	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 19	1991	337	8734					169	169						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET679	1670803				2022-12-01	WOS:A1991ET67900021
J	BRENOWITZ, EA				BRENOWITZ, EA			ALTERED PERCEPTION OF SPECIES-SPECIFIC SONG BY FEMALE BIRDS AFTER LESIONS OF A FOREBRAIN NUCLEUS	SCIENCE			English	Article							WHITE-CROWNED SPARROW; AUDITORY RESPONSES; SEXUAL DIMORPHISM; ZEBRA FINCHES; CANARY; RECOGNITION; NEURONS; SYSTEM; BRAIN	Female birds that do not normally sing possess brain nuclei associated with song production in males. To determine whether one song nucleus, the caudal nucleus of the ventral hyperstriatum (HVc), acts in conspecific song perception, courtship responses of female canaries to canary and white-crowned sparrow songs were compared before and after HVc lesions. Bilateral lesions of a portion of the HVc resulted in copulation solicitations to heterospecific song as well as conspecific song. Control females continued to respond only to conspecific song. This suggests that the HVc is critical for conspecific song perception in females. Because female canaries do not normally sing, neurons in female HVc must develop response selectivity by a mechanism different from that proposed for male birds in the motor theory of song perception.	UNIV WASHINGTON, DEPT ZOOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	BRENOWITZ, EA (corresponding author), UNIV WASHINGTON, DEPT PSYCHOL, SEATTLE, WA 98195 USA.		Galantucci, Bruno/E-5770-2010		NIDCD NIH HHS [DC 00487] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC000487] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BAKER MC, 1981, SCIENCE, V214, P819, DOI 10.1126/science.214.4522.819; BAKER MC, 1984, BRAIN RES, V295, P85, DOI 10.1016/0006-8993(84)90818-7; Baptista L. F., 1975, U CALIF PUBL ZOOL, V105; BRENOWITZ E A, 1986, Society for Neuroscience Abstracts, V12, P314; Ingle, 1983, ADV VERTEBRATE NEURO; KATZ LC, 1981, BRAIN RES, V221, P192, DOI 10.1016/0006-8993(81)91073-8; KELLEY DB, 1979, J COMP NEUROL, V183, P455, DOI 10.1002/cne.901830302; KING AP, 1977, SCIENCE, V195, P1002, DOI 10.1126/science.841321; LIBERMAN AM, 1982, AM PSYCHOL, V37, P148, DOI 10.1037/0003-066X.37.2.148; MARGOLIASH D, 1986, J NEUROSCI, V6, P1643; MILLER DB, 1979, NATURE, V280, P389, DOI 10.1038/280389a0; MILLER DB, 1979, ANIM BEHAV, V27, P376, DOI 10.1016/0003-3472(79)90172-6; NOTTEBOHM F, 1978, Z TIERPSYCHOL, V46, P298; NOTTEBOHM F, 1976, SCIENCE, V194, P211, DOI 10.1126/science.959852; NOTTEBOHM F, 1982, J COMP NEUROL, V207, P344, DOI 10.1002/cne.902070406; NOTTEBOHM F, 1987, HDB PHYSL 1, P85; NOTTEBOHM F, 1984, BIOL PERSPECTIVES LA, P65; PESCH A, 1985, J ORNITHOL, V126, P108, DOI 10.1007/BF01640450; SEARCY WA, 1984, Z TIERPSYCHOL, V66, P128; SEARCY WA, 1988, NATURE, V332, P152, DOI 10.1038/332152a0; VOLMAN S F, 1987, Society for Neuroscience Abstracts, V13, P870; WILLIAMS H, 1985, SCIENCE, V229, P279, DOI 10.1126/science.4012321	22	209	212	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 18	1991	251	4991					303	305		10.1126/science.1987645	http://dx.doi.org/10.1126/science.1987645			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET678	1987645				2022-12-01	WOS:A1991ET67800030
J	FRASER, JD; IRVING, BA; CRABTREE, GR; WEISS, A				FRASER, JD; IRVING, BA; CRABTREE, GR; WEISS, A			REGULATION OF INTERLEUKIN-2 GENE ENHANCER ACTIVITY BY THE T-CELL ACCESSORY MOLECULE CD28	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; ANTIGEN RECEPTOR COMPLEX; ACTIVATION PATHWAY; CHROMOSOMAL GENE; LYMPHOCYTES-T; EXPRESSION; INDUCTION; PROMOTER; EVENTS; REGION	The mechanism by which cell surface molecules regulate T cell production of lymphokines is poorly understood. Production of interleukin-2 (IL-2) can be regulated by signal transduction pathways distinct from those induced by the T cell antigen receptor. Stimulation of CD28, a molecule expressed on most human T cells, induced the formation of a protein complex that bound to a site on the IL-2 gene distinct from previously described binding sites and increased IL-2 enhancer activity fivefold. The CD28-responsive complex bound to the IL-2 gene between - 164 and - 154 base pairs from the transcription start site. The sequence of this element is similar to regions conserved in the 5' flanking regions of several other lymphokine genes.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT IMMUNOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	FRASER, JD (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FRASER JD, UNPUB; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; HARA T, 1985, J EXP MED, V161, P1513, DOI 10.1084/jem.161.6.1513; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NAGATA S, 1986, EMBO J, V5, P575, DOI 10.1002/j.1460-2075.1986.tb04249.x; QUILL H, 1987, J IMMUNOL, V138, P3704; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TSUCHIYA M, 1987, EUR J BIOCHEM, V165, P7, DOI 10.1111/j.1432-1033.1987.tb11187.x; WEISS A, 1986, J IMMUNOL, V137, P819; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; YANG YC, 1987, LYMPHOKINES, V15, P375	34	652	699	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 18	1991	251	4991					313	316		10.1126/science.1846244	http://dx.doi.org/10.1126/science.1846244			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET678	1846244				2022-12-01	WOS:A1991ET67800034
J	HILLIS, DM; MORITZ, C; PORTER, CA; BAKER, RJ				HILLIS, DM; MORITZ, C; PORTER, CA; BAKER, RJ			EVIDENCE FOR BIASED GENE CONVERSION IN CONCERTED EVOLUTION OF RIBOSOMAL DNA	SCIENCE			English	Article							HETERONOTIA-BINOEI GEKKONIDAE; NON-HOMOLOGOUS CHROMOSOMES; MULTIGENE FAMILIES; MOLECULAR DRIVE; LINKAGE DISEQUILIBRIUM; IMMUNOGLOBULIN GENES; PARTHENOGENESIS; SEQUENCES; VARIANTS; REGIONS	Concerted evolution is the production and maintenance of homogeneity within repeated families of DNA. Two mechanisms-unequal crossing over and biased gene conversion-have been the principal explanation of concerted evolution. Concerted evolution of ribosomal DNA (rDNA) arrays is thought to be largely the result of unequal crossing over. However, concerted evolution of rDNA in parthenogenetic lizards of hybrid origin is strongly biased toward one of two parental sequences, which is consistent with biased gene conversion as the operative mechanism. The apparent gene conversions are independent of initial genome dosage and result in homogenization of rDNA arrays across all nucleolar organizer regions.	UNIV QUEENSLAND, DEPT ZOOL, ST LUCIA, QLD 4067, AUSTRALIA; TEXAS TECH UNIV, DEPT BIOL SCI, LUBBOCK, TX 79409 USA	University of Queensland; Texas Tech University System; Texas Tech University	HILLIS, DM (corresponding author), UNIV TEXAS, DEPT ZOOL, AUSTIN, TX 78712 USA.		Moritz, Craig/A-7755-2012; Hillis, David/L-5421-2019; Hillis, David M/B-4278-2008	Moritz, Craig/0000-0001-5313-7279; 				ARNHEIM N, 1980, P NATL ACAD SCI-BIOL, V77, P7323, DOI 10.1073/pnas.77.12.7323; Arnheim N., 1983, P38; ARNHEIM N, 1979, GENE, V7, P83, DOI 10.1016/0378-1119(79)90025-8; ARNOLD ML, 1988, CHROMOSOMA, V96, P368, DOI 10.1007/BF00330703; BALTIMORE D, 1981, CELL, V24, P592, DOI 10.1016/0092-8674(81)90082-9; CIMINO MC, 1972, SCIENCE, V175, P1484, DOI 10.1126/science.175.4029.1484; COEN ES, 1982, NATURE, V295, P564, DOI 10.1038/295564a0; COEN ES, 1982, J MOL BIOL, V153, P841; DAWLEY RM, 1989, BIOL UNISEXUAL VERTE, P1; DOVER G, 1982, NATURE, V299, P111, DOI 10.1038/299111a0; DOVER G, 1982, BIOSCIENCE, V32, P526, DOI 10.2307/1308904; DOVER GA, 1986, TRENDS GENET, V2, P159, DOI 10.1016/0168-9525(86)90211-8; DOVER GA, 1989, GENETICS, V122, P249; GOODMAN M, 1987, COLD SPRING HARB SYM, V52, P875, DOI 10.1101/SQB.1987.052.01.096; GOODPASTURE C, 1975, CHROMOSOMA, V53, P37, DOI 10.1007/BF00329389; HILLIS DM, 1989, INT CONGR SER, V824, P355; HILLIS DM, 1986, EVOLUTION, V40, P1275, DOI 10.1111/j.1558-5646.1986.tb05751.x; HILLIS DM, 1987, MOL BIOL EVOL, V4, P117; KRYSTAL M, 1981, P NATL ACAD SCI-BIOL, V78, P5744, DOI 10.1073/pnas.78.9.5744; LONG EO, 1980, ANNU REV BIOCHEM, V49, P727, DOI 10.1146/annurev.bi.49.070180.003455; MORITZ C, 1989, EVOLUTION, V43, P994, DOI 10.1111/j.1558-5646.1989.tb02545.x; MORITZ C, 1984, CHROMOSOMA, V89, P151, DOI 10.1007/BF00292899; MORITZ C, 1983, SCIENCE, V220, P735, DOI 10.1126/science.220.4598.735; MORITZ C, 1990, COPEIA, P333, DOI 10.2307/1446339; Moritz C., 1989, BIOL UNISEXUAL VERTE, P87; MOYZIS RK, 1987, CHROMOSOMA, V95, P375, DOI 10.1007/BF00333988; NAGYLAKI T, 1982, GENETICS, V100, P315; NAGYLAKI T, 1988, GENETICS, V120, P291; OHTA T, 1980, GENET RES, V36, P181, DOI 10.1017/S0016672300019790; OHTA T, 1981, GENETICS, V99, P555; OHTA T, 1983, P NATL ACAD SCI-BIOL, V80, P4079, DOI 10.1073/pnas.80.13.4079; RASCH EM, 1982, HISTOCHEMISTRY, V73, P515, DOI 10.1007/BF00493366; SCHERER S, 1980, SCIENCE, V209, P1380, DOI 10.1126/science.6251545; SEPERACK P, 1988, GENETICS, V119, P943; SLATKIN M, 1986, GENETICS, V112, P681; SMITH GP, 1973, COLD SPRING HARB SYM, V38, P507, DOI 10.1101/SQB.1974.038.01.055; TARTOF KD, 1973, COLD SPRING HARB SYM, V38, P491, DOI 10.1101/SQB.1974.038.01.053; UZZELL T, 1970, AM NAT, V104, P433, DOI 10.1086/282678	38	337	353	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 18	1991	251	4991					308	310		10.1126/science.1987647	http://dx.doi.org/10.1126/science.1987647			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET678	1987647				2022-12-01	WOS:A1991ET67800032
J	HIRANO, S; FUSE, S; SOHAL, GS				HIRANO, S; FUSE, S; SOHAL, GS			THE EFFECT OF THE FLOOR PLATE ON PATTERN AND POLARITY IN THE DEVELOPING CENTRAL-NERVOUS-SYSTEM	SCIENCE			English	Article							ACID-BINDING-PROTEIN; RETINOIC ACID; CHICK-EMBRYO; NEURAL-TUBE; LOCAL APPLICATION; MOUSE; LIMB; EXPRESSION; ORIGIN; CELLS	The effect of floor plate on cellular differentiation in the neural tube of quail embryos was examined. In the developing neural tube the floor plate, which consists of specialized neuroepithelial cells, is located in the ventral midline of the neural tube. When Hensen's node was extirpated the floor plate and notochord did not develop, and the normal differentiation of the ventral horn motor neurons and dorsal and ventral roots did not occur. When one side of the neural tube was deprived of notochord, the ventro-dorsal differentiation took place on both sides. However, when one side of the neural tube was deprived of the floor plate, the ventral horn motor neurons and dorsal and ventral roots did not develop on that side. These observations suggest that the floor plate influences motor neuron differentiation and acts as an intrinsic organizer to establish pattern and polarity in the developing nervous system.	MED COLL GEORGIA, DEPT ANAT, AUGUSTA, GA 30912 USA; NIIGATA UNIV, SCH MED, DEPT ANAT, NIIGATA 951, JAPAN	University System of Georgia; Augusta University; Niigata University					NICHD NIH HHS [HD 17800, HD 18280] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017800, R01HD018280] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARRON DH, 1946, J COMP NEUROL, V85, P149, DOI 10.1002/cne.900850202; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; CAJAL SRR, 1929, STUDIES VERTEBRATE N; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; FUJITA S, 1964, J COMP NEUROL, V122, P311, DOI 10.1002/cne.901220303; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; Jacobson M, 1978, DEV NEUROBIOLOGY; JESSELL TM, 1989, CIBA F SYMP, V144, P255; MADEN M, 1990, DEVELOPMENT, V109, P75; MADEN M, 1989, DEV BIOL, V135, P124, DOI 10.1016/0012-1606(89)90163-2; MADEN M, 1989, DEVELOPMENT S, V109; MOMOI M, 1990, DEV BRAIN RES, V54, P161, DOI 10.1016/0165-3806(90)90138-O; NICOLET G, 1970, Journal of Embryology and Experimental Morphology, V23, P79; PEREZCASTRO AV, 1989, P NATL ACAD SCI USA, V86, P8813, DOI 10.1073/pnas.86.22.8813; ROSENQUIST GLENN C., 1966, CARNEGIE INST WASH PUBL, V38, P71; SCHOENWOLF GC, 1989, J EXP ZOOL, V249, P271, DOI 10.1002/jez.1402490305; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; SPRATT NT, 1952, J EXP ZOOL, V120, P109, DOI 10.1002/jez.1401200105; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; VAESSEN MJ, 1989, DIFFERENTIATION, V40, P99, DOI 10.1111/j.1432-0436.1989.tb00819.x; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WENTWORTH LE, 1978, J COMP NEUROL, V177, P611, DOI 10.1002/cne.901770406	26	75	77	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 18	1991	251	4991					310	313		10.1126/science.1987648	http://dx.doi.org/10.1126/science.1987648			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET678	1987648				2022-12-01	WOS:A1991ET67800033
J	SIMARD, C; JOLICOEUR, P				SIMARD, C; JOLICOEUR, P			THE EFFECT OF ANTINEOPLASTIC DRUGS ON MURINE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	SCIENCE			English	Article							C57BL/6 MICE; LEUKEMIA-VIRUS; RETROVIRUS; INDUCTION; LYMPHOMAS; DISEASE; MOUSE	The murine acquired immunodeficiency syndrome (MAIDS) is associated with proliferation of target cells that have been infected by a defective retrovirus. To control the growth of this primary neoplasia, virus-inoculated mice were treated with antineoplastic drugs. Paradoxically, cyclophosphamide, which is also immunosuppressive, was very effective in preventing the appearance and progression of the disease, in restoring a normal T cell function, and in depleting the number of infected target cells. This result suggests that the proliferating infected target cells were responsible for the immunodeficiency.	UNIV MONTREAL,DEPT MICROBIOL & IMMUNOL,MONTREAL H3C 3J7,QUEBEC,CANADA; CLIN RES INST MONTREAL,MOLEC BIOL LAB,MONTREAL H2W 1R7,QUEBEC,CANADA	Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal								AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BULLER RML, 1987, J VIROL, V61, P383, DOI 10.1128/JVI.61.2.383-387.1987; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; DUPLAN JF, 1970, B CANCER, V57, P23; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FAUCI AS, 1990, J ALLERGY CLIN IMMUN, V66, P5; FREI E, 1974, CANCER RES, V34, P184; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HUANG M, 1989, SCIENCE, V246, P1614, DOI 10.1126/science.2480643; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; LATARJET R, 1962, INT J RADIAT BIOL RE, V5, P339, DOI 10.1080/09553006214550911; LEGRAND E, 1981, LEUKEMIA RES, V5, P223, DOI 10.1016/0145-2126(81)90107-7; Maniatis T., 1982, MOL CLONING; MARCHALORIS JJ, 1988, LYMPHOCYTE STRUCTURE; MISTRY PB, 1973, B CANCER, V60, P287; MOMPARLER RL, 1985, PHARMACOL THERAPEUT, V30, P287, DOI 10.1016/0163-7258(85)90053-1; MOSIER DE, 1985, J EXP MED, V161, P766, DOI 10.1084/jem.161.4.766; MOSIER DE, 1986, IMMUNOL INVEST, V15, P233, DOI 10.3109/08820138609026687; PATTENGALE PK, 1982, AM J PATHOL, V107, P362; SIMARD C, UNPUB; TURK JL, 1972, CLIN EXP IMMUNOL, V10, P285; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0	24	39	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 18	1991	251	4991					305	308		10.1126/science.1987646	http://dx.doi.org/10.1126/science.1987646			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET678	1987646				2022-12-01	WOS:A1991ET67800031
J	BERRY, GT; HEIDENREICH, R; KAPLAN, P; LEVINE, F; MAZUR, A; PALMIERI, MJ; YUDKOFF, M; SEGAL, S				BERRY, GT; HEIDENREICH, R; KAPLAN, P; LEVINE, F; MAZUR, A; PALMIERI, MJ; YUDKOFF, M; SEGAL, S			BRANCHED-CHAIN AMINO-ACID FREE PARENTERAL-NUTRITION IN THE TREATMENT OF ACUTE METABOLIC DECOMPENSATION IN PATIENTS WITH MAPLE SYRUP URINE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV PENN,SCH MED,DEPT PEDIAT & MED,PHILADELPHIA,PA 19104	University of Pennsylvania	BERRY, GT (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV BIOCHEM DEV & MOLEC DIS,34TH ST & CIVIC CTR BLVD,PHILADELPHIA,PA 19104, USA.		Levine, Fred/L-2693-2013	Levine, Fred/0000-0002-7336-2526; Berry, Gerard/0000-0001-5299-3313	NCRR NIH HHS [RR240] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Danner DJ, 1989, METABOLIC BASIS INHE, P671; ELSAS LJ, 1988, MODERN NUTRITION HLT, P1337; RUTLEDGE SL, 1990, J PEDIATR-US, V116, P125, DOI 10.1016/S0022-3476(05)81661-0; TOWNSEND I, 1982, AM J CLIN NUTR, V36, P359, DOI 10.1093/ajcn/36.2.359; WENDEL U, 1982, J INHERIT METAB DIS, V5, P25, DOI 10.1007/BF01799811; 1985, WHO TECH REP SER, V724, P71; 1989, RECOMMENDED DIETARY	7	25	27	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	1991	324	3					175	179		10.1056/NEJM199101173240307	http://dx.doi.org/10.1056/NEJM199101173240307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER471	1898534				2022-12-01	WOS:A1991ER47100007
J	CEBRATHOMAS, JA; DECKER, CL; SNYDER, LC; PILDER, SH; SILVER, LM				CEBRATHOMAS, JA; DECKER, CL; SNYDER, LC; PILDER, SH; SILVER, LM			ALLELE-SPECIFIC AND HAPLOID-SPECIFIC PRODUCT GENERATED BY ALTERNATIVE SPLICING FROM A MOUSE T-COMPLEX-RESPONDER LOCUS CANDIDATE	NATURE			English	Article							DISTORTER GENES; HAPLOTYPES; FAMILY; DNA	MOUSE t haplotypes represent a variant form of chromosome 17 that has evolved the ability to propagate through natural populations by the phenomenon of 'transmission ratio distortion' (TRD), in which heterozygous +/t males transmit their t-carrying chromosome to 95% or more of their offspring 1,2. Although multiple t-associated loci have a role in expression of this phenotype, only one-the t complex responder (Tcr) locus-is responsible for determining which of the two homologues of chromosome 17 will be transmitted at a high ratio 3. A candiate gene (Tcp-10b) for Tcr that is expressed in both meiotic and post-meiotic male germ cells has been cloned 4. But for this candiate gene to function as the haploid effector of TRD, the t-allele of this gene (Tcp-10b(t)) must express a unique product in a haploid-specific manner. Here we show that a change in the splicing pattern of Tcp-10b(t) transcripts occurs during sperm differentiation. This change results in a unique allele-specific and haploid-specific transcript which could encode a variant polypeptide that would fulfil the conditions required of the Tcr effector of TRD.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University								Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BULLARD DC, 1990, GENETICS, V124, P957; Klein J., 1986, NATURAL HIST MAJOR H; LYON MF, 1986, CELL, V44, P357, DOI 10.1016/0092-8674(86)90770-1; LYON MF, 1984, CELL, V37, P621, DOI 10.1016/0092-8674(84)90393-3; ROSEN LL, 1990, GENOMICS, V8, P134, DOI 10.1016/0888-7543(90)90235-M; SCHIMENTI J, 1987, J MOL BIOL, V194, P583, DOI 10.1016/0022-2836(87)90235-X; SCHIMENTI J, 1988, CELL, V55, P71, DOI 10.1016/0092-8674(88)90010-4; SILVER LM, 1985, ANNU REV GENET, V19, P179, DOI 10.1146/annurev.ge.19.120185.001143; WOLGEMUTH DJ, 1985, GAMETE RES, V12, P1, DOI 10.1002/mrd.1120120102	10	45	46	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 17	1991	349	6306					239	241		10.1038/349239a0	http://dx.doi.org/10.1038/349239a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1987476				2022-12-01	WOS:A1991ET51900055
J	DUBACH, UC; ROSNER, B; STURMER, T				DUBACH, UC; ROSNER, B; STURMER, T			AN EPIDEMIOLOGIC-STUDY OF ABUSE OF ANALGESIC DRUGS - EFFECTS OF PHENACETIN AND SALICYLATE ON MORTALITY AND CARDIOVASCULAR MORBIDITY (1968 TO 1987)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WORKING FEMALE POPULATION; RENAL-DISEASE; URORENAL DISORDERS; HEART-DISEASE; NEPHROPATHY; PROSTACYCLIN; SWITZERLAND; ASPIRIN	Background. Phenacetin abuse is known to produce kidney disease; salicylate use is supposed to prevent cardiovascular disease. We conducted a prospective, longitudinal epidemiologic study to examine the effects of these drugs on cause-specific mortality and on cardiovascular morbidity. Methods. In 1968 we evaluated a study group of 623 healthy women 30 to 49 years old who had evidence of a regular intake of phenacetin, as measured by urinary excretion of its metabolites, and a matched control group of 621 women. Salicylate excretion was also measured. All subjects were examined over a period of 20 years. Results. Life-table analyses of mortality during the 20 years, with adjustment for the year of birth, cigarette smoking, and length of follow-up, revealed significant differences between the groups in overall mortality (study group vs. control group, 74 vs. 27 deaths; relative risk, 2.2; 95 percent confidence interval, 1.5 to 3.3), deaths due to urologic or renal disease (relative risk, 16.1; 95 percent confidence interval, 3.9 to 66.1), deaths due to cancer (relative risk, 1.9; 95 percent confidence interval, 1.1 to 3.3), and deaths due to cardiovascular disease (relative risk, 2.9; 95 percent confidence interval, 1.5 to 5.5). The relative risk of cardiovascular disease (fatal or nonfatal myocardial infarction, heart failure, or stroke) was 1.8, and the 95 percent confidence interval 1.3 to 2.6. The odds ratio for the incidence of hypertension was 1.6, and the 95 percent confidence interval 1.2 to 2.1. The effects of phenacetin on morbidity and mortality, with adjustment for base-line salicylate excretion, were similar. In contrast, salicylate use had no effect on either mortality or morbidity. Conclusions. Regular use of analgesic drugs containing phenacetin is associated with an increased risk of hypertension and mortality and morbidity due to cardiovascular disease, as well as an increased risk of mortality due to cancer and urologic or renal disease. The use of salicylates carries no such risk.	HARVARD UNIV,SCH MED,CHANNING LAB,BOSTON,MA 02115	Harvard University; Harvard Medical School	DUBACH, UC (corresponding author), UNIV BASEL,KANTONSSPITAL,MED POLIKLIN,DEPT INTERNAL MED,PETERSGRABEN 4,CH-4031 BASEL,SWITZERLAND.		Stürmer, Til/AAB-5459-2022					[Anonymous], 1982, EPIDEMIOLOGIC RES; ARMITAGE P, 1971, STATISTICAL METHODS; Bengtsson U, 2017, SCAND J UROL, V51, P213, DOI 10.3109/00365596809135358; BRODIE BB, 1948, J PHARMACOL EXP THER, V94, P22; BUCKALEW VM, 1986, MEDICINE, V65, P291, DOI 10.1097/00005792-198609000-00002; CIABATTONI G, 1984, NEW ENGL J MED, V310, P279, DOI 10.1056/NEJM198402023100502; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; COVESMIT.JR, 1973, LANCET, V2, P70; DUBACH UC, 1983, NEW ENGL J MED, V308, P357, DOI 10.1056/NEJM198302173080703; DUBACH UC, 1968, HELV MED ACTA, V34, P297; DUBACH UC, 1971, AM J EPIDEMIOL, V93, P425, DOI 10.1093/oxfordjournals.aje.a121276; DUBACH UC, 1975, LANCET, V1, P539; DUBACH UC, 1967, GER MED MON, V12, P380; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; GLOOR F, 1982, PATHOLOGE, V3, P132; KALADELFOS G, 1976, NEPHRON, V16, P388, DOI 10.1159/000180624; KINCAIDSMITH P, 1978, KIDNEY INT, V13, P1, DOI 10.1038/ki.1978.1; KRISHNAS.S, 1974, AUST NZ J MED, V4, P426; MCGIFF JC, 1980, CLIN SCI, V59, pS105, DOI 10.1042/cs059105s; Moncada S., 1980, GOODMAN GILMANS PHAR, V6th., P668; MURRAY TG, 1983, ARCH INTERN MED, V143, P1687, DOI 10.1001/archinte.143.9.1687; NANRA RS, 1978, KIDNEY INT, V13, P79, DOI 10.1038/ki.1978.11; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PRESCOTT LF, 1982, DRUGS, V23, P75, DOI 10.2165/00003495-198223010-00004; SANDLER DP, 1989, NEW ENGL J MED, V320, P1238, DOI 10.1056/NEJM198905113201903; SPUHLER O, 1953, Z KLIN MED, V151, P1; VANE JR, 1978, AGENTS ACTIONS, V8, P430, DOI 10.1007/BF01968671	27	86	86	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	1991	324	3					155	160		10.1056/NEJM199101173240304	http://dx.doi.org/10.1056/NEJM199101173240304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER471	1984193				2022-12-01	WOS:A1991ER47100004
J	GOTOH, Y; NISHIDA, E; MATSUDA, S; SHIINA, N; KOSAKO, H; SHIOKAWA, K; AKIYAMA, T; OHTA, K; SAKAI, H				GOTOH, Y; NISHIDA, E; MATSUDA, S; SHIINA, N; KOSAKO, H; SHIOKAWA, K; AKIYAMA, T; OHTA, K; SAKAI, H			INVITRO EFFECTS ON MICROTUBULE DYNAMICS OF PURIFIED XENOPUS M-PHASE-ACTIVATED MAP KINASE	NATURE			English	Article							SERINE-THREONINE KINASE; PROTEIN-KINASE; PHOSPHORYLATION; INSULIN; OOCYTES; EGGS; CENTROSOMES; MATURATION; TYROSINE; EXTRACTS	THE protein kinase MAP kinase, also called MAP2 kinase, is a serine/threonine kinase whose activation and phosphorylation are induced by a variety of mitogens 1-6, and which is thought to have a critical role in a network of protein kinases in mitogenic signal transduction 1-7. A burst in kinase activation 8,9 and protein phosphorylation 10 may also be important in triggering the dramatic reorganization of the cell during the transition from interphase to mitosis. The interphase-metaphase transition of microtubule arrays is under the control of p34cd2 kinase 11, a central control element in the G2-M transition of the cell cycle 12. Here we show that a Xenopus kinase, closely related to the mitogen-activated mammalian MAP kinase, is phosphorylated and activated during M phase of meiotic and mitotic cell cycles, and that the interphase-metaphase transition of microtubule arrays can be induced by the addition of purified Xenous M phase-activated MAP kinase or mammalian mitogen-activated MAP kinase to interphase extracts in vitro.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,INST ZOOL,TOKYO 113,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN	University of Tokyo; University of Tokyo; Osaka University				Shiina, Nobuyuki/0000-0002-1854-4239				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; STITH BJ, 1984, DEV BIOL, V102, P79, DOI 10.1016/0012-1606(84)90176-3; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0	26	424	430	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 17	1991	349	6306					251	254		10.1038/349251a0	http://dx.doi.org/10.1038/349251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1702878				2022-12-01	WOS:A1991ET51900060
J	HAGAN, P; BLUMENTHAL, UJ; DUNN, D; SIMPSON, AJG; WILKINS, HA				HAGAN, P; BLUMENTHAL, UJ; DUNN, D; SIMPSON, AJG; WILKINS, HA			HUMAN IGE, IGG4 AND RESISTANCE TO REINFECTION WITH SCHISTOSOMA-HAEMATOBIUM	NATURE			English	Article							PROTECTIVE IMMUNITY; ANTIBODIES; MANSONI; CELLS; RESPONSES; MACROPHAGES; INVITRO; GAMMA	A WELL recognized feature of the immune response to parasitic helminth infections, including schistosomiasis, is the production of large amounts of specific and nonspecific IgE 1,2. Immunological pathways involving IgE can lead to damage to the developing schistosomulum 3-9 and it has been suggested that responses involving IgE could have evolved as protection against helminth infections 10,11. There has been no epidemiological evidence to support this idea and the only significant IgE responses known in man are those involved in the pathogenesis of allergic disease 12. Here we measure serological response during reinfection with S. haematobium and demonstrate that IgE antibodies in man can be beneficial. Our results support the hypothesis that the slow build-up of IgE to high levels and the early production of IgG4 antibodies, which may block IgE pathways 13,14, are responsible for delaying the development of protective immunity to S. haematobium.	UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, LIVERPOOL L3 5QA, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND; MRC LABS, FAJARA, SENEGAMBIA	Liverpool School of Tropical Medicine; University of Liverpool; University of London; London School of Hygiene & Tropical Medicine	HAGAN, P (corresponding author), NATL INST MED RES, DIV PARASITOL, LONDON NW7 1AA, ENGLAND.		Simpson, Amelia/HGB-1823-2022	Hagan, Paul/0000-0002-3516-2283; Dunn, David/0000-0003-1836-4446				AURIAULT C, 1990, J CLIN MICROBIOL, V28, P1918, DOI 10.1128/JCM.28.9.1918-1924.1990; Bundy DAP, 1990, PARASITISM HOST BEHA; BUTTERWORTH AE, 1974, NATURE, V252, P503, DOI 10.1038/252503a0; CAPRON A, 1975, NATURE, V253, P474, DOI 10.1038/253474a0; CAPRON A, 1989, CIBA F SYMP, V147, P153; CAPRON A, 1977, AM J TROP MED HYG, V26, P39, DOI 10.4269/ajtmh.1977.26.39; CAPRON A, 1977, PATHOL BIOL, V25, P287; CAPRON A, 1980, AM J TROP MED HYG, V29, P849, DOI 10.4269/ajtmh.1980.29.849; CAPRON A, 1982, PROG ALLERGY, V31, P234; Capron M., 1980, T ROY SOC TROP MED H, V74, P44, DOI [10.1016/0035-9203(80)90272-2, DOI 10.1016/0035-9203(80)90272-2]; CHRETIEN I, 1988, J IMMUNOL, V141, P3128; DEAN DA, 1974, AM J TROP MED HYG, V23, P420, DOI 10.4269/ajtmh.1974.23.420; DESSAINT JP, 1975, CLIN EXP IMMUNOL, V20, P427; DUNNE DW, 1988, EUR J IMMUNOL, V18, P123, DOI 10.1002/eji.1830180119; HAGAN P, 1985, PARASITE IMMUNOL, V7, P625, DOI 10.1111/j.1365-3024.1985.tb00106.x; HAGAN P, 1987, T ROY SOC TROP MED H, V81, P938, DOI 10.1016/0035-9203(87)90359-2; HUSSAIN R, 1986, J IMMUNOL, V136, P1859; ISHIZAKA A, 1990, CLIN EXP IMMUNOL, V79, P392; ISKANDER R, 1981, INT ARCH ALLER A IMM, V66, P200, DOI 10.1159/000232819; JAMES SL, 1982, CELL IMMUNOL, V67, P255, DOI 10.1016/0008-8749(82)90218-0; KHALIFE J, 1986, J EXP MED, V164, P1626, DOI 10.1084/jem.164.5.1626; OGILVIE BM, 1964, NATURE, V204, P91, DOI 10.1038/204091a0; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; STANWORTH D R, 1973, Clinical Allergy, V3, P37, DOI 10.1111/j.1365-2222.1973.tb01307.x; STURROCK RF, 1983, T ROY SOC TROP MED H, V77, P363, DOI 10.1016/0035-9203(83)90166-9; TURNER KJ, 1989, CIBA F SYMP, V147, P205; WILKINS HA, 1987, T ROY SOC TROP MED H, V81, P29, DOI 10.1016/0035-9203(87)90273-2; WILKINS HA, 1988, BIOL SCHISTOSOMES	30	579	592	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 17	1991	349	6306					243	245		10.1038/349243a0	http://dx.doi.org/10.1038/349243a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1898985				2022-12-01	WOS:A1991ET51900057
J	HILLNER, BE; SMITH, TJ				HILLNER, BE; SMITH, TJ			EFFICACY AND COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY IN WOMEN WITH NODE-NEGATIVE BREAST-CANCER - A DECISION-ANALYSIS MODEL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; THERAPY; SURVIVAL; CARCINOMA	Background. In 1988 the National Cancer Institute issued a Clinical Alert that has been widely interpreted as recommending that all women with node-negative breast cancer receive adjuvant chemotherapy. Acceptance of this recommendation is controversial, since many women who would not have a recurrence would be treated. Methods. Using a decision-analysis model, we studied the cost effectiveness of chemotherapy in cohorts of 45-year-old and 60-year-old women with node-negative breast cancer by calculating life expectancy as adjusted for quality of life. The analysis evaluated different scenarios of the benefit of therapy: improved disease-free survival for five years, with a lesser effect on overall survival (base line); a lifelong benefit from chemotherapy; and a benefit in disease-free survival with no change in overall survival by year 10. The base-line analysis assumed a 30 percent reduction in the relative risk of recurrence for five years after treatment. Results. For the 45-year-old woman, the base-line analysis found an average lifetime benefit from chemotherapy of 5.1 quality-months at a cost of $15,400 per quality-year. The 60-year-old women gained 4.0 quality months at a cost of $18,800 per quality-year. Under the more and less optimistic scenarios, the benefit of chemotherapy varied from 1.4 to 14.0 quality-months for both groups. Conclusions. Chemotherapy substantially increases the quality-adjusted life expectancy of an average woman at a cost comparable to that of other widely accepted therapies. This benefit decreases markedly if the changes in long-term survival are less than in disease-free survival. Given its uncertain duration, the benefit may be too small for many women to choose chemotherapy. Selective use of chemotherapy to maximize the benefit to individual patients may be possible with refinements in risk stratification and explicit assessment of the patients' risk preferences.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,JOHN N DALTON ONCOL CLIN,RICHMOND,VA 23298	Virginia Commonwealth University	HILLNER, BE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,DIV GEN INTERNAL MED,BOX 170,MCV STN,RICHMOND,VA 23298, USA.		Hillner, Bruce/A-6852-2009	Smith, Thomas/0000-0003-3040-6434				BAKER MS, 1989, CANCER CARE AND COST, P127; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BONADONNA G, 1987, SEMIN ONCOL, V14, P8; BONADONNA G, 1989, J CLIN ONCOL, V7, P1380, DOI 10.1200/JCO.1989.7.10.1380; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; DETSKY AS, 1989, JAMA-J AM MED ASSOC, V262, P1795, DOI 10.1001/jama.262.13.1795; DEVITA VT, 1989, NEW ENGL J MED, V320, P527, DOI 10.1056/NEJM198902233200812; DURBIN M, 1988, PEDIATRICS, V82, P774; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FISHER B, 1989, NEW ENGL J MED, V320, P473, DOI 10.1056/NEJM198902233200801; FISHER B, 1975, SURG GYNECOL OBSTET, V140, P528; FISHER ER, 1986, NATL CANCER I MONOGR, V1, P29; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; GINSBURG AD, 1989, CAN MED ASSOC J, V141, P381; GOLDSMITH M, 1987, ONCOLOGY, V1, P54; HENDERSON IC, 1987, J CLIN ONCOL, V5, P1135, DOI 10.1200/JCO.1987.5.8.1135; HENDERSON IC, 1987, SEMIN ONCOL, V14, P34; HENDERSON IC, 1988, NEW ENGL J MED, V318, P443, DOI 10.1056/NEJM198802183180709; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; INGLE JN, 1990, NEW ENGL J MED, V322, P329, DOI 10.1056/NEJM199002013220511; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006; MCGUIRE WL, 1989, NEW ENGL J MED, V320, P525, DOI 10.1056/NEJM198902233200811; MULLEY AG, 1989, MED CARE, V27, pS269, DOI 10.1097/00005650-198903001-00021; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; NORTON L, 1985, SEMIN ONCOL, V12, P231; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SIMES RJ, 1989, P AN M AM SOC CLIN, V8, P52; SIMINOFF LA, 1989, J CLIN ONCOL, V7, P1192, DOI 10.1200/JCO.1989.7.9.1192; Sox HC, 1988, MED DECISION MAKING; STANGE PV, 1978, NEW ENGL J MED, V298, P372, DOI 10.1056/NEJM197802162980705; SULKES A, 1979, J NATL CANCER I, V62, P513, DOI 10.1093/jnci/62.3.513; TANNOCK IF, 1989, NEW ENGL J MED, V321, P471; TSEVAT J, 1989, MED DECIS MAKING, V9, P162, DOI 10.1177/0272989X8900900303; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; Weinstein MC, 1980, CLIN DECISION ANAL; WEINSTEIN ND, 1989, SCIENCE, V246, P1232, DOI 10.1126/science.2686031; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; [No title captured]; 1989, STATISTICAL ABSTRACT, P73; 1988, CLIN ALERT; 1985, JAMA-J AM MED ASSOC, V254, P3461; 1988, NEW ENGL J MED, V319, P1681; 1989, NEW ENGL J MED, V320, P491	47	193	194	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	1991	324	3					160	168		10.1056/NEJM199101173240305	http://dx.doi.org/10.1056/NEJM199101173240305			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER471	1898533				2022-12-01	WOS:A1991ER47100005
J	MCDONNELL, TJ; KORSMEYER, SJ				MCDONNELL, TJ; KORSMEYER, SJ			PROGRESSION FROM LYMPHOID HYPERPLASIA TO HIGH-GRADE MALIGNANT-LYMPHOMA IN MICE TRANSGENIC FOR THE T(14, 18)	NATURE			English	Article							C-MYC ONCOGENE; CHROMOSOME TRANSLOCATIONS; NUCLEOTIDE-SEQUENCE; FOLLICULAR LYMPHOMA; BURKITT-LYMPHOMA; CELL SURVIVAL; GENE; REGION; LOCUS; ACTIVATION	FOLLICULAR lymphoma, the most common human lymphoma, characteristically has a t(14; 18) interchromosomal translocation 1,2. Its is typically an indolent disease comprised of small resting B cells, but frequently develops into a high-grade lymphoma 3. The t(14; 18) translocates the Bcl-2 gene, generating a deregulated Bcl-2-immunoglobulin fusion gene 4-8. Bcl-2 is a novel inner mitochondrial membrane protein 9 that extends the survival of certain cells by blocking programmed cell death 9-11. To determine the oncogenic potential of the t(14; 18) translocation, we produced transgenic mice bearing a Bcl-2-immunoglobulin minigene that structurally mimicked the t(14; 18) (ref. 12). An indolent follicular hyperplasia in these transgenic mice progressed to a malignant diffuse large-cell lymphoma. The long latency, progression from polyclonal to monoclonal disease, and histological conversion, are all suggestive of secondary changes. Half of the immunoblastic high-grade lymphomas had a rearranged c-myc gene. Our transgenic mice provide an animal model for tumour progression in t(14; 18) lymphoma and show that prolonged B-cell life increases tumour incidence.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	MCDONNELL, TJ (corresponding author), WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, 660 S EUCLID, ST LOUIS, MO 63110 USA.							ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CRISSMAN HA, 1973, J CELL BIOL, V59, P766, DOI 10.1083/jcb.59.3.766; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCDONNELL TJ, 1990, CELL, V10, P1901; NUNEZ G, 1990, J IMMUNOL, V144, P3602; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; PATTENGALE PK, 1983, AM J PATHOL, V113, P235; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STANTON LW, 1982, NUCLEIC ACIDS RES, V10, P5993, DOI 10.1093/nar/10.19.5993; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	28	811	838	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 17	1991	349	6306					254	256		10.1038/349254a0	http://dx.doi.org/10.1038/349254a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1987477				2022-12-01	WOS:A1991ET51900061
J	PEVNY, L; SIMON, MC; ROBERTSON, E; KLEIN, WH; TSAI, SF; DAGATI, V; ORKIN, SH; COSTANTINI, F				PEVNY, L; SIMON, MC; ROBERTSON, E; KLEIN, WH; TSAI, SF; DAGATI, V; ORKIN, SH; COSTANTINI, F			ERYTHROID-DIFFERENTIATION IN CHIMERIC MICE BLOCKED BY A TARGETED MUTATION IN THE GENE FOR TRANSCRIPTION FACTOR GATA-1	NATURE			English	Article							DNA-BINDING FACTOR; STEM-CELLS; EXPRESSION; PROTEIN	THE zinc-finger transcription factor GATA-1 (previously known as GF-1, NF-E1 or Eryf 1 (refs 1-5)) binds to GATA consensus elements in regulatory regions of the alpha- and beta-globin gene clusters 2-6 and other erythroid cell-specific genes 7-9. Analysis of the effects of mutations in GATA-bindig sites in cell culture and in binding assays in vitro 2,5,10,11, as well as transactivation studies with GATA-1 expression vectors in heterologous cells 12, have provided indirect evidence that this factor is involved in the activation of globin and other genes during erythroid cell maturation. GATA-1 is also expressed in megakaryocyte 13,14 and mast cells, but not in other blood cell lineages or in non-haemopoietic cells. To investigate the role of this factor in haematopoiesis in vivo, we disrupted the X-linked GATA-1 gene by homologous recombination in a male (XY) murine embryonic stem cell line and tested the GATA-1-deficient cells for their ability to contribute to different tissues in chimaeric mice. The mutant embryonic stem cells contributed to all non-haemopoietic tissues tested and to a white blood cell fraction, but failed to give rise to mature red blood cells. This demonstrates that GATA-1 is required for the normal differentiation of erythroid cells, and that other GATA-binding proteins 15,16 cannot compensate for its absence.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,701 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Columbia University; Columbia University; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute			Simon, Celeste/AAG-3941-2021; Tsai, Shih-Feng/E-3997-2010					BRADY HJM, 1989, FEBS LETT, V257, P451, DOI 10.1016/0014-5793(89)81594-7; DICHIARA TM, 1990, NATURE, V344, P78; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FLEISCHMAN RA, 1982, CELL, V30, P351, DOI 10.1016/0092-8674(82)90233-1; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; MANSOUR SL, 1988, NATURE, V236, P438; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MCLAREN A, 1981, GENET RES CAMB, V37, P305; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RUSSELL ES, 1974, ANN NY ACAD SCI, V241, P25, DOI 10.1111/j.1749-6632.1974.tb21864.x; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YAMAMOTO M, IN PRESS GENES DEV; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	30	1111	1138	2	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 17	1991	349	6306					257	260		10.1038/349257a0	http://dx.doi.org/10.1038/349257a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1987478				2022-12-01	WOS:A1991ET51900062
J	SERAFINI, T; STENBECK, G; BRECHT, A; LOTTSPEICH, F; ORCI, L; ROTHMAN, JE; WIELAND, FT				SERAFINI, T; STENBECK, G; BRECHT, A; LOTTSPEICH, F; ORCI, L; ROTHMAN, JE; WIELAND, FT			A COAT SUBUNIT OF GOLGI-DERIVED NON-CLATHRIN-COATED VESICLES WITH HOMOLOGY TO THE CLATHRIN-COATED VESICLE COAT PROTEIN BETA-ADAPTIN	NATURE			English	Article							CELL-FREE SYSTEM; LUMINAL ER PROTEINS; BREFELDIN-A; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; INTERCOMPARTMENTAL TRANSPORT; SUCCESSIVE COMPARTMENTS; INTRACELLULAR-TRANSPORT; VESICULAR TRANSPORT; SECRETORY PROTEINS	Four high-molecular-weight proteins form the main subunits of the coat of Golgi-derived (non-clathrin) coated vesicles. One of these coat proteins, beta-COP, is identical to a Golgi-associated protein of relative mass 110,000 (110K) that shares homology with the adaptin proteins of clathrin-coated vesicles. This connection, and the comparable molecular weights of the coat proteins of Golgi-derived and clathrin-coated vesicles, indicates that they may be structurally related. The identification of beta-COP as the 110K protein explains the blocking of secretion by the drug brefeldin A.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; UNIV HEIDELBERG,INST BIOCHEM 1,W-6900 HEIDELBERG,GERMANY; MAX PLANCK INST BIOCHEM,GENZENTRUM,W-8033 MARTINSRIED,GERMANY; UNIV GENEVA,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND	Princeton University; Ruprecht Karls University Heidelberg; Max Planck Society; University of Geneva	SERAFINI, T (corresponding author), STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305, USA.							AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BALCH WE, 1983, METHOD ENZYMOL, V98, P37; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; JAMIESON JD, 1967, J CELL BIOL, V34, P577, DOI 10.1083/jcb.34.2.577; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1985, P NATL ACAD SCI USA, V82, P5385, DOI 10.1073/pnas.82.16.5385; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEARSE BMF, 1975, J MOL BIOL, V97, P93, DOI 10.1016/S0022-2836(75)80024-6; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; ROTHMAN JE, 1984, J CELL BIOL, V99, P260, DOI 10.1083/jcb.99.1.260; SCHOOK W, 1979, P NATL ACAD SCI USA, V76, P116, DOI 10.1073/pnas.76.1.116; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	51	311	318	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 17	1991	349	6306					214	220		10.1038/349215a0	http://dx.doi.org/10.1038/349215a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1898984				2022-12-01	WOS:A1991ET51900046
J	SPEISER, PW; AGDERE, L; UESHIBA, H; WHITE, PC; NEW, MI				SPEISER, PW; AGDERE, L; UESHIBA, H; WHITE, PC; NEW, MI			ALDOSTERONE SYNTHESIS IN SALT-WASTING CONGENITAL ADRENAL-HYPERPLASIA WITH COMPLETE ABSENCE OF ADRENAL 21-HYDROXYLASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA DEOXYCORTICOSTERONE; STEROID 21-HYDROXYLATION; DEFICIENCY; GENE; PROGESTERONE; WOMEN; CYTOCHROME-P-450-1; RADIOIMMUNOASSAY; REARRANGEMENTS; FASCICULATA	Background: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is a disorder of cortisol and aldosterone biosynthesis that results from mutations in the CYP21 gene encoding the adrenal 21-hydroxylase P-450c21. It can cause severe salt wasting in newborns that requires long-term treatment with glucocorticoids and mineralocorticoids. We describe a spontaneous partial recovery from this disorder in a 19-year-old woman who had discontinued treatment. Methods. We measured plasma and urinary levels of adrenal hormones, plasma renin activity, and sodium balance longitudinally in the patient and four other patients in whom adrenal hyperplasia had been diagnosed in infancy and in whom DNA analysis had predicted a complete absence of functional P-450c21. The ratio of plasma renin activity to urinary aldosterone was used as a measure of the response of the adrenal zona glomerulosa. Two patients underwent intravenous infusion of [H-3]progesterone for the measurement of extraadrenal production of 21-hydroxylated precursors of aldosterone. Results. The patient who had discontinued her medication excreted a normal amount of aldosterone (20.0 nmol per square meter of body-surface area per day) while following a diet low in sodium. Her ratio of plasma renin activity to urinary aldosterone-18-glucuronide excretion was 1.7 after three days of sodium restriction, as compared with a ratio of 4.7 at the age of nine years (normal range, 0.03 to 0.1). The percentage of extraadrenal conversion of progesterone to deoxycorticosterone was low. The four other patients had variable responses to sodium restriction after the neonatal period (range for plasma renin activity:urinary aldosterone-18-glucuronide, 1.9 to 19.4). Conclusions. Although patients with salt-wasting 21-hydroxylase deficiency have functionally equivalent mutations in their CYP21 genes, they may vary from one another and over time in their ability to produce mineralocorticoids. This variation may be attributable to another adrenal enzyme with 21-hydroxylase activity.			SPEISER, PW (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,DEPT PEDIAT,525 E 68TH ST,NEW YORK,NY 10021, USA.				NCRR NIH HHS [RR-47, RR-06020-01] Funding Source: Medline; NICHD NIH HHS [HD-00072] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD000072, R01HD000072] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; ANTONIPILLAI I, 1983, J CLIN ENDOCR METAB, V56, P93, DOI 10.1210/jcem-56-1-93; ANTONIPILLAI I, 1983, J CLIN ENDOCR METAB, V57, P580, DOI 10.1210/jcem-57-3-580; CHAKMAKJIAN ZH, 1974, ANAL LETT, V7, P97; CHIOU SH, 1990, J BIOL CHEM, V265, P3549; DIETER HH, 1982, BIOCHEM BIOPH RES CO, V105, P515, DOI 10.1016/0006-291X(82)91465-6; DUPONT B, 1984, HISTOCOMPATIBILITY T, P660; GLOBERMAN H, 1988, J CLIN INVEST, V82, P139, DOI 10.1172/JCI113562; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; HORNER JM, 1979, J CLIN ENDOCR METAB, V48, P776, DOI 10.1210/jcem-48-5-776; JOHNSON EF, 1989, ARCH BIOCHEM BIOPHYS, V273, P273, DOI 10.1016/0003-9861(89)90484-0; KORTHSCHUTZ S, 1978, J CLIN ENDOCR METAB, V46, P452, DOI 10.1210/jcem-46-3-452; KUHNLE U, 1981, J CLIN ENDOCR METAB, V52, P534, DOI 10.1210/jcem-52-3-534; LUETSCHER JA, 1962, T ASSOC AM PHYSICIAN, V75, P293; MACDONALD PC, 1982, J CLIN INVEST, V69, P469, DOI 10.1172/JCI110471; MELLON SH, 1989, J CLIN INVEST, V84, P1497, DOI 10.1172/JCI114325; MOREL Y, 1989, J CLIN INVEST, V83, P527, DOI 10.1172/JCI113914; MOREL Y, 1989, J CLIN ENDOCR METAB, V68, P592, DOI 10.1210/jcem-68-3-592; NEW MI, 1970, J CLIN ENDOCR METAB, V30, P361, DOI 10.1210/jcem-30-3-361; NEW MI, 1966, J CLIN INVEST, V45, P412, DOI 10.1172/JCI105356; OKINO ST, 1987, J BIOL CHEM, V262, P16072; OKINO ST, 1988, J BIOL CHEM, V263, P2576; PANG S, 1977, J CLIN ENDOCR METAB, V45, P1003, DOI 10.1210/jcem-45-5-1003; PRADER A, 1958, Helv Paediatr Acta, V13, P5; PREIBISZ JJ, 1982, CARDIOVASC REV REP, V3, P787; RAUH W, 1978, KLIN WOCHENSCHR, V56, P161, DOI 10.1007/BF01477468; ROSENBLOOM AL, 1966, PEDIATRICS, V38, P215; SINNOTT PJ, 1989, J MED GENET, V26, P10, DOI 10.1136/jmg.26.1.10; STONER E, 1986, CLIN ENDOCRINOL, V24, P9, DOI 10.1111/j.1365-2265.1986.tb03249.x; STRACHAN T, 1990, CLIN ENDOCRINOL, V32, P373, DOI 10.1111/j.1365-2265.1990.tb00878.x; TUKEY RH, 1985, J BIOL CHEM, V260, P3347; TUSIELUNA MT, 1990, J BIOL CHEM, V265, P20916; WHITE PC, 1989, ENDOCR RES, V15, P239, DOI 10.1080/07435808909039099; WHITE PC, 1984, P NATL ACAD SCI-BIOL, V81, P7505, DOI 10.1073/pnas.81.23.7505; WHITE PC, 1987, NEW ENGL J MED, V316, P1580, DOI 10.1056/NEJM198706183162506; WHITE PC, 1988, P NATL ACAD SCI USA, V85, P4436, DOI 10.1073/pnas.85.12.4436; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; WHITE PC, 1987, NEW ENGL J MED, V316, P1519, DOI 10.1056/NEJM198706113162406; WINKEL CA, 1980, J CLIN INVEST, V66, P803, DOI 10.1172/JCI109918; WINKEL CA, 1983, J CLIN ENDOCR METAB, V56, P104, DOI 10.1210/jcem-56-1-104	40	63	65	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	1991	324	3					145	149		10.1056/NEJM199101173240302	http://dx.doi.org/10.1056/NEJM199101173240302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER471	1984191				2022-12-01	WOS:A1991ER47100002
J	TEH, HS; GARVIN, AM; FORBUSH, KA; CARLOW, DA; DAVIS, CB; LITTMAN, DR; PERLMUTTER, RM				TEH, HS; GARVIN, AM; FORBUSH, KA; CARLOW, DA; DAVIS, CB; LITTMAN, DR; PERLMUTTER, RM			PARTICIPATION OF CD4 CORECEPTOR MOLECULES IN T-CELL REPERTOIRE SELECTION	NATURE			English	Article							ANTIGEN RECEPTOR; TRANSGENIC MICE; RECOGNITION; EXPRESSION; LINES; MOUSE; GENE	DURING thymocyte development, progenitor cells bearing both CD4 and CD8 coreceptor molecules mature into functional T lymphocytes that express these proteins in a mutually exclusive way 1. Although T-cell specificity is determined primarily by the structure of the T-cell antigen receptor (TCR) heterodimer 2, a developmentally regulated process acts to ensure that cells bearing class II-restricted TCRs are CD4+ and those bearing class I-restricted TCRs express, only CD8 (ref.3). To investigate this maturation process, we have engineered transgenic mice in which CD4 is expressed in all thymocyte subsets and in all peripheral T cells. Peripheral CD4+8+ T lymphocytes from these mice react with both class I and class II alloantigens. Moreover, expression of the CD4 transgene disrupts the positive selection of doubly transgenic thymocytes bearing a class I-restricted TCR specific for the male (H-Y) antigen. Hence the CD4 coreceptor participates directly in T-cell repertoire selection.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT IMMUNOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED MED GENET, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL, VANCOUVER V6T 1W5, BC, CANADA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of British Columbia			Teh, Hung-Sia/A-5710-2008					BAILEY DW, 1971, IMMUNOGENETICS H2 SY, P155; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; CHAFFIN K, IN PRESS EMBO J; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; GALLAGHER PF, 1989, P NATL ACAD SCI USA, V86, P10044, DOI 10.1073/pnas.86.24.10044; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEWIS DB, IN PRESS J EXP MED; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MCKENZIE IFC, 1979, J EXP MED, V150, P1323, DOI 10.1084/jem.150.6.1323; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROBEY E, 1990, CELL, V60, P697, DOI 10.1016/0092-8674(90)90082-P; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STAERZ UD, 1985, J IMMUNOL, V134, P3994; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; Teh H S, 1990, Dev Immunol, V1, P1, DOI 10.1155/1990/18208; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	27	85	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 17	1991	349	6306					241	243		10.1038/349241a0	http://dx.doi.org/10.1038/349241a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1824796				2022-12-01	WOS:A1991ET51900056
J	WATERS, MG; SERAFINI, T; ROTHMAN, JE				WATERS, MG; SERAFINI, T; ROTHMAN, JE			COATOMER - A CYTOSOLIC PROTEIN COMPLEX CONTAINING SUBUNITS OF NON-CLATHRIN-COATED GOLGI TRANSPORT VESICLES	NATURE			English	Article							BREFELDIN-A; ENDOPLASMIC-RETICULUM	GOLGI-derived coated vesicles contain a set of coat proteins of relative molecular mass 160,000 (M(r) 160K; alpha-COP), 110K (beta-COP), 98K (gamma-COP) and 61K (delta-COP), and several smaller subunits 1. We have now identified and purified a cytosolic complex containing the same four coat proteins as those of Golgi transport vesicles. We term this complex the Golgi coat promoter or 'coatomer'. The customer also contains polypeptides of M(r) 36K, 35K and 20K. It represents about 0.2% of soluble cytosolic protein. Gel filtration of unfractionated cytosol indicates that beta-COP resides exclusively in the coatomer complex. The complex seems to be a likely candidate for the unassembled precursor of Golgi coated vesicles, and its purification should help investigations of the role of coat proteins in membrane budding, for which it is necessary to use a refined cell-free system.			WATERS, MG (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.							ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	15	434	447	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 17	1991	349	6306					248	251		10.1038/349248a0	http://dx.doi.org/10.1038/349248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1898986				2022-12-01	WOS:A1991ET51900059
J	BATES, DW; GOLDMAN, L; LEE, TH				BATES, DW; GOLDMAN, L; LEE, TH			CONTAMINANT BLOOD CULTURES AND RESOURCE UTILIZATION - THE TRUE CONSEQUENCES OF FALSE-POSITIVE RESULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COSTS	To determine whether contaminant blood cultures increase resource utilization, we studied charge and length of stay data for episodes in which blood cultures were obtained from hospitalized adults. Compared with 1097 negative episodes, 94 false-positive episodes were associated with increased subsequent length of stay (median, 12.5 vs 8 days) and subsequent total charges (median, $13 116 vs $8731), pharmacy charges (median, $1456 vs $798), and laboratory charges (median, $2057 vs $1426). In multivariate analyses, contaminants were independently correlated with 20% and 39% increases in total subsequent laboratory charges and intravenous antibiotic charges, respectively. Thus, the true costs of contaminants may greatly exceed those of the test itself. Identifying patients at very low risk of bacteremia and attention to sterile technique may reduce costs by decreasing the frequency of contaminants.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CLIN EPIDEMIOL,75 FRANCIS ST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					AHRQ HHS [1 F32 HS00040-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ARONSON MD, 1987, ANN INTERN MED, V106, P246, DOI 10.7326/0003-4819-106-2-246; BATES DW, 1990, ANN INTERN MED, V113, P495, DOI 10.7326/0003-4819-113-7-495; BOR DH, 1988, J GEN INTERN MED, V3, P119, DOI 10.1007/BF02596115; BRANNEN AL, 1989, ARCH INTERN MED, V149, P1083, DOI 10.1001/archinte.149.5.1083; BUSHICK JB, 1989, J GEN INTERN MED, V4, P493, DOI 10.1007/BF02599547; DUNAGAN WC, 1989, AM J MED, V87, P253; EISENBERG JM, 1987, ANN INTERN MED, V107, P900, DOI 10.7326/0003-4819-107-6-900; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; MACGREGOR RR, 1972, ARCH INTERN MED, V130, P84, DOI 10.1001/archinte.130.1.84; MCCABE WR, 1962, ARCH INTERN MED, V110, P845; RATNER HB, 1985, J CLIN MICROBIOL, V21, P995, DOI 10.1128/JCM.21.6.995-996.1985; WAKEFIELD DS, 1987, MED CARE, V25, P481, DOI 10.1097/00005650-198706000-00003; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P35, DOI 10.1093/clinids/5.1.35	13	400	404	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 16	1991	265	3					365	369		10.1001/jama.265.3.365	http://dx.doi.org/10.1001/jama.265.3.365			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER256	1984535				2022-12-01	WOS:A1991ER25600026
J	FELSON, DT; SLOUTSKIS, D; ANDERSON, JJ; ANTHONY, JM; KIEL, DP				FELSON, DT; SLOUTSKIS, D; ANDERSON, JJ; ANTHONY, JM; KIEL, DP			THIAZIDE DIURETICS AND THE RISK OF HIP FRACTURE - RESULTS FROM THE FRAMINGHAM-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; MINERAL-CONTENT; BONE LOSS; CALCIUM	Thiazide diuretics may preserve bone mass and prevent elderly women's osteopenic fractures, but studies have not distinquished between thiazide preparations or examined former users. We performed a case-control study looking at thiazide use and subsequent hip fracture in postmenopausal female members of the Framingham Study cohort. Cases who had experienced a first hip fracture (n = 176) were compared with age-matched controls (n = 672). Results showed a modest protective effect of any recent thiazide use (not significant). However, recent pure thiazide users experienced significant protection against fracture (adjusted odds ratio, 0.31; 95% confidence interval, 0.11 to 0.88), whereas recent users of combination drugs containing thaizides experienced no protection (adjusted odds ratio, 1.16; 95% confidence interval, 0.44 to 3.05). Combination drugs generally contained only 25 mg of hydrochlorothiazide, suggesting that the small amount of thiazide was insufficient to preserve bone mass. Former thiazide users were not protected against fracture. In sum, recent pure thiazide use in women protects against hip fracture.	BOSTON CITY HOSP,DEPT MED,BOSTON,MA 02118; UNIV HOSP BOSTON,DEPT MED,BOSTON,MA 02118; BROWN UNIV,DIV GEN INTERNAL MED,PROGRAM MED,PROVIDENCE,RI 02912; RHODE ISL HOSP,PROVIDENCE,RI 02902	Boston Medical Center; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	FELSON, DT (corresponding author), BOSTON UNIV,SCH MED,CTR ARTHRITIS,A-203,80 E CONCORD ST,BOSTON,MA 02118, USA.			Kiel, Douglas/0000-0001-8474-0310; Felson, David/0000-0002-2668-2447	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-20613] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADLANDDAVENPORT P, 1985, AM J OBSTET GYNECOL, V152, P630, DOI 10.1016/S0002-9378(85)80035-1; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x; HASTINGS RP, 1986, SUGI SUPPLEMENTAL LI; HEANEY RP, 1982, AM J CLIN NUTR, V36, P986, DOI 10.1093/ajcn/36.5.986; KIEL DP, 1990, AM J EPIDEMIOL, V132, P675, DOI 10.1093/oxfordjournals.aje.a115709; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LJUNGHALL S, 1981, SCAND J UROL NEPHROL, V15, P257, DOI 10.3109/00365598109179613; RAY WA, 1989, LANCET, V1, P687; RIGGS BL, 1987, J CLIN INVEST, V80, P979, DOI 10.1172/JCI113191; TRANSBOL I, 1982, METABOLISM, V31, P383, DOI 10.1016/0026-0495(82)90115-9; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605	13	123	130	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 16	1991	265	3					370	373		10.1001/jama.265.3.370	http://dx.doi.org/10.1001/jama.265.3.370			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER256	1984536				2022-12-01	WOS:A1991ER25600027
J	GOODWIN, JS				GOODWIN, JS			MERCY KILLING - MERCY FOR WHOM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	13	13	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 16	1991	265	3					326	326		10.1001/jama.265.3.326	http://dx.doi.org/10.1001/jama.265.3.326			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER256	1984530				2022-12-01	WOS:A1991ER25600009
J	LACKRITZ, EM; LOBEL, HO; HOWELL, BJ; BLOLAND, P; CAMPBELL, CC				LACKRITZ, EM; LOBEL, HO; HOWELL, BJ; BLOLAND, P; CAMPBELL, CC			IMPORTED PLASMODIUM-FALCIPARUM MALARIA IN AMERICAN TRAVELERS TO AFRICA - IMPLICATIONS FOR PREVENTION STRATEGIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Data from the US National Malaria Surveillance System were analyzed to assess characteristics of travelers who acquired Plasmodium falciparum infections in Africa and evaluate the impact of chloroquine resistance on the incidence of imported malaria. Although the number of cases acquired in East Africa has stabilized, the number of imported P falciparum infections acquired in West Africa increased threefold from 1985 to 1988, and the proportion of travelers who reported failure of chloroquine prophylaxis increased from 10% to 48%. Fifty-eight percent of patients who acquired malaria in West Africa had not used chemoprophylaxis. To curb the rising incidence of P falciparum infections in American travelers, the Centers for Disease Control revised malaria prophylaxis recommendations to include the use of mefloquine in areas of chloroquine resistance. Use of malaria protection measures by travelers to West Africa must also be improved.			LACKRITZ, EM (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,DIV PARASIT DIS,MALARIA BRANCH,MAILSTOP F-12,1600 CLIFTON RD,ATLANTA,GA 30333, USA.			Lackritz, Eve/0000-0002-5397-7291				KEAN BH, 1979, JAMA-J AM MED ASSOC, V241, P395, DOI 10.1001/jama.241.4.395; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; LOBEL HO, 1991, JAMA-J AM MED ASSOC, V265, P361, DOI 10.1001/jama.265.3.361; LOBEL HO, 1985, J INFECT DIS, V152, P613, DOI 10.1093/infdis/152.3.613; LOBEL HO, 1988, TRAVEL MED, P81; MORAN JS, 1989, JAMA-J AM MED ASSOC, V262, P245, DOI 10.1001/jama.262.2.245; MORAN JS, 1987, AMA, V257, P2376; PHILLIPSHOWARD PA, 1990, LANCET, V335, P119, DOI 10.1016/0140-6736(90)90596-W; SANSONETTI PJ, 1985, LANCET, V1, P1154; 1988, MALARIA SURVEILLANCE; 1990, MMWR, V39, P630; 1988, EC SURVEY; 1990, CDC908280 US DEP HLT; 1990, MMWR, V39, P1	14	42	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 16	1991	265	3					383	385		10.1001/jama.265.3.383	http://dx.doi.org/10.1001/jama.265.3.383			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER256	1984539				2022-12-01	WOS:A1991ER25600030
J	PEREZMESA, C				PEREZMESA, C			PATHOLOGY EVALUATION OF LUMPECTOMY SPECIMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BREAST-CANCER; MASTECTOMY				PEREZMESA, C (corresponding author), ELLIS FISCHEL STATE CANC CTR,COLUMBIA,MO 65203, USA.							FERGUSON DJ, 1989, NEW ENGL J MED, V321, P689; FISHER B, 1985, WORLD J SURG, V9, P692, DOI 10.1007/BF01655182; FISHER ER, 1986, CANCER-AM CANCER SOC, V57, P1717, DOI 10.1002/1097-0142(19860501)57:9<1717::AID-CNCR2820570902>3.0.CO;2-H; LAGIOS MD, 1983, CANCER, V52, P2173, DOI 10.1002/1097-0142(19831201)52:11<2173::AID-CNCR2820521133>3.0.CO;2-0; ROSEN PP, 1975, CANCER, V35, P739, DOI 10.1002/1097-0142(197503)35:3<739::AID-CNCR2820350329>3.0.CO;2-5	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 16	1991	265	3					412	412		10.1001/jama.265.3.412	http://dx.doi.org/10.1001/jama.265.3.412			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER256	1984544				2022-12-01	WOS:A1991ER25600039
J	SCHAPIRA, DV; URBAN, N				SCHAPIRA, DV; URBAN, N			A MINIMALIST POLICY FOR BREAST-CANCER SURVEILLANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ROUTINE FOLLOW-UP; BONE SCANS; CARCINOMA; METASTASES		FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	SCHAPIRA, DV (corresponding author), UNIV S FLORIDA,COLL MED,H LEE MOFFITT CANC CTR & RES INST,CANC PREVENT SECT,TAMPA,FL 33612, USA.							BAKER RR, 1977, ANN SURG, V186, P363, DOI 10.1097/00000658-197709000-00014; BLUMENSCHEIN GR, 1983, 3RD EUR ONC RES TREA; BROYN T, 1982, ACTA CHIR SCAND, V148, P401; BURKETT FE, 1979, SURG GYNECOL OBSTET, V149, P523; CANTWELL B, 1982, IRISH J MED SCI, V151, P1, DOI 10.1007/BF02940131; CORCORAN RJ, 1976, RADIOLOGY, V121, P663, DOI 10.1148/121.3.663; HARTUNIAN NS, 1980, AM J PUBLIC HEALTH, V70, P1249, DOI 10.2105/AJPH.70.12.1249; HODGSON TA, 1982, MILBANK FUND Q, V60, P429, DOI 10.2307/3349801; HOLLAND JF, 1983, J CLIN ONCOL, V1, P74; KHANDEKAR JD, 1978, P AM ASSOC CANC RES, V19, P379; LEGHA SS, 1979, ANN INTERN MED, V91, P847, DOI 10.7326/0003-4819-91-6-847; LIPPMAN ME, 1988, DIAGNOSIS MANAGEMENT, P375; MCNEIL BJ, 1978, SURG GYNECOL OBSTET, V147, P745; OCONNELL MJ, 1978, MAYO CLIN PROC, V53, P221; PANDYA KJ, 1985, CANCER, V55, P202, DOI 10.1002/1097-0142(19850101)55:1<202::AID-CNCR2820550132>3.0.CO;2-X; PEDRAZZINI A, 1986, J CLIN ONCOL, V4, P389, DOI 10.1200/JCO.1986.4.3.389; PEREZ DJ, 1983, LANCET, V2, P613; ROSSING N, 1982, EUR J CANCER CLIN ON, V18, P629, DOI 10.1016/0277-5379(82)90208-5; RUSSELL L, 1986, IS PREVENTION BETTER, P116; SCANLON EF, 1980, CANCER, V46, P977, DOI 10.1002/1097-0142(19800815)46:4+<977::AID-CNCR2820461320>3.0.CO;2-0; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; WARNER KE, 1982, COST BENEFIT COST EF, P93; WICKERHAM L, 1983, BREAST CANCER RES TR, V1, P24; WINCHESTER DP, 1979, CANCER, V43, P956, DOI 10.1002/1097-0142(197903)43:3<956::AID-CNCR2820430326>3.0.CO;2-L; ZWAVELING A, 1987, J SURG ONCOL, V34, P194, DOI 10.1002/jso.2930340314; 1989, STATISTICAL ABSTRACT, P17; 1990, CANCER FACTS FIGURES, P6	27	100	102	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 16	1991	265	3					380	382		10.1001/jama.265.3.380	http://dx.doi.org/10.1001/jama.265.3.380			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER256	1984538				2022-12-01	WOS:A1991ER25600029
J	CHAO, NJ; DUNCAN, SR; LONG, GD; HORNING, SJ; BLUME, KG				CHAO, NJ; DUNCAN, SR; LONG, GD; HORNING, SJ; BLUME, KG			CORTICOSTEROID-THERAPY FOR DIFFUSE ALVEOLAR HEMORRHAGE IN AUTOLOGOUS BONE-MARROW TRANSPLANT RECIPIENTS	ANNALS OF INTERNAL MEDICINE			English	Note											CHAO, NJ (corresponding author), STANFORD UNIV, MED CTR, BONE MARROW TRANSPLANT PROGRAM, H-1353, STANFORD, CA 94305 USA.				NCI NIH HHS [CA 49605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		JULES-ELYSEE K, 1990, American Review of Respiratory Disease, V141, pA604; KAHN FW, 1987, AM REV RESPIR DIS, V136, P155, DOI 10.1164/ajrccm/136.1.155; LEATHERMAN JW, 1984, MEDICINE, V63, P343, DOI 10.1097/00005792-198411000-00002; ROBBINS RA, 1989, AM J MED, V87, P511	4	77	79	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1991	114	2					145	146		10.7326/0003-4819-114-2-145	http://dx.doi.org/10.7326/0003-4819-114-2-145			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER534	1984392				2022-12-01	WOS:A1991ER53400010
J	HULL, RD; RASKOB, GE				HULL, RD; RASKOB, GE			LOW-PROBABILITY LUNG-SCAN FINDINGS - A NEED FOR CHANGE	ANNALS OF INTERNAL MEDICINE			English	Note							SUSPECTED PULMONARY-EMBOLISM; VENTILATION-PERFUSION; ANGIOGRAPHY; DIAGNOSIS				HULL, RD (corresponding author), UNIV CALGARY, FOOTHILLS HOSP, DEPT MED, 3330 HOSP DR NW, CALGARY T2N 4N1, ALBERTA, CANADA.							ALDERSON PO, 1976, RADIOLOGY, V120, P633, DOI 10.1148/120.3.633; BIELLO DR, 1979, AM J ROENTGENOL, V133, P1033, DOI 10.2214/ajr.133.6.1033; CHEELY R, 1981, AM J MED, V70, P17, DOI 10.1016/0002-9343(81)90406-X; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1990, CHEST, V97, P23, DOI 10.1378/chest.97.1.23; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; MCNEIL BJ, 1980, J NUCL MED, V21, P319; MOSER KM, 1990, AM REV RESPIR DIS, V141, P235, DOI 10.1164/ajrccm/141.1.235; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753	9	82	83	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1991	114	2					142	143		10.7326/0003-4819-114-2-142	http://dx.doi.org/10.7326/0003-4819-114-2-142			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER534	1984390				2022-12-01	WOS:A1991ER53400008
J	MUDER, RR; BRENNEN, C; WAGENER, MM; VICKERS, RM; RIHS, JD; HANCOCK, GA; YEE, YC; MILLER, JM; YU, VL				MUDER, RR; BRENNEN, C; WAGENER, MM; VICKERS, RM; RIHS, JD; HANCOCK, GA; YEE, YC; MILLER, JM; YU, VL			METHICILLIN-RESISTANT STAPHYLOCOCCAL COLONIZATION AND INFECTION IN A LONG-TERM CARE FACILITY	ANNALS OF INTERNAL MEDICINE			English	Article							AUREUS NASAL CARRIAGE; NOSOCOMIAL INFECTIONS; NURSING-HOMES; STRAIN; CIPROFLOXACIN; HEMODIALYSIS; PROPHYLAXIS; OUTBREAK	Objective: To determine the natural history of colonization by methicillin-resistant Staphylococcus aureus (MRSA) among patients in a long-term care facility. We specifically sought to determine if MRSA colonization was predictive of subsequent infection. Design: Cohort study. Setting: Long-term Veterans Affairs Medical Center. Patients: A total of 197 patients residing on two units were followed with regular surveillance cultures of the anterior nares. Main Outcome Measurement: The development of staphylococcal infection. Results: Thirty-two patients were persistent carriers of MRSA and 44 were persistent carriers of methicillin-susceptible strains (MSSA). Twenty-five percent of MRSA carriers had an episode of staphylococcal infection compared with 4% of MSSA carriers and 4.5% of non-carriers (P < 0.01; relative risk 3.8%; 95% CI, 2.0 to 6.4). The rate of development of infection among MRSA carriers was 15% for every 100 days of carriage. Using logistic regression analysis, persistent MRSA carriage was the most significant predictor of infection (P < 0.001; odds ratio, 3.7). Seventy-three percent of all MRSA infections occurred among MRSA carriers. Isolates of MRSA from 7 patients were typed. Colonizing and infecting strains had the same phage type in all 7 patients and the same pattern of plasmid EcoRI restriction endonuclease fragments in 5 patients. Conclusions: Colonization of the anterior nares by MRSA predicts the development of staphylococcal infection in long-term care patients; most infections arise from endogenously carried strains. Colonization by MRSA indicates a significantly greater risk for infection than does colonization by MSSA. The results offer a theoretic rationale for reduction in MRSA infections by interventions aimed at eliminating the carrier state.	UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA 15261 USA; CTR DIS CONTROL, ATLANTA, GA 30333 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Centers for Disease Control & Prevention - USA	MUDER, RR (corresponding author), PITTSBURGH VET AFFAIRS MED CTR, INFECT DIS SECT, UNIV DR C, PITTSBURGH, PA 15240 USA.							AEILTS GD, 1982, J CLIN MICROBIOL, V16, P218, DOI 10.1128/JCM.16.2.218-223.1982; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOYCE JM, 1981, INFECT CONT HOSP EP, V2, P110, DOI 10.1017/S0195941700053881; BRENNEN C, 1990, AM J MED, V88, pN14; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; CEDERNA JE, 1990, INFECT CONT HOSP EP, V11, P13, DOI 10.1086/646072; CHOW JW, 1989, ARCH INTERN MED, V149, P1258, DOI 10.1001/archinte.149.6.1258; COLEMAN DC, 1986, J HOSP INFECT, V7, P29, DOI 10.1016/0195-6701(86)90005-8; CRAVEN DE, 1981, AM J MED, V71, P53, DOI 10.1016/0002-9343(81)90258-8; CROSSLEY KB, 1985, JAMA-J AM MED ASSOC, V254, P2918, DOI 10.1001/jama.254.20.2918; GARIBALDI RA, 1981, NEW ENGL J MED, V305, P731, DOI 10.1056/NEJM198109243051304; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; HALEY RW, 1982, ANN INTERN MED, V97, P297, DOI 10.7326/0003-4819-97-3-297; HSU CCS, 1988, ARCH INTERN MED, V148, P569, DOI 10.1001/archinte.148.3.569; ISCHHOROWICZ D, 1984, NUCLEIC ACIDS RES, V9, P2989; Kloos W, 1985, MANUAL CLIN MICROBIO, P143; LACEY RW, 1987, J HOSP INFECT, V9, P103, DOI 10.1016/0195-6701(87)90046-6; LINNEMANN CC, 1982, AM J EPIDEMIOL, V115, P941, DOI 10.1093/oxfordjournals.aje.a113381; LUZAR MA, 1990, NEW ENGL J MED, V322, P505, DOI 10.1056/NEJM199002223220804; MACRINA FL, 1978, PLASMID, V1, P417, DOI 10.1016/0147-619X(78)90056-2; MULLIGAN ME, 1987, AM J MED, V82, P215; PEACOCK JE, 1981, J INFECT DIS, V144, P575, DOI 10.1093/infdis/144.6.575; PRICE LE, 1985, INFECT CONT HOSP EP, V6, P437, DOI 10.1017/S0195941700064778; ROCCAFORTE JS, 1988, AM J INFECT CONTROL, V16, P141, DOI 10.1016/0196-6553(88)90024-7; SMITH PB, 1972, STAPHYLOCOCCI, P431; SMITH SM, 1989, ANTIMICROB AGENTS CH, V33, P181, DOI 10.1128/AAC.33.2.181; STORCH GA, 1987, INFECT CONT HOSP EP, V8, P24, DOI 10.1017/S0195941700066947; THOMAS JC, 1989, INFECT CONT HOSP EP, V10, P106, DOI 10.1086/645976; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; THORNSBERRY C, 1983, J CLIN MICROBIOL, V18, P1084, DOI 10.1128/JCM.18.5.1084-1091.1983; TUAZON CU, 1975, ANN INTERN MED, V82, P788, DOI 10.7326/0003-4819-82-6-788; WRIGHT CE, 1989, 29TH INT C ANT AG CH; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204	33	304	305	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1991	114	2					107	112		10.7326/0003-4819-114-2-1-107	http://dx.doi.org/10.7326/0003-4819-114-2-1-107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER534	1984384				2022-12-01	WOS:A1991ER53400002
J	SACHS, GA; MILES, SH; LEVIN, RA				SACHS, GA; MILES, SH; LEVIN, RA			LIMITING RESUSCITATION - EMERGING POLICY IN THE EMERGENCY MEDICAL SYSTEM	ANNALS OF INTERNAL MEDICINE			English	Article							PROSPECTIVE PAYMENT SYSTEM	Patients, families, and physicians frequently decide that a hospitalized patient will forgo cardiopulmonary resuscitation and document this decision with a do-not-resuscitate (DNR) order. In community settings (home, nursing home, hospice), these orders may conflict with paramedics' standing orders to provide cardiopulmonary resuscitation whenever it is medically indicated. We did a nationwide telephone survey of state offices for coordination of emergency medical services (EMS) to see how the states deal with this potential conflict. We identified eight states that have specific policies enabling EMS personnel to accept DNR orders for patients being transported by ambulance. State officials identified administrative complexities and legal concerns as the primary barriers to enacting prehospitalization DNR policies. We also identified 21 local EMS systems that have developed policies for accepting orders to withhold life-sustaining treatment. Four types of policy models, characterized according to procedure for validating DNR orders and telephone accessing the EMS system, show that regulatory reform can address policy barriers in the absence of enabling legislation.	UNIV CHICAGO, PRITZKER SCH MED, CHICAGO, IL 60637 USA; UNIV MINNESOTA, HENNEPIN CTY MED CTR, MINNEAPOLIS, MN 55415 USA	University of Chicago; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities								CRIMMINS TJ, 1988, MINN MED, V71, P708; CRIMMINS TJ, 1990, PREHOSP DISASTER MED, V5, P47; FITZGERALD JF, 1988, NEW ENGL J MED, V319, P1392, DOI 10.1056/NEJM198811243192106; LEWIS MA, 1985, GERONTOLOGIST, V25, P382, DOI 10.1093/geront/25.4.382; MARSHALL L, 1985, J EMERG MED SERV, P24; MILES SH, 1985, JAMA-J AM MED ASSOC, V254, P525, DOI 10.1001/jama.254.4.525; MILES SH, 1987, J AM GERIATR SOC, V35, P74, DOI 10.1111/j.1532-5415.1987.tb01323.x; MILES SH, 1989, PROTOCOLS ELECTIVE U; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; WAGNER A, 1984, NEW ENGL J MED, V310, P1129, DOI 10.1056/NEJM198404263101732; 1986, JAMA-J AM MED ASSOC, V255, P2979; 1988, ANN EMERG MED, V17, P1106; 1988, LONG TERM CARE STAND, P27; 1987, ACEP NEWS, V6, P11; 1987, GUIDELINES TERMINATI; 1985, PHYSICIAN HOPELESSLY; 1988, ACCREDITATION MANUAL, P90	18	29	29	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1991	114	2					151	154		10.7326/0003-4819-114-2-151	http://dx.doi.org/10.7326/0003-4819-114-2-151			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER534	1984394				2022-12-01	WOS:A1991ER53400012
J	WIERSINGA, WM; TRIP, MD; VANBEEREN, MH; PLOMP, TA; OOSTING, H				WIERSINGA, WM; TRIP, MD; VANBEEREN, MH; PLOMP, TA; OOSTING, H			AN INCREASE IN PLASMA-CHOLESTEROL INDEPENDENT OF THYROID-FUNCTION DURING LONG-TERM AMIODARONE THERAPY - A DOSE-DEPENDENT RELATIONSHIP	ANNALS OF INTERNAL MEDICINE			English	Article							THYROTROPIN SECRETION; HORMONE METABOLISM; RAT MYOCARDIUM; SERUM-LIPIDS; DESETHYLAMIODARONE; THYROXINE; PITUITARY; TRIIODOTHYRONINE; DRUG; ELEVATION	Objective: To determine whether long-term amiodarone treatment is associated with a rise in plasma cholesterol, and, if so, to analyze its relation with thyroid function. Design: Consecutive entry trial, including cardiac patients who initiated amiodarone medication but excluding those with abnormal thyroid function (defined as peak thyroid-stimulating hormone [TSH] response to thyrotropin-releasing hormone [TRH] < 2.8 or > 22.0 mU/L) either before or during amiodarone treatment. Patients: Twenty-three patients who remained euthyroid were studied. Intervention: Oral administration of amiodarone (mean duration of treatment, 17 months; range, 6 to 30 months). Measurements: Fasting plasma lipids, thyroid hormones, and peak TSH to TRH values were recorded before and every 6 months during amiodarone treatment. Results: Plasma cholesterol gradually increased from 5.1 +/- 0.2 mmol/L before treatment to 6.9 +/- 0.8 mmol/L after 30 months of amiodarone medication (P < 0.001); the peak TSH response to TRH did not change. When age- and sex-specific reference values were applied, 30% of the patients had cholesterol values above the 75th percentile before treatment; this number rose to 69% after 2 years of treatment. The rise in plasma cholesterol was associated with an equal increase in apoprotein B. Plasma cholesterol was not related to the daily dose of amiodarone or to plasma concentrations of amiodarone, desethylamiodarone, thyroxine (T4), triiodothyronine (T3), or reverse triiodothyronine (rT3). Linear regression analysis indicated a positive relation between plasma cholesterol and the cumulative dose of amiodarone (r = 0.25, P < 0.05). Conclusion: Long-term amiodarone treatment is associated with a dose-dependent increase in plasma cholesterol that is independent of thyroid function.	NETHERLANDS INST DRUGS & DOPING RES, UTRECHT, NETHERLANDS		WIERSINGA, WM (corresponding author), UNIV AMSTERDAM, ACAD MED CENTRUM F5258, DEPT ENDOCRINOL, MEIBERGDREEF 9, 1105 AZ AMSTERDAM, NETHERLANDS.							ADAMS PC, 1985, CIRCULATION, V72, P1064, DOI 10.1161/01.CIR.72.5.1064; ALBERS JJ, 1989, CLIN LAB MED, V9, P137, DOI 10.1016/S0272-2712(18)30646-2; ALBERT SG, 1987, J AM COLL CARDIOL, V9, P175, DOI 10.1016/S0735-1097(87)80098-0; BURGER A, 1976, J CLIN INVEST, V58, P255, DOI 10.1172/JCI108466; CEPPI JA, 1989, J ENDOCRINOL, V121, P431, DOI 10.1677/joe.0.1210431; DEBBAS NMG, 1983, EUR J CLIN INVEST, V13, P123, DOI 10.1111/j.1365-2362.1983.tb00076.x; FALIK R, 1987, AM J MED, V82, P1102, DOI 10.1016/0002-9343(87)90211-7; FRANKLYN JA, 1989, CLIN SCI, V76, P463, DOI 10.1042/cs0760463; FRANKLYN JA, 1987, CLIN ENDOCRINOL, V27, P373, DOI 10.1111/j.1365-2265.1987.tb01164.x; FREEDBERG AS, 1970, J PHYSIOL-LONDON, V207, P357, DOI 10.1113/jphysiol.1970.sp009066; HARTONG R, 1989, NUCLEAR THYROID HORM, P51; HOLT DW, 1983, AM HEART J, V106, P840, DOI 10.1016/0002-8703(83)90006-6; KANNAN R, 1982, ATHEROSCLEROSIS, V44, P19, DOI 10.1016/0021-9150(82)90049-1; KASIM SE, 1987, ENDOCRINOLOGY, V120, P1991, DOI 10.1210/endo-120-5-1991; KATO R, 1988, AM HEART J, V115, P351, DOI 10.1016/0002-8703(88)90481-4; KRONE W, 1988, AM HEART J, V116, P1729, DOI 10.1016/0002-8703(88)90222-0; LAMBERT M, 1988, ACTA ENDOCRINOL-COP, V118, P449, DOI 10.1530/acta.0.1180449; LATHAM KR, 1987, J AM COLL CARDIOL, V9, P872, DOI 10.1016/S0735-1097(87)80244-9; LINDENMEYER M, 1984, BRIT J PHARMACOL, V82, P275, DOI 10.1111/j.1476-5381.1984.tb16468.x; MEESE R, 1985, AM J CARDIOL, V55, P849, DOI 10.1016/0002-9149(85)90173-0; MELMED S, 1981, J CLIN ENDOCR METAB, V53, P997, DOI 10.1210/jcem-53-5-997; NORMAN MF, 1989, J CLIN INVEST, V83, P306, DOI 10.1172/JCI113874; OREILLY DS, 1988, J ENDOCRINOL, V118, P349, DOI 10.1677/joe.0.1180349; PLOMP TA, 1983, J CHROMATOGR, V273, P379, DOI 10.1016/S0378-4347(00)80958-5; POLLAK PT, 1988, AM J CARDIOL, V62, P562, DOI 10.1016/0002-9149(88)90655-8; PRITCHARD DA, 1975, BRIT HEART J, V37, P856; RIFKIND BM, 1983, JAMA-J AM MED ASSOC, V250, P1869, DOI 10.1001/jama.250.14.1869; SAFRAN M, 1986, AM J MED SCI, V292, P136, DOI 10.1097/00000441-198609000-00003; SILVA JE, 1978, J CLIN INVEST, V61, P1247, DOI 10.1172/JCI109041; SINGH BN, 1989, PROG CARDIOVASC DIS, V31, P249, DOI 10.1016/0033-0620(89)90033-9; SINGH BN, 1970, BRIT J PHARMACOL, V39, P657, DOI 10.1111/j.1476-5381.1970.tb09891.x; SONNENBLICK M, 1986, CARDIOLOGY, V73, P147, DOI 10.1159/000173998; STAUBLI M, 1981, SCHWEIZ MED WSCHR, V111, P1590; WIEGAND V, 1986, BASIC RES CARDIOL, V81, P482, DOI 10.1007/BF01907754; WIERSINGA WM, 1982, METHOD ENZYMOL, V84, P272; WIERSINGA WM, 1986, POSTGRAD MED J, V62, P909, DOI 10.1136/pgmj.62.732.909; WIERSINGA WM, 1980, NETH J MED, V23, P162	37	20	21	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1991	114	2					128	132		10.7326/0003-4819-114-2-128	http://dx.doi.org/10.7326/0003-4819-114-2-128			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER534	1984387				2022-12-01	WOS:A1991ER53400005
J	ZARCHY, TM; ERSHOFF, D				ZARCHY, TM; ERSHOFF, D			WHICH CLINICAL-VARIABLES PREDICT AN ABNORMAL DOUBLE-CONTRAST BARIUM ENEMA RESULT	ANNALS OF INTERNAL MEDICINE			English	Article							CANCER	Objective: To determine the relations among patient history, symptoms, objective indicators, and abnormal double-contrast barium enema results in outpatients. Patients and Setting: Seven hundred and ninety-four patients receiving care in a large multispecialty medical group. Design: Physicians completed a form before ordering a double-contrast barium enema, listing information about patient history, symptoms, and objective findings, including the results of a complete blood count, stool hemoccult, and sigmoidoscopy. Measurements and Main Results: Outcome measures were colon cancer and any abnormal finding. The results of 18.6% of the barium enemas were abnormal. The most frequent positive findings were of polyps (8.8%) and colon cancer (2.9%). Over 50% of the barium enemas were ordered solely on the basis of symptoms, yet there was no statistical correlation between symptoms and colon cancer or any positive finding. Using logistic regression, four variables were shown to be significant predictors of colon cancer (P < 0.05): abnormal sigmoidoscopy, iron deficiency anemia, positive stool hemoccult results, and relevant history. The respective odds ratios of these variables were 3.76 (95% CI, 2.89 to 4.90); 2.86 (CI, 2.13 to 3.74); 1.87 (CI, 1.46 to 2.39); and 1.91 (CI, 1.44 to 2.52), respectively. In a patient without any of these indicators, the predicted probability of having colon cancer was only 0.7%. In a patient with at least two objective indicators, the probability of having colon cancer was greater than 15%. Conclusions: Symptoms without objective indicators or pertinent risk factors do not correlate with an abnormal double-contrast barium enema result. Objective indicators are useful predictors of an abnormal barium enema result, particularly when looking for colon cancer.	HAWTHORNE COMMUNITY MED GRP, LOS ANGELES, CA USA; SO CALIF PERMANENTE MED GRP, PASADENA, CA USA	Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups								BARRY MJ, 1987, GASTROENTEROLOGY, V93, P301, DOI 10.1016/0016-5085(87)91019-5; DEVROEDE G, 1989, GASTROINTESTINAL DIS, P331; DROSSMAN DA, 1988, HOSP PRACT, V23, P119; DROSSMAN DA, 1989, ANN INTERN MED, V111, P627, DOI 10.7326/0003-4819-111-8-627; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; GERSON DE, 1979, RADIOLOGY, V130, P297, DOI 10.1148/130.2.297; GROSSMAN S, 1988, GASTROENTEROLOGY, V94, P395, DOI 10.1016/0016-5085(88)90427-1; HARVEY RF, 1987, LANCET, V1, P963; LODD DD, 1985, CARCINOMA LARGE BOWE, P133; MACEWAN DW, 1978, RADIOLOGY, V126, P39, DOI 10.1148/126.1.39; OTT DJ, 1985, SOUTHERN MED J, V78, P1033, DOI 10.1097/00007611-198509000-00002; TEDESCO FJ, 1978, ANN INTERN MED, V89, P907, DOI 10.7326/0003-4819-89-6-907; ZARCHY TM, 1984, GASTROENTEROLOGY, V86, P1307; 1987, MEDICARE BARIUM ENEM	15	13	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1991	114	2					137	141		10.7326/0003-4819-114-2-137	http://dx.doi.org/10.7326/0003-4819-114-2-137			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER534	1984389				2022-12-01	WOS:A1991ER53400007
J	DIXON, AK; SOUTHERN, JP; TEALE, A; FREER, CEL; HALL, LD; WILLIAMS, A; SIMS, C				DIXON, AK; SOUTHERN, JP; TEALE, A; FREER, CEL; HALL, LD; WILLIAMS, A; SIMS, C			MAGNETIC-RESONANCE-IMAGING OF THE HEAD AND SPINE - EFFECTIVE FOR THE CLINICIAN OR THE PATIENT	BRITISH MEDICAL JOURNAL			English	Article							COMPUTED-TOMOGRAPHY; POOR QUALITY	Objectives - To test how the results of magnetic resonance imaging influence clinicians' diagnoses and management plans for patients with cranial and spinal problems and to assess changes in the quality of life of these patients. Design - Survey of patients undergoing cranial and spinal magnetic resonance imaging with questionnaires about diagnoses and intended management plans before and after imaging and quality of life questionnaires at the time of imaging and again four months later. Setting - Regional magnetic resonance imaging and spectroscopy unit. Subjects - 100 consecutive patients referred for cranial imaging in early 1989; 100 similar patients referred for spinal imaging. Main outcome measures - Changes in clinicians' leading diagnoses after magnetic resonance imaging and their confidence in these diagnoses;changes in intended management plans; assessment of the contribution to the future management of the patient; changes in patients' quality of life. Results - Magnetic resonance imaging altered the clinicians' leading diagnoses in 35 of 169 (21%) cases. The clinicians became more confident about their leading diagnoses in 90 of 167 (54%). There was a change in management plan in 113 of 182 (62%). The clinicians considered that magnetic resonance imaging made an important contribution to management in 119 of 162 (73%) patients. Overall, the patients' quality of life was unchanged at the four month assessment. Conclusions - Magnetic resonance imaging of patients with cranial and spinal problems influences clinicians' diagnoses and management plans, but the quality of life of these patients remains unchanged.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	DIXON, AK (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT RADIOL,CAMBRIDGE CB2 2QQ,ENGLAND.							COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; DIXON AK, 1981, LANCET, V1, P1199; DOLLERY C, 1978, END AGE OPTIMISM, P59; FRANKEN EA, 1986, RADIOLOGY, V161, P377, DOI 10.1148/radiology.161.2.3763904; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; GUDEX C, 1988, 38 U YORK CTR HLTH E; Hillman B J, 1986, Invest Radiol, V21, P289, DOI 10.1097/00004424-198603000-00019; HILLMAN BJ, 1988, AM J ROENTGENOL, V151, P858, DOI 10.2214/ajr.151.5.858; KENT DL, 1988, ANN INTERN MED, V108, P402, DOI 10.7326/0003-4819-108-3-402; Moore A T, 1987, Health Trends, V19, P8; SHUMAN WP, 1988, AM J ROENTGENOL, V151, P857, DOI 10.2214/ajr.151.5.857; SIEGEL S, 1988, NONPARAMETRIC STAT, P298; STLEGER AS, 1989, BRIT MED J, V299, P1017, DOI 10.1136/bmj.299.6706.1017; TEASDALE GM, 1989, BRIT MED J, V299, P349, DOI 10.1136/bmj.299.6695.349; 1984, LANCET, V2, P961; [No title captured]; [No title captured]; 1979, LANCET, V1, P809	18	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					79	82		10.1136/bmj.302.6768.79	http://dx.doi.org/10.1136/bmj.302.6768.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995119	Bronze, Green Published			2022-12-01	WOS:A1991ER95100016
J	ECCLES, M; BRADSHAW, C				ECCLES, M; BRADSHAW, C			USE OF SECONDARY PROPHYLAXIS AGAINST MYOCARDIAL-INFARCTION IN THE NORTH OF ENGLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective - To record the use of secondary prophylactic drugs in patients discharged from hospital having had a myocardial infarction. Design - Prospective postal questionnaire survey of a random one in two sample of general practitioners in the region. Setting - The nine family practitioner committee areas within the Northern Regional Health Authority. Patients - Patients who had had a myocardial infarction and were discharged to their general practitioner. Main outcome measure - Whether beta-blockers or aspirin, or both, were given on discharge. Results - Of 267 patients, 158 (59%) were treated suboptimally in that they did not receive a secondary prophylactic drug to which they had no contraindication. For most patients this entailed underuse of one drug, but 17 (6%) of patients received no treatment. beta-blockers were 2.5 times less likely to be used than aspirin. Treatment was not associated with the age or sex of the patient, risk of further infarction, or hospital of discharge. Conclusions - Secondary prophylaxis after myocardial infarction is practised haphazardly. It should be offered to all patients who can tolerate it, after a trial period to assess any side effects of the drugs if necessary.	UNIV NEWCASTLE UPON TYNE, CTR HLTH SERV RES, NEWCASTLE UPON TYNE NE2 4AA, ENGLAND; MARSDEN RD HLTH CTR, S SHIELDS NE34 6RE, TYNE & WEAR, ENGLAND	Newcastle University - UK; Royal Marsden NHS Foundation Trust			Eccles, Martin P/AAD-4029-2020					[Anonymous], 1980, LANCET, V1, P1172; [Anonymous], 1988, LANCET, V2, P349; BLOOMFIELD P, 1987, BMJ-BRIT MED J, V3295, P1431; FRY J, 1979, COMMN DISEASES THEIR; HAMPTON JR, 1982, BRIT MED J, V285, P33, DOI 10.1136/bmj.285.6334.33; HANSTEEN V, 1982, BRIT MED J, V284, P155, DOI 10.1136/bmj.284.6310.155; JULIAN DG, 1988, BMJ-BRIT MED J, V297, P497, DOI 10.1136/bmj.297.6647.497; KAPLAN NM, 1987, ARCH INTERN MED, V147, P1160, DOI 10.1001/archinte.147.6.1160; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; ORME M, 1988, BRIT MED J, V296, P307, DOI 10.1136/bmj.296.6618.307; 1986, MORBIDITY STATISTICS; 1987, DRUG THER B, V25, P17; 1990, BRIT NATIONAL FORMUL; 1990, DRUG THER B, V28, P47	14	53	53	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 12	1991	302	6768					91	92		10.1136/bmj.302.6768.91	http://dx.doi.org/10.1136/bmj.302.6768.91			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1671652	Green Published, Bronze			2022-12-01	WOS:A1991ER95100022
J	JACOBSON, MA; BACCHETTI, P; KOLOKATHIS, A; CHAISSON, RE; SZABO, S; POLSKY, B; VALAINIS, GT; MILDVAN, D; ABRAMS, D; WILBER, J; WINGER, E; SACKS, HS; HENDRICKSEN, C; MOSS, A				JACOBSON, MA; BACCHETTI, P; KOLOKATHIS, A; CHAISSON, RE; SZABO, S; POLSKY, B; VALAINIS, GT; MILDVAN, D; ABRAMS, D; WILBER, J; WINGER, E; SACKS, HS; HENDRICKSEN, C; MOSS, A			SURROGATE MARKERS FOR SURVIVAL IN PATIENTS WITH AIDS AND AIDS RELATED COMPLEX TREATED WITH ZIDOVUDINE	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS TYPE-1; PLACEBO-CONTROLLED TRIAL; RECEIVING ZIDOVUDINE; SAN-FRANCISCO; INFECTION; SERUM; HIV; AZIDOTHYMIDINE; EXPERIENCE; EXPRESSION	Objective - To determine whether early effects of zidovudine treatment on CD4+ lymphocyte count and concentrations of beta-2 microglobulin, neopterin, or HIV p24 antigen or antibody are correlated with survival in patients with AIDS or AIDS related complex. Design - Retrospective study of changes in laboratory markers and survival. Setting - Multicentre trial at university hospital clinics. Subjects - '90 Patients with AIDS or AIDS related complex. Intervention - Patients started zidovudine 200 mg orally every four hours. Fifty six of the patients died a median 17 months after starting zidovudine; the remaining 34 patients were followed up for a median 25.5 months. Main outcome measures - Changes in CD4+ lymphocyte count and serum concentrations of p24 antigen and antibody, beta-2 microglobulin, and neopterin; survival of the patient. Results - The pretreatment characteristics that independently predicted poor survival were determined using a multivariate proportional hazards models: a diagnosis of AIDS (upsilon-AIDS related complex), age over 45 years, and the logarithm of serum neopterin concentration. When these baseline characteristics were controlled for the logarithm of CD4+ lymphocyte count at weeks 8-12 of treatment (p = 0.007) and an increase in serum beta-2 microglobulin concentration at weeks 8-12 (p = 0.05) also independently correlated with survival. In the 38 patients with a better pretreatment prognosis, 24 month survival estimated by the product-limit method was 88% for those with a good response on both surrogate markers during early treatment compared with only 50% for those with a poor response on either marker. In the 38 with a worse pretreatment prognosis, 24 month survival was estimated to be 49% for those with a good response on both surrogate markers compared with only 18% for those with a poor response on either. Conclusion - These data suggest that CD4+ lymphocyte count at 8-12 weeks and, perhaps, change in serum beta-2 microglobulin concentration could be surrogate end points for clinical outcome in trials of antiretroviral drugs for patients with HIV disease.	SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; BETH ISRAEL MED CTR,DEPT MED,NEW YORK,NY 10003; JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21218; MT SINAI MED CTR,DEPT MED,NEW YORK,NY 10029; MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021; TULANE UNIV,MED CTR,DEPT MED,NEW ORLEANS,LA 70118; BETH ISRAEL MED CTR,DIV INFECT DIS,NEW YORK,NY 10003; CALIF DEPT HLTH SERV,VIRAL & RICKETTSIAL DIS LAB,BERKELEY,CA 94704; IMMUNODIAGNOST LABS INC,SAN LEANDRO,CA; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOMATH,NEW YORK,NY 10029	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Cornell University; Tulane University; Harvard University; Beth Israel Deaconess Medical Center; California Department of Health Care Services; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	JACOBSON, MA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94110, USA.				NIAID NIH HHS [AI27663] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027663] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOWICZ M, 1986, MED LETT DRUGS THER, V28, P107; ANDERSON RE, 1990, ARCH INTERN MED, V150, P73, DOI 10.1001/archinte.150.1.73; BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; CHAISSON RE, 1988, ARCH INTERN MED, V148, P2151, DOI 10.1001/archinte.148.10.2151; COX DR, 1984, ANAL SURVIVAL DATA, P91; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOUDSMIT J, 1986, LANCET, V2, P177; HARRELL FE, 1986, 11TH P ANN SAS US GR; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; JACOBSON MA, 1989, J INFECT DIS, V159, P1029, DOI 10.1093/infdis/159.6.1029; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRAMER A, 1989, J ACQ IMMUN DEF SYND, V2, P291; KRUPPENBACHER JP, 1988, LANCET, V1, P298; Kubo R T, 1976, Contemp Top Immunobiol, V5, P267; Lehman EL, 1975, NONPARAMETRICS STATI, P120; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; STEINBERG JP, 1989, J ACQ IMMUN DEF SYND, V2, P229; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; Weiss R., 1990, SURROGATE ENDPOINTS; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; 1985, SUGI SUPPLEMENTAL LI	28	128	130	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					73	78		10.1136/bmj.302.6768.73	http://dx.doi.org/10.1136/bmj.302.6768.73			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1671651	Green Published, Bronze			2022-12-01	WOS:A1991ER95100015
J	KNEKT, P; REUNANEN, A; TEPPO, L				KNEKT, P; REUNANEN, A; TEPPO, L			SERUM-CHOLESTEROL CONCENTRATION AND RISK OF PRIMARY BRAIN-TUMORS	BRITISH MEDICAL JOURNAL			English	Article							CANCER		FINNISH CANC REGISTRY,SF-00170 HELSINKI,FINLAND	Finnish Cancer Registry	KNEKT, P (corresponding author), SOCIAL INSURANCE INST,SOCIAL SECUR RES INST,SF-00380 HELSINKI,FINLAND.							ABRAMSON ZH, 1985, BRIT J CANCER, V52, P93, DOI 10.1038/bjc.1985.154; BASU TK, 1974, INT J VITAM NUTR RES, V44, P14; DAVEYSMITH G, 1989, BMJ-BRIT MED J, V299, P26; KNEKT P, 1988, J CLIN EPIDEMIOL, V41, P519, DOI 10.1016/0895-4356(88)90056-X; NEUGUT AI, 1989, INT J EPIDEMIOL, V18, P798, DOI 10.1093/ije/18.4.798	5	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					90	90		10.1136/bmj.302.6768.90	http://dx.doi.org/10.1136/bmj.302.6768.90			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995123	Bronze, Green Published			2022-12-01	WOS:A1991ER95100021
J	MCGILL, N; DIEPPE, PA; BOWDEN, M; GARDINER, DJ; HALL, M				MCGILL, N; DIEPPE, PA; BOWDEN, M; GARDINER, DJ; HALL, M			IDENTIFICATION OF PATHOLOGICAL MINERAL-DEPOSITS BY RAMAN MICROSCOPY	LANCET			English	Note							CRYSTAL DEPOSITION	Raman microscopy-the analysis of scattered photons after excitation-is well established in non-biological sciences for the identification of crystals. It shows promise in biological (clinical) specimens also, as demonstrated here in studies of synovial fluid, and gouty tophus, selected for their known content of sodium urate and calcium pyrophosphate crystals.	NEWCASTLE POLYTECH,DEPT CHEM & LIFE SCI,NEWCASTLE TYNE NE1 8ST,TYNE & WEAR,ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP,RHEUMATOL UNIT,BRISTOL BS2 8HW,AVON,ENGLAND	Northumbria University; Bristol Royal Infirmary								ANDERSON HC, 1988, RHEUM DIS CLIN N AM, V14, P303; BOWDEN M, 1990, 12TH P INT C RAM SPE, P844; DIEPPE P, 1988, RHEUM DIS CLIN N AM, V14, P415; DIEPPE P, 1985, CLIN RHEUM DIS, V11, P367; ETZ ES, 1986, MICROBEAM ANAL, V21, P39; Gardiner D., 1989, PRACTICAL RAMAN SPEC; GARDINER DJ, 1986, PHILOS T R SOC A, V320, P295, DOI 10.1098/rsta.1986.0118; HARRIES JE, 1983, ANN RHEUM DIS, V42, P100, DOI 10.1136/ard.42.Suppl_1.100	8	27	27	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					77	78		10.1016/0140-6736(91)90738-B	http://dx.doi.org/10.1016/0140-6736(91)90738-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670728				2022-12-01	WOS:A1991ER47700006
J	PONCE, C; PONCE, E; MORRISON, A; CRUZ, A; KREUTZER, R; MCMAHONPRATT, D; NEVA, F				PONCE, C; PONCE, E; MORRISON, A; CRUZ, A; KREUTZER, R; MCMAHONPRATT, D; NEVA, F			LEISHMANIA-DONOVANI-CHAGASI - NEW CLINICAL VARIANT OF CUTANEOUS LEISHMANIASIS IN HONDURAS	LANCET			English	Article							INFANTUM SENSU-LATO; MONOCLONAL-ANTIBODIES; IDENTIFICATION	During surveillance for endemic visceral leishmaniasis on an island off the Pacific coast of Honduras, an unusual form of cutaneous leishmaniasis was encountered. By clinical and laboratory criteria, 17 cases were identified over 5 months; children aged 4 to 15 years were primarily affected. Lesions were generally few in number, small, always papular, and non-ulcerative, even when present for several years. Patients with skin lesions seemed otherwise healthy and were well nourished. Montenegro skin tests with Leishmania mexicana and L major antigens were positive in 10 of 17 patients tested, and lesions from 9 patients were positive by culture. Since the summer of 1988, cases of atypical cutaneous leishmaniasis continue to occur on the island (8) as well as on the mainland of southern Honduras (23). A total of 9 parasite isolates from skin lesions, 4 from bone marrow of patients with kala-azar, and 2 from sandflies were identified as L donovani chagasi and were indistinguishable from one another by isoenzyme analysis.	NIAID, PARASIT DIS LAB, BLDG 4, ROOM 126, BETHESDA, MD 20892 USA; YALE UNIV, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06520 USA; YOUNGSTOWN STATE UNIV, DEPT BIOL, YOUNGSTOWN, OH 44555 USA; HOSP ESCUELA TEGUCIGALPA, TEGUCIGALPA, HONDURAS; MINIST HLTH, CENT LAB, TEGUCIGAL, HONDURAS	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Yale University; University System of Ohio; Youngstown State University				Morrison, Amy/0000-0001-6224-5984				BELAZZOUG S, 1985, ANN PARASIT HUM COMP, V60, P1; CAHILL KM, 1964, AM J TROP MED HYG, V13, P794, DOI 10.4269/ajtmh.1964.13.794; GRAMICCIA M, 1989, T ROY SOC TROP MED H, V83, P76, DOI 10.1016/0035-9203(89)90713-X; GRAMICCIA M, 1987, T ROY SOC TROP MED H, V81, P235, DOI 10.1016/0035-9203(87)90225-2; GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270; JAFFE CL, 1984, J IMMUNOL, V133, P440; KILLICKKENDRICK R, 1980, ANN TROP MED PARASIT, V74, P563, DOI 10.1080/00034983.1980.11687385; KREUTZER RD, 1980, AM J TROP MED HYG, V29, P199, DOI 10.4269/ajtmh.1980.29.199; KREUTZER RD, 1983, AM J TROP MED HYG, V32, P703, DOI 10.4269/ajtmh.1983.32.703; KUMAR PV, 1989, AM J TROP MED HYG, V40, P150, DOI 10.4269/ajtmh.1989.40.150; LAINSON R, 1979, BIOL KINETOPLASTIDA, V2, P68; MANSONBAHR PEC, 1955, NATURE, V175, P433, DOI 10.1038/175433b0; NAVIN TR, 1987, AM J TROP MED HYG, V35, P1069; NETO MPO, 1986, ANN TROP MED PARASIT, V80, P587, DOI 10.1080/00034983.1986.11812072; NETO MPO, 1986, MEM I O CRUZ, V81, P303; PRATA A., 1956, Hospital (Rio de Janeiro, Brazil), V49, P481; REES PH, 1987, LEISHMANIASES BIOL M, V2, P605; ZELEDON R, 1989, T ROY SOC TROP MED H, V83, P786, DOI 10.1016/0035-9203(89)90328-3	18	85	90	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 12	1991	337	8733					67	70		10.1016/0140-6736(91)90734-7	http://dx.doi.org/10.1016/0140-6736(91)90734-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670724				2022-12-01	WOS:A1991ER47700002
J	STRACHAN, DP				STRACHAN, DP			VENTILATORY FUNCTION AS A PREDICTOR OF FATAL STROKE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; RISK-FACTORS; CHRONIC-BRONCHITIS; VITAL CAPACITY; LUNG-FUNCTION; MEN; MORTALITY; FRAMINGHAM; DEATH; BREATHLESSNESS	Objective - To investigate the relation between ventilatory function and subsequent mortality due to cerebrovascular disease. Design - Prospective longitudinal study. Subjects - A total of 18403 male civil servants aged 40-64 years at entry examination for the Whitehall study. Main outcome measures - Mortality from cerebrovascular disease (ICD8 430-438) after 18 years of follow up. Results - In all, 262 men with sinus rhythm at entry died due to stroke during the 18 years of follow up. Compared with men with a forced expiratory volume in one second of greater-than-or-equal-to 3.5 litres those with a value of < 3.0 litres were almost twice as likely to die of cerebrovascular disease (rate ratio adjusted for age and systolic blood pressure = 1.88, 95% confidence interval 1.32 to 2.69). This increased risk occurred within each tertile of systolic blood pressure. Nested case-control analyses were used to control precisely for confounding effects of age, height, and smoking (by matching) and employment grade and physiological risk factors (by modelling). The effect of forced expiratory volume in one second was independent of age, height, smoking habits, employment grade, blood pressure, weight, cholesterol concentration, glucose tolerance, electrocardiographic abnormalities, history of chest pain, and history of intermittent claudication. Conclusions - Measurements of ventilatory function may assist clinical decisions about whether to treat mild hypertension. Impaired ventilatory function and stroke may share common causes.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine								ABBOTT RD, 1987, JAMA-J AM MED ASSOC, V257, P949, DOI 10.1001/jama.257.7.949; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; BARRETTCONNOR E, 1988, AM J EPIDEMIOL, V128, P116, DOI 10.1093/oxfordjournals.aje.a114934; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P204; BROWN WS, 1989, HYPERTENSION S, V1, P51; COOK DG, 1988, EUR HEART J, V9, P1215, DOI 10.1093/oxfordjournals.eurheartj.a062432; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; DENNIS MS, 1987, BRIT J HOSP MED, V37, P194; DYKEN ML, 1984, STROKE, V15, P1105; EBIKRYSTON KL, 1989, INT J EPIDEMIOL, V18, P84, DOI 10.1093/ije/18.1.84; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FRIEDMAN GD, 1976, NEW ENGL J MED, V294, P1071, DOI 10.1056/NEJM197605132942001; FUGLMEYER AR, 1983, SCAND J REHABIL MED, P118; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; HILLBOM ME, 1987, ACTA MED SCAND, P93; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KALES A, 1984, LANCET, V2, P1005; KANNEL WB, 1983, AM HEART J, V105, P311, DOI 10.1016/0002-8703(83)90532-X; KANNEL WB, 1974, CIRCULATION, V49, P1160, DOI 10.1161/01.CIR.49.6.1160; KANNEL WB, 1983, VASCULAR DISEASE CEN, P1; KELLYHAYES M, 1988, ARCH PHYS MED REHAB, V69, P415; KRYZANOWSKI M, 1986, INT J EPIDEMIOL, V15, P56; LANGE P, 1988, AM REV RESPIR DIS, V137, P1119, DOI 10.1164/ajrccm/137.5.1119; MARCUS EB, 1988, AM REV RESPIR DIS, V138, P1398, DOI 10.1164/ajrccm/138.6.1398; PERSSON C, 1986, AM J EPIDEMIOL, V124, P942, DOI 10.1093/oxfordjournals.aje.a114483; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; REID DD, 1974, LANCET, V1, P469; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; ROSE G, 1978, BRIT HEART J, V40, P636; SCHWARTZ J, 1989, American Review of Respiratory Disease, V139, pA28; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILLIAMS DRR, 1985, RECENT ADV COMMUNITY, V3, P117; ZHANG ZF, 1988, AM J PUBLIC HEALTH, V78, P975, DOI 10.2105/AJPH.78.8.975; 1988, EGRET EPIDEMIOLOGICA; 1985, SAS USERS GUIDE BASI	36	51	51	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 12	1991	302	6768					84	87		10.1136/bmj.302.6768.84	http://dx.doi.org/10.1136/bmj.302.6768.84			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995121	Green Published, Bronze			2022-12-01	WOS:A1991ER95100018
J	THANABALASINGHAM, T; BECKETT, MW; MURRAY, V				THANABALASINGHAM, T; BECKETT, MW; MURRAY, V			LESSON OF THE WEEK - HOSPITAL RESPONSE TO A CHEMICAL INCIDENT - REPORT ON CASUALTIES OF AN ETHYLDICHLOROSILANE SPILL	BRITISH MEDICAL JOURNAL			English	Editorial Material									GUYS & ST THOMAS HOSP,NATL POISONS UNIT,LONDON SE1 9RT,ENGLAND; W MIDDLESEX UNIV HOSP,DEPT ACCID & EMERGENCY,ISLEWORTH,MIDDX,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Imperial College London								BAXTER PJ, 1989, BRIT MED J, V298, P1437, DOI 10.1136/bmj.298.6685.1437; CANADINE IC, 1990, INT C S SERIES, V155, P33; DALLOS V, 1990, INT C S SERIES, V155, P73; JERROM DA, 1990, INT C S SERIES, V155, P51; ROWE VK, 1948, J IND HYG TOXICOL, V30, P332; SACH M, 1988, BRIT J ACCIDENT EMER, V3, P9; TAYLOR D, 1990, INT C S SERIES, V155, P203; TONG TG, 1990, INT C S SERIES, V155, P141; 1985, TRADE UNION REPORT B; 1988, MMWR, V37, P733	10	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					101	102		10.1136/bmj.302.6768.101	http://dx.doi.org/10.1136/bmj.302.6768.101			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995104	Bronze, Green Published			2022-12-01	WOS:A1991ER95100027
J	YEUNG, CY; MA, YP; WONG, FHW; KWAN, HC; FUNG, KW; TAM, AYC				YEUNG, CY; MA, YP; WONG, FHW; KWAN, HC; FUNG, KW; TAM, AYC			AUTOMATIC END-EXPIRATORY AIR SAMPLING DEVICE FOR BREATH HYDROGEN TEST IN INFANTS	LANCET			English	Article							BOWEL TRANSIT-TIME; LACTOSE-MALABSORPTION; PREMATURE-INFANTS; H2 MEASUREMENTS; ABSORPTION; CHILDREN; H-2; EXCRETION; PRETERM	An automatic electronically operated end-expiratory air sampler has been developed for use in small infants. Upon expiration, which is detected by a hot-wire sensor, a small portion of the end-expiratory air is automatically collected into a syringe mounted on a syringe driver. The sampler obtained 87% of the end-expiratory air sample. Additionally, highly reproducible and consistent results were obtained for the respiratory gases (O2, N2, CO2). The sampler has been applied for studying breath hydrogen excretion to detect lactose malabsorption. It may also be applicable to study other expiratory gases in infants.	UNIV HONG KONG,ELECTR SERV UNIT,HONG KONG,HONG KONG; UNIV HONG KONG,DEPT CHEM,HONG KONG,HONG KONG	University of Hong Kong; University of Hong Kong	YEUNG, CY (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT PAEDIAT,HONG KONG,HONG KONG.							BOND JH, 1976, GASTROENTEROLOGY, V70, P1058; BOND JH, 1972, J CLIN INVEST, V51, P1219, DOI 10.1172/JCI106916; BOND JH, 1977, J LAB CLIN MED, V90, P30; BOND JH, 1975, J LAB CLIN MED, V85, P546; DOUWES AC, 1978, ARCH DIS CHILD, V53, P939, DOI 10.1136/adc.53.12.939; DUBOWSKI KM, 1974, CLIN CHEM, V20, P966; FERNANDES J, 1978, AM J CLIN NUTR, V31, P597, DOI 10.1093/ajcn/31.4.597; HOPPER AO, 1983, J PEDIATR GASTR NUTR, V2, P659, DOI 10.1097/00005176-198311000-00015; KIEN CL, 1987, J PEDIATR GASTR NUTR, V6, P286, DOI 10.1097/00005176-198703000-00022; KOCH G, 1968, BIOL NEONATORUM, V12, P136; LEVITT MD, 1970, J LAB CLIN MED, V75, P937; LEVITT MD, 1969, NEW ENGL J MED, V281, P122, DOI 10.1056/NEJM196907172810303; LIFSCHITZ CH, 1983, J PEDIATR GASTR NUTR, V2, P478, DOI 10.1097/00005176-198302030-00014; MACLEAN WC, 1980, J PEDIATR-US, V97, P383, DOI 10.1016/S0022-3476(80)80186-7; NIU HC, 1979, J LAB CLIN MED, V94, P755; NOSE O, 1979, ARCH DIS CHILD, V54, P436, DOI 10.1136/adc.54.6.436; OSTRANDER CR, 1983, J PEDIATR GASTR NUTR, V2, P525, DOI 10.1097/00005176-198302030-00022; ROGGERO P, 1986, J PEDIATR GASTR NUTR, V5, P214, DOI 10.1097/00005176-198605020-00009; Smith CA, 1976, PHYSL NEWBORN INFANT; STEVENSON DK, 1982, J PEDIATR GASTR NUTR, V1, P233, DOI 10.1097/00005176-198201020-00014; STEVENSON DK, 1982, J PEDIATR-US, V101, P607, DOI 10.1016/S0022-3476(82)80720-8; TADESSE K, 1986, HONG KONG J PEDIATR, V1, P75; VANDERKLEIVANMOORSEL JM, 1984, EUR J PEDIATR, V141, P221, DOI 10.1007/BF00572764; WILSON HK, 1986, SCAND J WORK ENV HEA, V12, P174, DOI 10.5271/sjweh.2159	24	4	5	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 12	1991	337	8733					90	93		10.1016/0140-6736(91)90746-C	http://dx.doi.org/10.1016/0140-6736(91)90746-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER477	1670735				2022-12-01	WOS:A1991ER47700013
J	ADACHI, Y; LUKE, M; LAEMMLI, UK				ADACHI, Y; LUKE, M; LAEMMLI, UK			CHROMOSOME ASSEMBLY INVITRO - TOPOISOMERASE-II IS REQUIRED FOR CONDENSATION	CELL			English	Article							XENOPUS-LAEVIS; SACCHAROMYCES-CEREVISIAE; MITOTIC CHROMOSOMES; DNA TOPOISOMERASES; NUCLEAR SCAFFOLD; CELL-CYCLE; YEAST; LOCALIZATION; CHROMATIN; ORGANIZATION	The role of topoisomerase II (topo II) in chromosome condensation was studied in a mitotic extract derived from Xenopus eggs by specific immunodepletion. HeLa nuclei, which have a high complement of endogenous topo II, are converted to mitotic chromosomes in the topo II-depleted extract equally well as in the control. Chicken erythrocyte nuclei, however, which have a very low content of topo II, do not convert to condensed chromosomes in the depleted extract, although their condensation is normal upon addition of purified topo II. Dosage experiments support the possible notion of a structural involvement of topo II in chromosome condensation. In the topo II-depleted extract the erythrocyte nuclei progress to precondensation chromosomes, which lack the nuclear membrane-lamina complex and consist of a cluster of swollen chromatids.	UNIV GENEVA, DEPT MOLEC BIOL, CH-1211 GENEVA 4, SWITZERLAND; SUNY STONY BROOK, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA	University of Geneva; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	ADACHI, Y (corresponding author), UNIV GENEVA, DEPT BIOCHEM, CH-1211 GENEVA 4, SWITZERLAND.		Adachi, Yasuhisa/GYA-3190-2022	Adachi, Yasuhisa/0000-0003-4197-092X; Galora De Mora, Raul Pavlov/0000-0001-8342-9782				ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; CHEN GL, 1984, J BIOL CHEM, V259, P3560; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GIAEVER GN, 1988, BIOPHYS CHEM, V29, P7, DOI 10.1016/0301-4622(88)87020-0; HARLOW E, 1988, ANTIBODIES; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER CF, 1986, J BIOL CHEM, V261, P3293; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LUKE M, 1989, DEV BIOL, V136, P459, DOI 10.1016/0012-1606(89)90271-6; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NAKAGAWA J, 1989, J CELL SCI, V94, P449; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; REITMAN M, 1990, CELL BIOL, V10, P2774; Sambrook J., 1989, MOL CLONING LAB MANU; SHIMAMURA A, 1989, METHOD ENZYMOL, V170, P603; Sternglanz R, 1989, CURR OPIN CELL BIOL, V1, P533, DOI 10.1016/0955-0674(89)90016-1; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WOODLAND HR, 1977, DEV BIOL, V57, P118, DOI 10.1016/0012-1606(77)90359-1; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; ZIERLER MK, 1985, J BIOL CHEM, V260, P974	48	388	397	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					137	148		10.1016/0092-8674(91)90215-K	http://dx.doi.org/10.1016/0092-8674(91)90215-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846085				2022-12-01	WOS:A1991ET17500015
J	CARLSON, LM; OETTINGER, MA; SCHATZ, DG; MASTELLER, EL; HURLEY, EA; MCCORMACK, WT; BALTIMORE, D; THOMPSON, CB				CARLSON, LM; OETTINGER, MA; SCHATZ, DG; MASTELLER, EL; HURLEY, EA; MCCORMACK, WT; BALTIMORE, D; THOMPSON, CB			SELECTIVE EXPRESSION OF RAG-2 IN CHICKEN B-CELLS UNDERGOING IMMUNOGLOBULIN GENE CONVERSION	CELL			English	Article							LIGHT CHAIN GENE; TRANSGENIC MICE; REARRANGEMENT; FABRICIUS; BURSA; RECOMBINATION; MECHANISM; SEGMENTS; OCCURS; REGION	Chickens create their immunoglobulin (Ig) repertoires during B cell development in the bursa of Fabricius by intrachromasomal gene conversion. Recent evidence has suggested that Ig gene conversion may involve cis-acting DNA elements related to those involved in V(D)J recombination. Therefore, we have examined the potential role of the V(D)J recombination activating genes, RAG-1 and RAG-2, in regulating chicken Ig gene conversion. In contrast to the coexpression of RAG-1 and RAG-2 observed in mammalian B cells that undergo V(D)J recombination, chicken B cells isolated from the bursa of Fabricius express high levels of the RAG-2 mRNA but do not express RAG-1 mRNA. The developmental and phenotypic characteristics of the bursal lymphocytes and chicken B cell lines that express RAG-2 mRNA demonstrate that selective RAG-2 expression occurs specifically in B cells undergoing Ig diversification by gene conversion. These data suggest that RAG-2 plays a fundamental role in Ig-specific gene conversion.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Rockefeller University	CARLSON, LM (corresponding author), UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA.		Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176; McCormack, Wayne/0000-0002-2117-8727	NCI NIH HHS [CA51466, CA48023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA048023, R01CA048023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILERA A, 1988, GENETICS, V119, P779; AGUILERA A, 1990, MOL CELL BIOL, V10, P1439, DOI 10.1128/MCB.10.4.1439; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BUCCHINI D, 1987, NATURE, V326, P409, DOI 10.1038/326409a0; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CARLSON LM, 1990, GENE DEV, V4, P536, DOI 10.1101/gad.4.4.536; CHAN MM, 1988, J IMMUNOL, V140, P2133; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLTEY M, 1989, J EXP MED, V170, P543, DOI 10.1084/jem.170.2.543; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GOODHARDT M, 1987, P NATL ACAD SCI USA, V84, P4229, DOI 10.1073/pnas.84.12.4229; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; KIM S, 1990, MOL CELL BIOL, V10, P3224, DOI 10.1128/MCB.10.6.3224; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; McCormack W T, 1990, Adv Immunol, V48, P41, DOI 10.1016/S0065-2776(08)60751-8; McCormack W T, 1989, Int Immunol, V1, P332, DOI 10.1093/intimm/1.4.332; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MCCORMACK WT, 1989, GENE DEV, V3, P838, DOI 10.1101/gad.3.6.838; MCCORMACK WT, 1990, GENE DEV, V4, P548, DOI 10.1101/gad.4.4.548; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PINK JRL, 1986, IMMUNOL REV, V91, P115, DOI 10.1111/j.1600-065X.1986.tb01486.x; PRATT LF, 1988, EMBO J, V7, P931, DOI 10.1002/j.1460-2075.1988.tb02898.x; RATCLIFFE MJH, 1985, IMMUNOL TODAY, V6, P223, DOI 10.1016/0167-5699(85)90039-8; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROUX KH, 1991, IN PRESS J IMMUNOL; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; THOMPSON CB, 1987, CELL, V51, P371, DOI 10.1016/0092-8674(87)90633-7; THOMPSON CB, 1989, MECHANISMS B CELL NE, P46; TJOELKER LW, 1990, P NATL ACAD SCI USA, V87, P7856, DOI 10.1073/pnas.87.20.7856; TONEGAWA S, 1983, SCIENCE, V241, P577; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WEILL JC, 1986, P NATL ACAD SCI USA, V83, P3336, DOI 10.1073/pnas.83.10.3336; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	42	121	126	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					201	208		10.1016/0092-8674(91)90221-J	http://dx.doi.org/10.1016/0092-8674(91)90221-J			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1986866	Green Published			2022-12-01	WOS:A1991ET17500021
J	CHUN, JJM; SCHATZ, DG; OETTINGER, MA; JAENISCH, R; BALTIMORE, D				CHUN, JJM; SCHATZ, DG; OETTINGER, MA; JAENISCH, R; BALTIMORE, D			THE RECOMBINATION ACTIVATING GENE-1 (RAG-1) TRANSCRIPT IS PRESENT IN THE MURINE CENTRAL-NERVOUS-SYSTEM	CELL			English	Article							DENTATE GYRUS; ORIGIN; TIME; SUPERFAMILY; NEURONS; SUBSETS; CORTEX; BRAIN; MICE; RAT	The recombination activating genes, RAG-1 and RAG-2, are likely to encode components of the V(D)J site-specific recombination machinery. We report here the detection of low levels of the RAG-1 transcript in the murine central nervous system by polymerase chain reaction, in situ hybridization, and Northern blot analyses. In contrast, an authentic RAG-2 transcript could not be detected reproducibly in the central nervous system. The RAG-1 transcript was found to be widespread in embryonic and postnatal neurons, with transcription being most apparent in regions of the postnatal brain with a high neuronal cell density (the cerebellum and the hippocampal formation). The results suggest that RAG-1 functions in neurons, where its role might be to recombine elements of the neuronal genome site-specifically, or to prevent detrimental alterations of the genome in these long-lived cells.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Massachusetts Institute of Technology (MIT); Rockefeller University	CHUN, JJM (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176	NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NCI NIH HHS [5R35-CA 44339, CA51466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILERA A, 1990, MOL CELL BIOL, V10, P1439, DOI 10.1128/MCB.10.4.1439; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ANGEVINE JAY B., 1965, EXP NEUROL SUPPL, V2, P1; ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BRAITENBERG V, 1958, J COMP NEUROL, V109, P1, DOI 10.1002/cne.901090102; CARLSON LM, 1991, CELL, V64, P201, DOI 10.1016/0092-8674(91)90221-J; CAVINESS VS, 1982, DEV BRAIN RES, V4, P293, DOI 10.1016/0165-3806(82)90141-9; CAVINESS VS, 1973, J COMP NEUROL, V151, P113, DOI 10.1002/cne.901510203; CHUN JJM, 1989, J NEUROSCI, V9, P1648; CLAYTON DF, 1988, NEURON, V1, P249, DOI 10.1016/0896-6273(88)90146-8; DREYER WJ, 1967, COLD SPRING HARB SYM, V32, P353, DOI 10.1101/SQB.1967.032.01.048; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FARRAR WL, 1987, IMMUNOL REV, V100, P361, DOI 10.1111/j.1600-065X.1987.tb00539.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; Goetzl E J, 1990, Adv Immunol, V48, P161, DOI 10.1016/S0065-2776(08)60754-3; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; Maniatis T., 1982, MOL CLONING; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARNES JR, 1987, IMMUNOL REV, V100, P109, DOI 10.1111/j.1600-065X.1987.tb00529.x; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; RALPH P, 1979, IMMUNOL REV, V48, P107, DOI 10.1111/j.1600-065X.1979.tb00300.x; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SCHLESSINGER AR, 1978, ANAT EMBRYOL, V154, P153, DOI 10.1007/BF00304660; SCHLESSINGER AR, 1975, J COMP NEUROL, V159, P149, DOI 10.1002/cne.901590202; SCHULER W, 1990, MOL BASIS B CELL DEV, V3, P132; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V	37	252	259	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					189	200		10.1016/0092-8674(91)90220-S	http://dx.doi.org/10.1016/0092-8674(91)90220-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1986864				2022-12-01	WOS:A1991ET17500020
J	DIRITA, VJ; MEKALANOS, JJ				DIRITA, VJ; MEKALANOS, JJ			PERIPLASMIC INTERACTION BETWEEN 2 MEMBRANE REGULATORY PROTEINS, TOXR AND TOXS, RESULTS IN SIGNAL TRANSDUCTION AND TRANSCRIPTIONAL ACTIVATION	CELL			English	Article							ESCHERICHIA-COLI; CHOLERA-TOXIN; VIBRIO-CHOLERAE; GENETIC-ANALYSIS; IDENTIFICATION; DETERMINANTS; COLONIZATION	ToxR is a transmembrane, DNA-binding protein that can activate transcription of genes encoding cholera toxin (ctxAB). Here we characterize ToxS, a 19 kd transmembrane regulatory protein that interacts with ToxR and stimulates its activity. If a portion of the periplasmic domain of ToxR is deleted, productive interaction with ToxS is abolished. A ToxR-PhoA fusion protein that retains most of the ToxR periplasmic region remains dependent on ToxS for its ToxR activity. ToxS protects this fusion from proteolytic cleavage, suggesting that these two proteins interact within the periplasm. Mutations in a short cytoplasmic domain of ToxR were isolated that disrupt the periplasmic interaction between ToxR and ToxS. This domain is shared by other bacterial transcriptional activators, suggesting that it may play a common role in function of these proteins and in the molecular mechanism of signal transduction.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School				DiRita, Victor/0000-0003-3617-7011	NIAID NIH HHS [AI08050, AI8045] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; DEGNEN GE, 1974, J BACTERIOL, V117, P477, DOI 10.1128/JB.117.2.477-487.1974; HALL MN, 1981, ANNU REV GENET, V15, P91, DOI 10.1146/annurev.ge.15.120181.000515; HICKMAN RK, 1988, J BACTERIOL, V170, P1715, DOI 10.1128/jb.170.4.1715-1720.1988; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; KUSHNER SR, 1987, ESCHERICHIA COLI SAL, P1225; Maniatis T., 1982, MOL CLONING; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; Miller JH., 1972, EXPT MOL GENETICS; MILLER VL, 1984, P NATL ACAD SCI-BIOL, V81, P3471, DOI 10.1073/pnas.81.11.3471; MILLER VL, 1989, J BACTERIOL, V171, P1288, DOI 10.1128/jb.171.3.1288-1293.1989; MILLER VL, 1985, J BACTERIOL, V163, P580, DOI 10.1128/JB.163.2.580-585.1985; MILLER VL, 1987, CELL, V48, P271, DOI 10.1016/0092-8674(87)90430-2; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; PETERSON KM, 1988, INFECT IMMUN, V56, P2822, DOI 10.1128/IAI.56.11.2822-2829.1988; SCHLESIN.MJ, 1967, J BIOL CHEM, V242, P1604; Silhavy T.J., 1984, EXPT GENE FUSIONS; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P433	23	164	172	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					29	37		10.1016/0092-8674(91)90206-E	http://dx.doi.org/10.1016/0092-8674(91)90206-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1898871				2022-12-01	WOS:A1991ET17500006
J	DJABALI, K; PORTIER, MM; GROS, F; BLOBEL, G; GEORGATOS, SD				DJABALI, K; PORTIER, MM; GROS, F; BLOBEL, G; GEORGATOS, SD			NETWORK ANTIBODIES IDENTIFY NUCLEAR LAMIN-B AS A PHYSIOLOGICAL ATTACHMENT SITE FOR PERIPHERIN INTERMEDIATE FILAMENTS	CELL			English	Article							ANTI-IDIOTYPIC ANTIBODIES; AMINO-ACID-SEQUENCE; PLASMA-MEMBRANE; AVIAN ERYTHROCYTES; MESSENGER-RNA; DESMIN DERIVATIVES; SIZED FILAMENTS; DYNAMIC ASPECTS; PROTEIN FAMILY; KERATIN CDNAS	We studied the molecular associations between peripherin (a neuronal, type III intermediate filament subunit) and nuclear lamins. We show here that isolated peripherin binds selectively to mammalian lamin B under in vitro conditions. We further demonstrate that a synthetic peptide, representing the proximal part of peripherin's tall domain (P(I)), also associates with mammalian lamin B in a saturable, cooperative, and specific fashion. Laboratory animals immunized with P(I) spontaneously develop idiotypic and antiidiotypic antibodies recognizing peripherin and lamin B, respectively. These data provide essentially in vivo evidence that lamin B represents a constitutive nuclear "receptor" site for the tail domains of peripherin intermediate filaments.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021; EUROPEAN MOLEC BIOL LAB,PROGRAMME CELL BIOL,W-6900 HEIDELBERG,GERMANY	Howard Hughes Medical Institute; Rockefeller University; European Molecular Biology Laboratory (EMBL)	DJABALI, K (corresponding author), COLL FRANCE,11 PL MARCELIN BERTHELOT,F-75231 PARIS 05,FRANCE.			Georgatos, Spyros/0000-0002-2078-7467				AARONSON RP, 1975, P NATL ACAD SCI USA, V72, P1007, DOI 10.1073/pnas.72.3.1007; AEBI U, 1983, J CELL BIOL, V97, P1131, DOI 10.1083/jcb.97.4.1131; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ALETTA JM, 1989, J BIOL CHEM, V264, P4619; BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; BOST KL, 1989, METHOD ENZYMOL, V168, P16; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; CARMO-FONSECA M, 1987, European Journal of Cell Biology, V45, P282; CARMOFONSECA M, 1990, ELECTRON MICROSC REV, V3, P115, DOI 10.1016/0892-0354(90)90017-M; CARTAUD A, 1989, J CELL BIOL, V109, P1745, DOI 10.1083/jcb.109.4.1745; CARTAUD A, 1990, J CELL BIOL, V111, P581, DOI 10.1083/jcb.111.2.581; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; CROIZAT B, 1979, CR ACAD SCI D NAT, V289, P1283; ESCURAT M, 1990, J NEUROSCI, V10, P764; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FRANKE WW, 1971, PROTOPLASMA, V73, P263, DOI 10.1007/BF01275600; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEISLER N, 1982, CELL, V30, P277, DOI 10.1016/0092-8674(82)90033-2; GEISLER N, 1986, STRUCTURAL ASPECTS I; GEORGATOS SD, 1985, J CELL BIOL, V100, P1955, DOI 10.1083/jcb.100.6.1955; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; GEORGATOS SD, 1985, J CELL BIOL, V100, P1962, DOI 10.1083/jcb.100.6.1962; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; GOLDMAN R, 1985, ANN NY ACAD SCI, V455, P1, DOI 10.1111/j.1749-6632.1985.tb50400.x; GRANGER BL, 1982, CELL, V30, P263, DOI 10.1016/0092-8674(82)90032-0; GUILLY MN, 1987, EUR J CELL BIOL, V43, P266; HANUKOGLU I, 1983, CELL, V33, P915, DOI 10.1016/0092-8674(83)90034-X; HARLOW E, 1968, ANTIBODIES LABORATOR; HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689; HOGER TH, 1988, EUR J CELL BIOL, V47, P283; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JERNE NK, 1985, EMBO J, V4, P847, DOI 10.1002/j.1460-2075.1985.tb03709.x; JONES JCR, 1982, CELL MOTIL CYTOSKEL, V2, P197, DOI 10.1002/cm.970020302; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; KAUFMANN S, 1989, J BIOL CHEM, V267, P13946; KROHNE G, 1987, EMBO J, V6, P3801, DOI 10.1002/j.1460-2075.1987.tb02716.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDON F, 1989, EMBO J, V8, P1719, DOI 10.1002/j.1460-2075.1989.tb03564.x; LANGLEY RC, 1985, J CELL BIOCHEM, V30, P101; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEHNER CF, 1987, J CELL BIOL, V105, P577, DOI 10.1083/jcb.105.1.577; LEHNER CF, 1986, J BIOL CHEM, V261, P3293; LEHTO VP, 1978, NATURE, V272, P175, DOI 10.1038/272175a0; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MULCHAHEY JJ, 1986, P NATL ACAD SCI USA, V83, P9714, DOI 10.1073/pnas.83.24.9714; NGAI J, 1990, CELL, V60, P415, DOI 10.1016/0092-8674(90)90593-4; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; PARYSEK LM, 1988, NEURON, V1, P395, DOI 10.1016/0896-6273(88)90189-4; PASCUAL DW, 1989, J IMMUNOL, V143, P3697; PETER M, 1989, J MOL BIOL, V208, P393, DOI 10.1016/0022-2836(89)90504-4; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; QUAX W, 1985, CELL, V43, P327, DOI 10.1016/0092-8674(85)90038-8; QUAX W, 1983, CELL, V35, P215, DOI 10.1016/0092-8674(83)90224-6; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; RAMAEKERS FCS, 1982, P NATL ACAD SCI-BIOL, V79, P3208, DOI 10.1073/pnas.79.10.3208; RENNER W, 1981, J MOL BIOL, V149, P285, DOI 10.1016/0022-2836(81)90303-X; RIVAS CI, 1988, P NATL ACAD SCI USA, V85, P6092, DOI 10.1073/pnas.85.16.6092; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHECHTER Y, 1984, J BIOL CHEM, V259, P6411; SHECHTER Y, 1982, SCIENCE, V216, P542, DOI 10.1126/science.7041258; SMITH LR, 1987, J IMMUNOL, V138, P7; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Stewart M, 1990, CURR OPIN CELL BIOL, V2, P91, DOI 10.1016/S0955-0674(05)80037-7; TOOZE J, 1989, EUR J CELL BIOL, V49, P259; VIKSTROM KL, 1989, P NATL ACAD SCI USA, V86, P549, DOI 10.1073/pnas.86.2.549; VORBURGER K, 1989, J MOL BIOL, V208, P405, DOI 10.1016/0022-2836(89)90505-6; WANG E, 1985, ANN NY ACAD SCI, V455, P32, DOI 10.1111/j.1749-6632.1985.tb50402.x; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; ZACKROFF RV, 1979, P NATL ACAD SCI USA, V76, P6226, DOI 10.1073/pnas.76.12.6226; ZEHNER ZE, 1987, J BIOL CHEM, V262, P8112	83	107	107	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					109	121		10.1016/0092-8674(91)90213-I	http://dx.doi.org/10.1016/0092-8674(91)90213-I			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1986862				2022-12-01	WOS:A1991ET17500013
J	GRAHAM, R; GILMAN, M				GRAHAM, R; GILMAN, M			DISTINCT PROTEIN TARGETS FOR SIGNALS ACTING AT THE C-FOS SERUM RESPONSE ELEMENT	SCIENCE			English	Article							MEDIATES TRANSCRIPTIONAL RESPONSE; GROWTH-FACTOR; PHORBOL ESTERS; BINDING-SITE; CYCLIC-AMP; GENE; IDENTIFICATION; INDUCTION; YEAST; EXPRESSION	The c-fos serum response element (SRE) is a primary nuclear target for intracellular signal transduction pathways triggered by growth factors. It is the target for both protein kinase C (PKC)-dependent and -independent signals. Function of the SRE requires binding of a cellular protein, termed serum response factor (SRF). A second protein, p62TCP, recognizes the SRE-SRF complex to form a ternary complex. A mutated SRE that bound SRF but failed to form the ternary complex selectively lost response to PKC activators, but retained response to PKC-independent signals. Thus, two different signaling pathways act through discrete nuclear targets at the SRE. At least one of these pathways functions by recruitment of a pathway-specific accessory factor (p62TCF). These results offer a molecular mechanism to account for the biological specificity of signals that appear to act through common DNA sequence elements.	COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory				graham, regina/0000-0003-0103-2971	NATIONAL CANCER INSTITUTE [R01CA045642, P01CA046370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI027270] Funding Source: NIH RePORTER; NCI NIH HHS [CA46370, CA45642] Funding Source: Medline; NIAID NIH HHS [AI27270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BUSCHER M, 1988, ONCOGENE, V3, P301; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; Curran T, 1988, ONCOGENE HDB, P307; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, UNPUB; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; JARVIS EE, 1988, MOL CELL BIOL, V8, P309, DOI 10.1128/MCB.8.1.309; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ORITA S, 1989, GENE, V75, P13; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAN S, 1990, NATURE, V62, P367; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2	33	238	241	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					189	192		10.1126/science.1898992	http://dx.doi.org/10.1126/science.1898992			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1898992				2022-12-01	WOS:A1991ET17300038
J	HANIFORD, DB; BENJAMIN, HW; KLECKNER, N				HANIFORD, DB; BENJAMIN, HW; KLECKNER, N			KINETIC AND STRUCTURAL-ANALYSIS OF A CLEAVED DONOR INTERMEDIATE AND A STRAND TRANSFER INTERMEDIATE IN TN10 TRANSPOSITION	CELL			English	Article							BACTERIOPHAGE-MU-DNA; RETROVIRAL INTEGRATION; TRANSPOSABLE ELEMENTS; INVITRO TRANSPOSITION; PROTEIN; SEQUENCES; MECHANISM; REARRANGEMENTS; ORGANIZATION; REPLICATION	Tn10 transposes by a nonreplicative "cut and paste" mechanism. We describe here two protein-DNA complexes that are reaction intermediates in the Tn10 transposition process: a cleaved donor complex whose DNA component consists of transposon sequences cleanly excised from flanking donor DNA, and a strand transfer complex whose DNA component contains transposon termini specifically joined to a target site. The kinetic behavior of the first species suggests that it is an early intermediate in the transposition reaction. These two Tn10 complexes are closely analogous to complexes identified in the pathway for replicative "cointegrate" formation by bacteriophage Mu and thus represent intermediates that may be common to both nonreplicative and replicative transposition. These and other results suggest that the Tn10 and Mu reactions are fundamentally very similar despite their very different biological outcomes. The critical difference between the two reactions is the fate of the DNA strand that is not joined to target DNA.			HANIFORD, DB (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; BERG DE, 1983, P NATL ACAD SCI-BIOL, V80, P792, DOI 10.1073/pnas.80.3.792; BOEKE JD, 1989, MOBILE DNA, P335; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CHACONAS G, 1981, J MOL BIOL, V150, P341, DOI 10.1016/0022-2836(81)90551-9; COEN ES, 1989, MOBILE DNA, P413; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FAELEN M, 1978, NATURE, V271, P580, DOI 10.1038/271580a0; FEDOROFF NV, 1989, MOBILE DNA, P375; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; FOSTER TJ, 1981, CELL, V23, P201, DOI 10.1016/0092-8674(81)90285-3; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; HALLING SM, 1982, P NATL ACAD SCI-BIOL, V79, P2608, DOI 10.1073/pnas.79.8.2608; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HARSHEY RM, 1983, P NATL ACAD SCI-BIOL, V80, P2012, DOI 10.1073/pnas.80.7.2012; HARSHEY RM, 1985, P NATL ACAD SCI USA, V82, P7676, DOI 10.1073/pnas.82.22.7676; HUISMAN O, 1989, EMBO J, V8, P2101, DOI 10.1002/j.1460-2075.1989.tb03619.x; ISBERG RR, 1985, J MOL BIOL, V182, P69, DOI 10.1016/0022-2836(85)90028-2; JENCKS WP, 1990, BIOCH MOL BIOL, V1, P1; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KLECKNER N, 1989, MOBILE DNA, P225; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LIEBART JC, 1982, P NATL ACAD SCI-BIOL, V79, P4362, DOI 10.1073/pnas.79.14.4362; LJUNGQUIST E, 1977, P NATL ACAD SCI USA, V74, P3143, DOI 10.1073/pnas.74.8.3143; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; Miller JH., 1972, EXPT MOL GENETICS; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; MORISATO D, 1984, CELL, V39, P181, DOI 10.1016/0092-8674(84)90204-6; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; SHEN MM, 1987, GENETICS, V116, P359; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SZATMARI GB, 1986, GENE, V41, P315, DOI 10.1016/0378-1119(86)90113-7; VARMUS H, 1989, MOBILE DNA, P53; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WEINERT TA, 1984, COLD SPRING HARB SYM, V49, P251, DOI 10.1101/SQB.1984.049.01.029	47	78	79	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					171	179						9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846088				2022-12-01	WOS:A1991ET17500018
J	HANNIGAN, GE; WILLIAMS, BRG				HANNIGAN, GE; WILLIAMS, BRG			SIGNAL TRANSDUCTION BY INTERFERON-ALPHA THROUGH ARACHIDONIC-ACID METABOLISM	SCIENCE			English	Article							INDUCED NUCLEAR FACTORS; SYNTHETASE GENE; PROMOTER ELEMENT; BINDING-PROTEIN; GROWTH-FACTOR; CELLS; ACTIVATION; EXPRESSION; ENHANCER; RAS	Molecular mechanisms that mediate signal transduction by growth inhibitory cytokines are poorly understood. Type I (alpha and beta) interferons (IFNs) are potent growth inhibitory cytokines whose biological activities depend on induced changes in gene expression. IFN-alpha induced the transient activation of phospholipase A2 in 3T3 fibroblasts and rapid hydrolysis of [H-3]arachidonic acid (AA) from prelabeled phospholipid pools. The phospholipase inhibitor, bromophenacyl bromide (BPB), specifically blocked IFN-induced binding of nuclear factors to a conserved, IFN-regulated enhancer element, the interferon-stimulated response element (ISRE). BPB also caused a dose-dependent inhibition of IFN-alpha-induced ISRE-dependent transcription in transient transfection assays. Specific inhibition of AA oxygenation by eicosatetraynoic acid prevented IFN-alpha induction of factor binding to the ISRE. Treatment of intact cells with inhibitors of fatty acid cyclooxygenase or lipoxygenase enzymes resulted in amplification of IFN-alpha-induced ISRE binding and gene expression. Thus, IFN-alpha-receptor-coupled AA hydrolysis may function in activation of latent transcription factors by IFN-alpha and provides a system for studying the role of AA metabolism in transduction of growth inhibitory signals.	HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Hannigan, Greg/A-5092-2009; Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; CREAGAN ET, 1988, CANCER, V61, P1787, DOI 10.1002/1097-0142(19880501)61:9<1787::AID-CNCR2820610911>3.0.CO;2-Q; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FITZPATRICK FA, 1980, J IMMUNOL, V125, P431; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; GARCIABLANCO MA, 1989, MOL CELL BIOL, V9, P1060, DOI 10.1128/MCB.9.3.1060; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; HAMMARSTROM S, 1977, BIOCHIM BIOPHYS ACTA, V487, P517, DOI 10.1016/0005-2760(77)90221-1; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HANNIGAN GE, UNPUB; HONG SL, 1981, J BIOL CHEM, V256, P5215; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; KIM B, 1989, SURGERY, V106, P248; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MILLS GB, 1985, 2 5A SYSTEM, P357; Pace-Asciak CR, 1983, ENZYMES LIPID ENZYMO, VXVI, P543; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; SHIER WT, 1982, J CELL PHYSIOL, V112, P171, DOI 10.1002/jcp.1041120204; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SWEATT JD, 1986, J BIOL CHEM, V261, P8667; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4	34	156	157	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					204	207		10.1126/science.1898993	http://dx.doi.org/10.1126/science.1898993			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1898993				2022-12-01	WOS:A1991ET17300043
J	LIN, HF; WOLFNER, MF				LIN, HF; WOLFNER, MF			THE DROSOPHILA MATERNAL-EFFECT GENE FS(1)YA ENCODES A CELL-CYCLE DEPENDENT NUCLEAR-ENVELOPE COMPONENT REQUIRED FOR EMBRYONIC MITOSIS	CELL			English	Article							FEMALE-STERILE MUTANTS; DNA-BINDING PROTEINS; MONOCLONAL-ANTIBODIES; DEVELOPMENTAL REGULATION; MITOTIC CONTROL; POLE CELLS; HEAT-SHOCK; MELANOGASTER; EMBRYOGENESIS; DIVISION	The maternal-effect gene fs(1)Ya is specifically required for embryonic mitosis in Drosophila. fs(1)Ya is involved in the initiation of the first embryonic mitosis and may also be necessary for subsequent embryonic mitotic divisions. fs(1)Ya encodes a 91.3 kd hydrophilic protein containing two putative MPF phosphorylation target sites and two potential nuclear localization signals. This protein is synthesized during postoogenic maturation from its maternal RNA and persists throughout embryogenesis. In early embryos, the fs(1)Ya protein is localized to the nuclear envelope from interphase to metaphase. During anaphase and telophase, it is dispersed in the nucleoplasm and cytoplasm, a behavior that is different from that of both the nuclear envelope and lamins. These results suggest that the fs(1)Ya protein is a cell cycle-dependent component of the nuclear envelope that specifically functions in embryonic mitosis.	CORNELL UNIV, GENET & DEV SECT, ITHACA, NY 14853 USA	Cornell University								ALLIS CD, 1977, DEV BIOL, V56, P372, DOI 10.1016/0012-1606(77)90277-9; BAKER BS, 1975, GENETICS, V80, P267; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLOW J, 1989, TRENDS GENET, V5, P166, DOI 10.1016/0168-9525(89)90067-X; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DIBENEDETTO AJ, 1990, DEV BIOL, V139, P134, DOI 10.1016/0012-1606(90)90284-P; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DOOLITTLE FR, 1986, URFS ORFS PRIMER ANA; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FOE VE, 1983, J CELL SCI, V61, P31; FOE VE, 1989, DEVELOPMENT, V107, P1; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX VE, 1983, J CELL SCI, V61, P31; FRASCH M, 1988, J CELL SCI, V90, P247; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; FUCHS JP, 1983, J CELL SCI, V64, P331; FUYAMA Y, 1984, JPN J GENET, V59, P91, DOI 10.1266/jjg.59.91; FUYAMA Y, 1986, GENETICS, V112, P237; GANS M, 1975, GENETICS, V81, P683; GERACE L, 1986, TRENDS BIOCHEM SCI, V11, P443, DOI 10.1016/0968-0004(86)90243-4; GILBERT SF, 1988, DEV BIOL, P785; GLOVER DM, 1989, J CELL SCI, V92, P137; GLOVER DM, 1990, NATURE, V348, P117, DOI 10.1038/348117a0; GOEBL M, 1988, CELL, V54, P739; GUO LH, 1984, GENE, V29, P251, DOI 10.1016/0378-1119(84)90186-0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JUDD BH, 1972, GENETICS, V71, P139; JUDD BH, 1973, COLD SPRING HARB SYM, V38, P573, DOI 10.1101/SQB.1974.038.01.061; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KOMALSKI D, 1976, BIOCHEMISTRY-US, V15, P4463; KROHNE G, 1986, EXP CELL RES, V162, P1, DOI 10.1016/0014-4827(86)90421-0; KROHNE G, 1989, J CELL BIOL, V109, P2003, DOI 10.1083/jcb.109.5.2003; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN H, 1989, MOL GEN GENET, V215, P257, DOI 10.1007/BF00339726; LOHKA MJ, 1989, J CELL SCI, V92, P131; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; Maniatis T., 1982, MOL CLONING; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MERRILL PT, 1988, DEVELOPMENT, V104, P495; MOHLER JD, 1977, GENETICS, V85, P259; MONSMA SA, 1988, GENE DEV, V2, P1063, DOI 10.1101/gad.2.9.1063; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PERRIMON N, 1986, GENETICS, V113, P695; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RAFF JW, 1989, CELL, V57, P611, DOI 10.1016/0092-8674(89)90130-X; RESTIFO LL, 1986, DEV BIOL, V115, P507, DOI 10.1016/0012-1606(86)90271-X; RISAU W, 1981, EXP CELL RES, V133, P47, DOI 10.1016/0014-4827(81)90355-4; ROBERTSON HM, 1988, GENETICS, V118, P461; SANTAMARIA P, 1980, NATURE, V287, P143, DOI 10.1038/287143a0; SAUMWEBER H, 1980, CHROMOSOMA, V80, P253, DOI 10.1007/BF00292684; SCHUPBACH T, 1989, GENETICS, V121, P101; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; Sonnenblick B., 1950, BIOL DROSOPHILA, P62; STAFSTROM JP, 1984, EUR J CELL BIOL, V34, P179; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WHITFIELD WGF, 1988, J CELL SCI, V89, P467; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0; WIESCHAUS E, 1988, DEVELOPMENT, V104, P483; WOLSTENHOLME DR, 1965, GENETICS, V52, P949; XIAO H, 1989, MOL CELL BIOL, V9, P1746, DOI 10.1128/MCB.9.4.1746; YOUNG MW, 1978, GENETICS, V88, P723; ZALOKAR M, 1976, DEV BIOL, V49, P425, DOI 10.1016/0012-1606(76)90185-8; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97; ZALOKAR M, 1975, DEV BIOL, V47, P419, DOI 10.1016/0012-1606(75)90295-X	103	67	68	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					49	62		10.1016/0092-8674(91)90208-G	http://dx.doi.org/10.1016/0092-8674(91)90208-G			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1986869				2022-12-01	WOS:A1991ET17500008
J	OEHEN, S; HENGARTNER, H; ZINKERNAGEL, RM				OEHEN, S; HENGARTNER, H; ZINKERNAGEL, RM			VACCINATION FOR DISEASE	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; TOXIC T-CELLS; RESPIRATORY SYNCYTIAL VIRUS; RECOMBINANT VACCINIA VIRUS; MURINE MODEL; HOST DISEASE; HEPATITIS-B; MICE; IMMUNIZATION; INFECTIONS	Recombinant virus vaccines that express a limited number of epitopes are currently being developed to prevent disease by changing the relative balance between viral spread and the immune response. Some circumstances, however, were found in infections with a noncytopathic virus in which vaccination caused disease; sensitive parameters included the genetic background of the host, the time or dose of infection, and the constituents of the vaccine. Thus, immunopathologic damage by T cells may be an unwanted consequence of vaccination with the new types of peptide or recombinant vaccines that are being investigated for the human immunodeficiency viruses and other pathogens.	UNIV ZURICH, INST PATHOL, EXPTL PATHOL LAB, CH-8091 ZURICH, SWITZERLAND	University of Zurich								AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; BAENZIGER J, 1986, EUR J IMMUNOL, V16, P387, DOI 10.1002/eji.1830160413; BIANCHI L, 1981, SPRINGER SEMIN IMMUN, V3, P421, DOI 10.1007/BF01951491; BOLOGNESI DP, 1989, NATURE, V340, P431, DOI 10.1038/340431a0; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; Cerottini J C, 1974, Adv Immunol, V18, P67, DOI 10.1016/S0065-2776(08)60308-9; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COLE GA, 1972, NATURE, V238, P335, DOI 10.1038/238335a0; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; DOHERTY PC, 1988, CLIN IMMUNOL IMMUNOP, V47, P19, DOI 10.1016/0090-1229(88)90141-9; EZZELL C, 1987, NATURE, V328, P747, DOI 10.1038/328747a0; FULGINITI VA, 1967, J AMER MED ASSOC, V202, P1075, DOI 10.1001/jama.202.12.1075; GOLLINS SW, 1986, NATURE, V321, P244, DOI 10.1038/321244a0; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HANY M, 1989, EUR J IMMUNOL, V19, P417, DOI 10.1002/eji.1830190302; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; HOTCHIN J, 1962, COLD SPRING HARB SYM, V27, P479, DOI 10.1101/SQB.1962.027.001.046; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; LEHMANNGRUBE F, 1977, J GEN VIROL, V37, P85, DOI 10.1099/0022-1317-37-1-85; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; LEIST TP, 1987, J IMMUNOL, V138, P2278; LEIST TP, 1988, J EXP MED, V167, P1749, DOI 10.1084/jem.167.5.1749; Mackett M., 1985, DNA CLONING PRACTICA, P191; MCCHESNEY MB, 1989, ADV IMMUNOL, V45, P335, DOI 10.1016/S0065-2776(08)60696-3; MICHEL F, 1988, EUR J IMMUNOL, V18, P1917, DOI 10.1002/eji.1830181208; MIMS CA, 1968, J IMMUNOL, V101, P717; MIMS CA, 1982, PATHOGENESIS INFECTI, P1; MOLLER G, 1983, IMMUNOL REV, V70, P5; MONDELLI M, 1984, SEMIN LIVER DIS, V4, P47, DOI 10.1055/s-2008-1040645; MUSTAFA AS, 1986, NATURE, V319, P63, DOI 10.1038/319063a0; NOTKINS AL, 1975, VIRAL IMMUNOLOGY IMM, P1; OLDSTONE MB, 1973, J EXP MED, V137, P1201, DOI 10.1084/jem.137.5.1201; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; ORENTAS RJ, 1990, SCIENCE, V248, P1234, DOI 10.1126/science.2190315; PANICALI D, 1983, P NATL ACAD SCI-BIOL, V80, P5364, DOI 10.1073/pnas.80.17.5364; PFAU CJ, 1982, J EXP MED, V156, P79, DOI 10.1084/jem.156.1.79; PFAU CJ, 1983, J GEN VIROL, V64, P1827, DOI 10.1099/0022-1317-64-8-1827; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROBINSON WE, 1990, P NATL ACAD SCI USA, V87, P3185, DOI 10.1073/pnas.87.8.3185; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SMITH GL, 1983, NATURE, V302, P490, DOI 10.1038/302490a0; STOTT EJ, 1985, ARCH VIROL, V84, P1, DOI 10.1007/BF01310552; VIA CS, 1987, J IMMUNOL, V139, P1840; VIA CS, 1988, IMMUNOL TODAY, V9, P207, DOI 10.1016/0167-5699(88)91215-7; ZAGURY D, 1987, NATURE, V326, P249, DOI 10.1038/326249a0; ZINKERNAGEL RM, 1986, J EXP MED, V164, P1075, DOI 10.1084/jem.164.4.1075; ZINKERNAGEL RM, 1985, NATURE, V316, P814, DOI 10.1038/316814a0	49	102	104	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 11	1991	251	4990					195	198		10.1126/science.1824801	http://dx.doi.org/10.1126/science.1824801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1824801				2022-12-01	WOS:A1991ET17300040
J	PATTERSON, B; GUTHRIE, C				PATTERSON, B; GUTHRIE, C			A U-RICH TRACT ENHANCES USAGE OF AN ALTERNATIVE 3' SPLICE SITE IN YEAST	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; MESSENGER-RNA INTRONS; SACCHAROMYCES-CEREVISIAE; SEQUENCES; PROTEIN; GENES; RECOGNIZES; MUTATIONS; SELECTION	There has been a long-standing belief that the mechanisms of mammalian and yeast splicing differ fundamentally in their requirement for a pyrimidine-rich motif preceding the 3' splice site. Using an in vivo assay, we have tested the influence of uridine content on competition between alternative 3' splice sites in yeast. We find that a uridine-rich tract preceding a PyAG greatly enhances its ability to compete as a splice acceptor. Moreover, a proximal PyAG is often overlooked if a more distal PyAG occurs in a superior sequence context; this observation cannot be accounted for by simple scanning models. Finally, we show that a distal (> 30 nucleotide) 3' splice site that is not preceded be uridines is a poor substrate for the second step of splicing; this argues that recognition of a uridine-rich motif is required for effective identification and utilization of distant splice sites.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1984, MOL CELL BIOL, V4, P1871, DOI 10.1128/MCB.4.9.1871; CASADABAN M, 1983, RECOMBINANT DNA METH, P293; CELLINI A, 1985, EMBO J, V5, P1023; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; FOUSER LA, 1987, MOL CELL BIOL, V7, P3511; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEER RJ, 1982, NUCLEIC ACIDS RES, V10, P5869, DOI 10.1093/nar/10.19.5869; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; PADGETT RA, 1986, ANN REV BIOCH, V55, P199; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PIKIELNY CW, 1983, CELL, V34, P395, DOI 10.1016/0092-8674(83)90373-2; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RODRIGUEZ JR, 1984, CELL, V39, P603, DOI 10.1016/0092-8674(84)90467-7; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; RYMOND BC, 1987, GENE DEV, V1, P238, DOI 10.1101/gad.1.3.238; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WISE JA, 1983, CELL, V35, P743, DOI 10.1016/0092-8674(83)90107-1	32	106	106	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					181	187		10.1016/0092-8674(91)90219-O	http://dx.doi.org/10.1016/0092-8674(91)90219-O			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846089				2022-12-01	WOS:A1991ET17500019
J	PRENDERGAST, GC; ZIFF, EB				PRENDERGAST, GC; ZIFF, EB			METHYLATION-SENSITIVE SEQUENCE-SPECIFIC DNA-BINDING BY THE C-MYC BASIC REGION	SCIENCE			English	Article							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; UPSTREAM ELEMENT; ONCOGENE; FOS; DIFFERENTIATION; EXPRESSION; CELLS; JUN; COMMITMENT	The function of the c-Myc oncoprotein and its role in cell growth control is unclear. A basic region of c-Myc is structurally related to the basic motifs of helix-loop-helix (HLH) and leucine zipper proteins, which provide sequence-specific DNA binding function. The c-Myc basic region was tested for its ability to bind DNA by attaching it to the HLH dimerization interface of the E12 enhancer binding factor. Dimers of the chimeric protein, termed E6, specifically bound an E box element (GGCCACGT-GACC) recognized by other HLH proteins in a manner dependent on the integrity of the c-Myc basic motif. Methylation of the core CpG in the E box recognition site specifically inhibited binding by E6, but not by two other HLH proteins. Expression of E6 (but not an E6 DNA binding mutant) suppressed the ability of c-myc to cooperate with H-ras in a rat embryo fibroblast transformation assay, suggesting that the DNA recognition specificity of E6 is related to that of c-Myc in vivo.	NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University	PRENDERGAST, GC (corresponding author), NYU,SCH MED,DEPT BIOCHEM,HOWARD HUGHES MED INST,NEW YORK,NY 10016, USA.			Ziff, Edward/0000-0001-7389-8649				BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BLACKWELL TK, COMMUNICATION; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANG C, 1989, NATURE, V339, P664; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JONES PA, 1986, CANCER RES, V46, P461; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MARUYAMA K, 1987, ONCOGENE, V1, P361; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, UNPUB; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701	31	491	504	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					186	189		10.1126/science.1987636	http://dx.doi.org/10.1126/science.1987636			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1987636				2022-12-01	WOS:A1991ET17300037
J	ROBEY, EA; FOWLKES, BJ; GORDON, JW; KIOUSSIS, D; VONBOEHMER, H; RAMSDELL, F; AXEL, R				ROBEY, EA; FOWLKES, BJ; GORDON, JW; KIOUSSIS, D; VONBOEHMER, H; RAMSDELL, F; AXEL, R			THYMIC SELECTION IN CD8 TRANSGENIC MICE SUPPORTS AN INSTRUCTIVE MODEL FOR COMMITMENT TO A CD4 OR CD8 LINEAGE	CELL			English	Article							T-CELL RECEPTOR; ANTIGEN RECEPTOR; POSITIVE SELECTION; LYMPHOCYTES-T; GENE; MOLECULES; EXPRESSION; RECOGNITION; ACTIVATION; ENGAGEMENT	Immature thymocytes, which coexpress CD4 and CD8, give rise to mature CD4+CD8- and CD4-CD8+ T cells. Only those T cells that recognize self-MHC are selected to mature, a process known as positive selection. The specificity of the T cell antigen receptor (TCR) for class I or class II MHC influences the commitment to a CD4 or CD8 lineage. This may occur by a directed mechanism or by stochastic commitment followed by a selection step that allows only CD8+, class I-specific and CD4+, class II-specific cells to survive. We have generated a mouse line expressing a CD8 transgene under the control of the T cell-specific CD2 regulatory sequences. Although constitutive CD8 expression does not affect thymic selection of CD4+ cells, selection of a class I-specific TCR in the CD8 subset is substantially improved. This outcome is consistent with a model for positive selection in which selection occurs at a developmental stage in which both CD4 and CD8 are expressed, and positive selection by class I MHC generates an instructive signal that directs differentiation to a CD8 lineage.	COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; NIAID, CELLULAR & MOLEC IMMUNOL LAB, BETHESDA, MD 20892 USA; CUNY MT SINAI SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA; NATL INST MED RES, GENE STRUCT & EXPRESS LAB, LONDON NW7 1AA, ENGLAND; BASEL INST IMMUNOL, CH-4005 BASEL, SWITZERLAND	Columbia University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; MRC National Institute for Medical Research	ROBEY, EA (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.			Axel, Richard/0000-0002-3141-4076				BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P545, DOI 10.1007/BF01572589; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; JANEWAY CA, 1988, NATURE, V335, P208, DOI 10.1038/335208a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MAGE MG, 1984, METHOD ENZYMOL, V108, P118; MAISSEN M, 1988, CELL, V55, P49; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; Robey E A, 1990, Semin Immunol, V2, P25; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTO T, 1989, J IMMUNOL, V143, P3379; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; YOUN HJ, 1988, IMMUNOGENETICS, V28, P353, DOI 10.1007/BF00364234; YOUN HJ, 1988, IMMUNOGENETICS, V28, P345, DOI 10.1007/BF00364233; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	41	217	218	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					99	107		10.1016/0092-8674(91)90212-H	http://dx.doi.org/10.1016/0092-8674(91)90212-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1898873				2022-12-01	WOS:A1991ET17500012
J	ROGGE, RD; KARLOVICH, CA; BANERJEE, U				ROGGE, RD; KARLOVICH, CA; BANERJEE, U			GENETIC DISSECTION OF A NEURODEVELOPMENTAL PATHWAY - SON OF SEVENLESS FUNCTIONS DOWNSTREAM OF THE SEVENLESS AND EGF RECEPTOR TYROSINE KINASES	CELL			English	Article							FAINT-LITTLE-BALL; DROSOPHILA-MELANOGASTER; COMPOUND EYE; CELL LINEAGE; RETINA; PROTEIN; HOMOLOG; MUTATIONS; ENCODES; DOMAIN	We have isolated a dominant mutation in a gene called Son of sevenless (Sos) that is an allele-specific suppressor of the sevenless phenotype. This suppressor function is autonomously required in R7 and is sensitive to the dosage of the Sos and bride of sevenless genes. Loss-of-function alleles of Sos are recessive lethals, but in the eye Sos has a role in R cell development. Mutations in Sos also interact with the Ellipse allele of the Drosophila EGF receptor. We propose a model suggesting that the Sos product is downstream of sevenless and the EGF receptor, and that the dominant suppression results from the overexpression or increased activity of the gene product.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	ROGGE, RD (corresponding author), UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA.			Rogge, Ronald/0000-0002-1875-3938	NEI NIH HHS [1 R01 EY08152-01A1] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008152] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BONNERFRASER M, 1988, NATURE, V335, P161; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BRENNER S, 1965, NATURE, V206, P994, DOI 10.1038/206994a0; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; GRIGLIATTI T, 1986, MUTAGENESIS DROSOPHI, P39; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HARTE A, 1990, IN PRESS GENES DEV; HODGKIN J, 1989, GENETICS, V123, P301; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; Lewis E., 1968, DROSOPHILA INFO SERV, V43, P193; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; WOODRUFF RC, 1979, GENETICS, V92, P133	30	191	192	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					39	48		10.1016/0092-8674(91)90207-F	http://dx.doi.org/10.1016/0092-8674(91)90207-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846090				2022-12-01	WOS:A1991ET17500007
J	SASAHARA, M; FRIES, JWU; RAINES, EW; GOWN, AM; WESTRUM, LE; FROSCH, MP; BONTHRON, DT; ROSS, R; COLLINS, T				SASAHARA, M; FRIES, JWU; RAINES, EW; GOWN, AM; WESTRUM, LE; FROSCH, MP; BONTHRON, DT; ROSS, R; COLLINS, T			PDGF B-CHAIN IN NEURONS OF THE CENTRAL-NERVOUS-SYSTEM, POSTERIOR PITUITARY, AND IN A TRANSGENIC MODEL	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-A-CHAIN; FACTOR RECEPTORS; MESSENGER-RNA; HUMAN-FIBROBLASTS; CELL-MEMBRANES; FACTOR-BINDING; FACTOR-ALPHA; RAT-BRAIN; C-SIS	Platelet-derived growth factors (PDGFs) are growth-regulatory molecules that stimulate chemotaxis, proliferation, and increased metabolism of primarily connective tissue cells. In a survey of normal tissues, we found specific immunostaining for PDGF B-chain in neurons, principal dendrites, some axons, and probable terminals throughout the brain, in the dorsal horn of the spinal cord, and in the posterior pituitary of the nonhuman primate (Macaca nemestrina). PDGF activity was extracted from brain cortex and posterior pituitary, and ubiquitous expression of transcripts for the two chains of PDGF and both PDGF receptors was detected throughout the brain and posterior pituitary. A transgenic model was also evaluated in which the chloramphenicol acetyltransferase gene was placed under transcriptional control of the PDGF B-chain promoter. The transgene was preferentially expressed within neural cell bodies in the cortex, hippocampus, and cerebellum. PDGF may act as a neuronal regulatory agent. Neuronal release of PDGF could contribute to nerve regeneration and to glial proliferation that leads to gliosis and scarring.	UNIV WASHINGTON,DEPT NEUROL SURG & BIOL STRUCT,SEATTLE,WA 98195; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; UNIV EDINBURGH,WESTERN GEN HOSP,HUMAN GENET UNIT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; University of Edinburgh	SASAHARA, M (corresponding author), UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195, USA.		Frosch, Matthew P/ABD-7456-2021; Fries, Jochen/AAM-5999-2020	Frosch, Matthew P/0000-0002-3940-9861; Fries, Jochen/0000-0003-2054-6345; Bonthron, David/0000-0001-8132-8179	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645, R01HL029873] Funding Source: NIH RePORTER; NCI NIH HHS [CA-36250] Funding Source: Medline; NHLBI NIH HHS [HL-29873, HL-18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BETSHOLTZ C, 1989, MOL CHEM NEUROPATHOL, V10, P27, DOI 10.1007/BF02969484; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESSLER JP, 1985, BRAIN RES, V344, P249, DOI 10.1016/0006-8993(85)90802-9; BRODAL A, 1981, NEUROLOGICAL RELATIO, P734; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; EK B, 1984, J BIOL CHEM, V259, P1145; Emoto N, 1989, GROWTH FACTORS, V2, P21, DOI 10.3109/08977198909069078; Fallon JH, 1990, GROWTH FACTORS, V2, P241, DOI 10.3109/08977199009071510; FALLON JH, 1984, SCIENCE, V224, P1107, DOI 10.1126/science.6144184; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARCIA RL, 1989, AM J PATHOL, V134, P733; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HANAI K, 1987, J CELL BIOL, V104, P1675, DOI 10.1083/jcb.104.6.1675; HARLOW E, 1988, ANTIBODIES LABORATOR, P594; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HARVEY AK, 1987, INVEST OPHTH VIS SCI, V28, P1092; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HEMMINGS HC, 1989, FASEB J, V3, P1583, DOI 10.1096/fasebj.3.5.2493406; Hogan B., 1986, MANIPULATING MOUSE E; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALDONADO PE, 1988, J MEMBRANE BIOL, V106, P203, DOI 10.1007/BF01872158; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MERCOLA M, 1985, SCIENCE, V227, P266, DOI 10.1126/science.3917575; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; NISHIMURA J, 1982, P NATL ACAD SCI-BIOL, V79, P4303, DOI 10.1073/pnas.79.14.4303; NISTER M, 1988, CANCER RES, V48, P3910; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; OVERBEEK PA, 1986, SCIENCE, V231, P1574, DOI 10.1126/science.3006249; OWEN AJ, 1982, P NATL ACAD SCI-BIOL, V79, P3203, DOI 10.1073/pnas.79.10.3203; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; PIKE LJ, 1983, J BIOL CHEM, V258, P9383; PLATASALAMAN CR, 1988, NEUROSCI LETT, V94, P161, DOI 10.1016/0304-3940(88)90288-1; PRENCE EM, 1990, J CELL BIOL, V110, P319, DOI 10.1083/jcb.110.2.319; Raines E. W., 1990, HDB EXPT PHARM PEPTI, V951, P173; RAINES EW, 1987, METHOD ENZYMOL, V147, P48; RAINES EW, 1985, METHOD ENZYMOL, V109, P749; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAIVICH G, 1987, J NEUROCYTOL, V16, P701, DOI 10.1007/BF01637661; RATNER L, 1987, NUCLEIC ACIDS RES, V15, P6017, DOI 10.1093/nar/15.15.6017; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; Shaw W V, 1975, Methods Enzymol, V43, P737; SHAW WV, 1991, IN PRESS ANN REV BIO; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SHIRAISHI T, 1989, CLIN CHIM ACTA, V184, P65, DOI 10.1016/0009-8981(89)90257-X; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; VANZOELEN EJJ, 1985, MOL CELL BIOL, V5, P2289, DOI 10.1128/MCB.5.9.2289; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WALICKE PA, 1988, DEV BRAIN RES, V40, P71, DOI 10.1016/0165-3806(88)90009-0; YOSHIZAWA T, 1990, SCIENCE, V247, P462, DOI 10.1126/science.2405487; YOUNG G, 1990, IN PRESS MOL CELL BI	69	383	405	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					217	227		10.1016/0092-8674(91)90223-L	http://dx.doi.org/10.1016/0092-8674(91)90223-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1986868				2022-12-01	WOS:A1991ET17500023
J	SZTUL, E; KAPLIN, A; SAUCAN, L; PALADE, G				SZTUL, E; KAPLIN, A; SAUCAN, L; PALADE, G			PROTEIN TRAFFIC BETWEEN DISTINCT PLASMA-MEMBRANE DOMAINS - ISOLATION AND CHARACTERIZATION OF VESICULAR CARRIERS INVOLVED IN TRANSCYTOSIS	CELL			English	Article							POLYMERIC IGA RECEPTOR; TRANS-CELLULAR TRANSPORT; INTESTINAL VILLUS CELLS; RAT HEPATOCYTES; COATED VESICLES; GOLGI-COMPLEX; MORPHOLOGICAL CHARACTERIZATION; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL-ANTIBODIES; MICROVILLUS MEMBRANES	We have isolated a population of vesicular carriers involved in the transport (transcytosis) of proteins from the basolateral to the apical plasma membrane of hepatocytes. The obtained fraction was enriched in compartments containing known transcytosed proteins and depleted in elements of the secretory pathway, Golgi elements, basolateral plasma membrane, as well as early endosomal components. The fraction was analyzed by biochemical and immunological procedures. Antibodies raised against the proteins in the fraction recognized a single 108K antigen. Based on its subcellular distribution, the 108K antigen may represent a novel marker for transcytotic vesicular carriers.	JOHNS HOPKINS UNIV,BALTIMORE,MD 21205; UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093	Johns Hopkins University; University of California System; University of California San Diego	SZTUL, E (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027303] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34989] Funding Source: Medline; NIGMS NIH HHS [GM 27303] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON DR, 1981, J CELL BIOL, V91, P270, DOI 10.1083/jcb.91.1.270; BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; Boyer J.L., 1986, PHYSL MEMBRANE DISOR, P609; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; CHAO YS, 1981, P NATL ACAD SCI-BIOL, V78, P597, DOI 10.1073/pnas.78.1.597; DANIELSEN EM, 1985, EUR J BIOCHEM, V152, P493, DOI 10.1111/j.1432-1033.1985.tb09223.x; DECURTIS I, 1989, CELL, V58, P719, DOI 10.1016/0092-8674(89)90106-2; DEVANEY E, 1985, EMBO J, V4, P3123, DOI 10.1002/j.1460-2075.1985.tb04054.x; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; EHRENREICH JH, 1973, J CELL BIOL, V59, P45, DOI 10.1083/jcb.59.1.45; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRUENBERG J, 1985, EUR J CELL BIOL, V38, P312; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; HUBBARD AL, 1985, J CELL BIOL, V100, P1115, DOI 10.1083/jcb.100.4.1115; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KUHN LC, 1983, ANN NY ACAD SCI, V409, P751, DOI 10.1111/j.1749-6632.1983.tb26914.x; LARKIN JM, 1986, P NATL ACAD SCI USA, V83, P4759, DOI 10.1073/pnas.83.13.4759; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MASSEY D, 1987, J MEMBRANE BIOL, V96, P19, DOI 10.1007/BF01869331; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MERISKO EM, 1982, J CELL BIOL, V92, P846, DOI 10.1083/jcb.92.3.846; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; QUARONI A, 1979, BIOCHEM J, V182, P213, DOI 10.1042/bj1820213; QUARONI A, 1979, BIOCHEM J, V182, P203, DOI 10.1042/bj1820203; RINDLER MJ, 1984, J CELL BIOL, V98, P1301; RODEWALD R, 1984, J CELL BIOL, V99, P595; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHIFF JM, 1984, J CELL BIOL, V98, P79, DOI 10.1083/jcb.98.1.79; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOLARI R, 1985, J BIOL CHEM, V260, P1141; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; SZTUL ES, 1983, J CELL BIOL, V97, P1582, DOI 10.1083/jcb.97.5.1582; TAKAHASHI I, 1982, J IMMUNOL, V128, P1181; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104	47	85	86	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					81	89		10.1016/0092-8674(91)90210-P	http://dx.doi.org/10.1016/0092-8674(91)90210-P			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1986870				2022-12-01	WOS:A1991ET17500010
J	TUOMANEN, E; LINDQUIST, S; SANDE, S; GALLENI, M; LIGHT, K; GAGE, D; NORMARK, S				TUOMANEN, E; LINDQUIST, S; SANDE, S; GALLENI, M; LIGHT, K; GAGE, D; NORMARK, S			COORDINATE REGULATION OF BETA-LACTAMASE INDUCTION AND PEPTIDOGLYCAN COMPOSITION BY THE AMP OPERON	SCIENCE			English	Article							PENICILLIN-BINDING PROTEINS; ESCHERICHIA-COLI; MUREIN; DELETION; GENE	The amp operon, which is located on the Escherichia coli chromosome, modulates the induction of plasmid-borne beta-lactamase genes by extracellular beta-lactam antibiotics. This suggests that the gene products AmpD and AmpE may function in the transduction of external signals. Beta-Lactam antibiotics are analogs of cell wall components that can be released during cell wall morphogenesis of enterobacteria. The amp operon was studied to determine its importance in signal transduction during cell wall morphogenesis. The peptidoglycan compositions of amp mutants were determined by high-performance liquid chromotography and fast atom bombardment mass spectrometry. When a chromosomal or plasmid-borne copy of ampD was present, the amount of pentapeptide-containing muropeptides in the cell wall increased upon addition of the cell wall constituent diaminopimelic acid to the growth medium. These results suggest that beta-lactamase induction and modulation of the composition of the cell wall share elements of a regulatory circuit that involves AmpD. Escherichia coli requires AmpD to respond to extracellular signaling amino acids, such as diaminopimelic acid, and this signal transduction system may regulate peptidoglycan composition in response to cell wall turnover products.	UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN; WASHINGTON UNIV,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; MICHIGAN STATE UNIV,NIH,MASS SPECT FACIL,DEPT BIOCHEM,E LANSING,MI 48824	Umea University; Washington University (WUSTL); Michigan State University; National Institutes of Health (NIH) - USA	TUOMANEN, E (corresponding author), ROCKEFELLER UNIV,MICROBIOL LAB,NEW YORK,NY 10021, USA.		Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023459, R01AI027913] Funding Source: NIH RePORTER; NCRR NIH HHS [DRR00480] Funding Source: Medline; NIAID NIH HHS [AI23459, AI27913] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROOMESMITH JK, 1982, J BACTERIOL, V152, P904; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; GALLENI M, 1990, 90TH ANN M AM SOC MI, P187; GALLENI M, UNPUB; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GOODELL EW, 1983, J BACTERIOL, V156, P136, DOI 10.1128/JB.156.1.136-140.1983; LANGLEY D, 1977, J GEN MICROBIOL, V99, P263, DOI 10.1099/00221287-99-2-263; LINDBERG F, 1987, J BACTERIOL, V169, P1923, DOI 10.1128/jb.169.5.1923-1928.1987; LINDBERG F, 1985, P NATL ACAD SCI USA, V82, P4620, DOI 10.1073/pnas.82.14.4620; LINDQUIST S, 1989, MOL MICROBIOL, V3, P1091, DOI 10.1111/j.1365-2958.1989.tb00259.x; MARKIEWICZ Z, 1985, ACTA MICROBIOL POL, V34, P121; METT H, 1980, J BACTERIOL, V144, P45, DOI 10.1128/JB.144.1.45-52.1980; SPRATT BG, 1977, EUR J BIOCHEM, V72, P341, DOI 10.1111/j.1432-1033.1977.tb11258.x; TIPPER D, 1956, P NATL ACAD SCI USA, V54, P1133; TOMASZ A, 1975, P NATL ACAD SCI USA, V72, P4162, DOI 10.1073/pnas.72.10.4162; TUOMANEN E, 1987, J BACTERIOL, V169, P5308, DOI 10.1128/jb.169.11.5308-5310.1987; TUOMANEN E, 1989, J BIOL CHEM, V264, P11093	17	41	49	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					201	204		10.1126/science.1987637	http://dx.doi.org/10.1126/science.1987637			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1987637				2022-12-01	WOS:A1991ET17300042
J	VONKRIES, JP; BUHRMESTER, H; STRATLING, WH				VONKRIES, JP; BUHRMESTER, H; STRATLING, WH			A MATRIX SCAFFOLD ATTACHMENT REGION BINDING-PROTEIN - IDENTIFICATION, PURIFICATION, AND MODE OF BINDING	CELL			English	Article							CHROMOSOMAL LOOP ANCHORAGE; DNA TOPOISOMERASE-II; HEAT-SHOCK GENE; INTERPHASE NUCLEI; CHROMATIN DOMAIN; XENOPUS OOCYTES; TRANSCRIPTION; METAPHASE; INVITRO; SITES	Matrix/scaffold attachment regions (MARs/SARs) partition chromatin into functional loop domains. Here we have identified a chicken protein that selectively binds to MARs from the chicken lysozyme locus and to MARs from Drosophila, mouse, and human genes. This protein, named ARBP (for attachment region binding protein), was purified to homogeneity and shown to bind to MARs in a cooperative fashion. ARBP is an abundant nuclear protein and a component of the internal nuclear network. Deletion mutants indicate that multiple AT-rich sequences, if contained in a minimal approximately 350 bp MAR fragment, can lead to efficient binding of ARBP. Furthermore, dimerization mutants show that, to bind ARBP efficiently, MAR sequences can act synergistically over large distances, apparently with the intervening DNA looping out. The binding characteristics of ARBP to MARs reproduce those of unfractionated matrix preparations, suggesting that ARBP is an important nuclear element for the generation of functional chromatin loops.			VONKRIES, JP (corresponding author), UNIV HAMBURG, KRANKENHAUS EPPENDORF, INST PHYSIOL CHEM, MARTINISTR 52, W-2000 HAMBURG 20, GERMANY.							ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COCKERILL PN, 1986, FEBS LETT, V204, P5, DOI 10.1016/0014-5793(86)81377-1; COOK PR, 1978, EUR J BIOCHEM, V84, P465, DOI 10.1111/j.1432-1033.1978.tb12188.x; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HUNG MC, 1984, NUCLEIC ACIDS RES, V12, P1863, DOI 10.1093/nar/12.4.1863; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; JOHNS EW, 1964, BIOCHEM J, V92, P55, DOI 10.1042/bj0920055; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P309, DOI 10.1016/0022-2836(82)90331-X; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUCHNIK AN, 1985, NUCLEIC ACIDS RES, V13, P1135, DOI 10.1093/nar/13.4.1135; MALKAS LH, 1989, P NATL ACAD SCI USA, V86, P70, DOI 10.1073/pnas.86.1.70; Maniatis T., 1982, MOL CLONING; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PETERS KE, 1982, EUR J BIOCHEM, V129, P221, DOI 10.1111/j.1432-1033.1982.tb07043.x; PETRYNIAK B, 1987, CELL, V48, P289, DOI 10.1016/0092-8674(87)90432-6; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAZIN SV, 1981, CELL, V27, P65, DOI 10.1016/0092-8674(81)90361-5; RENZ M, 1976, BIOCHEMISTRY-US, V15, P3220, DOI 10.1021/bi00660a010; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RYOJI M, 1984, CELL, V37, P21, DOI 10.1016/0092-8674(84)90297-6; SCALENGHE F, 1978, CHROMOSOMA, V66, P299, DOI 10.1007/BF00328531; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VILLEPONTEAU B, 1984, CELL, V39, P469, DOI 10.1016/0092-8674(84)90454-9; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VOELLMY R, 1982, P NATL ACAD SCI-BIOL, V79, P1776, DOI 10.1073/pnas.79.6.1776; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WLASCHEK M, 1988, CHROMOSOMA, V96, P145, DOI 10.1007/BF00331047	61	204	215	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					123	135		10.1016/0092-8674(91)90214-J	http://dx.doi.org/10.1016/0092-8674(91)90214-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846084				2022-12-01	WOS:A1991ET17500014
J	WELLS, V; MALLUCCI, L				WELLS, V; MALLUCCI, L			IDENTIFICATION OF AN AUTOCRINE NEGATIVE GROWTH-FACTOR - MOUSE BETA-GALACTOSIDE-BINDING PROTEIN IS A CYTOSTATIC FACTOR AND CELL-GROWTH REGULATOR	CELL			English	Article							EMBRYO FIBROBLASTS; CONCANAVALIN-A; MESSENGER-RNA; INTERFERON; LECTINS; SYNTHETASE; CYCLE; PURIFICATION; LYMPHOCYTES; EXPRESSION	Murine beta-galactoside-binding protein, a protein classified as a soluble lectin, is shown to be a cell growth-regulatory molecule and a cytostatic factor. The growth-inhibitory effect is not related to lectin properties, and competition assays indicate that the protein binds to specific cell surface receptors with high affinity. It exerts control in G0 and at G2, both as a regulator of cell replication and as a cytostatic factor.			WELLS, V (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,SCH MED,DIV MICROBIOL,CELLULAR & MOLEC BIOL LAB,LONDON SE1 9RT,ENGLAND.							ABBOTT WM, 1989, BIOCHEM J, V259, P291, DOI 10.1042/bj2590291; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BENNETT HPJ, 1980, J LIQ CHROMATOGR, V3, P1353, DOI 10.1080/01483918008062781; BOHMER FD, 1987, J BIOL CHEM, V262, P1537; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHILDS RA, 1979, BIOCHEM J, V183, P755, DOI 10.1042/bj1830755; CIERCH LB, 1988, BIOCHEMISTRY-US, V27, P692; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; CREASEY AA, 1983, MOL CELL BIOL, V3, P780, DOI 10.1128/MCB.3.5.780; DEWAARD A, 1976, J BIOL CHEM, V251, P7581; FROCKLICK CA, 1983, P NATL ACAD SCI USA, V80, P3676; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; HUNKAPILLER M, 1985, APPLIED BIOSYSTEMS P, V14; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; MACKLER BF, 1972, J NATL CANCER I, V49, P935; MALLUCCI L, 1983, J INTERFERON RES, V3, P181, DOI 10.1089/jir.1983.3.181; MASSAGUE J, 1985, TRENDS BIOCHEM SCI, V10, P237, DOI 10.1016/0968-0004(85)90141-0; MCCLAIN DA, 1976, J EXP MED, V144, P1494, DOI 10.1084/jem.144.6.1494; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; POWELL JT, 1980, BIOCHEM J, V187, P123, DOI 10.1042/bj1870123; RALPH P, 1973, J NATL CANCER I, V51, P883, DOI 10.1093/jnci/51.3.883; RAZ A, 1988, CANCER RES, V48, P645; REVEL M, 1982, TEX REP BIOL MED, V41, P452; ROBERTS AB, 1983, BIOCHEMISTRY-US, V22, P5692, DOI 10.1021/bi00294a002; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROFF CF, 1983, BIOCHEM J, V211, P625, DOI 10.1042/bj2110625; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; TROWBRIDGE IS, 1974, NATURE, V250, P304, DOI 10.1038/250304a0; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WANG LJ, 1987, CONCANAVALIN A TOOL, P194; WATERFIELD MD, 1981, BIOL BIOMEDICAL APPL, V18, P135; WATERFIELD MD, 1985, PRACTICAL PROTEIN BI, P181; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WELLS V, 1983, J CELL PHYSIOL, V117, P148, DOI 10.1002/jcp.1041170203; WELLS V, 1988, J INTERFERON RES, V8, P793, DOI 10.1089/jir.1988.8.793	37	259	268	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					91	97		10.1016/0092-8674(91)90211-G	http://dx.doi.org/10.1016/0092-8674(91)90211-G			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1986871				2022-12-01	WOS:A1991ET17500011
J	YAMANASHI, Y; KAKIUCHI, T; MIZUGUCHI, J; YAMAMOTO, T; TOYOSHIMA, K				YAMANASHI, Y; KAKIUCHI, T; MIZUGUCHI, J; YAMAMOTO, T; TOYOSHIMA, K			ASSOCIATION OF B-CELL ANTIGEN RECEPTOR WITH PROTEIN TYROSINE KINASE LYN	SCIENCE			English	Article							IMMUNOGLOBULIN GAMMA-CHAINS; LYMPHOCYTES-B; MEMBRANE IGM; CD4 RECEPTOR; P56LCK; GENE; INVOLVEMENT; ACTIVATION; HYDROLYSIS; EXPRESSION	Antigen is thought to cross-link membrane-bound immunoglobulins (Igs) of B cells, causing proliferation and differentiation or the inhibition of growth. Protein tyrosine kinases are probably involved in signal transduction for cell proliferation and differentiation. The Src-like protein tyrosine kinase Lyn is expressed preferentially in B cells. The Lyn protein and its kinase activity could be coimmunoprecipitated with IgM from detergent lysates. Cross-linking of membrane-bound IgM induced a rapid increase in tyrosine phosphorylation of at least ten distinct proteins of B cells. Thus, Lyn is physically associated with membrane-bound IgM, and is suggested to participate in antigen-mediated signal transduction.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; NATL INST HLTH,DEPT APPL IMMUNOL,SHINAGAWA KU,TOKYO 141,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ALLERGOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo; University of Tokyo								BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BOYD AW, 1981, J IMMUNOL, V126, P2466; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHENG HL, 1982, NATURE, V296, P410, DOI 10.1038/296410a0; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; GOLD MR, 1987, J IMMUNOL, V139, P3604; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOODNOW CC, 1989, ANNU REV IMMUNOL, V342, P385; GRUBER MF, 1989, J IMMUNOL, V142, P1444; GRUPP SA, 1985, J IMMUNOL, V134, P4087; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HARNETT MM, 1988, J IMMUNOL, V140, P3135; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KIM KJ, 1979, J IMMUNOL, V122, P549; KLAUS GGB, 1987, IMMUNOL REV, V99, P19, DOI 10.1111/j.1600-065X.1987.tb01170.x; MIZUGUCHI J, 1986, J IMMUNOL, V137, P2162; MONROE JG, 1989, BIOCHIM BIOPHYS ACTA, V1013, P273, DOI 10.1016/0167-4889(89)90146-8; NOSSAL GJV, 1989, ANNU REV IMMUNOL, V342, P340; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SEMBA K, 1990, GENES CANCER, P73; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8697; TYLER BM, 1982, P NATL ACAD SCI-BIOL, V79, P2008, DOI 10.1073/pnas.79.6.2008; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VASILOV RG, 1982, EUR J IMMUNOL, V12, P804, DOI 10.1002/eji.1830121003; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YAMANASHI Y, UNPUB; YAMAWAKIKATAOKA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2623, DOI 10.1073/pnas.79.8.2623	39	479	484	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					192	194		10.1126/science.1702903	http://dx.doi.org/10.1126/science.1702903			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1702903				2022-12-01	WOS:A1991ET17300039
J	YEH, HJ; RUIT, KG; WANG, YX; PARKS, WC; SNIDER, WD; DEUEL, TF				YEH, HJ; RUIT, KG; WANG, YX; PARKS, WC; SNIDER, WD; DEUEL, TF			PDGF A-CHAIN GENE IS EXPRESSED BY MAMMALIAN NEURONS DURING DEVELOPMENT AND IN MATURITY	CELL			English	Article							CENTRAL NERVOUS-SYSTEM; RAT OPTIC-NERVE; GROWTH-FACTOR; PROGENITOR-CELL; PLATELET; ASTROCYTE; DIFFERENTIATION; CULTURE; TRANSFORMATION; FIBROBLASTS	Platelet-derived growth factor (PDGF) may be a critical factor in the temporal differentiation of glial elements in the mammalian central nervous system. We have used in situ hybridization and immunoperoxidase staining to investigate the localization of PDGF A and have observed high levels of PDGF A-chain mRNA and immunoreactive PDGF A in neurons of embryonic and adult mice. PDGF A-chain expression was shown to be developmentally regulated and tissue specific. Every neuronal population examined in the central and peripheral nervous systems expresses PDGF A transcripts. Variable, significantly weaker signals are observed in glial cells. In contrast to known neurotrophic factors, the PDGF A transcripts are widely distributed among neurons. This generalized distribution of PDGF A transcripts, together with the known effects of PDGF on glial cells in vitro, suggests a unique role of neurons in regulating the proliferation and differentiation of glial cells in vivo.	WASHINGTON UNIV,MED CTR,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110; CHINESE ACAD SCI,SHANGHAI INST CELL BIOL,SHANGHAI,PEOPLES R CHINA	Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	YEH, HJ (corresponding author), WASHINGTON UNIV,MED CTR,DEPT MED,ST LOUIS,MO 63110, USA.		Parks, William C./AAH-6786-2021		NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL14147, HL31102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL031102, R01HL031102, P50HL014147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; BRESSLER JP, 1985, BRAIN RES, V344, P249, DOI 10.1016/0006-8993(85)90802-9; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DEUEL TF, 1982, J CLIN INVEST, V69, P1046, DOI 10.1172/JCI110509; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LILLIEN LE, 1990, NEURON, V4, P525, DOI 10.1016/0896-6273(90)90110-2; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; Nauta W.J.H., 1986, FUNDAMENTAL NEUROANA, P33; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; POMEROY SL, 1988, J CELL BIOL, V107, P1167, DOI 10.1083/jcb.107.3.1167; PRINGLE N, 1988, EMBO J, V18, P1049; PROSSER IW, 1989, AM J PATHOL, V135, P1073; RAFF MC, 1985, CELL, V42, P61, DOI 10.1016/S0092-8674(85)80101-X; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; SENIOR RM, 1983, J CELL BIOL, V96, P382, DOI 10.1083/jcb.96.2.382; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0; WALICKE PA, 1988, J NEUROSCI, V8, P2618; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7	31	335	338	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					209	216		10.1016/0092-8674(91)90222-K	http://dx.doi.org/10.1016/0092-8674(91)90222-K			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1986867				2022-12-01	WOS:A1991ET17500022
J	ZHONG, Y; WU, CF				ZHONG, Y; WU, CF			ALTERED SYNAPTIC PLASTICITY IN DROSOPHILA MEMORY MUTANTS WITH A DEFECTIVE CYCLIC-AMP CASCADE	SCIENCE			English	Article							ADENYLATE-CYCLASE; SHORT-TERM; POTASSIUM CURRENTS; POTENTIATION; MELANOGASTER; CALCIUM; FACILITATION; HIPPOCAMPUS; DISSECTION; DEFICIENT	Synaptic transmission was examined in Drosophila mutants deficient in memory function. These mutants, dunce and rutabaga, are defective in different steps of the cyclic adenosine 3',5'-monophosphate (cAMP) cascade. In both dunce and rutabaga larvae, voltage-clamp analysis of neuromuscular transmission revealed impaired synaptic facilitation and post-tetanic potentiation as well as abnormal responses to direct application of dibutyryl cAMP. In addition, the calcium dependence of transmitter release was shifted in dunce. The results suggest that the cAMP cascade plays a role in synaptic facilitation and potentiation and indicate that synaptic plasticity is altered in Drosophila memory mutants.			ZHONG, Y (corresponding author), UNIV IOWA,DEPT BIOL,IOWA CITY,IA 52242, USA.			Wu, Chun-Fang/0000-0002-4973-2021; Zhong, Yi/0000-0001-7810-9899; Zhong, Yi/0000-0002-7927-5976				ANDERSON MS, 1988, J NEUROSCI, V8, P242; ATWOOD HL, UNPUB; BALLING A, 1987, J NEUROGENET, V4, P65, DOI 10.3109/01677068709102334; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CASTRO CA, 1989, NATURE, V342, P545, DOI 10.1038/342545a0; CORFAS G, 1990, J NEUROSCI, V10, P491; DAVIS RL, 1986, MOL CELL BIOL, V6, P1464, DOI 10.1128/MCB.6.5.1464; DELANEY KR, 1989, J NEUROSCI, V9, P3558; DEVAY P, 1987, J NEUROGENET, V4, P275; DIXON D, 1989, J NEUROSCI, V9, P4266; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; DUDAI Y, 1983, NEUROSCI LETT, V42, P207, DOI 10.1016/0304-3940(83)90408-1; DUERR JS, 1982, P NATL ACAD SCI-BIOL, V79, P3646, DOI 10.1073/pnas.79.11.3646; ELIOT LS, 1989, P NATL ACAD SCI USA, V86, P9564, DOI 10.1073/pnas.86.23.9564; Ganetzky B, 1983, J NEUROGENET, V1, P17, DOI 10.3109/01677068309107069; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GREENBERG SM, 1987, J NEUROSCI, V7, P291; HAUGLAND FN, 1990, J NEUROSCI, V10, P1357; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; JAN YN, 1978, P NATL ACAD SCI USA, V75, P515, DOI 10.1073/pnas.75.1.515; JOHANSEN J, 1989, J NEUROSCI, V9, P710; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; Kim Y, UNPUB; LANDFIELD PW, 1978, BRAIN RES, V150, P85, DOI 10.1016/0006-8993(78)90655-8; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; NELSON TJ, 1989, BIOESSAYS, V10, P75, DOI 10.1002/bies.950100209; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; STANLEY EF, 1986, J NEUROSCI, V6, P782; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1984, BEHAV GENET, V14, P527, DOI 10.1007/BF01065446; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; ZHONG Y, 1989, Society for Neuroscience Abstracts, V15, P1141; ZHONG Y, UNPUB; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	38	245	256	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					198	201		10.1126/science.1670967	http://dx.doi.org/10.1126/science.1670967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1670967				2022-12-01	WOS:A1991ET17300041
J	BAGRODIA, S; CHACKALAPARAMPIL, I; KMIECIK, TE; SHALLOWAY, D				BAGRODIA, S; CHACKALAPARAMPIL, I; KMIECIK, TE; SHALLOWAY, D			ALTERED TYROSINE-527 PHOSPHORYLATION AND MITOTIC ACTIVATION OF P60C-SRC	NATURE			English	Article							OVEREXPRESSED PP60C-SRC; PROTEIN-KINASE; MITOSIS; TRANSFORMATION; SITES; ENTRY	The tyrosine kinase activity of p60c-src, the protein of the c-src gene, increase during mitosis 1,2; this may be important in initiating at least some of the cellular changes that occur during this phase of the cell cycle. Although there is evidence that p60c-src is phosphorylated at several sites during mitosis, phosphorylation in vitro does not increase its kinase activity 2,3. We now report that this kinase activity of a p60c-src mutant with residue tyrosine 527 changed to phenylanine does not change during the cell cycle, suggesting that changes in the phosphorylation state of this residue may be responsible for the activation of p60c-src at mitosis. Although changes in phosphorylation at Tyr527 cannot be detected with the wild-type protein we find that phosphorylation at Tyr527 of a mutant with reduced kinase activity decreased threefold during mitosis. On the basis of these results we suggest that activation of p60c-src at mitosis results from decreased phosphorylation on Tyr 527, and that p60c-src may be or may activate the kinase that phosphorylates Tyr 527.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; CORNELL UNIV,DEPT PATHOL,ITHACA,NY 14853	Cornell University; Cornell University				Kmiecik, Thomas/0000-0002-1367-443X				CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; OKADA M, 1989, J BIOL CHEM, V264, P20886; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; 1987, TP007 MILL INT; 1987, TP006 MILL INT	17	121	122	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					172	175		10.1038/349172a0	http://dx.doi.org/10.1038/349172a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1702522				2022-12-01	WOS:A1991ER41800064
J	BASHIR, ZI; ALFORD, S; DAVIES, SN; RANDALL, AD; COLLINGRIDGE, GL				BASHIR, ZI; ALFORD, S; DAVIES, SN; RANDALL, AD; COLLINGRIDGE, GL			LONG-TERM POTENTIATION OF NMDA RECEPTOR-MEDIATED SYNAPTIC TRANSMISSION IN THE HIPPOCAMPUS	NATURE			English	Article							COLLATERAL-COMMISSURAL PATHWAY; D-ASPARTATE RECEPTORS; MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; RAT HIPPOCAMPUS; ACTIVATION; ANTAGONISTS; EXPRESSION; INDUCTION; RESPONSES	Neurotransmission at most excitatory synapses in the brain operates through two types of glutamate receptor termed alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and N-methyl-D-aspartate (NMDA) receptors; these mediate the fast and slow components of excitatory postsynaptic potentials respectively 1-3. Activation of NMDA receptors can also lead to a long-lasting modification in synaptic efficiency at glutamatergic synapses; this is exemplified in the CAl region of the hippocampus, where NMDA receptors mediate the induction of long-term potentiation (LTP) 4. It is believed that in this region LTP is maintained by a specific increase in the AMPA receptor-mediated synaptic response can undergo robust, synapse-specific LTP. This findings has implications for neuropathologies such as epilepsy and neurodegeneration, in which excessive NMDA receptor activation has been implicated 7. It adds fundamentally to theories of synaptic plasticity because NMDA receptor activation may, in addition to causing increased synaptic efficiency, directly alter the plasticity of synapses.	UNIV BRISTOL, SCH MED SCI, DEPT PHARMACOL, BRISTOL BS8 1TD, AVON, ENGLAND; UNIV BIRMINGHAM, SCH MED, DEPT PHARMACOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND	University of Bristol; University of Birmingham; University of Bristol			Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020	Collingridge, Graham L/0000-0002-9572-5359; Bashir, Zafar/0000-0003-3650-2136; Randall, Andrew/0000-0001-8852-3671; Alford, Simon/0000-0002-0454-4246	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTOLA A, 1990, EUR J NEUROSCI, V2, P254, DOI 10.1111/j.1460-9568.1990.tb00417.x; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BINDMAN LJ, 1988, J PHYSIOL-LONDON, V406, pP176; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T V P, 1988, P3; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P283; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DALE N, 1985, J PHYSIOL-LONDON, V363, P35, DOI 10.1113/jphysiol.1985.sp015694; DANGELO E, 1990, NATURE, V346, P467, DOI 10.1038/346467a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DINGLEDINE R, 1986, J PHYSIOL-LONDON, V380, P175, DOI 10.1113/jphysiol.1986.sp016279; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; LEONARD J P, 1989, Society for Neuroscience Abstracts, V15, P535; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; RANDALL AD, 1990, NEUROSCI LETT, V114, P191, DOI 10.1016/0304-3940(90)90070-P; SCHARFMAN HE, 1989, SCIENCE, V246, P257, DOI 10.1126/science.2508225; SLATER NT, 1985, NEUROSCI LETT, V60, P25, DOI 10.1016/0304-3940(85)90376-3; STASHEFF SF, 1989, SCIENCE, V245, P648, DOI 10.1126/science.2569762; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121	31	318	325	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 10	1991	349	6305					156	158		10.1038/349156a0	http://dx.doi.org/10.1038/349156a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1846031				2022-12-01	WOS:A1991ER41800058
J	DOTTI, CG; PARTON, RG; SIMONS, K				DOTTI, CG; PARTON, RG; SIMONS, K			POLARIZED SORTING OF GLYPIATED PROTEINS IN HIPPOCAMPAL-NEURONS	NATURE			English	Article							CELLS; CULTURE	Our recent studies suggested that neurons and epithelial cells sort viral glycoproteins in a similar manner. The apical influenza virus haemagglutinin was preferentially delivered to the axon of hippocampal neurons in culture, whereas the basolateral vesicular stomatitis virus glycoprotein was sorted to the dendrites. 1 To investigate whether other membrane proteins showed similar sorting in neurons and epithelial cells, we have analysed the localization of a glypiated (glycosylphosphatidylinositol-anchored) protein, Thy-1, in hippocampal neurons in culture. In MDCk and other epithelial cells, endogenous glycosylphosphatidylinositol (GPI)-anchored proteins, as well as mutated exogenous proteins containing the GPI-attachment signal, undergo preferential delivery to the apical surface 2-4. This polarized sorting of GPI-anchored proteins has been been proposed to occur by the same mechanisms as the sorting of glycolipids to the apical surface 5,6. We report here that the neuronal GPI-protein Thy-1 is present in hippocampal neurons in culture and is exclusively located on the axonal surface. This finding further strengthens our hypothesis that the mechanisms of sorting of surface components may be similar in neurons and epithelial cells.			DOTTI, CG (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Dotti, Carlos G/I-5533-2015; Parton, Robert G/C-5673-2009	Dotti, Carlos G/0000-0003-4052-1719; Parton, Robert G/0000-0002-7494-5248; Simons, Kai/0000-0002-9231-9996				BANKER GA, 1988, INTRINSIC DETERMINAN, P61; BARTLETT WP, 1984, J NEUROSCI, V4, P1954; BENNETT MK, 1988, EMBO J, V7, P4075, DOI 10.1002/j.1460-2075.1988.tb03301.x; CACERES A, 1984, DEV BRAIN RES, V13, P314, DOI 10.1016/0165-3806(84)90167-6; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; LAEMMLI V, 1979, NATURE, V257, P418; LISANTI M, 1989, J CELL BIOL, V109, P2140; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MASON D, 1980, BIOCHEM J, V147, P1; MORRIS RJ, 1985, J NEUROCYTOL, V14, P427, DOI 10.1007/BF01217754; ROTHMAN S, 1981, J COMP NEUROL, V195, P141, DOI 10.1002/cne.901950108; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSON JM, 1990, J CELL SCI, V96, P143	20	218	220	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					158	160		10.1038/349158a0	http://dx.doi.org/10.1038/349158a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1670898				2022-12-01	WOS:A1991ER41800059
J	KOSTREWA, D; GRANZIN, J; KOCH, C; CHOE, HW; RAGHUNATHAN, S; WOLF, W; LABAHN, J; KAHMANN, R; SAENGER, W				KOSTREWA, D; GRANZIN, J; KOCH, C; CHOE, HW; RAGHUNATHAN, S; WOLF, W; LABAHN, J; KAHMANN, R; SAENGER, W			3-DIMENSIONAL STRUCTURE OF THE ESCHERICHIA-COLI DNA-BINDING PROTEIN FIS	NATURE			English	Article							SITE-SPECIFIC RECOMBINATION; HOST FACTOR; RESOLUTION; INVERSION; ENHANCER; LAMBDA; PHASE; REFINEMENT; REPRESSOR; GROWTH	The factor for inversion stimulation, FIS, is involved in several cellular processes, including site-specific recombination and transcriptional activation 1-4. In the reactions catalysed by the DNA invertases Gin, Hin and Cin, FIS stimulates recombination by binding to an enhancer sequence 1. Within the enhancer, two FIS dimers (each 2 x 98 amino acids) 5-7 bind to two 15-base-pair consensus sequences 8,9 (Fig. 1) and induce bending of DNA 10,11. Current models propose that the enhancer-FIS complex organizes a specific synapse, either through direct interactions with Gin, or by modelling the substrate into a configuration suitable for recombination 1,9,12. Using X-ray analysis at 2.0 angstrom resolution, we now show that FIS is composed of four alpha-helices tightly intertwined to form a globular dimer with two protruding helix-turn-helix motifs. The 24 N-terminal amino acids are so poorly defined in the electron density map as to make interpretation doubtful, indicating that they might act as 'feelers' suitable for DNA or protein (invertase) recognition. We infer from model building that DNA has to bend for tight binding to FIS.	INST GENBIOL FORSCH BERLIN GMBH,W-1000 BERLIN 33,GERMANY		KOSTREWA, D (corresponding author), FREE UNIV BERLIN,INST KRISTALLOG,TAKUSTR 6,W-1000 BERLIN 33,GERMANY.		Granzin, Joachim/G-8937-2013; Koch, Christian/W-5731-2019; Labahn, Jörg/G-9593-2013; Koch, Christian/J-5716-2013	Granzin, Joachim/0000-0001-6604-950X; Koch, Christian/0000-0001-8407-4952; Labahn, Jörg/0000-0002-0648-8145; Wolf, Wojciech/0000-0002-9162-9933				ANDERSON WF, 1981, NATURE, V290, P754, DOI 10.1038/290754a0; BETERMIER M, 1989, MOL MICROBIOL, V3, P459, DOI 10.1111/j.1365-2958.1989.tb00192.x; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRUIST MF, 1987, GENE DEV, V1, P762, DOI 10.1101/gad.1.8.762; CHOE HW, 1989, J MOL BIOL, V208, P209, DOI 10.1016/0022-2836(89)90098-3; HUBNER P, 1989, J MOL BIOL, V205, P493, DOI 10.1016/0022-2836(89)90220-9; HUNER P, 1989, EMBO J, V8, P577; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; JOHNSON RC, 1987, TRENDS GENET, V3, P262, DOI 10.1016/0168-9525(87)90261-7; KANAAR R, 1988, P NATL ACAD SCI USA, V85, P752, DOI 10.1073/pnas.85.3.752; KOCH C, 1986, J BIOL CHEM, V261, P5673; KOCH C, 1988, P NATL ACAD SCI USA, V85, P4237, DOI 10.1073/pnas.85.12.4237; KOCH C, 1988, THESIS FREIE U BERLI; NILSSON L, 1990, EMBO J, V9, P727, DOI 10.1002/j.1460-2075.1990.tb08166.x; PABO CO, 1990, SCIENCE, V247, P1210, DOI 10.1126/science.2315694; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PRAFFERTYJB, 1989, NATURE, V341, P705; RICE DW, 1981, ACTA CRYSTALLOGR A, V37, P491, DOI 10.1107/S0567739481001186; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; THOMPSON JF, 1987, CELL, V50, P901, DOI 10.1016/0092-8674(87)90516-2; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; 1986, CCP4 COOPERATIVE COM	28	141	143	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					178	180		10.1038/349178a0	http://dx.doi.org/10.1038/349178a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1986310				2022-12-01	WOS:A1991ER41800066
J	LOWRY, PW; BLANKENSHIP, RJ; GRIDLEY, W; TROUP, NJ; TOMPKINS, LS				LOWRY, PW; BLANKENSHIP, RJ; GRIDLEY, W; TROUP, NJ; TOMPKINS, LS			A CLUSTER OF LEGIONELLA-STERNAL WOUND INFECTIONS DUE TO POSTOPERATIVE TOPICAL EXPOSURE TO CONTAMINATED TAP WATER	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							NOSOCOMIAL LEGIONNAIRES-DISEASE; PNEUMOPHILA; EPIDEMIC; PATIENT; OUTBREAK; SYSTEMS		STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV INFECT DIS,RM H1537J,STANFORD,CA 94305; STANFORD UNIV HOSP,DEPT CARE REVIEW RISK MANAGEMENT,INFECT CONTROL PROGRAM,STANFORD,CA 94305; STANFORD UNIV,MED CTR,CLIN MICROBIOL LAB,STANFORD,CA 94305	Stanford University; Stanford University; Stanford University								AMPEL NM, 1985, ANN INTERN MED, V102, P630, DOI 10.7326/0003-4819-102-5-630; ARNOW PM, 1982, J INFECT DIS, V146, P460, DOI 10.1093/infdis/146.4.460; ARNOW PM, 1985, J INFECT DIS, V152, P145, DOI 10.1093/infdis/152.1.145; ARNOW PM, 1983, ANN INTERN MED, V98, P184, DOI 10.7326/0003-4819-98-2-184; BOPP CA, 1981, J CLIN MICROBIOL, V13, P714, DOI 10.1128/JCM.13.4.714-719.1981; BRABENDER W, 1983, JAMA-J AM MED ASSOC, V250, P3091, DOI 10.1001/jama.250.22.3091; BROOME CV, 1979, ANN INTERN MED, V90, P573, DOI 10.7326/0003-4819-90-4-573; CORDES LG, 1981, ANN INTERN MED, V94, P195, DOI 10.7326/0003-4819-94-2-195; DONDERO TJ, 1980, NEW ENGL J MED, V302, P365, DOI 10.1056/NEJM198002143020703; DORMAN SA, 1980, ANN INTERN MED, V93, P835, DOI 10.7326/0003-4819-93-6-835; DOURNON E, 1982, LANCET, V1, P1363; EDELSTEIN PH, 1985, MANUAL CLIN MICROBIO, P373; FISHERHOCH SP, 1981, LANCET, V1, P932; FRASER DW, 1977, NEW ENGL J MED, V297, P1189, DOI 10.1056/NEJM197712012972201; GROSS D, 1981, CHEST, V79, P232, DOI 10.1378/chest.79.2.232; HALEY CE, 1979, ANN INTERN MED, V90, P583, DOI 10.7326/0003-4819-90-4-583; HARRIS LF, 1981, ARCH INTERN MED, V141, P1385, DOI 10.1001/archinte.1981.00340100141031; KALWEIT WH, 1982, ANN INTERN MED, V96, P173, DOI 10.7326/0003-4819-96-2-173; LANDES BW, 1982, ARCH INTERN MED, V142, P1234, DOI 10.1001/archinte.142.6.1234; ROSNER BA, 1982, FUNDAMENTALS BIOSTAT, P417; SCHLANGER G, 1984, AM J MED, V77, P957, DOI 10.1016/0002-9343(84)90551-5; SIEGEL S, 1956, NONPARAMETRIC STAT, P184; STOUT J, 1982, NEW ENGL J MED, V306, P466, DOI 10.1056/NEJM198202253060807; TOBIN JOH, 1980, LANCET, V2, P118; TOMPKINS LS, 1987, J CLIN MICROBIOL, V25, P1875, DOI 10.1128/JCM.25.10.1875-1880.1987; TOMPKINS LS, 1988, NEW ENGL J MED, V318, P530, DOI 10.1056/NEJM198803033180902; WADOWSKY RM, 1982, APPL ENVIRON MICROB, V43, P1104, DOI 10.1128/AEM.43.5.1104-1110.1982	27	87	90	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 10	1991	324	2					109	113		10.1056/NEJM199101103240207	http://dx.doi.org/10.1056/NEJM199101103240207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ977	1984176				2022-12-01	WOS:A1991EQ97700007
J	NARDELLI, J; GIBSON, TJ; VESQUE, C; CHARNAY, P				NARDELLI, J; GIBSON, TJ; VESQUE, C; CHARNAY, P			BASE SEQUENCE DISCRIMINATION BY ZINC-FINGER DNA-BINDING DOMAINS	NATURE			English	Article							TRANSCRIPTION FACTOR TFIIIA; REPRESSOR-OPERATOR INTERACTIONS; RNA-POLYMERASE; NUCLEIC-ACIDS; FACTOR-IIIA; PROTEINS; EXPRESSION; GENE; RECOGNITION; RESOLUTION	Zinc fingers 1,2 constitute important eukaryotic DNA-binding domains, being present in many transcription factors 3-5. The Cys2/His2 zinc-finger class has conserved motifs of 28-30 amino acids which are usually present as tandem repeats 1,2. The structure of a Cys2/His2 zinc finger has been determined by nuclear magnetic resonance 6, but details of its interaction with DNA were not established. Here we identify amino acids governing DNA-binding specificity using in vitro directed mutagenesis guided by similarities between the zinc fingers of transcription factors Sp1 (ref. 7) and Krox-20 (ref. 8). Krox-20 is a serum-inducible transcription activator 8,9 which is possibly involved in the regulation of hindbrain development 10; it contains three zinc fingers similar to those of Ap1 (refs 7, 8, 11) and binds to a 9-base-pair target sequence which is related to that of Sp1 (ref. 9). Our results show that each finger spans three nucleotides and indicate two positions in Krox-20 zinc fingers that are important for base-pair selectivity. Modelling with molecular graphics suggests that these residues could bind directly with the bases and that other amino acid-base contracts are also possible.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	NARDELLI, J (corresponding author), ECOLE POLYTECH,GENET MOLEC LAB,CNRS,D1302,46 RUE ULM,F-75230 PARIS 05,FRANCE.		Nardelli, Jeannette/N-5739-2017; Vesque, Christine/Q-8461-2019; Vesque, Christine/L-9839-2017	Charnay, Patrick/0000-0002-3847-6042; Gibson, Toby James/0000-0003-0657-5166; Vesque, Christine/0000-0001-7983-4953				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BERG JA, 1990, REV BIOPHYS CHEM, V19, P405; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; BROWN RS, 1986, NATURE, V324, P215, DOI 10.1038/324215a0; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Dayhoff M., 1978, ATLAS PROTEIN SEQ ST, V5; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; HARTSHORNE TA, 1986, NATURE, V320, P283, DOI 10.1038/320283a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0	30	246	276	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					175	178		10.1038/349175a0	http://dx.doi.org/10.1038/349175a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1898772				2022-12-01	WOS:A1991ER41800065
J	ORHOLM, M; MUNKHOLM, P; LANGHOLZ, E; NIELSEN, OH; SORENSEN, TIA; BINDER, V				ORHOLM, M; MUNKHOLM, P; LANGHOLZ, E; NIELSEN, OH; SORENSEN, TIA; BINDER, V			FAMILIAL OCCURRENCE OF INFLAMMATORY BOWEL-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REGIONAL PATIENT GROUP; CROHNS-DISEASE; ULCERATIVE-COLITIS; PREVALENCE; COPENHAGEN; RELATIVES; COUNTY; RISK; PROGNOSIS	Background and Methods. We assessed the familial occurrence in inflammatory bowel disease in Copenhagen County, where there has been a long-term interest in the epidemiology of such disorders. In 1987 we interviewed 662 patients in whom inflammatory bowel disease had been diagnosed before 1979, asking whether their first- and second-degree relatives had this disorder. Ninety-six percent of the patients (504 with ulcerative colitis and 133 with Crohn's disease) provided adequate information. Results. As compared with the general population, the first-degree relatives of the 637 patients with ulcerative colitis or Crohn's disease had a 10-fold increase in the risk of having the same disease as the patients, after standardization for age and sex. The risk of having the other of the two diseases was also increased, but less so, and the increase in the risk of having Crohn's disease was not significant in the relatives of patients with ulcerative colitis. The risk of ulcerative colitis in first-degree relatives of patients with ulcerative colitis appeared to be virtually independent of the generation to which the first-degree relative belonged and of the sex of the patient and the relative. The risk of ulcerative colitis in first-degree relatives tended to be higher if the disease had been diagnosed in the patient before the age of 50, but the risk seemed to be independent of the current age of the relatives. The prevalence of the same disease as that of the patient (either ulcerative colitis or Crohn's disease) among second-degree relatives was increased; the prevalence of the other disease was not increased. Conclusions. The 10-fold increase in the familial risk of ulcerative colitis and Crohn's disease strongly suggests that these disorders have a genetic cause.	UNIV COPENHAGEN,HERLEV HOSP,DEPT MED GASTROENTEROL C,DK-2730 HERLEV,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital			Nielsen, Ole Haagen/AAK-2482-2021; Munkholm, Pia/ABD-2432-2021	Nielsen, Ole Haagen/0000-0003-4612-8635; 				BINDER V, 1966, Scandinavian Journal of Gastroenterology, V1, P49; BINDER V, 1985, GUT, V26, P146, DOI 10.1136/gut.26.2.146; BINDER V, 1982, GASTROENTEROLOGY, V83, P563; BOTH H, 1983, SCAND J GASTROENTERO, V18, P987, DOI 10.3109/00365528309182127; ELSON CO, 1988, INFLAMM BOWEL DIS, P97; FARMER RG, 1980, CLIN GASTROENTEROL, V9, P271; HAMMER B, 1968, GUT, V9, P17, DOI 10.1136/gut.9.1.17; HENDRIKSEN C, 1985, GUT, V26, P158, DOI 10.1136/gut.26.2.158; KHOURY MJ, 1988, AM J EPIDEMIOL, V127, P674, DOI 10.1093/oxfordjournals.aje.a114842; KIRSNER JB, 1963, ANN INTERN MED, V59, P133, DOI 10.7326/0003-4819-59-2-133; KORELITZ BI, 1981, RECENT ADV CROHNS DI, P208; LANGHOLZ E, 1989, SCAND J GASTROENTE S, V158, P66; LARSEN PM, 1989, SCAND J GASTROENTE S, V158, P67; LASHNER BA, 1986, GASTROENTEROLOGY, V91, P1396, DOI 10.1016/0016-5085(86)90193-9; LEWKONIA RM, 1976, GUT, V17, P235, DOI 10.1136/gut.17.3.235; MAYBERRY JF, 1980, BMJ-BRIT MED J, V1, P84; MCCONNELL RB, 1986, GENETICS EPIDEMIOLOG, V11, P1; MCCONNELL RB, 1980, DEV DIGESTIVE DISEAS, P129; MONSEN U, 1987, SCAND J GASTROENTERO, V22, P214, DOI 10.3109/00365528708991882; ROTH MP, 1989, GASTROENTEROLOGY, V96, P1016, DOI 10.1016/0016-5085(89)91618-1; SHERLOCK P, 1963, GASTROENTEROLOGY, V45, P413; SINGER HC, 1971, GASTROENTEROLOGY, V61, P423; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; WEISS KM, 1982, J CHRON DIS, V35, P539, DOI 10.1016/0021-9681(82)90073-X; WETERMAN IT, 1984, GASTROENTEROLOGY, V86, P449	25	505	528	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 10	1991	324	2					84	88		10.1056/NEJM199101103240203	http://dx.doi.org/10.1056/NEJM199101103240203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ977	1984188				2022-12-01	WOS:A1991EQ97700003
J	SHIODA, T; LEVY, JA; CHENGMAYER, C				SHIODA, T; LEVY, JA; CHENGMAYER, C			MACROPHAGE AND T-CELL LINE TROPISMS OF HIV-1 ARE DETERMINED BY SPECIFIC REGIONS OF THE ENVELOPE GP120 GENE	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; AIDS-ASSOCIATED RETROVIRUS; VARIANTS; TYPE-1; EXPRESSION; SEQUENCES; CAPACITY	Strains of human immunodeficiency virus type 1 (HIV-1) display a high degree of biological heterogeneity which may be linked to certain clinical manifestations of AIDS. They vary in their ability to infect different cell types 1-3, to replicate rapidly and to high titre in culture 4-6, to down-modulate the CD4 receptor 7,8, and to cause cytopathic changes in infected cells 7,9-11. Some of these in vitro properties correlate with pathogenicity of the virus in vivo 11,12. To map the viral determinants of the cellular host range of HIV-1, recombinant viruses were generated between biologically active molecular clones of HIV-1 isolates showing differences in infection of primary peripheral blood macrophages and established T-cell lines. We report here at a specific region of the envelope gp120 gene representing 159 amino-acid residues of glycoprotein gp 120 seems to determine macrophage tropism, whereas an overlapping region representing 321 amino-acid residues determines T cell-line tropism. These studies provide a basis for relating functional domains of the HIV-1 env gene to pathogenic potential.			SHIODA, T (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,CANC RES INST,SAN FRANCISCO,CA 94143, USA.							ASJO B, 1986, LANCET, V2, P660; BERMAN PW, 1988, J VIROL, V62, P3135, DOI 10.1128/JVI.62.9.3135-3142.1988; CASTRO BA, 1988, AIDS, V2, pS17, DOI 10.1097/00002030-198800001-00004; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CHENGMAYER C, 1989, P NATL ACAD SCI USA, V86, P8575, DOI 10.1073/pnas.86.21.8575; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; EVANS LA, 1987, J IMMUNOL, V138, P3415; EVANS LA, 1988, SCIENCE, V240, P1522, DOI 10.1126/science.2836951; FENYO EM, 1988, J VIROL, V62, P4414; FISHER AG, 1988, NATURE, V334, P444, DOI 10.1038/334444a0; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LEVY JA, 1986, ANN I PASTEUR, V138, P101; LUCIW PA, 1984, NATURE, V312, P760, DOI 10.1038/312760a0; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SANCHEZPESADOR R, 1986, SCIENCE, V227, P484; TATENO M, 1988, VIROLOGY, V167, P299, DOI 10.1016/0042-6822(88)90084-0; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; YORKHIGGINS D, 1990, J VIROL, V64, P4016, DOI 10.1128/JVI.64.8.4016-4020.1990; YOURNO J, 1989, AIDS RES HUM RETROV, V5, P565, DOI 10.1089/aid.1989.5.565	26	521	524	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					167	169		10.1038/349167a0	http://dx.doi.org/10.1038/349167a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1986308				2022-12-01	WOS:A1991ER41800062
J	SMALL, DM; OLIVA, C; TERCYAK, A				SMALL, DM; OLIVA, C; TERCYAK, A			CHEMISTRY IN THE KITCHEN - MAKING GROUND MEAT MORE HEALTHFUL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY	Background. The National Cholesterol Education Program recommends a diet containing less than 30 percent of calories in the form of fat, less than 10 percent in the form of saturated fat, and less than 300 mg of cholesterol per day. Since American's diets generally exceed these recommendations, we wished to find an easy kitchen method to reduce substantially saturated fat and cholesterol in ground meat. Methods. Raw ground meat was hated in vegetable oil and rinsed with boiling water to extract fat and cholesterol. The fat-free broth was recombined with the meat to restore flavor. The amounts of total fat, saturated fat, and cholesterol in the meat after extraction were compared with the amounts in meat cooked as patties and in stir-fried, rinsed meat. Results. When raw ground beef containing 9.6 to 20.8 percent fat was cooked as patties and the fat poured off, 6 to 17 percent of the fat and 1.3 to 4.3 percent of the cholesterol were lost. In stir-fried, rinsed ground beef, 23 to 59 percent of the fat and 9.0 to 18.8 percent of the cholesterol were lost. When vegetable oil was use to extract fat and cholesterol from beef containing 20.7 percent fat, a mean (+/- SD) of 67.7 +/- 1.6 percent of the fat and 39.2 +/- 5.1 percent of the cholesterol were lost. The differences between conventionally cooked meat and meat prepared by the extraction of fat were significant (P < 0.001). An average of 43 percent (range, 38 to 49) of cholesterol was extracted from a wide variety of ground meats. Although conventional cooking produced no change in fatty-acid composition as compared with raw meat, our extraction process greatly increased the ratio of unsaturated to saturated fat, from 1.32 in conventionally cooked meat to 2.92 to 4.56 in meat after extraction. Extraction resulted in the loss of 72 to 87 percent of saturated fat. Conclusions. This method produces a tasty meat product that is much lower in saturated fat and cholesterol than conventionally cooked meat, and that can be used in sauces, soups, and solid meat products.			SMALL, DM (corresponding author), BOSTON UNIV, SCH MED, HOUSMAN MED RES CTR, DEPT BIOPHYS, 80 E CONCORD ST, BOSTON, MA 02118 USA.			Small, Donald/0000-0002-3072-243X				BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; DOWNING DT, 1968, J CHROMATOGR, V38, P91, DOI 10.1016/0021-9673(68)85011-3; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GURR MI, 1989, FATS FUTURE, P41; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; MORRISON WR, 1964, J LIPID RES, V5, P600; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SMALL DM, 1979, NEW ENGL J MED, V300, P801, DOI 10.1056/NEJM197904053001421; SMALL DM, 1986, HDB LIPID RES, V64; 1980, 17 SUP CHROM SUPPL C, P25; 1988, ARCH INTERN MED, V48, P36	14	16	16	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 10	1991	324	2					73	77		10.1056/NEJM199101103240201	http://dx.doi.org/10.1056/NEJM199101103240201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ977	1984186				2022-12-01	WOS:A1991EQ97700001
J	WATSON, SR; FENNIE, C; LASKY, LA				WATSON, SR; FENNIE, C; LASKY, LA			NEUTROPHIL INFLUX INTO AN INFLAMMATORY SITE INHIBITED BY A SOLUBLE HOMING RECEPTOR-IGG CHIMERA	NATURE			English	Article							MONOCLONAL-ANTIBODY; GLYCOPROTEIN; INVIVO; LYMPHOCYTES; PREVENTION; PLATELETS; ADHESION; PROTEINS; CLONING	Neutrophil-mediated inflammation is involved in a number of human clinical manifestations, including the adult respiratory distress syndrome, multi-organ failure and reperfusion injury 1. One way of inhibiting this type of inflammatory response would be to block competitively the adhesive interactions between neutrophils and the endothelium adjacent to the inflamed region 2. The lectin-containing 3,4 murine adhesion molecule gp90MET, the homing receptor, is found on all leukocytic cells, including neutrophils. 5 MEL 14, a monoclonal antibody directed against this adhesion molecule, blocks lymphocyte traffic to lymph nodes 6 and extravasation of neutrophils from blood to inflammatory sites 7. Here we show that administration to mice of a soluble immunoglobulin chimaera containing the murine homing receptor extracellular domain significantly decreases the number of neutrophils that migrate to the peritoneum in response to the inflammatory irritant thioglycollate. These results indicate that soluble forms of a single type of adhesion molecule, the homing receptor, could be clinically effective compounds for the inhibition of neutrophil-mediated inflammation.			WATSON, SR (corresponding author), GENENTECH INC,DEPT IMMUNOBIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ARFORS KE, 1987, BLOOD, V69, P338; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOWEN B, 1990, J CELL BIOL, V110, P421; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; COSIMI AB, 1990, J IMMUNOL, V144, P4604; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FISCHER A, 1986, LANCET, V2, P1058; GALLATIN M, 1986, CELL, V44, P673, DOI 10.1016/0092-8674(86)90832-9; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; Goldstein I., 1988, INFLAMMATION BASIC P; IMAI Y, UNPUB J CELL BIOL; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1989, J IMMUNOL, V143, P3318; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MOUNTZ JD, 1988, J IMMUNOL, V140, P2943; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPRINGER T, 1990, NATURE, V436, P425; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221	23	297	351	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					164	166		10.1038/349164a0	http://dx.doi.org/10.1038/349164a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1986307				2022-12-01	WOS:A1991ER41800061
J	WOJCIECHOWSKI, AP; FARRALL, M; CULLEN, P; WILSON, TME; BAYLISS, JD; FARREN, B; GRIFFIN, BA; CASLAKE, MJ; PACKARD, CJ; SHEPHERD, J; THAKKER, R; SCOTT, J				WOJCIECHOWSKI, AP; FARRALL, M; CULLEN, P; WILSON, TME; BAYLISS, JD; FARREN, B; GRIFFIN, BA; CASLAKE, MJ; PACKARD, CJ; SHEPHERD, J; THAKKER, R; SCOTT, J			FAMILIAL COMBINED HYPERLIPEMIA LINKED TO THE APOLIPOPROTEIN AI-CIII-AIV GENE-CLUSTER ON CHROMOSOME-11Q23-Q24	NATURE			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; CORONARY HEART-DISEASE; DNA POLYMORPHISMS; LINKAGE ANALYSIS; LIPID-LEVELS; DEFICIENCY; HUMANS	Familial combined hyperlipidaemia (FCHL) is a common inherited disorder of lipid metabolism with a prevalence of 0.5-2.0% (refs 1,2). It is estimated to cause 10% of premature coronary heart disease 1,3. The underlying metabolic and genetic defects in FCHL have not been identified, but a population study has suggested an association between FCHL and an XmnI restriction fragment length polymorphism (RFLP) within the apolipoprotein AI-CIII-AIV gene cluster 4. Here we confirm this association and show that it results from linkage disequilibrium between FChl and the 6.6-kilobase (kb) allele of the XmnI RFLP. Subsequent analysis in seven FChl families, ascertained through a proband carrying the 6.6 kb XmnI allele, demonstrated linkage to the AI-CIII-AIV cluster on 11q23-q24, z = 6.86 with no recombinants. This assignment will facilitate the identification of the mutation that causes hyperlipidaemia in these families.	NORTHWICK PK HOSP & CLIN RES CTR,MRC,CLIN RES CTR,DIV MOLEC MED,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND; GLASGOW ROYAL INFIRM,INST PATHOL BIOCHEM,GLASGOW G4 0SF,SCOTLAND	Imperial College London; Medical Research Council Clinical Trials Unit; University of Glasgow				Thakker, Rajesh/0000-0002-1438-3220				BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BRESLOW JL, 1989, J CLIN INVEST, V84, P373, DOI 10.1172/JCI114176; BRUNZELL JD, 1976, METABOLISM, V25, P313, DOI 10.1016/0026-0495(76)90089-5; CHIVOT L, 1990, ATHEROSCLEROSIS, V82, P205, DOI 10.1016/0021-9150(90)90042-H; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GRIFFIN BA, 1990, ATHEROSCLEROSIS, V83, P59, DOI 10.1016/0021-9150(90)90131-2; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; HAYDEN MR, 1987, AM J HUM GENET, V40, P421; KESSLING AM, 1985, CLIN GENET, V28, P296; LANDER ES, 1988, MAPPING COMPLEX GENE, P171; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LAW A, 1986, LANCET, V1, P1301; NIKKILA EA, 1973, LANCET, V1, P954; NORUM RA, 1982, NEW ENGL J MED, V306, P1513, DOI 10.1056/NEJM198206243062503; OTT J, 1985, Genetic Epidemiology, V2, P79, DOI 10.1002/gepi.1370020108; ROSE HG, 1973, AM J MED, V54, P148, DOI 10.1016/0002-9343(73)90218-0; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; WILSON TME, IN PRESS NUCLEIC ACI; WINDLER E, 1985, J LIPID RES, V26, P556; 1980, NIH801527 PUBL, V1	24	175	176	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					161	164		10.1038/349161a0	http://dx.doi.org/10.1038/349161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1670899				2022-12-01	WOS:A1991ER41800060
J	FIRLIK, AD				FIRLIK, AD			MARGO LOGO	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	41	41	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 9	1991	265	2					201	201		10.1001/jama.265.2.201	http://dx.doi.org/10.1001/jama.265.2.201			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ602	1984141				2022-12-01	WOS:A1991EQ60200013
J	NIGHTINGALE, SL				NIGHTINGALE, SL			GUIDELINE FOR THE STUDY OF DRUGS IN THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 9	1991	265	2					182	182						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ602	1984138				2022-12-01	WOS:A1991EQ60200009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			GERIATRIC USE SUBSECTION PROPOSED ON DRUG LABELING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 9	1991	265	2					182	182						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ602	1984138				2022-12-01	WOS:A1991EQ60200008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CLOTRIMAZOLE AVAILABLE WITHOUT PRESCRIPTION FOR VAGINAL YEAST INFECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 9	1991	265	2					182	182						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ602	1984138				2022-12-01	WOS:A1991EQ60200010
J	STROUPBENHAM, CA; TREVINO, FM				STROUPBENHAM, CA; TREVINO, FM			REPRODUCTIVE CHARACTERISTICS OF MEXICAN-AMERICAN, MAINLAND PUERTO-RICAN, AND CUBAN-AMERICAN WOMEN - DATA FROM THE HISPANIC HEALTH AND NUTRITION EXAMINATION SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; UNITED-STATES; CONTRACEPTIVE USE; SOCIOECONOMIC-STATUS; DEPRESSIVE SYMPTOMS; NATIONAL SURVEY; FAMILY GROWTH; PREVALENCE; CANCER; FERTILITY	Data from the Hispanic Health and Nutrition Examination Survey were used to investigate reproductive characteristics of Hispanic females aged 15 to 45 years. Mexican-American and Puerto Rican women reported approximately 1.9 and 1.7 live births each, respectively, whereas Cuban-American women reported 1.1. Mexican-American women were more likely to be using oral contraceptives and were more likely to have had a hysterectomy or an oophorectomy than were Cubans and Puerto Ricans. The largest percentage fo tubal ligations were found among Puerto Rican women. Mexican women who had been pregnant in the previous 12 months were more likely than their Puerto Rican and Cuban-American counterparts to be breastfeeding. Further research is needed to investigate the decision processes and/or cultural variations that may be responsible for these differences in reproductive traits across national origin groups.			STROUPBENHAM, CA (corresponding author), UNIV TEXAS, MED BRANCH, CTR CROSS CULTURAL RES, OFF EDUC DEV, 144 GAIL BORDEN BLDG F-64, GALVESTON, TX 77550 USA.							BACHRACH CA, 1984, FAM PLANN PERSPECT, V16, P253, DOI 10.2307/2134914; BACHRACH CA, 1984, PHS851250 US DEP HLT; BLOOM B, 1981, PHS821250 US DEP HLT; BRYANT CA, 1982, SOC SCI MED, V16, P1757, DOI 10.1016/0277-9536(82)90269-6; DELEON CFM, 1988, AM J EPIDEMIOL, V127, P150; Diehl A K, 1989, Adv Intern Med, V34, P73; EHLING MB, 1981, CULTURE CHILDREARING, P192; FOMON SJ, 1971, ACTA PAEDIATR SC   S, V223, P3; FRERICHS RR, 1981, AM J EPIDEMIOL, V113, P691, DOI 10.1093/oxfordjournals.aje.a113149; HAMMAN RF, 1989, AM J EPIDEMIOL, V129, P295, DOI 10.1093/oxfordjournals.aje.a115134; HANIS CL, 1983, AM J EPIDEMIOL, V118, P659, DOI 10.1093/oxfordjournals.aje.a113677; HAZUDA HP, 1988, AM J EPIDEMIOL, V128, P1289, DOI 10.1093/oxfordjournals.aje.a115082; Herold J M, 1986, Fam Plann Perspect, V18, P185, DOI 10.2307/2947984; HIRSCHMAN C, 1979, VITAL HLTH STAT, V23; HOWE HL, 1984, AM J PUBLIC HEALTH, V74, P560, DOI 10.2105/AJPH.74.6.560; HUMBLE CG, 1985, AM J PUBLIC HEALTH, V75, P145, DOI 10.2105/AJPH.75.2.145; HUNT IF, 1984, AM J CLIN NUTR, V40, P508, DOI 10.1093/ajcn/40.3.508; KLEINMAN JC, 1985, AM J EPIDEMIOL, V121, P843, DOI 10.1093/oxfordjournals.aje.a114055; KOVAR MG, 1985, VITAL HLTH STAT, V1, pCH11; LACROIX AZ, 1989, AM J EPIDEMIOL, V129, P669, DOI 10.1093/oxfordjournals.aje.a115183; MOHRER J, 1979, MED ANTHROPOL, V39, P125; MOSHER WD, 1987, STUD FAMILY PLANN, V18, P83, DOI 10.2307/1966699; MOSHER WD, 1988, FAM PLANN PERSPECT, V20, P207, DOI 10.2307/2135622; MOSHER WD, 1981, VITA HLTH STAT, V23; NEWACHECK PW, 1989, PEDIATRICS, V84, P1056; POKRAS R, 1988, AM J PUBLIC HEALTH, V78, P852, DOI 10.2105/AJPH.78.7.852; PRAGER K, 1984, PUBLIC HEALTH REP, V99, P117; PRATT WF, 1984, POPUL BULL, V39, P3; PRESSER HB, 1980, INT FAM PLAN PERSPEC, V6, P20; RASSIN DK, 1984, PEDIATRICS, V73, P132; RICHARDSON JL, 1987, PREV MED, V16, P761, DOI 10.1016/0091-7435(87)90016-8; RUSSELLBRIEFEL R, 1985, AM J PUBLIC HEALTH, V75, P1173, DOI 10.2105/AJPH.75.10.1173; SAMUELS SE, 1985, AM J CLIN NUTR, V42, P504, DOI 10.1093/ajcn/42.3.504; SCRIBNER R, 1989, AM J PUBLIC HEALTH, V79, P1263, DOI 10.2105/AJPH.79.9.1263; SHAI D, 1986, PUBLIC HEALTH REP, V101, P547; SMITH JC, 1982, AM J PUBLIC HEALTH, V72, P59, DOI 10.2105/AJPH.72.1.59; SMITH PB, 1986, J DEV BEHAV PEDIATR, V7, P346; VEGA W, 1984, AM J EPIDEMIOL, V120, P592, DOI 10.1093/oxfordjournals.aje.a113921; VENTURA SJ, 1984, 33 DEP HLGH HUM SERV; WESTOFF CF, 1986, SCIENCE, V234, P554, DOI 10.1126/science.3532324; WRIGHT AL, 1988, PEDIATRICS, V82, P496; 1989, 1987 DEMOGRAPHIC YB, P698; 1989, STATISTIAL ABSTRACT; 1988, CURRENT POPULATI P20, V427; 1988, CURRENT POPULATI P60, V161; 1983, 1980 CENSUS POPULATI, V1	46	29	29	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 9	1991	265	2					222	226		10.1001/jama.265.2.222	http://dx.doi.org/10.1001/jama.265.2.222			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ602	1984151				2022-12-01	WOS:A1991EQ60200029
J	CHEINGSONGPOPOV, R; PANAGIOTIDI, C; BOWCOCK, S; ARONSTAM, A; WADSWORTH, J; WEBER, J				CHEINGSONGPOPOV, R; PANAGIOTIDI, C; BOWCOCK, S; ARONSTAM, A; WADSWORTH, J; WEBER, J			RELATION BETWEEN HUMORAL RESPONSES TO HIV GAG AND ENV PROTEINS AT SEROCONVERSION AND CLINICAL OUTCOME OF HIV-INFECTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHADENOPATHY-ASSOCIATED VIRUS; RETROVIRUSES HTLV-III; T-LYMPHOTROPIC VIRUS; ANTIBODY-RESPONSE; HOMOSEXUAL MEN; CORE ANTIBODIES; AIDS; ANTIGEN; RISK	Objective - To study the contribution of the humoral response to HIV-1 at seroconversion to disease outcome after 84 months. Design - A retrospective longitudinal study. Setting - Two haemophilia centres in the United Kingdom. Patients - 88 Haemophiliac patients infected with HIV-1 for whom sera were available from before seroconversion and in whom clinical follow up data were available. Results - Kaplan-Meier survival analysis showed a significant difference between a high titre (> 1600 p24 antibody response at seroconversion and prolonged time before the development of HIV related disease (p = 0.0008). In contrast, higher titres of antibody to gp120 at seroconversion (> 25 600) correlated with more rapid clinical deterioration (p = 0.025). Conclusions - The first humoral response to HIV proteins at seroconversion is associated with clinical outcome; patients with an initial low titre antibody response to the gagp24 protein have a significantly faster rate of progression to CDC stage IV disease. Patients with a high titre p24 antibody response progress to AIDS more slowly, and these data provide an explanation why p24 antigenaemia is not universally detected in patients with AIDS. It is unclear whether the association between a strong initial p24 antibody response and slower progression of HIV disease is causal and if so whether it is due to viral or host factors.	LORD MAYOR TRELOAR HOSP & COLL, TRELOAR HAEMOPHILIA CTR, ALTON, HANTS, ENGLAND; ST MARYS HOSP, SCH MED, ACAD DEPT PUBL HLTH, LONDON W2 1PG, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0HS, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT MED, INFECT DIS UNIT, LONDON W12 0HS, ENGLAND	Imperial College London; Imperial College London; Imperial College London								ALLAIN JP, 1986, LANCET, V2, P1233; BARIN F, 1985, SCIENCE, V228, P1094, DOI 10.1126/science.2986291; BIGGAR RJ, 1985, BRIT MED J, V291, P997, DOI 10.1136/bmj.291.6501.997; BRUNVEZINET F, 1984, LANCET, V1, P1253; CHEINGSONGPOPOV R, 1990, AIDS RES HUM RETROV, V6, P1099, DOI 10.1089/aid.1990.6.1099; CHEINGSONGPOPOV R, 1984, LANCET, V2, P477; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COOPER DA, 1987, J INFECT DIS, V155, P1113, DOI 10.1093/infdis/155.6.1113; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; FORSTER SM, 1987, AIDS, V1, P235; GAINES H, 1987, LANCET, V1, P1249; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; LANGE JMA, 1986, BRIT MED J, V292, P228, DOI 10.1136/bmj.292.6515.228; LANGE JMA, 1987, AIDS, V1, P15; LANGE JMA, 1986, BRIT MED J, V293, P1459, DOI 10.1136/bmj.293.6560.1459; MANCA F, 1990, LANCET, V335, P811, DOI 10.1016/0140-6736(90)90935-X; MCDOUGAL JS, 1987, J CLIN INVEST, V80, P316, DOI 10.1172/JCI113075; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; MORROW WJW, 1986, CLIN IMMUNOL IMMUNOP, V40, P515, DOI 10.1016/0090-1229(86)90196-0; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; NAYLOR PH, 1987, P NATL ACAD SCI USA, V84, P2951, DOI 10.1073/pnas.84.9.2951; PAN LZ, 1987, J INFECT DIS, V155, P626, DOI 10.1093/infdis/155.4.626; PAPSIDERO LD, 1989, J VIROL, V63, P267, DOI 10.1128/JVI.63.1.267-272.1989; PEDERSEN C, 1987, BRIT MED J, V295, P567, DOI 10.1136/bmj.295.6598.567; RANKI A, 1987, LANCET, V2, P589; ROBINSON WE, 1989, P NATL ACAD SCI USA, V86, P4710, DOI 10.1073/pnas.86.12.4710; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SCHUPBACH J, 1985, NEW ENGL J MED, V312, P265, DOI 10.1056/NEJM198501313120502; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937; SICILIANO RF, 1988, CELL, V54, P561; SIMMONDS P, 1988, BRIT MED J, V296, P593, DOI 10.1136/bmj.296.6622.593; STEEL CM, 1988, LANCET, V1, P1185; STEIMER KS, 1986, VIROLOGY, V150, P283, DOI 10.1016/0042-6822(86)90289-8; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; TSIQUAYE KN, 1988, AIDS, V2, P41, DOI 10.1097/00002030-198802000-00007; WEBER J, 1989, HUMAN RETROVIRUSES, P207; WEBER JN, 1987, LANCET, V1, P119, DOI 10.1016/S0140-6736(87)91964-7; 1986, ANN INTERN MED, V105, P234	39	75	76	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 5	1991	302	6767					23	26		10.1136/bmj.302.6767.23	http://dx.doi.org/10.1136/bmj.302.6767.23			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1899349	Green Published, Bronze			2022-12-01	WOS:A1991ER37200020
J	GOODALL, J				GOODALL, J			HELPING A CHILD TO UNDERSTAND HER OWN TESTICULAR FEMINIZATION	LANCET			English	Editorial Material								Children do not think as adults do. They would therefore be less worried than adults are about a diagnosis with serious or ominous implications, yet they are commonly left uninformed until someone judges that they are old enough to understand. For most, this means delivery of painful information during the very vulnerable teenage years. A better approach is to unfold the trust stage by stage, matching simple statements to the child's conceptual growth until the personal implication are finally realised as part of a maturing process. Use of this approach for a child with testicular feminisation is described.	N STAFFORDSHIRE HOSP,DEPT PAEDIAT,STOKE ON TRENT,ENGLAND	Keele University; University Hospital of North Staffordshire NHS Trust								BEADLE M, 1972, CHILDS MIND; BRANDON J, 1977, BRIT J SOC WORK, V7, P335; EISER C, 1983, CHILD CARE HLTH DEV, V9, P233, DOI 10.1111/j.1365-2214.1983.tb00320.x; GOODALL J, 1987, J ROY SOC HEALTH, V107, P224, DOI 10.1177/146642408710700606; Goodenough F. L., 1963, GOODENOUGH HARRIS DR; SPINETTA J, 1980, PSYCHOL ASPECTS CHIL	6	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					33	35		10.1016/0140-6736(91)93344-9	http://dx.doi.org/10.1016/0140-6736(91)93344-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EQ604	1702173				2022-12-01	WOS:A1991EQ60400018
J	HABIB, N; HOUSSIN, D; CAROL, C; CARDOSO, J; BOISSEAU, C; CALMUS, Y; OZIER, Y; QUERE, J; WOOD, C; MCINTYRE, N				HABIB, N; HOUSSIN, D; CAROL, C; CARDOSO, J; BOISSEAU, C; CALMUS, Y; OZIER, Y; QUERE, J; WOOD, C; MCINTYRE, N			EXPERIMENTAL REDUCTION OF PORTAL-HYPERTENSION BY MECHANICAL INCREASE OF LIVER PORTAL FLOW	LANCET			English	Note								Studies on the isolated perfused rat liver demonstrated that an increase in portal pressure is associated with an increase in the portal blood flow in normal and in cirrhotic livers. In two pigs with portal hypertension mesenteric portal pressure was lowered by mechanically increasing the liver portal blood flow by means of a balloon pump around the portal vein.	HAMMERSMITH HOSP,DEPT SURG,LONDON W12 0HS,ENGLAND; HOP COCHIN,SURG RES LAB,F-75674 PARIS 14,FRANCE; ECOLE NATL SUPER ARTS & METIERS,ANGERS,FRANCE	Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Arts et Metiers Institute of Technology	HABIB, N (corresponding author), ROYAL FREE HOSP,DEPT SURG,HEPATOBILIARY & LIVER TRANSPLANTAT UNIT,LONDON NW3 2QG,ENGLAND.								0	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					16	17		10.1016/0140-6736(91)93334-6	http://dx.doi.org/10.1016/0140-6736(91)93334-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670651				2022-12-01	WOS:A1991EQ60400008
J	LEE, J				LEE, J			EVERYDAY AIDS AND APPLIANCES - BREAST PROSTHESES	BRITISH MEDICAL JOURNAL			English	Editorial Material											LEE, J (corresponding author), BREASTCARE & MASTECTOMY ASSOC,LONDON WC1 8JG,ENGLAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					43	44		10.1136/bmj.302.6767.43	http://dx.doi.org/10.1136/bmj.302.6767.43			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1991190	Green Published, Bronze			2022-12-01	WOS:A1991ER37200027
J	LYNCH, TH; WAYMONT, B; BEACOCK, CJM; DUNN, JA; HUGHES, MA; WALLACE, DMA				LYNCH, TH; WAYMONT, B; BEACOCK, CJM; DUNN, JA; HUGHES, MA; WALLACE, DMA			FOLLOW-UP AFTER TRANSURETHRAL RESECTION OF PROSTATE - WHO NEEDS IT	BRITISH MEDICAL JOURNAL			English	Article											LYNCH, TH (corresponding author), QUEEN ELIZABETH MED CTR,DEPT UROL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.			Dunn, Janet/0000-0001-7313-4446				DORFLINGER T, 1988, J UROLOGY, V140, P1487, DOI 10.1016/S0022-5347(17)42081-7; Singh M, 1973, Br J Urol, V45, P93, DOI 10.1111/j.1464-410X.1973.tb00050.x; 1985, SERIES MB4 27; 1988, BMDP STATISTICAL SOF, V2; 1988, BMDP STATISTICAL SOF, V1	5	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					27	27		10.1136/bmj.302.6767.27	http://dx.doi.org/10.1136/bmj.302.6767.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1991183	Bronze, Green Published			2022-12-01	WOS:A1991ER37200021
J	MATHEW, CGP; EASTON, DF; NAKAMURA, Y; PONDER, BAJ				MATHEW, CGP; EASTON, DF; NAKAMURA, Y; PONDER, BAJ			PRESYMPTOMATIC SCREENING FOR MULTIPLE ENDOCRINE NEOPLASIA TYPE-2A WITH LINKED DNA MARKERS	LANCET			English	Article							MEDULLARY-THYROID CARCINOMA; GENETIC-LINKAGE MAP; CHROMOSOME 10; POLYMORPHISM; FAMILIES; LOCUS	Seven DNA markers from the pericentromeric region of chromosome 10 were tested for linkage to MEN 2A in a panel of 17 families. Four of the markers proved to be tightly linked and therefore suitable for predictive testing. The markers were used to estimate carrier risks for individuals who had a negative biochemical screening test for thyroid C-cell hyperplasia. The analysis substantially altered the carrier risks of most of these individuals, which suggests that typing with DNA markers should be introduced into the screening programme of MEN 2A families. Accurate prenatal diagnosis for this disorder is also now possible.	UNIV CAMBRIDGE,DEPT PATHOL,CANC RES CTR,HUMAN CANC GENET RES GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5PX,SURREY,ENGLAND; JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,TOKYO 170,JAPAN	University of Cambridge; University of London; Institute of Cancer Research - UK; Japanese Foundation for Cancer Research			Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK016684] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01 RR00054] Funding Source: Medline; NIADDK NIH HHS [5T32 AM0703910] Funding Source: Medline; NIDDK NIH HHS [5R37 DK16684] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CARTER C, 1987, CYTOGENET CELL GENET, V45, P33, DOI 10.1159/000132422; CHIN KS, 1988, NUCLEIC ACIDS RES, V16, P1645, DOI 10.1093/nar/16.4.1645; EASTON DF, 1989, AM J HUM GENET, V44, P208; EMERY AEH, 1976, METHODOLOGY MED GENE; GAGEL RF, 1988, NEW ENGL J MED, V318, P478, DOI 10.1056/NEJM198802253180804; GAGEL RF, 1982, J PEDIATR-US, V101, P941, DOI 10.1016/S0022-3476(82)80014-0; KAPLAN MM, 1989, 64TH M AM THYR ASS S; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LATHROP GM, 1988, GENOMICS, V2, P157; LIOU GI, 1987, NUCLEIC ACIDS RES, V15, P3196, DOI 10.1093/nar/15.7.3196; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MATHEW CGP, 1990, ANN HUM GENET, V54, P121, DOI 10.1111/j.1469-1809.1990.tb00368.x; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P374, DOI 10.1093/nar/16.1.374; NAKAMURA Y, 1988, GENOMICS, V3, P389, DOI 10.1016/0888-7543(88)90133-4; NAKAMURA Y, 1989, GENOMICS, V5, P199, DOI 10.1016/0888-7543(89)90046-3; NELKIN BD, 1989, JAMA-J AM MED ASSOC, V261, P3130, DOI 10.1001/jama.261.21.3130; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SOBOL H, 1988, LANCET, V1, P62; SOBOL H, 1989, NEW ENGL J MED, V321, P996, DOI 10.1056/NEJM198910123211502; TELENIUSBERG M, 1977, EUR J CLIN INVEST, V7, P7, DOI 10.1111/j.1365-2362.1977.tb01563.x; WHITE RL, 1990, GENOMICS, V6, P393, DOI 10.1016/0888-7543(90)90469-B; WU JS, 1989, HUM GENET, V83, P383, DOI 10.1007/BF00291386; YAMAMOTO M, 1989, HUM GENET, V82, P287, DOI 10.1007/BF00291173	26	71	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 5	1991	337	8732					7	11		10.1016/0140-6736(91)93329-8	http://dx.doi.org/10.1016/0140-6736(91)93329-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ604	1670689				2022-12-01	WOS:A1991EQ60400003
J	SELLAR, C; FERGUSON, JA; GOLDACRE, MJ				SELLAR, C; FERGUSON, JA; GOLDACRE, MJ			OCCURRENCE AND REPETITION OF HOSPITAL ADMISSIONS FOR ACCIDENTS IN PRESCHOOL-CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD INJURIES; EPIDEMIOLOGY; RATES	Objectives - To examine trends over time in the rates of admission to hospital for accidents of preschool children and to study patterns of repeated admissions for accidents in these children. Design - Analysis of linked, routine abstracts of hospital inpatient records for accidents. Setting - Six districts in the Oxford Regional Health Authority covered by the Oxford record linkage study. Subjects - Records for 19 427 children aged 5 years and under at the time of first recorded admission to hospital. Main outcome measure - Number of admissions to hospital. Results - Records were analysed in three groups: person based annual admission rates were calculated for each calendar year; each child's first recorded admission in 1976-85 was identified, and the child's record was followed up by linkage for one year from that admission; each child's first recorded admission in 1976-81 was identified and followed up for five years. Overall, 19 427 children from an average annual resident population of 163 000 children in 1976-86 had 20 657 admissions for accidents before they were 6 years of age. Of these admissions 13 983 were for injuries, 5717 for poisonings, and 957 for burns. Admission rates declined after 1976 for poisoning, but no substantial changes over time were found in admission rates for injuries or burns. A total of 17 724 children were followed up for one year and 10 889 for five years; 470 (2.6%) of the children who were followed up for one year and 926 (8.5%) of those followed up for five years had at least one further admission for an accident. Of those followed up for one year the 4 and 5 year old children were least likely and those under 1 and 1 year old were most likely to have a further admission for an accident. The number of children who had more than one accident was greater than would be expected if accidents were random occurrences. Those who had a poisoning at first admission were more likely to have another poisoning than an injury or burn; and those who had a burn at first admission were more likely to have another burn. Conclusions - Hospital admissions for accidents in children are common: on average 1 child in 88 in this population was admitted each year. Multiple admissions are uncommon but none the less occur more often than would be expected by chance.			SELLAR, C (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CLIN EPIDEMIOL UNIT,HEADINGTON,OXFORD OX3 7LF,ENGLAND.							AGASS M, 1990, BRIT J GEN PRACT, V40, P202; ARMITAGE P, 1987, STATISTICAL METHODS, P371; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BIJUR PE, 1988, PEDIATRICS, V82, P707; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; BOYCE WT, 1989, AM J DIS CHILD, V143, P338, DOI 10.1001/archpedi.1989.02150150096024; EMINSON CJ, 1986, J EPIDEMIOL COMMUN H, V40, P170, DOI 10.1136/jech.40.2.170; GOLDACRE MJ, 1988, BRIT MED J, V296, P583, DOI 10.1136/bmj.296.6621.583; HUSBAND P, 1973, PRACTITIONER, V211, P335; JACKSON RH, 1983, BRIT MED J, V287, P1468, DOI 10.1136/bmj.287.6403.1468-a; JACKSON RH, 1983, HUM TOXICOL, V2, P285, DOI 10.1177/096032718300200218; RIVARA FP, 1982, AM J DIS CHILD, V136, P399, DOI 10.1001/archpedi.1982.03970410017003; RIVARA FP, 1982, AM J DIS CHILD, V136, P502, DOI 10.1001/archpedi.1982.03970420026004; STEWARTBROWN S, 1986, INT J EPIDEMIOL, V15, P352, DOI 10.1093/ije/15.3.352; 1989, BASIC PRINCIPLES CHI; 1990, ELM901 DEP HLTH; 1967, MANUAL INT STATISTIC; 1990, ACTION ACCIDENT UNIQ; HOSPITAL PATIENT ENQ; MORTALITY STATISTICS; 1989, EL89P96 DEP HLTH SOC; [No title captured]	22	25	25	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					16	19		10.1136/bmj.302.6767.16	http://dx.doi.org/10.1136/bmj.302.6767.16			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER372	1991180	Bronze, Green Published			2022-12-01	WOS:A1991ER37200018
J	BANCHEREAU, J; DEPAOLI, P; VALLE, A; GARCIA, E; ROUSSET, F				BANCHEREAU, J; DEPAOLI, P; VALLE, A; GARCIA, E; ROUSSET, F			LONG-TERM HUMAN B-CELL LINES DEPENDENT ON INTERLEUKIN-4 AND ANTIBODY TO CD40	SCIENCE			English	Article							ACTIVATION; GROWTH; PROLIFERATION; MONOCYTES; RECEPTOR; ANTIGEN; BP35	CD40 is a 45- to 50-kilodalton transmembrane glycoprotein expressed on B lymphocytes, epithelial cells, and some carcinoma cell lines. Human resting B lymphocytes entered a state of sustained proliferation when incubated with both the mouse fibroblastic Ltk- cell line that had been transfected with the human Fc receptor (Fc-gamma-RII/CDw32) and monoclonal antibodies to CD40. In combination with interleukin-4, factor-dependent long-term normal human B cell lines were generated that were consistently negative for Epstein-Barr viral infection. Thus, cross-linking of CD40 is likely to represent an important phenomenon in the clonal expansion of B cells.			BANCHEREAU, J (corresponding author), SCHERING PLOUGH CORP,IMMUNOL RES LAB,F-69571 DARDILLY,FRANCE.		De Paoli, Paolo/AAG-2586-2021	De Paoli, Paolo/0000-0002-9502-1781				BANCHEREAU J, UNPUB; CLARK EA, 1985, P NATL ACAD SCI USA, V82, P1766, DOI 10.1073/pnas.82.6.1766; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; DARZYNKIEWICZ Z, 1980, CYTOMETRY, V1, P98, DOI 10.1002/cyto.990010203; DEFRANCE T, 1987, J IMMUNOL, V139, P1135; DEFRANCE T, 1990, CYTOKINES B LYMPHOCY, P65; KANEOKA H, 1983, J IMMUNOL, V131, P158; LEFKOVITS I, 1985, LIMITING DILUTION AN, P81; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; OGARRA A, 1988, IMMUNOL TODAY, V9, P45, DOI 10.1016/0167-5699(88)91259-5; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PELTZ GA, 1988, J IMMUNOL, V141, P1891; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; ROUSSET F, UNPUB; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPITS H, 1987, J IMMUNOL, V139, P1142; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TAX WJM, 1984, J IMMUNOL, V133, P1185; TISCH R, 1988, IMMUNOL TODAY, V9, P145, DOI 10.1016/0167-5699(88)91202-9; VALLE A, 1989, EUR J IMMUNOL, V19, P1463, DOI 10.1002/eji.1830190818	22	620	685	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					70	72		10.1126/science.1702555	http://dx.doi.org/10.1126/science.1702555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1702555				2022-12-01	WOS:A1991EQ60300028
J	CRESS, WD; TRIEZENBERG, SJ				CRESS, WD; TRIEZENBERG, SJ			CRITICAL STRUCTURAL ELEMENTS OF THE VP16 TRANSCRIPTIONAL ACTIVATION DOMAIN	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; DNA-BINDING PROTEINS; FUNCTIONAL DISSECTION; MUTATIONAL ANALYSIS; REGULATORY PROTEIN; TRANS-ACTIVATOR; FUSION PROTEINS; MAMMALIAN-CELLS; FACTOR VMW65; ALPHA-GENES	Virion protein 16 (VP16) of herpes simplex virus type 1 contains an acidic transcriptional activation domain. Missense mutations within this domain have provided insights into the structural elements critical for its function. Net negative charge contributed to, but was not sufficient for, transcriptional activation by VP16. A putative amphipathic alpha helix did not appear to be an important structural component of the activation domain. A phenylalanine residue at position 442 was exquisitely sensitive to mutation. Transcriptional activators of several classes contain hydrophobic amino acids arranged in patterns resembling that of VP16. Therefore, the mechanism of transcriptional activation by VP16 and other proteins may involve both ionic and specific hydrophobic interactions with target molecules.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University				Triezenberg, Steven/0000-0003-4184-5221	NIAID NIH HHS [AI 27323] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027323, R21AI027323] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACE CI, 1988, J GEN VIROL, V69, P2595, DOI 10.1099/0022-1317-69-10-2595; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, UNPUB; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GRAVES BJ, 1985, MOL CELL BIOL, V5, P1948, DOI 10.1128/MCB.5.8.1948; GREAVES R, 1989, J VIROL, V63, P1641, DOI 10.1128/JVI.63.4.1641-1650.1989; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1988, CELL, V54, P1043; INGLES CJ, UNPUB; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KRISTIE TM, 1987, P NATL ACAD SCI USA, V84, P71, DOI 10.1073/pnas.84.1.71; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; WERSTUCK G, 1989, J VIROL, V63, P5509, DOI 10.1128/JVI.63.12.5509-5513.1989; WERSTUCK G, 1989, GENE, V75, P213, DOI 10.1016/0378-1119(89)90267-9; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	39	402	418	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					87	90		10.1126/science.1846049	http://dx.doi.org/10.1126/science.1846049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1846049				2022-12-01	WOS:A1991EQ60300034
J	EARDLEY, DD; KOSHLAND, ME				EARDLEY, DD; KOSHLAND, ME			GLYCOSYLPHOSPHATIDYLINOSITOL - A CANDIDATE SYSTEM FOR INTERLEUKIN-2 SIGNAL TRANSDUCTION	SCIENCE			English	Article							PROTEIN KINASE-C; STIMULATORY FACTOR-I; MURINE B-CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; DIFFERENTIATION FACTORS; IL-2 RECEPTOR; KILLER CELLS; CHAIN GENE; INSULIN; EXPRESSION	The mechanism of interleukin-2 (IL-2) signal transduction was analyzed by use of an inducible B lymphoma. Like normal antigen-activated B lymphocytes, the lymphoma cells respond to IL-2 by proliferating and differentiating into antibody-secreting cells; both responses are blocked by a second interleukin, IL-4. Analyses of the signaling pathway showed that IL-2 stimulated the rapid hydrolysis of an inositol-containing glycolipid to yield two possible second messengers, a myristylated diacylglycerol and an inositol phosphate-glycan. The myristylated diacylglycerol response exhibited the same IL-2 dose dependence as the growth and differentiative responses, and the generation of both hydrolysis products was inhibited by IL-4. These correlations implicate the glycosyl-phosphatidylinositol system in the intracellular relay of the IL-2 signal.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106	University of California System; University of California Berkeley; University of California System; University of California Santa Barbara					PHS HHS [A107079] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; BROOKS K, 1983, NATURE, V302, P325; BROOKS KH, 1986, J IMMUNOL, V137, P3205; Cambier J C, 1987, Adv Exp Med Biol, V213, P195; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; FRNANDEZBOTRAN R, 1989, J EXP MED, V169, P329; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; KARRAY S, 1990, J IMMUNOL, V145, P1152; KAWAKAMI Y, 1989, J IMMUNOL, V142, P3452; KELLY KL, 1987, P NATL ACAD SCI USA, V84, P6404, DOI 10.1073/pnas.84.18.6404; KELLY KL, 1987, J BIOL CHEM, V262, P15285; LEGRAVEREND C, 1989, EXP CELL RES, V181, P273, DOI 10.1016/0014-4827(89)90201-2; LOUGHNAN MS, 1989, NATURE, V340, P76, DOI 10.1038/340076a0; MARTINEZ OM, 1990, J IMMUNOL, V144, P2211; MCHUGH Y, 1981, B LYMPHOCYTES IMMUNE, P467; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAGLER A, 1988, J IMMUNOL, V141, P2349; NAKANISHI K, 1984, J EXP MED, V160, P1736, DOI 10.1084/jem.160.6.1736; NAKANISHI K, 1984, J EXP MED, V160, P1605, DOI 10.1084/jem.160.6.1605; PAUL WE, 1987, FASEB J, V1, P456, DOI 10.1096/fasebj.1.6.3315808; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SALTIEL AR, 1987, ENDOCRINOLOGY, V120, P967, DOI 10.1210/endo-120-3-967; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5893; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SATO KL, 1987, J BIOL CHEM, V262, P2131; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SPITS H, 1988, J IMMUNOL, V141, P29; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WIDMER MB, 1987, J EXP MED, V166, P1447, DOI 10.1084/jem.166.5.1447; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	39	131	134	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					78	81		10.1126/science.1824727	http://dx.doi.org/10.1126/science.1824727			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1824727				2022-12-01	WOS:A1991EQ60300031
J	HAROOTUNIAN, AT; KAO, JPY; PARANJAPE, S; TSIEN, RY				HAROOTUNIAN, AT; KAO, JPY; PARANJAPE, S; TSIEN, RY			GENERATION OF CALCIUM OSCILLATIONS IN FIBROBLASTS BY POSITIVE FEEDBACK BETWEEN CALCIUM AND IP3	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; INOSITOL 1,4,5-TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; INTRACELLULAR CA-2+; PHOSPHOLIPASE-C; INDUCED RELEASE; PHOSPHATES; HEPARIN; MUSCLE; POTENT	A wide variety of nonexcitable cells generate repetitive transient increases in cytosolic calcium ion concentration ([Ca2+]i) when stimulated with agonists that engage the phosphoinositide signalling pathway. Current theories regarding the mechanisms of oscillation disagree on whether Ca2+ inhibits or stimulates its own release from internal stores and whether inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DG) also undergo oscillations linked to the Ca2+ spikes. In this study, Ca2+ was found to stimulate its own release in REF52 fibroblasts primed by mitogens plus depolarization. However, unlike Ca2+ release in muscle and nerve cells, this amplification was insensitive to caffeine or ryanodine and required hormone receptor occupancy and functional IP3 receptors. Oscillations in [Ca2+]i were accompanied by oscillations in IP3 concentration but did not require functional protein kinase C. Therefore, the dominant feedback mechanism in this cell type appears to be Ca2+ stimulation of phospholipase C once this enzyme has been activated by hormone receptors.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST M047,LA JOLLA,CA 92093	University of California System; University of California San Diego				Kao, Joseph/0000-0002-8875-2180	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177, R37NS027177] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31004] Funding Source: Medline; NINDS NIH HHS [NS 27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1988, J AM CHEM SOC, V110, P3212, DOI 10.1021/ja00218a034; AMBLER SK, 1987, MOL PHARMACOL, V32, P376; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; DEAN NM, 1989, ANAL BIOCHEM, V183, P199, DOI 10.1016/0003-2697(89)90468-5; EBERHARD DA, 1988, TRENDS NEUROSCI, V11, P517, DOI 10.1016/0166-2236(88)90174-9; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAROOTUNIAN A, UNPUB; HAROOTUNIAN A T, 1989, Journal of Cell Biology, V109, p99A; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P945; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KAPLAN JH, 1990, ANNU REV PHYSIOL, V52, P897; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KUBA K, 1980, J PHYSL, V298, P547; LIPSCOMBE D, 1988, NEURON, V1, P335; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; PALADE P, 1989, MOL PHARMACOL, V36, P673; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; RENARD D, 1987, BIOCHEM J, V243, P319; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Rink TJ, 1990, CURR OPIN CELL BIOL, V2, P198, DOI 10.1016/0955-0674(90)90007-2; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SEISHIMA M, 1988, BIOCHEM BIOPH RES CO, V156, P1077, DOI 10.1016/S0006-291X(88)80742-3; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VALDEOLMILLOS M, 1989, PFLUG ARCH EUR J PHY, V413, P676, DOI 10.1007/BF00581820; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8	40	302	304	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					75	78		10.1126/science.1986413	http://dx.doi.org/10.1126/science.1986413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1986413				2022-12-01	WOS:A1991EQ60300030
J	KRASNOW, MA; CUMBERLEDGE, S; MANNING, G; HERZENBERG, LA; NOLAN, GP				KRASNOW, MA; CUMBERLEDGE, S; MANNING, G; HERZENBERG, LA; NOLAN, GP			WHOLE ANIMAL-CELL SORTING OF DROSOPHILA EMBRYOS	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; FUSHI-TARAZU; EXPRESSION; PROTEINS; GENE; MELANOGASTER; ELEMENTS; CULTURES; INSITU; PCR	Use of primary culture cells has been limited by the inability to purify most types of cells, particularly cells from early developmental stages. In whole animal cell sorting (WACS), live cells derived from animals harboring a lacZ transgene are purified according to their level of beta-galactosidase expression with a fluorogenic beta-galactosidase substrate and fluorescence-activated cell sorting. With WACS, incipient posterior compartment cells that express the engrailed gene were purified from early Drosophila embryos. Neuronal precursor cells were also purified, and they differentiated into neurons with high efficiency in culture. Because there are many lacZ strains, it may be possible to purify most types of Drosophila cells. The same approach is also applicable to other organisms for which germ-line transformation is possible.	STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA	Stanford University	KRASNOW, MA (corresponding author), STANFORD UNIV, DEPT BIOCHEM, STANFORD, CA 94305 USA.		Nolan, Garry/AAE-7903-2019; Manning, Gerard/C-8308-2009	Nolan, Garry/0000-0002-8862-9043; Manning, Gerard/0000-0002-5087-9151	NCI NIH HHS [CA09151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTI S, 1987, CYTOMETRY, V8, P114, DOI 10.1002/cyto.990080203; ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; ARIAS AM, 1988, DEVELOPMENT, V103, P157; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; CHEN CH, COMMUNICATION; CUMBERLEDGE S, UNPUB; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FEDOROFF S, 1977, CELL TISSUE ORGAN CU; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FURST A, 1985, DEV BIOL, V109, P184, DOI 10.1016/0012-1606(85)90359-8; FURST A, 1985, DEV BIOL, V112, P467, DOI 10.1016/0012-1606(85)90419-1; GURDON JB, 1987, DEVELOPMENT, V99, P285; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HIROMI Y, COMMUNICATION; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KOELLE M, COMMUNICATION; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRASNOW MA, UNPUB; MOORE W, 1986, HDB EXPT IMMUNOLOGY, V1; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PARKS DR, 1989, FUNDAMENTAL IMMUNOLO, P781; PARKS DR, 1986, HDB EXPT IMMUNOLOGY, V1; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Sang JH, 1981, ADV CELL CULT, V1, P125; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; STORTI RV, 1978, CELL, V13, P589, DOI 10.1016/0092-8674(78)90210-6; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1	36	37	43	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	1991	251	4989					81	85		10.1126/science.1898782	http://dx.doi.org/10.1126/science.1898782			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1898782				2022-12-01	WOS:A1991EQ60300032
J	MANIATIS, T				MANIATIS, T			MECHANISMS OF ALTERNATIVE PRE-MESSENGER-RNA SPLICING	SCIENCE			English	Editorial Material							BINDING PROTEINS; GENE; SEX; INTRON; LEVEL				MANIATIS, T (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; Bindereif A, 1990, Genet Eng (N Y), V12, P201; BINGHAM P, COMMUNICATION; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FU XY, 1987, MOL CELL BIOL, V7, P738, DOI 10.1128/MCB.7.2.738; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KRAINER A, COMMUNICATION; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KRAINER AR, 1988, FRONTIERS MOL BIOL T, P131; LASKI FA, 1989, GENE DEV, V3, P720, DOI 10.1101/gad.3.5.720; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; McKeown M, 1990, Genet Eng (N Y), V12, P139; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROBERTSON HM, 1989, GENETICS, V123, P815; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752	35	221	222	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					33	34		10.1126/science.1824726	http://dx.doi.org/10.1126/science.1824726			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1824726				2022-12-01	WOS:A1991EQ60300022
J	MIKI, T; FLEMING, TP; BOTTARO, DP; RUBIN, JS; RON, D; AARONSON, SA				MIKI, T; FLEMING, TP; BOTTARO, DP; RUBIN, JS; RON, D; AARONSON, SA			EXPRESSION CDNA CLONING OF THE KGF RECEPTOR BY CREATION OF A TRANSFORMING AUTOCRINE LOOP	SCIENCE			English	Article							GROWTH-FACTOR; CELLS; DIFFERENTIATION; PURIFICATION; LIBRARIES; INSERTS; SYSTEM	An expression cloning strategy was devised to isolate the keratinocyte growth factor (KGF) receptor complementary DNA. NIH/3T3 fibroblasts, which secrete this epithelial cell-specific mitogen, were transfected with a keratinocyte expression complementary DNA library. Among several transformed foci identified, one demonstrated the acquisition of specific high-affinity KGF binding sites. The pattern of binding competition by related fibroblast growth factors (FGFs) indicated that this receptor had high affinity for acidic FGF as well as KGF. The rescued 4.2-kilobase complementary DNA was shown to encode a predicted membrane-spanning tyrosine kinase related to but distinct from the basic FGF receptor. This expression cloning approach may be generally applicable to the isolation of genes that constitute limiting steps in mitogenic signaling pathways.			MIKI, T (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOTTARO DP, UNPUB; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GUROFF G, 1987, ONCOGENES GENES GROW, P191; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KAHN P, 1986, ONCOGENES GROWTH CON; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; Miki T., UNPUB; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P8722; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUBIN J, UNPUB; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1988, ONCOGENE, V3, P9; RUTA M, 1989, P NATL ACAD SCI USA, V86, P5449; SAFRAN A, 1990, ONCOGENE, V5, P635; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8	35	448	475	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					72	75		10.1126/science.1846048	http://dx.doi.org/10.1126/science.1846048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1846048				2022-12-01	WOS:A1991EQ60300029
J	TRUJILLO, KA; AKIL, H				TRUJILLO, KA; AKIL, H			INHIBITION OF MORPHINE-TOLERANCE AND DEPENDENCE BY THE NMDA RECEPTOR ANTAGONIST MK-801	SCIENCE			English	Article							ANALGESIC TOLERANCE; LOCUS COERULEUS; MECHANISMS; NEURONS; RATS	The N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor is an important mediator of several forms of neural and behavioral plasticity. The present studies examined whether NMDA receptors might be involved in the development of opiate tolerance and dependence, two examples of behavioral plasticity. The noncompetitive NMDA receptor antagonist MK-801 attenuated the development of tolerance to the analgesic effect of morphine without affecting acute morphine analgesia. In addition, MK-801 attenuated the development of morphine dependence as assessed by nalox-one-precipitated withdrawal. These results suggest that NMDA receptors may be important in the development of opiate tolerance and dependence.			TRUJILLO, KA (corresponding author), UNIV MICHIGAN, MENTAL HLTH RES INST, 205 WASHTENAW PL, ANN ARBOR, MI 48109 USA.		Trujillo, Keith/E-8427-2012	Trujillo, Keith/0000-0002-8059-6347	NIDA NIH HHS [DA05336, DA02265] Funding Source: Medline; NIMH NIH HHS [MH422251] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [F32DA005336, R01DA002265] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0; ANDRADE R, 1983, EUR J PHARMACOL, V91, P161, DOI 10.1016/0014-2999(83)90461-2; BAKER TB, 1985, PSYCHOL REV, V92, P78, DOI 10.1037/0033-295X.92.1.78; BLASIG J, 1973, PSYCHOPHARMACOLOGIA, V33, P19; BUCHAN A, 1990, J NEUROSCI, V10, P311; Christie M J, 1987, NIDA Res Monogr, V78, P158; CHRISTIE MJ, 1987, MOL PHARMACOL, V32, P633; CLOUET DH, 1975, ANNU REV PHARMACOL, V15, P49, DOI 10.1146/annurev.pa.15.040175.000405; COLLIER HOJ, 1980, NATURE, V283, P625, DOI 10.1038/283625a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; CRISWELL HE, 1990, BRAIN RES, V512, P284, DOI 10.1016/0006-8993(90)90638-R; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DAFTERS R, 1989, BEHAV NEUROSCI, V103, P1082, DOI 10.1037/0735-7044.103.5.1082; FRANCIS DL, 1971, BRIT J PHARMACOL, V41, pP424; Goudie A. J., 1986, BEHAVIORAL BASIS DRU, P225; HARRIS LS, 1964, J PHARMACOL EXP THER, V143, P141; JOHNSON SM, 1989, PHARMACOL REV, V41, P435; KARLER R, 1989, LIFE SCI, V45, P599, DOI 10.1016/0024-3205(89)90045-3; LEWIS JW, 1987, BRAIN RES, V424, P65, DOI 10.1016/0006-8993(87)91193-0; NEHLS DG, 1990, BRAIN RES, V511, P271, DOI 10.1016/0006-8993(90)90172-8; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; RASMUSSEN K, 1989, BRAIN RES, V505, P346, DOI 10.1016/0006-8993(89)91466-2; RAY BA, 1988, NIDA RES MONOGR, V84; SHARP CW, 1984, NIDA RES MONOGR, V54; SIEGEL S, 1976, SCIENCE, V193, P323, DOI 10.1126/science.935870; Siegel S., 1983, RES ADV ALCOHOL DRUG, P207, DOI [10.1007/978-1-4613-3626-6_6, DOI 10.1007/978-1-4613-3626-6_]; TIFFANY ST, 1988, BEHAV NEUROSCI, V102, P534, DOI 10.1037/0735-7044.102.4.534; TUNG CS, 1990, ACTA PHYSIOL SCAND, V138, P581, DOI 10.1111/j.1748-1716.1990.tb08888.x; WATKINS JC, 1989, NMDA RECEPTOR; WEI E, 1973, PSYCHOPHARMACOLOGIA, V28, P35, DOI 10.1007/BF00413955; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; WIKLER A, 1948, AM J PSYCHIAT, V105, P329, DOI 10.1176/ajp.105.5.329; WIKLER A, 1976, PAVLOVIAN J BIOL SCI, V11, P191	34	1064	1112	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	1991	251	4989					85	87		10.1126/science.1824728	http://dx.doi.org/10.1126/science.1824728			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1824728				2022-12-01	WOS:A1991EQ60300033
J	ZHU, X; KOMIYA, H; CHIRINO, A; FAHAM, S; FOX, GM; ARAKAWA, T; HSU, BT; REES, DC				ZHU, X; KOMIYA, H; CHIRINO, A; FAHAM, S; FOX, GM; ARAKAWA, T; HSU, BT; REES, DC			3-DIMENSIONAL STRUCTURES OF ACIDIC AND BASIC FIBROBLAST GROWTH-FACTORS	SCIENCE			English	Article							TRYPSIN-INHIBITOR KUNITZ; MACROMOLECULAR CRYSTALLOGRAPHY; CRYSTAL-STRUCTURE; 2.8-A RESOLUTION; SEQUENCE; INTERLEUKIN-1-BETA; REFINEMENT; PROGRAMS; SYSTEM; GENE	Members of the fibroblast growth factor (FGF) family of proteins stimulate the proliferation and differentiation of a variety of cell types through receptor-mediated pathways. The three-dimensional structures of two members of this family, bovine acidic FGF and human basic FGF, have been crystallographically determined. These structures contain 12 antiparallel beta-strands organized into a folding pattern with approximate threefold internal symmetry. Topologically equivalent folds have been previously observed for soybean trypsin inhibitor and interleukins-1-beta and -1-alpha. The locations of sequences implicated in receptor and heparin binding by FGF are presented. These sites include beta-sheet strand 10, which is adjacent to the site of an extended sequence insertion in several oncogene proteins of the FGF family, and which shows sequence conservation among the FGF family and interleukin-1-beta.	CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	California Institute of Technology; Amgen								BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BENHARROCH D, 1990, ISRAEL J MED SCI, V26, P212; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FEIGE JJ, 1989, P NATL ACAD SCI USA, V86, P3174, DOI 10.1073/pnas.86.9.3174; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOX GM, 1988, J BIOL CHEM, V263, P18452; FOX GM, UNPUB; GIMENEZGALLEGO G, 1985, SCIENCE, V230, P1385, DOI 10.1126/science.4071057; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JONES TA, 1985, METHOD ENZYMOL, V115, P157; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MARICS I, 1989, ONCOGENE, V4, P335; MCLACHLAN AD, 1979, J MOL BIOL, V133, P557, DOI 10.1016/0022-2836(79)90408-X; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SENO M, 1990, EUR J BIOCHEM, V188, P239, DOI 10.1111/j.1432-1033.1990.tb15395.x; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; VEERAPANDIAN B, UNPUB; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	39	357	383	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	1991	251	4989					90	93		10.1126/science.1702556	http://dx.doi.org/10.1126/science.1702556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1702556				2022-12-01	WOS:A1991EQ60300035
J	ANIKSZTEJN, L; BENARI, Y				ANIKSZTEJN, L; BENARI, Y			NOVEL FORM OF LONG-TERM POTENTIATION PRODUCED BY A K+ CHANNEL BLOCKER IN THE HIPPOCAMPUS	NATURE			English	Article							SYNAPTIC TRANSMISSION; PYRAMIDAL CELLS; NMDA RECEPTORS; AFTER-HYPERPOLARIZATION; POTASSIUM CONDUCTANCES; LASTING POTENTIATION; NEURONS; CALCIUM; ANTAGONISTS; INVITRO	LONG-term potentiation (LTP) of synaptic transmission in the hippocampus is a widely studied model of memory processes1. In the CA1 region, LTP is triggered by the entry of CA2+ through N-methyl-D-aspartate (NMDA) receptor channels and maintained by the activation of CA2+-sensitive intracellular messengers2,3. We now report that in CA1, a transient block by tetraethylammonium of I(C), I(M) and the delayed rectifier (I(K)) produces a Ca2+-dependent NMDA-independent form of LTP. Our results suggest that this new form of LTP (referred as to LTP(K)) is induced by a transient enhanced release of glutamate which generates a depolarization by way of the non-NMDA receptors and the consequent activation of voltage -dependent Ca2+ channels.			ANIKSZTEJN, L (corresponding author), HOP PORT ROYAL,INSERM,U29,123 BLVD PORT ROYAL,F-75014 PARIS,FRANCE.		Aniksztejn, Laurent/E-2072-2017	Aniksztejn, laurent/0000-0001-9215-1698; Ben-Ari, Yehezkel/0000-0001-6208-8480				ANDERSEN P, 1980, J PHYSIOL-LONDON, V302, P463; BLAKE JF, 1988, NEUROSCI LETT, V89, P182, DOI 10.1016/0304-3940(88)90378-3; BROWN DA, 1983, J PHYSIOL-LONDON, V337, P303, DOI 10.1113/jphysiol.1983.sp014625; CHERUBINI E, 1987, NATURE, V328, P70, DOI 10.1038/328070a0; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; GHO M, 1986, BRAIN RES, V385, P411, DOI 10.1016/0006-8993(86)91093-0; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; HIGASHI H, 1990, NEUROSCIENCE, V34, P35, DOI 10.1016/0306-4522(90)90302-K; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KESSLER M, 1989, BRAIN RES, V489, P377, DOI 10.1016/0006-8993(89)90875-5; KRNJEVIC K, 1989, J NEUROPHYSIOL, V62, P896, DOI 10.1152/jn.1989.62.4.896; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P241; MALENKA RC, 1989, TRENDS NEUROSCI, V12, P444, DOI 10.1016/0166-2236(89)90094-5; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P262; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NEUMAN RS, 1988, NEUROSCI LETT, V92, P64, DOI 10.1016/0304-3940(88)90743-4; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; SEGAL M, 1984, J NEUROPHYSIOL, V51, P1409, DOI 10.1152/jn.1984.51.6.1409; SOTRM JF, 1990, PROG BRAIN RES, V83, P161; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; STURGESS NC, 1985, LANCET, V2, P474; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V125, P159, DOI 10.1111/j.1748-1716.1985.tb07703.x; WRIGHT J M, 1988, Society for Neuroscience Abstracts, V14, P1046	33	254	259	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					67	69		10.1038/349067a0	http://dx.doi.org/10.1038/349067a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1845914				2022-12-01	WOS:A1991EQ60100052
J	BARLOW, DP; STOGER, R; HERRMANN, BG; SAITO, K; SCHWEIFER, N				BARLOW, DP; STOGER, R; HERRMANN, BG; SAITO, K; SCHWEIFER, N			THE MOUSE INSULIN-LIKE GROWTH-FACTOR TYPE-2 RECEPTOR IS IMPRINTED AND CLOSELY LINKED TO THE TME LOCUS	NATURE			English	Article							T-COMPLEX; CHROMOSOME-17; HAPLOTYPE; GENE	T-ASSOCIATED maternal effect (Tme) is the only known maternal-effect mutation in the mouse1,2. The defect is nuclear-encoded3 and embryos that inherit a deletion of the Tme locus from their mother die at day 15 of gestation4. There are many genomically imprinted regions known in the mouse genome5,6, but so far no imprinted genes have been cloned. The Tme locus is absent in two chromosome-17 deletion mutants, T(hp) and the t(Lub2), and its position has been localized using these deletions to a 1-cM region7-10. We report here that the genes for insulin-like growth factor type-2 receptor (Igf2r) and mitochondrial superoxide dismutase-2 (Sod-2) are absent from both deletions. Probes for these genes and for plasminogen (Plg) and T-complex peptide 1 (Tcp-1) were used in pulsed-field gel mapping to show that Tme must lie within a region of 800-1,100 kb. We also demonstrate that embryos express Igf2r only from the maternal chromosome, and that Tcp-1, Plg and Sod-2 are expressed from both chromosomes. Therefore Igf2r is imprinted and closely linked or identical to Tme.	MAX PLANCK INST ENTWICKLUNGSBIOL,W-7400 TUBINGEN,GERMANY; VANDERBILT UNIV,NASHVILLE,TN 37232	Max Planck Society; Vanderbilt University	BARLOW, DP (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		allen, nick d/A-4336-2010; Reik, Wolf/I-6794-2012	Stoger, Reinhard/0000-0002-2301-0805				BEECHEY CV, 1990, MOUSE GENOME, V87, P64; BIBBINS KB, 1989, GENOMICS, V5, P139, DOI 10.1016/0888-7543(89)90098-0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEGAN SJF, IN PRESS GENOMICS; FAN JB, 1988, NUCLEIC ACIDS RES, V17, P2801; FIGUEROA F, 1988, IMMUNOGENETICS, V28, P260, DOI 10.1007/BF00345503; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HOLIDAY R, 1990, PHIL T R SOC B, V236, P177; JOHNSON DR, 1974, GENETICS, V76, P795; JOHNSON DR, 1975, GENET RES CAMB, V24, P207; LATON AK, 1982, THESIS CORNELL U MED; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; Maniatis T, 1989, DECONTAMINATION DILU; MANN EA, 1986, GENETICS, V114, P993; MCGRATH J, 1984, NATURE, V308, P550, DOI 10.1038/308550a0; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; SARVETNICK N, 1986, GENETICS, V113, P723; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SILVER LM, 1985, ANNU REV GENET, V19, P179, DOI 10.1146/annurev.ge.19.120185.001143; SOLTER D, 1988, ANNU REV GENET, V22, P127; SPENCE MA, 1989, CYTOGENET CELL GENET, V51, P149, DOI 10.1159/000132790; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; SURANI MA, 1990, PHIL T R SOC B, V326, P179; WILLISON K, 1987, EMBO J, V44, P469; WINKING H, 1984, GENETICS, V108, P1013	25	739	760	2	56	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					84	87		10.1038/349084a0	http://dx.doi.org/10.1038/349084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1845916				2022-12-01	WOS:A1991EQ60100059
J	BEARD, KC; KRISHTALKA, L; STUCKY, RK				BEARD, KC; KRISHTALKA, L; STUCKY, RK			1ST SKULLS OF THE EARLY EOCENE PRIMATE SHOSHONIUS-COOPERI AND THE ANTHROPOID-TARSIER DICHOTOMY	NATURE			English	Article							ORIGINS; OMOMYIDAE; EVOLUTION; TARSIIDAE; AFRICA	THE phylogenetic relationships of living tarsiers and extinct omomyid primates are critical for deciphering the origin and relationships of primate higher taxa, particularly anthropoids1-6. Three competing phylogenetic hypotheses are: (1) tarsiers are most closely related to early Cenozoic Omomyidae5-8, particularly genera such as Necrolemur from the late Eocene of Europe9-11; (2) tarsiers share a more recent common ancestry with anthropoids than they do with any known omoyid2-4,12,13; (3) tarsiers and/or omoyids are most closely related to strepsirhines14. The anatomy of four skulls of the early Eocene omomyid Shoshonius cooperi-the first cranial material recovered for this genus-strongly suggests that Schoshonius shares a more recent common ancestry with Tarsius than do either anthropoids or other Eocene omomyids for which cranial anatomy is known. If the primate suborder Haplorhini (anthropoids, omomyids, tarsiids) is monophyletic, the phylogenetic position of Shoshonius requires that anthropoids and Tarsius diverged by at least the early Eocene, some 15 million years before the first appearance of anthropoids in the fossil record15-17.	DENVER MUSEUM NAT HIST,DEPT EARTH SCI,DENVER,CO 80205		BEARD, KC (corresponding author), CARNEGIE MUSEUM NAT HIST,VERTEBRATE PALEONTOL SECT,4400 FORBES AVE,PITTSBURGH,PA 15213, USA.		Beard, K. Christopher/AAQ-4438-2021	Beard, K. Christopher/0000-0002-6279-9837				Cartmill M., 1980, P243; CARTMILL M, 1981, AM J PHYS ANTHROPOL, V56, P3; Cartmill M., 1978, RECENT ADV PRIMATOL, P205; CONROY GC, 1980, AM J PHYS ANTHROPOL, V52, P443, DOI 10.1002/ajpa.1330520316; DEBONIS L, 1988, CR ACAD SCI II, V306, P929; DEJONG WW, 1988, J HUM EVOL, V17, P575, DOI 10.1016/0047-2484(88)90085-1; DZELUSNIAK J, 1990, CURRENT MAMMALOGY, V2, P545; FLEAGLE JG, 1987, J HUM EVOL, V16, P483, DOI 10.1016/0047-2484(87)90036-4; GEBO DL, 1986, J HUM EVOL, V15, P421, DOI 10.1016/S0047-2484(86)80025-2; GINGERICH PD, 1981, J HUM EVOL, V10, P345, DOI 10.1016/S0047-2484(81)80057-7; GINSBURG L, 1987, CR ACAD SCI II, V304, P1213; KOOP BF, 1989, J BIOL CHEM, V264, P68; Krishtalka L., 1987, P77; Luckett WP., 1975, PHYLOGENY PRIMATES, P157, DOI [10.1007/978-1-4684-2166-8, DOI 10.1007/978-1-4684-2166-8]; MacPhee R.D.E., 1981, Contributions to Primatology, V18, P1; MacPhee R. D. E., 1986, COMP PRIM B, V1, P219; Martin R.D., 1990, PRIMATE ORIGINS EVOL; POCOCK RI, 1918, P ZOOL SOC LOND, P19; POLLOCK JI, 1987, AM J PHYS ANTHROPOL, V73, P65, DOI 10.1002/ajpa.1330730106; RASMUSSEN DT, 1986, J HUM EVOL, V15, P1, DOI 10.1016/S0047-2484(86)80060-4; Rosenberger A.L., 1980, P139; ROSENBERGER AL, 1985, FOLIA PRIMATOL, V45, P179, DOI 10.1159/000156227; SCHMID P, 1981, PRIMATE EVOLUTIONARY, P6; SCHWARTZ JH, 1987, J HUM EVOL, V16, P23, DOI 10.1016/0047-2484(87)90059-5; SIMONS EL, 1990, SCIENCE, V247, P1567, DOI 10.1126/science.2108499; SIMONS EL, 1985, NATURE, V313, P475, DOI 10.1038/313475a0; SIMONS EL, 1989, AM J PHYS ANTHROPOL, V79, P1, DOI 10.1002/ajpa.1330790103; SIMONS EL, 1989, P NATL ACAD SCI USA, V86, P9956, DOI 10.1073/pnas.86.24.9956; SIMONS ELWYN L., 1961, BULL BRIT MUS [NAT HIST] GEOL, V5, P43; STUCKY RK, 1990, GEOL SOC AM SPEC PAP, V243, P169; SZALAY F S, 1976, Bulletin of the American Museum of Natural History, V156, P157; SZALAY FS, 1976, FOLIA PRIMATOL, V25, P288, DOI 10.1159/000155721	32	59	65	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					64	67		10.1038/349064a0	http://dx.doi.org/10.1038/349064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EQ601	1985267				2022-12-01	WOS:A1991EQ60100051
J	BROWN, CJ; BALLABIO, A; RUPERT, JL; LAFRENIERE, RG; GROMPE, M; TONLORENZI, R; WILLARD, HF				BROWN, CJ; BALLABIO, A; RUPERT, JL; LAFRENIERE, RG; GROMPE, M; TONLORENZI, R; WILLARD, HF			A GENE FROM THE REGION OF THE HUMAN X-INACTIVATION CENTER IS EXPRESSED EXCLUSIVELY FROM THE INACTIVE X-CHROMOSOME	NATURE			English	Article							CONTROLLING ELEMENTS; LINKED GENE; MOUSE; DNA; LOCUS; HYPOTHESIS; DELETIONS; MUTATIONS; CELLS; CDNA	X-chromosome inactivation results in the cis-limited dosage compensation of genes on one of the pair of X chromosomes in mammalian females. Although most X-linked genes are believed to be subject to inactivation, several are known to be expressed from both active and inactive X chromosomes. Here we describe an X-linked gene with a novel expression pattern-transcript are detected only from the inactive X chromosome (X(i)) and not from the active X chromosome (X(a)). This gene, called XIST (for X(i)-specific transcripts), is a candidate for a gene either involved in or uniquely influenced by the process of X inactivation.	STANFORD UNIV,MED CTR,SCH MED,DEPT GENET,STANFORD,CA 94305; BAYLOR UNIV,INST MOLEC GENET,HOUSTON,TX 77030	Stanford University; Baylor College of Medicine; Baylor University			Tonlorenzi, Rossana/AAN-2241-2020; BALLABIO, Andrea/AAL-2672-2020; Brown, Carolyn J/A-5159-2014	BALLABIO, Andrea/0000-0003-1381-4604; Brown, Carolyn J/0000-0002-8959-0101; Tonlorenzi, Rossana/0000-0002-6060-8208; Grompe, Markus/0000-0002-6616-4345				BALLABIO A, 1987, P NATL ACAD SCI USA, V84, P4519, DOI 10.1073/pnas.84.13.4519; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1989, AM J HUM GENET, V45, P592; BROWN CJ, 1989, J HUM GENET, V45, pA178; BROWN SW, 1973, P NATL ACAD SCI USA, V70, P195, DOI 10.1073/pnas.70.1.195; BROWNCJ, 1990, NUCLEIC ACIDS RES, V18, P4191; BRWN CJ, 1990, J HUM GENET, V46, P273; CATTANACH BM, 1975, ANNU REV GENET, V9, P1, DOI 10.1146/annurev.ge.09.120175.000245; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIDSON RG, 1963, P NATL ACAD SCI USA, V50, P481, DOI 10.1073/pnas.50.3.481; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FLEJTER WL, 1984, AM J HUM GENET, V36, P218; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GOODFELLOW P, 1984, AM J HUM GENET, V36, P777; GRAVES JAM, 1986, SOMAT CELL MOLEC GEN, V12, P275, DOI 10.1007/BF01570786; GROMPE M, 1989, P NATL ACAD SCI USA, V86, P5888, DOI 10.1073/pnas.86.15.5888; JOHNSTON PG, 1981, GENET RES, V37, P151, DOI 10.1017/S0016672300020127; KEER JT, 1990, GENOMICS, V7, P566, DOI 10.1016/0888-7543(90)90200-E; KORNELUK RG, 1985, GENE, V40, P317, DOI 10.1016/0378-1119(85)90055-1; LYON MF, 1972, BIOL REV, V47, P1; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; LYON MF, 1986, J EMBRYOL EXP MORPH, V97, P75; MATTEI MG, 1981, HUM GENET, V56, P401, DOI 10.1007/BF00274702; MEYER WJ, 1975, P NATL ACAD SCI USA, V72, P1469, DOI 10.1073/pnas.72.4.1469; MIGEON BR, 1979, CELL, V18, P637, DOI 10.1016/0092-8674(79)90118-1; MIGEON BR, 1968, SCIENCE, V160, P425, DOI 10.1126/science.160.3826.425; NADON N, 1988, SOMAT CELL MOLEC GEN, V14, P541, DOI 10.1007/BF01535309; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RIGGS AD, 1990, AUST J ZOOL, V37, P419, DOI 10.1071/ZO9890419; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SHAPIRO LJ, 1979, SCIENCE, V204, P1224, DOI 10.1126/science.156396; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Summitt R L, 1978, Birth Defects Orig Artic Ser, V14, P219; THERMAN E, 1974, CHROMOSOMA, V44, P361; WILLARD HF, 1980, SOMAT CELL GENET, V6, P187, DOI 10.1007/BF01538795	41	1226	1273	3	95	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					38	44		10.1038/349038a0	http://dx.doi.org/10.1038/349038a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1985261				2022-12-01	WOS:A1991EQ60100042
J	HANSOTIA, P; BROSTE, SK				HANSOTIA, P; BROSTE, SK			THE EFFECT OF EPILEPSY OR DIABETES-MELLITUS ON THE RISK OF AUTOMOBILE ACCIDENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Previous studies of possible associations between chronic medical conditions and traffic safety have been inconsistent and subject to bias because of the incomplete identification of affected persons. Recent advances in the diagnosis and management of epilepsy and diabetes mellitus have improved the control of these disorders and suggest a need to reexamine the risk of traffic mishaps among patients with these conditions. Methods. We conducted a population-based retrospective cohort study of 30,420 subjects 16 to 90 years of age, with and without epilepsy or diabetes mellitus. Subjects included all the licensed drivers in seven contiguous ZIP Code areas in which the Marshfield Clinic and St. Joseph's Hospital, Marshfield, Wisconsin, are the primary sources of medical care. Standardized rates of moving violations and accidents over a four-year period (1985 through 1988) were compared in affected and unaffected cohorts. Results. Standardized mishap ratios for subjects with diabetes were 1.14 for all moving violations (P = 0.23) and 1.32 for accidents (P = 0.01); for subjects with epilepsy the ratios were 1.13 for moving violations (P = 0.26) and 1.33 for accidents (P = 0.04). Conclusions. We conclude that drivers with epilepsy or diabetes mellitus have slightly increased risks of traffic accidents as compared with unaffected persons. The increases in risk observed in our study were generally smaller than those in previous studies, and we believe they are not great enough to warrant further restrictions on driving privileges.	MARSHFIELD MED RES FDN, DEPT EPIDEMIOL & BIOSTAT, MARSHFIELD, WI USA		HANSOTIA, P (corresponding author), MARSHFIELD CLIN FDN MED RES & EDUC, DEPT NEUROL, 1000 N OAK AVE, MARSHFIELD, WI 54449 USA.							Checkoway H, 1989, RES METHODS OCCUPATI; CRANCER A, 1968, J AMER MED ASSOC, V205, P272, DOI 10.1001/jama.1968.03140310030006; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; GASTAUT H, 1987, NEUROLOGY, V37, P1613, DOI 10.1212/WNL.37.10.1613; HORMIA A, 1961, ACTA PSYCHIATR SCA S, V150, P210; KLEINBAUM DG, 1987, APPLIED REGRESSION A; ROTHMAN KJ, 1979, NIH791649 DEP HLTH P; SONGER TJ, 1988, DIABETES CARE, V11, P701, DOI 10.2337/diacare.11.9.701; Waller J.A, 1973, MED IMPAIRMENT DRIVI; WALLER JA, 1965, NEW ENGL J MED, V273, P1413, DOI 10.1056/NEJM196512232732605; YSANDER L, 1966, BRIT J IND MED, V23, P28; 1985, DHHS PHS861232 NAT C; 1980, DHHS PHS801260 DEP H	13	200	202	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 3	1991	324	1					22	26		10.1056/NEJM199101033240105	http://dx.doi.org/10.1056/NEJM199101033240105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ503	1984160	Bronze			2022-12-01	WOS:A1991EQ50300005
J	KOZLOWSKI, S; TAKESHITA, T; BOEHNCKE, WH; TAKAHASHI, H; BOYD, LF; GERMAIN, RN; BERZOFSKY, JA; MARGULIES, DH				KOZLOWSKI, S; TAKESHITA, T; BOEHNCKE, WH; TAKAHASHI, H; BOYD, LF; GERMAIN, RN; BERZOFSKY, JA; MARGULIES, DH			EXCESS BETA-2 MICROGLOBULIN PROMOTING FUNCTIONAL PEPTIDE ASSOCIATION WITH PURIFIED SOLUBLE CLASS-I MHC MOLECULES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; TOXIC LYMPHOCYTES-T; ENVELOPE PROTEIN; CELL HYBRIDOMAS; ANTIGEN; HLA; BETA-2-MICROGLOBULIN; RECOGNITION; H-2; DISSOCIATION	T LYMPHOCYTES expressing alpha-beta-receptors recognize antigenic peptide fragments bound to major histocompatibility complex class I (ref. 1) or class II (ref. 2) molecules present on the surface membranes of other cells. Peptide fragments are present in the two available HLA crystal structures3,4 and recent data indicate that peptide is required for the stable folding of the class I heavy chain and maintenance of its association with the class I light chain beta-2-microglobulin (beta-2-m), at physiological temperature5-7. To explain how the exogeneous peptide used to create targets for cytotoxic cells bearing CD8 antigen1 could associate with apparently peptide-filled extracellular class I molecules, we hypothesized that stable binding of exogenous peptide to mature class I molecules reflects either the replacement of previously bound peptide during the well documented beta-2m exchange process8 or the loading of 'empty' class I heavy chains dependent on the availability of excess beta-2m. In either case, free beta-2m should enhance peptide-class I binding. Using either isolated soluble class I molecules or living cells, we show here that free purified beta-2m markedly augments the generation of antigenic complexes capable of T-cell stimulation.	NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892; NCI,METAB BRANCH,MOLEC IMMUNOGENET & VACCINE RES SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KOZLOWSKI, S (corresponding author), NIAID,IMMUNOL LAB,MOLEC BIOL SECT,BETHESDA,MD 20892, USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020	Margulies, David/0000-0001-8530-7375				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HOCHMAN JH, 1988, J IMMUNOL, V140, P2322; HYAFIL F, 1979, P NATL ACAD SCI USA, V76, P5834, DOI 10.1073/pnas.76.11.5834; KANE KP, 1989, NATURE, V340, P157, DOI 10.1038/340157a0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARGULIES DH, 1986, P NATL ACAD SCI USA, V83, P5252, DOI 10.1073/pnas.83.14.5252; MCCLUSKEY J, 1988, J IMMUNOL, V141, P1451; PARHAM P, 1983, HUM IMMUNOL, V8, P207, DOI 10.1016/0198-8859(83)90038-1; PARKER KC, 1985, BIOCHEMISTRY-US, V24, P5543, DOI 10.1021/bi00341a039; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; TAKAHASHI H, 1989, J EXP MED, V170, P2023, DOI 10.1084/jem.170.6.2023; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WARD PJ, 1983, IMMUNOLOGY, V48, P87; WHITE J, 1989, J IMMUNOL, V143, P1822	23	151	164	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					74	77		10.1038/349074a0	http://dx.doi.org/10.1038/349074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1985269				2022-12-01	WOS:A1991EQ60100055
J	MENKE, A; JOCKUSCH, H				MENKE, A; JOCKUSCH, H			DECREASED OSMOTIC STABILITY OF DYSTROPHIN-LESS MUSCLE-CELLS FROM THE MDX MOUSE	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; GENE	HUMAN X-linked Duchenne and Becker muscular dystrophies are due to defects in dystrophin, the product of an exceptionally large gene1,2. Although dystrophin has been characterized as a spectrin-like3 submembranous4 cytoskeletal protein, there is no experimental evidence for its function in the structural maintenance of muscle5. Current hypotheses attribute necrosis of hystrophin-less fibres in situ to mechanical weakening of the outer membrane6, to an excessive influx of Ca2+ ions7,8, or to a combination of these two mechanisms, possibly mediated by stretch-sensitive ion channels9. Using hypo-osmotic shock to determine stress resistance10 and a mouse model (mdx)11,12 for the human disease, we show that functional dystrophin contributes to the stability of both cultured myotubes and isolated mature muscle fibres.			MENKE, A (corresponding author), UNIV BIELEFELD,DEV BIOL UNIT,W-4800 BIELEFELD 1,GERMANY.							BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; COOPER BJ, 1989, SOC NEUR ABSTR, V15, P412; CULLEN MJ, 1990, PROC R SOC SER B-BIO, V240, P197, DOI 10.1098/rspb.1990.0034; DUNCAN CJ, 1989, EXPERIENTIA, V45, P175, DOI 10.1007/BF01954866; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FOSTER AH, 1980, ANESTH ANALG, V58, P727; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; JOCKUSCH H, 1990, MUSCLE NERVE, V13, P551, DOI 10.1002/mus.880130613; JOCKUSCH H, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P429; KARPATI G, 1986, AM J MED GENET, V25, P653, DOI 10.1002/ajmg.1320250407; KOELTGEN D, IN PRESS MUSCLE NERV; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; MENKE A, 1990, J NEUROL SCI S, V98, P124; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Slater CR, 1989, CURR OPIN CELL BIOL, V1, P110, DOI 10.1016/S0955-0674(89)80046-8; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; WATKINS SC, 1989, MUSCLE NERVE, V12, P861, DOI 10.1002/mus.880121013	22	296	300	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					69	71		10.1038/349069a0	http://dx.doi.org/10.1038/349069a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1985268				2022-12-01	WOS:A1991EQ60100053
J	PARDO, JV; FOX, PT; RAICHLE, ME				PARDO, JV; FOX, PT; RAICHLE, ME			LOCALIZATION OF A HUMAN SYSTEM FOR SUSTAINED ATTENTION BY POSITRON EMISSION TOMOGRAPHY	NATURE			English	Article							INTRAVENOUS (H2O)-O-15; HUMAN-BRAIN; PET IMAGES; CORTEX	POSITRON emission tomographic (PET) studies of human attention have begun to dissect isolable components of this complex higher brain function, including a midline attentional system in a region of the anterior cingulate cortex1-3. The right hemisphere may play a special part in human attention4; neglect, an important phenomenon associated with damage to attentional systems, is more severe, extensive and long-lasting after lesions to the right hemisphere. Here we use PET measurements of brain flood flow in healthy subjects to identify changes in regional brain activity during simple visual and somatosensory tasks of sustained attention or vigilance. We find localized increases in blood flow in the prefrontal and superior parietal cortex primarily in the right hemisphere, regardless of the modality or laterality of sensory input. The anterior cingulate was not activated during either task. These data localize the vigilance aspects of normal human attention to sensory stimuli, thereby clarifying the biology underlying asymmetries of attention to such stimuli that have been reported in clinical lesions.	WASHINGTON UNIV,MED CTR,DEPT NEUROL & NEUROL SURG,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,DEPT PSYCHIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,MALLINCKRODT INST RADIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,MCDONNELL CTR STUDIES HIGHER BRAIN FUNCT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Fox, Peter/B-4725-2010	Fox, Peter/0000-0002-0465-2028				CAVADA C, 1989, J COMP NEUROL, V287, P393, DOI 10.1002/cne.902870402; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; FOX PT, 1989, J NUCL MED, V30, P141; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FOX PT, 1987, J NEUROSURG, V67, P34, DOI 10.3171/jns.1987.67.1.0034; FOX PT, 1987, J NEUROSCI, V7, P913; Fuster J, 1989, PREFRONTAL CORTEX; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; HEILMAN KM, 1987, HDB PHYSL 1, V5, P461; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; RAICHLE ME, 1983, J NUCL MED, V24, P790; Talairach J, 1967, ATLAS ANATOMIE STERE; YAMAMOTO M, 1982, IEEE T NUCL SCI, V29, P529, DOI 10.1109/TNS.1982.4335901	16	1055	1067	1	47	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					61	64		10.1038/349061a0	http://dx.doi.org/10.1038/349061a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1985266				2022-12-01	WOS:A1991EQ60100050
J	POLTEN, A; FLUHARTY, AL; FLUHARTY, CB; KAPPLER, J; VONFIGURA, K; GIESELMANN, V				POLTEN, A; FLUHARTY, AL; FLUHARTY, CB; KAPPLER, J; VONFIGURA, K; GIESELMANN, V			MOLECULAR-BASIS OF DIFFERENT FORMS OF METACHROMATIC LEUKODYSTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARYLSULFATASE-A; PSEUDODEFICIENCY; JUVENILE	Background. Metachromatic leukodystrophy is an autosomal recessive inherited lysosomal storage disorder caused by a deficiency or arylsulfatase A. Three forms of the disease can be distinguished according to severity and the age at onset: late infantile (1 to 2 years), juvenile (3 to 16), and adult (> 16). Methods and Results. To understand the molecular basis of the different forms of the disease, we analyzed arylsulfatase A alleles associated with metachromatic leukodystrophy. Two alleles (termed I and A) were identified and accounted for about half of all arylsulfatase A alleles among 68 patients with metachromatic leukodystrophy whom we examined. Sufficient information was available for 66 of the patients to allow classification of their disease. Of the six instances of homozygosity for allele I, all were associated with the late-infantile form of the disease; of the eight instances of homozygosity for allele A, five were associated with the adult form and three with the juvenile form. When both alleles were present, the juvenile form resulted (seven of seven instances). Heterozygosity for allele I (with the other allele unknown) is usually associated with late-infantile disease, and heterozygosity for allele A with a later onset of the disease. The clinical variability can be explained by the different levels of residual arylsulfatase A activity associated with these genotypes. Conclusions. Like many lysosomal storage disorders, metachromatic leukodystrophy shows clinical heterogeneity that seems to reflect genetic heterogeneity. One of the known alleles (allele I) is associated with earlier and more severe disease than the other (allele A).	UNIV GOTTINGEN,DEPT BIOCHEM 2,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY	University of Gottingen								CLARKE JTR, 1989, AM J MED GENET, V33, P10, DOI 10.1002/ajmg.1320330104; GIESELMANN V, 1989, P NATL ACAD SCI USA, V86, P9436, DOI 10.1073/pnas.86.23.9436; GIESELMANN V, IN PRESS HUM GENET; GUSTAVSON KH, 1971, ACTA PAEDIATR SCAND, V60, P585, DOI 10.1111/j.1651-2227.1971.tb06994.x; HERZ B, 1984, HUM GENET, V66, P147, DOI 10.1007/BF00286589; HOHENSCHUTZ C, 1988, AM J MED GENET, V31, P169, DOI 10.1002/ajmg.1320310120; HOHENSCHUTZ C, 1989, HUM GENET, V82, P45, DOI 10.1007/BF00288270; KAPPLER J, IN PRESS HUM GENET; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KOLODNY EH, 1989, METABOLIC BASIS INHE, V2, P1721; KREYSING J, 1990, EUR J BIOCHEM, V191, P627, DOI 10.1111/j.1432-1033.1990.tb19167.x; KRIVIT W, 1990, NEW ENGL J MED, V322, P28, DOI 10.1056/NEJM199001043220106; STEIN C, 1989, J BIOL CHEM, V264, P1252; TABOR S, 1987, CURRENT PROTOCOLS MO; VONFIGURA K, 1983, P NATL ACAD SCI-BIOL, V80, P6066	15	229	234	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	1991	324	1					18	22		10.1056/NEJM199101033240104	http://dx.doi.org/10.1056/NEJM199101033240104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ503	1670590	Bronze			2022-12-01	WOS:A1991EQ50300004
J	RORSMAN, P; BOKVIST, K; AMMALA, C; ARKHAMMAR, P; BERGGREN, PO; LARSSON, O; WAHLANDER, K				RORSMAN, P; BOKVIST, K; AMMALA, C; ARKHAMMAR, P; BERGGREN, PO; LARSSON, O; WAHLANDER, K			ACTIVATION BY ADRENALINE OF A LOW-CONDUCTANCE G- PROTEIN-DEPENDENT K+ CHANNEL IN MOUSE PANCREATIC B-CELLS	NATURE			English	Article							INSULIN-SECRETING CELLS; FREE CA-2+ CONCENTRATION; BETA-CELLS; SULFONYLUREAS; INHIBITION; GALANIN	INSULIN is produced and secreted by the B cells in the endocrine pancreas. In vivo, insulin secretion is under the control of a number of metabolic, neural and hormonal substances. It is now clear that stimulation of insulin release by fuel secretagogues, such as glucose, involves the closure of K+ channels that are sensitive ot the intracellular ATP concentration (K(ATP) channels)1. This leads to membrane depolarization and the generation of Ca2+-dependent action potentials2. The mechanisms whereby hormones and neurotransmitters such as adrenaline, galanin and somatostatin, which are released by intraislet nerve endings and the pancreatic D cells, produce inhibition of insulin secretion are not clear3. Here we show that adrenaline suppresses B-cell electrical activity (and thus insulin secretion) by a G protein-dependent mechanism, which culminates in the activation of a sulphonylurea-insensitive low-conductance K+ channel distinct from the K(ATP) channel.	KAROLINSKA INST,DEPT ENDOCRINOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT PHARMACOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet	RORSMAN, P (corresponding author), GOTHENBURG UNIV,DEPT MED PHYS,BOX 33031,S-40033 GOTHENBURG,SWEDEN.		Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767; Berggren, Per-Olof/0000-0001-8991-413X				ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; DEWEILLE J, 1988, P NATL ACAD SCI USA, V85, P1312; DUNNE MJ, 1989, EMBO J, V8, P413, DOI 10.1002/j.1460-2075.1989.tb03392.x; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HILLE B, 1984, IONIC CHANNELS EXCIT, P211; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; NILSSON T, 1988, J BIOL CHEM, V263, P1855; SCHMIDANTOMARCHI H, 1987, J BIOL CHEM, V262, P15840; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506	13	121	125	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					77	79		10.1038/349077a0	http://dx.doi.org/10.1038/349077a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1898674				2022-12-01	WOS:A1991EQ60100056
J	SELBY, R; STARZL, TE; YUNIS, E; BROWN, BI; KENDALL, RS; TZAKIS, A				SELBY, R; STARZL, TE; YUNIS, E; BROWN, BI; KENDALL, RS; TZAKIS, A			LIVER-TRANSPLANTATION FOR TYPE-IV GLYCOGEN-STORAGE-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							BRANCHING ENZYME-ACTIVITY; PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; DEFICIENCY; VARIANT; LIGHT		UNIV PITTSBURGH,UNIV HLTH CTR PITTSBURGH,CHILDRENS HOSP,DEPT SURG,3601 5TH AVE,PITTSBURGH,PA 15213; UNIV PITTSBURGH,UNIV HLTH CTR PITTSBURGH,CHILDRENS HOSP,DEPT PATHOL,PITTSBURGH,PA 15213; MARY BRIDGE CHILDRENS HOSP,TACOMA,WA; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL)					NIDDK NIH HHS [DK 29961, R01 DK029961-19] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961, R37DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN DH, 1952, CARBOHYD METABOL, P28; BANNAYAN GA, 1976, AM J CLIN PATHOL, V66, P702; BROWN BI, 1989, AM J HUM GENET, V44, P378; BROWN BI, 1966, P NATL ACAD SCI USA, V56, P725, DOI 10.1073/pnas.56.2.725; BROWN BI, 1986, MYOLOGY, P1653; BROWN DH, 1983, BIOCHEM BIOPH RES CO, V111, P636, DOI 10.1016/0006-291X(83)90354-6; FERGUSON IT, 1983, J NEUROL SCI, V60, P337, DOI 10.1016/0022-510X(83)90144-2; GREENE GM, 1987, ARCH PATHOL LAB MED, V111, P977; GREENE HL, 1988, HEPATOLOGY, V8, P302, DOI 10.1002/hep.1840080219; GUERRA AS, 1986, EUR J PEDIATR, V145, P179, DOI 10.1007/BF00446059; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HERS HG, 1989, METABOLIC BASIS INHE, V1, P425; ILLINGWORTH B, 1952, J BIOL CHEM, V199, P653; ISHIHARA T, 1975, ACTA PATHOL JAPON, V25, P613; ISHIHARA T, 1987, ACTA PATHOL JAPON, V37, P1591; MAZZAFERRO V, 1990, SURGERY, V107, P533; MCMASTER KR, 1979, ARCH PATHOL LAB MED, V103, P105; REED GB, 1968, LAB INVEST, V19, P546; SCHOCHET SS, 1970, ARCH PATHOL, V90, P354; SERVIDEI S, 1987, J PEDIATR-US, V111, P51, DOI 10.1016/S0022-3476(87)80341-4; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STARZL TE, 1976, LANCET, V1, P821; STARZL TE, 1989, NEW ENGL J MED, V321, P1014, DOI 10.1056/NEJM198910123211505; STARZL TE, 1979, GASTROENTEROLOGY, V77, P375; STARZL TE, IN PRESS TRANSPLANTA; ZELLWEGE.H, 1972, J PEDIATR-US, V80, P842	26	49	49	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	1991	324	1					39	42		10.1056/NEJM199101033240107	http://dx.doi.org/10.1056/NEJM199101033240107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ503	1984162	Green Accepted			2022-12-01	WOS:A1991EQ50300007
J	SMITH, JM; DOWSON, CG; SPRATT, BG				SMITH, JM; DOWSON, CG; SPRATT, BG			LOCALIZED SEX IN BACTERIA	NATURE			English	Review							PENICILLIN-BINDING PROTEINS; ESCHERICHIA-COLI; NEISSERIA-MENINGITIDIS; HEMOPHILUS-INFLUENZAE; GENETIC DIVERSITY; STRAINS; DNA; TRANSFORMATION; RECOMBINATION; GONORRHOEAE	Electrophoretic studies suggest that bacterial populations consist of a number of independent clones and that genetic recombination is rare in nature. But DNA sequencing reveals that individual bacterial genes have a mosaic structure that could have arisen only by recombination. How can these observations be reconciled and what is their relevance to prokaryotic evolution?			SMITH, JM (corresponding author), UNIV SUSSEX,SCH BIOL SCI,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.		Spratt, Brian G/A-1676-2009; Dowson, Christopher/ABG-5083-2021; Dowson, Chris/N-6195-2014	Dowson, Christopher/0000-0002-8294-8836; Dowson, Chris/0000-0002-8294-8836				ARTHUR M, 1990, INFECT IMMUN, V58, P471, DOI 10.1128/IAI.58.2.471-479.1990; BELTRAN P, 1988, P NATL ACAD SCI USA, V85, P7753, DOI 10.1073/pnas.85.20.7753; CAUGANT DA, 1987, J BACTERIOL, V169, P2781, DOI 10.1128/jb.169.6.2781-2792.1987; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; CERRITELLI S, 1989, P NATL ACAD SCI USA, V86, P9223, DOI 10.1073/pnas.86.23.9223; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; DOWSON CG, 1990, P NATL ACAD SCI USA, V87, P5858, DOI 10.1073/pnas.87.15.5858; DUBOSE RF, 1988, P NATL ACAD SCI USA, V85, P7036, DOI 10.1073/pnas.85.18.7036; DYKHUIZEN DE, 1986, GENETICS, V113, P871; GIBBS CP, 1989, NATURE, V338, P651, DOI 10.1038/338651a0; Griffith F, 1928, J HYG-CAMBRIDGE, V27, P113, DOI 10.1017/S0022172400031879; KROLL JS, 1990, J BACTERIOL, V172, P1374, DOI 10.1128/jb.172.3.1374-1379.1990; LACKS SA, 1986, CELL, V46, P993, DOI 10.1016/0092-8674(86)90698-7; Levin B. R., 1988, EVOLUTION SEX, P194; MARCA RL, IN PRESS ANTIMICROB; MICHOD RE, 1988, GENETICS, V118, P31; MILKMAN R, 1983, SCIENCE, V221, P378, DOI 10.1126/science.6346486; MUSSER JM, 1988, P NATL ACAD SCI USA, V85, P7758, DOI 10.1073/pnas.85.20.7758; MUSSER JM, 1985, P NATL ACAD SCI USA, V82, P5078, DOI 10.1073/pnas.82.15.5078; OLYHOEK T, 1987, REV INFECT DIS, V9, P665; ORSKOV F, 1983, J INFECT DIS, V148, P346, DOI 10.1093/infdis/148.2.346; PLOS K, 1989, INFECT IMMUN, V57, P1604, DOI 10.1128/IAI.57.5.1604-1611.1989; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; SAWYER S, 1989, MOL BIOL EVOL, V6, P526; SEIFERT HS, 1988, NATURE, V336, P392, DOI 10.1038/336392a0; Selander R.K., 1987, ESCHERICHIA COLI SAL, P1625; SELANDER RK, 1980, SCIENCE, V210, P545, DOI 10.1126/science.6999623; SHARP PM, 1987, MOL BIOL EVOL, V4, P222; SMITH NH, 1990, J BACTERIOL, V172, P2209, DOI 10.1128/jb.172.5.2209-2216.1990; SPRATT BG, 1988, REV INFECT DIS, V10, P699; SPRATT BG, 1988, NATURE, V332, P173, DOI 10.1038/332173a0; SPRATT BG, 1989, P NATL ACAD SCI USA, V86, P8988, DOI 10.1073/pnas.86.22.8988; SPRATT BG, 1989, HDB EXPT PHARM, V91, P77; STEPHENS JC, 1985, MOL BIOL EVOL, V2, P539; STEWART GJ, 1986, ANNU REV MICROBIOL, V40, P211, DOI 10.1146/annurev.mi.40.100186.001235; STOLTZFUS A, 1988, GENETICS, V120, P345; WHITTAM TS, 1983, P NATL ACAD SCI-BIOL, V80, P1751, DOI 10.1073/pnas.80.6.1751; WOJCIECHOWSKI MF, 1989, GENETICS, V121, P411	38	288	299	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					29	31		10.1038/349029a0	http://dx.doi.org/10.1038/349029a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1985260				2022-12-01	WOS:A1991EQ60100040
J	SVENSSON, BG; NILSSON, A; HANSSON, M; RAPPE, C; AKESSON, B; SKERFVING, S				SVENSSON, BG; NILSSON, A; HANSSON, M; RAPPE, C; AKESSON, B; SKERFVING, S			EXPOSURE TO DIOXINS AND DIBENZOFURANS THROUGH THE CONSUMPTION OF FISH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; POLYCHLORINATED-BIPHENYLS; ADIPOSE-TISSUE; VIETNAM VETERANS; MATCHED CONTROLS; BLOOD; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; MORTALITY; SAMPLES; PCDDS	Background. In some regions, including the Baltic Sea, fatty fish such as salmon and herring contain high levels of polychlorinated dibenzodioxins and dibenzofurans. We investigated human exposure to these potentially toxic substances in relation to the consumption of fish from the Baltic Sea. Methods. Plasma levels of 10 different dibenzofurans and 7 dioxins were analyzed in three groups of Swedish men: one group with a high intake of fish (fish eaten almost daily; n = 11), one with a moderate intake of fish (about once per week; n = 9), and one with no consumption of fish (usually because of allergy; n = 9). Results. Plasma levels of several of the compounds we measured were higher in the men with a high intake of fish than in those who consumed moderate amounts, and the levels were higher in those who ate moderate amounts of fish than in those who ate none. The median amounts of the most toxic dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin) were 8.0 pg per gram of plasma lipid (range, 2.0 to 13) in the high-intake group, 2.6 pg per gram (range, 1.2 to 4.2) in the moderate-intake group, and 1.8 pg per gram (range, 1.0 to 2.5) in the nonconsumers (P = 0.001 and 0.02, respectively). There were consistent and statistically significant associations between the reported amount of fish eaten and the plasma levels of several of the dibenzofurans and dioxins. Conclusions. Contaminated fish such as those from the Baltic Sea are an important source of exposure to polychlorinated dibenzofurans and dibenzodioxins in persons who eat fish regularly. However, the clinical consequences of such exposure remain uncertain.	UNIV LUND,DEPT MED & PHYSIOL CHEM,S-22101 LUND,SWEDEN; UMEA UNIV,INST ENVIRONM CHEM,S-90187 UMEA,SWEDEN	Lund University; Umea University	SVENSSON, BG (corresponding author), UNIV LUND HOSP,DEPT OCCUPAT & ENVIRONM MED,S-22185 LUND,SWEDEN.		Akesson, Bjorn/Q-9163-2017					ASPLUND L, 1990, CHEMOSPHERE, V20, P1481, DOI 10.1016/0045-6535(90)90301-9; BERGQVIST PA, 1989, CHEMOSPHERE, V19, P513, DOI 10.1016/0045-6535(89)90361-5; CHEN PHS, 1984, AM J IND MED, V5, P133; EKSTROM B, 1989, EUR J CLIN INVEST, V19, P259, DOI 10.1111/j.1365-2362.1989.tb00228.x; FEIN GG, 1984, J PEDIATR-US, V105, P315, DOI 10.1016/S0022-3476(84)80139-0; HAGBERG J, 1987, OKAD DIOXINHALT BLOD, P207; KAHN PC, 1988, JAMA-J AM MED ASSOC, V259, P1661, DOI 10.1001/jama.259.11.1661; KOLMODIN-HEDMAN B, 1973, Work-Environment-Health, V10, P100; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KUEHL DW, 1989, CHEMOSPHERE, V18, P1997, DOI 10.1016/0045-6535(89)90483-9; LINDSTROM G, 1988, THESIS U UMEA UMEA; MASUDA Y, 1984, AM J IND MED, V5, P31; NYGREN M, 1988, CHEMOSPHERE, V17, P1663, DOI 10.1016/0045-6535(88)90095-1; PAPKE O, 1989, CHEMOSPHERE, V19, P941, DOI 10.1016/0045-6535(89)90437-2; PATTERSON DG, 1986, JAMA-J AM MED ASSOC, V256, P2683, DOI 10.1001/jama.256.19.2683; PATTERSON DG, 1989, AM J IND MED, V16, P135, DOI 10.1002/ajim.4700160205; RAPPE C, 1990, CHEMOSPHERE, V20, P1649, DOI 10.1016/0045-6535(90)90325-N; RAPPE C, 1984, ENVIRON SCI TECHNOL, V18, pA78, DOI 10.1021/es00121a711; RAPPE C, 1989, CHEMOSPHERE, V18, P651, DOI 10.1016/0045-6535(89)90178-1; RAPPE C, 1987, ENVIRON SCI TECHNOL, V21, P964, DOI 10.1021/es50001a009; RAPPE C, 1982, CHLORINATED DIOXINS, P495; RONDAHL L, 1989, IVL PUBLICATION B, V951; SCHWARTZ PM, 1983, AM J PUBLIC HEALTH, V73, P293, DOI 10.2105/AJPH.73.3.293; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; SVENSSON BG, 1987, SCI TOTAL ENVIRON, V67, P101, DOI 10.1016/0048-9697(87)90204-X; YRJANHEIKKI E, IN PRESS WHO REG PUB; 1988, NORDISK DIOXINRISKBE, P7	28	139	145	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	1991	324	1					8	12		10.1056/NEJM199101033240102	http://dx.doi.org/10.1056/NEJM199101033240102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ503	1898530	Bronze			2022-12-01	WOS:A1991EQ50300002
J	VONMOLLARD, GF; SUDHOF, TC; JAHN, R				VONMOLLARD, GF; SUDHOF, TC; JAHN, R			A SMALL GTP-BINDING PROTEIN DISSOCIATES FROM SYNAPTIC VESICLES DURING EXOCYTOSIS	NATURE			English	Article							SECRETION; MEMBRANE; GLUTAMATE; SUGGESTS; CALCIUM; RELEASE	LOW-molecular-weight GTP-binding proteins are strong candidates for regulators of membrane traffic1-3. In yeast, mutations in the sec4 or ypt1 genes encoding small GTP-binding proteins inhibit constitutive membrane flow at the plasma membrane or Golgi complex, respectively4-6. It has been suggested that membrane fusion-fission events are regulated by cycling of small GTP-binding proteins between a membrane-bound and free state7, but although most of these small proteins are found in both soluble and tightly membrane-bound forms, there is no direct evidence to support such cycling. In rat brain a small GTP-binding protein, rab3A, is exclusively associated with synaptic vesicles, the secretory organelles of nerve terminals8,9. Here we use isolated nerve terminals to study the fate of rab3A during synaptic vesicle exocytosis. We find that rab3A dissociates quantitatively from the vesicle membrane after Ca2+-dependent exocytosis and that this dissociation is partially reversible during recovery after stimulation. These results are direct evidence for an association-dissociation cycle of a small GTP-binding protein during traffic of its host membrane.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Max Planck Society; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			von Mollard, Gabriele Fischer/O-9778-2019; von Mollard, Gabriele Fischer/A-3935-2012	von Mollard, Gabriele Fischer/0000-0003-3236-1401; von Mollard, Gabriele Fischer/0000-0003-3236-1401; Jahn, Reinhard/0000-0003-1542-3498				ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; DECAMILLI P, 1990, REV PHYSL, V52, P625; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; MCMAHON HT, IN PRESS J NEUROCHEM; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9	20	303	308	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					79	81		10.1038/349079a0	http://dx.doi.org/10.1038/349079a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1845915				2022-12-01	WOS:A1991EQ60100057
J	WEIDNER, N; SEMPLE, JP; WELCH, WR; FOLKMAN, J				WEIDNER, N; SEMPLE, JP; WELCH, WR; FOLKMAN, J			TUMOR ANGIOGENESIS AND METASTASIS - CORRELATION IN INVASIVE BREAST-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRENEOPLASTIC LESIONS; GROWTH-FACTOR; MARKER; NEOVASCULARIZATION; VESSELS; CANCER; CELLS; MELANOMA; MEMBRANE; BIOLOGY	Background. Experimental evidence suggests that the growth of a tumor beyond a certain size requires angiogenesis, which may also permit metastasis. To investigate how tumor angiogenesis correlates with metastases in breast carcinoma, we counted microvessels (capillaries and venules) and graded the density of microvessels within the initial invasive carcinomas of 49 patients (30 with metastases and 19 without). Methods. Using light microscopy, we highlighted the vessels by staining their endothelial cells immunocytochemically for factor VIII. The microvessels were carefully counted (per 200 x field), and their density was graded (1 to 4+), in the most active areas of neovascularization, without knowledge of the outcome in the patient, the presence or absence of metastases, or any other pertinent variable. Results. Both microvessel counts and density grades correlated with metastatic disease. The mean (+/- SD) count and grade in the patients with metastases were 101 +/- 49.3 and 2.95 +/- 1.00 vessels, respectively. The corresponding values in the patients without metastases were significantly lower - 45 +/- 21.1 and 1.38 +/- 0.82 (P = 0.003 and P less-than-or-equal-to 0.001, respectively). For each 10-microvessel increase in the count per 200 x field, there was a 1.59-fold increase in the risk of metastasis (95 percent confidence interval, 1.19 to 2.12; P = 0.003). The microvessel count and density grade also correlated with distant metastases. For each 10-microvessel increase in the vessel count per 200 x field, there was a 1.17-fold increase in the risk of distant metastasis (95 percent confidence interval, 1.02 to 1.34; P = 0.029). Conclusions. The number of microvessels per 200 x field in the areas of most intensive neovascularization in an invasive breast carcinoma may be an independent predictor of metastatic disease either in axillary lymph nodes or at distant sites (or both). Assessment of tumor angiogenesis may therefore prove valuable in selecting patients with early breast carcinoma for aggressive therapy.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	WEIDNER, N (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,75 FRANCIS ST,BOSTON,MA 02115, USA.				NCI NIH HHS [CA-37395-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037395, R01CA037395] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BREM SS, 1978, CANCER, V41, P239, DOI 10.1002/1097-0142(197801)41:1<239::AID-CNCR2820410133>3.0.CO;2-X; BREM SS, 1977, SCIENCE, V195, P880, DOI 10.1126/science.402692; CHODAK GW, 1980, ANN SURG, V192, P762, DOI 10.1097/00000658-198012000-00012; Cox DR, 2018, ANAL BINARY DATA; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Folkman J., 1987, THROMB DIATH HAEMO, P583; FOLKMAN J, 1989, NATURE, P339; HERLYN M, 1987, LAB INVEST, V56, P461; JENSEN HM, 1982, SCIENCE, V218, P293, DOI 10.1126/science.6181563; JENSEN HM, 1987, ANGIOGENESIS MECHANI, P155; LEDOUSSAL V, 1989, CANCER, V64, P1914, DOI 10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G; LIOTTA LA, 1974, CANCER RES, V34, P997; LIOTTA LA, 1976, CANCER RES, V36, P889; MOSCATELLI D, 1981, J CELL BIOL, V91, pA201; NAGY J A, 1988, Biochimica et Biophysica Acta, V948, P305; NICHOLSON GL, 1979, SCI AM, V240, P66; PINKUS GS, 1986, AM J CLIN PATHOL, V85, P269, DOI 10.1093/ajcp/85.3.269; POLVERINI PJ, 1984, LAB INVEST, V51, P635; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SILLMAN F, 1981, AM J OBSTET GYNECOL, V139, P154, DOI 10.1016/0002-9378(81)90438-5; SMITH SS, 1970, CAN J OPHTHALMOLOGY, V5, P175; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; SRIVASTAVA A, 1986, EUR J CANCER CLIN ON, V22, P1205, DOI 10.1016/0277-5379(86)90322-6; WEISS L, 1976, FUNDAMENTAL ASPECTS, P51; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314	29	4981	5616	7	331	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	1991	324	1					1	8		10.1056/NEJM199101033240101	http://dx.doi.org/10.1056/NEJM199101033240101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ503	1701519	Bronze			2022-12-01	WOS:A1991EQ50300001
J	WU, L; SCOLLAY, R; EGERTON, M; PEARSE, M; SPANGRUDE, GJ; SHORTMAN, K				WU, L; SCOLLAY, R; EGERTON, M; PEARSE, M; SPANGRUDE, GJ; SHORTMAN, K			CD4 EXPRESSED ON EARLIEST T-LINEAGE PRECURSOR CELLS IN THE ADULT MURINE THYMUS	NATURE			English	Article							HOMING PROGENITOR CELLS; INTERLEUKIN-2 RECEPTOR; MONOCLONAL-ANTIBODIES; PGP-1 GLYCOPROTEIN; MOUSE THYMUS; STEM-CELLS; THYMOCYTES; SURFACE; ANTIGEN; SUBPOPULATIONS	A CONTINUOUS but low input of stem cells or 'prothymocytes' is necessary to maintain T-cell development in the adult thymus1, but the colonizing cell has not been characterized. Precursors of T cells have been found in the minor CD4-8- population2 of thymocytes, but even the earliest cells of this population already have partially rearranged T-cell antigen receptor (TCR) genes3. We now demonstrate that the thymus contains a minute population of lymphoid cells similar in some but not all respects to bone marrow-derived haemopoietic stem cells. This population has TCR genes in a germline state. It gives a slow but extensive reconstitution of both alpha-beta and gamma-delta-lineages on transfer into an irradiated thymus, with kinetics indicating that it includes the earliest intrathymic precursor cells so far isolated. Surprisingly, these cells express low surface levels of the mature T-cell marker CD4.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute				Shortman, Ken/0000-0002-9107-3007				CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; Coffman R L, 1982, Immunol Rev, V69, P5; CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FOWLKES BJ, 1985, J EXP MED, V162, P802, DOI 10.1084/jem.162.3.802; FREDRICKSON GG, 1989, J EXP MED, V169, P1473, DOI 10.1084/jem.169.4.1473; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P3301, DOI 10.1073/pnas.86.9.3301; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P545, DOI 10.1007/BF01572589; HOLMES KL, 1986, J IMMUNOL, V137, P679; HYMAN R, 1986, CELL IMMUNOL, V101, P320, DOI 10.1016/0008-8749(86)90145-0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LESLEY J, 1985, CELL IMMUNOL, V91, P397, DOI 10.1016/0008-8749(85)90237-0; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; MIESCHER GC, 1989, IMMUNOL LETT, V23, P113, DOI 10.1016/0165-2478(89)90122-3; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; PEARSE MJ, 1988, IMMUNOL LETT, V18, P219, DOI 10.1016/0165-2478(88)90022-3; QUIN S, 1987, EUR J IMMUNOL, V17, P1159; SCOLLAY R, 1986, IMMUNOL REV, V91, P129, DOI 10.1111/j.1600-065X.1986.tb01487.x; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; Shortman K, 1990, Semin Immunol, V2, P3; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1990, EXP HEMATOL, V18, P920; SPANGRUDE GJ, IN PRESS J IMMUN; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; WILSON A, 1988, J IMMUNOL, V140, P1461; YAGITA H, 1989, EUR J IMMUNOL, V19, P2211, DOI 10.1002/eji.1830191206; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645	30	339	345	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					71	74		10.1038/349071a0	http://dx.doi.org/10.1038/349071a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1702186				2022-12-01	WOS:A1991EQ60100054
J	GAFNI, RI				GAFNI, RI			MOTHERHOOD IN MEDICAL-SCHOOL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GAFNI, RI (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,PHILADELPHIA,PA 19140, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					116	116		10.1001/jama.265.1.116	http://dx.doi.org/10.1001/jama.265.1.116			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EP555	1984109				2022-12-01	WOS:A1991EP55500042
J	HOOTON, TM; HILLIER, S; JOHNSON, C; ROBERTS, PL; STAMM, WE				HOOTON, TM; HILLIER, S; JOHNSON, C; ROBERTS, PL; STAMM, WE			ESCHERICHIA-COLI BACTERIURIA AND CONTRACEPTIVE METHOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT INFECTION; SEXUAL INTERCOURSE; DIAPHRAGM USE; RISK-FACTORS; YOUNG-WOMEN; COLONIZATION; ASSOCIATION; FLORA	We evaluated the effects of contraceptive method on the occurrence of bacteriuria and vaginal colonization with Escherichia coli in 104 women who were evaluated prior to having sexual intercourse, the morning after intercourse, and 24 hours later. After intercourse, the prevalence of E coli bacteriuria increased slightly in oral contraceptive users but dramatically in both foam and condom users and diaphragm-spermicide users. Twenty-four hours later, the prevalence of bacteriuria remained significantly elevated only in the latter two groups. Similarly, vaginal colonization with E coli was more dramatic and persistent in users of diaphragm-spermicide and foam and condoms. Vaginal colonization with Candida species, enterococci, and staphylococci also increased significantly in diaphragm-spermicide users after intercourse. We conclude that use of the diaphragm with spermicidal jelly or use of a spermicidal foam with a condom markedly alters normal vaginal flora and strongly predisposes users to the development of vaginal colonization and bacteriuria with E coli.	UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT OBSTET & GYNECOL,SEATTLE,WA 98104	Harborview Medical Center; University of Washington; University of Washington Seattle	HOOTON, TM (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT MED,325 9TH AVE,SEATTLE,WA 98104, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI012192] Funding Source: NIH RePORTER; NIAID NIH HHS [AI12192] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADATTO K, 1979, JAMA-J AM MED ASSOC, V241, P2525, DOI 10.1001/jama.241.23.2525; BUCKLEY RM, 1978, NEW ENGL J MED, V298, P321, DOI 10.1056/NEJM197802092980607; ELSTER AB, 1981, SOUTHERN MED J, V74, P704, DOI 10.1097/00007611-198106000-00018; EVANS DA, 1978, NEW ENGL J MED, V299, P536, DOI 10.1056/NEJM197809072991009; FIHN SD, 1986, J UROLOGY, V136, P853, DOI 10.1016/S0022-5347(17)45104-4; FIHN SD, 1985, JAMA-J AM MED ASSOC, V254, P240, DOI 10.1001/jama.254.2.240; FOXMAN B, 1985, AM J PUBLIC HEALTH, V75, P1308, DOI 10.2105/AJPH.75.11.1308; HSIAO V, 1986, J ADOLESCENT HEALTH, V7, P381, DOI 10.1016/S0197-0070(86)80238-8; KROHN MA, 1989, J CLIN MICROBIOL, V27, P1266, DOI 10.1128/JCM.27.6.1266-1271.1989; KUNIN CM, 1968, NEW ENGL J MED, V278, P635, DOI 10.1056/NEJM196803212781201; KUNIN CM, 1980, JAMA-J AM MED ASSOC, V243, P134; LEIBOVICI L, 1987, ARCH INTERN MED, V147, P345, DOI 10.1001/archinte.147.2.345; MCGROARTY JA, 1990, CURR MICROBIOL, V21, P219, DOI 10.1007/BF02092159; NICOLLE LE, 1982, J INFECT DIS, V146, P579, DOI 10.1093/infdis/146.5.579; PEDDIE BA, 1984, AUST NZ J OBSTET GYN, V24, P217, DOI 10.1111/j.1479-828X.1984.tb01494.x; PERCIVALSMITH R, 1983, CONTRACEPTION, V27, P497, DOI 10.1016/0010-7824(83)90046-X; REMIS RS, 1987, AM J EPIDEMIOL, V126, P685, DOI 10.1093/oxfordjournals.aje.a114708; Sobel J D, 1987, Infect Dis Clin North Am, V1, P751; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STONE KM, 1986, AM J OBSTET GYNECOL, V155, P180, DOI 10.1016/0002-9378(86)90108-0; STROM BL, 1987, ANN INTERN MED, V107, P816, DOI 10.7326/0003-4819-107-6-816; Svanborg Eden C, 1987, Infect Dis Clin North Am, V1, P731; VESSEY MP, 1987, INT J EPIDEMIOL, V16, P441, DOI 10.1093/ije/16.3.441; 1988, MMWR, V37, P133; 1985, ADV DATA, V128, P1	25	102	104	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					64	69		10.1001/jama.265.1.64	http://dx.doi.org/10.1001/jama.265.1.64			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1859519				2022-12-01	WOS:A1991EP55500029
J	MILLS, JL; KLEBANOFF, MA; GRAUBARD, BI; CAREY, JC; BERENDES, HW				MILLS, JL; KLEBANOFF, MA; GRAUBARD, BI; CAREY, JC; BERENDES, HW			BARRIER CONTRACEPTIVE METHODS AND PREECLAMPSIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRE-ECLAMPSIA	Recent investigations have suggested that women who use barrier methods of contraception may be at increased risk for preeclampsia. We used data from two prospective pregnancy studies to examine the relationship between contraceptive use before conception and preeclampsia. The preeclampsia rates among women using barrier contraceptives were not significantly higher than the rates in women using nonbarrier contraceptives or the rates in women using no contraceptives in either study. The odds ratios for preeclampsia in barrier contraceptive users in the two studies were 0.89 (95% confidence interval [Cl], 0.71 to 1.12) and 0.85 (95% Cl, 0.49 to 1.45) compared with nonbarrier contraceptive users and 0.91 (95% Cl, 0.71 to 1.16) and 0.81 (95% Cl, 0.48 to 1.35) compared with women using no contraceptives. After adjusting for other risk factors, we found no association between preeclampsia and barrier contraceptive use. Additional studies are needed to resolve this issues; however, we would recommend that women not be advised to avoid barrier contraceptives unless more data linking their use to preeclampsia appear.	NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MILLS, JL (corresponding author), NICHHD,PREVENT RES PROGRAM,EPN BLDG,ROOM 640,BETHESDA,MD 20892, USA.			Mills, James/0000-0003-4496-332X				ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; BEER AE, 1978, SEMIN PERINATOL, V2, P39; CHESLEY LC, 1984, CLIN OBSTET GYNECOL, V27, P801, DOI 10.1097/00003081-198412000-00004; Feeney JG, 1980, P 1 C INT SOC STUD H, P41; KONOFFCOHEN HS, 1989, JAMA-J AM MED ASSOC, V262, P3143; MARTI JJ, 1977, AM J OBSTET GYNECOL, V128, P489, DOI 10.1016/0002-9378(77)90030-8; Mosher W. D., 1990, ADV DATA, V182, P1; SCOTT JR, 1976, AM J OBSTET GYNECOL, V125, P418, DOI 10.1016/0002-9378(76)90579-2; SERHAL PF, 1987, LANCET, V2, P744; WOOLF B, 1956, ANN HUM GENET, V20, P309; 1983, BMDP BIOMEDICAL CO P; 1985, SAS USERS GUIDE STAT	12	23	23	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					70	73		10.1001/jama.265.1.70	http://dx.doi.org/10.1001/jama.265.1.70			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1984127				2022-12-01	WOS:A1991EP55500030
J	RAUB, W				RAUB, W			NEW REPORT ON HYPERTENSION IN PREGNANCY PUBLISHED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH, BLDG 31, ROOM 2B23, BETHESDA, MD 20892 USA.							1990, AM J OBSTET GYNECOL, V63, P1689	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					19	19						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1984118				2022-12-01	WOS:A1991EP55500009
J	RAUB, W				RAUB, W			RESEARCH ON EOSINOPHILIA-MYALGIA-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH, BLDG 31, ROOM 2B23, BETHESDA, MD 20892 USA.							1990, P NATL ACAD SCI USA, V87, P8647	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					19	19						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1984118				2022-12-01	WOS:A1991EP55500008
J	RAUB, W				RAUB, W			TAMOXIFEN AND CHEMOTHERAPY MORE EFFECTIVE THAN TAMOXIFEN ALONE IN TREATING BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH, BLDG 31, ROOM 2B23, BETHESDA, MD 20892 USA.							1990, J CLIN ONCOL, V8, P1005	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					19	19						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1984118				2022-12-01	WOS:A1991EP55500007
J	RAUB, W				RAUB, W			GENETIC MUTATION IN FAMILIAL AORTIC-ANEURYSMS IDENTIFIED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH, BLDG 31, ROOM 2B23, BETHESDA, MD 20892 USA.							1990, J CLIN INVEST, V86, P1465	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					19	19						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1984118				2022-12-01	WOS:A1991EP55500006
J	SCHULTZ, PN; SOBOL, WM				SCHULTZ, PN; SOBOL, WM			ANGIOID STREAKS AND PSEUDOXANTHOMA ELASTICUM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									UNIV IOWA HOSP & CLIN,DEPT OPHTHALMOL,RETINA SERV,IOWA CITY,IA 52242	University of Iowa								CLARKSON JG, 1982, SURV OPHTHALMOL, V26, P235, DOI 10.1016/0039-6257(82)90158-8; CONNOR PJ, 1961, AM J MED, V30, P537, DOI 10.1016/0002-9343(61)90078-X; ESTES JW, 1968, ANN INTERN MED, V68, P1237, DOI 10.7326/0003-4819-68-6-1237; LEBWOHL M, 1987, NEW ENGL J MED, V317, P347, DOI 10.1056/NEJM198708063170604; LEBWOHL MG, 1982, NEW ENGL J MED, V307, P228, DOI 10.1056/NEJM198207223070406; MCDONALD HR, 1988, OPHTHALMOLOGY, V95, P306; POPE FM, 1974, J MED GENET, V11, P152, DOI 10.1136/jmg.11.2.152; Scholz R, 1941, ARCH OPHTHALMOL-CHIC, V26, P677; SHIELDS JA, 1975, BRIT J OPHTHALMOL, V59, P257, DOI 10.1136/bjo.59.5.257; Singerman L J, 1981, Retina, V1, P75	10	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					45	45						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1984125				2022-12-01	WOS:A1991EP55500027
J	STERN, RS; BOUDREAUX, C; ARNDT, KA				STERN, RS; BOUDREAUX, C; ARNDT, KA			DIAGNOSTIC-ACCURACY AND APPROPRIATENESS OF CARE FOR SEBORRHEIC KERATOSES - A PILOT-STUDY OF AN APPROACH TO QUALITY ASSURANCE FOR CUTANEOUS SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In 1985 there were more than 40 million visits for ambulatory surgical procedures in the United States. Although benign cutaneous lesions are among the most frequent conditions to receive surgical treatment in ambulatory settings, their treatment is seldom subject to peer review. In this pilot study we assessed diagnostic accuracy and appropriateness of care using information available from the surgical pathology laboratory. We assessed these two measures of physician performance of 527 seborrheic keratoses removed by 133 clinicians affiliated with four different institutions. Overall, a correct preoperative diagnosis was provided in only 49% of cases. Dermatologists had the highest diagnostic accuracy (61% vs 35% for all other physicians). An appropriate procedure for the actual pathological diagnosis was performed in only 50% of cases. Lesions with a correct preoperative diagnosis were more than eight times more likely to receive appropriate care. Our data suggest that many clinicians fail to note a correct diagnosis of common cutaneous lesions before surgical removal, and many patients are treated with procedures that are more invasive than necessary for the final pathological diagnosis. Because the approach used in this pilot study relies on data already available, it has promise as a low-cost method of monitoring the quality of care of ambulatory surgery.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, CHARLES DANA RES INST, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	STERN, RS (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT DERMATOL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ARNDT KA, 1989, MANUAL DERMATOLOGIC, P106; CARO WA, 1985, DERMATOLOGY, P1533; CASHMORE RW, 1985, GERIATRICS, V40, P69; CLARK RA, 1983, J AM ACAD DERMATOL, V9, P787, DOI 10.1016/S0190-9622(83)70193-3; EPSTEIN E, 1969, J AMER MED ASSOC, V208, P1369; LEADER S, 1989, HEALTH AFFAIR, V8, P158, DOI 10.1377/hlthaff.8.1.158; LEDERMAN JS, 1985, J AM ACAD DERMATOL, V13, P983, DOI 10.1016/S0190-9622(85)70249-6; MOHS FE, 1970, J AMER MED ASSOC, V212, P1956; NORMAN GR, 1989, ARCH DERMATOL, V125, P1063, DOI 10.1001/archderm.125.8.1063; PALMER RH, 1988, INQUIRY-J HEALTH CAR, V25, P119; SRZEWIECKI KT, 1980, SCAND J PLAST RECONS, V14, P141; THOMPSON MS, 1984, AM J PUBLIC HEALTH, V74, P1244, DOI 10.2105/AJPH.74.11.1244; 1990, B AM ACAD DERMATOL S, V8, P12	13	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					74	77		10.1001/jama.265.1.74	http://dx.doi.org/10.1001/jama.265.1.74			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1824572				2022-12-01	WOS:A1991EP55500031
J	SULLIVAN, TJ				SULLIVAN, TJ			CROSS-REACTIONS AMONG FUROSEMIDE, HYDROCHLOROTHIAZIDE, AND SULFONAMIDES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							SUSCEPTIBILITY; SENSITIVITY				SULLIVAN, TJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DALLAS,TX 75235, USA.							ANDREWS AW, 1984, MUTAT RES, V135, P105, DOI 10.1016/0165-1218(84)90162-9; BARNHART ER, 1990, PHYSICIANS DESK REFE, P1046; BARNHART ER, 1989, PHYSICIANS DESK REFE, P1024; CARRINGTON DM, 1987, J ALLERGY CLIN IMMUN, V79, P442, DOI 10.1016/0091-6749(87)90361-7; GRUCHALLA R S, 1990, Journal of Allergy and Clinical Immunology, V85, P157; HANSBROUGH JR, 1987, J ALLERGY CLIN IMMUN, V80, P538, DOI 10.1016/0091-6749(87)90004-2; MITCHELL JR, 1976, J PHARMACOL EXP THER, V199, P41; MOSS C, 1985, CLIN EXP IMMUNOL, V61, P232; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; ROUJEAU JC, 1987, ARCH DERMATOL, V123, P1171, DOI 10.1001/archderm.123.9.1171; SCHNEIWEISS F, 1983, CLIN PHARMACY, V2, P510; SULLIVAN TJ, 1989, J ALLERGY CLIN IMMUN, V83, P270; SULLIVAN TJ, 1988, ALLERGY PRINCIPLES P, P1523	13	17	18	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					120	121		10.1001/jama.265.1.120	http://dx.doi.org/10.1001/jama.265.1.120			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1984112				2022-12-01	WOS:A1991EP55500045
J	HAYWARD, RA; SHAPIRO, MF				HAYWARD, RA; SHAPIRO, MF			A NATIONAL STUDY OF AIDS AND RESIDENCY TRAINING - EXPERIENCES, CONCERNS, AND CONSEQUENCES	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; NEEDLESTICK INJURIES; PHYSICIAN ATTITUDES; CARE; HOMOSEXUALITY; EPIDEMIC; MEDICINE; IMPACT	Objective: To examine residents' experiences in the care of patients with the acquired immunodeficiency syndrome (AIDS), and to examine factors that my influence their attitudes about such care. Design: Cross-sectional, self-administered questionnaire survey conducted in 1989. Participants: All senior internal medicine and family medicine residents in ten geographically representative states who were identified through the 1986 National Residency Matching Program. Measurements and Main Results: Seventy-four percent of residents reported that patients with AIDS accounted for 5% or more of general medicine admissions, and 50% of residents reported that they were currently following one or more human immunodeficiency virus (HIV)-infected patients in their continuity clinics. Among residents who had provided ambulatory care to patients with AIDS, 77% felt that it was an excellent educational experience, and among those who planned to do general primary care in their future practices, 74% planned on providing primary care to patients with AIDS. However, 61% expressed concerns about the adequacy of their training in AIDS ambulatory care. A greater amount of contact with outpatients who had AIDS, but not with inpatients who had AIDS, was associated with residents' intending to provide AIDS primary care in their future practices. Among all residents, 23% reported that, if given a choice, they would not provide care to any patients with AIDS, and 23% reported that they would not work in an area with a high prevalence of AIDS because of concern about contracting the syndrome. Nine percent of residents reported that they had been exposed to a blood-contaminated needlestick from an HIV-seropositive patient. Conclusions: Although most residents have substantial contact with inpatients and outpatients with AIDS, most still find their education in AIDS ambulatory care to be deficient. A minority of residents would prefer not to care for patients with AIDS. Residency curricula should include training and experience in ambulatory AIDS care, explicitly address negative attitudes toward caring for patients with AIDS, and include programs to reduce needlestick exposures.	UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90024 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								AOUN H, 1989, NEW ENGL J MED, V321, P693, DOI 10.1056/NEJM198909073211020; COHEN PT, AIDS KNOWLEDGE BASE; COONEY TG, 1986, J GEN INTERN MED, V1, P339, DOI 10.1007/BF02596215; CROWLEY AE, 1988, 1988 1989 DIRECTORY; DONDERO TJ, 1989, 5TH INT C AIDS MONTR, P45; DOUGLAS CJ, 1985, HOSP COMMUNITY PSYCH, V36, P1309; EDMOND M, 1988, INFECT CONT HOSP EP, V9, P114, DOI 10.1086/645806; FREEMAN G, AIDS ALERT; GERBERDING JL, 1987, J INFECT DIS, V156, P861, DOI 10.1093/infdis/156.6.861; GOLDWATER PN, 1989, INFECT CONT HOSP EP, V10, P21, DOI 10.1086/645910; GOTTLIEB MS, AIDS CLIN DIGEST; HAYWARD RA, 1991, IN PRESS J GEN INTER, V6; HENDERSON DK, 1990, AIDS UPDATES, V3, P1; JAMES JS, AIDS TREATMENT NEWS; KELLY JA, 1987, J MED EDUC, V62, P549; KELLY JA, 1987, AM J PUBLIC HEALTH, V77, P789, DOI 10.2105/AJPH.77.7.789; KENNEDY DA, 1988, J HOSP INFECT, V12, P315, DOI 10.1016/0195-6701(88)90074-6; LIEU TA, 1989, ACAD MED, V64, P622, DOI 10.1097/00001888-198910000-00015; LINK RN, 1988, AM J PUBLIC HEALTH, V78, P455, DOI 10.2105/AJPH.78.4.455; LINN LS, 1989, ACAD MED, V64, P408, DOI 10.1097/00001888-198907000-00016; MATHEWS WC, 1986, WESTERN J MED, V144, P106; MCKUSICK L, 1986, W J MED, V144, P750; MELZER SM, 1989, PEDIATRICS, V84, P211; MIZES JS, 1984, PUBLIC OPIN QUART, V48, P794, DOI 10.1086/268885; MORGAN DR, 1988, J HOSP INFECT, V12, P301, DOI 10.1016/0195-6701(88)90072-2; NESS R, 1989, ACAD MED, V64, P588, DOI 10.1097/00001888-198910000-00009; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; PRICHARD JG, 1988, J FAM PRACTICE, V27, P637; RICHARDSON JL, 1987, MED CARE, V25, P675, DOI 10.1097/00005650-198708000-00001; ROSNER F, 1989, AM J MED, V87, P601, DOI 10.1016/S0002-9343(89)80630-8; SADOVSKY R, 1989, AM FAM PHYSICIAN, V40, P121; WACHTER RM, 1986, NEW ENGL J MED, V314, P177, DOI 10.1056/NEJM198601163140310; WHITE LJ, 1988, ANN INTERN MED, V108, P460, DOI 10.7326/0003-4819-108-3-460; WORMSER GP, 1989, POSTGRAD MED, V86, P174; 1989, HIV AIDS SURVEILLANC, P1; 1990, AIDS UPDATE, V3, P3; 1987, MED WORLD NEWS, V28, P12; 1989, AIDS PRIMARY CARE PR; 1986, PUB HLTH REP, V101, P341; 1990, MMWR, V39, P1	40	67	67	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1991	114	1					23	32		10.7326/0003-4819-114-1-23	http://dx.doi.org/10.7326/0003-4819-114-1-23			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ040	1983928				2022-12-01	WOS:A1991EQ04000004
J	MANGANO, DT; BROWNER, WS; HOLLENBERG, M; LONDON, MJ; TUBAU, JF; TATEO, IM				MANGANO, DT; BROWNER, WS; HOLLENBERG, M; LONDON, MJ; TUBAU, JF; TATEO, IM			ASSOCIATION OF PERIOPERATIVE MYOCARDIAL-ISCHEMIA WITH CARDIAC MORBIDITY AND MORTALITY IN MEN UNDERGOING NONCARDIAC SURGERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERIPHERAL VASCULAR-SURGERY; STABLE ANGINA; DAILY LIFE; RISK; INFARCTION; SILENT; EXERCISE; ANESTHESIA; DISEASE; ABNORMALITIES	Background. Adverse cardiac events are a major cause of morbidity and mortality after noncardiac surgery. It is necessary to determine the predictors of these outcomes in order to focus efforts on prevention and treatment. Patients undergoing noncardiac surgery sometimes have postoperative cardiac events. It would be helpful to know which patients are at highest risk. Methods. We prospectively studied 474 men with coronary artery disease (243) or at high risk for it (231) who were undergoing elective noncardiac surgery. We gathered historical, clinical, laboratory, and physiologic data during hospitalization and for 6 to 24 months after surgery. Myocardial ischemia was assessed by continuous electrocardiographic monitoring, beginning two days before surgery and continuing for two days after. Results. Eighty-three patients (18 percent) had post-operative cardiac events in the hospital that were classified as ischemic events (cardiac death, myocardial infarction, or unstable angina) (15 patients), congestive heart failure (30), or ventricular tachycardia (38). Postoperative myocardial ischemia occurred in 41 percent of the monitored patients and was associated with a 2.8-fold increase in the odds of all adverse cardiac outcomes (95 percent confidence interval, 1.6 to 4.9; P < 0.0002) and a 9.2-fold increase in the odds of an ischemic event (95 percent confidence interval, 2.0 to 42.0; P < 0.0004). Multivariate analysis showed no other clinical, histological, or perioperative variable to be independently associated with ischemic events, including cardiac-risk index, a history of previous myocardial infarction or congestive heart failure, or the occurrence of ischemia before or during surgery. Conclusions. In high-risk patients undergoing noncardiac surgery, early postoperative myocardial ischemia is an important correlate of adverse cardiac outcomes.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	MANGANO, DT (corresponding author), UNIV CALIF SAN FRANCISCO,VET AFFAIRS MED CTR 129,DEPT ANESTHESIA,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL36744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1963, ANESTHESIOLOGY, V24, P111; ARKINS R, 1964, JAMA-J AM MED ASSOC, V190, P485; ASHBURN WL, 1980, RADIOL CLIN N AM, V18, P467; BELLER GA, 1971, NEW ENGL J MED, V284, P989, DOI 10.1056/NEJM197105062841801; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; BRAUNWALD E, 1984, HEART DISEASE TXB CA, V1, P1; CARLINER NH, 1985, AM J CARDIOL, V56, P51, DOI 10.1016/0002-9149(85)90565-X; CHAITMAN BR, 1979, CIRCULATION, V59, P560, DOI 10.1161/01.CIR.59.3.560; CHIERCHIA S, 1983, J AM COLL CARDIOL, V1, P924, DOI 10.1016/S0735-1097(83)80211-3; COHEN M, 1987, J AM COLL CARDIOL, V10, P17, DOI 10.1016/S0735-1097(87)80154-7; COHN PF, 1983, J AM COLL CARDIOL, V1, P931, DOI 10.1016/S0735-1097(83)80212-5; COHN PF, 1988, ANN INTERN MED, V109, P312, DOI 10.7326/0003-4819-109-4-312; CUTLER BS, 1987, J VASC SURG, V5, P91; DEANFIELD JE, 1984, AM J CARDIOL, V54, P1195, DOI 10.1016/S0002-9149(84)80066-1; DEANFIELD JE, 1983, LANCET, V2, P753; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DROSTE C, 1983, J AM COLL CARDIOL, V1, P940, DOI 10.1016/S0735-1097(83)80214-9; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; EPSTEIN SE, 1988, NEW ENGL J MED, V318, P1038, DOI 10.1056/NEJM198804213181606; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; GLAZIER JJ, 1986, AM J CARDIOL, V58, P667, DOI 10.1016/0002-9149(86)90335-8; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; HARRISON DC, 1985, AM J CARDIOL, V56, pC10, DOI 10.1016/S0002-9149(85)80003-5; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KNIGHT AA, 1988, ANESTHESIOLOGY, V68, P681, DOI 10.1097/00000542-198805000-00005; KRUCOFF MW, 1987, J ELECTROCARDIOL, V20, P15; LONDON MJ, 1988, ANESTHESIOLOGY, V69, P232, DOI 10.1097/00000542-198808000-00013; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; RAO TLK, 1983, ANESTHESIOLOGY, V59, P499, DOI 10.1097/00000542-198312000-00003; SILICIANO D, 1990, OPIOIDS ANESTHESIA, V2, P164; SMITH TW, 1984, PROG CARDIOVASC DIS, V27, P21, DOI 10.1016/0033-0620(84)90018-5; STEEN PA, 1978, JAMA-J AM MED ASSOC, V239, P2566, DOI 10.1001/jama.239.24.2566; TARHAN S, 1972, J AMER MED ASSOC, V220, P1451, DOI 10.1001/jama.220.11.1451; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; UDELSMAN R, 1987, J CLIN ENDOCR METAB, V64, P986, DOI 10.1210/jcem-64-5-986; VONKNORRING J, 1981, SURGERY, V90, P55; ZIPES DP, 1984, HEART DISEASE TXB CA, V1, P683; 1978, MANUAL OPERATIONS, V2; 1989, DHHS PHS891232 NAT C, P10	44	759	795	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	1990	323	26					1781	1788		10.1056/NEJM199012273232601	http://dx.doi.org/10.1056/NEJM199012273232601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP376	2247116				2022-12-01	WOS:A1990EP37600001
J	NORTHWAY, WH; MOSS, RB; CARLISLE, KB; PARKER, BR; POPP, RL; PITLICK, PT; EICHLER, I; LAMM, RL; BROWN, BW				NORTHWAY, WH; MOSS, RB; CARLISLE, KB; PARKER, BR; POPP, RL; PITLICK, PT; EICHLER, I; LAMM, RL; BROWN, BW			LATE PULMONARY SEQUELAE OF BRONCHOPULMONARY DYSPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; LONG-TERM SURVIVORS; ARTIFICIAL-VENTILATION; MEXICAN-AMERICAN; EXPIRATORY FLOW; OXYGEN-TOXICITY; NORMAL-CHILDREN; LUNG-DISEASE; YOUNG-ADULTS; INFANTS	Background. Bronchopulmonary dysplasia is a chronic lung disease that often develops after mechanical ventilation in prematurely born infants with repiratory failure. It has become the most common form of chronic lung disease in infants in the United States. The long-term outcome for infants with bronchopulmonary dysplasia has not been determined. Methods. We studied the pulmonary function of 26 adolescents and young adults, born between 1964 and 1973, who had bronchopulmonary dysplasia in infancy. We compared the results with those in two control groups: 26 age-matched adolescents and young adults of similar birth weight and gestational age who had not undergone mechanical ventilation, and 53 age-matched normal subjects. Results. Sixty-eight percent of the subjects with bronchopulmonary dysplasia in infancy (17 of the 25 tested) had airway obstruction, including decreases in forced expiratory volume in one second, forced expiratory flow between 25 and 75 percent of vital capacity, and maximal expiratory flow velocity at 50 percent of vital capacity, as compared with both control groups (P < 0.0001 for all comparisons). Twenty-four percent of the subjects with bronchopulmonary dysplasia in infancy had fixed airway obstruction, and 52 percent had reactive airway disease, as indicated by their responses to the administration of methacholine or a bronchodilator. Hyperinflation (an increased ratio of residual volume to total lung capacity) was more frequent in the subjects with a history of bronchopulmonary dysplasia than in either the matched cohort (P < 0.0006) or the normal controls (P < 0.0004). Six of the subjects who had bronchopulmonary dysplasia in infancy had severe pulmonary dysfunction or current symptoms of respiratory difficulty. Conclusions. Most adolescents and young adults who had bronchopulmonary dysplasia in infancy have some degree of pulmonary dysfunction, consisting of airway obstruction, airway hyperreactivity, and hyperinflation. The clinical consequences of this dysfunction are not known.	STANFORD UNIV, MED CTR, DEPT PEDIAT, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DEPT MED, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DEPT HLTH RES & POLICY, STANFORD, CA 94305 USA; STANFORD UNIV, CHILDRENS HOSP, STANFORD, CA 94305 USA	Stanford University; Stanford University; Stanford University; Children's Hospital Los Angeles; Stanford University	NORTHWAY, WH (corresponding author), STANFORD UNIV, MED CTR, DEPT DIAGNOST RADIOL & NUCL MED, STANFORD, CA 94305 USA.		Moss, Richard B./S-9218-2019	Moss, Richard B./0000-0003-3611-4221	NHLBI NIH HHS [HL36796] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036796] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABMAN SH, 1984, J PEDIATR-US, V104, P928, DOI 10.1016/S0022-3476(84)80501-6; ANDREASSON B, 1989, ARCH DIS CHILD, V64, P108, DOI 10.1136/adc.64.1.108; BADER D, 1987, J PEDIATR-US, V110, P693, DOI 10.1016/S0022-3476(87)80004-5; BATES DV, 1971, RESPIRATORY FUNCTION, P93; BERMAN W, 1982, PEDIATRICS, V70, P708; BONIKOS DS, 1976, HUM PATHOL, V7, P643, DOI 10.1016/S0046-8177(76)80077-9; BONIKOS DS, 1976, AM J PATHOL, V85, P623; BOYD E, 1935, GROWTH SURFACE AREA, P132; BRYAN MH, 1973, PEDIATRICS, V52, P169; BURROWS B, 1977, AM REV RESPIR DIS, V115, P751; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; FARRELL PM, 1986, BRONCHOPULMONARY DYS, P3; FENN WO, 1965, HDB PHYSL 3, V11, P930; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GERHARDT T, 1987, J PEDIATR-US, V110, P448, DOI 10.1016/S0022-3476(87)80516-4; GROOTHUIS JR, 1988, PEDIATRICS, V82, P199; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HARROD JR, 1974, J PEDIATR-US, V84, P277, DOI 10.1016/S0022-3476(74)80623-2; HSI BP, 1983, J PEDIATR-US, V102, P860, DOI 10.1016/S0022-3476(83)80012-2; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; Kanner R.E., 1975, CLIN PULMONARY FUNCT; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; KURZNER SI, 1988, PEDIATRICS, V81, P379; LOEBER NV, 1980, CRIT CARE MED, V8, P596, DOI 10.1097/00003246-198010000-00013; MACLUSKY IB, 1986, PEDIATR PULM, V2, P94, DOI 10.1002/ppul.1950020207; MARKESTAD T, 1981, J PEDIATR-US, V98, P597, DOI 10.1016/S0022-3476(81)80774-3; MELNICK G, 1980, PEDIATRICS, V66, P589; MORRAY JP, 1982, PEDIATR RES, V16, P290, DOI 10.1203/00006450-198204000-00009; MORRIS JF, 1975, AM REV RESPIR DIS, V111, P755; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; MOSS R, 1987, ANN ALLERGY, V59, P185; MOTOYAMA EK, 1987, AM REV RESPIR DIS, V136, P50, DOI 10.1164/ajrccm/136.1.50; MYERS MG, 1986, AM REV RESPIR DIS, V133, P1011; NICKERSON BG, 1980, PEDIATRICS, V65, P1140; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; NORTHWAY WH, 1979, J PEDIATR-US, V95, P815, DOI 10.1016/S0022-3476(79)80441-2; NORTHWAY WH, 1972, PEDIATRICS, V50, P67; Polgar P, 1971, PULMONARY TESTING CH, P100; RIEDEL F, 1987, ACTA PAEDIATR SCAND, V76, P24, DOI 10.1111/j.1651-2227.1987.tb10409.x; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; SELL EJ, 1988, BRONCHOPULMONARY DYS, P403; SMYTH JA, 1981, PEDIATRICS, V68, P336; SOBONYA RE, 1982, PEDIATR RES, V16, P969, DOI 10.1203/00006450-198211000-00014; TOCE SS, 1984, AM J DIS CHILD, V138, P581, DOI 10.1001/archpedi.1984.02140440065017; VANKESSEL AL, 1982, PULMONARY FUNCTION T, P165; VOHR BR, 1982, AM J DIS CHILD, V136, P443, DOI 10.1001/archpedi.1982.03970410061015; WATTS JL, 1977, PEDIATRICS, V60, P273	47	391	411	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 27	1990	323	26					1793	1799		10.1056/NEJM199012273232603	http://dx.doi.org/10.1056/NEJM199012273232603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP376	2247118				2022-12-01	WOS:A1990EP37600003
J	RHINEHART, E; SMITH, NE; WENNERSTEN, C; GORSS, E; FREEMAN, J; ELIOPOULOS, GM; MOELLERING, RC; GOLDMANN, DA				RHINEHART, E; SMITH, NE; WENNERSTEN, C; GORSS, E; FREEMAN, J; ELIOPOULOS, GM; MOELLERING, RC; GOLDMANN, DA			RAPID DISSEMINATION OF BETA-LACTAMASE PRODUCING, AMINOGLYCOSIDE-RESISTANT ENTEROCOCCUS-FAECALIS AMONG PATIENTS AND STAFF ON AN INFANT TODDLER SURGICAL WARD	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HIGH-LEVEL RESISTANCE; STREPTOCOCCUS-FAECALIS; RISK-FACTORS; CITROBACTER-DIVERSUS; HOSPITAL NURSERY; BACTEREMIA; GENTAMICIN; INFECTION; ENDOCARDITIS; EPIDEMIOLOGY		HARVARD UNIV,CHILDRENS HOSP,SCH MED,BACTERIOL LAB,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,EPIDEMIOL PROGRAM,BOSTON,MA 02115; HARVARD UNIV,BROCKTON W ROXBURY VET AFFAIRS HOSP,SCH MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School								BARRALL DT, 1985, ARCH SURG-CHICAGO, V120, P57; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BURKE JP, 1971, NEW ENGL J MED, V284, P115, DOI 10.1056/NEJM197101212840301; DOUGHERTY SH, 1983, ARCH SURG-CHICAGO, V118, P232; ELIOPOULOS GM, 1988, ANTIMICROB AGENTS CH, V32, P1528, DOI 10.1128/AAC.32.10.1528; Facklam RR, 1985, MANUAL CLIN MICROBIO, V4th, P154; GARRISON RN, 1982, ANN SURG, V196, P43, DOI 10.1097/00000658-198207000-00010; Goldmann D A, 1989, Infect Dis Clin North Am, V3, P779; GRAHAM DR, 1981, J INFECT DIS, V144, P203, DOI 10.1093/infdis/144.3.203; GROSS PA, 1976, AM J MED SCI, V272, P75, DOI 10.1097/00000441-197607000-00009; GULLBERG RM, 1989, REV INFECT DIS, V11, P74; HASLETT TM, 1988, J CLIN MICROBIOL, V26, P696, DOI 10.1128/JCM.26.4.696-701.1988; HINDES RG, 1989, ANTIMICROB AGENTS CH, V33, P1019, DOI 10.1128/AAC.33.7.1019; HOFFMANN SA, 1987, ANN INTERN MED, V106, P757, DOI 10.7326/0003-4819-106-5-757; Horan T C, 1986, MMWR CDC Surveill Summ, V35, p17SS; JONES WG, 1988, INFECT SURG, V7, P733; KINNEY JS, 1986, PEDIATR INFECT DIS J, V5, P192, DOI 10.1097/00006454-198603000-00006; KLIMEK JJ, 1980, AM J INFECT CONTROL, V8, P58, DOI 10.1016/S0196-6553(80)80047-2; KNITTLE MA, 1975, J PEDIATR-US, V86, P433, DOI 10.1016/S0022-3476(75)80980-2; LANDRY SL, 1989, AM J INFECT CONTROL, V17, P323, DOI 10.1016/0196-6553(89)90001-1; LARSON EL, 1987, ANTIMICROB AGENTS CH, V31, P1572, DOI 10.1128/AAC.31.10.1572; LIN FYC, 1987, PEDIATR INFECT DIS J, V6, P50, DOI 10.1097/00006454-198701000-00013; LUGINBUHL LM, 1987, PEDIATR INFECT DIS J, V6, P1022, DOI 10.1097/00006454-198706110-00003; MAKI DG, 1988, MEDICINE, V67, P248, DOI 10.1097/00005792-198807000-00005; MALONE DA, 1986, AM J MED, V81, P601, DOI 10.1016/0002-9343(86)90544-9; MAYHALL CG, 1980, INFECT CONT HOSP EP, V1, P239, DOI 10.1017/S019594170005308X; MEDERSKISAMORAJ BD, 1983, J INFECT DIS, V147, P751, DOI 10.1093/infdis/147.4.751; MORRISON AJ, 1986, ARCH INTERN MED, V146, P1549, DOI 10.1001/archinte.146.8.1549; MURRAY BE, 1986, ANTIMICROB AGENTS CH, V30, P861, DOI 10.1128/AAC.30.6.861; MURRAY BE, 1983, J CLIN INVEST, V72, P1168, DOI 10.1172/JCI111042; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; MURRAY BE, 1983, ANTIMICROB AGENTS CH, V23, P799, DOI 10.1128/AAC.23.6.799; PATTERSON JE, 1988, J INFECT DIS, V158, P1144, DOI 10.1093/infdis/158.5.1144; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; Rothman KJ, 1979, EPIDEMIOLOGIC ANAL P; SHLAES DM, 1981, ARCH INTERN MED, V141, P578, DOI 10.1001/archinte.141.5.578; WHITESIDE M, 1983, AM J INFECT CONTROL, V11, P125, DOI 10.1016/0196-6553(83)90028-7; ZERVOS MJ, 1987, ARCH INTERN MED, V147, P1591, DOI 10.1001/archinte.147.9.1591; ZERVOS MJ, 1987, ANN INTERN MED, V106, P687, DOI 10.7326/0003-4819-106-5-687; ZERVOS MJ, 1986, J INFECT DIS, V153, P1075, DOI 10.1093/infdis/153.6.1075; 1987, SAS STAT GUIDE PERSO; 1987, MMWR S2S, V36, pS1	42	161	163	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	1990	323	26					1814	1818		10.1056/NEJM199012273232606	http://dx.doi.org/10.1056/NEJM199012273232606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP376	2123301	Bronze			2022-12-01	WOS:A1990EP37600006
J	SILBER, SJ; ORD, T; BALMACEDA, J; PATRIZIO, P; ASCH, RH				SILBER, SJ; ORD, T; BALMACEDA, J; PATRIZIO, P; ASCH, RH			CONGENITAL ABSENCE OF THE VAS-DEFERENS - THE FERTILIZING-CAPACITY OF HUMAN EPIDIDYMAL SPERM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPERMATOZOA; TRANSIT	Background. Congenital absence of the vas deferens has been considered a virtually untreatable cause of male sterility. Furthermore, sperm that have not passed through at least the head of the epididymis have been thought to be incapable of causing pregnancy. We attempted to determine whether human sperm that had never passed through the epididymis could fertilize eggs in vitro and whether the technique could be used for men with congenital absence of the vas deferens. Methods. Twenty-eight men with congenital absence of the vas deferens underwent microsurgical aspiration of sperm from the epididymis and vasa efferentia for attempted in vitro fertilization of their wives' oocytes, with subsequent transfer of embryos. Thirty-two treatment cycles were begun (four were repeat cycles). Results. The most motile sperm were found in the proximal epididymis, at or near the vasa efferentia. Embryos were obtained for transfer in 21 cases (66 percent). Ninety-three embryos resulted from 352 mature oocytes (fertilization rate, 26 percent). Clinical pregnancy was achieved in 10 of the 32 treatment cycles (31 percent). Seven women delivered normal infants, and three miscarried. One of the seven live births was of twins. There were six girls and two boys. When fewer than 10 eggs were retrieved, no pregnancy occurred. When 10 or more eggs were retrieved (20 cases), the pregnancy rate was 50 percent. Conclusions. Sperm from the proximal caput epididymis and even sperm from the vasa efferentia (which have never passed through the epididymis) can fertilize the human oocyte in vitro and result in pregnancy with live birth.	UNIV CALIF IRVINE,DEPT OBSTET & GYNECOL,DIV REPROD ENDOCRINOL & INFERTIL,ORANGE,CA 92668	University of California System; University of California Irvine	SILBER, SJ (corresponding author), ST LUKES HOSP,224 S WOODS MILL RD,ST LOUIS,MO 63107, USA.		Patrizio, Pasquale/AGO-0674-2022					BALMACEDA JP, 1988, FERTIL STERIL, V50, P476; Bedford J M, 1973, J Reprod Fertil Suppl, V18, P199; BEDFORD JM, 1966, J EXP ZOOL, V163, P319, DOI 10.1002/jez.1401630310; ELITREBY A, 1961, INT J FERTIL, V6, P409; GADDUM P, 1968, ANAT REC, V161, P471, DOI 10.1002/ar.1091610409; GIRGIS SM, 1969, FERTIL STERIL, V20, P467; GLOVER TD, 1969, INT J FERTIL, V14, P216; JIMENEZCRUZ JF, 1980, J UROLOGY, V123, P885; JOHNSON L, 1988, BIOL REPROD, V39, P812, DOI 10.1095/biolreprod39.4.812; KELAMI A, 1976, AKTUEL UROL, V7, P167; KRYLOV VS, 1984, FERTIL STERIL, V41, P418; MOONEY JK, 1972, J UROLOGY, V108, P443, DOI 10.1016/S0022-5347(17)60766-3; ORD T, 1988, NOV INT S GAM PHYS N; Orgebin-Crist M. C., 1969, Biology of Reproduction Suppl, VNo.1, P155, DOI 10.1095/biolreprod1.Supplement_1.155; ORGEBINCRIST MC, 1967, NATURE, V216, P816, DOI 10.1038/216816a0; PRYOR J, 1984, LANCET, V2, P762; ROWLEY MJ, 1970, FERTIL STERIL, V21, P390; Sakatoku J, 1967, Hinyokika Kiyo, V13, P769; Schoysman R, 1972, Acta Chir Belg, V71, P261; SILBER SJ, 1988, FERTIL STERIL, V49, P373; SILBER SJ, 1989, HUM REPROD, V4, P298, DOI 10.1093/oxfordjournals.humrep.a136892; SILBER SJ, 1989, J ANDROL, V10, P263; TEMPLE-SMITH P D, 1985, Journal of In Vitro Fertilization and Embryo Transfer, V2, P119, DOI 10.1007/BF01131497; VICKERS MA, 1975, J UROLOGY, V114, P242, DOI 10.1016/S0022-5347(17)66997-0; Young WC, 1931, J EXP BIOL, V8, P151; YOVICH JL, 1988, FERTIL STERIL, V49, P858; ZORN JR, 1987, LANCET, V1, P385	27	183	186	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 27	1990	323	26					1788	1792		10.1056/NEJM199012273232602	http://dx.doi.org/10.1056/NEJM199012273232602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP376	2247117				2022-12-01	WOS:A1990EP37600002
J	BOLOS, AM; DEAN, M; LUCASDERSE, S; RAMSBURG, M; BROWN, GL; GOLDMAN, D				BOLOS, AM; DEAN, M; LUCASDERSE, S; RAMSBURG, M; BROWN, GL; GOLDMAN, D			POPULATION AND PEDIGREE STUDIES REVEAL A LACK OF ASSOCIATION BETWEEN THE DOPAMINE-D2 RECEPTOR GENE AND ALCOHOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									NIAAA,CLIN STUDIES LAB,GENET STUDIES LAB,9000 ROCKVILLE PIKE,BLDG 10,ROOM 3C-102,ROCKVILLE,MD 20852; PROGRAM RESOURCES INC,FREDERICK,MD; NIAAA,CLIN STUDIES LAB,FAMILY STUDIES UNIT,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)			Dean, Michael/R-7501-2019; Goldman, David/F-9772-2010; Dean, Michael/G-8172-2012	Goldman, David/0000-0002-1724-5405; Dean, Michael/0000-0003-2234-0631	OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASTON CE, 1990, AM J HUM GENET, V46, P879; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOHMAN M, 1981, ARCH GEN PSYCHIAT, V38, P965; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; DAUSSET J, 1990, GENOMICS, V6, P676; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DEVOR EJ, 1989, ANNU REV GENET, V23, P19, DOI 10.1146/annurev.ge.23.120189.000315; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILLIGAN SB, 1987, GENET EPIDEMIOL, V4, P395, DOI 10.1002/gepi.1370040602; GOODWIN DW, 1973, ARCH GEN PSYCHIAT, V28, P238; GOODWIN DW, 1974, ARCH GEN PSYCHIAT, V31, P164; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GRANDY DK, 1989, AM J HUM GENET, V45, P778; KAIJ L, 1960, ALCOHOLISM TWINS; MAINIATIS T, 1982, MOL CLONING LABORATO, P280; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SCHUCKIT MA, 1986, AM J PSYCHIAT, V143, P140; SCHUCKIT MA, 1972, AM J PSYCHIAT, V128, P1132, DOI 10.1176/ajp.128.9.1132; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; STABENAU JR, 1984, AM J PSYCHIAT, V141, P1178; VONKNORRING AL, 1985, ACTA PSYCHIAT SCAND, V72, P51; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0; WINOKUR G, 1971, BRIT J PSYCHIAT, V118, P525, DOI 10.1192/bjp.118.546.525; 1987, DIAGNOSTIC STATISTIC; 1990, ADM901656 US DEP HLT	28	225	233	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	1990	264	24					3156	3160						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EN614	1979357				2022-12-01	WOS:A1990EN61400035
J	JOHNSON, BA; POSES, RM; FORTNER, CA; MEIER, FA; DALTON, HP				JOHNSON, BA; POSES, RM; FORTNER, CA; MEIER, FA; DALTON, HP			DERIVATION AND VALIDATION OF A CLINICAL DIAGNOSTIC MODEL FOR CHLAMYDIAL CERVICAL INFECTION IN UNIVERSITY WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT INTERNAL MED,DIV INTERNAL MED & PRIMARY CARE,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOSTAT,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PATHOL,CLIN MICROBIOL LAB,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University								ADDISS DG, 1987, FAM PLANN PERSPECT, V19, P252, DOI 10.2307/2135105; BRUNHAM RC, 1984, NEW ENGL J MED, V311, P1, DOI 10.1056/NEJM198407053110101; CENTOR RM, 1983, MED DECIS MAKING, V3, P380; CHACKO MR, 1984, PEDIATRICS, V73, P836; CHERNESKY MA, 1986, J INFECT DIS, V154, P141, DOI 10.1093/infdis/154.1.141; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRISON HR, 1985, AM J OBSTET GYNECOL, V153, P244, DOI 10.1016/S0002-9378(85)80105-8; KENT GP, 1988, SEX TRANSM DIS, V15, P51, DOI 10.1097/00007435-198801000-00012; LEE KL, 1986, AM J MED, V80, P553, DOI 10.1016/0002-9343(86)90807-7; LINDNER LE, 1988, J REPROD MED, V33, P684; MAGDER LS, 1988, AM J EPIDEMIOL, V28, P298; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; PHILLIPS RS, 1989, AM J MED, V86, P515, DOI 10.1016/0002-9343(89)90377-X; POSES RM, 1986, ANN INTERN MED, V105, P586, DOI 10.7326/0003-4819-105-4-586; SCHACHTER J, 1983, WESTERN J MED, V138, P375; STAMM WE, 1988, ANN INTERN MED, V108, P710, DOI 10.7326/0003-4819-108-5-710; WIGTON RS, 1986, ARCH INTERN MED, V146, P81, DOI 10.1001/archinte.146.1.81; 1985, MMWR, V34, pS53	20	41	41	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	1990	264	24					3161	3165		10.1001/jama.264.24.3161	http://dx.doi.org/10.1001/jama.264.24.3161			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EN614	2255024				2022-12-01	WOS:A1990EN61400036
J	BARRETT, DS				BARRETT, DS			CAN ORTHOPEDIC SURGEONS WALK ON WATER	BMJ-BRITISH MEDICAL JOURNAL			English	Article											BARRETT, DS (corresponding author), ROYAL NATL ORTHOPAED HOSP, STANMORE HA7 4LP, MIDDX, ENGLAND.							Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; LONKA L, 1987, LANCET, V1, P857; MCCARTHY GF, 1969, MED J AUSTRALIA, V1, P481; MORTON DC, 1970, MED J AUSTRALIA, V1, P1256, DOI 10.5694/j.1326-5377.1970.tb84562.x; PATERSON DC, 1971, PRACTITIONER, V206, P655; RAMEY JR, 1974, J FLA MED ASSOC, V61, P162	6	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 22	1990	301	6766					1429	1430		10.1136/bmj.301.6766.1429	http://dx.doi.org/10.1136/bmj.301.6766.1429			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ039	2279162	Green Published, Bronze			2022-12-01	WOS:A1990EQ03900014
J	BRAHAMS, D				BRAHAMS, D			DUTY OF CARE TO UNBORN CHILD	LANCET			English	Editorial Material																			0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 22	1990	336	8730					1572	1572		10.1016/0140-6736(90)93335-M	http://dx.doi.org/10.1016/0140-6736(90)93335-M			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP037	1979383				2022-12-01	WOS:A1990EP03700021
J	BUNKER, CB; TERENGHI, G; SPRINGALL, DR; POLAK, JM; DOWD, PM				BUNKER, CB; TERENGHI, G; SPRINGALL, DR; POLAK, JM; DOWD, PM			DEFICIENCY OF CALCITONIN GENE-RELATED PEPTIDE IN RAYNAUDS-PHENOMENON	LANCET			English	Article							HUMAN-SKIN	Skin biopsy samples from the fingers of nine patients with primary Raynaud's phenomenon, nine with the disorder associated with systemic sclerosis, and eleven healthy controls were examined by immunocytochemistry. There were no differences between the groups in the distribution of PGP 9.5 (a pan-neuronal marker) immunoreactivity, but there was a significant reduction in the number of calcitonin gene-related peptide (CGRP) immunoreactive neurons in the skin of patients with primary Raynaud's phenomenon and those with systemic sclerosis. These finding implicate dysfunction of the CGRP neurovascular axis in the pathophysiology of Raynaud's phenomenon.	UNIV COLL & MIDDLESEX SCH MED,MIDDLESEX HOSP,DEPT DERMATOL,MORTIMER ST,LONDON W1N 8AA,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0HS,ENGLAND	University of London; University College London; Imperial College London				Bunker, Christopher/0000-0002-6693-7483				Allen EV, 1932, AM J MED SCI, V183, P187, DOI 10.1097/00000441-193202000-00004; BUNKER C B, 1990, British Journal of Rheumatology, V29, P1; BUNKER CB, 1990, LANCET, V335, P239, DOI 10.1016/0140-6736(90)90343-4; BUNKER CB, 1988, BRIT J DERMATOL, V119, P771, DOI 10.1111/j.1365-2133.1988.tb03502.x; BUNKER CB, 1989, BR J DERMATOL S34, V121, P43; BUNKER CB, IN PRESS J INVEST DE; Coffman JD., 1989, RAYNAUDS PHENOMENON; DALSGAARD CJ, 1989, HISTOCHEMISTRY, V91, P35, DOI 10.1007/BF00501907; DALSGAARD CJ, 1989, HISTOCHEMISTRY, V92, P385, DOI 10.1007/BF00492495; DOWD PM, 1990, LANCET, V336, P1014, DOI 10.1016/0140-6736(90)92481-V; GIBBINS IL, 1987, BRAIN RES, V414, P143, DOI 10.1016/0006-8993(87)91335-7; HOWDEN CW, 1988, CLIN SCI, V74, P413, DOI 10.1042/cs0740413; Lewis T, 1929, HEART-J STUD CIRC, V15, P7; Lewis T., 1927, BLOOD VESSELS HUMAN; LEWIS T, 1933, CLIN SCI, V1, P327; MARSHALL I, 1986, NEUROENDOCRINE MOL B, P1; PIOTROWSKI W, 1986, BRIT J DERMATOL, V114, P37, DOI 10.1111/j.1365-2133.1986.tb02777.x; RAYNAUD M, 1888, SELECTED MONOGRAPHS, V121; SHAWKET S, 1989, LANCET, V2, P1354; STRUTHERS AD, 1986, CLIN SCI, V70, P389, DOI 10.1042/cs0700389; WALLENGREN J, 1987, ACTA DERM-VENEREOL, V67, P185; ZAMORA MR, 1990, LANCET, V336, P1144, DOI 10.1016/0140-6736(90)92766-B; 1980, ARCH RHEUM, V23, P581	23	96	98	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 22	1990	336	8730					1530	1533		10.1016/0140-6736(90)93307-B	http://dx.doi.org/10.1016/0140-6736(90)93307-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP037	1979366				2022-12-01	WOS:A1990EP03700004
J	BURGER, BJ; BURGER, JD; BOS, CFA; OBERMANN, WR; ROZING, PM; VANDENBROUCKE, JP				BURGER, BJ; BURGER, JD; BOS, CFA; OBERMANN, WR; ROZING, PM; VANDENBROUCKE, JP			NEONATAL SCREENING AND STAGGERED EARLY TREATMENT FOR CONGENITAL DISLOCATION OR DYSPLASIA OF THE HIP	LANCET			English	Article							AVASCULAR NECROSIS; NEWBORN	In 14 264 consecutive newborn babies the results of screening and early treatment for congenital dislocation and/or dysplasia of the hip (CDH) were evaluated in a prospective follow-up study. Barlow's test was done and the family history was recorded. Babies who were positive (n = 140) were immediately given abduction treatment. If the screening result was doubtful (133) or if the test was negative but the family history positive (685) the child was radiographed at 5 months and abduction treatment was started if any form of CDH was seen. Among Barlow-negative children with no family history (13 306), two reference groups were selected - at age 5 months (596) and at age 2 years (4365). Dislocation was missed at screening in 0.02%. Dysplasia was seen at 5 months in 15% of Barlow-negative children with a positive family history and in 2-3% of the reference group children. Crude estimates of the lower limits of validity indices for the screening test showed that the test is efficient in the identification of dislocation but probably has not value for dysplasia. Of the babies in whom treatment was started immediately 17% had relapse dysplasia after withdrawal of therapy, 3% had avascular necrosis, and 78% were normal at 2 years. When treatment was started at 5 months were found no relapse dysplasia, only 1% avascular necrosis, and 53-63% success at 2 years. In children with dislocatable hips were propose a wait-and-see treatment strategy, with early ultrasonography or radiography at 5 months.	UNIV HOSP LEIDEN, DEPT RADIOL, 2300 RC LEIDEN, NETHERLANDS; UNIV HOSP LEIDEN, DEPT CLIN EPIDEMIOL, 2300 RC LEIDEN, NETHERLANDS; ELIZABETH GASTHUIS, HAARLEM, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	BURGER, BJ (corresponding author), UNIV HOSP LEIDEN, DEPT ORTHOPAED SURG, 2300 RC LEIDEN, NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				ANDREN L, 1961, ACTA ORTHOP SCAND, V30, P169; BARLOW TG, 1962, J BONE JOINT SURG BR, V44, P292, DOI 10.1302/0301-620X.44B2.292; BECKER F, 1979, Z ORTHOP, V106, P173; BJERKREIM I, 1987, ACTA ORTHOP SCAND, V58, P504, DOI 10.3109/17453678709146388; BRADLEY J, 1987, J BONE JOINT SURG BR, V69, P257, DOI 10.1302/0301-620X.69B2.3818757; CARDOSO AC, 1987, MONTHLY B HLTH STATI, V4, P22; DAVIES RW, 1970, J BONE JOINT SURG BR, V53, P704; DAVIES SJM, 1984, J BONE JOINT SURG BR, V66, P479, DOI 10.1302/0301-620X.66B4.6746677; DUNN PM, 1984, LANCET, V1, P846; DUNN PM, 1985, ARCH DIS CHILD, V60, P407, DOI 10.1136/adc.60.5.407; DUNN PM, 1976, CLIN ORTHOP RELAT R, V119, P11; HADLOW V, 1988, J BONE JOINT SURG BR, V70, P740, DOI 10.1302/0301-620X.70B5.3192572; JONES D, 1977, J BONE JOINT SURG BR, V59, P318, DOI 10.1302/0301-620X.59B3.893510; KALAMCHI A, 1980, J BONE JOINT SURG AM, V62, P876, DOI 10.2106/00004623-198062060-00002; KELLER MS, 1988, RADIOLOGY, V169, P733, DOI 10.1148/radiology.169.3.3055037; KLISIC PJ, 1989, J BONE JOINT SURG BR, V71, P136, DOI 10.1302/0301-620X.71B1.2914985; MacKenzie I G, 1972, J Bone Joint Surg Br, V54, P18; MITCHELL G P, 1972, Journal of Bone and Joint Surgery British Volume, V54, P4; ROBERTON NRC, 1984, LANCET, V1, P909; SAIES AD, 1988, J PEDIATR ORTHOPED, V8, P436, DOI 10.1097/01241398-198807000-00010; SERINGE R, 1982, REV CHIR ORTHOP, V68, P145; TONNIS D, 1976, CLIN ORTHOP RELAT R, P39; TONNIS D, 1984, CONGENITAL HIP DISLO; VONROSEN S, 1962, J BONE JOINT SURG BR, V44, P284, DOI 10.1302/0301-620X.44B2.284; WEINER DS, 1977, J BONE JOINT SURG AM, V59, P306, DOI 10.2106/00004623-197759030-00002; WILLIAMSON J, 1972, Journal of Bone and Joint Surgery British Volume, V54, P13	26	46	48	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 22	1990	336	8730					1549	1553		10.1016/0140-6736(90)93317-I	http://dx.doi.org/10.1016/0140-6736(90)93317-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP037	1979375				2022-12-01	WOS:A1990EP03700013
J	ESSEX, C				ESSEX, C			OVER 8000 PAIRS OF SPECS FOR AFRICA	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 22	1990	301	6766					1435	1436		10.1136/bmj.301.6766.1435	http://dx.doi.org/10.1136/bmj.301.6766.1435			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ039	2279166	Green Published, Bronze			2022-12-01	WOS:A1990EQ03900019
J	FOSTER, MC; UPSDELL, SM; OREILLY, PH				FOSTER, MC; UPSDELL, SM; OREILLY, PH			UROLOGICAL MYTHS	BRITISH MEDICAL JOURNAL			English	Article							INDWELLING CATHETERS; CHRONIC RETENTION; MANAGEMENT; URINE		STEPPING HILL HOSP,DEPT UROL,STOCKPORT SK2 7JE,ENGLAND									BLANDY JP, 1981, BRIT J HOSP MED, V26, P58; BLANDY JP, 1977, LECTURE NOTES UROLOG, P192; BROCKLEHURST JC, 1978, BRIT J UROL, V50, P102, DOI 10.1111/j.1464-410X.1978.tb03035.x; BROCKLEHURST JC, 1985, TXB GERIATRIC MED GE, P626; FERRIE BG, 1979, BMJ-BRIT MED J, V2, P1046, DOI 10.1136/bmj.2.6197.1046; GEORGE NJR, 1984, BRIT J UROL, V56, P9, DOI 10.1111/j.1464-410X.1984.tb07154.x; JONES DA, 1987, LANCET, V1, P1052; KENNEDY AP, 1982, J ADV NURS, V7, P411, DOI 10.1111/j.1365-2648.1982.tb00257.x; KENNEDY AP, 1983, J ADV NURS, V8, P207, DOI 10.1111/j.1365-2648.1983.tb00315.x; KERR WS, 1954, J APPL PHYSIOL, V6, P762, DOI 10.1152/jappl.1954.6.12.762; LAWRENCE WT, 1990, SURGERY, V77, P1838; MCGUIRE EJ, 1986, CAMPBELLS UROLOGY, P616; OREILLY PH, 1986, OBSTRUCTIVE UROPATHY, P103; PETERSON LJ, 1975, J UROLOGY, V113, P190, DOI 10.1016/S0022-5347(17)59440-9; PHILIP PF, 1975, BAILEY LOVES SHORT P, P1187; TIPTAFT RC, 1986, BAILEY LOVES SHORT P, P1254; Usberti M, 1975, Minerva Nefrol, V22, P299	17	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 22	1990	301	6766					1421	1423		10.1136/bmj.301.6766.1421	http://dx.doi.org/10.1136/bmj.301.6766.1421			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ039	2279158	Green Published, Bronze			2022-12-01	WOS:A1990EQ03900009
J	HOLLYHEAD, J				HOLLYHEAD, J			THANKS FOR CARING	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 22	1990	301	6766					1481	1482		10.1136/bmj.301.6766.1481	http://dx.doi.org/10.1136/bmj.301.6766.1481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ039	2279190	Green Published, Bronze			2022-12-01	WOS:A1990EQ03900043
J	HORNER, JS				HORNER, JS			WHY ME	BRITISH MEDICAL JOURNAL			English	Editorial Material											HORNER, JS (corresponding author), PRESTON HLTH AUTHOR,PRESTON PR2 4DX,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 22	1990	301	6766					1480	1481		10.1136/bmj.301.6766.1480	http://dx.doi.org/10.1136/bmj.301.6766.1480			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ039	2279189	Bronze, Green Published			2022-12-01	WOS:A1990EQ03900042
J	LAMONT, AC; LONDON, NJM				LAMONT, AC; LONDON, NJM			BELL RINGERS BRUISES AND BROKEN BONES - CAPERS AND CRISES IN CAMPANOLOGY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the incidence, aetiology, and outcome of injuries due to bell ringing. Design - Retrospective review of the last six years' issues of Ringing World, advertisement in Ringing World, and a postal questionnaire sent to 20 active ringing towers. Subjects - Regular bell ringers. Results - Seventy nine injuries were identified both from review and by advertisement in Ringing World. The incidence of injury among 221 ringers identified by postal questionnaire was 1.8% a year. Conclusion - Although sonerous, bell ringing can be dangerous and occasionally even fatal. Doctors should be aware of the dangers to which campanologists expose themselves.	LEICESTER ROYAL INFIRM,DEPT SURG,LEICESTER LE1 5WW,ENGLAND	University of Leicester	LAMONT, AC (corresponding author), LEICESTER ROYAL INFIRM,DEPT RADIOL,LEICESTER LE1 5WW,ENGLAND.							EASTON KE, 1978, INJURY, V14, P307; GULY HR, 1982, INJURY, V14, P194, DOI 10.1016/0020-1383(82)90058-4; LEE KG, 1984, RINGING WORLD, P489; LUCAS PB, 1988, RINGING WORLD, P906; Morris E., 1931, HIST ART CHANGE RING; RICHARDS R, 1989, RINGINT WORLD, P896	6	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 22	1990	301	6766					1415	1418		10.1136/bmj.301.6766.1415	http://dx.doi.org/10.1136/bmj.301.6766.1415			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ039	2279156	Bronze, Green Published			2022-12-01	WOS:A1990EQ03900007
J	MCFADZEAN, WA; BENNETT, JDC				MCFADZEAN, WA; BENNETT, JDC			THE SURGEONS SCISSOR-JAW REFLEX	BRITISH MEDICAL JOURNAL			English	Article									BRITISH MIL HOSP,RINTELN,ENGLAND										0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 22	1990	301	6766					1428	1429		10.1136/bmj.301.6766.1428	http://dx.doi.org/10.1136/bmj.301.6766.1428			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ039	2279161	Green Published, Bronze			2022-12-01	WOS:A1990EQ03900013
J	MEYTES, D; SCHOCHAT, B; LEE, H; NADEL, G; SIDI, Y; CERNEY, M; SWANSON, P; SHAKLAI, M; KILIM, Y; ELGAT, M; CHIN, E; DANON, Y; ROSENBLATT, JD				MEYTES, D; SCHOCHAT, B; LEE, H; NADEL, G; SIDI, Y; CERNEY, M; SWANSON, P; SHAKLAI, M; KILIM, Y; ELGAT, M; CHIN, E; DANON, Y; ROSENBLATT, JD			SEROLOGICAL AND MOLECULAR SURVEY FOR HTLV-I INFECTION IN A HIGH-RISK MIDDLE-EASTERN GROUP	LANCET			English	Article							CELL LEUKEMIA-VIRUS; DRUG-ABUSERS; ANTIBODIES; LYMPHOMA; INDIVIDUALS; PREVALENCE; FALASHAS; ISRAEL	To define the extent of human T-cell leukaemia virus (HTLV-1) infection among a group of Jewish immigrants to Israel with an increased frequency of adult T-cell leukaemia, various serological and molecular screening methods, including enzyme-linked immunosorbent assay (ELISA) for anti-HTLV-1, ELISA for antibody to recombinant HTLV-1 p40tax protein, and molecular detection of infection by polymerase chain reaction (PCR) amplification of HTLV-1 proviral DNA from peripheral blood mononuclear cell DNA, were used. By HTLV-1 ELISA overall rate of infection was 12% (24 of 208) among immigrants from Khurusan, northeastern Iran; no HTLV-1 carriers were detected among 111 unselected Jewish immigrants from other parts of Iran. There was unexplained clustering of HTLV-1 infection within a cohort of 32 elderly women of similar geographic origin in a home for old people - 14 were seropositive by ELISA and 19 of 29 were positive by PCR. The findings in this newly identified high-risk population suggest that in addition to ELISA, other screening techniques may be required to detect all carriers in high-risk populations.	EDITH WOLFSON MED CTR,HOLON,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,HOLON,ISRAEL; BEILINSON MED CTR,IL-49100 PETAH TIQWA,ISRAEL; MINIST HLTH,TEL AVIV,ISRAEL; ABBOTT LABS,DIV DIAGNOST,N CHICAGO,IL 60064; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024	Tel Aviv University; Sackler Faculty of Medicine; Rabin Medical Center; Abbott Laboratories; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				sidi, yechezkel/0000-0001-7781-6153	NCI NIH HHS [CA52410-01, CA01314] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001314, R01CA052410] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENISHAI Z, 1985, NATURE, V315, P665, DOI 10.1038/315665a0; BIGGAR RJ, 1985, LANCET, V2, P520; BLATTNER WA, 1983, LANCET, V2, P61; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501; EHRLICH GD, 1989, BLOOD, V74, P1658; EHRLICH GD, 1989, BLOOD, V74, P1066; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; HINUMA Y, 1986, AIDS RES, V2, P517; KAMIHIRA S, 1989, JPN J CANCER RES, V80, P1066, DOI 10.1111/j.1349-7006.1989.tb02260.x; KARPAS A, 1986, NATURE, V319, P794, DOI 10.1038/319794a0; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEOR J, 1988, ISRAEL J MED SCI, V24, P397; ROBERTGUROFF M, 1986, JAMA-J AM MED ASSOC, V255, P3133, DOI 10.1001/jama.255.22.3133; SIDI Y, 1990, CANCER, V65, P590, DOI 10.1002/1097-0142(19900201)65:3<590::AID-CNCR2820650334>3.0.CO;2-2; YOKATA T, 1989, INT J CANCER, V43, P970; 1972, ENCY JUDAICA, V11, P1399	16	77	78	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 22	1990	336	8730					1533	1535		10.1016/0140-6736(90)93308-C	http://dx.doi.org/10.1016/0140-6736(90)93308-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP037	1979367				2022-12-01	WOS:A1990EP03700005
J	PROBERT, CSJ; MADDISON, W; ROLAND, JM				PROBERT, CSJ; MADDISON, W; ROLAND, JM			DIET, DIABETES, AND MALE-CHAUVINISM	BRITISH MEDICAL JOURNAL			English	Article									PETERBOROUGH DIST GEN HOSP,PETERBOROUGH PE3 6DA,ENGLAND					Probert, Christopher/0000-0003-4550-0239				SCHAFER LC, 1986, DIABETES CARE, V9, P179, DOI 10.2337/diacare.9.2.179	1	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 22	1990	301	6766					1430	1431		10.1136/bmj.301.6766.1430	http://dx.doi.org/10.1136/bmj.301.6766.1430			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ039	2279163	Green Published, Bronze			2022-12-01	WOS:A1990EQ03900015
J	ROBERTS, RG; BENTLEY, DR; BARBY, TFM; MANNERS, E; BOBROW, M				ROBERTS, RG; BENTLEY, DR; BARBY, TFM; MANNERS, E; BOBROW, M			DIRECT DIAGNOSIS OF CARRIERS OF DUCHENNE AND BECKER MUSCULAR-DYSTROPHY BY AMPLIFICATION OF LYMPHOCYTE RNA	LANCET			English	Article							PRENATAL-DIAGNOSIS; DNA AMPLIFICATION; DMD CDNA; DELETION; GENE; PROBES	Rapid detection of deletion and duplication mutations that cause Duchenne and Becker muscular dystrophy was achieved in patients and carriers after amplification of small amounts of mRNA from peripheral blood lymphocytes. The entire coding region of the dystrophin mRNA was amplified in 10 sections by reverse transcription and nested polymerase chain reaction, and the products were directly visualised on acrylamide minigels with ethidium staining. Major structural gene mutations were identified by the appearance of a band of different size to that of the wild type. The altered band was readily detected in all patients and heterozygous relatives. This non-radioactive test of venous blood samples can be used for unambiguous and rapid identification of virtually all carriers of deletions or insertions within the dystrophin gene.			ROBERTS, RG (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS HOSP, DIV MED & MOLEC GENET, PAEDIAT RES UNIT, LONDON SE1 9RT, ENGLAND.		Roberts, Roland G/C-3596-2009	Roberts, Roland/0000-0001-6636-1579				BAKKER E, 1987, NATURE, V329, P554, DOI 10.1038/329554a0; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHEN JD, 1988, AM J HUM GENET, V42, P777; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; GILLARD EF, 1989, AM J HUM GENET, V45, P507; GREENPM, 1989, EMBO J, V8, P1067; HODGSON S, 1989, J MED GENET, V26, P682, DOI 10.1136/jmg.26.11.682; HODGSON SV, 1989, BRIT MED BULL, V45, P719, DOI 10.1093/oxfordjournals.bmb.a072354; HOLDING C, 1989, LANCET, V2, P532; KAARIAINEN H, 1990, CLIN GENET, V37, P179; KOENIG M, 1989, AM J HUM GENET, V45, P498; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; MAO YP, 1989, HUM GENET, V81, P193, DOI 10.1007/BF00293903; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; NORMAN AM, 1990, J MED GENET, V27, P236, DOI 10.1136/jmg.27.4.236; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIBERT JR, 1979, ARCH DIS CHILD, V54, P534, DOI 10.1136/adc.54.7.534; SPEER A, 1989, J MED GENET, V26, P1, DOI 10.1136/jmg.26.1.1; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; ZATZ M, 1977, LANCET, V1, P759	23	83	101	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 22	1990	336	8730					1523	1526		10.1016/0140-6736(90)93305-9	http://dx.doi.org/10.1016/0140-6736(90)93305-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP037	1979364				2022-12-01	WOS:A1990EP03700002
J	SHERRY, E				SHERRY, E			PROJECT ORBIS	BRITISH MEDICAL JOURNAL			English	Article											SHERRY, E (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP,BRISTOL BS2 8HW,AVON,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 22	1990	301	6766					1444	1445		10.1136/bmj.301.6766.1444	http://dx.doi.org/10.1136/bmj.301.6766.1444			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ039	2279170	Bronze, Green Published			2022-12-01	WOS:A1990EQ03900023
J	STOTT, EJ; CHAN, WL; MILLS, KHG; PAGE, M; TAFFS, F; CRANAGE, M; GREENAWAY, P; KITCHIN, P				STOTT, EJ; CHAN, WL; MILLS, KHG; PAGE, M; TAFFS, F; CRANAGE, M; GREENAWAY, P; KITCHIN, P			PRELIMINARY-REPORT - PROTECTION OF CYNOMOLGUS MACAQUES AGAINST SIMIAN IMMUNODEFICIENCY VIRUS BY FIXED INFECTED-CELL VACCINE	LANCET			English	Article							ANIMAL-MODELS; AIDS	Cynomolgus macaques were vaccinated with inactivated simian immunodeficiency virus-infected cells and 'Quil-A' as adjuvant at 0,4,8, and 36 weeks or at 0,4,8, and 16 weeks. 2 weeks later these animals, together with a similar unvaccinated group, were challenged with 10 MID50 (50% monkey infectious doses) of a pool of SIVmac251 previously titrated in vivo. Virus was repeatedly isolated from unvaccinated animals on at least five separate occasions and proviral DNA was detected in circulating lymphocytes by polymerase chain reaction amplification. By contrast, virus and proviral DNA were not found in any of the vaccinated animals. However, the same vaccination regimen used after live virus challenge did not eliminate virus from previously infected macaques.	NATL INST BIOL STAND & CONTROLS,DIV IMMUNOBIOL,POTTERS BAR EN6 3QG,HERTS,ENGLAND; CTR APPL MICROBIOL & RES,SALISBURY,WILTS,ENGLAND	National Institute for Biological Standards & Control	STOTT, EJ (corresponding author), NATL INST BIOL STAND & CONTROLS,CTR AIDS COLLABORATING,BLANCHE LANE,ROTTERS BAR EN6 3QG,HERTS,ENGLAND.		Mills, Kingston H/F-5684-2013	Mills, Kingston H/0000-0003-3646-8222				ALMOND N, 1990, J VIROL METHODS, V28, P305, DOI 10.1016/0166-0934(90)90124-X; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CARLSON JR, IN PRESS AIDS RES HU; CRANAGE MP, IN PRESS P INT M ANI; DANIEL MD, 1989, AIDS, V3, pS31; DESROSIERS RC, 1987, REV INFECT DIS, V9, P438; DESROSIERS RC, 1989, AIDS RES HUM RETROV, V5, P465, DOI 10.1089/aid.1989.5.465; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; GARDNER MB, 1989, J MED PRIMATOL, V18, P321; GARDNER MB, 1989, FASEB J, V3, P2593, DOI 10.1096/fasebj.3.14.2556312; GNANN JW, 1987, SCIENCE, V237, P1346, DOI 10.1126/science.2888192; KITCHIN PA, 1990, J VIROL METHODS, V28, P85, DOI 10.1016/0166-0934(90)90090-3; KITCHIN PA, IN PRESS P INT M ANI; LEVINE A, 1990, JUN SAN FRANC AIDS M; MILLS KHG, 1990, J IMMUNOL, V144, P1677; MONTEFIORI DC, 1990, J VIROL, V64, P113, DOI 10.1128/JVI.64.1.113-119.1990; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; PICARD O, 1990, LANCET, V336, P179, DOI 10.1016/0140-6736(90)91699-B; ROBINSON WE, 1990, JUN SAN FRANC AIDS M; SALK J, 1987, NATURE, V327, P473, DOI 10.1038/327473a0; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STOTT EJ, 1984, J HYG-CAMBRIDGE, V93, P251, DOI 10.1017/S0022172400064779; SUTJIPTO S, 1990, J VIROL, V64, P2290, DOI 10.1128/JVI.64.5.2290-2297.1990	24	159	166	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 22	1990	336	8730					1538	1541		10.1016/0140-6736(90)93310-L	http://dx.doi.org/10.1016/0140-6736(90)93310-L			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP037	1979369				2022-12-01	WOS:A1990EP03700007
J	WEN, L; PEAKMAN, M; LOBOYEO, A; MCFARLANE, BM; MOWAT, AP; MIELIVERGANI, G; VERGANI, D				WEN, L; PEAKMAN, M; LOBOYEO, A; MCFARLANE, BM; MOWAT, AP; MIELIVERGANI, G; VERGANI, D			T-CELL-DIRECTED HEPATOCYTE DAMAGE IN AUTOIMMUNE CHRONIC ACTIVE HEPATITIS	LANCET			English	Article							MEMBRANE LIPOPROTEIN; AUTOANTIBODIES; ANTIBODIES	To investigate the function of activated T lymphocytes in atuoimmune chronic active hepatitis, 7 or 15 T-cell clones from the peripheral blood of 8 patients were studied. These clones showed specificity for liver-membrane antigen with proliferation when stimulated by rabbit liver cell membranes. 6 of these clones reacted with liver-specific lipoprotein complex, and 1 clone (and 3 subclones) responded to the asialoglycoprotein receptor (ASGPR), both known targets of immune attack in autoimmune chronic active hepatitis. 2 of these clones stimulated autologous B lymphocytes to produce liver-membrane-specific autoantibodies and antibody to the ASGPR. These results suggest that liver-membrane-specific activated T lymphocytes in peripheral blood may be important in the autoimmune attack of chronic active hepatitis.	KINGS COLL,SCH MED & DENT,DEPT IMMUNOL,BESSEMER RD,LONDON SE5 9PJ,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT CHILD HLTH,LONDON WC2R 2LS,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,LIVER UNIT,LONDON WC2R 2LS,ENGLAND	University of London; King's College London; University of London; King's College London; University of London; King's College London			Vergani, Diego/H-7610-2019; Mieli-Vergani, Giorgina/G-5616-2011	Mieli-Vergani, Giorgina/0000-0002-8215-4489; Wen, Li/0000-0002-8805-2934	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BLUE ML, 1986, J IMMUNOL, V137, P1202; EDDLESTON ALW, 1974, LANCET, V2, P1543; Fiske CH, 1925, J BIOL CHEM, V66, P375; JENSEN DM, 1978, NEW ENGL J MED, V299, P1, DOI 10.1056/NEJM197807062990101; LOBOYEO A, 1987, CLIN EXP IMMUNOL, V67, P95; LONDEI M, 1985, SCIENCE, V228, P85, DOI 10.1126/science.3871967; MCFARLANE BM, 1986, J HEPATOL, V3, P196, DOI 10.1016/S0168-8278(86)80026-5; MCFARLANE IG, 1977, CLIN EXP IMMUNOL, V27, P381; MCFARLANE IG, 1984, LANCET, V2, P954; MIELI VERGANI G., 1979, Clinical and Experimental Immunology, V38, P16; NABHOLZ M, 1982, ISOLATION CHARACTERI, P163; Pertoft H., 1977, METHODS CELL, P25; SHERLOCK S, 1989, DISEASES LIVER BILIA, P348; SWANSON NR, 1989, CLIN IMMUNOL IMMUNOP, V52, P291, DOI 10.1016/0090-1229(89)90180-3; TASWELL C, 1981, J IMMUNOL, V126, P1614; VINCENT R, 1983, ANAL BIOCHEM, V135, P255	17	73	76	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 22	1990	336	8730					1527	1530		10.1016/0140-6736(90)93306-A	http://dx.doi.org/10.1016/0140-6736(90)93306-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP037	1979365				2022-12-01	WOS:A1990EP03700003
J	BORKOVICH, KA; SIMON, MI				BORKOVICH, KA; SIMON, MI			THE DYNAMICS OF PROTEIN-PHOSPHORYLATION IN BACTERIAL CHEMOTAXIS	CELL			English	Article							ESCHERICHIA-COLI; SENSORY TRANSDUCTION; SIGNAL TRANSDUCTION; IDENTIFICATION; SYSTEM; METHYLESTERASE; METHYLATION; RECEPTORS; MUTANTS; DOMAIN	The chemotaxis signal transduction pathway allows bacteria to respond to changes in concentration of specific chemicals (ligands) by modulating their swimming behavior. The pathway includes ligand binding receptors, and the CheA, CheY, CheW, and CheZ proteins. We showed previously that phosphorylation of CheY is activated in reactions containing receptor, CheW, CheA, and CheY. Here we demonstrate that this activation signal results from accelerated autophosphorylation of the CheA kinase. Evidence for a second signal transmitted by a ligand-bound receptor, which corresponds to inhibition of CheA autophosphorylation, is also presented. We postulate that CheA can exist in three forms: a "closed" form in the absence of receptor and CheW; an "open" form that results from activation of CheA by receptor and CheW; and a "sequestered" form in reactions containing ligand-bound receptor and CheW. The system's dynamics depends on the relative distribution of CheA among these three forms at any time.			BORKOVICH, KA (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.				NIGMS NIH HHS [GM11223] Funding Source: Medline; PHS HHS [IA 19296] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADLER J, 1974, SCIENCE, V184, P1293, DOI 10.1126/science.184.4143.1292; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HESS JF, 1988, COLD SPRING HARB SYM, V53, P41, DOI 10.1101/SQB.1988.053.01.008; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOSHLAND DE, 1988, BIOCHEMISTRY-US, V27, P5829, DOI 10.1021/bi00416a001; KUO SC, 1987, J BACTERIOL, V169, P1307, DOI 10.1128/jb.169.3.1307-1314.1987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LUPAS A, 1989, J BIOL CHEM, V264, P17337; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MUTOH N, 1986, J BACTERIOL, V167, P992, DOI 10.1128/jb.167.3.992-998.1986; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; PARKINSON JS, 1983, J BACTERIOL, V155, P265, DOI 10.1128/JB.155.1.265-274.1983; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SEGALL JE, 1982, NATURE, V296, P855, DOI 10.1038/296855a0; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STEWART RC, 1990, J BACTERIOL, V172, P3388, DOI 10.1128/jb.172.6.3388-3399.1990; STOCK A, 1987, J BIOL CHEM, V262, P535; STOCK AM, 1988, COLD SPRING HARB SYM, V53, P49, DOI 10.1101/SQB.1988.053.01.009; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TAYLOR BL, 1990, MEMBRANE TRANSPORT I, P69; TSANG N, 1973, SCIENCE, V181, P60, DOI 10.1126/science.181.4094.60; WEIS RM, 1988, P NATL ACAD SCI USA, V85, P83, DOI 10.1073/pnas.85.1.83; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WOLFE AJ, 1988, P NATL ACAD SCI USA, V85, P6711, DOI 10.1073/pnas.85.18.6711; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOLFE AJ, 1989, P NATL ACAD SCI USA, V86, P6973, DOI 10.1073/pnas.86.18.6973; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6	45	167	168	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 21	1990	63	6					1339	1348		10.1016/0092-8674(90)90429-I	http://dx.doi.org/10.1016/0092-8674(90)90429-I			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2261645				2022-12-01	WOS:A1990EN92300024
J	CHELLY, J; GILGENKRANTZ, H; LAMBERT, M; HAMARD, G; CHAFEY, P; RECAN, D; KATZ, P; DELACHAPELLE, A; KOENIG, M; GINJAAR, IB; FARDEAU, M; TOME, F; KAHN, A; KAPLAN, JC				CHELLY, J; GILGENKRANTZ, H; LAMBERT, M; HAMARD, G; CHAFEY, P; RECAN, D; KATZ, P; DELACHAPELLE, A; KOENIG, M; GINJAAR, IB; FARDEAU, M; TOME, F; KAHN, A; KAPLAN, JC			EFFECT OF DYSTROPHIN GENE DELETIONS ON MESSENGER-RNA LEVELS AND PROCESSING IN DUCHENNE AND BECKER MUSCULAR-DYSTROPHIES	CELL			English	Article							TERMINATION CODON; MOLECULAR-BASIS; MUSCLE; TRANSCRIPTION; PROTEIN; LOCUS	Muscle dystrophin mRNAs from Duchenne (DMD) and Becker (BMD) patients with internal deletion of the DMD gene were quantitated and sequenced. In all cases (eight DMD and three BMD), truncated mature transcripts were found, and their amount was correlated to the clinical phenotype and to the reading frame. We focused on four cases that were apparently not in agreement with the reading frame rule. In two DMD cases, slightly reduced amounts of in-frame truncated mRNA are present but no dystrophin is detected, suggesting impaired translation and/or instability of the protein. In two BMD patients with out-of-frame deletions, the presence of minor in-frame alternatively spliced mRNA species is congruent with the observed truncated dystrophin and the mild phenotype.	INSERM, U153, F-75005 PARIS, FRANCE; HOP NECKER ENFANTS MALAD, GENET MED CLIN, PARIS, FRANCE; UNIV HELSINKI, DEPT MED GENET, SF-00100 HELSINKI 10, FINLAND; FAC MED STRASBOURG 2, INST CHIM BIOL, DEPT GENET HUMAINE, STRASBOURG, FRANCE; SYLVIUS LABS, DEPT HUMAN GENET, LEIDEN, NETHERLANDS	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Helsinki	CHELLY, J (corresponding author), INSERM, U129, INST COCHIN GENET MOLEC, 17 RUE FER MOULIN, F-75005 PARIS, FRANCE.		Gilgenkrantz, Helene/G-5534-2017; Chelly, Jamel/J-7528-2015	Chelly, Jamel/0000-0002-0939-8719; gilgenkrantz, helene/0000-0001-6770-4561				BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; CHAMBERLAIN JS, 1988, SCIENCE, V239, P1416, DOI 10.1126/science.3347839; CHELLY J, 1990, EUR J BIOCHEM, V187, P691, DOI 10.1111/j.1432-1033.1990.tb15355.x; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; GILGENKRANTZ H, 1989, GENOMICS, V5, P574, DOI 10.1016/0888-7543(89)90025-6; GOSPE SM, 1989, NEUROLOGY, V39, P1277, DOI 10.1212/WNL.39.10.1277; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HUMPHRIES RK, 1984, BLOOD, V64, P23; KOENIG M, 1989, AM J HUM GENET, V45, P498; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LINDLOF M, 1989, AM J HUM GENET, V44, P496; MALHOTRA SB, 1988, SCIENCE, V242, P755, DOI 10.1126/science.3055295; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; MONACO AP, 1988, ADV HUM GENET, V17, P61; MUNTONI F, 1989, FEBS LETT, V252, P95, DOI 10.1016/0014-5793(89)80896-8; ORONZISCOTT M, 1988, SCIENCE, V239, P1418; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; TAKESHITA K, 1984, BLOOD, V64, P13; WORTON RG, 1988, ANNU REV GENET, V22, P601, DOI 10.1146/annurev.ge.22.120188.003125	27	147	152	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 21	1990	63	6					1239	1248		10.1016/0092-8674(90)90419-F	http://dx.doi.org/10.1016/0092-8674(90)90419-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2261642				2022-12-01	WOS:A1990EN92300014
J	COLLIN, C; PAPAGEORGE, AG; LOWY, DR; ALKON, DL				COLLIN, C; PAPAGEORGE, AG; LOWY, DR; ALKON, DL			EARLY ENHANCEMENT OF CALCIUM CURRENTS BY H-RAS ONCOPROTEINS INJECTED INTO HERMISSENDA NEURONS	SCIENCE			English	Article									NCI, CELLULAR ONCOL LAB, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	COLLIN, C (corresponding author), NINCDS, MOLEC & CELLULAR NEUROBIOL LAB, NEURAL SYST SECT, BETHESDA, MD 20892 USA.							ALKON DL, 1990, FASEB J, V4, P1567, DOI 10.1096/fasebj.4.6.2108074; ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; CAFFREY JM, 1987, SCIENCE, V236, P570, DOI 10.1126/science.2437651; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; COLLIN C, 1988, BIOPHYS J, V54, P955, DOI 10.1016/S0006-3495(88)83031-5; COLLIN C, 1990, BIOPHYS J, V58, P785, DOI 10.1016/S0006-3495(90)82421-8; DOLPHIN AC, 1988, TRENDS NEUROSCI, V11, P287, DOI 10.1016/0166-2236(88)90085-9; DOLPHIN AC, 1990, ANNU REV PHYSIOL, V52, P243; ESTACION M, 1990, J MEMBRANE BIOL, V113, P169, DOI 10.1007/BF01872890; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; HANLEY MR, 1988, NEURON, V1, P175, DOI 10.1016/0896-6273(88)90137-7; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; IVES HE, 1987, P NATL ACAD SCI USA, V84, P1950, DOI 10.1073/pnas.84.7.1950; KACZMAREK LK, 1988, ADV SEC MESS PHOSPH, V22, P113; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LACAL JC, 1988, ONCOGENE HDB; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LOWY DR, 1989, NATURE, V341, P384, DOI 10.1038/341384a0; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NELSON TJ, 1990, SCIENCE, V247, P1479, DOI 10.1126/science.2108498; PANDIELLA A, 1989, TRENDS PHARMACOL SCI, V10, P411; ROGERS M, 1990, J NEUROSCI RES, V26, P447, DOI 10.1002/jnr.490260407; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	35	53	54	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1743	1745		10.1126/science.2176747	http://dx.doi.org/10.1126/science.2176747			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2176747				2022-12-01	WOS:A1990EN92000052
J	CUNNINGHAM, BC; BASS, S; FUH, G; WELLS, JA				CUNNINGHAM, BC; BASS, S; FUH, G; WELLS, JA			ZINC MEDIATION OF THE BINDING OF HUMAN GROWTH-HORMONE TO THE HUMAN PROLACTIN RECEPTOR	SCIENCE			English	Article									GENENTECH INC, DEPT PROT ENGN, SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERFENSTAM R, 1952, ACTGA PAEDIATR U S82, V41; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BEWELY T, COMMUNICATION; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; CHAWLA RK, 1983, ANNU REV MED, V34, P519, DOI 10.1146/annurev.me.34.020183.002511; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BA, UNPUB; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; EDWARDS CK, 1988, SCIENCE, V239, P769, DOI 10.1126/science.2829357; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FUH G, 1990, J BIOL CHEM, V265, P3111; GOLD G, 1984, EXPERIENTIA, V40, P1105, DOI 10.1007/BF01971458; HERINGTON AC, 1985, BIOCHEM INT, V11, P853; HUGHES JP, 1985, ANNU REV PHYSIOL, V47, P469, DOI 10.1146/annurev.ph.47.030185.002345; HUTTON JC, 1984, EXPERIENTIA, V40, P1091, DOI 10.1007/BF01971456; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOPPELMAN MCS, 1989, J CLIN ENDOCR METAB, V68, P215, DOI 10.1210/jcem-68-1-215; KOPPELMAN MCS, 1988, MED HYPOTHESES, V25, P65, DOI 10.1016/0306-9877(88)90020-5; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KURTOGU S, 1987, Tokai Journal of Experimental and Clinical Medicine, V12, P325; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENTNER C, 1981, SCI TABLES, V3, P79; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; NISHI Y, 1989, J AM COLL NUTR, V8, P93; ONER G, 1984, ENDOCRINOLOGY, V114, P1860, DOI 10.1210/endo-114-5-1860; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PRASAD AS, 1985, CLIN ENDOCRINOL META, V14, P567, DOI 10.1016/S0300-595X(85)80007-4; RAY J, 1990, J BIOL CHEM, V265, P7939; ROOT AW, 1979, J NUTR, V109, P958, DOI 10.1093/jn/109.6.958; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SMITH WC, 1989, MOL ENDOCRINOL, V3, P9884; THORLACIUSUSSING O, 1987, NEUROENDOCRINOLOGY, V45, P233, DOI 10.1159/000124731; THORNER MO, 1988, J CLIN INVEST, V82, P745, DOI 10.1172/JCI113673; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	47	261	272	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1709	1712		10.1126/science.2270485	http://dx.doi.org/10.1126/science.2270485			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2270485				2022-12-01	WOS:A1990EN92000041
J	DENNER, LA; WEIGEL, NL; MAXWELL, BL; SCHRADER, WT; OMALLEY, BW				DENNER, LA; WEIGEL, NL; MAXWELL, BL; SCHRADER, WT; OMALLEY, BW			REGULATION OF PROGESTERONE RECEPTOR-MEDIATED TRANSCRIPTION BY PHOSPHORYLATION	SCIENCE			English	Article									BAYLOR UNIV, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor University					NICHD NIH HHS [HD-07857, HD-22061] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD007857] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022061, R37HD007857] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADSHAW MS, 1988, J BIOL CHEM, V263, P8485; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; BUCHLER W, 1988, FEBS LETT, V228, P27, DOI 10.1016/0014-5793(88)80577-5; CARSONJURICA MA, 1989, J STEROID BIOCHEM, V34, P1, DOI 10.1016/0022-4731(89)90060-5; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Conneely OM, 1989, GENE REGULATION STER, V4, P220; DENNER LA, 1987, J STEROID BIOCHEM, V27, P235, DOI 10.1016/0022-4731(87)90315-3; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1989, ENDOCRINOLOGY, V125, P3051, DOI 10.1210/endo-125-6-3051; DENNER LA, UNPUB; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; DONG Y, 1989, J BIOL CHEM, V264, P13679; DOUGHERTY JJ, 1982, J BIOL CHEM, V257, P4226; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEIL PD, 1988, ENDOCRINOLOGY, V123, P2506, DOI 10.1210/endo-123-5-2506; GARCIA T, 1986, P NATL ACAD SCI USA, V83, P7573, DOI 10.1073/pnas.83.20.7573; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRANDICS P, 1984, BIOCHEM BIOPH RES CO, V120, P59, DOI 10.1016/0006-291X(84)91413-X; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P50361; HORWITZ KB, 1985, DNA-J MOLEC CELL BIO, V4, P451, DOI 10.1089/dna.1985.4.451; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KURL RN, 1984, BIOCHEM BIOPH RES CO, V119, P700, DOI 10.1016/S0006-291X(84)80307-1; LOGEAT F, 1985, BIOCHEM BIOPH RES CO, V131, P421, DOI 10.1016/0006-291X(85)91819-4; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5705; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; POWER R, UNPUB; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SINGH VB, 1985, J BIOL CHEM, V260, P3684; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0	41	352	356	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1740	1743		10.1126/science.2176746	http://dx.doi.org/10.1126/science.2176746			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2176746				2022-12-01	WOS:A1990EN92000051
J	DODGE, KA; BATES, JE; PETTIT, GS				DODGE, KA; BATES, JE; PETTIT, GS			MECHANISMS IN THE CYCLE OF VIOLENCE	SCIENCE			English	Article									INDIANA UNIV, PSYCHOL, BLOOMINGTON, IN 47405 USA; CTR ADV STUDY BEHAV SCI, STANFORD, CA 94305 USA; AUBURN UNIV, FAMILY & CHILD DEV, AUBURN, AL 36844 USA	Indiana University System; Indiana University Bloomington; Auburn University System; Auburn University	DODGE, KA (corresponding author), VANDERBILT UNIV, PSYCHOL, NASHVILLE, TN 37203 USA.				PHS HHS [42498] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Achenbach T.M., 1986, MANUAL TEACHERS REPO; ALFARO JD, 1981, REPORT RELATIONSHIP; ALTEMEIER W, 1984, CHILD ABUSE NEGLECT, V12, P393; ASARNOW JR, 1985, J CONSULT CLIN PSYCH, V53, P500; BANDURA A, 1986, SOCIAL F THOUGHT ACT; Bandura A., 1973, AGGRESSION SOCIAL LE, DOI DOI 10.1086/225777; Bates J. E., 1989, TEMPERAMENT CHILDHOO, P321; BATES JE, 1984, MERRILL PALMER QUART, V30, P111; BELL RQ, 1968, PSYCHOL REV, V75, P81, DOI 10.1037/h0025583; BELSKY J, 1980, AM PSYCHOL, V35, P320, DOI 10.1037/0003-066X.35.4.320; Cicchetti D., 1981, NEW DIR CHILD ADOLES, V11, P31, DOI [10.1002/cd.23219811104, DOI 10.1002/CD.23219811104]; Crittenden P. M., 1989, CHILD MALTREATMENT T, P432, DOI [10.1017/CBO9780511665707.015, 10.1017/CBO9780511665707.015., DOI 10.1017/CBO9780511665707.015]; DODGE KA, 1987, SOC COGNITION, V5, P280, DOI 10.1521/soco.1987.5.3.280; DODGE KA, 1980, CHILD DEV, V51, P162, DOI 10.1111/j.1467-8624.1980.tb02522.x; DODGE KA, 1986, SOC RES CHILD DEV MO, V51; DUBOWITZ H, 1986, CHILD MALTREATMENT U; GARBARINO J, 1977, J MARRIAGE FAM, V39, P721, DOI 10.2307/350477; GELLES RJ, 1973, AM J ORTHOPSYCHIAT, V43, P611, DOI 10.1111/j.1939-0025.1973.tb00830.x; Gil D. G., 1970, VIOLENCE CHILDREN PH; HOROWITZ B, 1981, SOCIAL CONTEXT CHILD; HOTALING GT, 1989, FAMILY VIOLENCE, P18; KAUFMAN J, 1987, AM J ORTHOPSYCHIAT, V57, P186, DOI 10.1111/j.1939-0025.1987.tb03528.x; KLEIN M, 1971, AM J DIS CHILD, V122, P15, DOI 10.1001/archpedi.1971.02110010051005; LEWIS DO, 1979, J AM ACAD CHILD PSY, V18, P307, DOI 10.1016/S0002-7138(09)61045-1; MCCABE V, 1984, CHILD DEV, V55, P267, DOI 10.2307/1129851; MCFALL RM, 1982, BEHAV ASSESS, V4, P1; MISCHEL W, 1973, PSYCHOL REV, V80, P252, DOI 10.1037/h0035002; Nelson B.J., 1984, MAKING ISSUE CHILD A; OLWEUS D, 1979, PSYCHOL BULL, V86, P852, DOI 10.1037/0033-2909.86.4.852; Parke R. D., 1975, REV CHILD DEV RES, V5, P509; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; PERRY DG, 1986, CHILD DEV, V57, P700, DOI 10.2307/1130347; Pianta R., 1989, CHILD MALTREATMENT T, P203; ROSENBAUM M, 1986, AM J PSYCHIAT, V143, P367; Ross C. J., 1980, CHILD ABUSE AGENDA A, P63; RUBIN KH, 1986, MINN SYM CHILD PSYCH, V18, P1; Rutter M., 1983, JUVENILE DELINQUENCY; Sameroff A, 1975, REV CHILD DEV RES; SANCILIO MFM, 1989, DEV PSYCHOL, V25, P812, DOI 10.1037/0012-1649.25.5.812; SELTZER JA, 1988, SOC FORCES, V67, P473, DOI 10.2307/2579191; SLABY RG, 1988, DEV PSYCHOL, V24, P580, DOI 10.1037/0012-1649.24.4.580; SROUFE LA, 1986, CHILD DEV, V56, P1; Stern D.N., 1985, INTERPERSONAL WORLD; Straus M. A., 1988, FAMILY ABUSE ITS CON, P14; Straus M.A., 1980, CLOSED DOORS VIOLENC, DOI DOI 10.4324/9781351298681; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; TONGE W, 1975, BR J PSYCHIATR SPEC, V11; Wauchope B., 1990, PHYSICAL VIOLENCE AM, P133; WIDOM CS, 1989, SCIENCE, V244, P160, DOI 10.1126/science.2704995; WOLFE DA, 1985, PSYCHOL BULL, V97, P462, DOI 10.1037/0033-2909.97.3.462	50	1152	1169	1	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1678	1683		10.1126/science.2270481	http://dx.doi.org/10.1126/science.2270481			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2270481				2022-12-01	WOS:A1990EN92000033
J	FRANCY, DB; KARABATSOS, N; WESSON, DM; MOORE, CG; LAZUICK, JS; NIEBYLSKI, ML; TSAI, TF; CRAIG, GB				FRANCY, DB; KARABATSOS, N; WESSON, DM; MOORE, CG; LAZUICK, JS; NIEBYLSKI, ML; TSAI, TF; CRAIG, GB			A NEW ARBOVIRUS FROM AEDES-ALBOPICTUS, AN ASIAN MOSQUITO ESTABLISHED IN THE UNITED-STATES	SCIENCE			English	Article									UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN 46556 USA	University of Notre Dame	FRANCY, DB (corresponding author), CTR DIS CONTROL, CTR INFECT DIS, DIV VECTOR BORNE INFECT DIS, FT COLLINS, CO 80522 USA.							BERRY RL, 1983, P OHIO MOSQ CONTROL, V13, P13; BOROMISA RD, 1987, J AM MOSQUITO CONTR, V3, P378; BRANDT WE, 1967, AM J TROP MED HYG, V16, P339, DOI 10.4269/ajtmh.1967.16.339; CALISHER CH, 1988, AM J TROP MED HYG, V39, P117, DOI 10.4269/ajtmh.1988.39.117; CALISHER CH, 1983, CLIFORNIA SEROGROUP; CRAVEN RB, 1988, J AM MOSQUITO CONTR, V4, P138; EADS RB, 1972, MOSQ NEWS, V32, P113; EMMONS RW, 1983, J AM VET MED ASSOC, V183, P555; FRANCY DB, 1989, AM J TROP MED HYG, V41, P355, DOI 10.4269/ajtmh.1989.41.355; GRIMSTAD PR, 1989, J AM MOSQUITO CONTR, V5, P422; HEARD P, COMMUNICATION; HEDBERG CW, 1985, J AM MOSQUITO CONTR, V1, P89; HOFF G L, 1970, Journal of Wildlife Diseases, V6, P483; JUMALI, 1979, AM J TROP MED HYG, V28, P717; MANGIAFICO JA, 1988, AM J TROP MED HYG, V39, P593, DOI 10.4269/ajtmh.1988.39.593; MCGOWAN JE, 1973, AM J EPIDEMIOL, V97, P199, DOI 10.1093/oxfordjournals.aje.a121500; MCLEAN RG, 1985, AM J TROP MED HYG, V34, P1190, DOI 10.4269/ajtmh.1985.34.1190; METSELAAR D, 1980, B WORLD HEALTH ORGAN, V58, P937; MITCHELL CJ, 1990, J AM MOSQUITO CONTR, V6, P523; MITCHELL CJ, 1987, J AM MOSQUITO CONTR, V3, P460; NASCI RS, 1981, MOSQ NEWS, V41, P808; PANTUWATANA S, 1971, THESIS U WISCONSIN M; PRATT J J Jr, 1946, Mil Surg, V99, P785; REITER P, 1987, J AM MOSQUITO CONTR, V3, P494; SHROYER DA, 1986, J AM MOSQUITO CONTR, V2, P424; SPRENGER D, 1986, J AM MOSQUITO CONTR, V2, P217; TESH RB, 1980, AM J TROP MED HYG, V29, P657, DOI 10.4269/ajtmh.1980.29.657; TSAI TC, UNPUB; Wesson D., 1990, Proceedings of the Illinois Mosquito and Vector Control Association, V1, P11; YUILL TM, 1970, AM J TROP MED HYG, V19, P506, DOI 10.4269/ajtmh.1970.19.506; 1989, FOREIGN ANIM DIS REP, V17, P12; 1986, MORBID MORTAL WKLY R, V35, P649; 1987, FOREIGN ANIM DIS REP, V15, P2	33	48	48	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1738	1740		10.1126/science.2270489	http://dx.doi.org/10.1126/science.2270489			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2270489				2022-12-01	WOS:A1990EN92000050
J	GAUB, MP; BELLARD, M; SCHEUER, I; CHAMBON, P; SASSONECORSI, P				GAUB, MP; BELLARD, M; SCHEUER, I; CHAMBON, P; SASSONECORSI, P			ACTIVATION OF THE OVALBUMIN GENE BY THE ESTROGEN-RECEPTOR INVOLVES THE FOS-JUN COMPLEX	CELL			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING PROTEINS; PROTO-ONCOGENE FOS; LEUCINE-ZIPPER; CHICKEN OVALBUMIN; C-FOS; GLUCOCORTICOID REPRESSION; PROGESTERONE-RECEPTOR; REGULATORY ELEMENTS; RESPONSIVE ELEMENT	The proximal region of the ovalbumin gene promoter contains a half-palindromic estrogen-responsive element (ERE) that mediates cell-specific trans-activation by the estrogen receptor (ER). We show that the ovalbumin ERE binds a ubiquitous nucleoprotein complex containing oncoproteins c-Fos and c-Jun. Mutations altering the estrogen inducibility of the promoter prevent the complex formation, which is, however, found in the presence and absence of ER and estradiol. Mutagenesis indicates that the sequence 5'-TGGGTCA-3', containing the half-palindromic ERE, is responsible for induction by phorbol esters of the ovalbumin promoter and is a target for c-fos and c-jun trans-activation. Transfection experiments reveal that c-fos, c-jun, and ER coactivate the ovalbumin promoter. Direct ER interaction with the target sequence is not required, since an ER deleted for its DNA binding domain is functional in the coactivation with c-fos and c-jun. Our data indicate a convergence of hormonal induction and activation of signal transduction pathways at the transcriptional level.			GAUB, MP (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL, CNRS, GENET MOLEC EUCARYOTES LAB, INSERM, F-67085 STRASBOURG, FRANCE.		Sassone-Corsi, Paolo/H-6182-2011					AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1991, IN PRESS CELL; BAILLY A, 1986, EMBO J, V5, P3235, DOI 10.1002/j.1460-2075.1986.tb04634.x; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BELLARD M, 1986, EMBO J, V5, P567, DOI 10.1002/j.1460-2075.1986.tb04248.x; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHAMBON P, 1984, RECENT PROG HORM RES, V40, P1; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENNER LA, 1989, ENDOCRINOLOGY, V125, P3051, DOI 10.1210/endo-125-6-3051; DIERICH A, 1987, EMBO J, V6, P2305, DOI 10.1002/j.1460-2075.1987.tb02505.x; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; EVANS MI, 1981, CELL, V25, P187, DOI 10.1016/0092-8674(81)90243-9; EVANS MI, 1984, ENDOCRINOLOGY, V115, P368, DOI 10.1210/endo-115-1-368; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GAUB MP, 1987, EMBO J, V6, P2313, DOI 10.1002/j.1460-2075.1987.tb02506.x; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; KAYE JS, 1986, EMBO J, V5, P277, DOI 10.1002/j.1460-2075.1986.tb04210.x; KOHLER PO, 1969, J CELL BIOL, V40, P8, DOI 10.1083/jcb.40.1.8; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OKA T, 1969, J CELL BIOL, V43, P123, DOI 10.1083/jcb.43.1.123; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PALMITER RD, 1977, COLD SPRING HARB SYM, V42, P639, DOI 10.1101/SQB.1978.042.01.066; PASTORCIC M, 1989, NUCLEIC ACIDS RES, V17, P6693, DOI 10.1093/nar/17.16.6693; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SANDERS MM, 1988, BIOCHEMISTRY-US, V27, P6550, DOI 10.1021/bi00417a053; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SOLOMON JJ, 1976, TCS MANUAL TISSUE CU, V1, P7; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	73	456	470	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 21	1990	63	6					1267	1276		10.1016/0092-8674(90)90422-B	http://dx.doi.org/10.1016/0092-8674(90)90422-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2124518				2022-12-01	WOS:A1990EN92300017
J	GOELZ, SE; HESSION, C; GOFF, D; GRIFFITHS, B; TIZARD, R; NEWMAN, B; CHIROSSO, G; LOBB, R				GOELZ, SE; HESSION, C; GOFF, D; GRIFFITHS, B; TIZARD, R; NEWMAN, B; CHIROSSO, G; LOBB, R			ELFT - A GENE THAT DIRECTS THE EXPRESSION OF AN ELAM-1 LIGAND	CELL			English	Article							LEUKOCYTE-ENDOTHELIAL INTERACTIONS; ACTIVATED PLATELETS; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; MEMBRANE-PROTEIN; ANIMAL-CELLS; ADHESION; RECEPTOR; CDNA; NEUTROPHILS	The LECCAMs are a family of cell adhesion molecules implicated in certain inflammatory processes. ELAM-1, a LECCAM found on the surface of activated endothelial cells, can mediate adhesion of neutrophils, monocytes, and certain cell lines to endothelial cells in vitro. No ligand for any LECCAM has yet been fully characterized. Here we report the cloning of a cDNA, ELFT (ELAM-1 ligand fucosyltransferase), that can confer ELAM-1 binding activity when transfected into nonbinding cells lines. ELFT encodes a 46 kd protein that has alpha-(1,3)fucosyltransferase activity, suggesting that a fucosylated carbohydrate structure is an essential component of the ELAM-1 ligand. Furthermore, ELFT is expressed specifically in cell types that bind to ELAM-1, suggesting that this enzyme is an important regulator of inflammatory events in vivo.			GOELZ, SE (corresponding author), BIOGEN INC,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARSOUM J, 1990, DNA CELL BIOL, V9, P293, DOI 10.1089/dna.1990.9.293; BENJAMIN C, 1990, BIOCHEM BIOPH RES CO, V171, P348, DOI 10.1016/0006-291X(90)91400-M; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CARLOS T, 1990, IN PRESS BLOOD; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; DAVIS MM, 1986, HDB EXPT IMMUNOLOGY, V2, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HARLAN JM, 1985, BLOOD, V65, P513; HARLOW E, 1988, ANTIBODIES LABORATOR; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAXAM A, 1980, METHOD ENZYMOL, V68, P499; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OHMORI K, 1989, BLOOD, V74, P255; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PHILLIPS ML, 1990, IN PRESS SCIENCE; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TOONE EJ, 1989, TETRAHEDRON, V45, P5365, DOI 10.1016/S0040-4020(01)89487-4; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	44	305	324	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1349	1356		10.1016/0092-8674(90)90430-M	http://dx.doi.org/10.1016/0092-8674(90)90430-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	1702034				2022-12-01	WOS:A1990EN92300025
J	HUGHES, RE; HATFULL, GF; RICE, P; STEITZ, TA; GRINDLEY, NDF				HUGHES, RE; HATFULL, GF; RICE, P; STEITZ, TA; GRINDLEY, NDF			COOPERATIVITY MUTANTS OF THE GAMMA-DELTA RESOLVASE IDENTIFY AN ESSENTIAL INTERDIMER INTERACTION	CELL			English	Article							GAMMA-DELTA-RESOLVASE; SITE-SPECIFIC RECOMBINATION; TN3 RESOLVASE; RES-SITES; DNA; BINDING; EXPRESSION; ACTIVATION; CLEAVAGE; CLONING	Gamma-beta resolvase, a transposon-encoded site-specific recombinase, catalyzes the resolution of the cointegrate intermediate of gamma-delta transposition. The recombination reaction involves the formation of a catalytic nucleoprotein complex whose structure is determined by specific protein-DNA and protein-protein interactions. We have isolated many resolvase mutants and have identified four that are unable to mediate a subclass of higher order protein-protein interactions necessary for recombination. This mutant phenotype is characterized by an inability to catalyze recombination, a loss of cooperative binding to res DNA, and a failure to induce looping out of the DNA between two resolvase binding sites within res. The amino acid side chains identified by the cooperatively mutants cluster on a surface of the protein that mediates an interaction between resolvase dimers in a crystallographic tetramer. We have therefore identified a region of resolvase that mediates an interdimer protein-protein interaction necessary for the formation of the recombinogenic synaptic intermediate.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University			Steitz, Thomas A./C-6559-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028470, R37GM028470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28470, GM22778] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMEGUID SS, 1984, P NATL ACAD SCI-BIOL, V81, P2001, DOI 10.1073/pnas.81.7.2001; BENJAMIN HW, 1990, J BIOL CHEM, V265, P6441; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COZZARELLI NR, 1984, COLD SPRING HARB SYM, V49, P383, DOI 10.1101/SQB.1984.049.01.045; DROGE P, 1990, IN PRESS P NATL ACAD, V87; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; GRINDLEY NDF, 1985, ANNU REV BIOCHEM, V54, P863, DOI 10.1146/annurev.biochem.54.1.863; GRINDLEY NDF, 1982, CELL, V30, P19, DOI 10.1016/0092-8674(82)90007-1; GUARENTE L, 1980, CELL, V20, P543, DOI 10.1016/0092-8674(80)90640-6; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HATFULL GF, 1986, P NATL ACAD SCI USA, V83, P5429, DOI 10.1073/pnas.83.15.5429; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; HOCHSCHILD A, 1988, NATURE, V336, P353, DOI 10.1038/336353a0; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NEWMAN BJ, 1984, CELL, V38, P463, DOI 10.1016/0092-8674(84)90501-4; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REED RR, 1984, COLD SPRING HARB SYM, V49, P245, DOI 10.1101/SQB.1984.049.01.028; REED RR, 1981, CELL, V25, P721, DOI 10.1016/0092-8674(81)90179-3; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; RIMPHANITCHAYAKIT V, 1989, NUCLEIC ACIDS RES, V17, P1035, DOI 10.1093/nar/17.3.1035; RIMPHANITCHAYAKIT V, 1990, EMBO J, V9, P719, DOI 10.1002/j.1460-2075.1990.tb08165.x; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SCHLEIF R, 1988, SCIENCE, V240, P127, DOI 10.1126/science.3353710; SHERRATT D, 1989, MOBILE DNA, P163; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; VALENZUELA D, 1989, EMBO J, V8, P4345, DOI 10.1002/j.1460-2075.1989.tb08621.x	32	74	74	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1331	1338		10.1016/0092-8674(90)90428-H	http://dx.doi.org/10.1016/0092-8674(90)90428-H			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2175679				2022-12-01	WOS:A1990EN92300023
J	HUNTER, CP; WOOD, WB				HUNTER, CP; WOOD, WB			THE TRA-1 GENE DETERMINES SEXUAL PHENOTYPE CELL-AUTONOMOUSLY IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; POST-EMBRYONIC DEVELOPMENT; DOSAGE COMPENSATION; CHROMOSOME; LINEAGES; PROTEIN; FAMILY	The tra-1 gene plays a central role in C. elegans sex determination. XX animals develop as hermaphrodites when tra-1 is active and as males when it is not. By analyzing a large number of tra-1 genetic mosaics we have shown that, with the expected exception of vulval induction by the hermaphrodite gonad, tra-1 functions cell-autonomously, consistent with a role as an intracellular component of a signaling pathway. Moreover, all the sexual differentiation genes under tra-1 control must also function cell-autonomously. Our results have additional implications for several aspects of postembryonic development, including mechanisms of sex-specific directed cell migration and the question of an organizer in the male tail.			HUNTER, CP (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011762] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-11762] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BLUMENTHAL T, 1984, J MOL BIOL, V174, P1, DOI 10.1016/0022-2836(84)90361-9; BRENNER S, 1974, GENETICS, V77, P71; HEINE U, 1986, J MOL BIOL, V188, P301, DOI 10.1016/0022-2836(86)90156-7; HERMAN RK, 1984, GENETICS, V108, P165; HERMAN RK, 1989, J NEUROGENET, V5, P1, DOI 10.3109/01677068909167261; HERMAN RK, 1976, GENETICS, V83, P91; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1987, ANNU REV GENET, V21, P133, DOI 10.1146/annurev.ge.21.120187.001025; HODGKIN J, 1983, NATURE, V304, P267, DOI 10.1038/304267a0; HODGKIN J, 1988, NEMATODE CAENORHABDI, P491; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HORVITZ HR, 1979, MOL GEN GENET, V175, P129, DOI 10.1007/BF00425528; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KIMBLE J, 1983, DEV BIOL, V96, P189, DOI 10.1016/0012-1606(83)90322-6; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; LINK CD, 1988, DEVELOPMENT, V103, P485; MADL JE, 1979, GENETICS, V93, P393; MEYER BJ, 1988, TRENDS GENET, V4, P337, DOI 10.1016/0168-9525(88)90053-4; NIGON V, 1951, BIOL B FR BELG, V95, P187; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; SCHEDL T, 1989, GENETICS, V123, P755; SPIETH J, 1985, MOL CELL BIOL, V5, P2495, DOI 10.1128/MCB.5.10.2495; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; VILLENEUVE AM, 1990, GENETICS, V124, P91; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q	35	50	56	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1193	1204		10.1016/0092-8674(90)90415-B	http://dx.doi.org/10.1016/0092-8674(90)90415-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2261640				2022-12-01	WOS:A1990EN92300010
J	INTRONA, M; GOLAY, J; FRAMPTON, J; NAKANO, T; NESS, SA; GRAF, T				INTRONA, M; GOLAY, J; FRAMPTON, J; NAKANO, T; NESS, SA; GRAF, T			MUTATIONS IN V-MYB ALTER THE DIFFERENTIATION OF MYELOMONOCYTIC CELLS TRANSFORMED BY THE ONCOGENE	CELL			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; C-MYB; LEUKEMIA-VIRUS; TARGET-CELLS; HEMATOPOIETIC-CELLS; MYELOID CELLS; AMINO-ACID; DNA; EXPRESSION; GENE	Chick myelomonocytic cells transformed by the v-myb oncogene-containing viruses E26 and AMV differ in that the former resemble myeloblasts and express the v-myb-regulated granulocyte-specific mim-1 gene, while the latter resemble monoblasts and are mim-1 negative. We constructed a series of AMV-E26 chimeras and localized the critical differences between these viruses to three point mutations within the second repeat of the v-myb DNA binding domain. These three positions are altered in the v-myb protein of AMV relative to the proteins encoded by c-myb or E26 v-myb. Back mutating AMV v-myb at any of these three sites restored the oncogene's ability to activate the mim-1 gene. Surprisingly, two of these changes led to the transformation, in vitro and in vivo, of cells having a promyelocyte-like phenotype. These results indicate that different forms of v-myb impose alternate phenotypes of differentiation on transformed myeloid cells, probably by regulating unique sets of differentiation-specific genes.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Introna, Martino/AAA-5823-2019; Ness, Scott/AAV-4009-2020; Graf, Thomas/B-4252-2015; Golay, Josee/AAA-4085-2022	Introna, Martino/0000-0001-6216-0892; Ness, Scott/0000-0001-6965-8909; Graf, Thomas/0000-0003-2774-4117; Golay, Josee/0000-0002-7932-909X	NCI NIH HHS [CA08076] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER TP, 1986, CURR TOP MICROBIOL, V132, P153; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GRAF T, 1988, IARC SCI PUBL, V92, P165; GRAF T, 1987, MOL BASIS VIRAL BACT, V38, P91; Hansen N E, 1974, Ser Haematol, V7, P1; Hauser H, 1981, Haematol Blood Transfus, V26, P175; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JANSSON M, 1987, ONCOGENE, V1, P167; KASTAN MB, 1989, BLOOD, V74, P1517; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KRISTENSEN T, 1987, NUCLEIC ACIDS RES, V15, P5507, DOI 10.1093/nar/15.14.5507; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LUCAS AM, 1961, MONOGR USDA, V25; MANDI Y, 1987, IMMUNOBIOLOGY, V174, P292, DOI 10.1016/S0171-2985(87)80004-9; Maniatis T., 1982, MOL CLONING; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MOSCOVICI C, 1981, VIROLOGY, V129, P65; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P11154; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PESSANO S, 1979, MICROBIOLOGICA, V2, P379; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SAKAWA H, 1989, P NATL ACAD SCI USA, V86, P5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SOTIROV N, 1981, J NATL CANCER I, V66, P1143, DOI 10.1093/jnci/66.6.1143; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STOBERGRASSER U, 1988, J VIROL, V62, P1093; STOCKING C, 1985, P NATL ACAD SCI USA, V82, P5746, DOI 10.1073/pnas.82.17.5746; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TREISMAN J, 1989, CELL, V59, P553; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	57	157	159	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1287	1297		10.1016/0092-8674(90)90424-D	http://dx.doi.org/10.1016/0092-8674(90)90424-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2261644				2022-12-01	WOS:A1990EN92300019
J	JONES, LA; CHIN, LT; LONGO, DL; KRUISBEEK, AM				JONES, LA; CHIN, LT; LONGO, DL; KRUISBEEK, AM			PERIPHERAL CLONAL ELIMINATION OF FUNCTIONAL T-CELLS	SCIENCE			English	Article											JONES, LA (corresponding author), NCI, BIOL RESPONSE MODIFIERS PROGRAM, BETHESDA, MD 20892 USA.		Longo, Dan L./F-6022-2011					ABE R, 1988, J IMMUNOL, V140, P4132; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BRUCE J, 1981, J IMMUNOL, V127, P2496; DAVID CS, 1990, TRANSGENIC MICE AND MUTANTS IN MHC RESEARCH, P229; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; FRY AM, 1989, SCIENCE, V246, P1044, DOI 10.1126/science.2511630; GLASEBROOK AL, 1980, J EXP MED, V151, P876, DOI 10.1084/jem.151.4.876; HODES RJ, 1989, SCIENCE, V246, P1041, DOI 10.1126/science.2587987; JANEWAY CA, 1980, IMMUNOGENETICS, V10, P481, DOI 10.1007/BF01572583; JANEWAY CA, 1985, J IMMUNOL, V134, P2057; JONES LA, 1990, J EXP MED, V172, P1277, DOI 10.1084/jem.172.5.1277; JONES LA, UNPUB; JONES LA, 1989, PROG IMMUNOL, V7, P289; JORDAN RK, 1985, NATURE, V314, P454, DOI 10.1038/314454a0; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; KUBO RT, 1989, J IMMUNOL, V142, P2736; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; LYNCH DH, 1985, J IMMUNOL, V134, P2071; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MACDONALD HR, 1990, J EXP MED, V171, P1381, DOI 10.1084/jem.171.4.1381; MACDONALD HR, 1988, NATURE, V335, P174, DOI 10.1038/335174a0; MACPHAIL S, 1984, EUR J IMMUNOL, V14, P318, DOI 10.1002/eji.1830140408; MACPHAIL S, 1986, IMMUNOGENETICS, V24, P139; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MARRACK P, 1988, CELL, V53, P627, DOI 10.1016/0092-8674(88)90578-8; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MILLER J, 1990, J IMMUNOL, V144, P334; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; OZATO K, 1980, J IMMUNOL, V124, P533; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; READY AR, 1984, NATURE, V310, P231, DOI 10.1038/310231a0; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SMITH H, 1989, SCIENCE, V245, P749, DOI 10.1126/science.2788921; SPEISER DE, 1989, J EXP MED, V170, P595, DOI 10.1084/jem.170.2.595; SPEISER DE, 1989, J EXP MED, V170, P2165, DOI 10.1084/jem.170.6.2165; SPRENT J, 1976, CELL IMMUNOL, V21, P278, DOI 10.1016/0008-8749(76)90057-5; VACCHIO MS, 1989, J EXP MED, V170, P1335, DOI 10.1084/jem.170.4.1335; VONBOEHMER H, 1986, NATURE, V320, P626, DOI 10.1038/320626a0; VONBOEHMER H, 1984, EUR J IMMUNOL, V14, P1048, DOI 10.1002/eji.1830141116; WALL KA, 1983, J IMMUNOL, V131, P1056; WEBB SR, 1990, J EXP MED, V171, P953, DOI 10.1084/jem.171.3.953; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289	62	235	242	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1726	1729		10.1126/science.2125368	http://dx.doi.org/10.1126/science.2125368			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2125368				2022-12-01	WOS:A1990EN92000046
J	MAYENO, AN; LIN, F; FOOTE, CS; LOEGERING, DA; AMES, MM; HEDBERG, CW; GLEICH, GJ				MAYENO, AN; LIN, F; FOOTE, CS; LOEGERING, DA; AMES, MM; HEDBERG, CW; GLEICH, GJ			CHARACTERIZATION OF PEAK-E, A NOVEL AMINO-ACID ASSOCIATED WITH EOSINOPHILIA-MYALGIA-SYNDROME	SCIENCE			English	Article									MINNESOTA DEPT HLTH, ACUTE DIS EPIDEMIOL SECT, MINNEAPOLIS, MN 55440 USA; INDIANA UNIV, DEPT CHEM, BLOOMINGTON, IN 47405 USA; UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA; MAYO CLIN & MAYO FDN, DEPT ONCOL, ROCHESTER, MN 55905 USA	Minnesota Department of Health (MHD); Indiana University System; Indiana University Bloomington; University of California System; University of California Los Angeles; Mayo Clinic	MAYENO, AN (corresponding author), MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009728, R01AI015233, R01AI009728] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 07047, AI 09728, AI 15233] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; GONZALEZ C, 1985, HETEROCYCLES, V23, P1127; HUNT JN, 1968, HDB PHYSIOLOGY     6, V4, P1917; SAKIMOTO K, 1990, NEW ENGL J MED, V323, P992; SLUTSKER L, 1990, JAMA-J AM MED ASSOC, V264, P213, DOI 10.1001/jama.264.2.213; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; WILSON EM, 1965, TETRAHEDRON, V21, P2561, DOI 10.1016/S0040-4020(01)93911-0; 1990, MORB MORTAL WKLY REP, V39, P589; 1990, MORB MORTAL WKLY REP, V39, P587; 1990, MORB MORTAL WKLY REP, V39, P789	10	168	174	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1707	1708		10.1126/science.2270484	http://dx.doi.org/10.1126/science.2270484			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2270484				2022-12-01	WOS:A1990EN92000040
J	MCDONALD, HB; STEWART, RJ; GOLDSTEIN, LSB				MCDONALD, HB; STEWART, RJ; GOLDSTEIN, LSB			THE KINESIN-LIKE NCD PROTEIN OF DROSOPHILA IS A MINUS END-DIRECTED MICROTUBULE MOTOR	CELL			English	Article							CLARET LOCUS; IDENTIFICATION; MELANOGASTER; MOTILITY	The Drosophila ncd gene is required for chromosome segregation during female meiosis. Previous analyses suggested that the ncd gene encoded a protein with sequence similarity to the kinesin motor domain, which suggested that, like kinesin, the ncd protein might be a plus end-directed microtubule motor. Here we describe the expression of ncd protein in E. coli and the initial characterization of the ncd protein's motor properties. The ncd protein is indeed a microtubule motor, but the polarity of movement is minus end directed. The ncd protein also has microtubule bundling activity. These findings limit possible models for the in vivo functions of the ncd protein and suggest that motor proteins with similar sequence can generate movement in opposite directions along a microtubule.			MCDONALD, HB (corresponding author), HARVARD UNIV, DEPT CELLULAR & DEV BIOL, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GM 29301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM029301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker BS, 1976, GENETICS BIOL DROS B, P351; DAVIS DG, 1969, GENETICS, V61, P577; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; EUTENEUER U, 1981, J CELL BIOL, V89, P338, DOI 10.1083/jcb.89.2.338; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HYMAN A, 1990, IN PRESS METH ENZYMO; HYMAN AA, 1990, IN PRESS J CELL SC S; KIMBLE M, 1983, J CELL SCI, V62, P301; LEWIS EB, 1952, GENETICS, V37, P600; Lye R.J., 1989, CELL MOVEMENT, V2, P141; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; OTOUSA J, 1980, DROS INF SERV, V55, P119; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SEQUEIRA W, 1989, GENETICS, V123, P511; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VALE RD, 1986, TRENDS BIOCHEM SCI, V11, P464, DOI 10.1016/0968-0004(86)90248-3; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; YAMAMOTO AH, 1989, EMBO J, V8, P3543, DOI 10.1002/j.1460-2075.1989.tb08526.x; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	31	312	313	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 21	1990	63	6					1159	1165		10.1016/0092-8674(90)90412-8	http://dx.doi.org/10.1016/0092-8674(90)90412-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2261638				2022-12-01	WOS:A1990EN92300007
J	MOHR, IJ; CLARK, R; SUN, S; ANDROPHY, EJ; MACPHERSON, P; BOTCHAN, MR				MOHR, IJ; CLARK, R; SUN, S; ANDROPHY, EJ; MACPHERSON, P; BOTCHAN, MR			TARGETING THE E1 REPLICATION PROTEIN TO THE PAPILLOMAVIRUS ORIGIN OF REPLICATION BY COMPLEX-FORMATION WITH THE E2 TRANSACTIVATOR	SCIENCE			English	Article									TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, DEPT DERMATOL, BOSTON, MA 02111 USA; CETUS CORP, EMERYVILLE, CA 94608 USA	Tufts Medical Center; Tufts University	MOHR, IJ (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA.			Androphy, Elliot/0000-0002-8104-0703	NCI NIH HHS [CA-42414, CA-30490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042414, R37CA030490, R01CA030490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; [Anonymous], UNPUB; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOTCHAN MR, 1986, PAPILLOMAVIRUSES, P53; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CLERTANT P, 1984, NATURE, V311, P276, DOI 10.1038/311276a0; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DELUCIA AL, 1986, J VIROL, V57, P138, DOI 10.1128/JVI.57.1.138-144.1986; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; DIMAIO D, 1986, J VIROL, V57, P475, DOI 10.1128/JVI.57.2.475-480.1986; DIMAIO D, 1988, EMBO J, V7, P1197, DOI 10.1002/j.1460-2075.1988.tb02931.x; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; GILBERT DM, 1987, CELL, V50, P59, DOI 10.1016/0092-8674(87)90662-3; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HERMONAT PL, 1987, J VIROL, V61, P3889, DOI 10.1128/JVI.61.12.3889-3895.1987; HOWLEY PM, 1990, VIROLOGY, P1625; HUBBERT NL, 1988, P NATL ACAD SCI USA, V85, P5864, DOI 10.1073/pnas.85.16.5864; KELLEY T, 1988, EUKARYOTIC DNA REPLI; KLEINER E, 1986, EMBO J, V5, P1945, DOI 10.1002/j.1460-2075.1986.tb04448.x; KNIGHT J, UNPUB; KNIGHT J, IN PRESS P NATL ACAD; Kornberg A., 1980, DNA REPLICATION; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; LAMBERT PF, 1990, J VIROL, V64, P950, DOI 10.1128/JVI.64.2.950-956.1990; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LAMBERT PF, 1989, J VIROL, V63, P3151, DOI 10.1128/JVI.63.7.3151-3154.1989; LAMBERT PF, 1988, J VIROL, V62, P4009, DOI 10.1128/JVI.62.11.4009-4015.1988; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LUSKY M, 1985, J VIROL, V53, P955, DOI 10.1128/JVI.53.3.955-965.1985; LUSKY M, UNPUB; MACPHERSON P, UNPUB; MAIORELLA B, 1988, BIO-TECHNOL, V6, P1406, DOI 10.1038/nbt1288-1406; McBride A, COMMUNICATION; MCBRIDE AA, 1989, J VIROL, V63, P5076, DOI 10.1128/JVI.63.12.5076-5085.1989; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MUNEMITSU S, IN PRESS MOL CELL BI; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PRIVES C, 1987, MOL CELL BIOL, V7, P3694, DOI 10.1128/MCB.7.10.3694; RABSON MS, 1986, DNA TUMOR VIRUSES CO, P235; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; RIESE DJ, 1990, J VIROL, V64, P944, DOI 10.1128/JVI.64.2.944-949.1990; SARVER N, 1984, J VIROL, V52, P377, DOI 10.1128/JVI.52.2.377-388.1984; SCHILLER JT, 1989, J VIROL, V63, P1775, DOI 10.1128/JVI.63.4.1775-1782.1989; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SPALHOLZ BA, 1987, J VIROL, V61, P2128, DOI 10.1128/JVI.61.7.2128-2137.1987; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STILLMAN B, 1985, EMBO J, V4, P2933, DOI 10.1002/j.1460-2075.1985.tb04026.x; Summers MD, 1987, TEXAS AGR EXPT STATI; SUN S, 1990, J VIROL, V64, P5093, DOI 10.1128/JVI.64.10.5093-5105.1990; THORNER L, 1988, J VIROL, V62, P2474, DOI 10.1128/JVI.62.7.2474-2482.1988; Urban J.J., UNPUB; USTAV M, COMMUNICATION; WALDECK W, 1984, EMBO J, V3, P2173, DOI 10.1002/j.1460-2075.1984.tb02109.x; WELLS RD, 1988, J BIOL CHEM, V263, P1095; YAGES JL, 1988, EUKARYOTIC DNA REPLI, P197; ZYSKIND JW, 1986, CELL, V46, P489, DOI 10.1016/0092-8674(86)90873-1	74	364	384	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1694	1699		10.1126/science.2176744	http://dx.doi.org/10.1126/science.2176744			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2176744				2022-12-01	WOS:A1990EN92000036
J	MOSSING, MC; SAUER, RT				MOSSING, MC; SAUER, RT			STABLE, MONOMERIC VARIANTS OF LAMBDA-CRO OBTAINED BY INSERTION OF A DESIGNED BETA-HAIRPIN SEQUENCE	SCIENCE			English	Article									MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)				Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-16982] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON WF, 1981, NATURE, V290, P754, DOI 10.1038/290754a0; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; CHERVENKA CH, 1970, MANUAL METHODS ANAL; CREIGHTON TE, 1983, BIOPOLYMERS, V22, P49, DOI 10.1002/bip.360220110; HUDSON JM, 1989, BIOTECHNIQUES, V7, P812; JOHNSON A, 1978, P NATL ACAD SCI USA, V75, P1783, DOI 10.1073/pnas.75.4.1783; MOSSING MC, UNPUB; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; OHLENDORF DH, 1982, NATURE, V298, P718, DOI 10.1038/298718a0; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PAKULA AA, 1989, PROTEINS, V5, P202, DOI 10.1002/prot.340050303; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAMYATNIN AA, 1972, PROG BIOPHYS MOL BIO, V24, P1007	18	73	73	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1712	1715		10.1126/science.2148648	http://dx.doi.org/10.1126/science.2148648			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2148648				2022-12-01	WOS:A1990EN92000042
J	MURPHY, KM; HEIMBERGER, AB; LOH, DY				MURPHY, KM; HEIMBERGER, AB; LOH, DY			INDUCTION BY ANTIGEN OF INTRATHYMIC APOPTOSIS OF CD4+CD8+TCRLO THYMOCYTES INVIVO	SCIENCE			English	Article									WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	MURPHY, KM (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA.		Eckhardt, Erik/G-1567-2010					BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; CRIMMINS DL, 1988, J CHROMATOGR, V443, P63, DOI 10.1016/S0021-9673(00)94783-6; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; GUIDOS CJ, 1990, J EXP MED, V172, P853; HENGARTNER H, 1988, NATURE, V336, P388, DOI 10.1038/336388a0; JENKINSON EJ, 1989, EUR J IMMUNOL, V19, P2175, DOI 10.1002/eji.1830191132; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; Murphy Keith M., UNPUB; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SETTE A, 1989, J IMMUNOL, V142, P35; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHI Y, 1989, NATURE, V339; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0	25	1711	1740	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1720	1723		10.1126/science.2125367	http://dx.doi.org/10.1126/science.2125367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2125367				2022-12-01	WOS:A1990EN92000044
J	NASSAL, M; JUNKERNIEPMANN, M; SCHALLER, H				NASSAL, M; JUNKERNIEPMANN, M; SCHALLER, H			TRANSLATIONAL INACTIVATION OF RNA FUNCTION - DISCRIMINATION AGAINST A SUBSET OF GENOMIC TRANSCRIPTS DURING HBV NUCLEOCAPSID ASSEMBLY	CELL			English	Article							HEPATITIS-B VIRUS; EUKARYOTIC MESSENGER-RNA; SECONDARY STRUCTURE; ESCHERICHIA-COLI; XENOPUS OOCYTES; PROMOTER REGION; PRECORE REGION; EXPRESSION; SECRETION; MECHANISMS	Hepatitis B virus (HBV) is the prototype member of the hepadnaviridae, a family of small enveloped DNA viruses that replicate by reverse transcription. Assembly of replication-competent HBV nucleocapsids is based on specific interactions between the core protein, the product(s) of the P gene, and the RNA pregenome, which is marked for encapsidation by containing a sequence near its 5' end that acts in cis as an encapsidation signal. However, HBV produces several additional, almost identical, genomic transcripts that also bear the encapsidation sequence, but that are not encapsidated. The mechanism underlying this selection process has remained mysterious. Here we demonstrate that translating 80S ribosomes (but not scanning 40S ribosomal subunits) advancing into the encapsidation signal prevent its functioning. This finding reveals translational modulation of RNA function as a further regulatory mechanism employed by hepadnaviruses to utilize efficiently the restricted coding capacity of their extremely compact genome.			NASSAL, M (corresponding author), UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, NEUENHEIMER FELD 282, W-6900 HEIDELBERG, GERMANY.		Nassal, Michael/U-4529-2019	Nassal, Michael/0000-0003-2204-9158				BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BRUNETTO MR, 1990, J HEPATOL, V10, P258, DOI 10.1016/0168-8278(90)90062-V; CHANG LJ, 1990, P NATL ACAD SCI USA, V87, P5158, DOI 10.1073/pnas.87.13.5158; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; ENDERS GH, 1987, J VIROL, V61, P35, DOI 10.1128/JVI.61.1.35-41.1987; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRYCZAN TJ, 1980, NUCLEIC ACIDS RES, V8, P6081, DOI 10.1093/nar/8.24.6081; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; JUNKERNIEPMANN M, 1990, IN PRESS EMBO J; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MAGNIUS LO, 1972, J IMMUNOL, V109, P1017; MAYFORD M, 1989, EMBO J, V8, P4307, DOI 10.1002/j.1460-2075.1989.tb08617.x; NASSAL M, 1990, NUCLEIC ACIDS RES, V18, P3077, DOI 10.1093/nar/18.10.3077; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; SCHLICHT HJ, 1987, J VIROL, V61, P3701, DOI 10.1128/JVI.61.12.3701-3709.1987; SHAKIN SH, 1986, J BIOL CHEM, V261, P6018; STANDRING DN, 1988, P NATL ACAD SCI USA, V85, P8405, DOI 10.1073/pnas.85.22.8405; STORMO GD, 1987, TRANSLATIONAL REGULA, P27; WEIMER T, 1987, J VIROL, V61, P3109, DOI 10.1128/JVI.61.10.3109-3113.1987; WILL H, 1987, J VIROL, V61, P904, DOI 10.1128/JVI.61.3.904-911.1987; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YAGINUMA K, 1989, J VIROL, V63, P2914, DOI 10.1128/JVI.63.7.2914-2920.1989; YANOFSKY C, 1988, J BIOL CHEM, V263, P609; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495	35	119	126	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 21	1990	63	6					1357	1363		10.1016/0092-8674(90)90431-D	http://dx.doi.org/10.1016/0092-8674(90)90431-D			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2261646				2022-12-01	WOS:A1990EN92300026
J	PARKHURST, SM; BOPP, D; ISHHOROWICZ, D				PARKHURST, SM; BOPP, D; ISHHOROWICZ, D			X-A RATIO, THE PRIMARY SEX-DETERMINING SIGNAL IN DROSOPHILA, IS TRANSDUCED BY HELIX-LOOP-HELIX PROTEINS	CELL			English	Article							SCUTE GENE-COMPLEX; DOSAGE COMPENSATION; SEGMENTATION GENE; CAENORHABDITIS-ELEGANS; DNA-BINDING; IMAGINAL DISKS; FUSHI-TARAZU; LETHAL GENE; MELANOGASTER; DAUGHTERLESS	Drosophila determines its sex by "counting" X chromosomes. We show that premature expression of the pair-rule segmentation gene hairy interferes with this process, resulting in female-specific lethality by inhibiting initiation of the master control gene Sexlethal (Sxl). The female-specific lethality can be suppressed by a constitutive Sxl allele or by extra copies of X-linked "counting elements." These results are best explained by competition between hairy and other helix-loop-helix transcription factors that act in chromosome counting. We have confirmed this model by showing that misexpression of the achaete-scute T4 gene induces ectopic Sxl expression and male-specific lethality, confirming that achaete-scute T4 is the sisterless-b counting element. We propose that X chromosomes are counted through heterodimers of helix-loop-helix transcription factors that act synergistically to initiate Sxl expression.	UNIV OXFORD, DEPT ZOOL,DEV BIOL UNIT,IMPERIAL CANC RES FUND, DEV GENET LAB,S PARKS RD, OXFORD OX1 3PS, ENGLAND; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	University of Oxford; Princeton University			Bopp, Daniel/L-3517-2018	Bopp, Daniel/0000-0002-0740-9672; Ish-Horowicz, David/0000-0001-5684-7129				ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; BAKER BS, 1983, ANNU REV GENET, V17, P345, DOI 10.1146/annurev.ge.17.120183.002021; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; Bridges CB, 1925, AM NAT, V59, P127, DOI 10.1086/280023; Bridges CB, 1921, SCIENCE, V54, P252, DOI 10.1126/science.54.1394.252; Bull J.J., 1983, EVOLUTION SEX DETERM; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CARR DH, 1971, J MED GENET, V8, P164, DOI 10.1136/jmg.8.2.164; CARROLL SB, 1986, CELL, V45, P113, DOI 10.1016/0092-8674(86)90543-X; CARROLL SB, 1988, GENE DEV, V2, P883, DOI 10.1101/gad.2.7.883; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; CHANDRA HS, 1985, P NATL ACAD SCI USA, V82, P1165, DOI 10.1073/pnas.82.4.1165; CLINE TW, 1986, GENETICS, V113, P641; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1976, GENETICS, V84, P723; CLINE TW, 1980, GENETICS, V96, P903; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1979, DEV BIOL, V72, P266, DOI 10.1016/0012-1606(79)90117-9; CLINE TW, 1985, ORIGIN EVOLUTION SEX, P301; CRONMILLER C, 1987, CELL, V48, P479, DOI 10.1016/0092-8674(87)90198-X; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; CRONMILLER C, 1986, DEV GENET, V7, P205, DOI 10.1002/dvg.1020070406; DAMBLYCHAUDIERE C, 1988, ROUX ARCH DEV BIOL, V197, P419, DOI 10.1007/BF00398993; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P246; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; Dobzhansky T, 1934, J GENET, V28, P349, DOI 10.1007/BF02981760; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; Erlich H.A., 1989, PCR TECHNOLOGY; FALK R, 1963, AM NAT, V97, P129, DOI 10.1086/282263; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GERGEN JP, 1987, GENETICS, V117, P477; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; HODGKIN J, 1989, CELL, V56, P905, DOI 10.1016/0092-8674(89)90619-3; HODGKIN J, 1987, DEVELOPMENT, V101, P5; HODGKIN J, 1987, ANNU REV GENET, V21, P133, DOI 10.1146/annurev.ge.21.120187.001025; HODGKIN J, 1983, NATURE, V304, P267, DOI 10.1038/304267a0; HOOPER KL, 1989, DEVELOPMENT, V107, P489; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; INGHAM PW, 1985, GENETICS, V111, P463; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; ISHHOROWICZ D, 1987, CELL, V51, P405, DOI 10.1016/0092-8674(87)90636-2; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY DL, 1985, DROS INF SERV, V62; LUCCHESI JC, 1978, SCIENCE, V202, P711, DOI 10.1126/science.715437; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; LYON MF, 1972, BIOL REV, V47, P1; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MADL JE, 1979, GENETICS, V93, P393; MAINE EM, 1985, CELL, V43, P521, DOI 10.1016/0092-8674(85)90181-3; MANGE AP, 1973, GENETICS, V73, P73; MCCOUBREY WK, 1988, SCIENCE, V242, P1146, DOI 10.1126/science.2973125; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OLIVER B, 1988, GENETICS, V120, P159; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SALZ HK, 1987, GENETICS, V117, P221; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STEINMANNZWICKY M, 1988, EMBO J, V7, P3889, DOI 10.1002/j.1460-2075.1988.tb03275.x; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; VAVRA SH, 1989, DEVELOPMENT, V107, P663; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WARING GL, 1987, P NATL ACAD SCI USA, V84, P2843, DOI 10.1073/pnas.84.9.2843; Wieschaus E., 1986, P199	90	150	151	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 21	1990	63	6					1179	1191		10.1016/0092-8674(90)90414-A	http://dx.doi.org/10.1016/0092-8674(90)90414-A			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2124516				2022-12-01	WOS:A1990EN92300009
J	PAROUSH, Z; KESHET, I; YISRAELI, J; CEDAR, H				PAROUSH, Z; KESHET, I; YISRAELI, J; CEDAR, H			DYNAMICS OF DEMETHYLATION AND ACTIVATION OF THE ALPHA-ACTIN GENE IN MYOBLASTS	CELL			English	Article							GENOMIC SEQUENCING REVEALS; CHICKEN VITELLOGENIN GENE; DNA METHYLATION; 5' END; CELLS; DIFFERENTIATION; TRANSCRIPTION; REQUIREMENTS; PATTERNS; PROMOTER	Transient transfection into L8 myoblasts has been used to study the rat alpha-actin gene promoter. Demodification of specific sites occurs in two stages, with a hemimethylated intermediate formed within a few hours after entry of the alpha-actin gene construct into the cell. The removal of the methyl moiety from the complementary strand takes place after a delay of at least 48 hr, and both events are actively carried out in the absence of DNA replication. By assaying gene activity during the course of the transfection, it was possible to demonstrate that demethylation of both strands at the critical CpG loci is essential to activate transcription. Genetic analysis revealed the existence of cis-acting elements required for demethylation. The recognition of these sites early in the differentiation process probably leads to the demodification events required to make the gene accessible to its transcription factors.			PAROUSH, Z (corresponding author), HEBREW UNIV JERUSALEM,SCH MED,DEPT CELLULAR BIOCHEM,JERUSALEM,ISRAEL.		Yisraeli, Joel/S-2031-2019	Yisraeli, Joel/0000-0001-6538-6686				BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BEDNARIK DP, 1990, EMBO J, V9, P1157, DOI 10.1002/j.1460-2075.1990.tb08222.x; BENVENISTY N, 1985, P NATL ACAD SCI USA, V82, P267, DOI 10.1073/pnas.82.2.267; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHARNAY P, 1985, MOL CELL BIOL, V5, P1498, DOI 10.1128/MCB.5.6.1498; DEUMLING B, 1981, P NATL ACAD SCI-BIOL, V78, P338, DOI 10.1073/pnas.78.1.338; FRANK D, 1990, PHILOS T ROY SOC B, V326, P241, DOI 10.1098/rstb.1990.0008; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KELLEY DE, 1988, MOL CELL BIOL, V8, P930, DOI 10.1128/MCB.8.2.930; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; MACLEOD D, 1983, NATURE, V306, P200, DOI 10.1038/306200a0; Maniatis T., 1982, MOL CLONING; MELLOUL D, 1984, EMBO J, V3, P983, DOI 10.1002/j.1460-2075.1984.tb01917.x; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; SALUZ HP, 1986, P NATL ACAD SCI USA, V83, P7167, DOI 10.1073/pnas.83.19.7167; SELDEN RF, 1989, CURRENT PROTOCOLS MO, P924; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; SULLIVAN CH, 1986, P NATL ACAD SCI USA, V83, P329; THOMPSON JP, 1986, P NATL ACAD SCI USA, V83, P7688, DOI 10.1073/pnas.83.20.7688; TOTH M, 1989, P NATL ACAD SCI USA, V86, P3728, DOI 10.1073/pnas.86.10.3728; VEDEL M, 1983, NUCLEIC ACIDS RES, V11, P4335, DOI 10.1093/nar/11.13.4335; WEISSHAAR B, 1988, J MOL BIOL, V202, P255, DOI 10.1016/0022-2836(88)90456-1; WILKS A, 1984, NUCLEIC ACIDS RES, V12, P1163, DOI 10.1093/nar/12.2.1163; WILKS AF, 1982, P NATL ACAD SCI-BIOL, V79, P4252, DOI 10.1073/pnas.79.14.4252; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x; YISRAELI J, 1986, CELL, V46, P409, DOI 10.1016/0092-8674(86)90661-6; Yisraeli J, 1984, DNA METHYLATION, P352	28	150	150	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1229	1237		10.1016/0092-8674(90)90418-E	http://dx.doi.org/10.1016/0092-8674(90)90418-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2261641				2022-12-01	WOS:A1990EN92300013
J	PRIVALSKY, ML; SHARIF, M; YAMAMOTO, KR				PRIVALSKY, ML; SHARIF, M; YAMAMOTO, KR			THE VIRAL ERBA ONCOGENE PROTEIN, A CONSTITUTIVE REPRESSOR IN ANIMAL-CELLS, IS A HORMONE-REGULATED ACTIVATOR IN YEAST	CELL			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; HEAT-SHOCK PROTEIN; THYROID-HORMONE; GLUCOCORTICOID RECEPTOR; V-ERBA; TRANS-ACTIVATION; RESPONSE ELEMENT; BINDING DOMAIN; RETINOIC-ACID; GENE	The v-erbA oncogene is a retrovirus-transduced and altered copy of a cellular gene for a thyroid hormone receptor. In animal cells, the v-erbA protein fails to respond to hormone and acts as a dominant negative allele, inhibiting gene activation normally conferred by the wild-type thyroid hormone receptor. We report here that, unexpectedly, the v-erbA protein acts as a hormone-regulated transcriptional activator in S. cerevisiae. We suggest that the ability of v-erbA protein to function as a transcriptional repressor or an activator is determined by interaction with, or modification by, other cellular factors, and that this phenomenon may be relevant to understanding ligand regulation of the normal thyroid and steroid hormone receptors.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	PRIVALSKY, ML (corresponding author), UNIV CALIF DAVIS,DEPT MICROBIOL,DAVIS,CA 95616, USA.							AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER DM, 1989, MOL CELL BIOL, V9, P3878, DOI 10.1128/MCB.9.9.3878; BONDE BG, 1990, J VIROL, V64, P1314, DOI 10.1128/JVI.64.3.1314-1320.1990; BOUCHER P, 1990, ONCOGENE, V5, P1303; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DENIS M, 1989, CANCER RES, V49, pS2275; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; INOUE A, 1983, ANAL BIOCHEM, V134, P176, DOI 10.1016/0003-2697(83)90280-4; JONAT G, 1990, CELL, V62, P1189; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MENDEL DB, 1990, PROG CLIN BIOL RES, V322, P97; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1990, IN PRESS NATURE; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PRIVALSKY ML, 1991, IN PRESS J BIOL CHEM; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHENA M, 1990, IN PRESS METH ENZYMO; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	48	86	90	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1277	1286		10.1016/0092-8674(90)90423-C	http://dx.doi.org/10.1016/0092-8674(90)90423-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	1979758				2022-12-01	WOS:A1990EN92300018
J	SANDERSON, MR; FREEMONT, PS; RICE, PA; GOLDMAN, A; HATFULL, GF; GRINDLEY, NDF; STEITZ, TA				SANDERSON, MR; FREEMONT, PS; RICE, PA; GOLDMAN, A; HATFULL, GF; GRINDLEY, NDF; STEITZ, TA			THE CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF THE SITE-SPECIFIC RECOMBINATION ENZYME GAMMA-DELTA RESOLVASE AT 2.7-A RESOLUTION	CELL			English	Article							GAMMA-DELTA-RESOLVASE; TN3 RESOLVASE; RES-SITES; DNA; PROTEIN; MUTANTS; CLEAVAGE; INVITRO	The crystal structure of the catalytic domain of the site-specific recombination enzyme gamma-delta resolvase has been determined at 2.7 angstrom resolution. Its first 120 amino acids form a central five-stranded, beta-pleated sheet surrounded by five alpha-helices. In one of the four dyad-related dimers, the two active site Ser-10 residues are 19 angstrom apart, perhaps close enough to contact and become covalently linked to the DNA at the recombination site. This dimer also forms the only closely packed tetramer found in the crystal. The subunit interface at a second dyad-related dimer is more extensive and more highly conserved among the homologous recombinases; however, its active site Ser-10 residues are more than 30 angstrom apart. Side chains, identified by mutations that eliminate catalysis but not DNA binding, are located on the subunit surface near the active site serine and at the interface between a third dyad-related pair of subunits of the tetramer.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511; YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511	Yale University; Yale University; Howard Hughes Medical Institute; Yale University			Steitz, Thomas A./C-6559-2009	Freemont, Paul/0000-0002-5658-8486	NIGMS NIH HHS [GM28470, GM22778] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028470, R01GM028470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMEGUID SS, 1986, J BIOL CHEM, V261, P5934; ABDELMEGUID SS, 1984, P NATL ACAD SCI-BIOL, V81, P2001, DOI 10.1073/pnas.81.7.2001; BLOOMER AC, 1978, NATURE, V276, P362, DOI 10.1038/276362a0; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; FLETTERICK RJ, 1976, ACTA CRYSTALLOGR A, V32, P125, DOI 10.1107/S0567739476000235; GRINDLEY NDF, 1985, ANNU REV BIOCHEM, V54, P863, DOI 10.1146/annurev.biochem.54.1.863; GRINDLEY NDF, 1982, CELL, V30, P19, DOI 10.1016/0092-8674(82)90007-1; HAFFTER P, 1988, EMBO J, V7, P3991, DOI 10.1002/j.1460-2075.1988.tb03287.x; HATFULL GF, 1989, J MOL BIOL, V208, P661, DOI 10.1016/0022-2836(89)90156-3; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HATFULL GF, 1986, P NATL ACAD SCI USA, V83, P5429, DOI 10.1073/pnas.83.15.5429; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; MCKAY DB, 1980, J BIOL CHEM, V255, P6662; NEWMAN BJ, 1984, CELL, V38, P463, DOI 10.1016/0092-8674(84)90501-4; REED RR, 1984, COLD SPRING HARB SYM, V49, P245, DOI 10.1101/SQB.1984.049.01.028; REED RR, 1981, CELL, V25, P721, DOI 10.1016/0092-8674(81)90179-3; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; RIMPHANITCHAYAKIT V, 1989, NUCLEIC ACIDS RES, V17, P1035, DOI 10.1093/nar/17.3.1035; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; Shapiro JA, 1983, MOBILE GENETIC ELEME, P223; SHERRATT D, 1989, MOBILE DNA, P163; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079	27	98	100	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1323	1329		10.1016/0092-8674(90)90427-G	http://dx.doi.org/10.1016/0092-8674(90)90427-G			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2175678				2022-12-01	WOS:A1990EN92300022
J	SCHEFFNER, M; WERNESS, BA; HUIBREGTSE, JM; LEVINE, AJ; HOWLEY, PM				SCHEFFNER, M; WERNESS, BA; HUIBREGTSE, JM; LEVINE, AJ; HOWLEY, PM			THE E6 ONCOPROTEIN ENCODED BY HUMAN PAPILLOMAVIRUS TYPE-16 AND TYPE-18 PROMOTES THE DEGRADATION OF P53	CELL			English	Article							CELLULAR TUMOR-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; COLORECTAL CARCINOMAS; T-ANTIGEN; ONCOGENE; IMMORTALIZATION; IDENTIFICATION	The E6 protein encoded by the oncogenic human papillomavirus types 16 and 18 is one of two viral products expressed in HPV-associated cancers. E6 is an oncoprotein which cooperates with E7 to immortalize primary human keratinocytes. Insight into the mechanism by which E6 functions in oncogenesis is provided by the observation that the E6 protein encoded by HPV-16 and HPV-18 can complex the wild-type p53 protein in vitro. Wild-type p53 gene has tumor suppressor properties, and is a target for several of the oncoproteins encoded by DNA tumor viruses. In this study we demonstrate that the E6 proteins of the oncogenic HPVs that bind p53 stimulate the degradation of p53. The E6-promoted degradation of p53 is ATP dependent and involves the ubiquitin-dependent protease system. Selective degradation of cellular proteins such as p53 with negative regulatory functions provides a novel mechanism of action for dominant-acting oncoproteins.	PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544	Princeton University	SCHEFFNER, M (corresponding author), NCI,TUMOR VIRUS BIOL LAB,BETHESDA,MD 20892, USA.		Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128; Howley, Peter/0000-0002-8668-9579				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GIUS D, 1988, J VIROL, V62, P665, DOI 10.1128/JVI.62.3.665-672.1988; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAUSEN HZ, 1987, PAPOVAVIRIDAE, V2, P245; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MERCER WE, 1990, ONCOGENE, V5, P973; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROVINSKI B, 1988, ONCOGENE, V2, P445; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VUSDEN KH, 1988, ONCOGENE RES, V3, P167; WATANABE S, 1988, INT J CANCER, V41, P896, DOI 10.1002/ijc.2910410622; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YEE CL, 1985, AM J PATHOL, V119, P3261; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	54	3524	3658	9	220	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1129	1136		10.1016/0092-8674(90)90409-8	http://dx.doi.org/10.1016/0092-8674(90)90409-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2175676				2022-12-01	WOS:A1990EN92300004
J	SKOLNICK, MH; CANNONALBRIGHT, LA; GOLDGAR, DE; WARD, JH; MARSHALL, CJ; SCHUMANN, GB; HOGLE, H; MCWHORTER, WP; WRIGHT, EC; TRAN, TD; BISHOP, DT; KUSHNER, JP; EYRE, HJ				SKOLNICK, MH; CANNONALBRIGHT, LA; GOLDGAR, DE; WARD, JH; MARSHALL, CJ; SCHUMANN, GB; HOGLE, H; MCWHORTER, WP; WRIGHT, EC; TRAN, TD; BISHOP, DT; KUSHNER, JP; EYRE, HJ			INHERITANCE OF PROLIFERATIVE BREAST DISEASE IN BREAST-CANCER KINDREDS	SCIENCE			English	Article									UNIV UTAH, MED CTR, DEPT MED INFORMAT, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, MED CTR, DEPT INTERNAL MED, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, MED CTR, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	SKOLNICK, MH (corresponding author), UTAH REG CANC CTR, DEPT SURG, SALT LAKE CITY, UT 84132 USA.			Bishop, Tim/0000-0002-8752-8785; albright, lisa/0000-0003-2602-3668	NATIONAL CANCER INSTITUTE [R01CA028854, P01CA048711, P30CA042014] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42014, CA-28854, CA-48711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIBBO M, 1988, ACTA CYTOL, V32, P193; BISHOP DT, 1988, GENET EPIDEMIOL, V5, P151, DOI 10.1002/gepi.1370050303; BLACK MM, 1972, CANCER, V29, P338, DOI 10.1002/1097-0142(197202)29:2&lt;338::AID-CNCR2820290212&gt;3.0.CO;2-U; BROCA PP, 1866, TRAITES TUMEURS, V1, P80; CANNINGS C, 1977, CLIN GENET, V12, P208; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CANNONALBRIGHT LA, IN PRESS IMPORTANT A; CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995; CLAUS EB, IN PRESS AM J HUM GE; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DZIURA BR, 1979, ACTA CYTOL, V23, P332; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GALLAGER HS, 1969, CANCER, V24, P1170, DOI 10.1002/1097-0142(196912)24:6<1170::AID-CNCR2820240615>3.0.CO;2-6; HAMMOND S, 1987, ACTA CYTOL, V31, P276; Hasstedt SJ, 1981, 13 U UT DEP MED BIOP; HUNT SC, 1986, J CHRON DIS, V39, P809, DOI 10.1016/0021-9681(86)90083-4; KING MC, 1990, OCT M AM SOC HUM GEN; KNUDSON AG, 1985, CANCER RES, V45, P1437; LILLIENFELD AM, 1963, CANCER RES, V23, P1503; LYNCH HT, 1976, CANCER GENETICS, P389; MCLELLAN T, 1984, AM J HUM GENET, V36, P836; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; SKOLNICK M H, 1984, Genetic Epidemiology, V1, P363, DOI 10.1002/gepi.1370010408; SKOLNICK MH, UNPUB; WARD JH, 1990, J NATL CANCER I, V82, P964, DOI 10.1093/jnci/82.11.964; WELLINGS SR, 1973, JNCI, V50, P111; WILLIAMS W R, 1984, Genetic Epidemiology, V1, P7, DOI 10.1002/gepi.1370010104; WRIGHT EC, 1990, GENOMICS, V7, P103, DOI 10.1016/0888-7543(90)90524-X	29	93	98	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1715	1720		10.1126/science.2270486	http://dx.doi.org/10.1126/science.2270486			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2270486				2022-12-01	WOS:A1990EN92000043
J	SMITH, KA; GORMAN, PA; STARK, MB; GROVES, RP; STARK, GR				SMITH, KA; GORMAN, PA; STARK, MB; GROVES, RP; STARK, GR			DISTINCTIVE CHROMOSOMAL STRUCTURES ARE FORMED VERY EARLY IN THE AMPLIFICATION OF CAD GENES IN SYRIAN-HAMSTER CELLS	CELL			English	Article							1ST 3 ENZYMES; INSITU HYBRIDIZATION; DNA AMPLIFICATION; UMP SYNTHESIS; RESISTANT; TELOMERES; (TTAGGG)N; STABILITY; SEQUENCE; MUTANTS	As visualized by in situ hybridization with fluorescence detection, newly amplified CAD genes in 10(5) cell colonies are contained in multiple copies of very large regions of DNA, each tens of megabases long. The extra DNA is usually linked to the short arm of chromosome B9, which retains CAD at its normal site. The widely spaced genes are often interspersed with new G-negative regions. Individual cells within a clone have highly variable numbers of CAD genes (range 2-15). When resistant clones are examined later, at the 10(15) cell stage, the amplified genes are usually found in much more condensed structures. We propose that, in the initial event of CAD gene amplification, much of the short arm is transferred from one B9 chromosome to another. In subsequent cell cycles this initial duplication expands rapidly through unequal but homologous sister chromatid exchanges. Relatively rare secondary events lead to more condensed structures.			SMITH, KA (corresponding author), IMPERIAL CANC RES FUND,BOX 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; GIULOTTO E, 1986, EMBO J, V5, P2115, DOI 10.1002/j.1460-2075.1986.tb04474.x; GRODEN J, 1990, P NATL ACAD SCI USA, V87, P4315, DOI 10.1073/pnas.87.11.4315; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; KEMPE TD, 1976, CELL, V9, P541, DOI 10.1016/0092-8674(76)90036-2; LAWRENCE JB, 1988, CELL, V52, P51; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MEYNE J, 1990, CHROMOSOMA, V99, P3, DOI 10.1007/BF01737283; MIELE M, 1989, MUTAT RES, V219, P171, DOI 10.1016/0921-8734(89)90012-X; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; PADGETT RA, 1979, J BIOL CHEM, V254, P974; PAULETTI G, 1990, P NATL ACAD SCI USA, V87, P2955, DOI 10.1073/pnas.87.8.2955; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SAITO I, 1989, MOL CELL BIOL, V9, P2445, DOI 10.1128/MCB.9.6.2445; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; STARK GR, 1986, CANCER SURV, V5, P1; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; STARK GR, 1990, GENE REARRANGEMENT F, P99; Sutherland G, 1985, FRAGILE SITES HUMAN; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WAHL GM, 1989, CANCER RES, V49, P1333; WAHL GM, 1982, MOL CELL BIOL, V2, P308, DOI 10.1128/MCB.2.3.308; ZIEG J, 1983, MOL CELL BIOL, V3, P2089, DOI 10.1128/MCB.3.11.2089	28	134	147	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1219	1227		10.1016/0092-8674(90)90417-D	http://dx.doi.org/10.1016/0092-8674(90)90417-D			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	1979757				2022-12-01	WOS:A1990EN92300012
J	VACHER, J; TILGHMAN, SM				VACHER, J; TILGHMAN, SM			DOMINANT NEGATIVE REGULATION OF THE MOUSE ALPHA-FETOPROTEIN GENE IN ADULT LIVER	SCIENCE			English	Article											VACHER, J (corresponding author), PRINCETON UNIV, DEPT BIOL, HOWARD HUGHES MED INST, PRINCETON, NJ 08544 USA.				NCI NIH HHS [CA44976] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA044976] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BELAYEW A, 1982, MOL CELL BIOL, V2, P1427, DOI 10.1128/MCB.2.11.1427; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; MARIANI BD, 1988, P NATL ACAD SCI USA, V85, P3029, DOI 10.1073/pnas.85.9.3029; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; OLSSON M, 1977, J EXP MED, V145, P819, DOI 10.1084/jem.145.4.819; OTSURU A, 1988, CANCER, V62, P1105, DOI 10.1002/1097-0142(19880915)62:6<1105::AID-CNCR2820620613>3.0.CO;2-Z; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; POLIARD AM, 1986, J CELL BIOL, V103, P777, DOI 10.1083/jcb.103.3.777; SCOTT RW, 1983, MOL CELL BIOL, V3, P1295, DOI 10.1128/MCB.3.7.1295; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TRIPPUTI P, 1988, SCIENCE, V241, P1205, DOI 10.1126/science.2842865; TYNER AL, 1990, J CELL BIOL, V110, P915, DOI 10.1083/jcb.110.4.915; VACHER J, UNPUB; VOGT TF, 1987, SCIENCE, V236, P301, DOI 10.1126/science.2436297; WATANABE K, 1987, J BIOL CHEM, V262, P4812; WIDEN SG, 1986, P NATL ACAD SCI USA, V83, P8196, DOI 10.1073/pnas.83.21.8196; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X	32	125	127	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1732	1735		10.1126/science.1702902	http://dx.doi.org/10.1126/science.1702902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	1702902				2022-12-01	WOS:A1990EN92000048
J	WEBB, S; MORRIS, C; SPRENT, J				WEBB, S; MORRIS, C; SPRENT, J			EXTRATHYMIC TOLERANCE OF MATURE T-CELLS - CLONAL ELIMINATION AS A CONSEQUENCE OF IMMUNITY	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PANCREATIC BETA-CELLS; MLSA-ENCODED ANTIGENS; SELF-TOLERANCE; TRANSGENIC MICE; LYMPHOCYTES-T; B-CELLS; RECEPTOR; DETERMINANTS; EXPRESSION	The mechanism by which T lymphocytes are tolerized to self or foreign antigens is still controversial. Clonal deletion is the major mechanism of tolerance for immature thymocytes; for mature T cells, tolerance is considered to reflect anergy rather than deletion, and to be a consequence of defective presentation of antigen. This paper documents a novel form of tolerance resulting when mature T cells encounter antigen in immunogenic form. Evidence is presented that exposure of mature T cells to Mis(a) antigens in vivo leads to specific tolerance and disappearance of Mis(a)-reactive V-beta-6+ T cells. Surprisingly, the clonal elimination of V-beta-6+ cells is preceded by marked expansion of these cells. Thus, tolerance induction can be the end result of a powerful immune response. These data raise important questions concerning the relationship of tolerance and memory.			WEBB, S (corresponding author), Scripps Clinic, RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P01CA025803, R01CA038355, R01CA041993, R37CA038355] Funding Source: NIH RePORTER; NCI NIH HHS [CA25803, CA41993, CA38355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE R, 1988, NATURE, V335, P827, DOI 10.1038/335827a0; ABE R, 1989, ANNU REV IMMUNOL, V7, P683, DOI 10.1146/annurev.iy.07.040189.003343; AHMED A, 1977, J IMMUNOGENET, V4, P201; ANDERSON RE, 1974, EUR J IMMUNOL, V4, P199, DOI 10.1002/eji.1830040309; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BOEHMER HV, 1974, NATURE, V249, P363, DOI 10.1038/249363a0; BRUCE J, 1981, J IMMUNOL, V127, P2496; BYERS VS, 1968, J EXP MED, V127, P307, DOI 10.1084/jem.127.2.307; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; DENNERT G, 1980, CELL IMMUNOL, V53, P350, DOI 10.1016/0008-8749(80)90335-4; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; FRY AM, 1988, NATURE, V335, P830, DOI 10.1038/335830a0; GOWANS JL, 1965, PROG ALLERGY, V9, P1; GRAY D, 1990, CURR TOP MICROBIOL, V159, P1; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; JACOBSSON H, 1975, SCAND J IMMUNOL, V4, P181, DOI 10.1111/j.1365-3083.1975.tb02615.x; JANEWAY CA, 1980, IMMUNOGENETICS, V10, P481, DOI 10.1007/BF01572583; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MACDONALD HR, 1988, J EXP MED, V167, P2005, DOI 10.1084/jem.167.6.2005; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MACPHAIL S, 1985, J IMMUNOL, V135, P2967; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MILLER JFAP, 1960, BRIT J CANCER, V14, P93, DOI 10.1038/bjc.1960.11; MILLER RA, 1982, J IMMUNOL, V128, P2258; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SIMONSEN M, 1962, PROG ALLERGY, V6, P349, DOI 10.1159/000313805; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPEISER DE, 1989, J EXP MED, V170, P595, DOI 10.1084/jem.170.2.595; SPRENT J, 1976, CELL IMMUNOL, V21, P314, DOI 10.1016/0008-8749(76)90059-9; SPRENT J, 1976, CELL IMMUNOL, V21, P303, DOI 10.1016/0008-8749(76)90058-7; SPRENT J, 1976, CELL IMMUNOL, V21, P278, DOI 10.1016/0008-8749(76)90057-5; Sterzl J, 1967, Adv Immunol, V6, P337, DOI 10.1016/S0065-2776(08)60525-8; WAITE DJ, 1988, CELL IMMUNOL, V117, P78, DOI 10.1016/0008-8749(88)90078-0; WEBB SR, 1990, SCIENCE, V248, P1643; WEBB SR, 1989, J EXP MED, V169, P1, DOI 10.1084/jem.169.1.1	51	949	971	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 21	1990	63	6					1249	1256		10.1016/0092-8674(90)90420-J	http://dx.doi.org/10.1016/0092-8674(90)90420-J			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2148123				2022-12-01	WOS:A1990EN92300015
J	WUARIN, J; SCHIBLER, U				WUARIN, J; SCHIBLER, U			EXPRESSION OF THE LIVER-ENRICHED TRANSCRIPTIONAL ACTIVATOR PROTEIN DBP FOLLOWS A STRINGENT CIRCADIAN-RHYTHM	CELL			English	Article							TISSUE-SPECIFIC EXPRESSION; FACTOR STIMULATES TRANSCRIPTION; DNA-BINDING DOMAIN; ALBUMIN GENE; RAT-LIVER; PROMOTERS; SYSTEM; CONTAINS; CELLS	The liver-enriched transcriptional activator protein DBP accumulates in hepatocytes of adult rats according to a strictly controlled circadian rhythm. DBP is not detectable in liver nuclei during the morning hours. Its level raises sharply during the afternoon and reaches a maximum at about 8 p.m. During the night the cellular DBP concentration decreases below detectability. This oscillation is "free running," transcriptionally regulated, and may be under the negative control of glucocorticoid hormones. In keeping with the rhythmicity of DBP accumulation, the albumin gene, a putative target of DBP, is transcribed more efficiently in the evening than in the morning.			WUARIN, J (corresponding author), UNIV GENEVA,DEPT MOLEC BIOL,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.							Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BARGIELLO TA, 1987, NATURE, V328, P686, DOI 10.1038/328686a0; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BROUWER A, 1987, LIVER BIOL PATHOLOGY, P665; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARDINE H, 1990, NATURE, V343, P536; HARLOW E, 1988, ANTIBODIES LABORATOR; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; JONES EA, 1987, LIVER BIOL PATHOLOGY, P683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEIER AH, 1975, ENDOCRINOLOGY, V98, P1475; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; WONG NCW, 1989, J BIOL CHEM, V264, P4466; WUARIN J, 1990, J MOL BIOL, V214, P865, DOI 10.1016/0022-2836(90)90341-I	43	208	209	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 21	1990	63	6					1257	1266		10.1016/0092-8674(90)90421-A	http://dx.doi.org/10.1016/0092-8674(90)90421-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EN923	2261643				2022-12-01	WOS:A1990EN92300016
J	YUE, DT; BACKX, PH; IMREDY, JP				YUE, DT; BACKX, PH; IMREDY, JP			CALCIUM-SENSITIVE INACTIVATION IN THE GATING OF SINGLE CALCIUM CHANNELS	SCIENCE			English	Article											YUE, DT (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOMED ENGN, BALTIMORE, MD 21205 USA.				NHLBI NIH HHS [R29-HL43307] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07057] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; ARMSTRONG CM, 1987, SCIENCE, V236, P712, DOI 10.1126/science.2437654; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; BECHEM M, 1985, PFLUG ARCH EUR J PHY, V404, P10, DOI 10.1007/BF00581485; BREHM P, 1978, SCIENCE, V202, P1203, DOI 10.1126/science.103199; CAVALIE A, 1983, PFLUG ARCH EUR J PHY, V398, P284, DOI 10.1007/BF00657238; CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; COLQUHOUN D, 1977, PROC R SOC SER B-BIO, V199, P231, DOI 10.1098/rspb.1977.0137; DEMO SD, 1990, BIOPHYS J, V57, pA15; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; HADLEY RW, 1987, J PHYSIOL-LONDON, V389, P205, DOI 10.1113/jphysiol.1987.sp016654; HESS P, 1986, J GEN PHYSIOL, V88, P293, DOI 10.1085/jgp.88.3.293; KASS RS, 1984, J GEN PHYSIOL, V84, P705, DOI 10.1085/jgp.84.5.705; KOSTYUK P, 1989, ANN NY ACAD SCI, V560, P63, DOI 10.1111/j.1749-6632.1989.tb24081.x; LEE KS, 1985, J PHYSIOL-LONDON, V364, P395, DOI 10.1113/jphysiol.1985.sp015752; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; LUX HD, 1984, SCIENCE, V225, P432, DOI 10.1126/science.6330896; MILLER C, 1987, J GEN PHYSIOL, V90, P427, DOI 10.1085/jgp.90.3.427; PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0; RANE SG, 1987, PFLUG ARCH EUR J PHY, V409, P361, DOI 10.1007/BF00583789; ROSENBERG RL, 1988, J GEN PHYSIOL, V92, P27, DOI 10.1085/jgp.92.1.27; SCOTT RH, 1987, NATURE, V330, P760, DOI 10.1038/330760a0; SIGWORTH FJ, 1981, BIOPHYS J, V34, P111, DOI 10.1016/S0006-3495(81)84840-0; SWANDULLA D, 1989, P NATL ACAD SCI USA, V86, P1736, DOI 10.1073/pnas.86.5.1736; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TILLOTSON D, 1979, P NATL ACAD SCI USA, V76, P1497, DOI 10.1073/pnas.76.3.1497; YU DT, 1990, P NATL ACAD SCI USA, V87, P753; YUE DT, 1990, J GEN PHYSIOL, V95, P911, DOI 10.1085/jgp.95.5.911	29	174	175	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 21	1990	250	4988					1735	1738		10.1126/science.2176745	http://dx.doi.org/10.1126/science.2176745			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EN920	2176745				2022-12-01	WOS:A1990EN92000049
J	ARAI, H; HORI, S; ARAMORI, I; OHKUBO, H; NAKANISHI, S				ARAI, H; HORI, S; ARAMORI, I; OHKUBO, H; NAKANISHI, S			CLONING AND EXPRESSION OF A CDNA-ENCODING AN ENDOTHELIN RECEPTOR	NATURE			English	Article									KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN	Kyoto University								BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; DIXON RAF, 1988, ANNU REP MED CHEM, V23, P221; EMORI T, 1990, FEBS LETT, V263, P261, DOI 10.1016/0014-5793(90)81388-5; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOSEKI C, 1989, AM J PHYSIOL, V256, pR858, DOI 10.1152/ajpregu.1989.256.4.R858; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LORY P, 1989, FEBS LETT, V258, P289, DOI 10.1016/0014-5793(89)81676-X; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Nakanishi S, 1990, Recent Prog Horm Res, V46, P59; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1989, REV NEUROSCI, V12, P67; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALOFF D, 1990, FASEB J, V4, pA1851; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; WATANABE H, 1989, BIOCHEM BIOPH RES CO, V161, P1252, DOI 10.1016/0006-291X(89)91377-6; WILKES BM, 1990, AM J PHYSIOL, V258, pE864, DOI 10.1152/ajpendo.1990.258.5.E864; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	25	2674	2745	1	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 20	1990	348	6303					730	732		10.1038/348730a0	http://dx.doi.org/10.1038/348730a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EP049	2175396				2022-12-01	WOS:A1990EP04900059
J	AROIAN, RV; KOGA, M; MENDEL, JE; OHSHIMA, Y; STERNBERG, PW				AROIAN, RV; KOGA, M; MENDEL, JE; OHSHIMA, Y; STERNBERG, PW			THE LET-23 GENE NECESSARY FOR CAENORHABDITIS-ELEGANS VULVAR INDUCTION ENCODES A TYROSINE KINASE OF THE EGF RECEPTOR SUBFAMILY	NATURE			English	Article									KYUSHU UNIV,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 812,JAPAN	Kyushu University	AROIAN, RV (corresponding author), CALTECH,ARTHUR AMOS NOYES LAB CHEM PHYS,HOWARD HUGHES MED INST,DIV BIOL,PASADENA,CA 91125, USA.			Sternberg, Paul/0000-0002-7699-0173				ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BIETEL GJ, 1990, NATURE, V348, P503; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FERGUSON EL, 1989, GENETICS, V123, P109; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERMAN RK, 1978, GENETICS, V88, P49; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HORVITZ HR, 1980, GENETICS, V96, P435; HUNTER T, 1986, ENZYMES, V17; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KRAMER JM, 1990, J MOL CELL BIOL, V10, P2081; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; Maniatis T., 1982, MOL CLONING; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; PARSONS JT, 1990, TRENDS GENET, V6, P169; RUVKUN G, 1989, GENETICS, V121, P501; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; SCHLESSINGER J, 1983, CRC CR REV BIOCH MOL, V14, P93, DOI 10.3109/10409238309102791; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SIGURDSON DC, 1984, GENETICS, V108, P331; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; Sulston JHJ, 1988, NEMATODE CAENORHABDI; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1985, NATURE, V313, P576; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	56	371	382	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 20	1990	348	6303					693	699		10.1038/348693a0	http://dx.doi.org/10.1038/348693a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EP049	1979659				2022-12-01	WOS:A1990EP04900046
